PROSPECTUS
Dated: September 6, 2021

Please read Section 32 of the Companies Act, 2013
100% Book Built Offer

fe) WWAYA
===) pIAGNosTIC

wisava] CENTRE
VIJAYA DIAGNOSTIC CENTRE LIMITED

 

 

 

 

(Our Company was incorporated as Vijaya Diagnostic Centre Private Limited on June 5, 2002 with a certificate of incorporation issued by the Registrar af Companies, Andhra Pradesh at Hyderabad, Subsequently,
cour Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on March 22, 2021 and the name of our

‘Company was changed to Vijaya Diagnostic Centre Limited on March 26, 2021, and a fresh certificate of incorporation consequent on change of name was granted by the Registrar of Companies, Telangana at
Hyderabad. For further details, see “History and Certain Corporate Matters” on page 131.

Registered Office: 36-16 & 17, Street No. 19, Himayatnagar, Hyderabad, 500 029, Telangana, India; Tel: +91 40 2342 0411

Corporate Office: # 6-3-883/F, Ground Floor of Family Planning Association of India, Panjagutta, Hyderabad-500 082, Indi

Website: www.vijayadiagnostic.com; Contact Person: V. Sri Lakshmi, Company Secretary and Compliance Officer; E-mail: ir@vijayadiagnostic.in
Corporate Identity Number: U851951G2002P1C039075

 

Pe ENDRANATH REDDY

INITIAL PUBLIC OFFER OF EQUITY SHARES OF FACE VALUE OF 1 JAYA DIAGNOSTIC CENTRE LIMITED (*COMPANY” OR “ISSUER”) FOR
CASH AT A PRICE OF 3531’ PER EQUITY SHARE (“OFFER PRICE”), THROUGH AN OFFER FOR SALE OF 35,688,064 EQUITY SHARES AGGREGATING TO 218,942.56 MILLION
OFFER") BY THE SELLING SHAREHOLDERS, COMPRISING OF 5,098,296 EQUITY SHARES AGGREGATING TO 22,706.08 MILLION BY DR. S. SURENDRANATH REDDY
(PROMOTER SELLING SHAREHOLDER"), 29,487,290 EQUITY SHARES AGGREGATING TO 215,651.30 MILLION BY KARAKORAM LIMITED AND 1,102,478 EQUITY SHARES
AGGREGATING TO 8585.18 MILLION BY KEDAARA CAPITAL ALTERNATIVE INVESTMENT FUND ~ KEDAARA CAPITAL AIF 1 (“KARAKORAM LIMITED TOGETHER WITH
KEDAARA CAPITAL ALTERNATIVE INVESTMENT FUND ~ KEDAARA CAPITAL AIF 1 REFERRED TO AS “INVESTOR SELLING SHAREHOLDERS”) (INVESTOR SELLLING
SHAREHOLDERS TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER REFERRED TO AS THE “SELLING SHAREHOLDERS"), THIS OFFER INCLUDED A RESERVATION
OF 150,000" EQUITY SHARES AGGREGATING UP TO 271.85 MILLION (CONSTITUTING UP TO 0.15% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR PURCHASE
BY ELIGIBLE EMPLOYEES (THE “EMPLOYEE RESERVATION PORTION”). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS
‘THE “NET OFFER”. THE OFFER AND THE NET OFFER CONSTITUTES AT LEAST 35.00% AND 34.85%, RESPECTIVELY, OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.
OUR COMPANY AND THE SELLING SHAREHOLDERS IN CONSULTATION WITH THE BRLMS, OFFERED A DISCOUNT OF 10% (EQUIVALENT TO 252 PER EQUITY SHARE) TO
THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION (“EMPLOYEE DISCOUNT”).

‘THE OFFER PRICE IS %531 PER EQUITY SHARE AND IS 531 TIMES THE FACE VALUE OF THE EQUITY SHARES. THE ANCHOR INVESTOR OFFER PRICE IS 8531 PER EQUITY
SHARE.

“SUBJECT TO FINALISATION OF THE BASIS OF ALLOTMENT
“A DISCOUNT OF 252 PER EQUITY SHARE WAS OFFERED TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATON PORTION

      

 

 

 

 

"The Offer was made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR,
Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer was available for allocation on a proportionate basis to Qualified Institutional
Buyers (“QBs”) (the "QIB Portion”), Our Company and the Selling Shareholders in consultation with the BRLMSs allocated 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third
of the Anchor Investor Portion was reserved for domestic Mutual Funds, subject to valid Bids having been received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of
the QUB Portion (excluding the Anchor Investor Portion) was made available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QUB Portion was made available for
allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids having been received at or above the Offer Price. Further, not less than 15%
of the Net Offer was made available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer was made available for allocation to RIBs in accordance with
the SEBI ICDR Regulations, subject to valid Bids having been received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying
under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilise the
Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank account (including UPI ID for RIBs using UPI Mechanism), in which the corresponding Bid Amounts
‘were blocked by the SCSBs or the Sponsor Bank, as applicable. Anchor Investors were not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure” on page 272

 

 

 

“This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of the Equity Shares is 81. The Offer Price as determined and justified by our Company
and the Selling Shareholders in consultation with the BRLMS, in accordance with the SEBI ICDR Regulations, as stated under “Basis for Offer Price” on page 72 should not be taken to be indicative of the

market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active andor sustained trading in the Equity Shares nor regarding the price at which the Equity
Shares will be traded after listing

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing thelr entire investment. Investors
are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer,
including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI"), nor does SEBI guarantee the accuracy or
adequacy of the contents ofthis Prospectus, Specific attention of the prospective investors is invited to “Risk Factors” on page 21

ISSUER'S AND THE SELLING SHAREHOLDERS’ ABSOLUTE RESPONSIBILITY
‘Our Company, having made al reasonable inquiries, accepts responsiblity for and confirms that this Prospectus contains all information with regard to our Company and the Offer, which is material in the
context of the Offer, that the information contained in this Prospectus is true and correct in all material aspects and is not misleading in any material respect, that opinions and intentions expressed herein are
honestly held and that there are no other facts, the omission of which makes this Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material
respect. Each of the Selling Shareholders, severally and not jointly, accept responsibility for and confirm that the statements specifically made or confirmed by such Selling Shareholder in this Prospectus to
the extent of information specifically pertaining to itself and its portion of the Offered Shares in the Offer for Sale and assume responsibility that such statements are true and correct in all material respects.
and not misleading in any material respect. Each of the Selling Shareholders, severally and not jointly, assume no responsibility for any other statement, including, inter alia, any of the statements made by or

as to our: copa ‘or its business or any other sal Shareholders.

"The Equity Shares offered through the Red Herring Prospectus and this Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received ‘in-prineiple’ approval from BSE and NSE
forthe listing of the Equity Shares pursuant to letters dated July 5, 2021 and June 30, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red
Herring Prospectus and a signed copy of this Prospectus shall be delivered for filing with the RoC. in accordance with Section 26(4) of the Companies Act. For details of the material contracts and documents,
‘which were made available for inspection from the date of the Red Herring Prospectus up to the Bid/ Offer Closing Date, see “Material Contracts and Documents for Ins

 

 

sction” on page 291.

 

BOOK RUNNING LEAD MANAGERS Rea

erences @ Edelweiss kotak’ MrINTECH

Investment Banking

 

 

 

   

TGIGI Securities Limited Edelweiss Financial Services Limited ‘Kotak Mahindra Capital Company Limited | KFin Technologies Private Limited

ICICI Centre, H.T. Parekh Marg 6" Floor, Edelweiss House 1" Floor, 27 BKC, Plot No. 27 Selenium, Tower B, Plot No- 31 and 32,
‘Churchgate, Mumbai 400 020 Off C...Road, Kalina G Block, Bandra Kurla Complex Financial’ District, —__-Nanakramguda,
Maharashtra, India Mumbai 400 098 Bandra (Fast), Mumbai 400 051 Serilingampally, Hyderabad, Rangareedi 500
Tel: +91 22 2288 2460 ‘Maharashtra, India Maharashira, india 032, Telangana, india

E-mail vijaya.po@icicisecuities.com ‘Tel: #91 22 4009 4400 ‘Tel: +91 22.4336 0000 ‘Fel: +91 40 6716 2222/ 1800 309 4001
Investor grievance e-mail: | E-mail: ijayadiagnosticipo@edelweissfin.com | E-mail: vijayadiagnosticjpo@kotak.com E-mail: vijaya.ipo@kintech.com
customercare@icicisecurities.com ‘Website: www.edelwweissfin.com Investor grievance ‘e-mail | Investor grievance

Website: www.icicisecurites.com Investor Grievance email kmecredressal@kotak com inward sis@kfintech.com

Contact Person: Sameer Purohit/ Nidhi | customerservice,mb@edelweissfin.com ‘Website: hitps:/investmentbank kotak com Website: www.kfintech.com

Wangnoo ‘Contact person: Lokesh Shab/Nilesh Roy ‘Contact Person: Ganesh Rane Contact Person: M Murali Krishna

SEBI Registration No.: INM000011179 ‘SEBI Registration No.: INM0000010650 SEBI Registration No.: INM000008704 SEBI Registration No.: INRO00000221

 

 

 

BID/ OFFER OPENED ON ‘SEPTEMBER 1, 2021") BID/ OFFER CLOSED ON ‘SEPTEMBER 3, 2021
The Anchor Investor Bid/ Offer Period was one Working Day prior tothe Bid/ Offer Opening Date Le, Tuesday, August 31, 2021

 

 
(This page is intentionally left blank)
TABLE OF CONTENTS

SECTION I: GENERAL. woe

DEFINITIONS AND ABBREVIATIONS ...... eee:
OFFER DOCUMENT SUMMARY ...... sa ll
CERTAIN CONVENTIONS, PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA AND
CURRENCY OF PRESENTATION .... ero LF
FORWARD-LOOKING STATEMENTS ...... en 2O

wee 21
we AL
41

 

 

 

 

 

SECTION II: RISK FACTORS...

 

SECTION III: INTRODUCTION....

THE OFFER ......
SUMMARY OF FINANCIAL INFORMATION .. . 43
GENERAL INFORMATION 48
CAPITAL STRUCTURE.... 56
OBJECTS OF THE OFFER. . 70
BASIS FOR OFFER PRICE 2
STATEMENT OF SPECIAL TAX BENEFITS... 6 ED:

 

 

 

 

 

 

 

SECTION IV: ABOUT OUR COMPANY...

INDUSTRY OVERVIEW
OUR BUSINESS ......

KEY REGULATIONS AND POLICIES...
HISTORY AND CERTAIN CORPORATE MATTERS
OUR MANAGEMENT
OUR PROMOTER AND PROMOTER GROUP..
OUR GROUP COMPANIES...
DIVIDEND POLICY...

 

 

 

 
 
 
 
 

SECTION V: FINANCIAL INFORMATION

FINANCIAL STATEMENTS .......
OTHER FINANCIAL INFORMATION ..
CAPITALISATION STATEMENT ..
FINANCIAL INDEBTEDNESS...
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONG.......

SECTION VI: LEGAL AND OTHER INFORMATION ...

 

 

 

 

 

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS.
GOVERNMENT AND OTHER APPROVALS
OTHER REGULATORY AND STATUTORY DISCLOSURES

SECTION VII: OFFER INFORMATION...

TERMS OF THE OFFER
OFFER STRUCTURE..
OFFER PROCEDURE......
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIE:
SECTION VIII: DESCRIPTION OF EQUITY SHARES AND TERMS OF ARTICLES OF ASSOCIATION......... 287

SECTION IX: OTHER INFORMATION....

 
 
 

 

 

 

 

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION ...

 

DECLARATION ....

 
SECTION I: GENERAL
DEFINITIONS AND ABBREVIATIONS

This Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies, shall have
the meaning as provided below. References to any legislation, act, regulation, rules, guidelines or policies shall be to such
legislation, act, regulation, rules, guidelines or policies as amended, supplemented or re-enacted from time to time, and any
reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.

  

The words and expressions used in this Prospectus but not defined herein shall have, to the extent applicable, the same meaning
ascribed to such terms under the SEBI ICDR Regulations, the Companies Act, the SCRA, the Depositories Act and the rules
and regulations made thereunder. Notwithstanding the foregoing, the terms used in “Industry Overview”, “Key Regulations
and Policies”, “Statement of Special Tax Benefits”, “Financial Statements”, “Basis for Offer Price”, “Outstanding Litigation
and Material Developments” and “Description of Equity Shares and Terms of Articles of Association” on pages 80, 127, 75,
162, 72, 245 and 287, respectively shall have the meaning ascribed to them in the relevant section.

 

 

 

General Terms
Term Description
“our Company”, “the Company”, | Vijaya Diagnostic Centre Limited, a company incorporated under the Companies Act, 1956 having its
or “the Issuer” Registered Office at 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad, Telangana, India
“we”, “us” or “our” Unless the context otherwise indicates or implies, refers to our Company and our Subsidiaries, as

applicable, as at and during the relevant period/ Financial Year

 

Company and Selling Shareholders Related Terms

 

 

 

Term Description
‘Articles of Association or AoA _| Articles of association of our Company, as amended
Audit Committee Audit committee of our Company, constituted in accordance with the applicable provisions of the
Companies Act, the Listing Regulations, and as described in “Our Management — Audit Committee” on
page 144

 

Auditors or Statutory Auditors Current statutory auditors of our Company, namely, B S R & Associates LLP

“Board” or “Board of Directors” [Board of directors of our Company, as constituted from time to time, including a duly constituted
committee thereof

CCPs Compulsory Convertible Preference Shares

CEO Chief Executive Officer of our Company, being Sura Suprita Reddy. For details, see “Our Management
— Key Managerial Personnel” on page 152

CFO or Chief Financial Officer __ | Chief Financial Officer of our Company, being Narasimha Raju K.A. For details, see “Our Management
— Key Managerial Personnel” on page 152

 

 

 

 

 

 

 

 

Company Secretary and ‘Company Secretary and Compliance Officer of our Company, being V. Sri Lakshmi. For details, see

Compliance Officer “Our Management ~ Key Managerial Personnel” on page 153

Corporate Social Responsibility | Corporate social responsibility committee of our Company constituted in accordance with the applicable

Committee provisions of the Companies Act and as described in “Our Management — Corporate Social
Responsibility Committee” on page 147

Corporate Office # 6-3-883/F, Ground Floor of Family Planning Association of India, Panjagutta, Hyderabad-500 082,
India

CRISIL Report Report titled “Assessment of the diagnostic industry in India” issued in May, 2021 read with the

addendum to the report dated August 2021, issued by CRISIL Limited which has been commissioned
by our Company

 

 

 

Director(s) The directors on our Board, as appointed from time to time
ESOP Plan 2018 VDCL Employee Stock Option Plan 2018
ESOP Schemes 2018 VDCL Employee Stock Option 2018 — Scheme 1, VDCL Employee Stock Option 2018 — Scheme 2,

VDCL Employee Stock Option 2018 — Scheme 3, VDCL Employee Stock Option 2018 — Scheme 4,
VDCL Employee Stock Option 2018 — Scheme 5 and VDCL Employee Stock Option 2018 — Scheme

 

 

 

 

 

 

6
Equity Shares Equity shares of our Company of face value of 1 each
Executive Director An executive director of our Company
Group Companies ‘Our group companies, namely Park Health Systems Private Limited and Vijaya Hospitals Private
Limited, as disclosed in “Our Group Companies” on page 157
Non Executive, Independent Non-executive independent directors on our Board, appointed as per the Companies Act and the Listing
Director or Independent Director _| Regulations, and as described in “Our Management” on page 139
Investor Selling Shareholders Karakoram Limited and Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1
Investment Agreement Investment Agreement dated November 23, 2016 amongst our Company, Dr. S. Surendranath Reddy,

K. Sunil Chandra, S. Suprita Reddy, S. Geetha Reddy, B Vishnu Priya, Karakoram Limited and Kedaara
Capital Alternative Investment Fund — Kedaara Capital AIF 1 as amended by waiver cum amendment
agreement dated May 27, 2021.

 

 

 

IPO Committee The IPO committee of our Company as described in “Our Management — IPO Committee” on page 148

Key Managerial Personnel or Key managerial personnel of our Company in accordance with Regulation 2(1)(bb) of the SEBI ICDR

KMP Regulations and Section 2(51) of the Companies Act, 2013 and as described in “Our Management” on
page 152

MDSL Medinova Diagnostic Services Limited

 

 

 

 

1
 

Term

Description

 

MDSL SPA

Share purchase agreement dated March 27, 2014 amongst M/s. Standard Medical and Pharmaceuticals
Limited, our Company, and MDSL

 

Major Shareholders

Dr. S. Surendranath Reddy, Sunil Chandra Kondapally, Sura Suprita Reddy, S. Geeta Reddy, B Vishnu
Priya

 

Managing Director or MD

A Director of our Company, as identified under Section 2(54) of the Companies Act

 

Materiality Policy

The policy on materiality adopted by our Board with regard to the following:

1. disclosures relating to litigations to be made in this Prospectus by way of a resolution dated May
27, 2021;

2. identification of our Group Companies by way of a resolution dated August 16, 2021; and

3. disclosures relating to outstanding material dues to creditors of our Company by way of a
resolution dated August 16, 2021

 

Memorandum of Association or
MoA

Memorandum of association of our Company, as amended

 

Nomination and Remuneration

Committee

Nomination and remuneration committee of our Company, constituted in accordance with the applicable
provisions of the Companies Act and the Listing Regulations, as described in “Our Management —
Nomination and Remuneration Committee” on page 146

 

Non-executive Director

A director on our Board, as appointed from time to time, other than the Executive Directors and the
Managing Director

 

Promoter

Promoter of our Company, namely, Dr. S. Surendranath Reddy. For details, see “Our Promoter and
Promoter Group” on page 155

 

Promoter Group

Persons and entities constituting the promoter group of our Company in terms of Regulation 2(1)(pp)
of the SEBI ICDR Regulations, as disclosed in “Our Promoter and Promoter Group — Promoter Group”
on page 156

 

Promoter Selling Shareholder

Dr. S. Surendranath Reddy

 

Registered Office

3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad, Telangana, India

 

Registrar of Companies or RoC

Registrar of Companies, Telangana at Hyderabad

 

Restated Financial Information

The restated consolidated financial information of the Company and the Subsidiaries, comprise of the
restated consolidated balance sheet as at June 30, 2021, June 30, 2020, March 31, 2021, March 31, 2020,
March 31, 2019, the related restated consolidated statement of profit and loss (including other
comprehensive income), the restated consolidated statement of changes in equity, and the restated
consolidated statement of cash flows for the periods/ years ended June 30, 2021, June 30, 2020, March
31, 2021, March 31, 2020, and March 31, 2019, and the significant accounting policies and restated
consolidated other financial information

 

Selling Shareholders

Promoter Selling Shareholder and Investor Selling Shareholders

 

Shareholders

Shareholders of our Company from time to time

 

Stakeholders’ Relationship
Committee

Stakeholders’ relationship committee of our Company, constituted in accordance with the applicable
provisions of the Companies Act and the Listing Regulations and as described in “Our Management —
Stakeholders’ Relationship Committee” on page 147

 

 

 

 

Subsidiary(ies) Subsidiaries of our Company, as of the date of this Prospectus and as identified under the provisions of
the Companies Act, namely:
1. Doctorslab Medical Services Private Limited;
2. Medinova Diagnostic Services Limited;
3. Medinova Millennium MRI Services, LLP (step-down subsidiary);
4. Namrata Diagnostic Centre Private Limited (step-down subsidiary); and
5. _ VDC Diagnostic (Karnataka) LLP

Offer Related Terms

Term Description
Abridged Prospectus Abridged prospectus means a memorandum containing such salient features of a prospectus as may be

specified by the SEBI in this behalf

 

‘Acknowledgement Slip

The slip or document issued by a Designated Intermediary(ies) to a Bidder as proof of registration of
the Bid cum Application Form

 

Allot, Allotment or Allotted

Unless the context otherwise requires, transfer of the Equity Shares pursuant to the Offer to successful
Bidders

 

Allotment Advice

Note or advice or intimation of Allotment sent to the successful Bidders who have been or are to be
Allotted the Equity Shares after the Basis of Allotment has been approved by the Designated Stock
Exchange

 

Allottee

A successful Bidder to whom the Equity Shares are Allotted

 

Anchor Investor

A Qualified Institutional Buyer, who applied under the Anchor Investor Portion in accordance with the
requirements specified in the SEBI ICDR Regulations and the Red Herring Prospectus and who has Bid
for an amount of at least %100 million. For further details, see “Offer Procedure” on page 272

 

Anchor Investor Allocation Price

2531 at which Equity Shares were allocated to Anchor Investors in terms of the Red Herring Prospectus
and this Prospectus, which was decided by our Company and the Selling Shareholders in consultation
with the BRLMs during the Anchor Investor Bid/ Offer Period

 

 

Anchor Investor Application | Form used by an Anchor Investor to make a Bid in the Anchor Investor Portion and which was
Form considered as an application for Allotment in terms of the Red Herring Prospectus and this Prospectus
Anchor Investor Bid/ Offer | August 31, 2021 being one Working Day prior to the Bid/ Offer Opening Date, on which Bids by Anchor
Period Investors were submitted and allocation to Anchor Investors was completed

 

 

Anchor Investor Offer Price

 

2531 per Equity Share.

 

 

 
 

Term

Description

 

The Anchor Investor Offer Price was decided by our Company and the Selling Shareholders in
consultation with the BRLMs

 

Anchor Investor Portion

60% of the QIB Portion consisting of 10,661,418" Equity Shares which were allocated by our Company
and the Selling Shareholders in consultation with the BRLMs, to Anchor Investors on a discretionary
basis

“Subject to finalisation of the Basis of Allotment

One-third of the Anchor Investor Portion was reserved for domestic Mutual Funds, subject to valid Bids
having been received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in
accordance with the SEBI ICDR Regulations

 

Application Supported
Blocked Amount or ASBA

by

Application, whether physical or electronic, used by ASBA Bidders to make a Bid and authorizing an
SCSB to block the Bid Amount in the ASBA Account and which includes applications made by RIBs
using the UPI Mechanism where the Bid Amount was blocked upon acceptance of UPI Mandate
Request by RIBs

 

ASBA Account

Bank account maintained with an SCSB by an ASBA Bidder, as specified in the ASBA Form submitted
by ASBA Bidders for blocking the Bid Amount mentioned in the relevant ASBA Form and includes
the account of an RIB which were blocked upon acceptance of a UPI Mandate Request made by the
RIBs using the UPI Mechanism

 

 

 

ASBA Bid A Bid made by an ASBA Bidder
‘ASBA Bidder(s) All Bidders except Anchor Investors
ASBA Form Application form, whether physical or electronic, used by ASBA Bidders which was considered as the

application for Allotment in terms of the Red Herring Prospectus and this Prospectus

 

Bankers to the Offer

Collectively, the Escrow Collection Bank, the Public Offer Bank, the Sponsor Bank and the Refund
Bank, as the case may be

 

Basis of Allotment

Basis on which Equity Shares will be Allotied to successful Bidders under the Offer and which is
described in “Offer Procedure” on page 272

 

Bid

Indication to make an offer during the Bid/ Offer Period by an ASBA Bidder pursuant to submission of
the ASBA Form, or during the Anchor Investor Bid/ Offer Period by an Anchor Investor, pursuant to
submission of the Anchor Investor Application Form, to subscribe or purchase the Equity Shares at a
price within the Price Band, including all revisions and modifications thereto as permitted under the
SEBI ICDR Regulations and in terms of the Red Herring Prospectus and the Bid cum Application Form.
The term “Bidding” shall be construed accordingly

 

Bid Amount

The highest value of optional Bids indicated in the Bid cum Application Form (less Employee Discount
as applicable) and, in the case of Retail Individual Bidders Bidding at the Cut off Price, the Cap Price
multiplied by the number of Equity Shares Bid for by such Retail Individual Bidder and mentioned in
the Bid cum Application Form and payable by the Bidder or blocked in the ASBA Account of the
Bidder, as the case may be, upon submission of the Bid.

Eligible Employees applied in the Employee Reservation Portion applied at the Cut off Price and the
Bid Amount shall be Cap Price net of Employee Discount, multiplied by the number of Equity Shares
Bid for by such Eligible Employee and mentioned in the Bid cum Application Form. The maximum Bid
Amount under the Employee Reservation Portion by an Eligible Employee did not exceed $500,000
(net of Employee Discount). However, the initial Allotment to an Eligible Employee in the Employee
Reservation Portion did not exceed %200,000 (net of Employee Discount) in value.

 

Bid cum Application Form

Anchor Investor Application Form or the ASBA Form, as the context requires

 

Bid Lot

28 Equity Shares and in multiples of 28 Equity Shares thereafter

 

Bid/ Offer Closing Date

Except in relation to any Bids received from the Anchor Investors, September 3, 2021

 

Bid/ Offer Opening Date

Except in relation to any Bids received from the Anchor Investors, September 1, 2021

 

Bid/ Offer Period

Except in relation to Anchor Investors, the period between September 1, 2021 and September 3, 2021,
inclusive of both days

 

Bidder

Any investor who made a Bid pursuant to the terms of the Red Herring Prospectus and the Bid cum
Application Form and unless otherwise stated or implied, includes an Anchor Investor

 

Bidding Centres

Centres at which the Designated Intermediaries accepted the ASBA Forms, ie., Designated SCSB
Branches for SCSBs, Specified Locations for the Syndicate, Broker Centres for Registered Brokers,
Designated RTA Locations for RTAs and Designated CDP Locations for CDPs

 

Book Building Process

Book building process, as provided in Schedule XIII of the SEBI ICDR Regulations, in terms of which
the Offer is being made

 

Book Running Lead Managers or
BRLMs

The book running lead managers to the Offer, namely, I-Sec, Edelweiss and Kotak

 

Broker Centres

Centres notified by the Stock Exchanges where ASBA Bidders could have submitted the ASBA Forms
to a Registered Broker

The details of such Broker Centres, along with the names and contact details of the Registered Brokers
are available on the respective websites of the Stock Exchanges (www.bseindia.com and
www.nseindia.com)

 

 

CAN or Confirmation of | Notice or intimation of allocation of the Equity Shares sent to Anchor Investors, who have been
Allocation Note allocated the Equity Shares, on or after the Anchor Investor Bid/ Offer Period
Cap Price 2531 per Equity Share

 

 

Cash Escrow and Sponsor Bank
Agreement

 

Agreement dated August 19, 2021 entered into amongst our Company, the Selling Shareholders, the
Registrar to the Offer, the BRLMs, the Syndicate Member, the Sponsor Bank, the Escrow Collection
Bank, the Public Offer Bank and the Refund Bank in respect of collection of the Bid Amounts and

 

 
 

Description

 

where applicable, remitting refunds (if any) on the terms and conditions thereof and the appointment of
Sponsor Bank in accordance with the UPI Circulars

 

Client ID

Client identification number maintained with one of the Depositories in relation to demat account

 

Collecting Depository Participant
or CDP

A depository participant as defined under the Depositories Act, 1996 registered with SEBI and who is
eligible to procure Bids at the Designated CDP Locations in terms of circular no.
CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI as per the list available
on the websites of the Stock Exchanges

 

Cut-off Price

Offer Price, that is 531 per Equity Share finalised by our Company and the Selling Shareholders in
consultation with the BRLMs

Only Retail Individual Bidders Bidding in the Retail Portion and Eligible Employees under the
Employee Reservation Portion were entitled to Bid at the Cut-off Price. QIBs and Non-Institutional
Bidders were not entitled to Bid at the Cut-off Price

 

Demographic Details

The demographic details of the Bidders including the Bidders’ address, name of the Bidders’
father/husband, investor status, occupation, bank account details and UPI ID, wherever applicable

 

Designated SCSB Branches

Such branches of the SCSBs which collected the ASBA Forms, a list of which is available on the website
of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes or at such other
website as may be prescribed by SEBI from time to time

 

Designated CDP Locations

Such locations of the CDPs where Bidders submitted the ASBA Forms

The details of such Designated CDP Locations, along with names and contact details of the Collecting
Depository Participants eligible to accept ASBA Forms are available on the respective websites of the
Stock Exchanges (www.bseindia.com and www.nseindia.com), as updated from time to time

 

Designated Date

The date on which the Escrow Collection Bank transfers funds from the Escrow Account to the Public
Offer Account or the Refund Account, as the case may be, and the instructions are issued to the SCSBs
(in case of RIBs using UPI Mechanism, instruction issued through the Sponsor Bank) for the transfer
of amounts blocked by the SCSBs in the ASBA Accounts to the Public Offer Account or the Refund
Account, as the case may be, after finalisation of the Basis of Allotment in terms of this Red Herring
Prospectus following which Equity Shares will be Allotted in the Offer

 

Designated Intermediary(ies)

In relation to ASBA Forms submitted by RIBs by authorising an SCSB to block the Bid Amount in the
ASBA Account, Designated Intermediaries shall mean SCSBs

In relation to ASBA Forms submitted by RIBs where the Bid Amount was blocked upon acceptance of
UPI Mandate Request by such RIB using the UPI Mechanism, Designated Intermediaries shall mean
Syndicate, sub-syndicate/agents, Registered Brokers, CDPs and RTAs

In relation to ASBA Forms submitted by QIBs and Non-Institutional Bidders, Designated
Intermediaries shall mean Syndicate, Sub-Syndicate/ agents, SCSBs, Registered Brokers, the CDPs and
RTAs

 

Designated RTA Locations

Such locations of the RTAs where Bidders submitted the ASBA Forms to RTAs. The details of such
Designated RTA Locations, along with names and contact details of the RTAs eligible to accept ASBA
Forms are available on the respective websites of the Stock Exchanges (www.bseindia.com and
www.nseindia.com)

 

Designated Stock Exchange

NSE

 

Draft Red Herring Prospectus or
DRHP.

The draft red herring prospectus dated June 5, 2021 issued in accordance with the SEBI ICDR
Regulations, which did not contain complete particulars of the price at which the Equity Shares will be
Allotted and the size of the Offer

 

Edelweiss

Edelweiss Financial Services Limited

 

Employee Discount

Discount of 10% (equivalent to %52 per Equity Share) to the Offer Price given to Eligible Employees
bidding in the Employee Reservation Portion as decided by our Company and the Selling Shareholders
in consultation with the BRLMs

 

Eligible Employees

Permanent employees, working in India, of our Company or of our Subsidiaries or a Director of our
Company, whether whole-time or not, as on the date of the filing of the Red Herring Prospectus with
the RoC, but not including (i) Promoter; (ii) persons belonging to the Promoter Group; or (iii) Directors
who either themselves or through their relatives or through any body corporate, directly or indirectly,
hold more than 10% of the outstanding Equity Shares of our Company.

The maximum Bid Amount under the Employee Reservation Portion by an Eligible Employee did not
exceed %500,000 (net of Employee Discount). However, the initial Allotment to an Eligible Employee
in the Employee Reservation Portion did not exceed 220,000 (net of Employee Discount)

 

Eligible FPIs

FPIs from such jurisdictions outside India where it is not unlawful to make an offer / invitation under
the Offer and in relation to whom the Bid cum Application Form and the Red Herring Prospectus
constitute an invitation to subscribe to the Equity Shares

 

Eligible NRI(S)

NRI(s) from jurisdictions outside India where it is not unlawful to make an Offer or invitation under the
Offer and in relation to whom the ASBA Form and this Prospectus constituted an invitation to subscribe
to or to purchase the Equity Shares

 

 

Employee Reservation Portion

 

The portion of the Offer being up to 150,000” Equity Shares aggregating to 271.85 million which was
available for allocation to Eligible Employees, on a proportionate basis.

“Subject to finalisation of the Basis of Allotment
‘A discount of 252 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion

 

 
 

Term

Description

 

Escrow Account

Non lien and non-interest bearing accounts to be opened with the Escrow Collection Bank(s) and in
whose favour the Anchor Investors transferred money through NACH/direct credit/NEFT/RTGS in
respect of the Bid Amount when submitting a Bid

 

Escrow Collection Bank

Bank which is a clearing member and registered with SEBI as banker to an offer, under the Securities
and Exchange Board of India (Bankers to an Issue) Regulations, 1994, and with whom the Escrow
Account in relation to the Offer for Bids by Anchor Investors, will be opened, in this case being HDFC
Bank Limited

 

First or sole Bidder

Bidder whose name is mentioned in the Bid cum Application Form or the Revision Form and in case of
joint Bids, whose name also appeared as the first holder of the beneficiary account held in joint names

 

Floor Price

522 per Equity Share

 

General Information Document

The General Information Document for investing in public issues prepared and issued in accordance
with the SEBI circular no. SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020 and the UPI
Circulars, as amended from time to time. The General Information Document shall be available on the
websites of the Stock Exchanges and the BRLMs

 

I-Sec

ICICI Securities Limited

 

Kotak

Kotak Mahindra Capital Company Limited

 

Maximum RIB Allottees

Maximum number of RIBs who can be allotted the minimum Bid Lot. This is computed by dividing the
total number of Equity Shares available for Allotment to RIBs by the minimum Bid Lot, subject to valid
Bids having been received at or above the Offer Price

 

Mutual Fund Portion

5% of the Net QIB Portion, or 355,381 Equity Shares which was made available for allocation to Mutual
Funds only on a proportionate basis, subject to valid Bids having been received at or above the Offer
Price.

 

Net Offer

The Offer less the Employee Reservation Portion

 

Net Proceeds

Proceeds of the Offer less Offer expenses. For further details regarding the use of the Net Proceeds and
the Offer expenses, see “Objects of the Offer” on page 70

 

Net QIB Portion

The QIB Portion less the number of Equity Shares allocated to the Anchor Investors

 

Non-Institutional Bidders

All Bidders that are not QIBs or Retail Individual Bidders or Eligible Employees Bidding in the
Employee Reservation Portion and who have Bid for Equity Shares for an amount of more than
%200,000 (but not including NRIs other than Eligible NRIs)

 

Non-Institutional Portion

Portion of the Net Offer being not less than 15% of the Net Offer consisting of 5,330,710" Equity Shares
which was made available for allocation on a proportionate basis to Non-Institutional Bidders, subject
to valid Bids having been received at or above the Offer Price

“Subject to finalisation of the Basis of Allotment

 

Non-Resident

Person resident outside India, as defined under FEMA and includes NRIs, FVCIs, VCFs, and FPIs

 

Offer

The initial public offer of 35,688,064" Equity Shares of face value of 21 each for cash at a price of 2531
per Equity Shares aggregating to 218,942.56 million through an Offer for Sale by the Selling
Shareholders.

“Subject to finalisation of the Basis of Allotment

 

Offer Agreement

‘Agreement dated June 5, 2021 amongst our Company, the Selling Shareholders and the Book Running
Lead Managers, pursuant to which certain arrangements have been agreed to in relation to the Offer

 

Offer for Sale

The offer for sale of the Offered Shares, at the Offer Price aggregating to 218,942.56 million offered
for sale by the Selling Shareholders in the Offer

 

Offer Price

%531 per Equity Share, being the final price (within the Price Band) at which Equity Shares will be
Allotted to ASBA Bidders in terms of the Red Herring Prospectus and this Prospectus. Equity Shares
will be Allotted to Anchor Investors at the Anchor Investor Offer Price which was be decided by our
Company and the Selling Shareholders in consultation with the BRLMs in terms of the Red Herring
Prospectus and this Prospectus.

The Offer Price was decided by our Company and the Selling Shareholders in consultation with the
BRLMs on the Pricing Date in accordance with the Book-building Process and this Prospectus.

 

Offered Shares

35,688,064" Equity Shares offered for sale, comprising of 5,098,296" Equity Shares by Dr. S.
Surendranath Reddy, 29,487,290" Equity Shares by Karakoram Limited and 1,102,478" Equity Shares
by Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1

“Subject to finalisation of the Basis of Allotment

 

Price Band

Price band of a minimum price of %522 per Equity Share (Floor Price) and the maximum price of 531
per Equity Share (Cap Price)

 

Pricing Date

Date on which our Company and the Selling Shareholders in consultation with the BRLMs, finalised
the Offer Price, being September 6, 2021

 

Prospectus

This Prospectus dated September 6, 2021 to be filed with the RoC on or after the Pricing Date in
accordance with Section 26 of the Companies Act, and the SEBI ICDR Regulations containing, inter
alia, the Offer Price, the size of the Offer and certain other information, including any addenda or
corrigenda hereto

 

Public Offer Account

No lien and non-interest bearing account to be opened with the Public Offer Bank, under Section 40(3)
of the Companies Act to receive monies from the Escrow Account and ASBA Accounts on the
Designated Date

 

Public Offer Bank

A bank which is a clearing member and registered with SEBI as a banker to an offer and with which the
Public Offer Account will be opened, in this case being HDFC Bank Limited

 

 

QIB Portion

 

The portion of the Net Offer (including the Anchor Investor Portion) being not more than 50% of the
Net Offer consisting of 17,769,031" Equity Shares which were made available for allocation to QIBs

 

5

 
 

Description

 

(including Anchor Investors), subject to valid Bids having been received at or above the Offer Price or
Anchor Investor Offer Price (for Anchor Investors)

“Subject to finalisation of the Basis of Allotment

 

Qualified Institutional Buyers or
QIBs or QIB Bidders

Qualified institutional buyers as defined under Regulation 2(1)(ss) of the SEBI ICDR Regulations

 

Red Herring Prospectus or RHP

The Red Herring Prospectus dated August 24, 2021 issued in accordance with Section 32 of the
Companies Act and the provisions of the SEBI ICDR Regulations, which did not have complete
particulars of the Offer Price and the size of the Offer

 

Refund Account(s)

No lien and non-interest bearing account opened with the Refund Bank(s), from which refunds, if any,
of the whole or part of the Bid Amount to the Bidders shall be made

 

Refund Bank

Banker to the Offer and with whom the Refund Account will be opened, in this case being HDFC Bank
Limited

 

Registered Brokers

Stock brokers registered with SEBI and the stock exchanges having nationwide terminals, other than
the members of the Syndicate and eligible to procure Bids in terms of the SEBI circular number
CIR/CFD/14/2012 dated October 4, 2012 issued by SEBI

 

Registrar Agreement

Agreement dated June 4, 2021 amongst our Company, the Selling Shareholders and the Registrar to the
Offer, in relation to the responsibilities and obligations of the Registrar to the Offer pertaining to the
Offer

 

Registrar and Share Transfer
Agents or RTAs

Registrar and share transfer agents registered with SEBI and eligible to procure Bids at the Designated
RTA Locations as per the list available on the websites of the Stock Exchanges, and the UPI Circulars

 

Registrar to the Offer

KFin Technologies Private Limited

 

Retail Individual Bidder(s) or
RIB(s)

Individual Bidders, who have Bid for the Equity Shares for an amount not more than %200,000 in any
of the bidding options in the Offer (including HUEs applying through their karta and Eligible NRIs)

 

Retail Portion

Portion of the Net Offer being not less than 35% of the Net Offer consisting of 12,438,323" Equity
Shares which was made available for allocation to Retail Individual Bidders (subject to valid Bids
having been received at or above the Offer Price)

“Subject to finalisation of the Basis of Allotment

 

Revision Form

Form used by the Bidders to modify the quantity of the Equity Shares or the Bid Amount in any of their
ASBA Form(s) or any previous Revision Form(s)

QIB Bidders and Non-Institutional Bidders are not allowed to withdraw or lower their Bids (in terms of
quantity of Equity Shares or the Bid Amount) at any stage. Retail Individual Bidders and Eligible
Employees Bidding in the Employee Reservation Portion could revise their Bids during the Bid/ Offer
Period and withdraw their Bids until Bid/ Offer Closing Date

 

Self-Certified Syndicate Bank(s)
or SCSB(s)

The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA,
where the Bid Amount will be blocked by authorising an SCSB, a list of which is available on the
website of SEBI at www.sebi.gov.in/sebiweb/other/OtherA ction.do?doRecognisedFpi=yes&intmId=34
and updated from time to time and at such other websites as may be prescribed by SEBI from time to
time, (ii) in relation to RIBs using the UPI Mechanism, a list of which is available on the website of
SEBI at https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=40 or such
other website as updated from time to time

Applications through UPI in the Offer could be made only through the SCSBs mobile applications
(apps) whose name appears on the SEBI website. A list of SCSBs and mobile application, which, are
live for applying in public issues using UPI mechanism is available on the website of SEBI at
https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43. The said
list shall be updated on the SEBI website

 

Share Escrow Agent

Escrow agent to be appointed pursuant to the Share Escrow Agreement, namely, KFin Technologies
Private Limited

 

Share Escrow Agreement

Agreement dated August 19, 2021 entered into amongst our Company, the Selling Shareholders and the
Share Escrow Agent in connection with the transfer of the Offered Shares by the Selling Shareholders
and credit of such Equity Shares to the demat account of the Allottees

 

Specified Locations

Bidding Centres where the Syndicate accepted ASBA Forms from Bidders, a list of which is available
on the website of SEBI (www.sebi.gov.in) and updated from time to time

 

Sponsor Bank

HDFC Bank Limited, being a Banker to the Offer, appointed by our Company to act as a conduit
between the Stock Exchanges and NPCI in order to push the mandate collect requests and / or payment
instructions of the RIBs using the UPI Mechanism and carry out other responsibilities, in terms of the
UPI Circulars

 

Syndicate or Members of the
Syndicate

Together, the BRLMs and the Syndicate Members

 

Syndicate Agreement

‘Agreement dated August 23, 2021 entered into amongst our Company, the Selling Shareholders, the
Syndicate Members and the Registrar to the Offer, in relation to collection of Bids by the Syndicate

 

Syndicate Members

Intermediaries (other than the BRLMs) registered with SEBI who are permitted to accept bids,
applications and place order with respect to the Offer and carry out activities as an underwriter, namely,
Kotak Securities Limited and Edelweiss Securities Limited

 

Underwriters

The BRLMs and the Syndicate Members

 

Underwriting Agreement

Agreement dated September 6, 2021 entered into amongst our Company, the Selling Shareholders and
the Underwriters

 

 

UPI

 

Unified payments interface which is an instant payment mechanism, developed by NPCI

 

 
 

Term

Description

 

UPI Circulars

The SEBI circular no. SEBI/HO/CED/DIL2/CIR/P/2018/138 dated November 1, 2018, SEBI circular
no. SEBI/HO/CED/DIL2/CIR/P/2019/50 dated April 3, 2019, SEBI circular no.
SEBI/HO/CED/DIL2/CIR/P/2019/76 dated June 28, ~=«- 2019, SEBI_—circular_—_no.
SEBI/HO/CED/DIL2/CIR/P/2019/85 dated July 26, +2019, SEBI_—circular_—no.
SEBI/HO/CED/DCR2/CIR/P/2019/133 dated November 8, 2019, SEBI circular no.
SEBI/HO/CED/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no.
SEBI/HO/CED/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no.
SEBI/HO/CED/DIL2/CIR/P/2021/47_ dated March = 31, —«2021,_-« SEBI_—circular_no.
SEBI/HO/CED/DIL2/P/CIR/2021/570 dated June 2, 2021 and any subsequent circulars or notifications
issued by SEBI in this regard

 

UPIID

ID created on the UPI for single-window mobile payment system developed by the NPCI

 

UPI Mandate Request

A request (intimating the RIB by way of a notification on the UPI linked mobile application as disclosed
by SCSBs on the website of SEBI and by way of an SMS on directing the RIB to such UPI linked
mobile application) to the RIB initiated by the Sponsor Bank to authorise blocking of funds on the UPI
application equivalent to Bid Amount and subsequent debit of funds in case of Allotment

 

UPI Mechanism

The bidding mechanism that was used by an RIB submitted with intermediaries with UPI as a mode of
payment in accordance with the UPI Circulars to make an ASBA Bid in the Offer

 

UPI PIN

Password to authenticate a UPI transaction

 

Wilful Defaulter

An entity or person categorised as a wilful defaulter by any bank or financial institution or consortium
thereof, in terms of regulation 2(1)(III) of the SEBI ICDR Regulations

 

Working Day

 

All days on which commercial banks in Mumbai are open for business. In respect of announcement of
Price Band and Bid/ Offer Period, Working Day shall mean all days, excluding Saturdays, Sundays and
public holidays, on which commercial banks in Mumbai are open for business. In respect of the time
period between the Bid/ Offer Closing Date and the listing of the Equity Shares on the Stock Exchanges,
“Working Day” shall mean all trading days of the Stock Exchanges, excluding Sundays and bank
holidays in India, as per circulars issued by SEBI, including the UPI Circulars

 

Technical/ Industry Related Terms/ Abbreviations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Term Description

AMC Annual Maintenance Contracts

ARC The ARCs refer to our hub centres offering pathology tests, basic radiology tests and advanced
radiology tests such as MRI, HRCT, SPECT and PET CT.

Bactec Automated blood culture systems

CBCT ‘Cone-beam Computed Tomography

CHE Current Healthcare Expenditure

CMC Comprehensive Maintenance Contracts

CME Programs Continuing Medical Education Programs

COVID-19 The novel Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered
coronavirus.

CT Scan ‘Computerized Tomography Scan

DALYs Disability-Adjusted Life Years

dd-PCR Droplet Digital-Polymerase Chain Reaction

DEXA Dual-energy X-ray Absorptiometry

DICOM Digital Imaging and Communications in Medicine

ECG Electrocardiogram

ERP. Enterprise Resource Planning

FISH Fluorescent In-situ Hybridisation

HPLC High-Performance Liquid Chromatography

HRCT High-Resolution Computed Tomography

IMA Indian Medical Authority

Iso International Organization for Standardization

LIMS Laboratory Information Management Systems

 

MALDI-TOF-MS

The MALDI-TOF mass spectrometry refers to the matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry (MS) ionization technique, with the mass spectrometer as the time-of-flight (TOF)
analyser.

 

 

 

 

 

 

 

 

 

 

 

 

 

MGIT Mycobacterium Tuberculosis

MRI Magnetic Resonance Imaging

NABL National Accreditation Board for Testing and Calibration Laboratories
NABH National Accreditation Board for Hospitals & Healthcare Providers
NCD. Non-communicable Disease

NSDP. Net State Domestic Product

OOPE Out-of-Pocket Expenditure

PACS Picture Archive and Communication Systems

PET-CT Scan Positron Emission Tomography Computerized Tomography Scan
Phlebotomist A phlebotomist is a person trained to collect blood for transfusion, analysis or experimental testing
RIS Radiology Information Systems

RT-PCR Reverse Transcription—Polymerase Chain Reaction

SAP Systems Applications and Products

 

 

SPECT Scan

 

Single Photon Emission Computed Tomography Scan

 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Term Description
TAT Turn-around Time
TB Tuberculosis
THE Total Health Expenditure
USG Ultrasonography
WHO World Health Organization
Conventional and General Terms or Abbreviations
Term Description
%, Rs., Rupees or INR Indian Rupees
ACH Automated Clearing House
Adjusted EBITDA EBITDA minus other income
AIFs Alternative Investments Funds, as defined in and registered with SEBI under the Securities and Exchange
Board of India (Alternative Investments Funds) Regulations, 2012
BSE BSE Limited
CAGR Compounded Annual Growth Rate (CAGR) is a business and investing specific term for the geometric
progression ratio that provides a constant rate of return over the time period calculated as (end value /
start value) A (1 / years )- 1
CSR Corporate Social Responsibility

 

Calendar Year

‘A calendar year is a one-year period that begins on January 1 and ends on December 31, based on the
commonly-used Gregorian calendar

 

Category I AIF

AIFs who are registered as “Category I Alternative Investment Funds” under the SEBI AIF Regulations

 

Category I FPIs

  

FPIs who are registered as “Category I Foreign Portfolio Investors” under the SEBI FPI Regulations

 

Category II AIF

AIFs who are registered as “Category II Alternative Investment Funds” under the SEBI AIF Regulations

 

Category II FPIs

 

FPIs who are registered as “Category II Foreign Portfolio Investors” under the SEBI FPI Regulations

 

 

Category IIT AIF

AIFs who are registered as “Category III Alternative Investment Funds” under the SEBI AIF Regulations

 

 

 

 

Copyright Act The Copyright Act, 1957

CDSL Central Depository Services (India) Limited
CIN Corporate Identity Number

Civil Code The Code of Civil Procedure, 1908

 

Companies Act

Companies Act, 2013, along with the relevant rules, clarifications and modifications made thereunder

 

Companies Act, 1956

Companies Act, 1956, along with the relevant rules made thereunder

 

Companies Act, 2013

Companies Act, 2013, along with the relevant rules made thereunder

 

 

 

 

 

Depositories NSDL and CDSL

Depositories Act The Depositories Act, 1996

DIN Director Identification Number

DPUT Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry,
Government of India (earlier known as the Department of Industrial Policy and Promotion)

DPID Depository Participant Identification

 

DP/ Depository Participant

Depository participant as defined under the Depositories Act

 

EBITDA

Earnings before interest, taxes, depreciation and amortisation

 

 

 

 

 

 

 

 

EGM Extraordinary General Meeting

EPFMP Act Employees’ Provident Funds and Miscellaneous Provisions Act, 1952

ESI Act Employees State Insurance Act, 1948

EPS Earnings Per Share

FCNR Foreign Currency Non-Resident

FDI Foreign direct investment

FDI Policy Consolidated Foreign Direct Investment Policy notified by the DPIIT through notification dated October
28, 2020 effective from October 15, 2020, issued by the DPIIT

FEMA Foreign Exchange Management Act, 1999, read with rules and regulations thereunder

 

FEMA Non-Debt Instruments
Rules

Foreign Exchange Management (Non-debt Instruments) Rules, 2019 issued by the Ministry of Finance,
Gol

 

FIR,

First Information Report

 

“Financial Year” or “Fiscal”
“EY”

Unless stated otherwise, the period of 12 months ending March 31 of that particular year

 

 

 

 

FPI(s) Foreign portfolio investors as defined under the SEBI FPI Regulations

FVCK(s) Foreign venture capital investors as defined and registered under the SEBI FVCI Regulations
GAAR General Anti Avoidance Rules

Gazette Gazette of India

 

Gol or Government or Central
Government

Government of India

 

 

 

 

 

GST Goods and Services Tax

HUF Hindu Undivided Family(ies)

ICAL The Institute of Chartered Accountants of India
IFRS International Financial Reporting Standards
IFSC Indian Financial System Code

 

Ind AS or Indian Accounting
Standards

Indian Accounting Standards referred to in the Companies Act and notified under Section 133 of the
Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended

 

India

Republic of India

 

 

IPO.

 

Initial public offering

 

 
 

Term

Description

 

 

 

 

 

IRDAL Insurance Regulatory and Development Authority of India
IsT Indian Standard Time

IT Information Technology

IT Act The Income Tax Act, 1961

ITGC Information technology general control

 

Listing Regulations

Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015

 

 

 

 

 

 

 

 

 

MCA Ministry of Corporate Affairs, Government of India
MoSPI Ministry of Statistics and Implementation, Government of India

MSME Micro, small or medium enterprise

Mutual Fund(s) Mutual Fund(s) means mutual funds registered under the SEBI (Mutual Funds) Regulations, 1996
N/A Not applicable

NACH National Automated Clearing House

NAV Net Asset Value

NBEC Non-banking financial company

NEFT National Electronic Funds Transfer

 

National Investment Fund

National Investment Fund set up by resolution F. No. 2/3/2005-DD-II dated November 23, 2005 of the
Gol, published in the Gazette of India

 

NPCI

National Payments Corporation of India

 

NRI

Person resident outside India, who is a citizen of India or a person of Indian origin, and shall have the
meaning ascribed to such term in the Foreign Exchange Management (Deposit) Regulations, 2016 or an
overseas citizen of India cardholder within the meaning of section 7(A) of the Citizenship Act, 1955.

 

NRE Account

Non-resident rupee account

 

 

 

NRO Account Non-resident ordinary account
NSDL National Securities Depository Limited
NSE National Stock Exchange of India Limited

 

OCB/Overseas Corporate Body

A company, partnership, society or other corporate body owned directly or indirectly to the extent of at
least 60% by NRIs including overseas trusts, in which not less than 60% of beneficial interest is
irrevocably held by NRIs directly or indirectly and which was in existence on the date of commencement
of the Foreign Exchange Management (Withdrawal of General Permission to Overseas Corporate Bodies
(OCBs) Regulations, 2003 i.e October 3, 2003 and immediately before such date had taken benefits
under the general permission granted to OCBs under FEMA. OCBs are not allowed to invest in the Offer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPBDIT. Operating Profit Before Depreciation, Interests and Taxes
OsP Other Service Provider

p.a. Per annum

P/E Price/earnings

P/E Ratio Price/earnings ratio

PAN Permanent account number

PAT Profit after tax

PPP Public-Private Partnership

RBI The Reserve Bank of India

RBI Act The Reserve Bank of India Act, 1934

RoNW Return on Net Worth

RTA Registrars to an Issue and Share Transfer Agents
Regulation S Regulation S under the U.S. Securities Act

RTGS Real Time Gross Settlement

Rule 144A Rule 144A under the U.S. Securities Act

SCRA Securities Contracts (Regulation) Act, 1956

SCRR Securities Contracts (Regulation) Rules, 1957

SEBI Securities and Exchange Board of India constituted under the SEBI Act
SEBI Act Securities and Exchange Board of India Act, 1992

 

SEBI AIF Regulations

Securities and Exchange Board of India (Alternative Investments Funds) Regulations, 2012

 

SEBI FPI Regulations

Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019

 

SEBI FVCI Regulations

SEBI (Foreign Venture Capital Investors) Regulations 2000

 

SEBI ICDR Regulations

Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations,
2018

 

SEBI Intermediaries Regulations

Securities and Exchange Board of India (Intermediaries) Regulations, 2008

 

SEBI Merchant Banker
Regulations

SEBI (Merchant Bankers) Regulations, 1992

 

SEBI SBEB Regulations

Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations,
2021

 

SEBI VCF Regulations

The erstwhile Securities and Exchange Board of India (Venture Capital Fund) Regulations, 1996 as
repealed pursuant to the SEBI AIF Regulations

 

State Government

The government of a state in India

 

Stock Exchanges

BSE and NSE

 

sTT

Securities transaction tax

 

Systemically Important Non-
Banking Financial Company

Systemically important non-banking financial company as defined under Regulation 2(1)(iii) of the SEBI
ICDR Regulations

 

 

Takeover Regulations

 

Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations,
2011

 

 
 

 

 

 

 

 

 

 

 

Term Description
TAN Tax deduction account number

Trade Mark Act Trade Mark Act, 1999

U.S. GAAP Generally Accepted Accounting Principles in the United States
U.S. Securities Act U.S. Securities Act of 1933, as amended

U.S., USA or United States United States of America

USD or USS or $ United States Dollars, the official currency of the United States

 

VCFs

Venture Capital Funds as defined in and registered with SEBI under the SEBI VCF Regulations

 

Wilful Defaulter

 

An entity or person categorised as a wilful defaulter by any bank or financial institution or consortium
thereof, in terms of regulation 2(1)(III) of the SEBI ICDR Regulations

 
OFFER DOCUMENT SUMMARY

The following is a general summary of the terms of the Offer and is neither exhaustive, nor purports to contain a summary of
all the disclosures in the Draft Red Herring Prospectus, the Red Herring Prospectus or this Prospectus, or all details relevant
to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed
information appearing elsewhere in this Prospectus, including “Risk Factors”, “Objects of the Offer”, “Our Busines
“Industry Overview”, “Capital Structure”, “The Offer”, “Financial Statements”, “Outstanding Litigation and Material
Developments”, “Offer Procedure” and “Description of Equity Shares and Terms of Articles of Association” on pages 21, 70,
111, 80, 56, 41, 162, 245, 272 and 287 respectively.

 

 

Summary of the] We are the largest integrated diagnostic chain in southern India, by revenue, and also one of the fastest-growing
primary business | diagnostic chain by revenue, for fiscal year 2020 (Source: CRISIL Report). We offer an one-stop solution for pathology
of the Company | and radiology testing services to customers through our extensive operational network, which consists of 81 diagnostic
centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh, and
the National Capital Region and Kolkata.

Summary of the| The Indian diagnostics market was valued at approximately 2710 billion to 730 billion in FY 2021, and is projected
Industry to reach approximately 920 billion to %980 billion by FY 2023, driven by rise in health awareness and disposable
incomes, increase in demand for better healthcare facilities and quality of care of individuals, and increase in spending
on preventive and wellness. The diagnostics market in Telangana and Andhra Pradesh, in which we have significant
presence in, is projected to grow to approximately 2120 billion to 2130 billion by FY 2023. (Source: CRISIL Report)

 

 

 

Name of | Dr. S. Surendranath Reddy. For details, see “Our Promoters and Promoter Group” on page 155
Promoter
Offer size Offer for Sale of 35,688,064" Equity Shares for cash at a price of %531° per Equity Share aggregating to 218,942.56

million, comprising of 5,098,296" Equity Shares aggregating to 22,706.08 million by Dr. S. Surendranath Reddy,
29,487,290" Equity Shares aggregating to 15,651.30 million by Karakoram Limited and 1,102,478" Equity Shares
aggregating to 585.18 million by Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1. The Offer
shall constitute up to 35.00% of the post-Offer paid-up Equity Share capital of our Company.

*Subject to finalisation of the Basis of Allotment

‘A discount of %52 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion

Objects of the| The objects of the Offer are to (i) to carry out the Offer for Sale of 35,688,064" Equity Shares by the Selling
Offer Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. For further details, see
“Objects of the Offer” on page 70.

“Subject to finalisation of the Basis of Allotment

‘Aggregate pre-|(a) The aggregate pre-Offer shareholding of our Promoter and Promoter Group as a percentage of the pre-Offer paid-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Offer up Equity Share capital of the Company is set out below:

shareholding of

our Promoter and Name ‘No. of Equity Shares Percentage of the pre-Offer Equity

Promoter Group, Share Capital (%)

and Selling Promoter

Shareholders as a Dr. S. Surendranath Reddy 38,521,195 37.78

percentage of our Total (A) 38,521,195 37.78

paid-up Equity Promoter Group

Share capital Sura Suprita Reddy 9,176,933 9.00
Sunil Chandra Kondapally 9,106,933 8.93
S. Geeta Reddy 4,058,638 3.98
B. Vishnu Priya 27,922 0.03
Birudavolu Gautam 10,000 0.01
PV Sanjay Kumar 10,000 0.01
P Madhulika Reddy 10,000 0.01
‘Manjula Kankanthi 10,000 0.01
Birudavolu Jalaja 5,000 0.00
Birudavolu Dayakar Reddy 5,000 0.00
Nanda Birudavolu Kumar 5,000 0.00
Charita Birudavolu Redd 5,000 0.00
Total (B) 22,430,426 22.00
Total (C=A+B) 60,951,621 59.78

 

 

 

 

 

(b) The aggregate pre-Offer and post-Offer shareholding of the Selling Shareholders and as a percentage of the pre-Offer paid-
up Equity Share capital and post-Offer paid-up Equity Share capital of the Company is set out below:

 

 

 

 

 

 

Name No. of Equity | Percentage of the pre- | No. of Equity Shares | Percentage of the post
Shares(pre- | Offer Equity Share | (post completion of the} Offer Equity Share
Offer) Capital (%) Offer) Capital (%)

Karakoram Limited 39,316,387 38.56 9,829,097] 9.64]
Dr. 5. Surendranath 38,521,195 37.78 33,422,899] 32.78|
Reddy

Kedaara Capital 1,469,970 144 367,492] 0.36]
Altemative Investment

Fund - Kedaara Capital

AIF 1

Total 79,307,552 77.78 43,619,488| 42.78]

 

 

 

 

 

 

 

 

 

 
 

Summary of
Selected Financial
Information

(a) The details of our share capital, net worth, net asset value per Equity Share and Total Borrowings as at three
month periods ended June 30, 2021 and June 30, 2020 and Fiscals ended March 31, 2021, 2020 and 2019 derived
from the Restated Financial Information are as follows:

(@ in million, except per share data)

 

 

 

 

 

 

 

Particulars As at,

June 30, 2021 June 30, 2020 | March 31, 2021 | March 31, 2020 | March 31, 2019

(A)__Equity share capital 101.97 45.32 45.32 45.32 45.29

(B) Net worth! 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10

(C) Net asset value per 38.53, 27.05 35.23 26.89 20.32
share?

(D) Total Borrowings 11.92 306.56 44.72 328.40 424.26

 

 

 

 

 

 

 

!"Net worth” means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities
premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated
losses, deferred expenditure and miscellaneous expenditure not written off, derived from the Restated Financial Information,
but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

 

(Zin million, except per share data)

 

 

 

 

 

 

 

 

 

 

Particulars As at,
June 30, | June30, | March3i, | March3i, | March 31,
2021 2020 2021 2020 2019

Equity share capital (A) 101.97 45.32 45.32 45.32 45.29
Instruments entirely equity in nature (B) : - - - 24.13
Other equity (C) 3,821.29 | 2,718.93 | 3,544.74 2,700.11 2,004.40
Equity attributable to owners of the 3,923.26 | 2,764.25 | 3,590.06 2,745.43, 2,073.82
Company (D) = (A)+(B)+(C)
Non-controlling interest (E) 5.82 (6.97) 2.26 (4.04) (3.72)
Net Worth (F) = (D)+(E) 3,929.08 | 2,758.28 | 3,592.32 2,741.39 2,070.10

 

 

 

 

 

 

Net assets value per share (in ®): Net asset value per share is calculated by dividing net worth by number of equity shares
outstanding at the end of the year
(@ in million, except per share data)

 

 

 

 

 

 

 

 

Particulars As at,
June 30, Tune 30, March 31, ‘March 31, | March 31,
2021 2020 2021 2020 2019
Net Worth (A) 3,929.08 2,758.28, 3,592.32, 2,741.39 2,070.10
Nos of equity shares outstanding* (B) | 101,965,926 | 101,965,926 | 101,965,926 | _101,965,926 | 101,898,292
‘Net asset value per share (C) 38.53 27.05 35.23 26.89 20.32

 

 

 

 

 

*Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021,
sub-divided the equity shares of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March
31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share
has been issued in the ratio of 5 equity shares for every 4 equity shares. Net asset value per share is considered post sub-
division and bonus issue

‘b) The details of our total income, profit after tax and earnings per Equity Share (basic and diluted) for three month
Pp gs per Equity
period ended June 30, 2021 and June 30, 2020 and Fiscals 2021, 2020 and 2019 derived from Restated Financial
Information are as follows:

(Zin million, except per share data)

 

 

 

 

 

 

 

Particulars For the financial period/ year ended
June 30, 2021 June 30, 2020 March 31, 2021 | March 31, 2020 | March 31, 2019
Total income 1,259.70 539,92 3,885.93, 3,541.82 3,029.44
Profit/ (loss) for the period / 333.25, 18.10 849.11 625.07 462.72
year
Earnings per share*
: Basic 3.23 0.19 8.26 6.13 4.50
Diluted 3.23 0.19 8.26 6.13 4.50

 

 

 

 

 

 

 

 

*Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021,
sub-divided the equity shares of face value of 210 each to Equity Shares of face value of @1 each. Further subsequent to March
31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share
has been issued in the ratio of 5 equity shares for every 4 equity shares. Basic and diluted EPS are considered post sub-division
and bonus issue

The earnings per share for the three month periods ended June 30, 2021 and June 30, 2020 are not annualized

 

‘Auditor's
qualifications

which have not
been given effect
to in the Restated

There are no auditor qualifications which have not been given effect to in the Restated Financial Information.

 

 

Financial

Information

Summary table of | A summary of outstanding litigation proceedings involving our Company, Promoter, Directors and Subsidiaries as
outstanding disclosed in “Outstanding Litigation and Material Developments” on page 245, in terms of the SEBI ICDR Regulations
litigations and the materiality policy approved by our Board pursuant to a resolution dated May 27, 2021, as of the date of this

 

Prospectus is provided below :

(@ in million, unless otherwise specified)

 

 

 

 

 

 

 

 

Nature of cases No. of cases ‘Total amount involved"
Litigation involving our Company
‘Against our Company
Material civil litigation proceedings 1 9.90

 

12
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Criminal cases 2 Not quantifiable
‘Action taken by statutory and regulatory authorities Nil Nil
Taxation cases 4.03
By our Company
Civil cases Nil Nil
‘Criminal cases 1 0.50
Litigation involving our Subsidiaries
‘Against our Subsidiaries
Civil cases 2 26.72
(Criminal cases i Not quantifiable
‘Action taken by statutory and regulatory authorities 1 Not quantifiable
Taxation cases Nil Nil
By our Subsidiaries
Civil cases 1 0.50
‘Criminal cases Nil Nil
Litigation involving our Directors
Against our Directors
Civil cases 1 26.72
(Criminal cases Nil Nil
‘Action taken by statutory and regulatory authorities Nil Nil
Taxation cases Nil Nil
By our Directors
Civil cases Nil Nil
‘Criminal cases Nil Nil
Litigation involving our Promoter
‘Against our Promoter
Civil cases Nil Nil
(Criminal cases Nil Nil
‘Action taken by statutory and regulatory authorities Nil Nil
Disciplinary actions including penalties imposed by SEBI or the Nil Nil
Stock Exchanges in the last five financial years including any
outstanding action
Taxation cases Nil Nil
By our Promoter
Civil cases Nil Nil
(Criminal cases Nil Nil

 

 

 

 

 

Risk Factors

For details of the risks applicable to us, see “Risk Factors” on page 21. Investors are advised to read the risk factors
carefully before taking an investment decision in the Offer.

 

Summary table of

The following is a summary table of our contingent liabilities as at June 30, 2021 as per Ind AS 37 — Provisions,

 

 

 

 

 

 

 

 

contingent Contingent Liabilities and Contingent Assets:
liabilities
(Zin million)
Particulars As at June 30, 2021
Demand for Provident Fund for the year 1998-2001 0.56.
* Provident fund matter relates to the years 1998-2001 towards interest and provident fund
For further details of our contingent liabilities as per Ind AS 37 — Provisions, Contingent Liabilities and Contingent
Assets, see “Financial Statements — Annexure VII — Note 38” on page 204
Summary of | The details of related party transactions of our Company for the three month periods ended June 30, 2021 and June 30,
related party | 2020 and Fiscals ended March 31, 2021, 2020 and 2019, as per Ind AS 24 — Related Party Disclosures as per Restated
transactions Financial Information are set forth in the table below:

 

 

 

 

Description of relationship Name of the related parties

Persons exercising control __| Dr. S Surendranath Reddy (Executive Chairman) (also a KMP)

Key management personnel | Dr. S Surendranath Reddy (Executive Chairman)

(KMP) S Suprita Reddy (Chief Executive Officer), Retired as Managing Director w.e.f October 31,

2019 and appointed as CEO w.e.f November 01, 2019.

K Sunil Chandra (Executive Director)

S Geetha Reddy (Additional Director w.e.f November 21, 2019)

Nishant Sharma (Nominee Director)

Y K Priyadarshini (Company Secretary upto July 17, 2018)

Vijay Gupta (Company Secretary w.e.f October 15, 2018 upto June 03, 2019)
V Sri Lakshmi (Company Secretary w.e.f July 18, 2019)

Sandhya Rani.S (Chief Financial Officer upto April 18, 2021)

Narasimha Raju.K.A (Chief Financial Officer w.e.f May 1, 2021)
Subsidiaries Medinova Diagnostic Services Limited

 

 

 

 

 

 

13,

 
 

Doctors Lab Medical Services Private Limited
VDC Diagnostics (Kamataka) LLP

 

Step down subsidiaries ‘Namrata Diagnostic Centre Private Limited
Medinova Millennium MRI Services LLP

 

Enterprise where KMP has | Vijaya Hospitals Private Limited
Significance Influence Summit Nutracueticals Private Limited
Kshetra Agritech Private Limited
Trikona Pharmaceuticals Private Limited
Trikona Holdings LLP

Vijaya Holdings India LLP

Vaishnavi Diagnostic Private Limited

S Square Properties LLP

Park Health Systems Private Limited
IFFCO Kisan Sez Limited

 

Relative of KMP B Vishnu Priya (Wife of K Sunil Chandra)

C Damodar Reddy (Husband of S Suprita Reddy)
C Rhea Reddy (Daughter of S Suprita Reddy)

C Arjun Reddy (Son of S Suprita Reddy)

S Suhas Reddy (Son of K Sunil Chandra)

S Sushmita Reddy (Daughter of K Sunil Chandra)

 

Independent Directors Dr. D. Nageshwar Reddy

SP Singh

Satyanarayana Murthy Chavali
PS Narasimha

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Controlled Trust Vijaya Diagnostic Charitable Trust
For the financial period/ year ended
June 30,2021 ] June 30,2020 ] March31, | March31, | March 31,
2021 2020 2019
Details of transactions during the year (all amounts are in ® million)
Rent paid
Dr. S Surendranath Reddy 10.53 5.85 36.27 38.36 34.66
K Sunil Chandra 2.61 1.16 7.22 7.61
S Suprita Reddy 1.75 0.65 4.08 4.33
S Geetha Reddy 9.21 3.69 22.78 24.16 20.44
B Vishnu Priya 0.04 0.02 0.15 0.16 0.14
Vijaya Hospitals Private Limited 2.50 1.46 8.95 9.78 9.26
Rental deposits given, net
Dr. S Surendranath Redd) 0 0 0 151 5.02
S Suprita Reddy 1.26 0 0.82 0.35 0.17,
K Sunil Chandra 0 0 0.82 0 0.28
S Geetha Reddy 1.26 0 4.24 0 3
Purchase of consumables
Park Health Systems Private Limited 0 0 0.10 0 0
Sale of services
Park Health Systems Private Limited 1.79 1.09 654 554 16.53
Loans Repaid
Dr. S Surendranath Redd) 28.50 0 0 0 0
K Sunil Chandra 4.25, 0 0 0 0
Interest expense
Dr. S Surendranath Reddy 0.35, 057 2.28 2.28 2.28
K Sunil Chandra 0.05, 0.09 0.34 0.34 0.34
Remuneration to KMP and their relatives
Dr. S Surendranath Reddy 467 3.00 16.50 18.00 18,00
K Sunil Chandra 1.83 1.00 5.50 6.00 6.00
S Suprita Reddy 4.79 2.50 13.75 15.00 12.00
Salaries to KMP
Y K Priyadarshini 0 0 0 0
Vijay Gupta 0 0 0 0.13
V Sri Lakshmi 0.25 0.18 0.85 0.62
Sandhya Rani.S 414 1.49 8.65 9.08
KA Narasimha Raju 0.86 0 0 0 0
Independent directors sitting fee
Dr. D. Nageshwar Redd 0.30 0 0 0 0
SP Singh 0.30 0 0 0 0
Satyanarayana Murthy Chavali 0.30 0 0 0 0
P'S Narasimha 0.30 0 0 0 0
For the financial period/ year ended
June 30, ] June30, | March3i, | March31, | March
2021 2020 2021 2020 31, 2019
Amounts due (to)/ from related parties (all amounts are in @ million)
Rent payable
Dr. S Surendranath Redd 3.21 0 2.25 2.74
S Suprita Reddy 0.53 0 0.25 0.33
K Sunil Chandra 0.80 0 0.40 0.51
Vijaya Hospitals Private Limited 0.76 0 0.57 0.76
S Geetha Reddy 2.81 0 1.42 1.83
B Vishnu Priya 0.01 0 0.01 0
Rental deposits*

 

 

14

 

 

 

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vijaya Hospitals Pvt. Lid. 3.49 3.50 3.49 3.49 3.49
Dr. $ Surendranath Reddy 114i 141 114i 141 99)
S Suprita Reddy 3.82 1.74 2.56 173 1.39
K Sunil Chandra 3.30 2.48 3.30 2.48 2.48
S Geetha Reddy 13.02, 7.53 11.76 7.18 7.19
B Vishnu Priya 0.07 0.07 0.07 0.07 0.07
Trade receivables

Park Health Systems Private Limited 0.60 17 0.66 1.02 O91
Loans outstanding

Dr. $ Surendranath Reddy 0 28.50 28.50 28.50 28.50
K Sunil Chandra 0 4.25 4.25 4.25 4.25
Interest payable

Dr. $ Surendranath Reddy 0 11.64 13.18 11.07, 9.02
K Sunil Chandra 0 116 1.39 1.07 0.77
‘Remuneration payable to KMP

Dr. S Surendranath Reddy 1.09) 0.49 0 0.98 1.20
K Sunil Chandra 0.57 0.17 0 0.35 0.49
S Suprita Reddy Lal 0.45 0 0.81 0.88
Salaries payable to KMP.

Sri Lakshmi. V 0.09 0:38 0 0.07 0
Vijay Gupta 0 0 0 0 0.06
KA Narasimha Raju 0:38 0 0 0 0
Sandhya Rani.S 0.35 0.05 0 1.48 1.10
Independent directors sitting fee/commission payable

Dr.D.Nageshwar Reddy 0.29 0 0 0 0
SP Singh 0.29 0 0 0 0
Satyanarayana Murthy Chavali 0.29 0 0 0 0
P'S Narasimha 0.29 0 0 0 0

 

 

 

 

 

 

 

For deta

see “Financial Statement — Annexure VII — Note 45” on page 208

 

Details of all
financing
arrangements
whereby the
Promoter,
members of the
Promoter Group,
our Directors and
their relatives
have financed the
purchase by any
other person of
securities of the
Company other
than in the
normal course of
the business of the
financing entity
during the period
of six months
immediately
preceding the
date of the Red

Our Promoter, members of our Promoter Group, our Directors and their relatives have not financed the purchase by
any person of securities of our Company other than in the normal course of the business of the financing entity during
the period of six months immediately preceding the date of the Red Herring Prospectus and this Prospectus.

 

 

Herring

Prospectus and

this Prospectus

Weighted average Category of Shareholder ‘Number of Equity Shares] Weighted average price of acquisition

price at which the acquired** per Equity Share ()"

specified Promoter

securities were ||_Dr. S. Surendranath Reddy* 21,510,635, Nil

acquired by our|| Selling Shareholders

Promoter and Karakoram Limited 21,842,437 Nil
Kedaara Capital Alternative Investment Fund 816,650 Nil

Selling
Shareholders, in
the last one year

 

 

 

 

 

 

Kedaara Capital AIF 1

 

 

“Also a Selling Shareholder
“Acquired through bonus issue

 

 

Average cost of
acquisition of
shares of our
Promoter and the
Selling
Shareholders

 

*As certified by M. Anandam & Co, Chartered Accountants, in their certificate dated August 24, 2021

 

 

 

 

 

Kedaara Capital AIF 1

 

Name Number of Equity Shares | Average cost of acquisition per Equity
acquired Share (2)"
Promoter
Dr. S. Surendranath Reddy* 38,521,195 0.34
Selling Shareholders
Ki oram Limited 39,316,387
Kedaara Capital Alternative Investment Fund 1,469,970

 

 

 

 

* As certified by M. Anandam & Co, Chartered Accountants, in their certificate dated August 24, 2021

 

15,

 
 

“Also a Selling Shareholder

 

Size of the pre-
IPO placement
and _allottees,
upon completion
of the placement

Not applicable.

 

 

Any issuance of
Equity Shares in
the last one year
for consideration

Our Company has not issued any Equity Shares in the last one year from the date of this Prospectus, for consideration
other than cash.

 

other than cash

‘Any Pursuant to the Board resolution dated March 22, 2021 and the Shareholders’ resolution dated March 22, 2021, the
split/consolidatio | equity shares of face value 210 were subdivided into Equity Shares of face value 21.

n of Equity Shares

in the last one
year

 

 

16

 
CERTAIN CONVENTIONS, PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA AND
CURRENCY OF PRESENTATION

Certain Conventions

All references to “India” in this Prospectus are to the Republic of India, All references to the “Government”, “Indian
Government”, “Gol”, “Central Government” or the “State Government” are to the Government of India, central or state, as
applicable. All references to “USA”, “US” and “United States” are to the United States of America

Unless stated otherwise, all references to page numbers in this Prospectus are to the page numbers of this Prospectus.
Financial Data

Unless stated otherwise or the context otherwise requires, the financial data in this Prospectus is derived from the Restated
Financial Information. For further information, see “Financial Statements” on page 162. The Restated Financial Information of
our Company and Subsidiaries, as at the three month periods ended June 30, 2021 and June 30, 2020 and as at March 31, 2021,
March 31, 2020 and March 31, 2019 together with its notes, annexures and schedules derived from respective audited financial
statements, prepared in accordance with the applicable provisions of the Companies Act, Ind AS and restated in accordance
with the Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by ICAI and the SEBI ICDR Regulations.
Certain other additional financial information pertaining to our Group Companies are derived from their respective audited
financial statements.

Our Company’s Financial Year commences on April 1 and ends on March 31 of the next year. Accordingly, all references to a
particular Financial Year, unless stated otherwise, are to the 12 month period ended on March 31 of that year. Unless the context
otherwise requires, all references to a year in this Prospectus are to a calendar year.

There are significant differences between Ind AS and U.S. GAAP and IFRS. Our Company does not provide reconciliation of
its financial information to IFRS or U.S. GAAP. Our Company has not attempted to explain those differences or quantify their
impact on the financial data included in this Prospectus and it is urged that you consult your own advisors regarding such
differences and their impact on our Company’s financial data. Accordingly, the degree to which the financial information
included in this Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with
Indian accounting principles, policies and practices, the Companies Act and the SEBI ICDR Regulations. Any reliance by
persons not familiar with Indian accounting principles, policies and practices on the financial disclosures presented in this
Prospectus should accordingly be limited.

Unless the context otherwise indicates, any percentage amounts, as set forth in “Risk Factors”, “Our Business” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 21, 111 and 226
respectively, and elsewhere in this Prospectus have been calculated on the basis of the Restated Financial Information.

In this Prospectus, any discrepancies in any table between the total and the sums of the amounts listed are due to rounding off.
Except as otherwise stated, all figures in decimals have been rounded off to the second decimal and all the percentage figures
have been rounded off to two decimal places.

Currency and Units of Presentation

All references to:

. “Rupees” or “2” or “INR” or “Rs.” are to the Indian Rupee, the official currency of India; and

. “USD” or “USS” or “S”are to the United States Dollar, the official currency of the United States;

Our Company has presented all numerical information in this Prospectus in “million” units or in whole numbers where the
numbers have been too small to represent in millions. One million represents 1,000,000.

Figures sourced from third-party industry sources may be expressed in denominations other than millions or may be rounded
off to other than two decimal points in the respective sources, and such figures have been expressed in this Prospectus in such
denominations or rounded-off to such number of decimal points as provided in such respective sources.

Exchange Rates

This Prospectus contains conversion of certain other currency amounts into Indian Rupees that have been presented solely to
comply with the SEBI ICDR Regulations. These conversions should not be construed as a representation that these currency

amounts could have been, or can be converted into Indian Rupees, at any particular rate or at all.

The following table sets forth, for the periods indicated, information with respect to the exchange rate between the Rupee and
the respective foreign currencies:

17
 

Currency As at
Tune 30, 20219 June 30, 2020 March 31,2021 | March 31, 2020 | _ March 31, 2019
1USD 74.35 75.53 73.50 75.39 69.17

Source: www.rbi.org.in and www. bil.org.in
© If the RBI reference rate is not available on a particular date due to a public holiday, exchange rates of the previous working day have been disclosed

 

 

 

 

 

 

 

 

 

 

Non-Generally Accepted Accounting Principles Financial Measures

Certain non-generally accepted accounting principle (“Non-GAAP”) measures such as, Adjusted EBITDA, EBITDA, Net
Worth, Net asset value per equity share, Return on net worth, net tangible assets and Average operating profit (“Non-GAAP
Measures”) presented in this Prospectus are a supplemental measure of our performance and liquidity that are not required by,
or presented in accordance with, Ind AS or IFRS. Further, these Non-GAAP Measures are not a measurement of our financial
performance or liquidity under Ind AS or IFRS and should not be considered in isolation or construed as an alternative to cash
flows, profit/ (loss) for the year/ period or any other measure of financial performance or as an indicator of our operating
performance, liquidity, profitability or cash flows generated by operating, investing or financing activities derived in accordance
with Ind AS or IFRS. In addition, these Non-GAAP Measures are not a standardised term, hence a direct comparison of similarly
titled Non-GAAP Measures between companies may not be possible. Other companies may calculate the Non-GAAP Measures
differently from us, limiting its usefulness as a comparative measure. Although the Non-GAAP Measures are not a measure of
performance calculated in accordance with applicable accounting standards, our Company’s management believes that they are
useful to an investor in evaluating us because they are widely used measures to evaluate a company’s operating performance.

Industry and Market Data

Unless stated otherwise, industry and market data used in this Prospectus has been obtained or derived from publicly available
information as well as industry publication and sources. Industry publications generally state that the information contained in
such publications has been obtained from publicly available documents from various sources believed to be reliable but their
accuracy, completeness and underlying assumptions are not guaranteed and their reliability cannot be assured. The data used
in these sources may have been re-classified by us for the purposes of presentation. Data from these sources may also not be
comparable. Such data involves risks, uncertainties and numerous assumptions and is subject to change based on various factors,
including those discussed in “Risk Factors” on page 21. Accordingly, investment decisions should not be based solely on such
information.

The sections “Offer Document Summary”, “Industry Overview”, “Our Business” and “Management's Discussion and Analysis
of Financial Conditions and Results of Operations” of this Prospectus contain data and statistics from the report titled
“Assessment of the diagnostic industry in India” dated May, 2021, read with the addendum to the report dated August 2021,
prepared by CRISIL Limited, and commissioned and paid by our Company specifically for the purposes of the Offer pursuant
to the engagement confirmed vide email dated March 20, 2021 between our Company and CRISIL, which is subject to the
following disclaimer:

“CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this report (Report)
based on the Information obtained by CRISIL from sources which it considers reliable (Data). However, CRISIL does not
guarantee the accuracy, adequacy or completeness of the Data / Report and is not responsible for any errors or omissions or
for the results obtained from the use of Data / Report. This Report is not a recommendation to invest / disinvest in any entity
covered in the Report and no part of this Report should be construed as an expert advice or investment advice or any form of
investment banking within the meaning of any law or regulation. CRISIL especially states that it has no liability whatsoever to
the subscribers / users / transmitters/ distributors of this Report. Without limiting the generality of the foregoing, nothing in
the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not
have the necessary permission and/or registration to carry out its business activities in this regard. Vijaya Diagnostic Centre
Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Report or part
thereof outside India. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL
Ratings Limited / CRISIL Risk and Infrastructure Solutions Ltd (CRIS), which may, in their regular operations, obtain
information of a confidential nature. The views expressed in this Report are that of CRISIL Research and not of CRISIL Ratings
Limited / CRIS. No part of this Report may be published/reproduced in any form without CRISIL’s prior written approval”.

For risks in this regard, see “Risk Factors - We have commissioned and paid for an industry report from CRISIL Limited
specifically for the purpose of the Offer, which have been used for industry related data in this Prospectus” on page 24.

The extent to which the market and industry data used in this Prospectus is meaningful depends on the reader’s familiarity with
and understanding of the methodologies used in compiling such data. There are no standard data gathering methodologies in
the industry in which the business of our Company is conducted, and methodologies and assumptions may vary widely among
different industry sources.

Accordingly, no investment decision should be made solely on the basis of such information. Such data involves risks,
uncertainties and numerous assumptions and is subject to change based on various factors, including those disclosed in “Risk
Factors” on page 21.

In accordance with the SEBI ICDR Regulations, the section “Basis for Offer Price” on page 72 includes information relating
to our listed industry peer. Such information has been derived from publicly available sources.

18
NOTICE TO PROSPECTIVE INVESTORS IN THE UNITED STATES

The Equity Shares have not been recommended by any U.S. federal or state securities commission or regulatory authority.
Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this Prospectus or
approved or disapproved the Equity Shares. Any representation to the contrary is a criminal offence in the United States. In
making an investment decision, investors must rely on their own examination of our Company and the terms of the Offer,
including the merits and risks involved. The Equity Shares have not been and will not be registered under the U.S. Securities
Act of 1933, as amended or any other applicable law of the United States and, unless so registered, may not be offered or sold
within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements
of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in
the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the
U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act and (b) outside the United States in offshore transactions
as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are
made.

19
FORWARD-LOOKING STATEMENTS

This Prospectus contains certain “forward-looking statements”. All statements contained in this Prospectus that are not
statements of historical fact constitute “forward-looking statements”. All statements regarding our expected financial condition
and results of operations, business, plans and prospects are “forward-looking statements”. These forward-looking statements

generally can be identified by words or phrases such as “aim”, “anticipate”, “believe”, “expect”, “estimate”, “intend”, “likely
to”, “seek to”, “shall”, “objective”, “plan”, “project”, “will”, “will continue”, “will pursue” or other words or phrases of similar
import. Similarly, statements that describe our strategies, objectives, plans or goals are also forward-looking statements. All
forward-looking statements whether made by us in this Prospectus are based on our current plans, estimates, presumptions and
expectations and are subject to corresponding risks, uncertainties and assumptions about us that could cause actual results to
differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, regulatory
changes pertaining to the industries we serve and our ability to respond to them, our ability to successfully implement our
strategy, our growth and expansion, technological changes, our exposure to market risks, general economic and political
conditions which have an impact on our business activities or investments, the monetary and fiscal policies of India, inflation,
deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, the
performance of the financial markets in India and globally, changes in domestic laws, regulations and taxes and changes in
competition. Important factors that could cause actual results to differ materially from our expectations include, but are not
limited to, the following:

« Our inability to maintain and grow our brand name and brand image;
« Adverse effect by global health epidemics, including the recent COVID-19 outbreak, and the continuing effect of the same;
« Any interruptions at our fligship centre and other diagnostic centres;

« Dependence on third parties to provide us our testing equipments and reagents or recall of existing testing equipment and
reagents;

«Failure or malfunction of our equipment; and

« Non-compliance with and changes in any of the applicable laws, rules or regulations, including pricing, safety, health and
environmental laws.

For further discussion of factors that could cause the actual results to differ from the expectations, see “Risk Factors”, “Our
Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on pages 21, 111
and 226, respectively. By their nature, certain market risk disclosures are only estimates and could be materially different from
what actually occurs in the future. As a result, actual future gains or losses could materially differ from those that have been
estimated and are not a guarantee of future performance.

Forward-looking statements reflect our current views as of the date of this Prospectus and are not a guarantee of our future
performance. There can be no assurance to investors that the expectations reflected in these forward-looking statements will
prove to be correct.

These statements are based on our management’s belief and assumptions, which in turn are based on currently available
information. Although we believe the assumptions upon which these forward looking statements are based on are reasonable,
any of these assumptions could prove to be inaccurate and the forward looking statements based on these assumptions could be
incorrect. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements
and not to regard such statements as a guarantee of future performance. Neither our Company, the Selling Shareholders, our
Promoter, our Directors, the BRLMs nor any of their respective affiliates have any obligation to update or otherwise revise any
statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the
underlying assumptions do not come to fruition. In accordance with the requirements of SEBI, our Company and each of the
Selling Shareholders (in respect of statements/ disclosures made by them in this Prospectus) shall, severally and not jointly,
ensure that investors in India are informed of material developments from the date of the Red Herring Prospectus until the date
of Allotment.

20
SECTION II: RISK FACTORS

An investment in Equity Shares involves a high degree of risk. You should carefully consider all the information in this
Prospectus, including the risks and uncertainties described below, before making an investment in our Equity Shares. The risks
described below are not the only ones relevant to us or our Equity Shares, the industry and segments in which we operate or to
India. Additional risks and uncertainties, not presently known to us or that we currently deem immaterial may also impair our
business, results of operations, financial condition and cash flows. If any of the following risks, or other risks that are not
currently known or are currently deemed immaterial, actually occur, our business, results of operations, financial condition
and cash flows could suffer, the trading price of our Equity Shares could decline, and you may lose all or part of your investment.
To obtain a complete understanding of our Company, prospective investors should read this section in conjunction with “Our
Business”, “Industry Overview”, “Financial Statements” and “Management's Discussion and Analysis of Financial Condition
and Results of Operations” on pages 111, 80, 162 and 226, respectively, as well as the financial, statistical and other
information contained in this Prospectus.

Our financial year ends on March 31 of each year, so all references to a particular financial or fiscal year are to the twelve-
month period ended March 31 of that year. Unless otherwise indicated or the context otherwise requires, the financial
information for the three months ended June 30, 2021 and 2020 and the financial years 2021, 2020 and 2019 included herein
is derived from the Restated Financial Information, included in this Prospectus. For further information, see “Financial
Statements” on page 162.

To the extent the COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of
heightening many of the other risks described in this section. In making an investment decision, prospective investors must rely
on their own examination of us and the terms of the Offer including the merits and risks involved. You should consult your tax,
financial and legal advisors about the particular consequences to you of an investment in our Equity Shares.

This Prospectus also contains certain forward-looking statements that involve risks, assumptions, estimates and uncertainties.
Our actual results could differ from those anticipated in these forward-looking statements as a result of certain factors,
including the considerations described below and elsewhere in this Prospectus. See “Forward-Looking Statements” on page
20.

Unless otherwise indicated, industry and market data used in this section have been derived from the report “Assessment of
the diagnostic industry in India” dated May 2021 and its addendum to the report dated August 2021 (the “CRISIL Report”)
prepared and released by CRISIL Limited and commissioned and paid for by our Company to confirm our understanding of
our industry specifically for the purpose of the Offer.

Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify the financial or other
implications of any of the risks described in this section.

Internal Risk Factors
Risks relating to our Business

1. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand
image.

Since we primarily derive almost all of our revenues from walk-in customers, our brand and reputation are critical for the
success of our business and operations. Our ability to maintain and improve our brand name and brand image is dependent on
factors such as quality, accuracy and efficiency of our diagnostic tests, turnaround time and patient satisfaction, the performance
of our service network, the introduction of new tests and services. Further, as we expand into new geographic markets within
India, and as the market becomes increasingly competitive, maintaining and enhancing our brand may become costly and
difficult.

Our services are designed to diagnose and detect early symptoms of diseases and to help prevent diseases and other health
conditions by monitoring a variety of health indicators. While there have not been any past material incidences of errors, users
of our services have a greater sensitivity to errors than users of services or products that are not intended for the diagnosis,
treatment and prevention of diseases. There are three instances of alleged negligence in the accuracy of diagnosis. For further
details, see “Outstanding Litigation and Material Developments — Litigation involving our Company” on page 245. We train
our medical personnel, including physicians, radiologists, technicians and other staff to provide accurate and timely test results.
However, any delays or inaccuracies in the results we provide, including due to inherent limitations in the technology and
equipment used or due to wrong interpretation of test results by doctors, may result in the wrong treatment being prescribed to
a patient, which may cause potential harm to such patient and may induce negative publicity and cause other harm to our brand
and reputation. In addition, if our personnel make errors in the handling and labelling of patient specimens, or in the operation
of our complex medical equipment, or if they inadequately or improperly extract specimens from patients causing bodily harm,
our test results may not be accurate and we may become liable under healthcare or other laws for acts or omissions by our
employees, which may adversely affect our brand and reputation.

 

21
Further, our quality certifications and accreditations are critical for our brand image. As of June 30, 2021, all of our laboratories
hold NABL accreditations and three of our diagnostic centres hold NABH accreditations. If our testing services fail to meet
accreditation standards, or if we fail to adapt to evolving diagnostic standards, we could lose one or more of our accreditations,
which may adversely affect our business and prospects.

2. Our CEO, Sura Suprita Reddy was named in a criminal proceeding.

Our CEO, Sura Suprita Reddy, was charged in a criminal proceeding wherein the State alleged that Sura Suprita Reddy with
another (collectively the “Defendants) had committed offences under Sections 304-A, 336 and 338 of the Indian Penal Code,
1860 due to an accident resulting in a fire at the Park Hospital, Hyderabad in which several persons were injured and three
persons subsequently lost their lives while undergoing treatment.

Sura Suprita Reddy was a non-executive director on the board of directors of Park Health Systems Private Limited (“Park
Health”), the company which operated the Park Hospital, at the time of the accident. The matter was tried before the XXIII
Special Magistrate, Hyderabad, who by his judgement dated November 24, 2017 (the “Judgement”) held the Defendants were
guilty and sentenced the Defendants to (I) (a) undergo six months imprisonment each; and (b) a fine of 10,000 each and in
default two months simple imprisonment for offence under section 304-A of the IPC; (II) (a) undergo simple imprisonment for
a period of six months each; and (b) a fine of 21,000 each and in default one month simple imprisonment each, for offence
under Section 338 of the IPC; and (III) a fine of 2250 each and in default one week simple imprisonment for offence under
Section 336 of the IPC. All the aforesaid sentences pronounced pursuant to the Judgement were to run concurrently. The
Defendants have already paid monetary penalty imposed under the Judgement.

Aggrieved by the above Judgement, the Defendants filed a criminal appeal before the Hon’ble Metropolitan Sessions Judge,
Hyderabad (“Sessions Judge”) praying for (i) the Judgement to be set aside; (ii) their acquittal; and (iii) suspension of the
sentence pending disposal of the appeal. The Sessions Judge by way of its order dated December 20, 2017 suspended the
sentence of imprisonment. The matter is currently pending.

Any adverse order or dismissal of such appeal or any further appeals may lead to our CEO not being able to continue in such
position, and for our Board to have to look for a replacement for her. Such adverse decision may also lead to negative publicity
for our Company and affect our business and reputation. For further details, see “Outstanding Litigation and Material
Developments — Outstanding Criminal Litigations against our Chief Executive Officer” on page 249.

3. Our business, financial condition and results of operations may be adversely affected by global health epidemics,
including the recent COVID-19 outbreak, and the continuing effect of the same cannot be predicted.

During the first half of 2020, COVID-19 spread to a majority of countries across the world, including India. The COVID-19
pandemic has had, and may continue to have, significant repercussions across local, national and global economies and financial
markets. The global impact of the COVID-19 pandemic has been rapidly evolving and public health officials and governmental
authorities have responded by taking measures, such as prohibiting people from assembling in large numbers, instituting
quarantines, restricting travel, issuing “stay-at-home” orders and restricting the types of businesses that may continue to operate,
among many others. On March 14, 2020, India declared COVID-19 as a “notified disaster” and imposed a nationwide lockdown
beginning on March 25, 2020. The lockdown lasted until May 31, 2020, and was extended periodically by varying degrees by
state governments and local administrations. The lifting of the lockdown across various regions has been regulated with limited
and progressive relaxations being granted for movement of goods and people in other places and calibrated re-opening of
businesses and offices. The recent surge in COVID-19 infections has led to states in India having imposed and other states
considering the imposition of additional regional or local lockdowns or curfews. For example, the state of Telangana on May
12, 2021 and the state of Andhra Pradesh on May 5, 2021, imposed partial lock downs, each to prevent the further spread of
COVID-19.

 

There is significant uncertainty regarding the duration and long-term impact of the COVID-19 pandemic, as well as possible
future responses by the Government, which makes it impossible for us to predict with certainty the impact that COVID-19 will
have on our business, operations or potential expansion plans in the future. The COVID-19 pandemic has affected and may
continue to affect our business, results of operations and financial condition in a number of ways such as reduction of working
hours at a few of our centres, reduction of demand of certain tests, preference of COVID-19 test over the others and delays in
expansion plans. We currently provide RT-PCR tests for detection of COVID-19 at 25 diagnostic centres across nine cities and
towns. The impact of COVID-19 pandemic on our future results of operations and financial condition remains uncertain and is
dependent on the spread of COVID-19 and steps taken by the Government to mitigate the economic impact and may differ
from our estimates. We are closely monitoring the impact of COVID-19 on our financial condition, liquidity, operations,
suppliers and work force. Any intensification of the COVID-19 pandemic or any future outbreak of another highly infectious
or contagious disease may adversely affect our business, results of operations and financial condition. Further, we have
experienced and may further experience, Government instructions to reduce or cap the price of COVID-19 tests, which may
adversely affect our business, results of operations and financial condition. For example, the Government of Telangana had in
November 2020 reduced the maximum price of the RT-PCR tests from % 2,200 to = 850 and subsequently in December 2020
to 2 500 (for samples collected at laboratories), and the Government of Andhra Pradesh had fixed the price of the RT-PCR tests
for samples sent by individuals to approved laboratories from to 2 2,900 to = 1,000 in November 2020 and subsequently to 2
499 in December 2020, though our Company is not aware of any material financial impact to our Company brought by the

22
pricing policies implemented for the RT-PCR tests. For further details relating to risks relating to implementation of pricing
policies by the Government or other authorities, see “- Non-compliance with and changes in any of the applicable laws, rules
or regulations, including pricing, safety, health and environmental laws, may adversely affect our business, results of operations
and financial condition and cash flows.” on page 26.

4. Any interruptions at our flagship centre and other diagnostic centres may affect our ability to process diagnostic tests,
which in turn may adversely affect our business, results of operations and financial condition.

Our flagship centre, which is located in Himayatnagar, Hyderabad, is our main ‘hub’ and equipped to conduct majority of the
tests offered by us. In addition to walk-in patients, our flagship centre also receives test requests and related specimens from
certain other diagnostic centres in our network. Revenues from our flagship centre constituted 14.63%, 17.75%, 17.53% and
20.51% of our revenue from operations for the three months ended June 30, 2021 and the financial years 2021, 2020 and 2019,
respectively. Though we have not encountered any interruption to our flagship centre in the past three years, if we experience
any interruptions at our flagship centre, or if it fails to function, in whole or in part, because of events such as a fire, natural
disaster or a loss of licenses, certifications or permits or other reasons or events beyond our control, our services at such
diagnostic centre may be adversely affected or suspended. Further, while we have two other diagnostic centres (located at
Dilshunagar and Habsiguda) in the vicinity of our flagship centre to maintain our continuity of services, there are certain tests
that we only perform at our flagship centre. As a result, the occurrence of such events could also cause us to lose our patients
and we may face significant increase in costs for test processing, transport and logistics which we may not be able to pass on
to our patients. Any failure, malfunction, shutdown or partial or complete destruction of our flagship centre could adversely
affect our business, prospects, results of operations and financial condition.

Further, we have 20 hub centres, which are equipped to conduct all of pathology specimens collection, basic radiology tests
and certain advanced radiology tests. Revenues from our hub centres constituted 49.16%, 45.66%, 46.06% and 44.24% of our
revenue from operations for the three months ended June 30, 2021 and the financial years 2021, 2020 and 2019, respectively.
Any interruptions at these service centres or any failure in operating in whole or in part of these facilities may also adversely
affect our business, results of operations and financial condition.

5. Our operations are concentrated in south India, and any loss of business in such region could have an adverse effect
on our business, results of operations and financial condition.

While we have presence across 13 cities and towns in India, as of June 30, 2021, a significant portion of our operations are
concentrated in the states of Telangana and Andhra Pradesh in south India. We derived 87.18%, 86.21%, 89.83% and 88.04%
of our revenue from operations from Telangana for the three months ended June 30, 2021 and the financial years 2021, 2020
and 2019, respectively. We also derived 8.73%, 9.99%, 6.62% and 6.64% of our revenue from operations from Andhra Pradesh
for the three months ended June 30, 2021 and the financial years 2021, 2020 and 2019, respectively. Further, as of June 30,
2021, 64 out of 81 of our diagnostic centres are in Hyderabad. In the event of a regional slowdown in the economic activity in
south India, or any other developments including political or civil unrest, disruption or sustained economic downturn that reduce
the demand for our services in the states of Telangana and Andhra Pradesh, could adversely affect our business, results of
operations and financial condition, which are largely dependent on the performance and other prevailing conditions affecting
the economies of south India.

6. One of our Subsidiaries MDSL was in non-compliance of the Listing Regulations in the past which have since been
rectified. Further our Company has made a delayed filing under regulation 31(4) of the Takeover Regulations in
relation to the equity shares held by it in its capacity as a promoter of MDSL. We cannot assure you that the SEBI or
BSE will not take any further action against us or MDSL as a result of such non-compliance or delayed filing

Our Subsidiary, MDSL’s equity shares are listed on the BSE. MDSL is therefore required to comply with the provisions as
prescribed by SEBI including the SEBI Act, the rules and regulations thereunder including the Listing Regulations and various
circulars issued thereunder. In terms of regulation 33(1)(d) of the Listing Regulations a listed entity is required to ensure that
the limited review reports or audit reports submitted to the stock exchanges on a quarterly or annual basis are to be given only
by an auditor who has subject himself to a peer review process of the ICAI. In the past MDSL’s erstwhile statutory auditor did
not hold a peer review certificate of the ICAI. MDSL has since appointed a statutory auditor which holds a valid peer reviewed
certificate of the ICAI.

Further under regulation 31(4) of the Takeover Regulations, a promoter of every listed company is required to file on a yearly
basis, within seven working days from the end of each financial year to every stock exchange where the shares of the listed
company are listed, a declaration that the promoter along with the persons acting in concert have not made any encumbrance,
directly or indirectly, other than those disclosed during the financial year. Our Company has made a delayed filing under
regulation 31(4) of the Takeover Regulations for the financial year ended March 31, 2021 by eight days in respect of the equity
shares of MDSL held by it in its capacity as a promoter. We cannot assure you that the SEBI or BSE will not take any further
action against us or MDSL as a result of such non-compliance or delayed filing.

7. There are outstanding legal proceedings involving our Company, Subsidiaries and Directors which may adversely affect
our business, financial condition and results of operations

23
There are outstanding legal proceedings involving our Company, Subsidiaries and Directors. These proceedings are pending at
different levels of adjudication before various courts, tribunals, enquiry officers and appellate tribunals. Such proceedings could
divert management time and attention, and consume financial resources in their defence. Further, an adverse judgment in some
of these proceedings could have an adverse impact on our business, financial condition and results of operations.

A summary of the outstanding proceedings involving our Company, Subsidiaries and Directors as disclosed in this Prospectus,
to the extent quantifiable, have been set out below:

(in million, unless otherwise specified)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nature of cases No. of cases Total amount involved”
Litigation involving our Company
Against our Company
Material civil litigation proceedings 1 9.90
Criminal cases 2 Not quantifiable
Action taken by statutory and regulatory authorities Nil Nil
Taxation cases 4 4.03
‘By our Company
Civil cases Nil Nil
Criminal cases 1 0.50
Litigation involving our Subsidiaries
‘Against our Subsidiaries
Civil cases 2 26.72
Criminal cases 1 Not quantifiable
Action taken by statutory and regulatory authorities 1 Not quantifiable
Taxation cases Nil Nil
By our Subsidiaries
Civil cases 1 0.50
Criminal cases Nil Nil
Litigation involving our Directors
Against our Directors
Civil cases 1 26.72
Criminal cases Nil Nil
Action taken by statutory and regulatory authorities Nil Nil
Taxation cases Nil Nil
By our Directors
Civil cases Nil Nil
Criminal cases Nil Nil
Litigation involving our Promoter
‘Against our Promoter
Civil cases Nil Nil
Criminal cases Nil Nil
Action taken by statutory and regulatory authorities Nil Nil
Disciplinary actions including penalties imposed by SEBI or the Stock Nil Nil
Exchanges in the last five financial years including any outstanding
action
Taxation cases Nil Nil
By our Promoter
Civil cases Nil Nil
Criminal cases Nil Nil

 

 

 

 

For further details of legal proceedings and notices involving our Company and Directors, see “Outstanding Litigation and
Material Developments” on page 245.

Our Company has received an order from the Directorate of Enforcement, Government of India (“ED”) through a letter dated
July 5, 2021 (“ED Letter”) directing us to produce certain documents/information, such as details of our Directors, details of
foreign inward/outward remittances along with supporting documents, and financials and income tax returns of our Company
for the last five years, for the purpose of an investigation under the Foreign Exchange Management Act, 1999. Our Company
has responded to the ED Letter by way of a letter dated August 5, 2021 and submitted requisite documents and information
sought in the ED Letter. Though the ED Letter makes no allegations as to any violation by our Company, we cannot assure you
that this investigation will not result in initiation of further inquiries, proceedings or legal actions against us. In the event the
ED were to commence proceedings against us, it may result in the diversion of our management’s time and attention and could
have an adverse impact on our business, financial condition, future cash flows and results of operations.

We cannot provide assurance that these legal proceedings will be decided in our favour. Decisions in such proceedings may
have an adverse effect on our business, results of operations and financial condition.

8. We have commissioned and paid for an industry report and its addendum from CRISIL Limited specifically for the
purpose of the Offer, which have been used for industry related data in this Red Herring Prospectus

24
We have commissioned and paid for an industry report titled “Assessment of the diagnostic industry in India” dated May 2021
and its addendum to the report dated August 2021 specifically for the purpose of the Offer. The report uses certain
methodologies for market sizing and forecasting. We cannot assure you that the report is complete or reliable. Accordingly,
investors should read the industry related disclosure in this Prospectus in this context. Industry sources and publications are
also prepared based on information as of specific dates and may no longer be current or reflect current trends. Industry sources
and publications may also base their information on estimates, projections, forecasts and assumptions that may prove to be
incorrect. While industry sources take due care and caution while preparing their reports, they do not guarantee the accuracy,
adequacy or completeness of the data. Accordingly, investors should not place undue reliance on, or base their investment
decision solely on this information.

While we believe data obtained from industry publications and other industry sources referred to in this Prospectus to be true,
we cannot assure you that such data is complete or reliable. Such data may also be produced on different bases from those used
in the industry publications we have referenced. Therefore, discussions of matters relating to India, its economy and the industry
and geography in which we currently operate are subject to the caveat that the statistical and other data upon which such
discussions are based may be incomplete or unreliable and prospective investors are advised not to place undue reliance on
such data. See “Industry Overview” on page 80.

9. Our Group Companies have incurred losses in the past and may incur losses in the future

Our Group Companies have incurred loss in the past. The following table sets forth information on losses incurred by our Group
Companies in the past:

 

 

 

 

 

 

 

(in million)
‘Name of the Group Company Particulars For the financial year ended March 31,
2020 2019 2018
Park Health Systems Private Limited | Profit/(Loss) after tax 25.35 (39.27) 14.27
Vijaya Hospitals Private Limited Profit/(Loss) after Tax 4.68 6.42 (1.18)

 

 

 

 

There can be no assurance that our Group Companies will not incur losses in the future, which may have an adverse effect on
our reputation and business.

10. We will not receive any proceeds from the Offer for Sale. The Selling Shareholders will receive the net proceeds from
the Offer for Sale.

The Offer consists of the Offer for Sale. The Selling Shareholders shall be entitled to the net proceeds from the Offer for Sale,
which comprise proceeds from the Offer for Sale net of Offer expenses shared by the Selling Shareholders, and our Company
will not receive any proceeds from the Offer for Sale.

11. We depend on third-parties to provide us our testing equipment and reagents, and any failure to continue to do so or
recall of existing testing equipment and reagents could adversely affect our business, results of operations and financial
condition.

We depend on third-party vendors and suppliers to procure our testing equipment and reagents and we enter into lease
agreements and rental agreements with fixed term with them. Certain of these agreements require us to purchase minimum
quantity or value of purchases. We cannot assure you that we will be able to continue to obtain adequate supplies of equipment,
reagents and test kits, in a timely manner and without any defects, in the future. Any disruption in our business may also result
in us not meeting our minimum purchase obligations under these agreements resulting in an event of default and leading to
potential disruption to our supply of equipment or reagents. Any such reductions or interruptions in the supply of equipment or
reagents, defects in reagent and test kits and any inability on our part to find alternate sources for the procurement of such items,
may have an adverse effect on our ability to provide our services in a timely or cost effective manner. Further, the procurement
cost of testing equipment and reagents produced outside India may increase due to depreciation of Indian Rupee, and the
suppliers may therefore demand to re-negotiate the supply contracts with us. In the event of an increase in the price of such
items, we cannot assure you that we will be able to correspondingly increase the price of our services.

In addition, under our lease and reagent supply agreements, the supplier typically has the discretion to terminate the agreement
with written notice in the event of a breach of any material term or condition of such agreement, including on account of a
default in the purchase of a committed amount of reagents, movement of the leased equipment without prior consent of the
manufacturer. Further, the equipment is at all times the exclusive property of the manufacturer and our Company has rights
only as a lessee. In addition, manufacturers may discontinue the supply of, or recall reagents, test kits, instruments or equipment
which could adversely affect our operations. Any such recall or termination and consequent removal of the installed equipment
can adversely affect our business, results of operations and financial condition. Additionally, in fiscal 2017 one of our
subsidiaries, MDSL, has defaulted on certain equipment loans availed from its lenders. Due to these defaults, MDSL paid =
0.07 million in delay charges and interest payment on delay charges to the lender. Further, Medinova Millennium MRI Services
LLP, one of our Subsidiaries, has delayed the payment of instalments of its equipment loans in fiscal years 2017, 2018 and
2019 and as a result paid delay charges and interest payment on delay charges of @ 0.51 million to the lender. We cannot assure
you that the Company or its subsidiaries will not default on any of their financing facilities in the future. Any such default can
adversely affect our business, results of operations and financial condition.

25
12. Failure or malfunction of our equipment could adversely affect our ability to conduct our operations.

Our operations are subject to risks inherent in the use of complex medical equipment. We have experienced routine breakdowns
and may experience breakdowns and failures or there could be injury to our employees or others either because of defects,
faulty maintenance or repair, or improper use or lack of timely servicing of our equipment. Our Company has entered into
comprehensive maintenance contracts for which we pay fixed fees for maintenance of major medical equipment and have not
incurred any material costs associated with repair and maintenance of medical equipment in the past three fiscal years. However,
any significant malfunction or breakdown of our equipment may entail significant repair and maintenance costs and cause
disruptions and delays in our operations. Any injury caused by our medical equipment in our diagnostic centres due to
equipment defects, improper maintenance or improper operation could subject us to liability claims. We cannot assure you that
we would be able to effectively respond to any such events, in a timely manner and at an acceptable cost, which could lead to
an inability to effectively provide our services and, therefore, affect our business and reputation.

13. Non-compliance with and changes in any of the applicable laws, rules or regulations, including pricing, safety, health
and environmental laws, may adversely affect our business, results of operations and financial condition and cash flows.

Our diagnostic centres through which we provide our services are subject to stringent health and safety laws. We are required
to maintain licenses under various health and safety legislations and regulations which, among others, include registration under
the Clinical Establishments (Registration and Regulations) Act, 2010 or under respective State clinical establishment legislation,
specifically Telangana Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002 and Andhra
Pradesh Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002 and rules thereunder, as
applicable, issued by the appropriate State authority, authorizations under the Bio-Medical Waste (Management and Handling)
Rules, 2016, issued by the respective State Pollution Control Boards, registration for operation of medical diagnostic x-ray
equipment issued by the Atomic Energy Regulatory Board and no objection certificates for the radioactive substances which
are in our possession and covered under the applicable Shops and Establishments Acts, in Telangana, Andhra Pradesh, Haryana
and West Bengal. Additionally, our diagnostic centres also possess licenses to operate X-ray equipment, such as the bone
densitometer, mammography machine and computer tomography (CT) scanners, as required under the Atomic Energy Rules.

In addition to this, our Company and our diagnostic centres are also required to obtain trade licenses as issued by appropriate
local municipalities under applicable local laws, relevant registrations under the Employees’ State Insurance Act, 1948, the
Contract Labour (Registration and Abolition) Act, 1970, Telangana Tax on Profession Trade, Calling and Employment Act,
1987 and a shops and establishments registration, in the states that we operate. For some of our diagnostic centres we are also
required, depending on the height and the proportion of the premises we occupy, to obtain a fire no objection certificate (“Fire
NOC”) from the relevant local authorities. For certain diagnostic centres located in multistoried buildings, we occupy part of
the building with other tenants occupying the balance building. As on the date of the Red Herring Prospectus, (i) our Company
was not required to obtain a Fire NOC for certain diagnostic centres (a) since the height of the building in which such diagnostic
centres are located is less than the height statutorily prescribed for obtaining Fire NOCs; or (b) because we occupy only a part
of the building even though the height of the building is more than the height statutorily prescribed for obtaining Fire NOCs
since the owner of such building is required to obtain the Fire NOCs; and (ii) our Company has been unable to apply for the
Fire NOC for one diagnostic centre in Hyderabad, namely at Himayatnagar, due to the non-availability of the stipulated setback
area around the premises as per the National Building Code of India, 2016. However, our Company made an application dated
June 13, 2021 to the Government of Telangana for a fire audit certificate for the above referred diagnostic centre at
Himayatnagar. Subsequently, the Government of Telangana by way of a fire audit letters dated July 5, 2021 and July 8, 2021
has provided additional fire safety observations for the Himayatnagar diagnostic centre such as deficiencies in open spaces
around the building, deficiencies in fire fighting equipment, emergency power and safety systems and fire safety equipment.
The Himayatnagar diagnostic centre contributes 14.63% and 17.75% of our revenue from operations for the three months ended
June 30, 2021 and the financial year 2021, respectively. While we have ensured that and our staff is well versed with the fire
safety protocols and all our diagnostic centres are equipped with the requisite fire-fighting equipment and have been recently
audited by a retired fire officer, due to structural issues at Himayatnagar diagnostic centre there maybe challenges in case of
any untoward incident. The relevant local authorities may also institute any civil or criminal actions (including the temporary
sealing of the premises) for any non-compliance of this requirement at this aforesaid location which may in turn interrupt our
operations or collections at this diagnostic centre, and consequently our results of operations, financial conditions and cash
flows.

 

Our business operations are primarily conducted on premises leased from third parties (including certain related parties). The
owners of these premises are required to obtain, depending on the date of completion of construction of the premises, an
occupancy certificate. As on the date of the Red Herring Prospectus, the owners for certain locations in which our diagnostic
centres are located have not applied for an occupancy certificate. We cannot assure you that such owners will apply for or obtain
the occupancy certificate for such premises in a timely manner or at all. Any non-possession of occupancy certificates may
result in the functional agencies not providing a regular connections for electricity, water, drainage and sewerage or imposition
of higher property tax and water and electricity charges.

If a determination is made that we are in violation of any of the applicable laws, rules or regulations, including conditions in

the permits required for our operations, we may be subjected to regulatory sanctions, have to pay fines, modify or discontinue
our operations, incur additional operating costs or make capital expenditures which would adversely affect our business, results

26
of operations, financial position and cash flows. Uncertainty in the applicability, interpretation or implementation of any
amendment to, or change in, applicable laws, rules or regulations or policies, may also adversely affect the viability of our
current business or restrict our ability to grow our business in the future. Further, the adoption of stricter applicable laws and
regulations, stricter interpretations of existing laws, increased governmental enforcement of laws or other developments in the
future may require that we make additional capital expenditures, incur additional expenses or take other actions in order to
remain compliant and maintain our current operations. Complying with, and changes in, these laws and regulations or terms of
approval may increase our compliance costs and adversely affect our business, results of operations, financial condition and
cash flows.

Weare also subject to the laws and regulations governing relationships with employees in such areas as minimum wage, gratuity,
provident fund and maximum working hours, overtime, working conditions, hiring and termination of employees, contract
labour and work permits. There is a risk that we may inadvertently fail to comply with such regulations, which could lead to
enforced shutdowns and other sanctions imposed by the relevant authorities, as well as the withholding or delay in receipt of
regulatory approvals. We cannot assure you that we will not be involved in future litigation or other proceedings or be held
liable in any litigation or proceedings including in relation to safety, health and environmental matters, the costs of which may
be significant.

14, We require certain approvals, licenses, registrations and permits for conducting our business and our inability to obtain,
retain or renew them ina timely manner, or at all, may adversely affect our business, results of operations and financial
condition.

Our operations are subject to extensive government regulation and we are required to obtain and maintain a number of statutory
and regulatory registrations, permits and approvals under central, state and local government rules in India, generally for
carrying out our business and for each of our facilities. Our Company has made applications for the renewal of certain licenses,
such as trade licenses granted by the Greater Hyderabad Municipal Corporation for some of our branches and we await the
receipt of such licenses. Further, the authorizations under the Bio-medical waste management (Management and Handling)
Rule, 2016, Pre-Natal Diagnostic Techniques (Regulation and Prevention of Misuse) Act, 1994, Bio-Medical Waste
(Management and Handling) Rules, 2016, Telangana Allopathic Private Medical Care Establishments (Registration and
Regulation) Act, 2002 and Andhra Pradesh Allopathic Private Medical Care Establishments (Registration and Regulation) Act,
2002 for some of its diagnostic centres are pending renewal. For details, see “Government and Other Approvals — Approvals
applied for but not received” on page 252. The regulatory licenses that we require are typically granted for a limited term and
are subject to renewal at the end of such terms. We cannot assure that we will be able to obtain or renew all necessary licenses
and registrations as and when required, within a reasonable time, or at all.

Our diagnostic centres are located on properties leased by us, and it is the responsibility of the lessors to procure occupancy
certificates. An absence of such certificates on accord of the lessors could also adversely affect our business and operations.

Our licenses and approvals are subject to various conditions, including periodic renewal and maintenance of standards that are
subject to inspection and may require us to incur substantial expenditure. Any actual or alleged failure on our part to comply
with the terms and conditions of such regulatory licenses and registrations could expose us to significant compliance costs or
liabilities or could affect our ability to continue our operations. Further, in the event certain accreditations, are made compulsory,
either by law or as a condition for empanelment, our business and operations may be adversely affected until such time we
receive such accreditations.

If we fail to obtain or renew any applicable approvals, licenses, registrations or consents in a timely manner, we may not be
able to undertake certain operations of our business, or at all, which may affect our business, results of operations and financial
condition. We cannot assure you that the approvals, licenses, registrations or permits issued to us will not be suspended or
revoked in the event of non-compliance or alleged non-compliance with any terms or conditions thereof, or pursuant to any
regulatory action. In addition, any suspension, revocation or termination of one or more of our operational licenses may also
lead to consequences under the terms of our other licenses. Any failure to renew the approvals that have expired, or to apply
for and obtain the required approvals, licenses, registrations or consents, or any suspension or revocation of any of the approvals,
licenses, registrations or consents that have been or may be issued to us, may adversely affect our business, results of operations
and financial condition.

15. Our inability to effectively manage our growth or to successfully implement our business plan and growth strategy could
have an adverse effect on our business, results of operations and financial condition.

We have experienced considerable growth and we have significantly expanded our operations from 61 diagnostic centres as on
March 31, 2019 to 81 diagnostic centres as on June 30, 2021. Our revenue from operations was = 1,226.86 million and our
profit/(loss) was = 333.25 million for the three months ended June 30, 2021. Our revenue from operations grew from 2 2,925.87
million for the financial year 2019 to = 3,767.46 million for the financial year 2021, while our profit/(loss) for the year grew
from 2 462.72 million for the financial year 2019 to = 849.11 million for the financial year 2021. However, we cannot assure
you that we will be able to continue to grow further, or at such rate.

27
As part of our growth strategy, among others, we seek to increase the penetration of our existing test services in the Indian
market by opening new diagnostic centres and make strategic acquisitions of other diagnostic service providers. See “Our
Business — Our Strategy” on page 115. Our inability to manage our expansion effectively and execute our growth strategy in a
timely manner, or within budget estimates or our inability to meet the expectations of our stakeholders could have an adverse
effect on our business, results of operations and financial condition. We cannot assure you that our existing or future
management, operational and financial systems, procedures and controls will be adequate to support our future operations, or
establish or develop business relationships beneficial to our future operations. Failure to manage growth effectively could have
an adverse effect on our business, results of operations and financial condition.

16. We operate in a highly competitive business environment, and our inability to compete effectively could have an adverse
effect on our business, results of operations and financial condition.

The diagnostics industry in India is highly competitive with several companies present in the market, and therefore it is
challenging to improve market share and profitability. Our competitors include diagnostic healthcare service providers in India,
hospital-based laboratories, independent clinical laboratories, other smaller-scale providers of diagnostic services (with more
established local and regional presence in certain geographies) such as pathology, radiology laboratories and preventive care
providers as well as international service providers, which may establish and expand their operations in future. We compete on
the breadth of our test offerings, the geographical reach of our network, our ability to accurately process specimens and report
data in a timely manner and our customer relationships. Some of our competitors may have greater financial, research and
development, marketing and other resources, broader service offerings, more experience in obtaining regulatory approvals or
greater geographic reach or economies of scale. Further, the diagnostics industry is highly fragmented, the lack of regulations
and low entry barriers allow a multitude of organised and unorganised players to compete in the market.

Also, the pricing-related competition may intensify in the near future which may have an adverse effect on the results of our
operations, including our profit margins. Increase in the number of comparable diagnostic healthcare facilities may exert
additional pricing pressure on some or all of our services. The manufacturers of laboratory equipment and test kits may also
enter the diagnostic industry by marketing point-of-care laboratory equipment to physicians and by selling self-test kits, which
may be more convenient to the patients and cheaper than our services. If we are unable to compete effectively, our business
could decline or contract and our business, results of operations and financial condition could be adversely affected.

17. We may become subject to professional malpractice liability claims, which could be costly and, therefore, could
negatively affect our business, results of operations and financial condition.

The delivery of diagnostic services involve certain inherent risks. Although we do not believe our operations or activities
constitute the practice of medicine, nevertheless, claims, suits or complaints relating to services provided by our employees at
our diagnostic centres may be asserted against us in the future. We provide advanced radiology testing services such as MRI,
CT, Spect and Pet CT. While performing these tests, we might need to do certain invasive or anesthetic procedures based on
the prescription given by the doctors. There is a risk that patient suffers injury and inconvenience, or develops any kind of
reaction and we may face claims from such patients and/or regulatory authorities, whether it includes medical negligence by
our staff or doctors or not. For instance, there are two complaints (one consumer complaint and one criminal complaint) against
us and certain of our employees for alleged gross negligence and recklessness in the accuracy of diagnosis and subsequent
treatment. The total damages claimed under the consumer complaint is %9.90 million. In addition, we may be subject to
professional liability claims, including, without limitation, for improper use or malfunction of our diagnostic equipment or for
accidental contamination or injury from exposure to radiation. For further details see “Outstanding Litigation and Material
Developments — Litigation involving our Company — Litigation against our Company” on page 245.

Any claim made against our Company that is not fully covered by insurance could be costly to defend, result in a substantial
damage award against us and divert the attention of our management from our operations, which could have an adverse effect
on our business, results of operations and financial condition.

18. Any inadequacy in collection of, or failure or delay in the delivery of, specimens to our processing laboratories could
compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations
and financial condition.

The process of collecting specimens is highly dependent on the skill and performance of our front-end employees. Any losses,
errors or delays in the specimen collection, preparation, labelling and storage process could result in us not being able to
effectively provide our services and adversely affect our business and reputation.

The timely pickup, transportation and delivery of specimens depend on several factors beyond our control, including weather
and road conditions. Any disruptions in transportation services on account of natural disasters, strikes, lock-outs, terrorism,
inadequacies in the road or air infrastructure, weather related problems, or other events could affect our ability to receive
specimens and generate test results in a timely manner. For example, the lockdown due to the outbreak of COVID-19 has
marginally affected the process and timeliness of collection and delivery of specimens. While most of our diagnostic centres
are serviced through our in-house logistics team, we also rely on the services of third-party phlebotomists and logistics providers
including for collection of COVID-19 samples. As a result, we may experience loss of specimens, delays and inefficiencies,
including mislabeling of specimen, which are not within our control. If we are unable to deliver or receive specimens at our

28
processing laboratories in a timely manner, their integrity as well as the outcome of results may be compromised, or the
reporting of results of tests to patients may be delayed, which could adversely affect our reputation. Further, specimens may be
lost, damaged or contaminated due to mishandling while in transit. In the event specimens are lost, destroyed, damaged or
contaminated, we may incur additional costs, such as the cost of re-administering tests or from delays in the generation of
critical test results. The occurrence of any such events could adversely affect our reputation, business, results of operations and
financial condition.

Further, certain agreements we entered into with the third-party phlebotomists and logistics providers include clauses for
termination without cause with advance notice. In the event the services provided by these third-party phlebotomists and
logistics providers are terminated, we may not be able to find replace in a timely manner, or at all, which may adversely affect
our business, results of operations and financial condition.

19. Our inability to protect or use our intellectual property rights or comply with intellectual property rights of others may

adversely affect our business and results of operations.

WIJAVA
We filed an application for the registration of our corporate logo tena *, under class 44 of the Trade Mark Act, 1999

and received partial approval to the extent of words “Vijaya Diagnostic Centre”. Additionally, as on the date of this Prospectus,

 

seven of our trademarks have been objected to by various third parties, including an objection to which forms part of
our corporate logo, and the proceedings in respect of these objections are currently ongoing. Our inability to obtain or maintain
these registrations may adversely affect our competitive business position. The measures we take to protect our intellectual
property include relying on Indian laws and initiating legal proceedings, which may not be adequate to prevent unauthorized
use of our intellectual property by third parties. Notwithstanding the precautions we take to protect our intellectual property
rights, it is possible that third parties may copy or otherwise infringe on our rights, which may have an adverse effect on our
business and results of operations. We may also be unable to prevent infringement of our trademarks. In the event our
application for our corporate logo is rejected, we will take necessary steps to appeal such rejection and apply for alternative
designs and logo as suggested by the Board of Directors.

20. We are dependent on a number of key personnel, including our senior management and qualified and experienced
laboratory professionals, and the loss of, or our inability to attract or retain such persons could adversely affect our
business, results of operations and financial condition.

Our performance depends largely on the efforts and abilities of our Key Managerial Personnel. Our individual Promoter and
Executive Chairman, Dr. S. Surendranath Reddy, our Executive Director, Sunil Chandra Kondapally and our CEO, Sura Suprita
Reddy, have an average of over 18 years each in the medical diagnostic industry. The inputs and experience of our Key
Managerial Personnel are valuable for the development of business and operations and the strategic directions taken by our
Company. Within our Key Managerial Personnel, we faced attrition of one person during the three months ended June 30, 2021
and three, two and one persons during the financial years 2021, 2020 and 2019. We cannot assure you that we will be able to
retain these employees or find adequate replacements in a timely manner, or at all. We may require a long period of time to hire
and train replacement personnel when qualified personnel terminate their employment with our Company. We may also be
required to increase our levels of employee compensation more rapidly than in the past to remain competitive in attracting
employees that our business requires.

In addition, our sustained growth depends on our ability to attract, train, motivate and retain qualified and experienced
laboratory professionals, including physicians, radiologists and technicians. Our diagnostic services are provided by a medical
professional team consisting of 74 laboratory doctors, 19 physicians and 105 radiologists and 1,027 well-trained technical staff
in our network, as of June 30, 2021. We faced attrition of 9% laboratory and radiology professionals during the three months
ended June 30, 2021 and 31%, 39% and 31% laboratory and radiology professionals during the financial years 2021, 2020 and
2019. Our inability to retain and/or attract such skilled personnel, especially in smaller cities in India, could result in a decrease
in the quality of our services. We also cannot assure you that these individuals will not leave us or join a competitor. Therefore,
the loss of services of our healthcare professionals and technicians, failure to recruit suitable replacements in a timely manner
or the need to incur additional expenses to recruit and train new personnel could adversely affect our operations.

Further, if any of our executive officers or key employees joins a competitor or forms a competing company, we may lose
know-how, trade secrets, customers and key professionals and staff. The occurrence of any such events could have an adverse
effect on our business, results of operations and financial condition.

21. Implementation of pricing policies by the Government or other authorities could adversely affect our business, results
of operations and financial condition.

The prices that we charge for our services could become subject to recommended or maximum fees set by the Government or
other authorities. For example, the government could introduce “price lists” for services that could be mandatory or, even if not
mandatory, result in guidance for the prices we charge for our diagnostic healthcare services. Further, we are empanelled
diagnostic centre under the Central Government Health Scheme (“CGHS”), beneficiaries of CGHS are entitled to enjoy our
services at CGHS rates and/or CGHS recommended rates. We generated 2.39%, 2.55%, 2.99% and 2.87% of our revenue from

29
operations from CGHS for the three months ended June 30, 2021 and the financial years 2021, 2020 and 2019, respectively.
The implementation of such policies and the restriction under CGHS affecting the prices we charge could, in effect, limit our
ability to charge customers higher prices for our services, which may have an adverse effect on our business, results of
operations and financial condition.

22. Failure to introduce new tests, services and technologies or acquire new or improved equipment could adversely affect
our business, results of operations and financial condition.

The diagnostic healthcare services industry is subject to constant innovations in, and improvements to tests and services,
processes and technologies. In order to maintain our position in our industry, we must continue to anticipate and keep abreast
of the demands and needs of our patients through investing in technologies and equipment to develop new tests and services
and improve existing tests and services. If we fail to anticipate trends in the industry, or we are not able to introduce or develop
new tests, services and technologies before or at least concurrently with our competitors and at competitive prices, we may
consequently be unable to deliver our diagnostic healthcare services involving new tests, services or technologies in an efficient
and effective manner. As a result, our business, results of operations and financial condition may be adversely affected.

In addition, technological advancement could lead to the development of more cost-effective technologies or non-invasive
diagnostic healthcare tests which are more convenient or less expensive than the tests that we offer. The introduction of such
technology and its subsequent use by our existing and potential patients could lead to a decline in the demand for our services.
Advances in technology may lead to the development of more cost-effective tests that can be performed outside a commercial
clinical laboratory, such as tests that can be performed by hospitals in their own laboratories, point-of-care tests that can be
performed by doctors in their surgeries, or home-testing that can be performed by patients or other non-medical professionals
themselves, such as pregnancy and diabetes tests. In addition, manufacturers of laboratory equipment and test kits could seek
to increase their sales by marketing point-of-care laboratory equipment to physicians and by selling test kits approved for home
use to both physicians and patients. Increased testing by physicians in their offices and home use by patients could affect the
market for our services and, therefore, adversely affect our business, results of operations and financial condition.

23. We rely on our information technology systems and third-party platform for the operation of our business and any
disruption to our systems and/or third-party platform could adversely affect our business and reputation and result in
litigation.

We rely on information technology systems and third-party website to support our business processes, including for placing
order for tests by our customers, conducting tests, transmission of testing results, billing services, quality control, tracking
logistics, human resources, finance and other patient service functions. As a result, our business depends on the capacity and
reliability of third-party vendors whom we engage and will continue to do so. Interruptions in these technology systems and/or
the third-party website, whether due to fire, power loss, telecommunications failures, system failures or errors, human errors,
malicious software, physical or electronic break-ins, denial-of-service attacks, or otherwise could affect the availability of our
services and prevent or hinder the ability of consumers to access our services. For example, from time to time, we have suffered
interruptions in our technology systems, for short durations at one or more of our centres due telecommunications failures.
Effective response to such interruptions will require effort and diligence on the part of our third-party vendors and employees
to avoid any adverse effect to our business operations. Sustained system failures or interruption of our information technology
systems (including systems of third-party vendors) in one or more of our diagnostic centre operations could disrupt our ability
to process laboratory requisitions, perform testing, provide test results in a timely manner and bill the appropriate party. The
occurrence of any such events could adversely affect our business, interrupt our operations, subject us to increased operating
costs and expose us to litigation.

24, Cyber threats and non-compliance with and changes in privacy laws and regulations may adversely affect our business,
results of operations and financial condition and cash flows.

We may face cyber threats such as (i) phishing and trojans - targeting constituents, wherein fraudsters send unsolicited mails to
the constituents seeking account sensitive information or to infect their systems to search and attempt ex-filtration of account
sensitive information; (ii) hacking — wherein attackers seek to hack into our website and portal with the primary intention of
causing reputational damage to us by disrupting services; (iii) data theft — wherein cyber criminals may attempt to intrude into
our network with the intention of stealing our data or information; and (iv) advanced persistent threat — a network attack in
which an unauthorised person gains access to our network and remains undetected for a long period of time with an intention
to steal our data or information rather than to cause damage to our network or organization.

Our systems are also potentially vulnerable to data security breaches, whether by our employees, or others that may expose
sensitive data to unauthorised persons. We process and transfer data, including personal information, financial information and
other confidential data provided to us by constituents. Although we maintain systems and procedures to prevent unauthorised
access and other security breaches, it is possible that unauthorised individuals could improperly access our systems, or
improperly obtain or disclose sensitive data that we process or handle. Data security breaches could lead to the loss of
intellectual property or could lead to the public exposure of personal information (including sensitive financial and personal
information) of constituents. Any such security breaches or compromises of technology systems could result in damage to our
reputation, institution of legal proceedings against us and potential imposition of penalties, which may have an adverse effect
on our business and results of operations.

30
Further, we must comply with privacy laws and regulations with respect to the use, storage and disclosure of protected patients’
health information, as well as laws pertaining to the electronic transmission of such information, such as the Information
Technology (Reasonable security practices and procedures and sensitive personal data on information) Rules, 2011 (“IT
Rules”). In the ordinary course of our business, we receive certain personal information about our customers and their patients,
including by electronic means. Under the provisions of the IT Rules, we are required to and we have ensured security of all
personal data collected by us, formulated a privacy policy and subsequently published such policy on our website. Accordingly,
we depend upon our internal information technology system for the storage and transmission of such confidential information.
A compromise in our security systems (including systems of third-party information technology vendors) that results in
customer or patient personal information being obtained by unauthorised persons or our failure to comply with security
requirements for use, storage and transmission of sensitive information could adversely affect our reputation with our customers
and result in litigation against us or the imposition of penalties and fines, all of which may adversely impact our business, results
of operations, financial condition and liquidity. Further, new requirements for additional security and protection of the privacy
of patient information could prove technically difficult, time-consuming or expensive to implement. Failure to comply with
privacy laws and regulations may adversely impact our business and reputation and result in litigation.

 

25. If we pursue strategic acquisitions, we may not be able to successfully consummate favourable transactions or
successfully integrate acquired businesses.

From time to time, we may evaluate potential acquisitions that would further the strategic objectives of our Company. However,
we may not be able to (i) identify or secure suitable investment or acquisition opportunities, or our competitors may capitalise
on such opportunities before we do; (ii) obtain requisite approvals from governmental authorities on a timely basis; (iii)
consummate a transaction without delay and on terms that are favourable to us; or (iv) achieve expected returns and other
benefits as a result of integration challenges or anti-monopoly regulations. Further, companies or operations acquired by us
may not be profitable and may have unidentified issues not discovered in our due diligence process including hidden liabilities
and legal contingencies or may not achieve sales levels and profitability that justify the investments made. Our corporate
development activities may entail financial and operational risks, including diversion of management attention and other
resources from our existing core businesses, difficulty in integrating, retaining or separating personnel and financial and other
systems, and negative impacts on existing business relationships with suppliers and customers, difficulty in maintaining
standards among diagnostic centres in different regions and complexity of large scale business operations. If we fail to
successfully source, execute and integrate investments or acquisitions, we may have to discontinue the operations of acquired
companies and write off our investments, and as a result our overall growth could be impaired, and our business, results of
operations and financial condition could be adversely affected. Future acquisitions could also result in potentially dilutive
issuances of equity securities, the incurrence of debt, contingent liabilities and increased operating expenses, all of which could
adversely affect our business, financial condition, results of operations and prospects.

26. Employee misconduct or failure of our internal processes or procedures could harm us by impairing our ability to attract
and retain patients and subject us to significant legal liability and reputational harm.

Our business is exposed to the risk of employee misconduct or the failure of our internal processes and procedures. For example,
misconduct by employees could involve the improper use or disclosure of confidential information, which could result in costly
litigation and serious reputational or financial harm. While we strive to monitor, detect and prevent fraud or misappropriation
by our employees, through various internal control measures, internal policies and insurance coverage, we may be unable to
adequately prevent or deter such activities in all cases. While we have been able to identify such issues in the past, there could
be instances of fraud and misconduct by our employees, which may go unnoticed for certain periods of time before corrective
action is taken. For instance, there was one instance of cash misappropriation by one our employees at the billing counter at
one of our centres for 70.10 million in March 2019. In addition, we may be subject to regulatory or other proceedings in
connection with any such unauthorised transaction, fraud or misappropriation by our employees, which could adversely affect
our goodwill, business prospects and future financial performance. Even when we identify instances of fraud and other
misconduct and pursue legal recourse or file claims with our insurance carriers, we cannot assure you that we will recover any
amounts lost through such fraud or other misconduct.

27. If we are unable to establish and maintain an effective internal controls and compliance system, over financial reporting,
our reputation could be adversely affected.

We take reasonable steps to maintain appropriate procedures for compliance and disclosure and to maintain effective internal
controls over our financial reporting so that we produce reliable financial reports and prevent financial fraud. As risks evolve
and develop, internal controls must be reviewed on an ongoing basis. Maintaining such internal controls requires human
diligence and compliance and is therefore subject to lapses in judgment and failures that result from human error. Any lapses
in judgment or failures that result from human error can affect the accuracy of our financial reporting, resulting in a loss of
investor confidence and a decline in the price of our equity shares.

28. Our business operations are being conducted on premises owned by and leased from third parties, including our

Promoter and members of our Promoter Group. Our inability to continue operating from such premises, or to seek
renewal or extension of such leases may adversely affect our business and results of operations

31
Our business operations are primarily conducted on premises owned by and leased from third parties, including our Promoter
and members of our Promoter Group, and we may continue to enter such transactions in future. Our Registered Office,
Corporate Office and all our diagnostic centres, except two of our diagnostic centres, are situated and operated from leased
premises. Our leases may expire in the ordinary course. We cannot assure you that we will continue to be able to continue
operating out of our existing premises or renew our leases at favourable terms or at all. For example, the lease for the diagnostic
centre operated by MDSL has expired and the lessors have filed a suit for eviction against MDSL and MDSL has filed a suit
for specific performance against the lessors for the renewal of such lease. For further details see “Outstanding Litigation and
Other Material Developments” on page 245. Any such event may adversely impact our operations (including by way of
temporary disruptions) and cash flows and may divert management attention from our business operations. In case of any
deficiency in the title of the owners from whose premises we operate, breach of the contractual terms of any lease, leave and
license agreements, or if any of the owners of these premises do not renew the agreements under which we occupy the premises,
or if they seek to renew such agreements on terms and conditions unfavourable to us, or if they terminate our agreements, we
may suffer a disruption in our operations and will have to look for alternate premises.

Given that our operations are conducted on premises leased from third parties, any encumbrance or adverse impact, or
deficiency in, the title, ownership rights or development rights of the owners from whose premises we operate, breach of the
contractual terms of any lease or leave and license agreements, or any inability to renew such agreements on acceptable terms
or at all may adversely affect our business and results of operations. In the event of relocation, we may be required to obtain
fresh regulatory licenses and approvals. Until we receive these, we may suffer disruptions in our operations and our business
which may also adversely affect our business and results of operations. For further details, see “Our Promoter and Promotor
Group - Interests of our Promoter” and “Our Promoter and Promotor Group - Payment or benefits to our Promoter or our
Promoter Group” on page 155.

29. Our insurance coverage may not be sufficient or may not adequately protect us against all material hazards, which
may adversely affect our business, results of operations and financial condition.

The principal types of coverage under our insurance policies include directors’ and officers’ liability, fire and special perils
policy for all centres and godown, money insurance policy for certain centres, burglary (house breaking) policy for our
diagnostic centres and godowns, errors and omissions policy and fidelity guarantee policy for all the centres, commercial vehicle
insurance policies and two wheeler package policies. The insurance coverage which we maintain is reasonably adequate to
cover the normal risks associated with the operation of our businesses. Even if we have insurance for the incident giving rise to
the loss, we may be required to pay a significant deductible on any claim for recovery of such a loss, or the amount of the loss
may exceed our coverage for the loss. However, we cannot assure you that any claim under the insurance policies maintained
by us will be honoured fully, in part or on time, or that we have obtained sufficient insurance to cover all our losses. In addition,
our insurance coverage expires from time to time. We apply for the renewal of our insurance coverage in the normal course of
our business, and while we have no reason to believe that we will not be able to renew our existing insurance coverage as and
when such policies expire, or obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct our businesses as now conducted, we cannot assure you that such renewals will be granted in a timely manner, or at
acceptable cost, or at all. To the extent that we suffer loss or damage, or successful assertion of one or more large claims against
us for events for which we are not insured, or for which we did not obtain or maintain insurance, or which is not covered in full
or part by insurance, exceeds our insurance coverage or where our insurance claims are rejected, the loss would have to be
borne by us and our results of operations, financial condition and cash flows could be adversely affected. We carry insurance
in total amount in excess of our total assets as of June 30, 2021. For further details on our insurance arrangements, see “Our
Business — Insurance” on page 126.

30. Our ability to attract individual patients is largely dependent on the disposable income and increasing general health
awareness of India’s general population, which could decline due to a variety of factors.

Our key source of income is from individual patients. Our individual consumer business contributed to 92.09% of our revenue
from operations for the fiscal year 2021. The growth of these types of customers is dependent on brand recognition, wider
acceptance of our business in the communities in which we operate and our ability to compete effectively within our industry,
all of which we may be negatively affected by a wide variety of reasons. For example, individual decisions regarding when to
access healthcare services may be impaired by the absence of a developed health insurance sector or the lack of appropriate
government programs to cover the costs of healthcare. Moreover, given the small proportion of people in India presently with
health insurance, customers in India generally are responsible for all or part of the cost of diagnostic healthcare services, which
means that a decrease in disposable income that can be allocated for healthcare services, or even the perception thereof, such
as during times of economic downturn, can lead to a reduction in individuals’ expenditures for healthcare services. In addition,
we cannot assure you that the current increasing trend in health awareness and demand for preventive healthcare services will
continue, and it may even reverse. Any of the above reasons may affect our ability to maintain or increase growth in walk-in
customers, which may adversely affect our business, financial condition, results of operations and cash flows.

31. We face foreign exchange risks that could adversely affect our results of operations.
We make payment for most of our equipment in Indian Rupees. However, most of our third-party vendors and suppliers of our

testing equipment and reagents import materials from countries other than India, as such, the prices of the testing equipment
and reagents may be exposed to fluctuations in exchange rates against the Indian Rupee. We may incur additional costs if

32
currencies fluctuate significantly. Any such increase in costs due to foreign exchange fluctuations may adversely affect our
results of operations.

32. Our Promoter and Promoter Group will continue to hold a significant equity stake and control in our Company after
the Offer and their interests may differ from those of the other shareholders

As on the date of this Prospectus, our Promoter and Promoter Group together hold 59.79% (including nominee shareholding)
of our pre-Offer Equity Share capital. For further details, see “Capital Structure” page 56. Following the completion of the
Offer, our Promoter and Promoter Group, shall continue to hold a majority of our Company’s post-Offer Equity Share capital.
This concentration of ownership could limit your ability to influence corporate matters requiring shareholders’ approval. Our
Promoter and Promoter Group will have the ability to significantly influence matters requiring shareholders’ approval, including
the ability to appoint Directors on our Board and the right to approve significant actions at Board and at shareholders’ meetings,
including the issuance of Equity Shares and dividend payments, business plans, mergers and acquisitions, any consolidation or
joint venture arrangements, any amendment to our Memorandum of Association and Articles of Association. In addition, if our
shareholders do not act together, such matters requiring shareholders’ approval may be delayed or may not occur at all, which
could adversely affect our business. Moreover, these shareholders are not obligated to provide any business opportunities to us.
If such other shareholders invest in another company in competition with us, we may lose the support provided to us by them,
which could adversely affect our business, results of operations, financial condition and cash flows. While efforts shall be made
to resolve any conflict of interests between our existing shareholders with other shareholders or our Company, we cannot assure
you that such conflicts of interest will not arise or be resolved. Any such conflict may adversely affect our ability to execute
our business strategy or to operate our business.

33. We have in the past entered into related party transactions and may continue to do so in the future.

We have entered into various transactions with related parties, such as for rental of properties, purchase of consumables, sale
of services, loans incurred and laboratory services to Park Health. For further details of the laboratory services to Park Health,
see “Our Group Companies - Business interest of our Group Companies in our Company” on page 160. While we have
encountered delay in certain payments from Park Health, we did not face any difficulties in payment collections and we believe
that all such transactions have been conducted on an arm’s length basis and contain commercially reasonable terms, which are
in the interest of the Company and its minority shareholders and in compliance with the Listing Regulations and will continue
to adhere to these aforementioned standards in the future, we cannot assure you that we could not have achieved more favourable
terms had such transactions been entered into with unrelated parties. It is likely that we may enter into related party transactions
in the future. For details on our related party transactions, see “Financial Statements — Annexure VII — Note 45” on page 208.
While we have in the past written-off trade receivables from one of our subsidiaries, Medinova Diagnostic Services Limited of
an amount of 218.90 million for Fiscal 2017, and made investments and loans to other loss making subsidiaries, we cannot
assure you that such transactions, individually or in the aggregate, even if entered into at arm’s length terms will not have an
adverse effect on our business, results of operations, cash flows and financial condition.

34, Certain of our Promoter, members of Promoter Group, Directors and Key Managerial Personnel have interests in our
Company in addition to their normal remuneration or benefits and reimbursement of expenses incurred.

Certain of our Promoter, members of Promoter Group, Directors and Key Managerial Personnel have interests in our Company
that are in addition to reimbursement of expenses and normal remuneration payable to them. Our Promoter, Directors and Key
Managerial Personnel may be deemed to be interested to the extent of Equity Shares held by them, as well as to the extent of
any dividends, bonuses or other distributions on such Equity Shares. Further, as of June 30 2021, 16 diagnostic centres were
leased by our Promoter, Promoter Group, certain members of Promoter Group, certain of our Directors and one Key Managerial
Personnel of our Company and they are interested in certain lease agreements entered into by the Company. Such diagnostic
centres include premises located at (i) Himayatnagar, Kukatpally, Dilsuknagar (all of which are located in Hyderabad), which
are co-owned by our Promoter, S. Geeta Reddy, Sura Suprita Reddy and Sunil Chandra Kondapally; (ii) Chandanagar,
Hyderabad Kurnool, Bakaram, Hyderabad Santosh Nagar, Hyderabad and Madina, Hyderabad which are owned by our
Promoter; (iii) Habsiguda and Safilguda (both in Hyderabad) which are co-owned by our Promoter and S Geeta Reddy; (iv)
Vizag which is co-owned by our Promoter, S. Geeta Reddy, Sura Supritta Reddy, Sunil Chandra Kondapally and Vishnu Priya;
(v) Gurgaon which is co-owned by our Promoter, S. Geeta Reddy and Sunil Chandra Kondapally; (vi) Ameerpet, Hyderabad
which is co-owned by our Promoter, S. Geeta Reddy and Sura Suprita Reddy; (vii) AS Rao Nagar which is co-owned by S.
Geeta Reddy and Sura Suprita Reddy; (viii) Vijayanagar, Hyderabad which is co-owned by S. Geeta Reddy, Sura Suprita Reddy
and Sunil Chandra Kondapally; and (xi) Karimnagar is owned by S. Geeta Reddy. These lease agreements are valid as on the
date of this Prospectus and the term of these lease agreements typically range from seven to 15 years. The rent paid to them
accounted for 2.17%, 2.11%, 2.50% and 2.60% of our total revenue from operations for the three months ended June 30, 2021
and the financial years 2021, 2020 and 2019, respectively. While we believe that our Promoter, Directors and our Key
Management Personnel shall exercise their rights as shareholders to the benefit and best interest of the Company, there can be
no assurance our Promoter, Directors and our Key Management Personnel shall do so. For further details of such interests, see
“Our Management” and “Financial Statements” on pages 139 and 162, respectively. For further details of our Promoter, see
“Our Promoter and Promotor Group - Interests of our Promoter” and “Our Promoter and Promotor Group - Payment or
benefits to our Promoter or our Promoter Group” on page 155.

33,
35. Certain information in this Prospectus is based on our internal classification methodologies, which may change and
which may or may not be consistent with companies operating in our industry, and hence we cannot assure you of the
completeness or the accuracy of such data.

Certain statements contained in this Prospectus, such as the categorisation of our customers and revenues generated from our
individual consumer business and our institutional business is based on our internal classification methodologies and the way
we operate our business. For example, our individual consumer business customers comprise of: (i) customers who visit our
diagnostic centres and avail our services as per our price list; (ii) customers whose samples are collected at their residence and
processed by us; (iii) customers who avail our services basis discretionary discounts provided by us as part of our various
marketing and other initiatives; and (iv) customers who are employees of Government companies or are covered under
Government initiatives or are beneficiaries of life / health insurance policies and choose to undergo tests at our diagnostic
centres. For further details, see “Our Business - Description of Our Business - Our Customers” on page 120. There may be
variation in the manner in which we and other companies operating in our industry categorise customers. Depending on our
assessment and focus from time to time, this mix may change and there is no assurance that we will continue to see a substantial
part of our business as being individual consumer business. In the future, we may have to focus more on our institutional
business, which may result in the reduction of the proportion of our individual consumer business to our total business, and
subject us to competitive pricing, increased discounts and reduced margins, which in turn may adversely affect our results of
operations and financial condition.

36. We have a contingent liability that has not been provided for in our financial statements, which, if it materialises, may
adversely affect our results of operations.

The following table sets forth certain information relating to our contingent liability, which has not been provided for, as of
June 30, 2021:

 

Particulars Amount ( in million)
Demand for Provident Fund for the year 1998-2001 0.56
Total 0.56

 

 

 

 

 

 

If this liability materialises, it could have an adverse effect on our results of operations. For further details, see “Financial
Statements — Annexure VII — Note 38” on page 204. Our Company has not made provisions for the above contingent liabilities,
as they are either probable obligations whose existence will be confirmed only by future uncertain events outside the control of
our Company, or are present obligations where the outflow of economic resources may not be probable or cannot be measured
reliably.

37. We have incurred other expenses including but not limited to legal and professional expenses.

We have incurred other expenses for the three months ended June 30, 2021 and the financial years 2021, 2020 and 2019 in the
amount of 2286.00 million, 962.39 million, ¥998.93 million and 901.09 million, respectively, which mainly consist of legal
and professional fees in the amount of 7145.09 million, 462.01 million, 7507.03 million and 2454.43 million during the same
period/ year. The other expenses and legal and professional fees are not fixed in nature. We cannot provide assurance that these
other expenses and such legal and professional fees will not be increased in the future and may have an adverse effect on our
business, results of operations and financial condition.

38. One of our Subsidiaries, MDSL and one of our Group Companies, PHSPL, has delayed in depositing its undisputed
statutory dues

One of our Group Companies, PHSPL, has delayed in depositing undisputed statutory dues such as tax deducted at source,
provident fund, ESI dues, PT dues, sales tax, professional tax and tax deducted at source for contractors and interest for the
financial years ended March 31, 2018, 2019 and 2020. For further details, see “Our Group Companies — Park Health Systems
Private Limited” on page 157. Further, our subsidiary, MDSL, has delayed in making certain interest and penalty payments
under the Customs Act, 1962 and Income Tax, Act, 1961. For details, see "Financial Statements - Annexure VI" on page 172.

39. Our ability to pay dividends in the future will depend on our earnings, financial condition, working capital requirements,
capital expenditures and restrictive covenants of our financing arrangements.

Our ability to pay dividends in the future will depend on our earnings, financial condition, cash flow, working capital
requirements and capital expenditure. Any future determination as to the declaration and payment of dividends will be at the
discretion of our Board and will depend on factors that our Board deems relevant, including among others, our future earnings,
financial condition, cash requirements, business prospects and any other financing arrangements. Additionally, our ability to
pay dividends may also be restricted by the terms of financing arrangements that we may enter into. Dividends distributed by
us will attract dividend distribution tax at rates applicable from time to time. We cannot assure you that we will be able to pay
dividends in the future. For further details, see “Dividend Policy” on page 161.

34
External Risk Factors
Risks relating to India

40. Political, economic or other factors that are beyond our control may have an adverse effect on our business and results
of operations.

The Indian economy and capital markets are influenced by economic, political and market conditions in India and globally.
Adverse economic developments, such as rising fiscal or trade deficit, in other emerging market countries may also affect
investor confidence and cause increased volatility in Indian securities markets and indirectly affect the Indian economy in
general. Our Company is incorporated in India, and our assets and employees are all located in India. As a result, we are
dependent on prevailing economic conditions in India and our results of operations are affected by factors influencing the Indian
economy. Further, the following external risks may have an adverse impact on our business and results of operations, should
any of them materialise. Such incidents could also create a greater perception that investment in Indian companies involves a
higher degree of risk and could have an adverse effect on our business and the price of the Equity Shares:

. increase in interest rates may adversely affect our access to capital and increase our borrowing costs, if any, which
may constrain our ability to grow our business and operate profitably;

. downgrade of India’s sovereign debt rating by an independent agency;

° political instability, resulting from a change in governmental or economic and fiscal policies, may adversely affect
economic conditions in India;

. strikes, lock-outs, work stoppages or increased wage demands by employees, suppliers or other service providers;
° civil unrest, acts of violence, terrorist attacks, regional conflicts or situations or war;
. fires and/or severe weather, which can result in damage to our property or inventory and generally reduce our

productivity and may require us to evacuate personnel and suspend operations.

. India has experienced epidemics and natural calamities such as earthquakes, tsunamis, floods, and drought in recent
years;

° financial instability and turmoil in other countries; and

° contagious diseases such as the COVID-19 pandemic, the highly pathogenic H7N9, H5N1 and HIN1 strains of

influenza in birds and swine. A worsening of the current COVID-19 pandemic or any similar future outbreaks of
COVID-19, avian or swine influenza or a similar contagious disease could adversely affect the Indian economy and
economic activity in the region.

We are dependent on domestic and regional economic and market conditions. Our performance, growth and market price of
our Equity Shares are and will be dependent to a large extent on the health of the economy in which we operate. Any slowdown
or perceived slowdown in the Indian economy, or in specific sectors of the Indian economy, could adversely affect our business,
results of operations and financial condition and the price of the Equity Shares. Our performance and the growth of our business
depend on the overall performance of the Indian economy as well as the economies of the regional markets in which we operate.

41. Our operations may be adversely affected by the effects of health pandemics, civil disturbances, social unrest, hostilities
or acts of terrorism, natural disasters such as extreme weather events and other criminal activities.

Certain events that are beyond our control, such as health pandemics, terrorist attacks, natural calamities and other acts of
violence or war, may adversely affect worldwide financial and Indian markets, and could potentially lead to a severe economic
recession, which could adversely affect our business, results of operations, financial condition and cash flows, and more
generally, any of these events could lower confidence in India’s economy.

India has experienced social unrest in some parts of the country. If such tensions occur in other parts of the country leading to
overall political and economic instability, it could have an adverse effect on our business, financial condition, results of
operations and the trading price of our Equity Shares. India has also experienced natural calamities such as earthquakes,
tsunamis, floods and droughts in the past. Instances of floods or other natural calamities could have an adverse effect on our
business, financial condition, results of operations and the trading price of our Equity Shares. Such events may result in a
temporary decline in the number of patients who seek clinical testing services or in our employees’ ability to perform their
duties. In addition, such events may temporarily interrupt our ability to transport specimens, to receive materials from our
suppliers or otherwise to provide our services.

35,
42. Changing laws, rules and regulations and legal uncertainties, including any adverse application of tax laws and
regulations across the multiple states we operate in, could have an adverse effect on our business, financial condition,
results of operations and cash flows

The regulatory and policy environment in which we operate is evolving and subject to change. Such changes, including the
instances mentioned below, may adversely affect our business, results of operations and prospects, to the extent that we are
unable to suitably respond to and comply with any such changes in applicable law and policy. For example:

° the Government of India has implemented a comprehensive national GST regime that combines taxes and levies by
the Central and State Governments into a unified rate structure. In this regard, the Constitution (One hundred and first
Amendment) Act, 2016 enables the Government of India and state governments to introduce GST. Any future
increases or amendments may adversely affect the overall tax efficiency of companies operating in India and may
result in significant additional taxes becoming payable. If, as a result of a particular tax risk materializing, the tax costs
associated with certain transactions become greater than anticipated, it could affect the profitability of such
transactions; and

. the Finance Act, 2021 has introduced various amendments having an impact across various sectors including the sector
in which we operate. For further details in relation to the risks relating to the Finance Act, 2021, see “- Investors may
be subject to Indian taxes arising out of capital gains on the sale of Equity Shares” on page 39.

Unfavourable changes in or interpretations of existing, or the promulgation of new, laws, rules and regulations including foreign
investment and stamp duty laws governing our business and operations could result in us being deemed to be in contravention
of such laws and may require us to apply for additional approvals. For instance, the Supreme Court of India has in a decision
clarified the components of basic wages which need to be considered by companies while making provident fund payments,
which resulted in an increase in the provident fund payments to be made by companies. Any such decisions in future or any
further changes in interpretation of laws may have an impact on our results of operations. We may incur increased costs and
other burdens relating to compliance with such new requirements, which may also require significant management time and
other resources, and any failure to comply may adversely affect our business, results of operations and prospects. Uncertainty
in the application, interpretation or implementation of any amendment to, or change in, governing law, regulation or policy,
including by reason of an absence, or a limited body, of administrative or judicial precedent may be time consuming as well as
costly for us to resolve and may impact the viability of our current business or restrict our ability to grow our businesses in the
future.

43. Investors may not be able to enforce a judgment of a foreign court against us, our Directors, the Book Running Lead
Managers or any of their directors and executive officers in India respectively, except by way of a law suit in India

Our Company is incorporated under the laws of India. Our Company’s assets are located in India and all of our Company’s
Directors and Key Managerial Personnel are residents of India. As a result, it may not be possible for investors to effect service
of process upon our Company or such persons in jurisdictions outside India, or to enforce against them judgments obtained in
courts outside India. Moreover, it is unlikely that a court in India would award damages on the same basis as a foreign court if
an action were brought in India or that an Indian court would enforce foreign judgments if it viewed the amount of damages as
excessive or inconsistent with Indian public policy or if judgments are in breach or contrary to Indian law.

Recognition and enforcement of foreign judgments is provided for under Section 13 and Section 44A of the Code of Civil
Procedure, 1908 (“CPC”). India has reciprocal recognition and enforcement of judgments in civil and commercial matters with
a limited number of jurisdictions, which includes, the United Kingdom, Singapore, United Arab Emirates and Hong Kong. A
judgment from certain specified courts located in a jurisdiction with reciprocity must meet certain requirements of the CPC.
The United States and India do not currently have a treaty providing for reciprocal recognition and enforcement of judgments
in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any federal or state court
in a non-reciprocating territory, such as the United States, for civil liability, whether or not predicated solely upon the general
laws, including securities laws of the non-reciprocating territory, including United States, would not be enforceable in India
under the CPC as a decree of an Indian court.

The United Kingdom, Singapore, United Arab Emirates and Hong Kong have been declared by the Government of India to be
reciprocating territories for purposes of Section 44A of the Civil Code. Section 13 of the Civil Code provides that foreign
judgments shall be conclusive regarding any matter directly adjudicated upon between the same parties or parties litigating
under the same title, except (i) where the judgment has not been pronounced by a court of competent jurisdiction, (ii) where the
judgment has not been given on the merits of the case, (iii) where it appears on the face of the proceedings that the judgment is
founded on an incorrect view of international law or refusal to recognise the law of India in cases to which such law is applicable,
(iv) where the proceedings in which the judgment was obtained were opposed to natural justice, (v) where the judgment has
been obtained by fraud or (vi) where the judgment sustains a claim founded on a breach of any law then in force in India. Under
the Civil Code, a court in India shall, on the production of any document purporting to be a certified copy of a foreign judgment,
presume that the judgment was pronounced by a court of competent jurisdiction, unless the contrary appears on record. The
CPC only permits the enforcement of monetary decrees, not being in the nature of any amounts payable in respect of taxes,
other charges, fines or penalties. Judgments or decrees from jurisdictions which do not have reciprocal recognition with India

36
cannot be enforced by proceedings in execution in India. Even if an investor obtained a judgment in such a jurisdiction against
us, our officers or directors, it may be required to institute a new proceeding in India and obtain a decree from an Indian court.

However, the party in whose favour such final judgment is rendered may bring a new suit in a competent court in India based
on a final judgment that has been obtained in the United States or other such jurisdiction within three years of obtaining such
final judgment. In addition, any person seeking to enforce a foreign judgment in India is required to obtain the prior approval
of the RBI to repatriate any amount recovered.

44, Under Indian law, foreign investors are subject to investment restrictions that limit our ability to attract foreign
investors, which may adversely affect the trading price of the Equity Shares.

Foreign ownership of Indian securities is subject to Government regulation. Under foreign exchange regulations currently in
force in India, transfer of shares between non-residents and residents are freely permitted (subject to certain exceptions), if they
comply with the pricing and reporting requirements specified under applicable laws. If a transfer of shares is not in compliance
with such requirements and does not fall under any of the exceptions specified under such applicable laws, then prior regulatory
or government approval is required. Additionally, shareholders who seek to convert Rupee proceeds from a sale of shares in
India into foreign currency and repatriate that foreign currency from India require a no-objection or a tax clearance certificate
from the Indian income tax authorities. As provided in the foreign exchange controls currently in effect in India, the RBI has
provided that the price at which the Equity Shares are transferred be calculated in accordance with internationally accepted
pricing methodology for the valuation of shares at an arm’s length basis, and a higher (or lower, as applicable) price per share
may not be permitted. Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the
Department for Promotion of Industry and Internal Trade and the Foreign Exchange Management (Non-debt Instruments)
Amendment Rules, 2020 which came into effect from April 22, 2020, any investment, subscription, purchase or sale of equity
instruments by entities of a country which shares a land border with India or where the beneficial owner of an investment into
India is situated in or is a citizen of any such country, will require prior approval of the Government of India, as prescribed in
the Consolidated FDI Policy and the Foreign Exchange Management (Non-Debt Instrument) Rules, 2019. These investment
restrictions shall also apply to subscribers of offshore derivative instruments. We cannot assure you that any required approval
from the RBI or any other governmental agency can be obtained on any particular term or at all. For further details, see
“Restrictions on Foreign Ownership of Indian Securities” on page 286.

 

45. Rights of shareholders under Indian laws may be more limited than under the laws of other jurisdictions

Indian legal principles related to corporate procedures, directors’ fiduciary duties and liabilities, and shareholders’ rights may
differ from those that would apply to a company in another jurisdiction. Shareholders’ rights including in relation to class
actions, under Indian law may not be as extensive as shareholders’ rights under the laws of other countries or jurisdictions.
Investors may have more difficulty in asserting their rights as shareholder in an Indian company than as shareholder of a
corporation in another jurisdiction.

46. A slowdown in economic growth in India or political instability or changes in the Government in India could adversely
affect our business.

Our performance and the growth of our business are necessarily dependent on the health of the overall Indian economy. In the
recent past, Indian economy has been affected by global economic uncertainties and liquidity crisis, domestic policy and
political environment, volatility in interest rates, currency exchange rates, commodity and electricity prices, adverse conditions
affecting agriculture, rising inflation rates and various other factors. Risk management initiatives by banks and lenders in such
circumstances could affect the availability of funds in the future or the withdrawal of our existing credit facilities. The Indian
economy is undergoing many changes and it is difficult to predict the impact of certain fundamental economic changes on our
business. Conditions outside India, such as a slowdown or recession in the economic growth of other major countries, have an
impact on the growth of the Indian economy. Additionally, an increase in trade deficit, a downgrading in India’s sovereign debt
rating or a decline in India’s foreign exchange reserves could negatively affect interest rates and liquidity, which could adversely
affect the Indian economy and our business. Any downturn in the macroeconomic environment in India could adversely affect
our business, financial condition, results of operation and the trading price of our Equity Shares. Volatility, negativity, or
uncertain economic conditions could undermine the business confidence and could have a significant impact on our results of
operations. Changing demand patterns from economic volatility and uncertainty could have a significant negative impact on
our results of operations.

47. Any adverse change in India’s sovereign credit rating by an international rating agency could adversely affect our
business, results of operations and cash flows.

Our access to the debt capital markets depend significantly on the credit ratings of India. India’s sovereign rating decreased
from Baa2 with a “negative” outlook to Baa3 with a “negative” outlook by Moody’s and from BBB with a “stable” outlook to
BBB with a “negative” outlook (Fitch) in June 2020; and from BBB “stable” to BBB “negative” by DBRS in May 2020. India’s
sovereign ratings from S&P is BBB-with a “stable” outlook. Any such adverse revisions to India’s credit ratings for domestic
and international debt by international rating agencies may adversely impact our ability to raise debt financing. A downgrading
of India’s credit ratings may occur, for example, upon a change of government tax or fiscal policy, which are outside our control.
This could have an adverse effect on our ability to fund our growth on favourable terms and consequently adversely affect our

37
business and financial performance and the price of the Equity Shares.
Risks relating to the Equity Shares and the Offer
48. The Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares after the Offer.

The Offer Price of the Equity Shares shall be determined by our Company and the Selling Shareholders in consultation with
the Book Running Lead Managers, and through the Book Building Process. This price would be based on numerous factors, as
described under “Basis for Offer Price” on page 72 and may not be indicative of the market price for the Equity Shares after
the Offer. The market price of the Equity Shares could be subject to significant fluctuations after the Offer, and may decline
below the Offer Price. We cannot assure you that you will be able to resell your Equity Shares at or above the Offer Price.

49. The Equity Shares have never been publicly traded, and, after the Offer, the Equity Shares may experience price and
volume fluctuations, and an active trading market for the Equity Shares may not develop.

Prior to the Offer, there has been no public market for the Equity Shares, and an active trading market on the Stock Exchanges
may not develop or be sustained after the Offer. Listing and quotation does not guarantee that a market for the Equity Shares
will develop, or if developed, the liquidity of such market for the Equity Shares. The Offer Price of the Equity Shares shall be
determined through a book-building process and may not be indicative of the market price of the Equity Shares at the time of
commencement of trading of the Equity Shares or at any time thereafter. The market price of the Equity Shares may be subject
to significant fluctuations in response to, among other factors, variations in our operating results of our Company, market
conditions specific to the industry we operate in, developments relating to India, volatility in securities markets in jurisdictions
other than India, variations in the growth rate of financial indicators, variations in revenue or earnings estimates by research
publications, and changes in economic, legal and other regulatory factors.

50. Fluctuation in the exchange rate between the Indian Rupee and foreign currencies may have an adverse effect on the
value of our Equity Shares, independent of our operating results.

On listing, our Equity Shares will be quoted in Indian Rupees on the Stock Exchanges. Any dividends in respect of our Equity
Shares will also be paid in Indian Rupees and subsequently converted into the relevant foreign currency for repatriation, if
required. Any adverse movement in currency exchange rates during the time that it takes to undertake such conversion may
reduce the net dividend to foreign investors. In addition, any adverse movement in currency exchange rates during a delay in
repatriating outside India the proceeds from a sale of Equity Shares, for example, because of a delay in regulatory approvals
that may be required for the sale of Equity Shares may reduce the proceeds received by Equity Shareholders. For example, the
exchange rate between the Rupee and the U.S. dollar has fluctuated in recent years and may continue to fluctuate substantially
in the future, which may have an adverse effect on the returns on our Equity Shares, independent of our operating results.

51. You may not be able to immediately sell any of the Equity Shares you subscribe to in this Offer on an Indian Stock
Exchange.

In accordance with Indian law and practice, permission for listing of the Equity Shares will not be granted till the Equity Shares
in this Offer have been issued and allotted and all relevant documents are submitted to the Stock Exchanges. Further, certain
actions must be completed prior to the commencement of listing and trading of the Equity Shares such as the demat accounts
of the Investors are expected to be credited within three Working Days of the date on which the Basis of Allotment is finalised
with the Designated Stock Exchange. In addition, upon receipt of listing and trading approval from the Stock Exchanges, trading
of Equity Shares is expected to commence within six Working Days from Bid/ Offer Closing Date. However, we cannot assure
you that the trading in the Equity Shares will commence in a timely manner or at all. Any failure or delay in obtaining the
approvals would restrict your ability to dispose of your Equity Shares.

52. There is no assurance that our Equity Shares will remain listed on the stock exchange.

Although it is currently intended that the Equity Shares will remain listed on the Stock Exchanges, there is no guarantee of the
continued listing of the Equity Shares. Among other factors, we may not continue to satisfy the listing requirements of the Stock
Exchanges. Accordingly, Shareholders will not be able to sell their Equity Shares through trading on the Stock Exchanges if
the Equity Shares are no longer listed on the Stock Exchange.

53. Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by us may dilute your
shareholding and adversely affect the trading price of the Equity Shares.

Any future issuance of the Equity Shares, convertible securities or securities linked to the Equity Shares by us, including through
exercise of employee stock options may dilute your shareholding in our Company, adversely affect the trading price of the
Equity Shares and our ability to raise capital through an issue of our securities. In addition, any perception by investors that
such issuances or sales might occur could also affect the trading price of the Equity Shares. We cannot assure you that we will
not issue additional Equity Shares or convertible securities or other equity-linked securities.

38
54, Holders of Equity Shares may be restricted in their ability to exercise pre-emptive rights under Indian law and thereby
suffer future dilution of their ownership position.

A public company incorporated in India must offer its equity shareholders pre-emptive rights to subscribe and pay for a
proportionate number of equity shares to maintain their existing ownership percentages prior to issuance of any new equity
shares, unless the pre-emptive rights have been waived by the adoption of a special resolution by holders of three-fourths of the
equity shares voting on such resolution.

However, if the law of the jurisdiction that you are in does not permit the exercise of such pre-emptive rights without our filing
an offering document or registration statement with the applicable authority in such jurisdiction, you will be unable to exercise
such pre-emptive rights, unless we make such a filing. If we elect not to file a registration statement, the new securities may be
issued to a custodian, who may sell the securities for your benefit. The value such custodian receives on the sale of any such
securities and the related transaction costs cannot be predicted. To the extent that you are unable to exercise pre-emptive rights
granted in respect of our Equity Shares, your proportional interests in our Company would be diluted.

55. Investors may be subject to Indian taxes arising out of capital gains on the sale of the Equity Shares.

Under current Indian tax laws, unless specifically exempted, capital gains arising from the sale of equity shares in an Indian
company are generally taxable in India. The Income Tax Act levies taxes on such long-term capital gains exceeding 7100,000
arising from sale of equity shares on or after April 1, 2018, while continuing to exempt the unrealised capital gains earned up
to January 31, 2018 on such equity shares subject to specific conditions. Accordingly, you may be subject to payment of long-
term capital gains tax in India, in addition to payment of a securities transaction tax (“STT”), on the sale of any Equity Shares
held for more than 12 months. STT will be levied on and collected by an Indian stock exchange on which the Equity Shares are
sold.

Further, any gain realised on the sale of listed equity shares held for a period of 12 months or less will be subject to short term
capital gains tax in India. Capital gains arising from the sale of the Equity Shares will be exempt from taxation in India in cases
where the exemption from taxation in India is provided under a treaty between India and the country of which the seller is
resident. Generally, Indian tax treaties do not limit India’s ability to impose tax on capital gains. As a result, residents of other
countries may be liable for tax in India as well as in their own jurisdiction on a gain upon the sale of the Equity Shares.

The Finance Act, 2019, had clarified that in the absence of a specific provision under an agreement, the buyer shall be liable to
pay stamp duty in case of sale of securities through stock exchanges, and the transferor shall be liable to pay stamp duty in case
of transfer for consideration through a depository. The stamp duty for transfer of securities other than debentures, on a delivery
basis is specified at 0.015% and on a non-delivery basis is specified at 0.003% of the consideration amount. These provisions
have been notified with effect from July 1, 2020. The Government of India had announced the union budget for financial year
2022 and the Finance Act, 2021 received assent from the President of India on March 28, 2021 and was made effective from
April 1, 2021. There is no certainty on the impact that the Finance Act, 2021 may have on our business and operations or in the
industry we operate in.

56. QIBs and Non-Institutional Investors are not permitted to withdraw or lower their Bids (in terms of quantity of Equity
Shares or the Bid Amount) at any stage after submitting a Bid.

Pursuant to the SEBI ICDR Regulations, QIBs and Non-Institutional Investors are not permitted to withdraw or lower their
Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage after submitting a Bid. RIBs can revise or withdraw
their Bids during the Bid/Offer Period. While our Company is required to complete all necessary formalities for listing and
commencement of trading of our Equity Shares on the Stock Exchanges where such Equity Shares are proposed to be listed
and the Allotment pursuant to the Offer within such period as may be prescribed under applicable law, events affecting the
Bidders’ decision to invest in the Equity Shares, including adverse changes in international or national monetary policy,
financial, political or economic conditions, our business, results of operation or financial condition may arise between the date
of submission of the Bid and Allotment. Our Company may complete the Allotment of the Equity Shares even if such events
occur, and such events limit the Bidders’ ability to sell the Equity Shares Allotted pursuant to the Offer or cause the trading
price of the Equity Shares to decline on listing.

57, Government regulation of foreign ownership of Indian securities may have an adverse effect on the price of our Equity
Shares.

Foreign ownership of Indian securities is subject to Government regulation. In accordance with foreign exchange regulations
currently in effect in India, under certain circumstances RBI must approve the sale of the Equity Shares from a non-resident of
India to a resident of India or vice-versa if the sale does not meet certain requirements specified by RBI. Additionally, any
person who seeks to convert the Rupee proceeds from any such sale into foreign currency and repatriate that foreign currency
from India is required to obtain a no-objection or a tax clearance certificate from the Indian income tax authorities. As provided
in the foreign exchange controls currently in effect in India, RBI has provided that the price at which the Equity Shares are
transferred be calculated in accordance with internationally accepted pricing methodology for the valuation of shares at an
arm’s length basis, and a higher (or lower, as applicable) price per share may not be permitted. We cannot assure investors that
any required approval from RBI or any other government agency can be obtained on terms favourable to a non-resident investor

39
in a timely manner or at all. Because of possible delays in obtaining requisite approvals, investors in the Equity Shares may be
prevented from realising gains during periods of price increase or limiting losses during periods of price decline.

58. Our ability to raise foreign capital may be constrained by Indian Law.

As a company registered in India, we are subject to exchange controls that regulate borrowing in foreign currencies. Such
regulatory restrictions limit our financing sources and could constrain our ability to obtain financings on competitive terms and
refinance existing indebtedness. In addition, we cannot assure you that any required regulatory approvals for borrowing in
foreign currencies will be granted to us without onerous conditions, or at all. Limitations on foreign debt may have an adverse
effect on our business growth, results of operations and financial condition.

40
SECTION III: INTRODUCTION

THE OFFER

The following table sets forth details of the Offer:

 

Equity Shares Offered

 

Offer of Equity Shares”

35,688,064" Equity Shares, aggregating up to 218,942.56 million

 

The Offer consists of:

 

Offer for Sale”)

35,688,064" Equity Shares, aggregating up to 218,942.56 million

 

 

 

of which:
Employee Reservation Portion® 150,000” Equity Shares aggregating up to 871.85 million
Net Offer Up to 35,538,064" Equity Shares aggregating up to 218,870.71

million

 

A) QIB Portion®®

Not more than 17,769,031" Equity Shares

 

of which:

 

- Anchor Investor Portion

Up to 10,661,418" Equity Shares

 

- Net QIB Portion (assuming the Anchor Investor Portion is
fully subscribed)

7,107,613" Equity Shares

 

of which:

 

- Mutual Fund Portion (5% of the Net QIB Portion)

355,381" Equity Shares

 

- Balance for all QIBs including Mutual Funds

6,752,232" Equity Shares

 

B) Non-Institutional Portion

Not less than 5,330,710" Equity Shares

 

C) Retail Portion®)

Not less than 12,438,323" Equity Shares

 

 

Pre and post-Offer Equity Shares

 

Equity Shares outstanding prior to and after the Offer

101,965,926" Equity Shares

 

Use of Net Proceeds of the Offer

 

 

See “Objects of the Offer” on page 70 for information about the use
of the proceeds from the Offer. Our Company will not receive any
proceeds from the Offer since it only involves the Offer for Sale.

 

 

“Subject to finalisation of the Basis of Allotment

“A discount of 252 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion
© The Offer has been approved by our Board of Directors pursuant to the resolution passed at its meeting dated June 4, 2021, the Draft Red Herring
Prospectus was approved by our Board pursuant to a resolution passed on June 4, 2021 and the Red Herring Prospectus has been approved by our
Board pursuant to a resolution passed on August 24, 2021. Our Board also took on record the approval for the Offer for Sale for the Offered Shares by

the Selling Shareholders pursuant to a resolution dated June 4, 2021.

® The Equity Shares being offered by the Selling Shareholders are eligible for being offered for sale pursuant to the Offer in terms of the SEBI ICDR
Regulations. The Selling Shareholders have, severally and not jointly, confirmed and approved their participation in the Offer for Sale as set out below:

 

 

 

 

 

 

Selling Shareholder ‘Number of Equity Shares offered Date of board resolution/
in the Offer for Sale Authorisation
Dr. S. Surendranath Reddy 5,098,296 June 4, 2021
Karakoram Limited 29,487,290 May 31, 2021
Kedaara Capital Alternative Investment Fund ~ Kedaara Capital AIF 1 1,102,478 May 20, 2021
Total 35,688,064

 

 

 

 

“Subject to finalisation of the Basis of Allotment

For further details, please see “Offer Procedure

Undertakings by the Selling Shareholders” on page 284.

© In the event of under-subscription in the Employee Reservation Portion, the unsubscribed portion was made available for allocation and Allotment,
proportionately to all Eligible Employees who have Bid in excess of 2200,000, subject to the maximum value of Allotment made to such Eligible Employee
not exceeding %500,000. The unsubscribed portion, if any, in the Employee Reservation Portion (after allocation up to 500,000), was added to the Net
Offer. Our Company and the Selling Shareholders, in consultation with the BRLMs, may offer a discount of up to 10% (equivalent to up to %52 per
Equity Share) to the Eligible Employees Bidding under the Employee Reservation Portion.

Our Company and the Selling Shareholders in consultation with the BRLMs, has allocated up to 60% of the QIB Portion to Anchor Investors on a
discretionary basis. The QIB Portion will accordingly be reduced for the Equity Shares allocated to Anchor Investors. One-third of the Anchor Investor
Portion was reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor
Allocation Price Further, 5% of the Net QIB Portion was required to be made available for allocation on a proportionate basis only to Mutual Funds,
and spill-over from the remainder of the Net QIB Portion was required to be made available for allocation on a proportionate basis to all QIBs (other
than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. For details, see “Offer Procedure”

on page 272.

© Subject to valid Bids having been received at or above the Offer Price, under-subscription, if any, in any category except the QIB Portion, would be
allowed to be met with spill over from any other category or combination of categories at the discretion of our Company and the Selling Shareholders
in consultation with the BRLMs and the Designated Stock Exchange. Under-subscription, if any, in the QIB Portion would not be allowed to be met with
spill-over from other categories or a combination of categories. For further details, see “Offer Structure " on page 270.

Allocation to all categories, except the Anchor Investor Portion and the Retail Portion, shall be made on a proportionate basis
subject to valid Bids received at or above the Offer Price, as applicable. The allocation to each Retail Individual Bidder shall
not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available
Equity Shares, if any, shall be allocated on a proportionate basis. For further details, see “Offer Procedure” on page 272. For

41
details of the terms of the Offer, see “Terms of the Offer” on page 265. For details, including in relation to grounds for rejection
of Bids, refer to “Offer Structure” and “Offer Procedure” on pages 270 and 272, respectively.

42
SUMMARY OF FINANCIAL INFORMATION
The following tables set forth the summary financial information derived from the Restated Financial Information for the three
month periods ended June 30, 2021 and June 30, 2020 and Fiscals ended March 31, 2021, March 31, 2020 and March 31, 2019.
The summary financial information presented below should be read in conjunction with “Financial Information” and
“Management's Discussion and Analysis of Financial Condition and Results of Operations” on pages 162 and 226, respectively.

(The remainder of this page has intentionally been left blank)

43
RESTATED CONSOLIDATED BALANCE SHEET DATA

(@ in million)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars As at
June 30, | June30, | March3i, | March 3i, March 31,
2021 2020 2021 2020 2019
ASSETS
NON-CURRENT ASSETS
Property, plant and equipment 1,341.97 1,395.22 1,357.64 1,398.47 1,437.29
Capital work-in-progress 60.71 153.49 81.82 92.61 27.09
Goodwill 53.37 53.37, 53.37 53.37 68.79
Other intangible assets 14.98 9.26 6.01 10.36 7.46
Right of use asset 1,452.58. 1,277.17 1,260.01 1,253.77 1,078.81
Intangible assets under development 3.51 3.65 12.36 3.65 :
Financial assets
(i)_Investments 0.40 0.40 0.40 0.40 0.40
(ii) Other financial assets 185.13 52.30 122.22 54.85 43.18
Deferred tax assets, (net) 69.55 51.65 60.97 15.81 11.78
Income tax assets (net) 3.70 8.81 5.70 9.13 B41
Other assets 7791 34.98 61.09 66.62 6.50
3,263.81 | 3,040.30 3,021.59 2,959.04 2,689.71
CURRENT ASSETS
Inventories 62.95 35.31 26.44 27.73 21.78
Financial assets
(i) Investments 279.57, 276.27 546.74 688.37
(ii) Trade receivables 55.52 64.08 79.97 91.25
(iii) Cash and cash equivalents 101.58 66.86 555.69 96.21
(iv) Bank balances other than Cash and cash equivalents 2,147.90 1,875.55 626.23 430.12
(v) Other financial assets 93.30 51.89 5.42 29.72
Other current assets 41.15 26.72 21,74 17.14
2,781.97 2,387.81 1,863.52 1,374.59
TOTAL ASSETS 6,045.78 5,409.40 4,822.56 4,064.30
EQUITY AND LIABILITIES
EQUITY
Equity share capital 101.97 45.32 45.32 45.32 45.29
Instruments entirely equity in nature - - - - 24.13
Other equity 3,821.29 2,718.93 3,544.74 2,700.11 2,004.40
Equity attributable to owners of the Company 3,923.26 | 2,764.25 3,590.06 2,745.43 2,073.82
Non-controlling interest 5.82 (6.97) 2.26 (4.04) (G72)
3,929.08 | 2,758.28 3,592.32 2,741.39 2,070.10
LIABILITIES
NON-CURRENT LIABILITIES
Financial liabilities
(i) Borrowings : 197.41 32.75 221.33 315.35,
(ii) Lease liabilities 1,463.36 1,248.64 1,264.72 1,196.10 1,034.16
(iii) Other financial liabilities 0.73 6.80 2.18 8.75 18.73
Provisions 80.66 76.79 77.02 67.41 53.19
Other liabilities 0.82 0.91 0.53 1.18 1.37
1,545.57 | __ 1,530.55 1,377.20 1,494.77 1,422.80
CURRENT LIABILITIES
Financial liabilities
(i) Borrowings 11.92 109.15 11,97 107.07 108.91
(ii) Lease liabilities 108.23 90.52 101.03 87.77 72.64
(iii) Trade payables
- Due to micro and small enterprises 1.01 0.07 2.68 0.33 :
- Due to creditors other than micro and small enterprises 258.24 201.73 218.88 216.60 217.54
(iv) Other financial liabilities 82.97 182.63 61.27 129.69 114.96
Income tax liabilities 78.54 5.88 16.24 14.47 15.99
Provisions 8.88 10.57 7.36 10.37 10.80
Other liabilities 21.34 12.45 20.45 20.10 30.56
571.13 613.00 439.88 586.40 571.40
TOTAL EQUITY AND LIABILITIES 6,045.78 4,901.83 5,409.40 4,822.56 4,064.30

 

#For details in relation to the "Right of Use Assets” see "Financial Statements - Annexure VII - Note 6 (Right of use asset (ROU)" on page 189
‘For details in relation to the Bank balances other than cash and cash equivalents see "Financial Statements - Annexure VII - Note 14 "Bank balances other
than Cash and cash equivalents" on page 194
RESTATED CONSOLIDATED STATEMENT OF PROFIT AND LOSS DATA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(@ in million)
Particulars For the financial period/ year ended
June 30, | June 30, | March 31, | March 31, | March 31,
2021 2020 2021 2020 2019

INCOME
Revenue from operations 1,226.86 517.10 3,767.46 3,388.21 2,925.87
Other income 32.84 22.82 118.47 153.61 103.57
Total Income 1,259.70 539.92 3,885.93 3,541.82 3,029.44
EXPENSES
Cost of materials consumed 210.84 75.54 570.95 439.06 404.78
Employee benefits expense 161.47 128.52 574.35, 624.01 538.80
Finance costs 40.03 38.40 153.85 135.33
Depreciation and amortisation expense 119.21 116.35 491.70 396.26
Other expenses 286.00 174.63 962.39 998.93 901.09
Total expenses 817.55, 533.44 2,764.69 2,707.55, 2,376.26
Profit/(loss) before tax 442.15 6.48 1,121.24 834.27 653.18
Tax expenses:
Current tax 117.41 23.60 317.41 230.64 196.66
Deferred tax (8.51) | (35.22) (45.28) (21.44) (6.20)
Total tax expense 108.90 (11.62) 272.13 209.20 190.46
Profit (loss) for the period/year 333.25 18.10 849.11 625.07 462.72
Other comprehensive income /(loss) (OCI)
1. Items that will not be reclassified to profit or loss
i. Re-measurement gains/ (losses) of post-employment defined (0.28) (2.61) (0.02) (1.75) (2.19)
benefit plans
ii, Income tax related to above 0.06 0.62 (0.12) 0.44 0.57
Other comprehensive income /(loss) (OCI) for the period/year, (0.22) (199) (0.14) (131) (1.62)
net of tax
Total comprehensive income /(loss) (OCI) for the period/year 333.03 16.11 848.97 623.76 461.10
Profit for the period/year attributable to:
Owners of the Company 329.69 19.13 625.38 458.74
Non controlling interests 3.56 (2.03) (0.31) 3.98
Other comprehensive income/(loss) attributable to:
Owners of the Company (0.22) (2.09) 0.04 (2.30) (1.56)
Non controlling interests (0.00) (0.90) (0.18) (0.01) (0.06)
Total comprehensive income/(loss) attributable to:
Owners of the Company 329.47 18.04 842.67 624.08, 457.18
Non controlling interests 3.56 (1.93) (0.32) 3.92
Earnings per equity share (Face value of Rs 1 each*) (Not
annualized for the period ended June 30, 2021 and June 30,
2020)
1. Basic (Rs) 3.23 0.19 6.13 4.50
2. Diluted (Rs) 3.23 0.19 6.13 4.50

 

*Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares

of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021
and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to issue bonus Equity Shares in the ratio of 5

Equity Shares for every 4 Equity Shares held

45,
RESTATED CONSOLIDATED STATEMENT OF CASH FLOWS DATA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(@ in million)
Particulars For the financial period/ year ended
June 30, | June30, | March3i, | March31, | March 3i, 2019
2021 2020 2021 2020
(A) CASH FLOW FROM _ OPERATING
ACTIVITIES
Profit/(loss) before tax: 442.15 6.48 1,121.24 834.27 653.18
‘Adjustments for:

Depreciation and Amortisation Expense 119.21 116.35 504.53 396.26
Net gain on sale/ retirement of property, plant and 51 (1 (156) (3.68)
equipment
Profit on slump sale of diagnostic centre = - = -
Interest income (28.47) (20.77) (95.96) (28.65)
Profit on sale of investment in mutual fund = (2.85) (1.57) (9.06)
Provision made /(reversed) for bad and doubtful 3 1.37 3.39 12.07
receivables
Fair value movement on financial instruments (3.30) z (8.29) (16.81) (43.65)
Liabilities written back 2 z (15.44) (7.35) (17.36)
Employee stock option expense 3.73 0.78 1.96 4.10 2.22
Finance cost 1.88 8.49 20.96 40.02 37.81
Bad and doubtful debts written-off - : 3.32 0.57 0.39
Advances Written Off : : 2.59 0.86 :
Interest expense on lease liabilities 33.61 28.01 114.13 99.25 84.69
Operating profit before working capital adjustments 568.30 138.75 1,654.30 1,326.44 1,084.22
Adjustments for working capital :

(Increase)/Decrease in Inventories (36.51) (7.58) 1.29 (5.95) 2.43

(Increase)/Decrease in trade and other receivables 8.55 6.32 9.19 7.03 (26.54)

(Increase)/ Decrease in other financial assets and loans 28.55 (0.46) (19.69) (2.04) (9.48)

(Increase) in other assets (73.52) (14.07) (8.40) (40.22) (22.42)

Increase/ (decrease) in trade payables 37.64 (14.95) 4.67 (0.62) 41.80

Increase/ (decrease) in other financial liabilities 39.80 (6.29) (30.14) 11.90 28.22

(Decrease) in provision and other liabilities (10.25) (3.84) (2.58) (2.55) (6.04)
562.56 98.88 1,608.64 1,293.99 1,092.19

Income tax paid (53.11) |_(31.87) (312.21) (232.87) (186.92)

NET CASH FLOW FROM OPERATING 509.45 67.01 1,296.43 1,061.12 905.27

ACTIVITIES

(B) CASH FLOW FROM INVESTING

ACTIVITIES

Payment for purchase and construction of property, (82.56) (48.70) (821.36) (475.47) (610.39)

plant and equipment including movement in capital

work-in-progress, capital advances and capital creditors

Proceeds from disposal of Property, plant and 181 0.11 9.03 100.60 19.13

equipment

Investment/redemption of debt oriented liquid mutual - 535.73, 275.31 207.46 95.83

funds, (net)

Deposits placed/ (matured) having original maturity of | (331.95) | (745.11) (2,308.05) (196.15) (409.42)

more than 3 months, net

Dividend Received : : : : 1.21

Interest received 43.57 5.44 47.50 57.34 5.18

NET CASH FLOW USED IN INVESTING | (369.13) | (252.53) (1,297.57) (306.22) (898.46)

ACTIVITIES

(C) CASH FLOW FROM FINANCING

ACTIVITIES

Repayment of long term borrowings (32.75) (22.57) (282.60) (89.38) (94.67)

Proceeds from long term borrowings ss = ~ : 168.77

(Repayment) / proceeds from short term borrowing (0.05) 0.72 (1.08) (6.49) 19.13

(Net)

Repayment of lease liabilities (including interest) (57.62) (85.70) (189.65) (167.51) (136.02)

Interest paid (15.18) (6.36) (14.36) (82.04) (28.98)

NET CASH FLOW FROM/((USED) IN | (105.60) (63.91) (487.69) (295.42) (71.77)

FINANCING ACTIVITIES

Net increase/(decrease) in cash and cash equivalents 34.72 | (249.43) (488.83) 459.48 (64.96)

(A+B+C)

Cash and cash equivalents at the beginning of the 66.86 555.69 555.69 96.21 161.17

period/year

Cash and cash equivalents at the end of the period/ 101.58 306.26 66.86 555.69 96.21

 

 

 

 

 

 

 

46
 

Particulars

For the financial period/ year ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30, | June30, | March3i, | March31, | March 3i, 2019
2021 2020 2021 2020

year

Reconciliation of Cash and Cash equivalents with the

Balance Sheet

Cash and Bank Balances as per Balance Sheet

Balance with banks

On current accounts 59.19 230.52 58.67 552.96 87.96

In deposit accounts having maturity less than 3 months 36.25 68.15 = - -
Cash on hand 6.14 7.59 8.19 2.73 8.25

Cash and cash equivalents at the end of the period/ 101.58 306.26 66.86 555.69 96.21

year

Movement in financial liabilities:

Opening balance

Non-current borrowings 32.75 221.33 221.33 315.35, 330.62

Current borrowings 11.97 107.07 107.07 108.91 0.41

Lease liabilities 1,365.75 | _ 1,283.87 1,283.87 1,101.11 z

Interest accrued but not due on borrowings 14.57 13.25 13.25 11.23 8.42

Movement

Cash flows (105.60) (63.91) (487.69) (295.42) (71.77)

Interest expense 34.22 35.12 129.80 133.32 116.48

Other non-cash movements

- Additions / Disposals to lease liabilities (net) 229.85 62.98 157.41 251.02 1,158.13

Closing balance

Non-current borrowings : 197.41 32.75 221.33 315.35,

Current borrowings 11,92 109.15 11,97 107.07 108.91

Lease liabilities 1,571.59 |_1,339.16 1,365.75 1,283.87 1,106.80

Interest accrued but not due on borrowings - 13.99 14.57 13.25 11,23

 

 

 

 

 

 

47

 
GENERAL INFORMATION

Registered Office of our Company

3-6-16 & 17, Street No. 19,

Himayatnagar, Hyderabad 500 029, Telangana, India
CIN: U85195TG2002PLC039075

Corporate Office of our Company
# 6-3-883/F, Ground Floor of Family Planning Association of India,
Panjagutta, Hyderabad 500 082, India

Address of the RoC with which our Company is registered

Our Company is registered with the RoC situated at the following address:
Registrar of Companies

2" Floor, Corporate Bhawan

GSI Post, Tattiannaram, Nagole

Bandlaguda, Hyderabad 500 068

Telangana, India

Board of Directors

As on the date of this Prospectus, our Board comprises the following:

 

 

 

 

 

Name Designation DIN ‘Address

Dr. S. Surendranath Reddy Executive Chairman 00108599 |No. 8-10-178/3/B, Nagarjuna Hills, Punjagutta,
Hyderabad 500 082, Telangana, India

S Geeta Reddy Non-Executive Director 01073233 |8-2-178/10/3/B Nagarjuna Hills, Panjagutta,
Hyderabad, 500 082, Telangana, India

Sunil Chandra Kondapally Executive Director 01409332 [H. No. 8-12-293/82/A/603, road no. 32 and 33,
Jubilee Hills, Hyderabad 500 033, Telangana, India

Nishant Sharma Non-executive, Nominee Director | 03117012 |Tower 2, APT 102, Planet Godrej Simplex Mills,

Mahalaxmi, Mumbai 400 011, India

Dr. D Nageshwar Reddy | Non-executive, Independent Director | 00324725 |A-27 Journalist Colony, Jubilee Hills, Shaikpet
Jubilee Hill, Hyderabad, Andhra Pradesh 500 033
Shekhar Prasad Singh Non-executive, Independent Director | 00969209 | 8-2-293/82/PN/176, Road No. 72 Prashasan Nagar,
Jubilee Hills, Hyderabad, Andhra Pradesh 500 033
Satyanaryana  Murthy| Non-executive, Independent Director | 00142138 | 2-293/82/A/408, Plot No.408, Road No-22A, Jubilee
Chavali Hills, Shaikpet, Hyderabad 500 033, Telangana, India
Manjula Anagani Non-executive, Independent Director | 03501757 | Flat No. 208, Aparna Chandradeep Apartments Road
No. 7, Near E Seva Center, Banjara Hills, Hyderabad
500 034, Telangana, India

 

 

 

 

 

 

 

 

 

 

For further details of our Directors, see “Our Management” on page 139.
Company Secretary and Compliance Officer

V. Sri Lakshmi

3-6-16 & 17, Street No. 19,

Himayatnagar, Hyderabad, Telangana, India
Tel: 40-23420411

E-mail: ir@vijayadiagnostic.in

Investors may contact the Compliance Officer and Company Secretary or the Registrar to the Offer in case of any pre-Offer or
post-Offer related problems such as non-receipt of Allotment Advice, non-credit of Allotted Equity Shares in the respective
beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc.

All Offer related grievances, other than those of Anchor Investors may be addressed to the Registrar to the Offer with a copy
to the relevant Designated Intermediary with whom the Bid-cum Application Form was submitted, giving full details such as
name of the sole or First Bidder, Bid cum Application Form number, Bidder’s DP ID, Client ID, PAN, address of Bidder,
number of Equity Shares applied for, ASBA Account number in which the amount equivalent to the Bid Amount was blocked
or the UPI ID (for Retail Individual Investors who make the payment of Bid Amount through the UPI Mechanism), date of Bid
cum Application Form and the name and address of the relevant Designated Intermediary where the Bid was submitted. Further,
the Bidder shall enclose the Acknowledgment Slip or the application number from the Designated Intermediary in addition to
the documents or information mentioned hereinabove. All grievances relating to Bids submitted through Registered Brokers
may be addressed to the Stock Exchanges with a copy to the Registrar to the Offer.

All grievances of the Anchor Investors may be addressed to the Registrar to the Offer, giving full details such as the name of
the sole or first Bidder, Bid cum Application Form number, Bidders’ DP ID, Client ID, PAN, date of the Bid cum Application

48
Form, address of the Bidder, number of the Equity Shares applied for, Bid Amount paid on submission of the Bid cum
Application Form and the name and address of the BRLMs where the Bid cum Application Form was submitted by the Anchor

Investor.

Book Running Lead Managers

ICICI Securities Limited
ICICI Centre, H. T. Parekh Marg,

Churchgate Off C.S.T.Road, Kalina
Mumbai 400 020 Mumbai 400 098
Maharashtra, India Maharashtra, India

Tel: +91 22 2288 2460

Email: vijaya.ipo@icicisecurities.com

Investor grievance e-mail: customercare@icicisecurities.com
Website: www. icicisecurities.com

Contact Person: Sameer Purohit/ Nidhi Wangnoo

SEBI Registration No.: INM000011179

Kotak Mahindra Capital Company Limited
1st Floor, 27 BKC, Plot No. 27

G Block, Bandra Kurla Complex

Bandra (East)

Mumbai 400 051

Maharashtra, India

Tel: +91 22 4336 0000

E-mail: vijayadiagnosti

  

o@kotak.com

Investor grievance e-mail: kmccredressal@kotak.com

Website: https:,

  

investmentbank.kotak.com

Contact Person: Ganesh Rane
SEBI Registration No.: INM000008704

Inter-se allocation of responsibilities

 

Tel: +91 22 4009 4400
E-mail: vijayadiagnostic.ipo@edelweissfin.com
Website: www.edelweissfin.com
Investor Grievance email: customerservice.mb@edelweissfin.com
Contact person: Lokesh Shah/Nilesh Roy
SEBI Registration No.: INM0000010650

Edelweiss Financial Services Limited
6" Floor, Edelweiss House

The following table sets forth the inter-se allocation of responsibilities for various activities among the Book Running Lead

Managers:

 

S.No.

Activity

Responsibility

Coordinator

 

2

Capital structuring, due diligence of the Company including its
operations/management/business plans/legal etc. Drafting and design of the Draft
Red Herring Prospectus, Red Herring Prospectus, Prospectus, abridged
prospectus and application form. The BRLMs shall ensure compliance with
stipulated requirements and completion of prescribed formalities with the Stock
Exchanges, RoC and SEBI including finalisation of Prospectus and RoC filing

BRLMs

I-Sec

 

Drafting and approval of all statutory advertisement

BRLMs

I-Sec

 

Drafting and approval of all publicity material other than statutory advertisement
as mentioned above including corporate advertising, brochure, etc. and filing of
media compliance report

BRLMs

Edelweiss

 

Appointment of intermediaries - Registrar to the Offer and advertising agency,
including coordination of agreements to be entered into with such intermediaries

BRLMs

I-Sec

 

‘Appointment of intermediaries - Banker(s) to the Offer, Sponsor Bank, printer
and other intermediaries, including coordination of all agreements to be entered
into with such intermediaries

BRLMs

Kotak

 

International institutional marketing of the Offer, which will cover, inter alia:
« marketing strategy;

* Finalizing the list and division of investors for one-to-one meetings; and
* Finalizing road show and investor meeting schedule

«Preparation of roadshow presentation and frequently asked questions

BRLMs

Kotak

 

Domestic institutional marketing of the Offer, which will cover, inter alia:
«marketing strategy;

Finalizing the list and division of investors for one-to-one meetings; and
* Finalizing road show and investor meeting schedule

BRLMs

I-Sec

 

 

 

Non-institutional and retail marketing of the Offer, which will cover, inter alia,

Finalising media, marketing and public relations strategy including list of
frequently asked questions at retail road shows;

*  Finalising centres for holding conferences for brokers, etc.;

* Follow-up on distribution of publicity and Offer material including
application form, the Prospectus and deciding on the quantum of the Offer
material; and

__ Finalising collection centres

 

BRLMs

 

Edelweiss

 

49

 
 

 

 

 

S.No. Activity Responsibility | Coordinator
9. Coordination with Stock Exchanges for book building software, bidding BRLMs Edelweiss
terminals, mock trading, payment of 1% security deposit, anchor coordination,
anchor CAN and intimation of anchor allocation
10. __| Managing the book and finalization of pricing in consultation with the Company BRLMs T-Sec
H1, Post-Offer activities, which shall involve essential follow-up with Bankers to the BRLMs Kotak

 

 

Offer and SCSBs to get quick estimates of collection and advising Company
about the closure of the Offer, based on correct figures, finalisation of the basis
of allotment or weeding out of multiple applications, listing of instruments,
dispatch of certificates or demat credit and refunds, payment of STT on behalf of
the Selling Shareholders and coordination with various agencies connected with
the post-Offer activity such as Registrar to the Offer, Bankers to the Offer,
Sponsor Bank, SCSBs including responsibility for underwriting arrangements, as
applicable.

Coordinating with Stock Exchanges and SEBI for submission of all post-Offer
reports including the initial and final post-Offer report to SEBI, release of 1%
security deposit post closure of the Offer

 

 

 

Legal Counsel to our Company and the Promoter Selling Shareholder as to Indian Law

Cyril Amarchand Mangaldas
Prestige Falcon Tower

3" Floor, Brunton Road

Craig Park Layout, Victoria Road
Bengaluru 560 001

Tel: +91 80 6792 2000

Legal Counsel to the BRLMs as to Indian Law

Khaitan & Co

3r‘ floor, Embassy Quest
45/1 Magrath Road
Bengaluru 560 025
Karnataka, India

Tel: +91 80 4339 7000

International Legal Counsels to the BRLMs

Sidley Austin LLP

Level 31, Six Battery Road
Singapore 049909

Tel: +65 6230 3900

Legal Counsel to the Investor Selling Shareholders as to Indian Law

IndusLaw

#1502B, 15th Floor, Tower —1C
"One World Centre", Senapati Bapat Marg
Lower Parel, Mumbai 400 013

Registrar to the Offer

KFin Technologies Private Limited
Selenium, Tower B,

Plot No- 31 and 32, Financial District,
Nanakramguda, Serilingampally
Hyderabad, Rangareedi 500 032
Telangana, India

Tel: 40 6716 2222/ 1800 309 4001
E-mail: vijaya.ipo@kfintech.com
Investor grievance E-mail: einward.ris@kfintech.com
Website: www.kfintech.com

Contact Person: M. Murali Krishna
SEBI Registration No.: INR000000221

Syndicate Members

Kotak Securities Limited

50

 
4" Floor, 12 BKC, G Block

Bandra Kurla Complex, Bandra (East)
Mumbai 400 051

Maharashtra, India

Tel: +91 22 6218 5470

E-mail: umesh.gupta@kotak.com
Website: www.kotak.com

Contact Person: Umesh Gupta

SEBI Registration No.: INZ000200137

Edelweiss Securities Limited

Edelweiss House, Off CST Road, Kalina
Mumbai 400 098

Maharashtra, India

Tel: +91 22 4063 5569

E-mail: prakash.boricha@edelweissfin.com
Website: www.edelweissfin.com

Contact Person: Prakash Boricha

SEBI Registration No.: INZ000166136

Banker to the Offer
Escrow Collection Bank/ Refund Bank/ Public Offer Bank/ Sponsor Bank

HDFC Bank Limited

FIG - OPS Department - Lodha,

I Think Techno Campus O-3 Level, Next to Kanjurmarg, Railway Station, Kanjurmarg (East)
Mumbai 400 042

Maharashtra, India

Tel: +91 22 30752927/28/2914

E-mail: neerav.desai@hdfcbank.com, eric.bacha@hdfcbank.com, Siddharth.jadhav@hdfcbank.com,
sachin.gawade@hdfcbank.com, Tushar.gavankar@hdfcbank.com
Prasanna.uchil@hdfcbank.com/neerav.desai@hdfcbank.com

Website: www.hdfcbank.com

Contact Person: Neerav Desai, Eric Bacha, Siddharth Jadhav, Sachin Gawade, Tushar Gavankar
SEBI Registration number: INBI00000063

Bankers to our Company

ICICI Bank Limited HDFC Bank Limited

No 9&10, Uma Chambers Ground floor, Kalpavruksha,
Nagarjuna hills, Panjagutta Adj to Laxmi Hyundai show room,
Hyderabad- 500 082 Himayat Nagar Main Road,
Telephone No.: +91 8978779539 Hyderabad- 500 029

Contact Person: Kaleru Srinivas Telephone No.: +91 9391852801
Website: www.icicibank.com Contact Person: Pritam Mehta
Email: kaleru.srinivas@icicibank.com Website: www.hdfcbank.com

Email: Pritam.mehta@hdfcbank.com
Designated Intermediaries
Self-Certified Syndicate Banks

The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA, where the Bid Amount will
be blocked by authorising an SCSB, a list of which is available on the website of SEBI at
https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 and updated from time to time and
at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to RIBs using the UPI Mechanism, a list
of which is available on the website of SEBI at
https://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedF pi=yes&intmId=40 or such other website as updated from
time to time.

Applications through UPI in the Offer can be made only through the SCSBs mobile applications (apps) whose name appears
on the SEBI website. A list of SCSBs and mobile application, which, are live for applying in public issues using UPI mechanism
is appearing in the “list of mobile applications for using UPI in public issues” displayed on the SEBI website. The said list shall
be updated on the SEBI website.

SCSBs and mobile applications enabled for UPI Mechanism

51
In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 and SEBI Circular No.
SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, Retail Individual Bidders Bidding using the UPI Mechanism may
apply through the SCSBs and mobile applications whose names appears on the website of the SEBI
(https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=40) and
(https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=43) respectively, as updated from
time to time

 

Syndicate SCSB Branches

In relation to Bids (other than Bids by Anchor Investors and RIBs) submitted under the ASBA process to a member of the
Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of
Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI
(https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=35)and updated from time to time.
For more information on such branches collecting Bid cum Application Forms from the Syndicate at Specified Locations, see
the website of the SEBI http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes as updated from time to
time.

Registered Brokers

The list of the Registered Brokers eligible to accept ASBA forms, including details such as postal address, telephone number
and e-mail address, is provided on the websites of the Stock Exchanges at
www .bseindia.com/Markets/PublicIssues/brokercentres_new.aspx? and

www.nseindia.com/products/content/equities/ipos/ipo_mem_terminal.htm, respectively, as updated from time to time.
Registrar and Share Transfer Agents

The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address,
telephone number and e-mail address, is provided on the websites of the Stock Exchanges at
www .bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and
www.nseindia.com/products/content/equities/ipos/asba_procedures.htm respectively, as updated from time to time.

Collecting Depository Participants

The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as their name and
contact details, is provided on the websites of the Stock Exchanges at
www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and
www.nseindia.com/products/content/equities/ipos/asba_procedures.htm, respectively, as updated from time to time.

Statutory Auditors to our Company

BSR & Associates LLP, Chartered Accountants
Salarpuria Knowledge City, Orwell, 6th Floor, Unit-3
Sy.No.83/1, Plot No.2,

Raidurg, Hyderabad- 500081, India

Tel: +91 40 6111 6000

Email: smahalingam@bsraffiliates.com

Firm registration number: 116231W/W-100024
Peer review number: 011719

There has been no change in our auditors in the last three years.

Experts

Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent dated August 16, 2021 from our Statutory Auditors to include their name as an
“expert” as defined under Section 2(38) of the Companies Act, read with Section 26(5) of the Companies Act and SEBI ICDR
Regulations, in relation to the Restated Financial Information, the examination report dated August 16, 2021 on the Restated
Financial Information, and the statement of special tax benefits dated June 5, 2021 included in this Prospectus, and such consent
has not been withdrawn as on the date of this Prospectus. However, the term “expert” shall not be construed to mean an “expert”
as defined under the U.S. Securities Act.

Independent Auditors

The restated financial statements of Vijaya Diagnostic Centre Limited as of March 31, 2021, 2020 and 2019 and for each of the

years then ended, and as of June 30, 2021 and for the three month period then ended, included in this Prospectus, have been
examined by B S R & Associates LLP, independent auditors, as stated in their report appearing herein.

52
Monitoring Agency

As the Offer is an offer for sale of Equity Shares by the Selling Shareholders, our Company is not required to appoint a
monitoring agency for this Offer.

Appraising Entity

As the Offer is an offer for sale of Equity Shares by the Selling Shareholders, our Company will not receive any proceeds from
the Offer. Accordingly, no appraising entity has been appointed for the Offer.

Credit Rating

As the Offer is an offer for sale of Equity Shares by the Selling Shareholders, there is no credit rating required.

IPO Grading

No credit agency registered with SEBI has been appointed in respect of obtaining grading for the Offer.

Trustees

As the Offer is an offer for sale of Equity Shares by the Selling Shareholders, the appointment of trustees is not required.
Green Shoe Option

No green shoe option is contemplated under the Offer.

Filing

A copy of the Draft Red Herring Prospectus was filed electronically on the SEBI Intermediary Portal at
https://siportal.sebi.gov.in/intermediary/index.huml, in accordance with SEBI circular bearing reference
SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018 and emailed at cfddil@sebi.gov.in. in accordance with the
instructions issued by the SEBI on March 27, 2020, in relation to “Easing of Operational Procedure — Division of Issues and
Listing —- CFD.”

A copy of the Red Herring Prospectus, along with the material contracts and documents required to be filed under Section 32
of the Companies Act was filed with the RoC, and a copy of this Prospectus shall be filed with the RoC as required under
Section 26 of the Companies Act and through the electronic portal at http://www.mca.gov.in/mcafoportal/loginvalidateuser.do.

Registrar of Companies

2" Floor, Corporate Bhawan
GSI Post, Tattiannaram Nagole
Bandlaguda, Hyderabad, 500 068
Telangana, India

Book Building Process

Book Building Process, in the context of the Offer, refers to the process of collection of Bids from investors on the basis of the
Red Herring Prospectus, the Bid cum Application Forms and the Revision Forms within the Price Band. The Price Band and
minimum Bid Lot size and the amount of Employee Discount, were decided by our Company and the Selling Shareholders in
consultation with the BRLMs and advertised in all editions of Financial Express, an English national daily newspaper and all
editions of Jansatta, a Hindi national daily newspaper and Hyderabad edition of Surya Telugu Daily, a Telugu daily newspaper
(Telugu being the regional language of Telangana, where our Registered Office is located), each with wide circulation, at least
two Working Days prior to the Bid/ Offer Opening Date and were made available to the Stock Exchanges for the purpose of
uploading on their respective websites. The Offer Price was determined by our Company and the Selling Shareholders in
consultation with the BRLMs after the Bid/ Offer Closing Date.

All Bidders, except Anchor Investors, were mandatorily required to use the ASBA process for participating in the Offer
by providing details of their respective ASBA Account in which the corresponding Bid Amount will be blocked by
SCSBs. In addition to this, the RIBs participated through the ASBA process by either (a) providing the details of their
respective ASBA Account in which the corresponding Bid Amount will be blocked by the SCSBs; or (b) through the
UPI Mechanism. Anchor Investors were not permitted to participate in the Offer through the ASBA process.

In accordance with the SEBI ICDR Regulations, QIBs and Non-Institutional Bidders were not allowed to withdraw or
lower the size of their Bids (in terms of the quantity of the Equity Shares or the Bid Amount) at any stage. Retail
Individual Bidders and Eligible Employees Bidding in the Employee Reservation Portion could revise their Bids during
the Bid/ Offer Period and withdraw their Bids on or before the Bid/ Offer Closing Date. Further, Anchor Investors
could not withdraw their Bids after the Anchor Investor Bid/ Offer Period. Allocation to the QIBs (other than Anchor

53
Investors) and Non-Institutional Buyers has been on a proportionate basis while allocation to the Anchor Investors has
been on a discretionary basis.

Each Bidder by submitting a Bid in the Offer, will be deemed to have acknowledged the above restrictions and the terms
of the Offer.

Our Company will comply with the SEBI ICDR Regulations and any other directions issued by SEBI in relation to this Offer.
In this regard, our Company along with the Selling Shareholders have appointed the BRLMs to manage this Offer and procure
Bids for this Offer.

The Book Building Process is in accordance with guidelines, rules and regulations prescribed by SEBI and are subject
to change from time to time. Bidders are advised to make their own judgement about an investment through this process
prior to submitting a Bid.

For further details on the method and procedure for Bidding, see “Offer Structure” and “Offer Procedure” on pages 270 and
272, respectively.

Bidders should note that the Offer is also subject to obtaining (i) final listing and trading approvals of the Stock Exchanges,
which our Company shall apply for after Allotment; and (ii) final approval of the RoC after the Prospectus is filed with the
RoC.

Illustration of Book Building and Price Discovery Process
For an illustration of the Book Building Process and the price discovery process, see “Offer Procedure” on page 272.
Underwriting Agreement

Our Company and the Selling Shareholders have entered into an Underwriting Agreement with the Underwriters for the Equity
Shares proposed to be issued and offered in the Offer. The extent of underwriting obligations and the Bids to be underwritten
by each BRLM shall be as per the Underwriting Agreement. The Underwriting Agreement is dated September 6, 2021. Pursuant
to the terms of the Underwriting Agreement, the obligations of each of the Underwriters are several and are subject to certain
conditions specified therein.

The Underwriters have indicated their intention to underwrite the following number of Equity Shares pursuant to the
Underwriting Agreement:

 

 

Name, Address, Telephone Number and Email | _ Indicative Number of Equity Shares to be ‘Amount Underwritten
Address of the Underwriters Underwritten (in million)
ICICI Securities Limited ICICI Centre, H. T. 11,896,022 6,316.79

Parekh Marg
Churchgate

Mumbai 400 020

Tel: +91 22 2288 2460

Email: vijaya.ipo@icicisecurities.com
Edelweiss Financial Services Limited 11,895,921 6,316.73
6" Floor, Edelweiss House

Off C.S.T.Road, Kalina

Mumbai 400 098

Tel: +91 22 4009 4400

E-mail:
vijayadiagnostic.ipo@edelweissfin.com
Kotak Mahindra Capital Company Limited 11,895,921 6,316.73
1st Floor, 27 BKC, Plot No. 27

G Block, Bandra Kurla Complex

Bandra (East)

Mumbai 400 051

Tel: +91 22 4336 0000

E-mail: vijayadiagnostic.ipo@kotak.com
Kotak Securities Limited 100 0.05
4 Floor, 12 BKC, G Block

Bandra Kurla Complex, Bandra (East)
Mumbai 400 051

Tel: +91 22 6218 5470

E-mail: umesh.gupta@kotak.com
Edelweiss Securities Limited 100 0.05
Edelweiss House, Off CST Road, Kalina
Mumbai 400 098

Tel: +91 22 4063 5569

E-mail: prakash.boricha@edelweissfin.com

 

 

 

 

 

 

 

 

 

54
The abovementioned underwriting commitments are indicative and will be finalised after finalisation of the Basis of Allotment
and actual allocation in accordance with provisions of the SEBI ICDR Regulations.

In the opinion of our Board, the resources of the abovementioned Underwriters are sufficient to enable them to discharge their
respective underwriting obligations in full. The abovementioned Underwriters are registered with the SEBI under Section 12(1)
of the SEBI Act or registered as brokers with the Stock Exchanges. Our Board/ IPO Committee, at its meeting held on
September 6, 2021, has accepted and entered into the Underwriting Agreement mentioned above on behalf of our Company.

Allocation among the Underwriters may not necessarily be in proportion to their underwriting commitment set forth in the table
above.

Notwithstanding the above table, the Underwriters shall be severally responsible for ensuring payment with respect to the Equity
Shares allocated to investors respectively procured by them in accordance with the Underwriting Agreement.

55
CAPITAL STRUCTURE

The share capital of our Company, as on the date of this Prospectus, is set forth below:
(In & except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sr. No. Particulars Aggregate value at face | Aggregate value at Offer
value Price*

A. AUTHORIZED SHARE CAPITAL®

120,500,000 Equity Shares of face value @1 each 120,500,000 63,985,500,000
B. ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL

BEFORE AND AFTER THE OFFER

101,965,926 Equity Shares of face value 1 each 101,965,926 54,143,906,706
C. PRESENT OFFER

Offer for Sale of 35,688,064 Equity Shares by the Selling 35,688,064 18,942,561,984"

Shareholders aggregating to 218,942.56 million® ©)

Employee Reservation Portion of 150,000 Equity Shares®

aggregating up to 271.85 million

Net Offer of 35,538,064 Equity Shares 35,538,064 18,870,711,984
D. SECURITIES PREMIUM ACCOUNT

Before and after the Offer 459,022,264

 

 

 

 

 

“Subject to finalisation of the Basis of Allotment

‘A discount of 252 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion

# Including 150,000 Equity Shares to be Allotted under the Employee Reservation Portion at a price of @ 479 aggregating to % 71.85 million, subject to

finalization of Basis of Allotment

© For details in relation to the changes in the authorised share capital of our Company, see “History and Certain Corporate Matters — Amendments to the
Memorandum of Association” on page 131.

© The Offer has been authorised by our Board of Directors pursuant to the resolution passed at its meetings dated June 4, 2021, and the Draft Red Herring
Prospectus was approved by our Board pursuant to a resolution passed on June 4, 2021. The Red Herring Prospectus has been approved by our Board
pursuant to a resolution passed on August 24, 2021. This Prospectus has been approved by our Board/ IPO Committee pursuant to a resolution passed
on September 6, 2021

© Each Selling Shareholder severally and not jointly confirms that the Offered Shares have been held by such Selling Shareholder for a period of at least
one year prior to the filing of the Draft Red Herring Prospectus in accordance with Regulation 8 of the SEBI ICDR Regulations and accordingly, are
eligible for the Offer in accordance with the provisions of the SEBI ICDR Regulations. For details on the authorization of each of the Selling Shareholders
in relation to their respective Offered Shares, see “The Offer” on page 41.

Eligible Employees bidding in the Employee Reservation Portion must ensure that the maximum Bid Amount does not exceed 2500,000 (net of Employee
Discount). However, the initial Allotment to an Eligible Employee in the Employee Reservation Portion shall not exceed %200,000 (net of Employee
Discount). Only in the event of an under-subscription in the Employee Reservation Portion post the initial Allotment, such unsubscribed portion may be
Allotted on a proportionate basis to Eligible Employees Bidding in the Employee Reservation Portion, for a value in excess of ®200,000 (net of Employee
Discount), subject to the total Allotment to an Eligible Employee not exceeding %500,000 (net of Employee Discount)

Notes to the Capital Structure
1. Share Capital History of our Company
(a) Equity Share capital

The history of the Equity Share capital of our Company is set forth in the table below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Date of Number Face Issue Nature Nature of | Cumulative | Cumulative
allotment of Equity | value | Price per of allotment number of paid-up
Shares per Equity consider Equity Equity
allotted | Equity | Share (%) ation Shares Share
Share capital (%)
@)
May 29, 10,000 10 10 | Cash Initial 10,000 100,000
2002 subscription
to the MoA”
January 5, | 2,000,000 10 10 | Cash Further 2,010,000 | 20,100,000
2006 allotment?
December 2,010,000 10 - | Not Bonus issue 4,020,000 | 40,200,000
14, 2007 Applicab | in the ratio of
le one bonus
equity shares
for every one
existing
equity Share
8
May 29, 215,481 10 57.50 | Other Private 4,235,481 | 42,354,810
2014 than cash | Placement“)
March 28, 146,079 10 10 | Other Allotment of 4,381,560 | 43,815,600

 

 

56
 

Date of Number Face Issue Nature Nature of | Cumulative | Cumulative

 

 

 

 

 

 

 

 

 

 

 

 

allotment of Equity | value | Price per of allotment number of paid-up
Shares per Equity consider Equity Equity
allotted | Equity | Share (%) ation Shares Share
Share capital (%)
@)
2016 than cash | equity shares
pursuant to
the scheme
of
amalgamatio
n®
March = 22, 147,253 10 3,327.61 | Cash Private 4,528,813 | 45,288,130
2017 Placement
April 10, 1 10 - | Not Conversion 4,531,819 | 45,318,190
2019 Applicab | of 1,413,071
le" Series A
Compulsory
3,005 10 ~ | Not Convertible
Applicab Preference
le Shares
(“CCPS”)
and 3,005
Series B
ccps”
March 22, | Subdivision of Equity Shares from face value of 210 each to %1 | 45,318,190 | 45,318,190
2021 each
May 27, | 56,647,736 1 - | Not Bonus issue | 101,965,926 | 101,965,926
2021 Applicab | in the ratio of
le five bonus
Equity
Shares for
every four
existing
Equity Share
®
Total 101,965,926 | 101,965,926

 

 

 

 

 

* Series A CCPS were issued by way of a bonus issue
* Cash was paid at the time of allotment of Series B CCPS

M

2
a

(4)

(6)

©
”

@

(b)

Allotment of 4,000 equity shares to Dr. S. Surendranath Reddy, 2,000 equity shares to S. Geeta Reddy, 2,000 equity shares to Sunil Chandra
Kondapally, 1,000 equity shares to B. Vishnu Priya and 1,000 equity shares to Sura Suprita Reddy

Allotment of 2,000,000 equity shares to Dr. S. Surendranath Reddy

Allotment of 2,004,000 equity shares to Dr. S. Surendranath Reddy, 2,000 equity shares to S. Geeta Reddy, 2,000 equity shares to Sunil
Chandra Kondapally, 1,000 equity shares to B. Vishnu Priya and 1,000 equity shares to Sura Suprita Reddy.

Allotment of 212,873 equity shares to Dr. S. Surendranath Reddy in consideration for conveyance and improvements on the properties
situated at (i) D. No.: 17-1-383/M, Plot No. 4, Survey Nos. 210/1, 210/2 and 211 of Saidabad, Santosh Nagar, Hyderabad; (ii) D.No.:
50/760A-116 on plot No: 81 and 82 in Sy. No.: 755/B2, Ward No.: 50 LP No: 83/93 at Gayathri Estate, Kurnool; and (iii) D.No: Survey No
15, Habsiguda Village, Habsiguda Rangareddy District in favour of our Company, 1,304 equity shares each to S. Geeta Reddy and Sura
Suprita Reddy in consideration for conveyance and improvements on the property situated at D.No.: 1-16-124/A2, AS. Rao Nagar,
Hyderabad.

Allotment of 100,276 equity shares to Dr. S. Surendranath Reddy, 25 equity shares to S. Geeta Reddy, 45,013 equity shares to Sunil Chandra

Kondapally, and 765 equity shares to Sura Suprita Reddy pursuant to the scheme of amalgamation of Vijaya Diagnostic Private Limited,

Bhadrakali Medical Center Private Limited, Vijaya Diagnostic Centre (Mancherial) Private Limited with our Company. For details, see
“History and Certain Corporate Matters ~ Details regarding material acquisitions or divestments of business/ undertakings, mergers,

amalgamations or any revaluation of assets, in the last 10 years” on page 134

Allotment of 147,253 equity shares to Karakoram Limited

Allotment of one equity share to Dr. S. Surendranath Reddy, 2,897 equity shares to Karakoram Limited and 108 equity shares to Kedaara

Capital Alternative Investment Fund ~ Kedaara Capital AIF 1

Allotment of 21,510,635 Equity Shares to Dr. S. Surendranath Reddy, 2,265,910 Equity Shares to S. Geeta Reddy, 5,098,296 Equity Shares

to Sunil Chandra Kondapally, 5,098,296 Equity Shares to Sura Suprita Reddy, 15,512 Equity Shares to B, Vishnu Priya, 21,842,437 Equity

Shares to Karakoram Limited and 816,650 Equity Shares to Kedaara Capital Alternative Investment Fund ~ Kedaara Capital AIF 1

  

  

Preference Share capital

Our Company does not have any outstanding preference shares as on the date of the filing of this Prospectus.

Offer of Equity Shares at a price lower than the Offer Price in the last year

Our Company has not issued any equity shares at a price lower than the Offer Price, in the last year.

Offer of shares for consideration other than cash or out of revaluation of reserves

57
@
Gi)

Our Company has not issued any equity shares out of revaluation reserves since its incorporation.

Our Company has not issued any equity shares for consideration other than cash, as on the date of this Prospectus,

 

 

 

 

 

 

 

 

 

 

 

  

except as disclosed below:
Dateof | Numberof | Face | Issue price | Reason for allotment Benefits accrued to our Company
allotment equity | Value per | per equity
shares equity | share (%)
allotted | share ()
May 29, 215,481 10} 57.50 | Private Placement") Conveyance and improvements on the
2014 properties situated at ((i) D. No.: 17-1-383/M,
Plot No. 4, Survey Nos. 210/1, 210/2 and 211
of Saidabad, Santosh Nagar, Hyderabad; (ii)
D.No.: 50/760A-116 on plot No: 81 and 82 in
Sy. No.: 755/B2, Ward No.: 50 LP No: 83/93
at Gayathri Estate, Kurnool; and (iii) D.No:
Survey No 15, Habsiguda Village, Habsiguda
Rangareddy District
March 28, 146,079 10 10 Allotment of equity | Amalgamation of Bhadrakali Medical Center
2016 shares pursuant to the| Private Limited, Vijaya Diagnostic Private
scheme of| Limited, and Vijaya Diagnostic (Mancherial)
amalgamation ® Private Limited with our Company
(@)_— Allotment of 212,873 equity shares to Dr. S. Surendranath Reddy in consideration for conveyance and improvements on the properties
situated at (i) D. No.: 17-1-383/M, Plot No. 4, Survey Nos. 210/1, 210/2 and 211 of Saidabad, Santosh Nagar, Hyderabad; (ii) D.No.:
50/760A-116 on plot No: 81 and 82 in Sy. No.: 755/B2, Ward No.: 50 LP No: 83/93 at Gayathri Estate, Kurnool; and (iii) D.No: Survey No
15, Habsiguda Village, Habsiguda Rangareddy District in favour of our Company, 1,304 equity shares each to S. Geeta Reddy and Sura
Suprita Reddy in consideration for conveyance and improvements on the property situated at D.No.: 1-16-124/A2, A.S. Rao Nagar,
Hyderabad.
(2) Allotment of 100,276 equity shares to Dr. S. Surendranath Reddy, 25 equity shares to S. Geeta Reddy, 45,013 equity shares to Sunil Chandra

Kondapally, and 765 equity shares to Sura Suprita Reddy.

Offer of Equity Shares pursuant to schemes of arrangement

Ext

‘cept as stated below, our Company has not allotted any Equity Shares pursuant to a scheme of amalgamation

approved under Section 391 to 394 of the Companies Act, 1956 or Sections 230 to 234 of the Companies Act.

 

 

 

Dateof | Numberof | Face value | Issue price | Nature of Nature of | Cumulative | Cumulative
allotmen | equity shares | per equity | per equity | consideration | transaction | number of | paid-up equity
t allotted share (%) | share () equity share capital
shares ®@
March 28, 146,079 10 10 | Other than | Allotment of | — 4,381,560 43,815,600
2016 cash equity shares

pursuant to
the scheme of

amalgamatio
n®

 

 

 

 

 

 

 

 

M

Allotment of 100,276 equity shares to Dr. S. Surendranath Reddy, 25 equity shares to S. Geeta Reddy, 45,013 equity shares to Sunil Chandra
Kondapally, and 765 equity shares to Sura Suprita Reddy pursuant to the scheme of amalgamation of Vijaya Diagnostic Private Limited,
Bhadrakali Medical Center Private Limited, Vijaya Diagnostic Centre (Mancherial) Private Limited with our Company. For details, see
“History and Certain Corporate Matters — Details regarding material acquisitions or divestments of business/ undertakings, mergers,
amalgamations or any revaluation of assets, in the last 10 years” on page 134.

History of the Equity Share capital held by our Promoter

As

on the date of this Prospectus, our Promoter holds 38,521,195 Equity Shares equivalent to 37.78% of the issued,

subscribed and paid-up Equity Share capital of our Company on a fully diluted basis.

(a)

Build-up of the shareholding of our Promoter in our Company

The details regarding the equity shareholding of our Promoter since incorporation of our Company is set forth
in the table below.

 

 

 

 

Date of Nature of No. of Nature of Face | Issue/ | Percentage | Percentage
allotment/ transaction Equity | consideration] Value | transfer | of the pre- | of the post-
transfer and Shares per Price Offer Offer
made fully paid- Equity! per | capital* | capital*
up Share | Equity | (%) (%)
@® | Share
@
Dr. S. Surendranath Reddy
May 29, 2002 ‘Initial subscription to 4,000 Cash 10 10 0.04 0.04
the MoA.

 

 

 

 

 

 

 

 

 

58

 
(b)

 

Date of Nature of No. of Nature of Face | Issue/ | Percentage | Percentage

 

 

alloument/ transaction Equity | consideration] Value | transfer | of the pre- | of the post-
transfer and Shares per | Price | Offer Offer
made fully paid- Equity per | capital* | capital*
up Share | Equity | (%) (%)
® | Share
®
January 5, 2006 _| Further allotment 2,000,000 ‘Cash 10 10 19.61 19.61
December 14,|Bonus issue in the 2,004,000 Not 10 - 19.65, 19.65
2007 ratio of one bonus Applicable

equity shares for
every one existing
equity share

 

 

 

 

 

 

 

 

May 29, 2014 Private Placement 212,873] Other than 10 57.50 2.09 2.09
cash

March 28, 2016 | Allotment of equity 100,276} Other than 10 10 0.98 0.98
shares pursuant to the cash
scheme of
amalgamation

December 21,|Transfer of equity] (1,296,348) Cash 10 | 1825.83 (12.71) (12.71)

2016 shares)

March 22,2017 |Transfer of equity] (343,199) Cash 10 | 3327.61 (3.37) (3.37)
shares?)

April 10,2019 | Conversion of 1 Not 10 =| Negligible] Negligible
1,413,071 Series A Applicable*
CCPS

March 22, 2021 _| Subdivision of Equity Shares from face value of 210 each to 21 each

May 24,2021 |Transfer of Equity] (9,607,522) Gift 1 - (9.42) (9.42)
Shares

May 27, 2021 Bonus issue in the} 21,510,635 Not 1 - 21.10 21.10
ratio of five bonus Applicable

Equity Shares for
every four existing
Equity Shares

 

 

 

 

 

 

 

 

 

 

 

August 13,2021 Transfer of equity] (187,948)| Cash 1 245 (0.18) (0.18)
shares

August 13,2021 [Transfer of equity[ (10,000)| Cash 1 300 (0.01) (0.01)
shares

Total 38,521,195 37.78 37.78

 

 

*As adjusted for split in the face value of the Equity shares from 210 each to @1 each

* Issuance of Series A CCPS by way of bonus issue

(1) Transfer of 1,267,097 equity shares from Dr. S. Surendranath Reddy to Karakoram Limited and transfer of 29,251 equity shares
to Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1

(2) Transfer of 330,148 equity shares from Dr. S. Surendranath Reddy to Karakoram Limited and transfer of 13,051 equity shares to
Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1

(3) Transfer of 1,779,658 Equity Shares to S. Geeta Reddy, transfer of 3,774,477 Equity Shares to Sunil Chandra Kondapally, and
transfer of 4,053,387 Equity Shares to Sura Suprita Reddy

(4) Transfer of 7,000 Equity Shares to Akila Narasimhan, 1,500 Equity Shares to D VP R Vittal, 10,000 Equity Shares to Anuj Jain,
10,000 Equity Shares to Krishna Mohan Potala, 2,448 Equity Shares to Shaik Abdul Raheem, 10,000 Equity Shares to Varsha
Mehesh Joshi, 7,000 Equity Shares to Sireesha Prabhala, 7,000 Equity Shares to Srujana Lakshmi Kapuganty, 1,200 Equity Shares
to Baleswari Gola, 5,000 Equity Shares to Anjaneyavara Prasad Gunturi, 10,000 Equity Shares to Pritam Manohar Patil, 10,000
Equity Shares to Venkatapathy RajasekharKattari, 5,000 Equity Shares to Umashankar Tallam, 5,150 Equity Shares to Nandigam
Santosh Kumar, 3,500 Equity Shares to Divyaraju Alluri, 1,500 Equity Shares to Sudhir Shamgar Borelli, 1,500 Equity Shares to
Chakilam Venkateswara Rao, 7,000 Equity Shares to Vijayanand Kelkari, 7,000 Equity Shares to Sriramineni Deepthi, 7,000
Equity Shares to Deepak Bulla, 7,000 Equity Shares to Dileep Kumar Komarapu, 1,500 Equity Shares to Karthik Rayasam, 7,000
Equity Shares to Uma Maheshwari, 1,200 Equity Shares to Pallavi Satish Pawar, 7,000 Equity Shares to Ankit Balani, 7,000
Equity Shares to Chada Pradeep Kumar, 3,000 Equity Shares to SandhyaRani Rachakulla, 7,000 Equity Shares to Bhushan M S.,
7,000 Equity Shares to Gurram Swetha, 5,000 Equity Shares to Pavani Vallam, 1,200 Equity Shares to Vaishnavi Danda, 7,000
Equity Shares to Venkatasubba Reddy Yerrabandi, 5,000 Equity Shares to Vikas Maini, and 3.250 Equity Shares to Rajyalakshmi
Vadapalli

(8) Transfer of 6,650 Equity Shares to Chigarapalli Srinivas Kaushik and 3,350 Equity Shares to Preethi Reddy

All the Equity Shares held by our Promoter were fully paid-up on the respective dates of acquisition of such
Equity Shares.

As of the date of this Prospectus, none of the Equity Shares held by our Promoters are pledged.

Details of Promoter’s contribution and lock-in

@ Pursuant to Regulations 14 and 16 of the SEBI ICDR Regulations, an aggregate of 20% of the fully
diluted post-Offer Equity Share capital of our Company held by the Promoter, shall be locked in for
a period of three years as minimum Promoter’s contribution from the date of Allotment and the
shareholding of the Promoter in excess of 20% of the fully diluted post-Offer Equity Share capital
shall be locked in for a period of one year from the date of Allotment.

59
(i)

(iii)

(iv)

(vy)

Our Promoter has consented pursuant to his letter dated June 4, 2021, to the inclusion of such number
of Equity Shares held by him, as may constitute 20% of the fully diluted post-Offer Equity Share
capital of our Company as minimum Promoter’s contribution and have agreed not to sell, dispose,
transfer, charge, pledge or otherwise encumber in any manner the minimum Promoter’s contribution
from the date of filing of this Prospectus until the expiry of the lock-in period specified above, or
for such other time as required under the SEBI ICDR Regulations, except as may be permitted, in
accordance with the SEBI ICDR Regulations

Details of the Equity Shares to be locked-in for three years from the date of Allotment as minimum
Promoter’s contribution are set forth in the table below:

 

Name of | Number | Dateof | Natureof | Face | Issue) | Percentage |Percent| Date up
the | of Equity | allotmen| allotment | Value | Acquisitio | of the pre- | age of | to which
Promoter | Shares tof per | nprice |Offerpaid-| the | Equity
locked-in | Equity Equity | per Equity | up capital | post- | Shares
Shares Share | Share(%) |  (%) Offer | are
and ®@ paid- | subject to
when up | lock-in
made capital
fully (%)
paid-up*

 

Dr. S.] 20,393,186 | May 27, |Bonus issue} 1 Not 20 20 | September
Surendran 2021 | in the ratio Applicable 7, 2024
ath Reddy of five
bonus
Equity
Shares for
every four
existing
Equity

 

 

 

 

 

 

 

 

 

 

Shares

 

All Equity Shares allotted to our Promoter were fully paid-up at the time of allotment.

Our Company undertakes that the Equity Shares that are being locked-in are not ineligible for
computation of Promoter’s contribution in terms of Regulation 15 of the SEBI ICDR Regulations.

In this connection, please note that:

a. The Equity Shares offered for Promoter’s contribution do not include (i) Equity Shares acquired
in the three immediately preceding years for consideration other than cash and revaluation of
assets or capitalisation of intangible assets was involved in such transaction, (ii) Equity Shares
resulting from bonus issue by utilization of revaluation reserves or unrealised profits of our
Company or bonus shares issued against Equity Shares, which are otherwise ineligible for
computation of minimum Promoter’s contribution.

b. | The minimum Promoter’s contribution does not include any Equity Shares acquired during the
immediately preceding one year at a price lower than the price at which the Equity Shares are
being offered to the public in the Offer.

c. Our Company has not been formed by the conversion of one or more partnership firms or a
limited liability partnership firm.

d. As on the date of this Prospectus, none of the Equity Shares held by our Promoter are pledged.

e. All the Equity Shares held by our Promoter shall be in dematerialised form.

(c) Other lock-in requirements:

@

In addition to the 20% of the fully diluted post-Offer shareholding of our Company held by the
Promoter locked in for three years as specified above, the entire pre-Offer Equity Share capital of
our Company will be locked-in for a period of one year from the date of Allotment, including any
unsubscribed portion of the Offer for Sale, except for (i) the Equity Shares offered pursuant to the
Offer for Sale; (ii) any Equity Shares held by the eligible employees (whether currently employees
or not) of our Company which have been or will be allotted to them under the ESOP Plan 2018 and
ESOP Schemes 2018; (iii) the minimum promoter’s contribution which shall be locked for a period
of three years as detailed above; and (iv) the Equity Shares held by VCFs or Category I AIF or
Category II AIF or FVCI, subject to certain conditions set out in Regulation 17 of the SEBI ICDR
Regulations, provided that such Equity Shares will be locked-in for a period of at least one year from
the date of purchase by the VCFs or Category | AIF or Category II AIF or FVCI. Accordingly, all

60
Gi)

(iii)

(iv)

Equity Shares held by Kedaara Capital Alternative Investment Fund - Kedaara Capital AIF 1 and
Karakoram Limited shall be exempt from the aforesaid lock-in requirement since Kedaara Capital
Alternative Investment Fund - Kedaara Capital AIF 1 and Karakoram Limited is a category 1 AIF
and FVCI respectively.

Our Promoter have agreed not to sell, transfer, charge, pledge or otherwise encumber in any manner,
the Promoter’s contribution from the date of filing this Prospectus, until the expiry of the lock-in
specified above, or for such other time as required under SEBI ICDR Regulations, except as may be
permitted, in accordance with the SEBI ICDR Regulations.

Any Equity Shares Allotted to Anchor Investors under the Anchor Investor Portion shall be locked-
in for a period of 30 days from the date of Allotment.

The Equity Shares held by any person other than our Promoters and locked-in for a period of one
year from the date of Allotment in the Offer may be transferred to any other person holding the
Equity Shares which are locked-in, subject to continuation of the lock-in in the hands of transferees
for the remaining period (and such transferees shall not be eligible to transfer until the expiry of the
lock-in period) and compliance with the Takeover Regulations.

61
6.

Shareholding Pattern of our Company

The table below presents the equity shareholding pattern of our Company as on the date of this Prospectus.

         

 

 

 

 

 

 

(A) _ [Promoter and 60,951,621 60,951,621 60,951,621 60,951,621
Promoter Group

®) [Public 41] 41,014,305 41,014,305 40.22[ 41,014,305] 40.22 40.22 41,014,305]

(© _ [Non Promoter- Non| | -| : q am | | -|
[Public

(Ci) [Shares underlying] | | + + -| | 3 3
IDRs

(C2) [Shares held _ by| | z 4 zi 2 z zi y
[Employee Trusts
[Total 54] 101,965,926 101,965,926] 100.00] 101,965,926| 100.00] 100.00] 101,965,926

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

62

 
Details of equity shareholding of the major Shareholders of our Company

@

Gi)

(iii)

(iv)

The Shareholders holding 1% or more of the paid-up Equity Share capital of our Company and the number
of Equity Shares held by them as on the date of this Prospectus are set forth in the table below:

 

 

 

 

 

 

 

 

Sr. | Name ofthe Shareholder _| Number of Equity Shares on | Percentage of the pre- Offer Equity Share
No. a fully diluted basis capital (%) on a fully diluted basis
1.__| Karakoram Limited 39,316,387 38.56
2.__| Dr. S. Surendranath Reddy 38,521,195, 37.78
3.__| Sura Suprita Reddy 9,176,933 9.00
4. | Sunil Chandra Kondapally 9,106,933 8.93
5._|S. Geeta Reddy 4,058,638 3.98
6. |Kedaara Capital Alternative 1,469,970 1.44
Investment Fund - Kedaara
Capital AIF 1
Total 101,650,056 99.69

 

The Shareholders who held 1% or more of the paid-up Equity Share capital of our Company and the number

 

 

 

 

 

 

 

 

 

 

 

 

 

 

of Equity Shares held by them 10 days prior to the date of this Prospectus are set forth in the table below:
Sr. | Name ofthe Shareholder _] Number of Equity Shares on | Percentage of the pre- Offer Equity Share
No. a fully diluted basis capital (%) on a fully diluted basis
1, | Karakoram Limited 39,316,387 38.56
2.__| Dr. S. Surendranath Reddy 37.78
3.__| Sura Suprita Redd: 9.00
4._| Sunil Chandra Kondapally 8.93
5.__|S. Geeta Reddy 3.98
6. |Kedaara Capital Alternative 1.44
Investment Fund - Kedaara
Capital AIF 1
Total 101,650,056 99.69

 

The Shareholders who held 1% or more of the paid-up equity share capital of our Company and the number
of equity shares held by them one year prior to the date of this Prospectus are set forth in the table below:

 

 

 

 

 

 

Sr. | Name ofthe Shareholder | Number of equity shares* ] Percentage of the pre- Offer equity share*
No. ona fully diluted basis capital (%) on a fully diluted basis
1. _ | Dr. S. Surendranath Reddy 2,681,603 59.17
2. [Karakoram Limited 1,747,395 38.56
3. |Kedaara Capital Alternative 65,332 1.44
Investment Fund - Kedaara
Capital AIF 1
Total 4,494,330 99.17

 

*equity shares of face value @10 each

The Shareholders who held 1% or m
of equity shares held by them two years prior to the date of this P!

ore of the paid-up equity share capital of our Company and the number

rospectus are set forth in the table below:

 

 

 

 

 

 

 

 

Sr.No.] Name of the Shareholder | Number of equity shares* | Percentage of the pre-Offer equity share*
ona fully diluted basis capital (%) on a fully diluted basis
1. [Dr. S. Surendranath Reddy 2,681,603 59.21
2. | Karakoram Limited 1,747,395 38.52
3. |Kedaara Capital Alternative 65,332 1.44
Investment Fund - Kedaara
Capital AIF 1
Total 4,494,330 99.17

 

 

 

*equity shares of face value @10 each

Details of Equity Shares held by our Directors, Key Managerial Personnel, and members of our Promoter

Group

@

Except as disclosed below our Directors and Key Managerial Personnel do not hold Equity Shares and
employee stock options in our Company:

63
10.

1,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

s. Name No. of Equity | Percentage of | Number of | Percentage of the
No. Shares the pre-Offer | employee post-Offer of
Equity Share | stock options | Equity Share
Capital (%) | outstanding Capital (%)
Directors of our Company
1,_| Dr. S. Surendranath Reddy 38,521,195 37.78 - 32.78
2._| Sunil Chandra Kondapally 9,106,933 8.93 - 8.93
3._|S. Geeta Reddy 4,058,638 3.98 : 3.98
‘Sub Total (A) 51,686,766 50.69 . 45.69
Key Managerial Personnel
1._| Sura Suprita Reddy 9,176,933 9.00 - 9.00
2._| Anuj Jain 10,000 0.01 - 0.01
Sub Total (B) 9,186,933 9.01 = 9.01
Total (A+B) 60,873,699 59.70 * 54.07
(id) Set out below are the details of the Equity Shares held by our Promoter and the members of the Promoter
Group, in our Company:
Ss. Name No. of Equity Shares Percentage | Number of | Percentage of
No. ofthe pre- | employee | the post-Offer
Offer Equity] stock Equity Share
Share options Capital (%)
Capital (%) | outstanding
Promoter
1._|Dr. S. Surendranath Reddy 38,521,195 37.78 : 32.78
Sub - Total (A) 38,521,195 37.78 32.78
Promoter Group
1 Sura Suprita Reddy 9,176,933 9.00 - 9.00
2.__| Sunil Chandra Kondapally 9,106,933 8.93 : 8.93
3.__|S. Geeta Reddy 4,058,638 3.98 : 3.98
4. |B. Vishnu Priya 27,922 0.03 - 0.03
5.__| Birudavolu Gautam 10,000 0.01 - 0.01
6._|P V Sanjay Kumar 10,000 0.01 - 0.01
7.__|P Madhulika Reddy 10,000 0.01 - 0.01
8. | Manjula Kankanthi 10,000 0.01 : 0.01
9.__| Birudavolu Jalaja 5,000, 0.00 - 0.00
10. | Birudavolu Dayakar Reddy 5,000 0.00 - 0.00
11. | Nanda Birudavolu Kumar 5,000. 0.00 - 0.00
12. | Charita Birudavolu Reddy 5,000 0.00 - 0.00
Sub - Total (B) 22,430,426 22.00 - 22.00
Total (A+B) 60,951,621 59.78 = 54.78

 

 

 

 

 

 

 

None of the BRLMs or their respective associates (as defined under the SEBI Merchant Bankers Regulations) hold
any Equity Shares in our Company as on the date of this Prospectus.

There are no partly paid-up Equity Shares as on the date of this Prospectus and all Equity Shares were fully paid-up as
on the date of allotment.

Employee Stock Option Plan 2018 and ESOP Schemes 2018

Our Company, pursuant to the resolutions passed by the Board and the Shareholders of the Company on April 13,
2018 and May 3, 2018, respectively adopted the ESOP Plan 2018. The ESOP Plan 2018 was last modified pursuant to
the resolutions passed by the Board and the Shareholders of the Company, each dated August 16, 2021. The Board
and the Shareholders of the Company through their resolutions passed on meetings held on April 13, 2018 and May 3,
2018, respectively, approved the VDCL Employee Stock Option 2018 — Scheme 1, VDCL Employee Stock Option
2018 — Scheme 2, VDCL Employee Stock Option 2018 — Scheme 3, and VDCL Employee Stock Option 2018

Scheme 4. The Board and the Shareholders of the Company through their resolutions passed on meetings held on
March 22, 2021 and March 24, 2021, respectively, approved VDCL Employee Stock Option 2018 — Scheme 5 and
VDCL Employee Stock Option 2018 — Scheme 6. The terms of the ESOP Schemes 2018 were last amended pursuant
to the resolutions passed by the Board and the Shareholders of the Company, each dated August 16, 2021. The
maximum number of shares that may be issued pursuant to the exercise of options granted to participants under the
ESOP Plan 2018 shall not exceed 1,625,000 Equity Shares. Upon exercise and payment of the exercise price, the

64
option holder will be entitled to be allotted one Equity Share per employee stock option. The ESOP Plan 2018 provides
that the maximum number of options granted to any grantee shall not exceed 1.00% of the of the issued share capital
(excluding outstanding warrants and conversions) at the date of the grant of options under one or more of the ESOP
Schemes 2018 unless an approval of the Shareholders is taken by way of special resolution in a general meeting. The
objectives of ESOP Plan 2018 are, among others, for the benefit of the eligible employees of the Company and of its
Subsidiaries (present/future) in order to attract and retain qualified, talented and competent personnel, and to reward
the hard work, dedication and support of the employees of the Company as well as that of the Subsidiaries. The details
of the grants of employee stock options, the terms and conditions of vesting and the price at which such employee
stock options can be exercised is provided in the respective ESOP Schemes 2018.

The ESOP Plan 2018 and the ESOP Schemes 2018 have been framed in compliance with the SEBI SBEB Regulations.
As on the date of this Prospectus, 933,808 employee stock options of face value %1 each have been granted by our
Company under the ESOP Plan 2018. The details of the ESOP Plan 2018 and the ESOP Schemes 2018 are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Fiscal 2019 Fiscal 2020 Fiscal 2021 Three month From June Cumulative
period ended 30, 2021 till | (as on date of
June 30, 2021 the date of the
the Prospectus)
Prospectus

Options granted 472,750* 75,780 385,278 Nil Nil 933,808

*1% grant - 463,750

24 grant — 9,000
Exercise price of | 1* grant— 220.00 236.90 250.00 Nil Nil NA
options (in %) 24 grant — 233.90
Vesting period 1* scheme - Four | 2" scheme - | 4" scheme - 2™4 Nil Nil NA

years, starting from 2™ | Four years, | year from grant

year from grant date starting from 3" | date

year from grant

2m scheme - Four | date 5 scheme —

years, starting from 3% over a period of

year from grant date 3rd scheme - | three years

Four years,

3rd scheme - Four | starting from 3] 6" scheme —

years, starting from 3“ | year from grant | over a period of

year from grant date date four years
Options vested and Nil Nil Nil Nil Nil Nil
not exercised
Options exercised Nil Nil Nil Nil Nil Nil
The total number of Nil Nil Nil Nil Nil Nil
Equity Shares arising
as a result of exercise
of options
Options 472,750 75,780 Nil Nil Nil 548,530
forfeited/lapsed
Variation of terms of Nil Nil Nil Nil Nil Nil
options
Money realized by Nil Nil Nil Nil Nil Nil
exercise of options
Total number of Nil Nil 385,278 Nil Nil 385,278
options in force as on
Red Herring
Prospectus
Employee-wise
detail of — options
granted to:
i. Key managerial
personnel
e Narasimha Raju Nil Nil 40,000 Nil Nil 40,000
© SV Balaji Nil Nil 20,000 Nil Nil 20,000
 P Vijaya Bhavani Nil Nil 10,000 Nil Nil 10,000
it ‘Any other
employee who

 

 

 

 

 

 

 

65,

 
 

Particulars

Fiscal 2019 Fiscal 2020 Fiscal2021_| Threemonth | FromJune | Cumulative
periodended | 30,2021 till | (as on date of
June 30, 2021 | the date of the

the Prospectus)
Prospectus

 

received a grant in

any one year of

options amounting to

5% or more of the

options granted

during the year

Ram Ray

Sandhya Rani

¢ Anup

¢ Narasimha Raju
KA.

Puja Gaur

SV Balaji

299,300 Nil Nil Nil Nil NA
111,950 18,280 Nil Nil Nil NA
35,000 Nil Nil Nil Nil NA
Nil 30,000 40,000 Nil Nil NA

Nil 25,000 Nil Nil Nil NA
Nil Nil 20,000 Nil Nil NA

 

iii. Identified
employees who were
granted options
during any one year
equal to or exceeding
1% of the issued
capital (excluding
outstanding warrants
and conversions) of
the Company at the
time of grant

Nil Nil Nil Nil Nil Nil

 

Fully diluted
Earnings per Equity
Share — (face value
21 per Equity Share)
pursuant to issue of
Equity Shares on
exercise of options
calculated in
accordance with
applicable
accounting standard
for ‘Earnings per
Share”

4.50 6.13 8.26 a3 NA NA

 

Lock-in

 

 

 

 

 

Nil Nil Nil Nil Nil Nil

 

Difference, if any,
between employee
compensation cost
calculated using the
intrinsic value of
stock options and the
employee
compensation cost
calculated on the
basis of fair value of
stock options and its
impact on profits and
on the Earnings per
Equity Share — (face
value @1 per Equity
Share)

Not Applicable, as the company is calculating employee compensation cost using fair value at grant date

 

 

Description of the

pricing formula
method and
significant

assumptions —_ used
during the year to

 

The fair value of equity share options is estimated at the date of grant using Black - Scholes model, taking into account
the terms and conditions upon which the share options were granted. Based on the historical trends, 50% of stock
options are expected to be vested and exercised, accordingly the total compensation cost recognised in the statement
of profit and loss for three months period ended June 30, 2021 is Rs. 3.73 million (March 31, 2021: Rs 1.96 million,
March 31, 2020: Rs. 4.10 million, March 31, 2019 - Rs 2.22 million and June 30, 2020 — Rs. 0.78 million).

 

66

 
 

Particulars

Fiscal 2019 Fiscal 2020 Fiscal 2021 | Threemonth | From June
period ended | 30,2021 till
June 30,2021 | the date of
the
Prospectus

 

 

 

 

 

‘Cumulative
(as on date of
the
Prospectus)

 

estimate the fair
values of options,
including weighted-
average information,
namely, risk-free
interest rate,
expected life,
expected volatility,
expected dividends
and the price of the
underlying share in
market at the time of
grant of the option

 

Key Assumptions

 

© Weighted average
exercise price for
outstanding
options at year/
period ended

220.90 226.56 241.89 249.70 NA

NA

 

Weighted average
remaining
contractual life for
outstanding
options at year/
period end

9.15 Years 8.45 Years 9.19 Years 9.74 Years NA

NA

 

Range of exercise
prices for
outstanding
options at year/
period end

220.00-233.90 220.00-236.90 220.00-250.00 250.00 NA

NA

 

Dividend yield

1* grant - 0% 0% 0% NA NA
24 grant — 0%

NA

 

Risk -free interest
rate

1* grant - 7.95% 2nd 7.15% 6.12% NA NA
grant -7.84%

NA

 

Expected life of
options granted in
years

5.5 Years to 7 Years 5.5 Years to 7 5.5 Years to 7 NA NA
Years Years

NA

 

« Expected volatility

1 grant - 21.32% 2" 29.52% 43.78% NA NA
grant - 24.95%

 

 

 

 

 

NA

 

Impact on profit and
Earnings per Equity
Share — (face value
21 per Equity Share)
of the last three years
if the accounting
policies prescribed in
the SEBI SBEB
Regulations had been
followed in respect
of options granted in
the last three years

Not Applicable
As the company is calculating employee compensation cost using fair value at grant date.

 

 

Intention of the Key
managerial personnel
and whole-time
directors who are
holders of Equity
Shares allotted on
exercise of options
granted to sell their

 

Not Applicable, as none of the options outstanding as on date are vested.

 

67

 
 

Particulars Fiscal 2019 Fiscal 2020 Fiscal 2021 Three month From June Cumulative

period ended 30, 2021 till | (as on date of

 

 

 

 

 

June 30, 2021 | the date of the
the Prospectus)
Prospectus

 

equity shares within
three months after
the date of listing of
Equity
pursuant to the Offer

Shares

 

Intention to _ sell | Not Applicable, as none of the options outstanding as on date are vested.

Equity Shares arising
out of the ESOP Plan
2018 within three
months
listing
Shares, by Directors,
senior
personnel and
employees _ having
Equity Shares arising
out of an employee
stock option scheme,
amounting to more
than 1% of the issued
capital
outstanding warrants
and conversions)

 

after the
of Equity

management

(excluding

 

 

12.

‘Note: The employee stock options, and the exercise price mentioned above are pre-bonus issuance

Except as disclosed below, our Promoter Group, our Promoter, our Directors or their relatives have not purchased,
acquired, gifted or sold any securities of our Company during the period of six months immediately preceding the date
of filing of this Prospectus

 

 

Date ofallotment | Numberof | Face value | Issue Price per | Nature of Nature of allotment
Equity Shares | per Equity | Equity Share | consideration
allotted Share ®
May 27, 2021 56,647,736 1 Not Applicable Not Bonus issue in the ratio of five

Applicable | bonus Equity Shares for Every
four existing Equity Share

 

 

 

 

 

 

 

 

 

 

 

 

May 24, 2021 (9,607,522) 1 | Not Applicable Gift Transfer of Equity Shares
August 13, 2021 (187,948) 1 245. Cash Transfer of equity shares
August 13, 2021 (20,000) 1 300 Cash Transfer of equity shares
August 13, 2021 (70,000) 1 300 Cash Transfer of equity shares
August 13, 2021 (20,000) 1 300 Cash Transfer of equity shares™

 

(1) Allotment of 21,510,635 Equity Shares to Dr. S. Surendranath Reddy, 2,265,910 Equity Shares to S. Geeta Reddy, 5,098,296 Equity Shares to
Sunil Chandra Kondapally, 5,098,296 Equity Shares to Sura Suprita Reddy, 15,512 Equity Shares to S. Vishnu Priya, 21,842,437 Equity
Shares to Karakoram Limited and 816,650 Equity Shares to Kedaara Capital Alternative Investment Fund ~ Kedaara Capital AIF 1

(2) Transfer of 1,779,658 Equity Shares to S. Geeta Reddy, transfer of 3,774,477 Equity Shares to Sunil Chandra Kondapally, and transfer of
4,053,387 Equity Shares to Sura Suprita Reddy

(3) Transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Akila Narasimhan, transfer of 1,500 Equity Shares from Dr. S.
Surendranath Reddy to D V P R Vittal, transfer of 10,000 Equity Shares from Dr. S, Surendranath Reddy to Anuj Jain, transfer of 10,000
Equity Shares from Dr. S. Surendranath Reddy to Krishna Mohan Potala, transfer of 2,448 Equity Shares from Dr. S. Surendranath Reddy to
Shaikh Abdul Raheem, transfer of 10,000 Equity Shares from Dr. S. Surendranath Reddy to Varsha Mahesh Joshi, transfer of 7,000 Equity
Shares from Dr. S. Surendranath Reddy to Sireesha Prabhala, transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Lakshmi
Srujana K, transfer of 1,200 Equity Shares from Dr. S. Surendranath Reddy to Baleswari Golla, transfer of 5,000 Equity Shares from Dr. S.
Surendranath Reddy to Anjaneyavara Prasad Gunturi, transfer of 10,000 Equity Shares from Dr. S. Surendranath Reddy to Pritam Manohar
Patil, transfer of 10,000 Equity Shares from Dr. S. Surendranath Reddy to Rajasekhar Kattari, transfer of 5,000 Equity Shares from Dr. S.
Surendranath Reddy to Umashankar Tallam, transfer of 5,150 Equity Shares from Dr. S. Surendranath Reddy to Santosh Kumar Nandigam,
transfer of 3,500 Equity Shares from Dr. S. Surendranath Reddy to Divyaraju Alluri, transfer of 1,500 Equity Shares from Dr. S. Surendranath
Reddy to Sudhir Shamgar Borelli, transfer of 1,500 Equity Shares from Dr. S. Surendranath Reddy to Venkateswara Rao Chakilam, transfer
of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Vijayanand Kelkari, transfer of 7,000 Equity Shares from Dr. S. Surendranath
Reddy to Sriramineni Deepthi, transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Deepak Bulla, transfer of 7,000 Equity
Shares from Dr. S. Surendranath Reddy to Dileep Kumar Komarapu, transfer of 1,500 Equity Shares from Dr. S. Surendranath Reddy to
Karthik Rayasam, transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Uma Maheshwari, transfer of 1,200 Equity Shares from
Dr. S. Surendranath Reddy to Pallavi Satish Pawar, transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Ankit Balani, transfer
of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Chada Pradeep Kumar, transfer of 3,000 Equity Shares from Dr. S. Surendranath
Reddy to SandhyaRani Rachakulla, transfer of 7,000 Equity Shares from Dr. S. Surendranath Reddy to Bhushan M S, transfer of 7,000 Equity

68

 
13.

14.

15.

16.

17.

18.

19.

Shares from Dr. S. Surendranath Reddy to Gurram, Swetha transfer of 5,000 Equity Shares from Dr. S. Surendranath Reddy to Pavani Vallam,
transfer of 1,200 Equity Shares from Dr. S. Surendranath Reddy to Vaishnavi Danda, transfer of 7,000 Equity Shares from Dr. S. Surendranath
Reddy to Venkatasubba Reddy Yerrabandi, transfer of 5,000 Equity Shares from Dr. S. Surendranath Reddy to Vikas Maini and 3.250 Equity
Shares to Rajyalakshmi Vadapalli

(4) Transfer of 6,650 Equity Shares from Dr. S. Surendranath Reddy to Chigarapalli Srinivas Kaushik and 3,350 Equity Shares from Dr. S.
Surendranath Reddy to Preethi Reddy

(8) Transfer of 5,000 Equity Shares from Sunil Chandra Kondapally to Birudavolu Jalaja, 5,000 Equity Shares from Sunil Chandra Kondapally
to Birudavolu Dayakar Reddy, 10,000 Equity Shares from Sunil Chandra Kondapally to Birudavolu Gautam, 5,000 Equity Shares from Sunil
Chandra Kondapally to Nanda Kumar Birudavolu, 5,000 Equity Shares from Sunil Chandra Kondapally to Charita Reddy Birudavolu, 10,000
Equity Shares from Sunil Chandra Kondapally to Manjula Kankanthi, 10,000 Equity Shares from Sunil Chandra Kondapally to Rakesh Reddy
Tanguturu, 10,000 Equity Shares from Sunil Chandra Kondapally to Adala Vamsee Krishna , 10,000 Equity Shares from Sunil Chandra
Kondapally to Sharath Chandra Reddy Gunupati

(6) Transfer of 10,000 Equity Shares from S Geeta Reddy to P Madhulika and 10,000 Equity Shares from S Geeta Reddy to P.V Sanjay Kumar

As of the date of the filing of this Prospectus, the total number of our Shareholders is 54.

Our Company, our Directors and the BRLMs have not made any or entered into any buy-back arrangements for
purchase of Equity Shares.

Except for Equity Shares that may be allotted pursuant to the conversion of employee stock options granted under the
ESOP Plan 2018 and the ESOP Schemes 2018 and the Equity Shares allotted pursuant to the Offer, there will be no
further issue of Equity Shares whether by way of issue of bonus shares, rights issue, preferential issue or any other
manner during the period commencing from the date of filing of this Prospectus until the listing of the Equity Shares
on the Stock Exchanges pursuant to the Offer. or all application monies have been refunded, or the application moneys
are unblocked in the ASBA Accounts on account of non-listing, under-subscription etc., as the case may be.

There have been no financing arrangements whereby Promoter, our Promoter Group, our Directors, and their relatives
have financed the purchase by any other person of securities of our Company other than in the normal course of the
business of the financing entity, during a period of six months preceding the date of filing of the Red Herring Prospectus
and this Prospectus.

Our Company presently does not intend or propose and is not under negotiations or considerations to alter its capital
structure for a period of six months from the Bid/ Offer Opening Date, by way of split or consolidation of the
denomination of Equity Shares or further issue of Equity Shares (including issue of securities convertible into or
exchangeable, directly or indirectly for Equity Shares) whether on a preferential basis or by way of issue of bonus
shares or on a rights basis or by way of further public issue of Equity Shares or qualified institutions placements or
otherwise. Provided, however, that the foregoing restrictions do not apply to any issuance, pursuant to the exercise of
employee stock options under the ESOP Plan 2018 and ESOP Schemes 2018.

Except employee stock options granted pursuant to the ESOP Plan 2018 and ESOP Schemes 2018, there are no
outstanding convertible securities or any other right which would entitle any person any option to receive Equity
Shares, as on the date of this Prospectus.

There are no outstanding convertible securities or any warrant, option or right to convert a debenture, loan or other
instrument which would entitle any person any option to receive Equity Shares, as on the date of this Prospectus.

69
OBJECTS OF THE OFFER

The objects of the Offer are to (i) to carry out the Offer for Sale of 35,688,064" Equity Shares by the Selling Shareholders; and
(ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. Our Company will not receive any proceeds from
the Offer and all such proceeds (net of any Offer related expenses to be borne by the Selling Shareholders) will go to the Selling
Shareholders. For details of the Selling Shareholder and the number of Equity Shares offered by the Selling Shareholder in the
Offer see “The Offer” on page 41.

*Subject to finalisation of the Basis of Allotment

Further, our Company expects that listing of the Equity Shares will enhance our visibility and brand image and provide liquidity
to our Shareholders and will also provide a public market for the Equity Shares in India.

Utilisation of the Net Offer Proceeds by Selling Shareholders

Our Company will not directly receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be
received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of
the Offer. For details of Offered Shares by each Selling Shareholder, see “The Offer” on page 41.

Offer related expenses

The total expenses of the Offer are estimated to be approximately 7825.49 million. The Offer related expenses primarily include
the listing fee, fees payable to the BRLMs and legal counsels, fees payable to the auditors, brokerage and selling commission,
underwriting commission, commission payable to Registered Brokers, RTAs, CDPs, SCSBs’ fees, Registrar’s fees, printing
and stationery expenses, advertising and marketing expenses and all other incidental and miscellaneous expenses for listing the
Equity Shares on the Stock Exchanges.

Other than (i) the listing fees, which will be solely borne by our Company; and (ii) fees for counsel to each Selling Shareholder, which shall
be solely borne by the respective Selling Shareholders, all costs, charges, fees and expenses that are associated with and incurred in connection
with the Offer including, inter-alia, filing fees, book building fees and other charges, fees and expenses of the SEBI, the stock exchanges, the
registrar of companies and any other governmental authority, advertising (except any advertisements constituting corporate communication
not related to the Offer which shall be solely borne by our Company), printing, road show expenses, fees and expenses of the legal counsel
to our Company and the legal counsel to the Managers as to Indian law and the international legal counsel to the Managers, fees and expenses
of the statutory auditors (to the extent not attributable to the Offer which shall be solely borne by our Company), registrar fees and broker
fees (including fees for procuring of applications), bank charges, fees and expenses of the Managers, syndicate members, self-certified
syndicate banks, other designated intermediaries and any other consultant, advisor or third party in connection with the Offer shall be borne
by each of the selling shareholders participating in the Offer in proportion to the number of Equity Shares transferred by such Selling
Shareholders pursuant to the Offer. All the expenses relating to the Offer shall be paid by our Company in the first instance. Upon
commencement of listing and trading of the Equity Shares on the stock exchanges pursuant to the Offer, each Selling Shareholder shall,
severally and not jointly, reimburse our Company for any expenses in relation to the Offer paid by our Company on behalf of the respective
selling shareholder directly from the Public Offer Account. The estimated Offer related expenses are as under:

 

 

 

 

 

 

 

 

 

 

 

 

 

Activity Estimated Offer As a % of the total Asa % of the
expenses) estimated Offer expenses” | total Offer size“
(& in million)

BRLMs’ fees and commissions (including underwriting 447.04 54.16 2.36
commission, brokerage and selling commission)
Selling commission/processing fee for SCSBs and Bankers to the 34,17 4.14 0.18
Offer and fee payable to the Sponsor Bank for Bids made by RIBs
using UPI 2)
Brokerage and selling commission and bidding charges for 10.44 1.27 0.06
Members of the Syndicate, Registered Brokers, RTAs and
CDPs24)
Fees payable to the Registrar to the Offer 0.47 0.06 0.00
Fees payable to the other advisors to the Offer 65.40 7.92 0.35
Others
= Listing fees, SEBI filing fees, upload fees, the Stock 59.68 7.23 0.32

Exchanges processing fees, book building software fees and

other regulatory expenses
=__ Printing and stationery 14.50 1.76 0.08
= ___ Advertising and marketing expenses 77.80 9.42 0.41
= __ Fee payable to legal counsels 63.37 7.68 0.33
: Miscellaneous 52.62 6.37 0.28
Total estimated Offer expenses 825.49 100.00 4.36

 

 

 

 

 

 

70
0
2

@

o

Offer expenses include applicable taxes. Offer expenses are estimates and are subject to change.
Selling commission payable to the SCSBs on the portion for Retail Individual Investors, Eligible Employees and Non-Institutional Investors which are
directly procured by the SCSBs, would be as follows:

 

 

 

Portion for Retail Individual Investors* 0.35% of the Amount Allotted (plus applicable taxes)
Portion for Eligible Employees* 0.25% of the Amount Allotted (plus applicable taxes)
Portion for Non-Institutional Investors* 0.20% of the Amount Allotted (plus applicable taxes)

 

*Amount Allotted is the product of the number of Equity Shares Allotied and the Offer Price

No additional uploading/processing fees shall be payable by our Company to the SCSBs on the Bid cum Applications Forms directly procured by them.
Processing fees payable to the SCSBs on the portion for Retail Individual Investors, Eligible Employees and Non-Institutional Bidders which are procured
by the members of the Syndicate/sub-Syndicate/Registered Broker/RTAs/ CDPs and submitted to SCSB for blocking, would be as follows:

 

 

 

 

 

 

Portion for Retail Individual Investors* 210 per valid Bid cum Application Form (plus applicable taxes)
Portion for Eligible Employees* 210 per valid Bid cum Application Form (plus applicable taxes)
Portion for Non-Institutional Investors* 210 per valid Bid cum Application Form (plus applicable taxes)

 

*Amount Alloited is the product of the number of Equity Shares Allotied and the Offer Price

Brokerages, selling commission and processing/uploading charges on the portion for Retail Individual Investors (using the UPI mechanism), Eligible
Employees and Non-Institutional Investors which are procured by members of the Syndicate (including their sub-Syndicate Members), Registered
Brokers, RTAs and CDPs or for using 3-in-I type accounts- linked online trading, demat & bank account provided by some of the brokers which are
members of Syndicate (including their Sub-Syndicate Members) would be as follows:

 

 

 

 

 

 

 

 

Portion for Retail Individual Investors* 0.35% of the Amount Allotted (plus applicable taxes)
Portion for Non-Institutional* Investors 0.20% of the Amount Allotted (plus applicable taxes)
Portion for Eligible Employees* 0.25% of the Amount Allotted (plus applicable taxes)

 

“Amount Allotted is the product of the number of Equity Shares Allotted and the Offer Price

The selling commission payable to the Syndicate / Sub-Syndicate Members will be determined on the basis of the application form number / series,
provided that the application is also bid by the respective Syndicate / Sub-Syndicate Member. For clarification, if a Syndicate ASBA application on the
application form number! series of a Syndicate/ Sub-Syndicate Member, is bid by an SCSB, the selling commission will be payable to the SCSB and not
the Syndicate/ Sub-Syndicate Member.

The payment of selling commission payable to the sub-brokers / agents of Sub-Syndicate Members are to be handled directly by the respective Sub-
Syndicate Member.

 

    

The selling commission payable to the RTAs and CDPs will be determined on the basis of the bidding terminal id as captured in the bid book of BSE or
NSE.

Uploading charges/ processing charges of %30 per valid application (plus applicable taxes) are applicable only in case of bid uploaded by the members
of the Syndicate, RTAs and CDPs:

* for applications made by Retail Individual Investors using the UPI Mechanism

* Uploading charges/ processing charges of 210 per valid application (plus applicable taxes) are applicable only in case of bid uploaded by the
members of the Syndicate, RTAs and CDP:
+ for applications made by Retail Individual Investors using 3-in-1 type accounts

+ for Non-Institutional Bids using Syndicate ASBA mechanism / using 3- in -1 type accounts

 

The Bidding/uploading charges payable to the Syndicate / Sub-Syndicate Members, RTAs and CDPs will be determined on the basis of the bidding
terminal id as captured in the bid book of BSE or NSE.

For Registered Brokers

Selling commission payable to the registered brokers on the portion for Retail Individual Bidders and Non-Institutional Bidders which are directly
rocured by the Registered Brokers and submitted to SCSB for processing would be as follows:
Portion for Retail Individual Bidders & Non-Institutional Bidders 210 per valid Bid cum Application Form* (plus applicable taxes).
* Based on valid applications.

 

 

 

 

 

For Sponsor Bank

Processing fees for applications made by Retail Individual Bidders using the UPI Mechanism will be
‘Sponsor Bank | Nil

The Sponsor Bank shalll be responsible for making payments to the third parties such as remitter bank, NPCI and such other
parties as required in connection with the performance of its duties under the SEBI circulars, the Syndicate Agreement and other
applicable laws.

 

 

 

 

 

Monitoring of Utilization of Funds

As the Offer is an offer for sale of Equity Shares by the Selling Shareholders, our Company will not receive any proceeds from
the Offer. Accordingly, no monitoring agency is appointed for the Offer.

Other Confirmations

Except to the extent of any proceeds received pursuant to the sale of Equity Shares proposed to be sold by the Selling
Shareholders, none of our Promoter, Directors, KMPs, Promoter Group or Group Companies will receive any portion of the
Offer Proceeds.

71
BASIS FOR OFFER PRICE

The Offer Price will be determined by our Company and the Selling Shareholders in consultation with the BRLMs, on the basis
of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of
quantitative and qualitative factors as described below. The face value of the Equity Shares is 21 each and the Offer Price is
522 times the Floor Price and 531 times the Cap Price of the Price Band. Bidders should also see “Our Business”, “Risk
Factors”, “Management's Discussion and Analysis of Financial Condition and Results of Operations” and “Financial
Statements” on pages 111, 21, 226 and 162, respectively, to have an informed view before making an investment decision.

Qualitative Factors

Some of the qualitative factors and our strengths which form the basis for computing the Offer Price are:

e Largest and fastest growing diagnostic chain with dominant position in south India (Source: CRISIL Report), well
positioned to leverage the high growth in Indian diagnostics industry;

e Integrated diagnostics provider that offers one-stop solution at affordable price with focus on superior quality standards;

e — High brand recall driving high individual consumer business share and customer stickiness;

e Strong technical capabilities, quality infrastructure and state of the art medical technology with strong IT infrastructure;

and
« Dedicated management team with significant industry experience
For details, see “Our Business - Our Competitive Strengths” on page 111.

Quantitative Factors

Some of the information presented below relating to our Company is derived from the Restated Financial Information. For
details, see “Financial Statements” on page 162.

Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:
A. Basic and Diluted Earnings Per Share (“EPS”), as adjusted for changes in capital:

As derived from the Restated Financial Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial Year/ period ended Basic EPSA (Face value | Diluted EPS (Face value Weight
of 21 each) of 21 each)
(in? (ind)
Year ended March 31, 2021 26 8.26 3
‘Year ended March 31, 2020 6.13 2
Year ended March 31, 2019 4.50 1
Weighted average 6.92
Three month period ended June 30, 2021 (not 3.23
annualised)
Three month period ended June 30, 2020 (not 0.19 0.19
annualised)
Notes:
The ratios have been computed as under:
1; Basic and diluted EPS: Restated profit for the year attributable to equity shareholders of the Company divided by total weighted average
number of equity shares outstanding during the period. Basic and diluted EPS are computed in accordance with Ind AS 33 - Earnings
er share;
a Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. (EPS x Weight) for each year/Total
of weights

‘. Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the
equity shares of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board
resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to
issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held.. Basic and diluted EPS are considered post sub-division
and bonus issue.

 

 

B. Price/Earning (“P/E”) ratio in relation to the in relation to Price Band of %522 to 7531 per Equity Share:
Particulars P/E at the lower end of the Price | P/E at the higher end of the
Band (no. of times) Price Band (no. of times)
Based on basic EPS for year ended March 31, 2021 63.20 64.29

 

 

 

 

 

72
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars P/E at the lower end of the Price | P/E at the higher end of the
Band (no. of times) Price Band (no. of times)
Based on diluted EPS for year ended March 31, 2021 63.20 64.29
Industry Peer Group P/E ratio
Particulars P/E Ratio
Highest 107.3
Lowest 74.4
‘Average 90.8
Return on Net Worth (“RoNW”)
As derived from the Restated Financial Information:
Financial Period / Year ended RoNW (%) Weight
March 31, 2021 23.64% 3
March 31, 2020 22.80% 2
March 31, 2019 22.35% 1
Weighted Average 23.14%
June 30, 2021 (not annualised) 8.48%
June 30, 2020 (not annualised) 0.66%

 

 

 

 

Notes:
The ratio has been computed as under:

1. Return on net worth %: Profit after tax for the year attributable to equity shareholders of the Company divided by net worth as attributable to
equity shareholders of the Company at the end of the year™100.

2. Net worth = net worth means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities premium
account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure
and miscellaneous expenditure not written off, derived from the Restated Financial Information, but does not include reserves created out of
revaluation of assets, write-back of depreciation and amalgamation..

3. The Weighted Average Return on Net Worth is a product of Return on Net Worth and respective assigned weight, dividing the resultant by total
aggregate weight. i.e. (RONW x Weight) for each year/Total of weights

 

As the Offer consists only of an offer for sale by the Selling Shareholders, there will be no change in the Net Worth
post completion of the Offer.

Net Asset Value (“NAV”) per Equity Share

 

 

 

 

 

 

 

As at Restated Financial Information (%)
June 30, 2021 38.53
Offer Price 531.00
Notes:

Net assets value per share (in 2): Net asset value per share is calculated by dividing net worth by number of equity shares outstanding at the end of
the year.

As the Offer consists only of an offer for sale by the Selling Shareholders, there will be no change in the NAV post
completion of the Offer.

Comparison with Listed Industry Peers

 

 

 

Name of the Face P/E | Net Profit | EPS EPS Net worth | RoNW | Net Asset Closing
company value per (in | (Basic) | (Diluted) | (in (%) Value/ Share
equity million) | ® million) Equity | Price as on
share () Share | August 11,
® 2021
(& per
equity
share)
Vijaya Diagnostic i NA 849.11 8.26 8.26 3,592.32 23.64% 35.23 NA
Centre Limited
Dr. Lal Path Labs 10] 107.3 2,916 35.33 35.25 12,450} 23.42% 149.38 3,791.15
Limited

 

 

 

 

 

 

 

 

 

 

 

 

73
 

 

 

Name of the Face P/E | Net Profit | EPS EPS Net worth | RoNW | Net Asset Closing
company value per (in | (Basic) | (Diluted) | (in (%) Value/ Share
equity million) @ ®@ million) Equity | Price as on
share (2) Share | August 11,
® 2021
(& per
equity
share)
Metropolis 2) 74.4 1,831] 35.97 35.79 7,066] 25.91% 138.23] 2,675.65
Healthcare
Limited

 

 

 

 

 

 

 

 

 

 

 

Source: All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual audited
financial results of the company for the year ended March 31, 2021

Source for our Company: Based on the Restated Financial Information for the year ended March 31, 2021

Basic and diluted EPS are computed in accordance with Ind AS 33 - Earnings per share.

‘Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the
equity shares of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board
resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to
issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held. Basic and diluted EPS are considered post sub-division
and bonus issue.

Notes:

(1) PE Ratio has been computed based on the closing market price of equity shares on BSE on August 11, 2021, divided by the Basic EPS.

(2) Net Profit is the Profit for the year attributable to equity shareholders of the Company

(3) Return on net worth %: Profit for the year attributable to equity shareholders of the Company divided by net worth as attributable to equity
shareholders of the Company at the end of the year

(4) Net worth has been computed as sum of paid-up share capital and other equity.
(5) NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Our Company has, pursuant to a Board
resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of 210 each to
Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders
resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares. Net asset value per share is
considered post sub-division and bonus issue.

The Offer Price is 531 times of the face value of the Equity Shares
The Offer Price of 3531 has been determined by our Company and the Selling Shareholders in consultation with the
BRLMs, on the basis of market demand from investors for Equity Shares through the Book Building Process and is
justified in view of the above qualitative and quantitative parameters.
Investors should read the above mentioned information along with “Risk Factors”, “Our Business”, “Management's
Discussion and Analysis of Financial Condition and Results of Operations” and “Financial Statements” on pages 21,

111, 226 and 162, respectively, to have a more informed view.

The trading price of the Equity Shares could decline due to the factors mentioned in the “Risk Factors” on page 21
and you may lose all or part of your investment.

74
STATEMENT OF SPECIAL TAX BENEFITS
REPORT ON THE STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS

The Board of Directors

Vijaya Diagnostic Centre Limited
3-6-16 & 17, Street No. 19,
Himayatnagar,

Hyderabad — 500 029

Telangana, India

Date: 05 June 2021
Dear Sirs,

Subject: Statement of possible special tax benefits (“the Statement”) available to Vijaya Diagnostic Centre Limited
(formerly known as ‘Vijaya Diagnostic Centre Private Limited’) (“the Company”) and its shareholders (the
“Shareholders”) prepared in accordance with the requirement under Schedule VI — Part A - Clause (9) (L) of Securities
and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“the SEBI
ICDR Regulations”)

This report is issued in accordance with the engagement letter dated 12 April 2021.

We hereby report that the enclosed Annexure I and Annexure II prepared by the Company, initialed by us and the Company
for identification purpose, states the possible special tax benefits available to the Company and to the Shareholders under direct
and indirect taxes as stated in Annexure I (together with the Act, “the Tax Laws”), presently in force in India as on the signing
date. These possible special tax benefits are dependent on the Company and the Shareholders fulfilling the conditions prescribed
under the relevant provisions of the Tax Laws. Hence, the ability of the Company and the Shareholders to derive these possible
special tax benefits is dependent upon their fulfilling such conditions, which is based on business imperatives the Company
may face in the future and accordingly, the Company and the Shareholders may or may not choose to fulfill.

The benefits discussed in the enclosed Annexure I cover the possible special tax benefits available to the Company and the
Shareholders and do not cover any general tax benefits available to them. Further, the preparation of the enclosed Annexure I
and Annexure II and its contents is the responsibility of the management of the Company. We were informed that the Statement
is only intended to provide general information to the investors and is neither designed nor intended to be a substitute for
professional tax advice. In view of the individual nature of the tax consequences and the changing tax laws, each investor is
advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in
the proposed initial public offering of equity shares of the through offer for sale of equity shares by certain Shareholders (the
“Proposed Offer”) particularly in view of the fact that certain recently enacted legislation may not have a direct legal precedent
or may have a different interpretation on the possible special tax benefits, which an investor can avail. Neither are we suggesting
nor are we advising the investors to invest money based on this Statement.

We conducted our examination in accordance with the “Guidance Note on Reports or Certificates for Special Purposes (Revised
2016)” (“Guidance Note”) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we
comply with ethical requirements of the Code of Ethics issued by the Institute of Charted Accountants of India.

We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for
Firms that Perform Audits and Reviews of Historical Financial information, and Other Assurance and Related Services
Engagements.

We do not express any opinion or provide any assurance as to whether:

i) the Company and the Shareholders will continue to obtain these possible special tax benefits in future; or
ii) the conditions prescribed for availing the possible special tax benefits where applicable, have been/would be met with.

The contents of enclosed Annexure are based on the information, explanation and representations obtained from the Company,
and on the basis of our understanding of the business activities and operations of the Company.

75
Our views expressed herein are based on the facts and assumptions indicated to us. No assurance is given that the revenue
authorities/ courts will concur with the views expressed herein. Our views are based on the existing provisions of the Tax Laws
and its interpretation, which are subject to change from time to time. We do not assume responsibility to update the views
consequent to such changes. We shall not be liable to the Company for any claims, liabilities or expenses relating to this
assignment except to the extent of fees relating to this assignment, as finally judicially determined to have resulted primarily
from bad faith or intentional misconduct. We will not be liable to any other person in respect of this Statement.

We hereby give consent to include this Statement in the Draft Red Herring Prospectus, Red Herring Prospectus, Prospectus and
in any other material used in connection with the Proposed Offer, and is not to be used, referred to or distributed for any other
purpose without our prior written consent.

For B S R & Associates LLP
Chartered Accountants
ICAI firm registration number: 116231W/ W-100024

Sriram Mahalingam

Partner

Membership No.: 049642

ICAI UDIN: 21049642AAAACE5102

Place: Palakkad
Date: 05 June 2021

Ce:

ICICI Securities Limited
ICICI Centre

H.T. Parekh Marg, Churchgate
Mumbai — 400020
Maharashtra, India

Edelweiss Financial Services Limited
6th Floor, Edelweiss House

Off C.S.T. Road,

Kalina

Mumbai - 400 098

Maharashtra, India

Kotak Mahindra Capital Company Limited
1% Floor, 27 BKC, Plot No. — 27

"G" Block, Bandra Kurla Complex

Bandra (East),

Mumbai — 400051

Maharashtra, India

76
ANNEXURE I

 

 

 

 

 

 

 

 

Details of Tax Laws

1. Income Tax Act, 1961 and Income Tax Rules, 1962, each as amended and read with respective circulars
and notifications made thereunder

2: Central Goods and Services Tax Act, 2017, as amended

ox Integrated Goods and Services Tax Act, 2017, as amended

4. State Goods and Services Tax Act, 2017, as amended

5. Customs Act, 1962 and Customs Tariff Act, 1975, each as amended and read with respective rules,
circulars and notifications made thereunder

6. The Foreign Trade Policy 2015-2020

 

 

77

 
ANNEXURE II

ANNEXURE TO THE STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS AVAILABLE TO THE COMPANY
AND THE SHAREHOLDERS UNDER THE APPLICABLE DIRECT AND INDIRECT TAX LAWS (“TAX LAWS”)
IN INDIA

Outlined below are the possible special tax benefits available to the Company and the Shareholders under the Tax Laws.
These possible special tax benefits are dependent on the Company or the Shareholders fulfilling the conditions prescribed
under the Tax Laws. Hence, the ability of the Company or the Shareholders to derive the possible special tax benefits is
dependent upon fulfilling such conditions, which are based on business imperatives it faces in the future, it may or may not
choose to fulfill.

UNDER THE TAX LAWS
A. Direct taxation
1. Special tax benefits available to the Company

a. Section 115BAA of the IT Act, as inserted vide The Taxation Laws (Amendment) Act, 2019, provides that the domestic
company can opt for a rate of tax of 22% (plus applicable surcharge and cess) for the Financial Year 2019-20 (relevant to
Assessment Year 2020-21) onwards, provided the total income of the company is computed without claiming certain
specified incentives/ deductions or carry forward and set-off of certain losses, additional depreciation etc. and claiming
depreciation determined in the prescribed manner. In case the Company opts for Section 115BAA of the IT Act, provisions
of Minimum Alternate Tax (“MAT”) under Section 115JB of the IT Act would not be applicable and also MAT credit of
the earlier year(s) will not be available for set-off. The option needs to be exercised on or before the due date of filing the
tax return. Option once exercised, cannot be subsequently withdrawn for the same or any other tax year.

We have been informed by the Company that it has opted concessional tax regime as provided under provisions of for
Section 115BAA of the IT Act from the Assessment Year 2020-2021.

In accordance with the provisions of Section 80M of the IT Act, dividend received by the company from any other
domestic company or a foreign company or a business trust, a deduction of an amount equal to so much of the amount of
income by way of dividends received from such other domestic company or foreign company or business trust as does not
exceed the amount of dividend distributed by the company on or before one month prior to due date of furnishing the
income-tax return under Section 139(1) for the relevant year, be allowed.

Further, any deduction, in respect of the amount of dividend distributed by the domestic company, has been allowed under
Section 80M(1) of the IT Act in any previous year, no deduction shall be allowed in respect of such amount in any other
previous year.

b. In accordance with and subject to fulfilment of conditions as laid out under Section 35D of the IT Act, the Company may
be entitled to amortize preliminary expenditure, being expenditure incurred in connection with the issue for public
subscription or in connection with expenditure as prescribed under Section 35D of the IT Act, subject to the limit specified
in Section 35D of the IT Act. The deduction is allowable for an amount equal to one-fifth of such expenditure for each of
five successive previous years beginning with the previous year in which the business commences or as the case may be,
the previous year in which the extension of the undertaking is completed or the new unit commences production or
operation.

c. Inaccordance with and subject to fulfilment of conditions as laid out under Section 80JJAA of the IT Act, the Company
may be entitled to claim deduction of an amount equal to thirty per cent of additional employee cost (relating to specified
category of employees) incurred in the course of business in the previous year, for three assessment years including the
assessment year relevant to the previous year in which such employment is provided.”

2. Special tax benefits available to Shareholders

The Shareholders of the Company are not eligible to any special tax benefits under the Income Tax Act, 1961 and Income Tax
Rules, 1962 identified supra.

B. Indirect taxation
78
1. Special tax benefits available to the Company

The Company is not eligible to any special tax benefits under the Central Goods and Services Tax Act, 2017, as amended;
Integrated Goods and Services Tax Act, 2017, as amended; State Goods and Services Tax Act, 2017, as amended; Customs
Act, 1962 and Customs Tariff Act, 1975, each as amended and read with respective rules, circulars and notifications made
thereunder; and The Foreign Trade Policy 2015-2020.

2. Special tax benefits available to Shareholders

The Shareholders of the Company is also not eligible to any special tax benefits under the Central Goods and Services Tax
Act, 2017, as amended; Integrated Goods and Services Tax Act, 2017, as amended; State Goods and Services Tax Act, 2017,
as amended; Customs Act, 1962 and Customs Tariff Act, 1975, each as amended and read with respective rules, circulars and
notifications made thereunder; and The Foreign Trade Policy 2015-2020

NOTES:
1. The above is as per the current tax laws, as amended by the Finance Act, 2021.
2. The above Statement of possible special tax benefits sets out the provisions of Tax Laws in a summary manner only and

is not a complete analysis or listing of all the existing and potential tax consequences of the purchase, ownership and
disposal of equity shares of the Company.

3. The possible special tax benefits are subject to conditions and eligibility criteria which need to be examined for tax
implications.
4. This Statement does not discuss any tax consequences in any country outside India of an investment in the equity

shares of the Company. The Shareholders / investors in any country outside India are advised to consult their own
professional advisors regarding possible income tax consequences that apply to them under the laws of such
jurisdiction.

5. The tax benefits discussed in the Statement are not exhaustive and are only intended to provide general information to
the investors and hence, is neither designed nor intended to be a substitute for professional tax advice. In view of the
individual nature of the tax consequences and the changing tax laws, each investor is advised to consult his or her own
tax consultant with respect to the specific tax implications arising out of their participation in the issue

6. In respect of non-residents, the tax rates and the consequent taxation mentioned above shall be further subject to any
benefits available under the applicable double taxation avoidance agreement, if any, between India and the country in
which the non-resident has fiscal domicile.

For Vijaya Diagnostic Centre Limited
Authorized Signatory

Place: Hyderabad
Date: 05 June 2021

79
SECTION IV: ABOUT OUR COMPANY
INDUSTRY OVERVIEW

The information contained in this section is derived from the industry report titled “Assessment of the diagnostic industry in
India” dated May 2021 and its addendum to the report dated August 2021 (the “CRISIL Report”) prepared and released by
CRISIL Limited (“CRISIL Research”) and commissioned and paid for by our Company to confirm our understanding of our
industry specifically for the purpose of the Offer. Unless specified otherwise, all information in this section has been derived
from the CRISIL Report. Industry sources and publications generally state that the information contained therein has been
obtained from sources generally believed to be reliable, but that their accuracy, completeness and underlying assumptions are
not guaranteed and their reliability cannot be assured. Industry publications are also prepared based on information as of
specific dates and may no longer be current or reflect current trends.

MACROECONOMIC OVERVIEW OF INDIA

A review of India’s GDP growth

In 2015, the Ministry of Statistics and Programme Implementation (“MoSPI”) changed the base year for calculating the gross
domestic product (“GDP”) between fiscal year 2005 and fiscal year 2012. Based on this, India’s GDP increased at an eight-
year compound annual growth rate (“CAGR”) of 6.6% to & 146 trillion in fiscal year 2020 from % 87 trillion in fiscal year 201 2.

Real GDP growth in India (new GDP series)

64% 8%

. 8 -
4%

am 2%
80 0%
60 -2%
io 4%
20 i

0

10%
FY20 FY21AE

&e
&

=EEEGDP (Rs trillion)  O—Y-0-Y GDP growth rate

Note: AE: Advance estimates
Source: Provisional estimates of Annual National Income 2020-21, Central Statistics Office (CSO), MoSPI, CRISIL Research

After contracting in the first half of fiscal year 2021 because of the Covid-19 pandemic, the economy rebounded in the second
half, growing 0.5% and 1.6% on-year in the third and fourth quarters, respectively. While the economy shrank as a whole in
fiscal year 2021, agriculture and allied activities, and electricity, gas, water supply and other utility services were the outliers,
logging positive growth. On the other hand, contact-intensive trade, hotels and transport sectors, and services related to
broadcasting were hit the most and continued to shrink in all the quarters. Construction — a labour-intensive sector — was also
severely hit in the first half, but rebounded in the second half.

80
Quarter-wise real GDP growth in FY21

45 0.5% 1.6% 5%
40 -
35: _7 Ao 5%
30 ee
25 10%
20 -15%
"5

: -20%
10

5 -25%

0 -30%

QI FY21 AE Q2 FY21 AE Q3 FY21 AE Q4 FY21 AE

mam GDP (Rs billion) =O=Y-c-Y GDP growth rate

Note: AE: Advance estimates
Source: Provisional estimates of Annual National Income 2020-21, Central Statistics Office (CSO), MoSPl, CRISIL Research

From the supply side i.e., gross value added (“GVA”), a much better measure of the economic performance for last fiscal, the
economy shrank a lesser 6.3% (compared with 4.1% growth in fiscal 2020). In absolute terms, real GVA was 2 124.5 trillion
last fiscal, down from Rs 127.4 trillion in fiscal 2019.

GVA at basic prices (constant FY12 prices)

 

PRT) Fyi2 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 |FY21AE| CAGR

GVAatbasicprices 81.1 | 855 | 906 | 97.1 | 1049 113.3 | 120.3 | 127.4 | 1327 124.5) 4.9%

 

Y-o-y growth (%) 5.4% | 6.1% | 7.2% | 8.0% | 8.0% | 6.2% | 5.9% | 4.1% 62%

Note: CAGR is between fiscal 2012 and 2021
Source: CRISIL Research

 

 

 

 

 

 

 

 

 

 

Fiscal year 2022 base case GDP growth expected to be 9.5%

India is getting back on its feet slowly, with divergent growth trends. Though data suggests there has been some pick-up in
recent months, recovery is weak and uneven. The scars of the pandemic continue to run deep for small businesses, the urban
poor and most of the services sector.

Fiscal year 2022 is seen emerging as a story of two halves. The first half will be characterised by a base effect-driven recovery
amid the challenge associated with resurgence in Covid-19 infections, while a more broad-based growth is expected in the
second half, as vaccine rollout and herd immunity support sectors that are lagging. The gains made by the economy in the fourth
quarter of fiscal 2021 seem to have fizzled out in the first quarter of fiscal year 2022 because of the fierce second wave of
Covid-19, leading to localised lockdowns in most states. At the same time, monetary policy has begun normalising, and some
tightness in domestic financial conditions is inevitable. Against this backdrop, policy support remains critical, apart from action
in the external environment.

In fiscal year 2021, the policy response to the pandemic focused more on damage control and measures to support the economy.
In the current fiscal, the government is expected to normalise some of the extraordinary or unconventional policy moves, while
trying to ensure there is smooth revival in growth. This will pertain to most of the services sectors, especially contact-based
travel, tourism and entertainment. Also, stronger global growth should support India’s exports to some extent. Revival will not
be uniform across sectors, though. So far, the rural economy has been more resilient than the urban.

81
Real GDP growth (% on-year)

Fy24P a 57:
Fy23 P 78%
FY22 P ee 9.5%
FY2AE 7.3%
FY20 a |e.
FY19 65%
FY18 ee 6.8%
Fyi7 83%
FYI6 80%
FY15 EL)
FY14 —— mmm) C4.
FY13 65
9.0% 7.0% 5.0% 3.0%  -1.0% 1.0% 3.0% 5.0% 7.0% 9.0%

AE: Advance estimates; P: Projected by CRISIL Research; GDP calls updated as of June 2021;
Source: Provisional estimates of national income 2020-21, CSO, MoSPI, CRISIL Research

Forecasts fiscal year 2022 GDP growth to rebound to 9.5%
CRISIL Research forecasts that India’s GDP growth will rebound to 9.5% in fiscal year 2022, as four drivers converge:
1. Weak base: A 7.3% contraction in GDP in fiscal 2021 will provide a statistical push to growth next fiscal.

2. Global upturns: Higher global growth in calendar year 2021, as world GDP is set to rise by 5.0%, advanced economies
by 4.3% and emerging economies by 6.3%, should lift exports.

3. COVID-19 curve: India is witnessing the second wave of COVID-19 infections and at the same time learning to live with
the virus, with the rollout of vaccines. These should broaden growth next fiscal year, especially in the services and
unorganised sectors.

4. Fiscal push: A stretch in the fiscal year glide path and focus of Union Budget 2021/2022 on capital expenditure are
expected to have a multiplier effect on growth.

Risks to the fiscal 2022 forecast

The base case of 9.5% GDP growth assumes that Covid-19 restrictions will continue and mobility will remain affected in
some form or other, at least till August. The pace of economic recovery will also be a function of what the pace of vaccination
is in the coming months. We find that countries with over 40% of their population vaccinated are seeing a faster and more
broad-based economic recovery. The government plans to vaccinate India’s entire adult population (68% of total population)
by this December — a tall order even if there are sufficient vaccines available. CRISIL Research’s base case is 70% of the
adult population vaccinated by December.

A third wave would pose a significant downside risk to the growth forecast, as would a slower-than-anticipated pace of
vaccination. In such a pessimistic case, CRISIL Research sees GDP growing at 8% in fiscal 2022.

India expecting to surpass global GDP growth in next three fiscals

82
India to surpass global GDP growth in next three fiscals enn R Rea hier!

year 2022 on the back of a very weak
(%, y-o-y) etre mal MeCite pe) (eleclee (Micra

9.5%

CRISIL Research sees India’s GDP growth
rebounding to 9.5% this fiscal due to a very
weak base, flattening of the Covid-19
curve, rollout of vaccinations, investment-
focused government spending, and benefit

from the ‘rising global tide lifts all boats’
effect. Yet, the economy is expected to
reach pre-pandemic levels only by the
second quarter of this fiscal. Services will

 

73%
take longer to recover than manufacturing.
FY20 FY21E FY22P FY23P. FY24P Beyond fiscal year 2022, India is seen
growing faster than the world. Over fiscal
—Omindia =sOmWorld year 2023 to fiscal year 2025, growth is

seen averaging at around 6.0% annually.

 

Note: Forecasts for World are for calendar year; FY20 corresponds to 2019 and
so on; P: Projected; updated as of June 2021; India numbers for FY20 and FY21 are based on MoSPI’s latest GDP estimates and FY22
onwards are CRISIL Research’s forecast. World GDP growth rates are from IMF world economic outlook update as of April 2021.
Source: S&P Global Ratings, CRISIL

India’s per capita income rose at a healthy pace between fiscal year 2012 and fiscal year 2020

India’s per capita income, a broad indicator of living standards, rose from 2 63,462 in fiscal year 2012 to 2 94,556 in fiscal
year 2020, at 5.1% CAGR. This growth was led by better job opportunities, propped up by overall GDP growth. Moreover,
population growth remained fairly stable at around 1% CAGR.

Per capita net national income at constant prices

 

Ceo ca cc) | FY17 aes se aaa

 

Per-capita net
national income 63,462 | 65,538 | 68,572 | 72,805 77,659 | 82,931 | 87,828 | 92,241 | 94,556 | 86,659
(Rs)

On-year arowth (%) | 2.1 33 46 6.2 67 68 59 5.0 25 84 |

 

 

 

 

 

 

 

RE: Revised estimates; AE: Advance estimates;
Source: Second Advance Estimates of Annual National Income, 2020-21, CSO, MoSPI, CRISIL Research

Key fiscal measures by the Centre to deal with the COVID-19 pandemic impact

In view of the COVID-19 pandemic’s impact on the economy, the Government of India has announced 12 key measures, as
part of its stimulus to the economy, under Aatmanirbhar Bharat 3.0. The total stimulus announced by the Government and
Reserve Bank of India (“RBI”) till date, to help the nation tide over the COVID-19 pandemic, works out to = 29.87 trillion,
which is 15% of the national GDP. Out of this, a stimulus worth 9% of GDP has been provided by the Government.

Social and healthcare-related parameters

India’s current healthcare expenditure lower than other developing countries

 

According to the Global Health Expenditure Database compiled by the World Health Organization (the “WHO”),
India's current expenditure on healthcare was 3.5% of GDP in 2018. To put this into greater perspective, while
India’s real GDP in fiscal year 2019 was = 139.8 trillion (at constant fiscal year 2012 prices), India’s current
healthcare expenditure (“CHE”) was approximately 2 4.9 trillion. In fact, India trailed not just developed
countries, such as the US and the UK, but also developing countries, such as Brazil, Malaysia, Nepal, Singapore,
Sri Lanka, Thailand, and Vietnam, in terms of healthcare spending as a percentage of GDP as of 2018.

83
Current healthcare expenditure as % of GDP (2018)

™ aS
—
= Ee
=a
=a
"Ee

 

0% 2% 4% 6% 8% 10% 12% 14% 16% 18%

Source: Global Health Expenditure Database - World Health Organisation, CRISIL Research

India’s current healthcare expenditure steadily growing with its GDP but with private sector accounting for lion’s
share

 

India's CHE, though, has increased with its expanding GDP. Between 2010 and 2018, the current healthcare
expenditure has grown at a CAGR of 6.2%

Current healthcare expenditure (CHE) as % of GDP in India
3.6%

3.5%
3.5%
3.5%
3.4%
34% 3.3%
3.3%
3.2%
2010 2018

Source: Global Health Expenditure Database - World Health Organization, CRISIL Research

However, at an overall level, the healthcare expenditure in India is low primarily because of under-penetration of
healthcare services and low individual spending on healthcare. Further, India's per-capita total expenditure on
healthcare (at international dollar rate, adjusted for purchasing-power parity) was only $73 in 2018 compared to
other emerging countries such as $112 for Indonesia, $152 for Vietnam, $157 for Sri Lanka, $276 for Thailand,
$427 for Malaysia and $848 for Brazil.
General expenditure on health as % of CHE (2018)

Government
expenditure
27%

India's CHE is skewed towards private expenditure. Government
expenditure on healthcare ranged 20 to 30% of CHE from 2010 to
2018. The government expenditure on health has registered a
CAGR of 6.5% between 10 and 2018. The rest of the
expenditure (70 to 80%) was private in nature, i.e. expenditure

  

from resout with no government control, such as voluntary
7» health insurance, and direct payments for health by corporations
‘Private expenditure it, not-for-profit, and non-government organisations) and
73% olds. However, the Government aims to increase public
parrot oan Co} of GDP from the current 1.2%,

7 according to the National Health Poli PA

 

Source: Global Health Expenditure Database - World Health Organization, CRISIL Research

Out-of-pocket expenditure towards healthcare is high in India

Private health expenditure includes components such as voluntary health insurance, other private health
expenditure and out-of-pocket expenditure. In terms of private health expenditure by means of voluntary health
insurance and other private health expenditure (excluding out-of-pocket expenditure), India fares poorly
compared with Brazil, Malaysia, South Africa, and Thailand. In India, out-of-pocket expenditure on health
accounted for approximately 63% of the total health expenditure as of 2018 (the highest among countries
compared).

Out-of-pocket as % of CHE (2018)

=|

Nepal, 50.8%
‘WED sti Lanka, 50.7%

 

EXE. United kingdom, 16.7%
ms) Thailand, 11.09%

= United States of America, 10.8%

 

0% 10% 20% 30% 40% 50% 60% 70%
Source: Global Health Expenditure Database- World Health Organization, CRISIL Research

DIAGNOSTIC INDUSTRY IN INDIA

Structure of healthcare market

85
     
   
 
     
   
  
 

pS
onony
ess te1 9)

Healthcare

Health PE ey
Boece TE
(FY21)

 

 

Source: CRISIL Research

De Cv lenect merle Comm ele MEM re-Celhmarrsatatce min ten
e Healthcare delivery market (hospitals) which valued at approximately % 4,400 billion* is
projected to grow at a CAGR of 17 to 18% during fiscal PAPA Om tral
Pharmaceuticals industry of which the domestic formulations segment was valued at approximately
Fao tee cnC Nata ener Ce) amen URES a en ec rINe Rie me ienmtnite mie tg
Diagnostic industry which was valued at % 710 to % 730 billion* is projected to grow at a CAGR of
ren arate A to fiscal year 202

Healthcare insurance industry of which the health insurance premium market stood at = 583 billion
as of fisci 1 and is expected to achieve a GR of 18 to 19% between fisca
fiscal year

*As per CRISIL Res estimates for fiscal year 2021

NOAM em REM Me ae CTL G 21h me) Noe em ee) (TUMOR ACO L OOM ULAR Se ate
these cannot be consolidated to arrive at market size of the Indian healthcare market.

 

Market size of the diagnostic industry in India
Diagnostic services is a key sub-segment of Indian healthcare market

Evidence-based treatment has become the norm for many doctors, as diagnosis enables prescription of correct therapy, and,
thereby, faster recovery. Hence, in the spectrum of healthcare delivery services, diagnostic services play the key role of
information intermediary, providing useful information for correct diagnosis and treatment of diseases.

Diagnostic services currently have an 8 to 14% share in the overall healthcare spending on account of variation between rural
and urban across institutions such as government-owned, charitable/trust-based and private.

Indian diagnostic industry to sustain pace of growth up to fiscal years 2023

With diagnostic services becoming the cornerstone for recommending requisite treatments, as well as monitoring recovery post-
treatment, the industry has posted healthy growth over the past few years. The diagnostic industry achieved a healthy CAGR
of 13 to 14% from fiscal years 2017 to 2020, tracking the growth of healthcare delivery services. However, in fiscal year 2021,
CRISIL Research estimates the industry’s growth rate will sharply decelerate to approximately 4% on-year to = 710 to = 730
billion, owing to the fallout of the COVID-19 pandemic. In fiscal year 2021, COVID-19 put the brakes, albeit temporarily, on
the growth story of the diagnostic sector, especially for small laboratories. With treatments at hospitals being deferred,
outpatient footfalls dropping and lockdowns in quarter 1 of fiscal year 2021, the regular volume of diagnostic services took a
hit. According to industry players, after a sharp fall in revenue in April and May 2020, there was some revival in demand from

86
June 2020 onwards. Pent-up healthcare demand contributed to revenue during a traditionally lean quarter from a diagnostic
perspective, with recovery to pre-COVID-19 levels occurring in the third quarter of fiscal year 2021.

However, between fiscal years 2020 and 2023, the industry is expected to return to a healthy growth trajectory of 12 to 13%
CAGR, reaching % 920 to 980 billion. The industry is however expected to achieve a higher CAGR between fiscal year 2021
and fiscal year 2023 in the range of 14 to 16% on account of a low growth in fiscal year 2021 due to the COVID-19 pandemic
impact on the industry.

Indian diagnostic industry holds potential for medium term

(2 in billion)

 

    

(ao

Ja, OD.
=) Es
FY17 FY18 FY19 FY21E FY22P FY23 P

E: Estimated; P: Projected
Source: CRISIL Research

Going forward, CRISIL Research expects there to be medium-term growth arising from the increase in demand for in-patient
as well as outpatients treatments. The demand for diagnostic services in any given year also experiences marginal seasonality
during epidemics, such as dengue and malaria, and the flu season. Moreover, as literacy rates, health awareness and disposable
incomes rise, individuals increasingly demand better healthcare facilities and quality of care, and increase their spending on
preventive and wellness, leading to high volume growth of in-patients and outpatient treatments. The rise in healthcare demand
has also received a boost from increases in urbanisation and lifestyle-related diseases, such as cardiac diseases, diabetes and
cancer, prompting many diagnostic service providers to enhance their offerings in metropolitan areas and tier-I and tier-II cities.

Structure of diagnostic industry in India

Based on business model

Diagnostic centres in India can be classified
into hospital-based, diagnostic chains, and
EWtecl ey tarea nase
e Hospital-based diagnostic centres are
located in hospitals for captive use. The:
FTeomtnCekyt moh iY nSem DN MHL
given to third parties to manage
Diagnostic chains are owned dia

erates

a Tey

oat TALK Me we tileyeoacn Loca
operate through a hub-and-:
model of collection centres

 

Standalone diagnostic centres are single
unit centres. Majority of these have small-
scale of operations, and offer either
pathology, basic radiology or advanced
radiology serv

 

Source: Industry, CRISIL Research

87
Hospital-based diagnostic centres

Usually, secondary and tertiary hospitals have pathology laboratories and radiology centres in-house; but some also engage
third-party players such as SRL Limited (“SRL”), Metropolis Healthcare Limited (“Metropolis”), and Apollo Diagnostics
(“Apollo Diagnostics”) (a division of Apollo Health and Lifestyle Limited) to manage their diagnostic facilities. Major hospital
chains, such as Apollo Hospitals Enterprise Ltd, HCG, Max Healthcare and Fortis Healthcare have diagnostic arms.

Typically, hospitals with 100 to 150 beds or less prefer to outsource their tests rather than set up an in-house laboratory testing
facility. Tertiary hospitals, which may not have the equipment to conduct advanced tests, may also send samples to advanced
laboratories. Given that equipment for advanced tests is expensive, many hospitals find it economically unviable to operate
these, owing to the low testing volume. For example, a hospital may have the equipment to test whether a patient is HIV-positive
or not; but to determine a virus count, the sample is sent to a specialised pathology lab. Specialised tests with low patient volume
at the hospital may also be outsourced to a chain or standalone diagnostic laboratories offering advanced diagnostic facilities.

Diagnostic chains

Diagnostic chains such as Thyrocare Technologies Limited (“Thyrocare”), Dr Lal PathLabs Limited (“DLPL”), SRL,
Metropolis, Apollo Diagnostics are present either in a specific region/geography or have a multi-regional presence, and offer
either or both, pathology and radiology testing services. There are also prominent regional chains in different geographies, such
as Vijaya Diagnostic Centre Private Limited (”Vijaya”), Medall Healthcare Private Limited (“Medall”), Suraksha Diagnostics
Private Limited (“Suraksha”), Suburban Diagnostics (India) Private Limited, Aarthi Scans Private Limited (“Aarthi”), etc,
which have created brand resonance. These players’ operating margins tend to be on par with multi-regional chains.

Standalone centres

Standalone diagnostic centres make up 45 to 50% share of the market. Low entry barriers and the absence of stringent
regulations have helped small pathology laboratories and radiology centres proliferate. These carry out basic tests that require
minimal investment and space, and typically have a conventional X-ray and an ultrasound machine. There are also centres with
restricted presence offering specialised tests such as magnetic resonance imaging (“MRI”) scans, computerised tomography
(“CT”) scans, advanced positron emission tomography CT (“PET CT”) scans and gamma.

Other business models in diagnostic industry in India

Different business models are being introduced in the diagnostic industry. These are shop-in-shop or PPP model, aggregator
model, chain model (via franchisees) and players which focus only on niche tests. Diagnostic chains provide a bouquet of
services to a diversified clientele, process samples from smaller hospitals and diagnostic centres, and offer corporate wellness
programmes. Players also operate on an aggregator-based model, controlling logistics and quality with partner laboratories.
Out-of-hospital diagnostics market in India to log 12 to 13% CAGR over fiscal years 2020 to 2023

Out-of-hospital has higher share in diagnostics market

FY21E

The out-of-hospital diagnostics market is
estimated to account for 56 to 58% of the

ic diagnostics market as of fiscal
A(T

 

Note: Hospital based diagnostic market includes diagnostic services provided to in-patients inside hospital premises by in-house diagnostic
facilities setup by the hospital or outsourced to a diagnostic centre/chain
Source: CRISIL Research

As per CRISIL Research estimates, the Indian out-of-hospital diagnostic industry is valued at 390 billion to = 395 billion in
the fiscal year 2020, having achieved a CAGR of approximately 12% over fiscal years 2017 to 2020. Deeper penetration of

88
diagnostic chains has given the out-of-hospital market a push in the past three fiscals. Diagnostic chains have not only increased
penetration by way of consolidation with standalone diagnostic players, but also tied up with hospitals to cater to their diagnostic
services. The latter not only reduces hospitals’ capital expenditure on equipment, but also helps them save on the effort needed
to maintain their diagnostic services. The out-of-hospital market, estimated to account for 56 to 58% of the entire domestic
diagnostics market, is estimated at % 400 to % 410 billion as of fiscal year 2021. The out-of-hospital market is further projected
to grow at a CAGR of 12 to 13% over fiscal years 2020 to 2023 to reach % 555 to % 565 billion in fiscal year 2023. This growth
can be attributed to consolidation in the industry and increase in B2C business on account of increasing health awareness among
people. Also, the COVID-19 pandemic has boosted demand for radiology testing services, as dependence on high-realisation
radiology tests (CT scan over X-ray) has gained traction.

Out-of-hospitals diagnostics market size in India

   

 

(in billion)
wa) CAGR: 12-13%
< > ¢ >
555-565
390-395 400-410
. a a
FY17(E) FY20(E) FY21 (E) FY23 (P)

E: Estimated; P: Projected

Note: Hospital based diagnostic market includes diagnostic services provided to in-patients inside hospital premises by in-house diagnostic
facilities setup by the hospital or outsourced to a diagnostic centre/chain
Source: CRISIL Research

Out-of-hospital diagnostics market in Andhra Pradesh and Telangana to log 12 to 13% CAGR over fiscal years 2020 to 2023

Out-of-hospital based diagnostic market in Andhra Pradesh and Telangana
FY21E

   

The out-of-hospital diagnostics market is
estimated to account for 58 to 59% of the
entire diagnostics market in Andhra Pradesh
and Telangana in fiscal year 2021.

eneaeneastcl

Note: Hospital based diagnostic market includes diagnostic services provided to in-patients inside hospital premises by in-house diagnostic
facilities setup by the hospital or outsourced to a diagnostic centre/chain
Source: CRISIL Research

Within the Indian diagnostic industry, South India forms about 27 to 29% of the total diagnostic market as of fiscal year 2020.
Among the South India market, the share of Andhra Pradesh and Telangana diagnostic market is about 44 to 46% with a value
of approximately 2 87 billion as of fiscal year 2020, making it one of the largest markets in South India.

CRISIL Research estimates the size of the diagnostic industry in Andhra Pradesh and Telangana to have grown to approximately
% 87 billion in fiscal year 2020 from approximately % 59 billion fiscal year 2017, at a healthy CAGR of approximately 14%,
mirroring growth of the South Indian diagnostic industry market (estimated at = 190 to = 195 billion as of fiscal year 2020).
The out-of-hospital market, which accounts for 58 to 59% of the diagnostics market in Andhra Pradesh and Telangana, is

89
estimated to have grown to @ 51 billion in fiscal year 2020 from % 35 billion in fiscal year 2017, at a CAGR of approximately
13%.

Out-of-hospital diagnostic industry market size in Andhra Pradesh and Telangana

(2 in Billion)

 

tie}
Sea ey |==)
FY17 FY18 FY19 FY20 FY21E FY22P FY23P

E: Estimated; P: Projected

Note: Hospital based diagnostic market includes diagnostic services provided to in-patients inside hospital premises by in-house diagnostic
facilities setup by the hospital or outsourced to a diagnostic centre/chain

Source: CRISIL Research

 

Going forward, the diagnostic industry in Andhra Pradesh and Telangana is expected to grow at a three-year CAGR of 12.5 to
13.5% to reach & 120 billion to 2 130 billion in fiscal year 2023 similar to the projected growth of the South India diagnostics
industry that is expected to reach % 275 to 285 billion in fiscal year 2023, at a CAGR of 13 to 14% during fiscal years 2020 and
2023. This growth can be attributed to rising non-communicable diseases (“NCDs”) in the state, increasing share of aged
population along with the other fundamental growth drivers such as rising health awareness, conducive government schemes
related to healthcare and growing health insurance coverage. Mirroring growth in the Andhra Pradesh and Telangana market,
the out-of-hospital diagnostics market is projected to grow to % 70 to % 75 billion in fiscal year 2023 from % 51 billion in fiscal
year 2020, at a CAGR of 12 to 13%.

Service-wise review and projections of the diagnostic industry

Diagnostic entities can be broadly classified
Based on provision of services TCM rete ots

Pathology examination and

laboratory analysis of body fluids (blood,
urine, etc) or organs and tissues to diagnose
Col lyaentoc

Za iS

Radiology involves usage of imaging
eK — technologies such as X- adiogra
eS = Ini tieersroyt ute a y o diagno

fel 5

oe

 

Radiology can be further broken down into

Pathology Radiology PN adiology a oi

. Ora

(Basic + advanced) y, and advanced radiology,

Source: Industry, CRISIL Research 5 0 Ny single photon

computed tomography (“SPECT”),
(gamma camera), multi-slice
m computed tomography systems
(3D dental), DE doteyites
VICeyan Cem iamreT aCe ma telunrbe (eye ] 0) oh

 
A diagnostic centre generally offers either pathology or radiology services, but few offer both. Typically, advanced radiology
testing services are rendered by either secondary or tertiary care hospitals or standalone radiology centres (owned by the MD
radiologist) or diagnostic chains (regional/multi-regional) as they entail heavy investments in order to obtain the best-in-class
equipment, technology and specially trained professional to operate the equipment. Advanced radiology tests such as PET CT,
CBCT and bone densitometry are critical, but at the same time there is a paucity of these services. Specialised testing has also
seen many new entrants since substantial growth is expected in this area owing to the shift in disease epidemiology in India, as
well as inclinations toward preventive and early diagnosis.

Multi-regional diagnostic chains such as DLPL, Thyrocare, and SRL offer both pathology as well as radiology testing services
(SRL and DLPL offer both basic and advanced radiology testing services whereas Thyrocare offers only advanced radiology
service). Among regional diagnostic chains, Vijaya provides a combination of diagnostic services under an integrated services
model across pathology, radiology, nuclear medicine, imaging, gastroenterology, cardiology and neurology, making it a
comprehensive diagnostic centre.

Comprehensive laboratory preferred due to multiple services under one roof and convenience to customers

A comprehensive laboratory has many advantages, including:

Availability of multiple diagnostic services under a single roof;

Convenience and comfort to customers;

The diagnostic centre does not lose opportunities (due to their inability to provide either radiology or pathology testing services)
to its competitors, thus enabling it to capture a higher wallet share than others who provide only select services;

Higher chances of B2B partnerships, as the packages offered are wholesome in nature; and

Trust among doctors as a comprehensive laboratory will need to employ only trained professionals in order to handle equipment
and qualified doctors in order to ensure quality of results.

Pathology and radiology testing are equally important segments of the diagnostic industry

Segment-wise break-up of the diagnostic industry (fiscal year 2021E)

Pathology Acco ) ISIL Research estimates, pathology testing
57% a her share of the diagnostics market. Typically,
a battery of tests is prescribed under a single pathology test panel

for a single patient.

Though the volumes of pathology tests prescribed are greater,
the price of a single pathology test is lower than a single imaging
ich as an MRI or even an X SUB Elion cl meee

to three times more than a regular pathology test.

 

Radiology
43%

 

 

 

  

E: Estimated;
The above analysis excludes COVID-19 testing.
Source: CRISIL Research

Radiology to achieve a CAGR of 13 to 14% over fiscal years 2020 to 2023

As per CRISIL Research estimates, the Indian radiology market achieved a three-year CAGR of 14% to reach % 291 billion in
fiscal year 2020. Going forward, CRISIL expects the radiology business to grow at a higher trajectory with adequate support
from factors such as newer and advanced technology, growing dependence on radiology, and preference for high-realisation

91
radiology tests such as CT scans over X-rays. Fundamental factors such as higher dependence on evidence-based treatments
along with growing NCDs in India also support growth. Thus, the radiology market is projected to reach around 2 420 billion
to % 430 billion by fiscal year 2023, at a three-year CAGR of 13 to 14%.

Indian radiology testing market size review and outlook

(Zin billion) P|

 

FY17 FY18 FY19 FY20 FY21E FY22P FY23 P

E: Estimated; P: Projected
Source: CRISIL Research

On the other hand, pathology market in the India is valued at % 393 billion during fiscal year 2020 registering a CAGR of
approximately 12% between the fiscal years 2017 and 2020. The pathology market is projected to reach a value of % 550 to 565
billion in fiscal year 2023, achieving a CAGR of 12 to 13% between fiscal years 2020 and 2023, slightly lower than the growth
rate for radiology during the same period.

COVID-19 has fuelled demand for radiology, increasing its share in diagnostic services

COVID-19 testing has fuelled demand for both pathology and radiology testing services. However, increasingly, reverse
transcription polymerase chain reaction (“RT-PCR”) testing is being used to detect the virus due to its higher sensitivity. As
per industry sources, radiology testing services have been crucial to gauge the intensity of infection, especially in the lungs.
Hence, a lot of impetus has been given to chest CT scans by practitioners to detect early warning.

The share of radiology testing services within diagnostic services increased from nearly 41% in fiscal year 2017 to
approximately 43% in fiscal year 2020 at approximately 14% CAGR; CRISIL expects the share to be maintained at 43 to 44%
in fiscal year 2023.

Share of radiology within diagnostic services

 

100%
Radiology
CAGR (FY17-20):
80% phe )ey PAS) 420-430
60%
40%
277 393 550-565 Pathology
“it CAGR (FY17-20):
~12%
CAGR (FY20-23): 12-
0% 13%
FY17 FY20 FY23 (P)

Pathology ™ Radiology

P: Projected
Source: CRISIL Research

92
Industry shifting towards diagnostic chains

Estimated split of the Indian diagnostic industry, fiscal year 2020

Hospital-based centres,
35-40%

Multi-regional
chains
35-40%

12-17% __Diagnostic

Regional

chains

60-65%

 

  

Standalone centres,
45-50%

Source: CRISIL Research

The Indian diagnostics industry is highly fragmented given the high proportion of standalone centres and hospital-based centres,
which collectively comprise 83 to 88% of the total market as of fiscal year 2020. Diagnostic chains comprise only 12 to 17%
as of fiscal years 2020 further split into regional and multi-regional chains, of which regional chains account for the majority.
However, the industry has witnessed a shift from standalone centres to diagnostic chains due to increasing trend of patients’
reliance on diagnostic chains for their quality of service and unavailability of complex tests with standalone centres, not only
at an overall country level but also in regional markets.

The profitability of the industry is defined on the basis of high volume of testing and optimal utilisation of laboratories. Also,
high capital expenditure requirements for radiology testing services deter standalone players from investing beyond basic
radiology. Given the low entry barriers and lack of a strong regulatory environment, the industry has many standalone players.
This has made the industry highly competitive and fragmented, and hence smaller players are finding it hard to stay profitable.
Competition has intensified with the entry of aggregators (online healthcare players), who prefer to partner with established
diagnostic chains.

On the regional front, players in Andhra Pradesh and Telangana with a strong brand value and trust (like Vijaya and others)
have been able to maintain growth in volumes and profitability. However, smaller players are witnessing a decline in volumes,
margins and market share due to intense competition and high expectations by consumers in the region. Hence, large regional
players are looking at favourable acquisitions of smaller standalone labs in places which might not only attract them higher
volumes, but also help them increase their penetration and reach over the long term.

Diagnostic chains, on the other hand, have stronger financial discipline and negotiating power with suppliers, greater capital
and administrative resources to meet the needs in order to sustain the business compared with standalone diagnostic centres.
Diagnostic chains have expanded into geographies where they have limited presence via inorganic routes. Tier II and III cities
are the major focus of these established players, where struggling standalone centres become prime opportunities for acquisition.

Preventive and wellness testing packages to boost biochemistry testing

Mid-sized to large diagnostic chains and hospital-based diagnostic centres are increasingly marketing their test menus in the
form of preventive and wellness packages. These health packages help identify pre-existing diseases or the likely risk from
particular diseases before the actual symptoms appear. The tests are expected to help people take corrective action before
chronic conditions take hold.

Most packages either specifically screen for a given chronic disease or contain a slew of tests to ascertain the overall health of
a person. Moreover, most of the preventive and wellness tests consist of biochemistry tests to check an individual's risk to
chronic diseases, such as cardiovascular diseases and diabetes, among others. However, some diagnostic centres, which have
both pathology and radiology services, may add basic imaging tests such as ECG, X-ray, and ultrasound to the test packages.

93
Many diagnostic chains are currently providing bundled services (primarily comprising pathological tests, and a few even offer
basic imaging tests). Corporate tie-ups occur majorly with accredited centres, which fall under the diagnostic chains category.
Moreover, for wellness test services to be successful, substantial investments in marketing, a wide distributor network, and a
strong brand are vital. So, diagnostic chains have more potential to absorb and cater to new demand for preventive health and
wellness packages. Further, comprehensive diagnostic players have high potential, since they can provide a good mix of services
under one bucket, owing to the nature of services provided by them under a single roof.

As per CRISIL Research estimates, the market for
Di (ea TavexsomeeT Ce Oy cca Mer OmCL ETA CONSE COCR MT EOLUT HTC MCE Co)
SLO Mey mtn Cole mele T neste uy ite ceam weer |
year 2020. Rising disposable income combined with
a i } Tune Crete m Ta On Nacho rls les
‘ 90% y preventive healthcare, thereby b Tiemann lem Co

: . diagnostic services. This segment is expected to
account for around 11% share of the diagnostic pie,
achieving a CAGR of 20 to 21% over the next three
years to fiscal year

 

= Wellness & preventive
= Rest of the market

E: Estimated; P: Projected;
Source: Industry, CRISIL Research

 

Hub-and-spoke model is most preferred for diagnostic chains

Diagnostic chains typically adopt a hub-and-spoke model to widen their catchment area. However, this model is more prominent
in pathology testing services. Nevertheless, players in radiology testing services also operate on a similar model, by way of
referring patients to hub centres from spoke centres for specialised testing, which are carried out at the hub centres.
Hub-and-spoke model

 
      

Bute Caen Omen ee MEE

Collectio referen Memes sr Mae Piacente meso cd

Meant)

Pe Me Te Ree! areas

 

Note: The mentioned hierarchy represents a typical flow of samples from the collection centre to the national reference lab. However, the
hierarchy/ terminology may vary from player to player.
Source: Industry, CRISIL Research

National centre (main centre): These are located centrally, usually in large metropolitan areas, serving as the corporate
headquarters of diagnostic chain companies. These are equipped to conduct routine as well as specialised pathology and
radiology tests, and may be spread over 10,000 square feet. Reports generated by the regional / national centre are sent to
patients through the collection centres/satellite centres, or can be viewed online. The usual turn-around time (“TAT”) for a
national centre for report generation ranges between a few hours (for routine tests, such as blood analysis and sugar tests) and
two to four days, depending on the type of test being carried out. Diagnostic centres opt for air logistics for transporting samples
collected at their collection centres in other cities. These are usually done for specialised tests that can only be performed at the
national centres or, in the context of a hub-and-spoke model, at regional centres. In the case of advanced radiology testing

94
services, an integrated diagnostic company may refer a patient to its main/national centre, which houses advanced equipment
such as MRI machines and PET-CT scan machines.

Regional centres: Similar to a national/main centre, regional centres are also usually situated in large metropolitan cities, and
act as hubs that collect samples from the satellite centres and collection centres across India. The regional centres also offer
comprehensive and specialised testing facilities. With respect to radiology testing services, some of the advanced/ niche imaging
tests are also generally carried out in regional centres.

Satellite centres: Satellite centres offer limited range of services. These mainly act as feeders for regional centres and
national/main centres. Based on complexity of the test, a satellite centre may choose to transfer samples to a regional centre or
a national reference centre (whichever is nearer). Satellite centres may be either owned or franchised by a diagnostic chain
company. A satellite centre may also house basic radiology tests, such as ECG, X-ray and sonography. For advance tests,
patients may be referred to either the regional centre or main/national centre.

Collection centres: Collection centres are usually located in hospitals, nursing homes, pathology labs, clinics, prime
commercial properties, and retail spaces, among other places. These could be company-owned or a franchisee usually catering
to an area of 3 to 5 km radius. Collection centres do not carry out testing. The centres have basic equipment in the form of a
refrigerator and a centrifuge, and employ minimal staff, such as a receptionist, laboratory technician, attendants, and delivery
staff.

Urban areas account for higher proportion of revenue

Geography-wise break-up of diagnostic industry (fiscal year 2021)

Rural diagnostics
26%

Urban diagnostics
74%

E: Estimated.

Note: Urban centres are classified as units or towns with a municipality, corporation, cantonment board or notified town area committee.
Urban centres also fulfil the following criteria: have a minimum population of 5,000, about 75% of male work force is engaged in non-
agricultural work, and town has a density of population of at least 400 people per square km. All other areas that do not fulfil the requirements
of urban centres are classified as rural centres.

Source: CRISIL Research.

Growth in the Indian diagnostics market is driven by favourable changes in demographics, improvements in health awareness,
increased spend on preventive care and wellness, increase in lifestyle-related ailments and rising penetration of insurance in
India. According to CRISIL Research estimates, India's urban population (approximately 31% of India’s total) contributes up
to 74% of the overall diagnostics market revenue.

Urban centres, especially in metropolitan areas and tier I/ II cities, have better healthcare delivery systems in the form of
hospitals (private and public), clinics and diagnostic centres due to greater participation of the private sector and the presence
of a large pool of doctors. Secondary sources reveal that 78 to 80% of the population in urban areas prefers private hospitals/
clinics. Consequently, urban areas have registered high growth in diagnostic care services. On the other hand, rural centres are
largely primary health centres, and government and private dispensaries that have small-scale facilities to carry out basic tests.
For more advanced diagnostic tests, rural patients are referred to the nearest urban centre. In terms of preference of place of
treatment, an estimated 70 to 75% of the rural population prefers to be treated at private hospitals and clinics.

Growth drivers, success factors and risks

95,
Fundamental growth drivers for the diagnostic industry

A combination of economic and demographic factors is expected to drive healthcare demand in India.

/

= Dz
aol v

Changin Rising income Increasing health
demographics levels awareness

Be

.,

>

 

 

ty ‘
= ® @
= (| NCDs
=. Ye A-
Sonduciye: Changing disease Health insurance
g policies profiles coverage

Source: CRISIL Research
With life expectancy improving and changing demographic profile, healthcare services are a must

With improving life expectancy, India’s demographics are also witnessing a change. According to the Report on Status of
Elderly in Select States of India, 2011, published by the United Nations Population Fund in November 2012, chronic ailments,
such as arthritis, hypertension, diabetes, asthma, and heart diseases, were commonplace among the elderly, with approximately
66% of the respective population reporting at least one of these. With the Indian population expected to grow to approximately
1.4 billion by 2026 with and an expected surge of 60 years or more to approximately 13% by 2026 from 8% in 2011, considering
the above mentioned factors, the need to ensure that healthcare services are provided to this vast populace is an imperative.

Population in over 60 age group to grow faster

9
100% D 10.0% 13.0%
80% 13.6% a axing 16.0'

20.5% Pay eR
0% 23.0% ny)
w09g 28.6% Kg ay ye
20%
26.0% 23.0%
0%

 

2001 2011 2016E 2021P 2026P
m0-14 years m14-29 years 30-44 years 45-59 years m60+ years

Source: Census, CRISIL Research
Rising income to make quality healthcare services more affordable and preferred

Even though healthcare is considered a non-discretionary expense, considering that an estimated 83% of households in India
had an annual income of less than 2 0.2 million in fiscal year 2012, affordability of quality healthcare facilities remains a major

96
constraint. Growth in household income and, consequently, disposable income, are critical to the overall growth in demand for
healthcare delivery services in India. The share of households falling in the income bracket above % 0.2 million is expected to
go up to approximately 35% in fiscal year 2022 from approximately 23% in fiscal year 2017. Higher income levels will also
accentuate spending on preventive and wellness tests, thus aiding the diagnostic industry over the long term.

Income demographics

100% oo ae
90% 14%
0% 19%
70%
60%
50%
40%
30%
20%
10%
0%

   

2011-12E 2016-17E 2021-22P

Below 20.2 million ™2%0.2 to 0.5 million 20.5 to 1 million ™% Imillion and above
Source: CRISIL Research
Increasing health awareness to boost preventive/wellness tests
The majority of healthcare enterprises in India are more concentrated in urban areas. With increasing urbanisation (migration
of population from rural to urban areas), awareness among the general populace regarding presence and availability of
healthcare services for both preventive and curative care is expected to increase, thus paving the way for growth of the diagnostic

industry as well.

Urban population in India as a percentage of total population

40%
35%
30%
25%
20%

15%

 

10%
5%

0%
1901 1911 1921 1931 1941 1951 1961 1971 1981 1991 2001 2011 2021P 2023P

=O= Urbanisation (%)

Source: UN World Urbanisation Prospects: The 2018 revisions

Non-communicable diseases: A silent killer

97
As opposed to the decreasing rate in communicable diseases, the contribution of NCDs to the disease profile has risen from
30% in 1990 to 55% in 2016. Statistics show that these illnesses accounted for nearly 62% of all deaths in India in 2016. CRISIL
Research believes that NCDs exhibit a tendency to increase in tandem with rising income. The WHO also projects an increasing
trend in NCDs by 2030, following which CRISIL forecasts demand for healthcare services associated with lifestyle-related
diseases, such as cardiac ailments, cancer and diabetes, to rise.

Causes of death in India

100%
90%
80%

:

11% 11%

  

 

2008 2016 2030P
=Communicable diseases mCancer Cardiovascular diseases ® Other non-communicable diseases Others

Source: WHO global burden of disease, India: Health of the Nation's States, CRISIL Research
Growing health insurance penetration to propel demand for the overall healthcare delivery market, including diagnostics

Low health-insurance penetration is one of the major impediments to the growth of the healthcare delivery industry in India, as
affordability of quality healthcare facilities by the lower-income groups remains an issue. As per the Insurance Regulatory and
Development Authority (“IRDA”), nearly 499 million people have health insurance coverage in India (as of fiscal year 2020),
as against 288 million (in fiscal year 2015), but despite this robust growth, the penetration in fiscal year 2020 stood at only
36%. CRISIL Research believes that while low penetration is a key concern, it also presents a huge opportunity for the growth
of healthcare delivery industry in India. With the Pradhan Mantri Jan Arogya Yojana, India’s insurance coverage is expected
to increase substantially over the next five fiscals. Furthermore, with health insurance coverage in India set to increase,
hospitalisation rates are likely to go up. In addition, health check-ups, which form a mandatory part of health insurance coverage,
are also expected to increase, boosting demand for a robust healthcare delivery platform.

Health insurance coverage in India in numbers (million) and penetration

1000 ‘Si8h ae 36% 36% 40%

35%
30%
25%
20%

481 472
359
400 ae 287 15%
212 207 216 9
200 10%
Hon ”
0 0%

2011-12) 2012-13. 2013-14. 2014-15. 2015-16 = 2016-17. 2017-18 2018-19 2019-20

     

800
23%

600
17% 17% 17% 438

same Number of insured population (million) —liCoverage (RHS)

Source: IRDA Annual Report

98
Success factors for diagnostic players

 

*Good quality reagents, fully automated systems with qualified pathologists make a diagnostic centre stand out in
terms of quality and accuracy of tests. This, in turn, helps in proper diagnosis. Proper maintenance of equipment,
and periodic quality controls and checks are also critical in ensuring that test results are accurate. More and more
medical practitioners begin to trust and avail of the services of a particular diagnostic centre, if it offers high-
quality and accurate test results.

 

 

+ A strong brand name draws patient walk-ins and ensures lower dependence on other tie-ups for revenue.

 

 

+ Location of a diagnostic centre is also crucial for its success. Factors such as the age and income profile of target
customers residing in the locality should be considered, while setting up a diagnostic centre at a particular
location. Competition from other diagnostic centres in the vicinity and brand equity of the diagnostic chain also
need to be considered while setting up a centre.

 

+ An integrated diagnostic centre also aids to the success by providing both pathology as well as radiology services
under a single roof. Convenience acts as an important aggregator to volume, thus providing success to the centre.
The diagnostic centre does not lose to its competitors thus capturing a higher wallet share.

 

* The latest and advanced equipment technology such as CT, MRI, nuclear medicine, PET and fusion imaging.
helps a centre gain an edge over its peers by presenting a differentiating factor against. Equipment technology and
IT in diagnostics not only enhances the quality of tests but also adds to the success of a diagnostic centre by
encouraging higher volumes.

 

+ Accreditation provides a diagnostic centre a superior edge over the ones that are not recognised. Accreditiaon
adds on to higher trust, reliability, and acceptance for a diagnostic centre

 

 

 

Source: CRISIL Research

In addition to the above mentioned factors, offering a wide range of services, such as organising health camps, health and
wellness packages, online delivery of reports and home collection of samples, also acts in favour of a diagnostic company.
Also, a wide reach and robust logistics network helps increase economies of scale and reduce TAT. Another factor leading to
success is the use of multiple channels to generate revenue, such as of tie-ups with smaller labs, hospital-based labs, corporate
clients or doctors’ networks.

NABL accreditation gives diagnostic centres a distinct advantage

The National Accreditation Board for Testing and Calibration Laboratories (“NABL”) is an accreditation body, with its
accreditation system established in accordance with ISO/ IEC 17011. NABL has been established with the objective of
providing the Government, industry associations and the industry in general with a scheme of conformity assessment body’s
accreditation which involves third-party assessment of the technical competence of testing including medical and calibration
laboratories, proficiency testing providers and reference material producers.

Key risks
The industry faces shortage of skilled manpower, rising cost of technology upgradation and aggressive pricing in an intensely

competitive market.
99
Shortage of High cost of

Totty
ES tile) acto (or-1

competition

manpower advancement

 

Source: CRISIL Research
Shortage of skilled manpower

Considerable shortages of full-time doctors and staff in the diagnostics industry prompt several laboratories to recruit them on
an hourly basis, with many of them visiting more than one lab. Another area of concern is the training and retention of critical
employees such as laboratory technicians, who are employed at laboratories and collection centres for the collection and
preservation of patient samples. The situation is even more critical for standalone diagnostic centres, which may not be able to
employ well-trained laboratory technicians and pathologists, thereby affecting the quality of outcomes.

High cost of technical advancement

Diagnostic centres have to constantly upgrade their technology to stay ahead of the competition. However, these upgrades not
only involve significant capital investment, but also increase maintenance cost, thereby increasing overheads. Capital intensity
is higher for advanced radiology and molecular diagnostics, which require high-end equipment.

Intense competition

Apart from renowned multi-regional and regional diagnostic chains/centres, the diagnostics industry is highly fragmented. Since
this sector has negligible-to-few entry barriers and is largely unregulated, small laboratories have proliferated. The diagnostic
chains face competition in terms of patient sample volumes and aggressive pricing of tests, causing the profitability of major
chains to remain bound in the near future. However, the last decade has seen consolidation by diagnostic chains via acquisitions
of laboratories across India, as well as the establishment of regional reference laboratories to enhance penetration.

Geographical concentration

Many small diagnostic chains that operate three to four centres and are concentrated in a particular place or region are
susceptible to the demand-supply dynamics of that particular location.

Impact of COVID-19 on healthcare delivery market

The healthcare delivery segment saw a drop in footfall during the lockdown. Surgeries were deferred as well. This impacted
the cash flow of industry players. Nevertheless, the market is driven by strong fundamentals, conducive government policies
and improving affordability. The market is expected to sustain robust growth in the medium term.

Shift towards specialised testing, increased home collection requests, and B2C business enabled recovery to pre-pandemic
levels for diagnostic players in the third quarter of fiscal year 2021

As hospital treatments and outpatient footfall declined due to the nationwide lockdown, samples and footfall at diagnostic
centres also mirrored this impact. Eventually, private COVID-19 testing picked up, but it was not until the third quarter of fiscal
year 2021 that private laboratories saw their revenue rebounding to pre-pandemic levels due to demand revival.

COVID-19 testing has been a booster for multi-regional and regional diagnostic labs

While regular business took a backseat in fiscal year 2021, COVID-19 testing has helped larger players. The Indian Council of

Medical Research (“ICMR”) has approved nearly 1,223 private laboratories for COVID-19 testing as of April 12, 2021). With

the requisite permission from the ICMR to venture into COVID-19 testing, these are large accredited laboratories having RT-

PCR testing capabilities, leaving smaller laboratories with minimal revenue (especially in the first half of fiscal year 2021).
100
Initially, some state Governments had partnered with private laboratories for COVID-19 testing, but gradually the demand
profile for the latter shifted towards the institutional and home collection business. Diagnostic chains also witnessed improved
B2C footfall on account of delayed medical interventions, self-check-ups, and COVID-19 tests pertaining to government-bound
notifications set for travel purpose. Also, with the focus on quality during the COVID-19 pandemic, players in the industry
adopted digitisation and other technologies to reduce the TAT and cater to the rising demand. This has further motivated the
customer preference towards regional and multi-regional diagnostic chains.

The ICMR has permitted antigen and antibody testing subject to state regulations, apart from the gold-standard RT-PCR test,
to scale up testing in India. The earlier price cap of = 4,500 for RT-PCR has been significantly revised downwards to = 500 to
% 1,500 (varies across states) since domestic manufacturing of kits has picked up in a big way. Although COVID-19 testing is
top line-accretive, the cost of reagents for the test, along with procurement cost, eroded margins in the first quarter of fiscal
year 2021. Nonetheless, COVID-19 testing helped meet fixed-cost obligations at a time when regular demand was muted and
still recovering. Apart from large diagnostic chains, diagnostic laboratories with a footing in genomic and molecular testing
have benefitted from their testing capabilities with regards to COVID-19 patients. The NABL has also granted necessary
clearances and approvals to them for testing. But with improvement in domestic sourcing of testing kits, high-realisation
COVID-19 tests were a benign addition to EBITDA levels, more evident in the second and third quarter margins of fiscal year
2021.

State-wise macroeconomic indicators

Telangana and Andhra Pradesh among the top five high-growing* states in India

Between fiscal years 2015 and 2020, Karnataka (9.9%), Telangana (9.8%), Gujarat (9.4%), Haryana (9.1%) and Andhra Pradesh
(8.6%) were the highest growing states (India GDP CAGR of 6.7%). Punjab, Chhattisgarh and Jharkhand had ranked at the
bottom in fiscal years 2015 to 2020.

GSDP growth between fiscal year 2015 and fiscal year 2020 (CAGR, %)

India GDP CAGR (FY15
9.9% 9.8% 9 4 9.1% Loe 74}

8.6%
8.3% 82% g.0% 7.99
12% pop

 
  

6.7% 6.7% 6.4%

  

Bihar
Kerala
Punjab

g
36

Karnataka
Telangana
Gujarat

Haryana

Andhra Pradesh
‘Tamil Nadu
Madhya Pradesh
Uttar Pradesh
Maharashtra
West Bengal
Rajasthan
Chhattisgarh
Jharkhand

Note: 17 states as classified by the RBI under non-special category have been considered for this analysis.
* States that managed to maintain GSDP growth higher than the all-India GDP growth during fiscal years 2015 to 2020.
Source: CSO, CRISIL Research

Telangana, Andhra Pradesh among the top five states in terms of average per-capita income growth between fiscal years
2015 and 2020

In terms of CAGR from fiscal years 2015 to 2020 for per-capita NSDP at constant prices, Telangana, Gujarat, Karnataka, and
Andhra Pradesh were the top states.

Telangana and Andhra Pradesh among the top five states in terms of per capita NSDP CAGR (fiscal years 2015 to 2020)

101
CAGR (FY15-20)

India per capita income: & 94,566

 

12.0% CAGR (FY15-20): 5.4%
10.0%
8.296 82% 7.9% 7 55 7.506 7.4% 7.206 2
8.0%
6.1% 5.9% 5.8%
6.0%
gS AT so,
4.0% =e
2.0% |
0.0%
"2 & S$ se 2 2 88 £ # © € Be 2 8
2s Ee 2 34 4 € B@ 248 8
2 2 2522 2325 6 § 4 5 ¢ FR |G a
2° § 223 2a 2 23 e “ Bes
& =: & 5 -

Note: Per capita income for states refers to ‘per capita NSDP at constant prices as of fiscal year 2020; base year 2011-12 has been
considered. All India per capita income refers to ‘Per capita net national income at constant prices as of FY20’.
Source: CSO, CRISIL Research

Andhra Pradesh among the top five states in terms of per capita OOPE as a share (%) of per-capita total healthcare
expenditure, as of fiscal year 2017

As per the National Health Accounts Estimates, fiscal year 2017, the top five states in terms of Out-of-Pocket Expenditure
(“OOPE”) as a percentage of Total Healthcare Expenditure (“THE”) are Bihar (78%), Punjab (77%), Uttar Pradesh (75%),
West Bengal (74%) and Andhra Pradesh (72%).

The top three states in terms of per capita total healthcare expenditure are Kerala ( 8,083), Punjab (= 5,960) and Maharashtra
(% 5,210). In terms of per capita government healthcare expenditure (“GHE”), the top three states are Kerala ( 2,149), Gujarat
(& 1,429) and Karnataka (= 1,389). While in terms of per capita out of pocket expenditure, the top three states are Kerala (%
5,419), Punjab (% 4,608) and Andhra Pradesh (% 3,322).

OOPE and GHE as a % of THE

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%

0%

 

5
a
a

Uttar Pradesh
West Bengal
Andhra Pradesh
Madhya Pradesh
Odisha

Kerala
Jharkhand
Tamil Nadu
Maharashtra
Rajasthan
Chhattisgarh
Karnataka
Gujarat

mShare (%) of OOPE in THE —_m Share (%) of GHE in THE

102
Note: The values given in the bars are in INR.
Source: National Health Accounts Estimates 2016-2017, CRISIL Research

Diagnostic industry in Andhra Pradesh and Telangana
Andhra Pradesh and Telangana among the states with high NCD burden (>50%) in India

According to reports, the contribution of NCDs (being cardiovascular diseases, diabetes, chronic respiratory diseases, mental
health and neurological disorders, cancers, musculoskeletal disorders, chronic kidney disease) to India’s total disease burden
has increased over the years. Disability-adjusted life years (“DALY(s)”) represent the total number of years lost to illness,
disability, or premature death within a given population. Of the total disease burden in India measured as DALYs, the share of
communicable, maternal, neonatal, and nutritional diseases (termed infectious and associated diseases in this summary for
simplicity) dropped from 61% in 1990 to 33% in 2016. There was a corresponding increase in the contribution of NCDs to the
total disease burden from 30% to 55%, and of injuries from 9% to 12%.

The wide variations between the states in this epidemiological transition are reflected in the range of the contribution of major
disease groups to the total disease burden in 2016: 48 to 75% for NCDs, 14 to 43% for infectious and associated diseases, and
9 to 14% for injuries. Among the leading NCDs, the largest disease burden or DALY rate increase from 1990 to 2016 was for
diabetes (80%) and ischaemic heart disease (34%). As per the National Health Profile 2019, out of 65,194,599 patients who
attended NCD clinics, 4.75% were diagnosed with diabetes, 6.19% with hypertension, 0.30% with cardiovascular ailments,
0.10% with stroke, and 0.26% with common cancers. Of the 17 states compared, Tamil Nadu, Rajasthan, and Uttar Pradesh
had the highest number of persons diagnosed with NCDs out of those screened in calendar year 2018, followed by Andhra
Pradesh, West Bengal, and Maharashtra.

   

State-wise proportion of total disease burden from NCDs in 2016 ee sl
Kerala 74.60%
Punjab 66.00%
Tamil Nadu 65.30%
a Maharashtra 63.10%

West Bengal 62.70%

Karnataka 62.00%

‘7

~& Telangana

Dh Haryana .

- Gujarat .
Odisha 52.10%

     

Andhra Pradesh

  

Madhya Pradesh 50.50%

Chhattisgarh 50.40%
More than 70% |

Rajasthan 49.30%
60-70% ‘
50-60% ' Jharkhand 48.30%
40-50%

Uttar Pradesh 47.90%

Bihar 47.60%

* Proportion of total disease burden from NCDs in 2016.

ICMR, Public Health Foundation of India (“PHFI”), and the Institute for Health Metrics and Evaluation (“IHME”) published report titled
‘India: Health of the Nation’s States — The India State-Level Disease Burden Initiative’.

103
 

17 states under the non-special category given by the RBI (except Goa) have been considered for the analysis, i.e., Andhra Pradesh, Bihar,
Chhattisgarh, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu,
Telangana, Uttar Pradesh and West Bengal.

Source: ICMR, PHFI, IHME, Ministry of Health and Family Welfare, CRISIL Research

Andhra Pradesh has one of the highest percentage of population aged 15 years and above, as per census 2011

As per Census 2011 data, India’s age-wise national average statistics indicates that 29.5% people fall in the 0 to 14 year group,
62.5% in the 15 to 59 year bracket and 8% are over 60. In Andhra Pradesh (including the current state of Telangana),
approximately 67% of its population is aged 15 to 59 years and 9.4% above 60 years, which collectively is nearly 5.7% higher
than the national average. This increases the state’s vulnerability towards NCDs, thus necessitating greater focus on healthcare.
Tamil Nadu, Karnataka and West Bengal follow Andhra Pradesh in terms of higher percentage of aged population in the states.

State-wise age group-wise population for 2011

Andhra Pradesh

 

Tamil Nadu BG 66.4 ie)
Karnataka

West Bengal

 

Punjab
Kerala pie iis) eRe]
Haryana Pra] oie aa
Maharashtra pie] 64 ee
Gujarat iy 64 Ey
Odisha

 

 

(sn
Chhattisgarh eB ss Bey vA)
Madhya Pradesh 5B) 60.7 Es
Rajasthan 31.8 [site bil
Jharkhand EE 60.1 coKsy
Uttar Pradesh Ewes 59.7 yes
Bihar Ere bio ia

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

m0-14 915-59 m60+

Note: 17 states under the non-special category given by the RBI (except Goa) have been considered for the analysis ~ Andhra Pradesh, Bihar,
Chhattisgarh, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu,
Telangana, Uttar Pradesh, and West Bengal.

Telangana data is not available as per Census 2011. The data for the same is included in Andhra Pradesh figures.

Source: Census 2011, CRISIL Research

Vijaya Diagnostic Centre is the largest integrated diagnostic chain in south India by operating revenue as of fiscal year 2020

Some of the key diagnostic chains operating in the Andhra Pradesh and Telangana region are Vijaya, Thyrocare, SRL,
Metropolis, Lucid Medical Diagnostics Private Limited (“Lucid”), Medall and Tenet Medcorp Private Limited (“Tenet”),
among others.

104
Multi-regional chains SEER etter cad

 

 

Ayer Banas Nera
Note: The list above is only indicative and not exhaustive.

* South-based diagnostic centres’ are indicative of those players, who have a higher share of operations from the southern states of India.
Source: Industry, CRISIL Research

   

The regional cluster of Andhra Pradesh / Telangana has presence of both multi-regional players, namely DLPL, SRL,
Thyrocare, Metropolis and others, as well as prominent south-based players such as Vijaya, Tenet, Medall, Aarthi, Lucid,
Neuberg Diagnostics Pvt Ltd (“Neuberg”), Focus Diagnostics and Tesla Medcorp Pvt Ltd.

Vijaya has the highest revenue from Southern region among other key players as of fiscal year 2020

ONS ron enn ne nr

 

i (EY20)
Vijaya 3,388 3,298
Metropolis 8,569 2,228
SRL 10,123 1,215
Thyrocare 4,354 2 1,132
DLPL 13,309 799

 

Note: The revenue mix is not available for rest of the peers under consideration
Source: Company annual reports, CRISIL Research

Among the peers compared above, the top five players in terms of operating income for fiscal year 2020 are DLPL, SRL,
Metropolis, Thyrocare and Vijaya. However, in terms of revenue from the southern region for fiscal year 2020, Vijaya has the
highest revenue in comparison with the key players compared above, namely DLPL, SRL, Metropolis and Thyrocare. Vijaya
is the largest integrated* diagnostic company in South India as of fiscal year 2020 based on operating revenue from south
region.

*A diagnostic centre which provides a combination of diagnostic services across pathology, basic radiology and advanced
radiology services is hereby defined as an integrated diagnostic centre.

Among the prominent south-based players, Vijaya operates majorly in Andhra Pradesh and Telangana accounting for 96.4% of
revenue for the company as of fiscal year 2020. For further details of city-wise revenue of Vijaya, see “Our Business -
Description of Our Business - Our Geographical Spread” on page 116. As on March 31, 2021, Vijaya has 11 laboratories and
80 centres including those of its subsidiary companies. With an operating revenue of % 3,388 million during fiscal year 2020,
Vijaya accounts for a market share of approximately 7% within the out-of-hospital diagnostic market in the Andhra Pradesh
and Telangana region as of fiscal year 2020 and a market share of approximately 2% within the entire South India diagnostic
market as of fiscal year 2020. Medall, on the other hand, has more than 1,900 points of presence with the majority in the south.
Tenet also has a major presence in Telangana with a total 11 centres across Telangana, Andhra Pradesh and Karnataka. Lucid
has a total of 24 centres spread across Telangana, Andhra Pradesh and Karnataka.

Presence in key cities further offers diagnostic players a high demand potential

As the southern market is known to be brand-conscious and value quality of tests more than the test charges, the market is
expected to be led by players who have an established brand image and trust among consumers and healthcare professionals.
Further, the major diagnostic players are situated in some of the highly populous cities namely Hyderabad, Visakhapatnam and
Vijaywada, which offer them a high demand potential. The prominent diagnostic chains present in the southern region, such as

105
Vijaya, Apollo Diagnostics, Medall, Thyrocare, SRL, Metropolis, are also well equipped to match up to the customers’ demand
by employing better equipment, qualified laboratory technicians and advanced technology. They also encourage the rising
consumer preference towards wellness and preventive tests, as people in the region are health-conscious. As a result, they
strengthen the case for a higher growth outlook for the out-of-hospital diagnostics market in Andhra Pradesh and Telangana
region.

Population of key cities/urban agglomerations in Andhra Pradesh & Telangana, as per Census 2011

Hyderabad 4,344,437
Visakhapatnam 1,057,118
Vijaywada 845,756
Warangal 467,757
Rajahmundry 401,397
Kakinada 327,541
Kurnool 275,360
Cuddapah 215,866
Tirupati U.A. 188,904
Vizianagaram 177,022
Khammam 149,077
Chirala 142,778
Ongole 128,648
Kothagudem 102,137

* Urban Agglomeration has been considered
Source: Census 2011; CRISIL Research

However, an established regional presence gives players an upper hand

Key multi-regional diagnostic players in India have established themselves across India, allowing them to cater to untapped
markets. However, a strong regional presence has its own advantages, as can be seen across players such as Vijaya.

1. Some of the key advantages of having a regional presence are:

¢ Understanding the personality of people (consumers) in a particular region forms a crucial part of connecting and
establishing long-term relationships for any healthcare delivery industry. Players with regional presence often have a
strong grasp of the regional languages, culture, expectations, and affordability, among other aspects, which help them
connect and bond with their patients from a long-term perspective.

¢ Understanding the doctors’ requirements is also an important aspect for a diagnostic centre. Having a regional
presence not only gives players access to the key doctors and their expectations from a diagnostic centre, but it also helps
players with the possibility of doctors recommending a particular diagnostic centre over the others present in the region,
because of well-established trust and strong brand image among doctors.

¢ Integrating talent from well-established workforce, such as laboratory technicians, pathologists and radiologists, also
augurs well for established players. There are additional benefits for employees associated with a regional chain, such
as easy location transfers for any personal reasons, being closer to home, ease of travel and being associated with a brand.

COMPETITIVE MAPPING OF KEY PLAYERS

Comparative analysis of players in the diagnostics sector

CRISIL Research compared the key players in the diagnostics industry. It obtained data from publicly-available sources,
including annual reports and investor presentations of listed players, regulatory filings, rating rationales, and/or company
websites, as relevant.

For this assessment, CRISIL considered the following key players: DLPL, SRL, Metropolis, Thyrocare, Vijaya, Medall,
Suraksha, Lucid, Tenet and Neuberg.

Primera : [Cre aT TC EEN ic

 

 

 

DLPL. 1995 69% 6% 14% 8%
SRL 1997 35% 12% 21% 28%
‘Metropolis 1981 9% 26% 6% 54%
Thyrocare 2000 Multi-region 24% 26% 17% 31%
Vijaya 2002 Southern region

 

106
Medall 2009 Southern region

Suraksha 2005, Eastem region

Lucid 2007 Southern region

Tenet 2017 Southern region

Neuberg 2017 Southern and Western region
Note:

**Regions contributing to more than 10% of the revenue mix have been considered. For players, Medal, Surekha, Lucid, Tenet and Neuberg,
the geographic presence has been arrived at using the concentration of diagnostic centres, and hence, it is only indicative.

#All players’ regional bifurcation (in terms of revenue) have been represented as presented in the respective company annual reports/investor
presentations for fiscal year 2020.

CRISIL Research has considered the following bifurcation of states into regions: The West includes Maharashtra, Goa, Gujarat, and Madhya
Pradesh; North includes Uttarakhand, Delhi, Haryana, Rajasthan, Bihar, Himachal Pradesh, Jammu and Kashmir, Punjab, Uttar Pradesh,
and Chandigarh; South includes Andhra Pradesh, Telangana, Karnataka, Kerala, Tamil Nadu, Andaman and Nicobar Islands, and
Puducherry; East includes West Bengal, Chhattisgarh, Jharkhand, Odisha, Meghalaya, Assam, Arunachal Pradesh, Sikkim, Mizoram,
Nagaland, Tripura, and Manipur.

Source: Company annual reports/investor presentations/company website; CRISIL Research

Key operational parameters of major diagnostics players

Test and patient volume CAGR from fiscal year 2017 to fiscal year 2020
‘%
ee 15% 18%
150 © 14% 13%
5%

13%
1196: 10% 10%

10%
.. UL

Vijaya DLPL Metropolis Thyrocare SRL*

-10%
-10%
-15%
Volume of tests
“For SRL, year-on-year growth between fiscal year 2020 and fiscal year 2019 has been considered on account of difference in disclosures
of test volume data for fiscal year 2017 and fiscal year 2018 (JVs were considered for these years).
Source: Companies’ annual reports/investor presentations, company website, CRISIL Research

In terms of growth in the number of patients served, Vijaya has registered a robust CAGR of 14% during fiscal
year 2017 to 2020. This growth in patients is higher when compared to the three major players, DLPL (13%),
Metropolis (13%) and Thyrocare (10%).

In terms of CAGR over fiscal years 2017 to 2020 for volume of tests among the companies compared above
(DLPL, SRL, Metropolis, Thyrocare and Vijaya), DLPL has maintained the top position with a CAGR of 18%,
followed by Vijaya at a CAGR of 15%.

Vijaya has higher tests per patient among other key players (as compared below) as of fiscal year 2020

ast Eq

60.0
477
50.0
40.0 30
30.0 194 196
m9 = || = =
za oq
. => Mo
Vijaya DLPL SRL Mefropolis
Volume of tests (million) Volume of patients (million)

Vijaya has higher tests per patient among other key plyers (as compared below) as of fiscal year 2021

107
F3 |

60.0

50.0
50.0
40.0
30.0 24.0
20.0 19.0

20.0 os 11.0 10.0
10.0 26

: — | Oo

Vijaya DLPL SRL Metropolis
Volume of tests (million) — ™ Volume of patients (million)

Note: The figures in the boxes above the bars denote ‘tests per patient’ value for the respective companies

Thyrocare has been excluded from this analysis as disclosures do not match the definition of other competitors and are not directly
comparable

Source: Companies’ annual reports/investor presentations, CRISIL Research

In terms of average tests per patient, Vijaya takes the lead among its peers compared above with a ratio of 2.8 tests per patient
in fiscal year 2020, followed by DLPL at 2.5 tests per patient. Vijaya’s lead can be attributed to its integrated diagnostic
offerings.

Operational parameters, fiscal year 2020

 

Diagnostic services Pathology and Pathology and Pathology and Pathology and
: 8 Pathology 8
radiology radiology radiology radiology
Test offerings Approximately 2,150 408 More than 3,700 More than 4,000 4,953
Basic radiology Digital X-ray, oi Digital X-ray, ECG,
offerings® ultrasound, . Digital X-ray, ultrasound,
- ultrasound scanning, NA.
mammography, among mammography, among
among others.
others. others.
‘Advanced radiology MRI, Multi slice CT,
offerings® CBCT (BD dental), PET PET CT scan, MRI,
CT, SPECT, PET/CT imaging cardiac CT, Myocardial '
DEXA/bone services perfusion imaging test, iiss pone ens tome
densitometry, among among others.
others.
B2C )B2B retio/ 93:7 23:77 40:60 44:56 60:40
business model*
B2C revenue
@ million)* 3,136 1,001 4,049 3,770 7,985

N.A.: Not available

B2B: Business to business; B2C: Business to consumer

*Players’ B2C to B2B bifurcation has been represented as presented in the respective company annual reports/investor
presentations/conference call transcripts basis their internal classification, for fiscal 2020.

‘Calculated based on operating income for fiscal year 2020

@The list of radiology offerings is not exhaustive

Source: Company annual reports/investor presentationsAebsite, CRISIL Research

The segment mix varies across players, with the mix skewed more towards B2B in case of SRL (40:60) and Thyrocare (23:77). Vijaya
commands a higher share of B2C revenue (93%) among the key players (DLPL, SRL, Metropolis and Thyrocare) compared above. Vijaya is
one of the largest integrated* diagnostic company in India as of fiscal year 2020 based on operating revenue.

*A diagnostic centre which provides a combination of diagnostic services across pathology, basic radiology and advanced radiology services
is hereby defined as an integrated diagnostic centre

Key financial parameters of major diagnostics players

Key financial parameters

 

DLPL. 13,309 13% 3,441 2,276
SRL 10,123 3% 1,743 856
      
 

   

8,569 2,176 1,276

Thyrocare 4,354 12% 1,747 884 27%
Vijaya 3,388 15% 1,326 625 24%
Medal 3,258 -1% 654 -203 68%
Suraksha 1,570 8% 3,400 150 50%
Lucid 71 28% 118 19 20%
Tenet* 339 nm. -55 -92 nm,
Neuberg* 1,601" - 1654 - 478 -

Note: The above financials in the report for Lucid, Suraksha and Tenet are on standalone basis and the rest are on consolidated basis;
n.m.: Not meaningful; OPBDIT: Operating profit before depreciation, interest and tax; PAT: Profit after tax

#Neuberg’s financials are only available for fiscal years 2018 and 2019

Figures for fiscal year 2019 and year-on-year growth for fiscal year 2019 over fiscal year 2018

“Financials available for fiscal years 2018 to 2020 only. CAGR considered for calculations are from fiscal years 2018 to 2020.
Source: Company annual reports, CRISIL Research

Large players with a strong presence in South India such as Vijaya (16%) have registered better on-year growth in terms of
operating income than players like DLPL (11%), SRL (1%), Metropolis (13%) and Thyrocare (7%) over fiscal year 2020.

In terms of CAGR during fiscal years 2017 to 2020 for operating income, Lucid registered 28% growth followed by Vijaya (15%).

When compared with the large players in terms of operating income growth during fiscal years 2017 to 2020, Vijaya logged a
CAGR of 15%, making it one of the fastest-growing diagnostic firms in terms of revenue among the large scale players compared
above.

In terms of OPBDIT growth rates for fiscal year 2020 Vijaya led the charts when compared to the peer set above, with a growth
of 41% year-on-year, followed by Lucid (39%) and DLPL (17%).

In terms of on-year growth in PAT in fiscal year 2020, Lucid (52%) and Vijaya (26%) led the charts among the peers compared
above. In contrast, during the same period, the on-year growth of certain players under consideration has been less than 5% or
negative (Thyrocare, Metropolis, SRL, and Medall). Among the large peers with positive PAT, the highest CAGR during fiscal
years 2017 to 2020 was achieved by Thyrocare (27%) and Vijaya (24%).

Note: For the sake of assessment, CRISIL Research has classified the players under consideration with operating income above =
3,000 million as large (DLPL, SRL, Metropolis, Thyrocare, Vijaya and Medall) and major southern region players (Vijaya,
Medall, Lucid, Tenet and Neuberg).

Vijaya has higher operating income and OPBDIT per test among other key players (as compared below) as of fiscal year
2020

Re
600.0
437 428
400.0 333
es, 29) 227
o = LL - a - a -
Metropolis Vijaya SRL DLPL Thyrocare
m Operating income per test. = OPBDIT per test

Source: Company annual reports/investor presentations, CRISIL Research

Vijaya has the highest operating income and OPBDIT per patient among other key players (as compared below) as of fiscal
year 2020

®

1,500.0 1,214

1,250.0

1,000.0 8s 797 686
750.0 475
500.0 218 177 217
2500 D a a =

Vijaya Metropolis SRL DLPL Thyrocare
Operating income per patient = OPBDIT per patient

Source: Company annual reports/investor presentations, CRISIL Research

109
An analysis of OPBDIT per test for fiscal 2020 reveals Vijaya (2 168) as the leading player among the large peers compared
above, followed by Metropolis (% 111). In terms of operating income per test, Vijaya (% 428) holds the second position after
Metropolis (% 437).

Further, an analysis of operating income per patient and OPBDIT per patient for fiscal year 2020 also reveals Vijaya as a leading
player among the large players considered for assessment, followed by Metropolis. This lead of Vijaya among key players
indicates a strong brand recall and trust among customers. Vijaya’s regional presence, combined with a comprehensive suite of
diagnostic services under an integrated model across pathology, radiology, nuclear medicine, imaging, gastroenterology,
cardiology and neurology can be attributed as its growth drivers, enabling it to capture a larger wallet share in the industry.

Key financial ratios of major diagnostics players

 
  

  

25.9
35% 17.2

  
  
 

Metropolis* 51% 25.4
Thyrocare 55% 40.1

Vijaya 62% 39.1

Medall 39% 20.1

Suraksha NA 21.6

Lucid 31% 16.5

Tenet® 12% (16.1) -258 J

Neuberg** 34% 10.3 4.0 “55 NA. NA.

Note: The above financials in the report for Lucid, Suraksha and Tenet are on standalone basis and the rest are on consolidated basis;

n.m.: Not meaningful; RoCE: Return on capital employed; NA: Not available due to insufficient data;

*These players have negligible debt

**Neuberg’s financials are available only for fiscal years 2019 and 2018 in public domain

#These ratios have been considered as an average over fiscal years 2017 to 2020

@CFO/OPBDIT and FOCF/OPBDIT for Tenet are an average over fiscal years 2018 to 2020

Ratios calculated as per CRISIL Research standards are described below:

© OPBDIT margin = OPBDIT / operating income

© Net profit margin = Profit after tax / operating income

© RoCE = Profit before interest and tax (PBIT) / [total debt + adjusted net worth (includes only goodwill as part of intangible net worth)
+ deferred tax liability]

© Working capital days = receivable days + inventory days - payable days

* CFO = Cash flow from operations

«  FOCF = Free operating cash flow

CRISIL Research takes into account tangible net worth for calculation of gearing ratio.

Source: Companies’ annual reports, CRISIL Research

Among the peers considered above, Vijaya ranks first in terms of gross margin as of fiscal year 2020. Among the peers considered
above, the top three players with the highest OPBDIT margin for fiscal year 2020 are Thyrocare (40.1%), Vijaya (39.1%) and
DLPL (25.9%). Among the major southern region players compared above, Vijaya has the highest OPBDIT margin (39.1%) for
fiscal year 2020, followed by Medall (20.1%).

The highest net profit margins for fiscal year 2020, among all the players considered, are held by Thyrocare with 20.3%, followed
by Vijaya at 18.4% and DLPL at 17.1%. Among the major southern region players compared above, Vijaya ranked higher than
the others in terms of net profit margins with 18.4% growth for fiscal year 2020.

Among all the peers compared above, the highest RoCE is held by Metropolis (40.3%), followed by Thyrocare (35.5%), DLPL
(34.1%) and Vijaya (30.9%). However, among the major southern players compared above, the highest RoCE for fiscal year 2020
was held by Vijaya, followed by Lucid at 11.3%.

Note: For the sake of assessment, CRISIL Research has classified the players under consideration with operating income above =

3,000 million (DLPL, SRL, Metropolis, Thyrocare, Vijaya and Medall) as large and major southern players (Vijaya, Medall,
Lucid, Tenet and Neuberg).

110
OUR BUSINESS

Unless otherwise indicated, industry and market data used in this section have been derived from the CRISIL Report prepared
and released by CRISIL Limited and commissioned and paid for by our Company to confirm our understanding of our industry
specifically for the purpose of the Offer.

OVERVIEW

We are the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing
diagnostic chain by revenue for fiscal year 2020 (Source: CRISIL Report). We offer a one-stop solution for pathology and
radiology testing services to our customers through our extensive operational network, which consists of 81 diagnostic centres
and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National
Capital Region and Kolkata as on June 30, 2021. For the three months ended June 30, 2021 and the fiscal year 2021, we derived
95.91% and 96.20% of our revenue from operations from our core geographies, Hyderabad and rest of Telangana and Andhra
Pradesh, respectively.

Our history can be traced back to 1981, when our Promoter and Chairman, Dr. S. Surendranath Reddy established the first
Vijaya Diagnostic Centre in Hyderabad, with a vision of providing comprehensive, innovative and high quality diagnostic
services under one roof, in a reliable, affordable and customer-centric manner. The business was carried out under sole
proprietorship, which was later taken over by our Company in 2005. According to the CRISIL Report, the Indian diagnostics
market was valued at approximately = 710 billion to 2 730 billion in the fiscal year 2021, and is projected to grow at CAGR of
around 12% to 13% to reach approximately = 920 billion to = 980 billion by fiscal year 2023, driven by rise in health awareness
and disposable incomes, increase in demand for better healthcare facilities and quality of care of individuals, and increase in
spending on preventive and wellness. Furthermore, according to the CRISIL Report, the diagnostics market in Telangana and
Andhra Pradesh, the states in which we have a significant presence, is projected to grow to approximately 2 120 billion to =
130 billion by fiscal year 2023. We believe that the combination of our strong brand position driven by our long operating
history in our core geographies, extensive network and reputation for providing quality diagnostic services positions us well to
continue to grow our business in Telangana and Andhra Pradesh markets and take advantage of the growth of the Indian
diagnostic industry.

We offer a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic
and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Our test menu includes
pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests,
and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including
computerised tomography (“CT”) scans, magnetic resonance imaging (“MRI”) scans, single photon emission computed
tomography (“SPECT”) and advanced positron emission tomography CT (“PET CT”). We also offer a broad spectrum of
health and wellness packages to our customers as per their requirements. We focus on a customer centric approach to enhance
the overall quality of our services for optimal customer satisfaction. For convenience of our customers, we provide value-added
services such as home collection of specimens, house calls and various delivery or access modes (i.e., at diagnostic centres,
SMS, email and web portal) for test reports. Several factors, including the strength of our brand, integrated services model,
quality of our diagnostic services, center infrastructure and customer experience, convenience of our operational network and
home collection in our core geographies are important differentiating factors in customers choosing us as their preferred
diagnostic service provider, which helps us in retaining our customers, and sets us apart from our competitors.

We have implemented a ‘hub and spoke’ model, whereby specimens are collected across multiple locations within a catchment
area or a region for delivery to our reference laboratories for diagnostic testing. This model provides greater economies of scale
and enhances consistency of our testing procedures and results. All of our centres offer integrated diagnostics services
(pathology and radiology tests under one roof) with smaller spokes offering pathology tests and basic radiology tests and hub
centres (ARCs) offering pathology tests, basic radiology tests and advanced radiology tests such as MRI, HRCT, SPECT and
PET CT. As of June 30, 2021, our operational network consists of diagnostic centre network of (i) a flagship centre located in
Hyderabad, which is our main ‘hub’ and equipped to conduct all of pathology specimens collection, basic and advanced
radiology tests; (ii) 20 hub centres, which are equipped to conduct all of pathology specimens collection, basic radiology tests
and certain advanced radiology tests; and (iii) 60 diagnostic centres, which are equipped to conduct a majority of pathology
specimen collection and certain basic radiology tests; and a laboratory network of (i) a national reference laboratory co-located
with our flagship centre; and (ii) 10 reference laboratories co-located with certain hub centres and diagnostic centres. Our
diagnostic services are provided by a medical professional team consisting of 74 laboratory doctors, 19 physicians, 105
radiologists and 1,027 well-trained technical staff in our operational network, as of June 30, 2021. As of June 30, 2021, all of
our laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and three of our
diagnostic centres hold Patient Safety & Quality of Care (“NABH”) accreditations.

dil
Our individual consumer business contributed to 93.06% and 92.09% of our revenue from operations for the three months
ended June 30, 2021 and the fiscal year 2021, owing to the trust built while rendering, over decades, quality diagnostic services
and experience gained. Over the years, we have received several awards that recognize the strength of our brand and our focus
on offering superior diagnostic services. For examples, we were recognized as “One of the Best Healthcare Brands-2021” by
The Economic Times in 2021, “For excellence in Quality and Accuracy” under the category Leading Diagnostics company
with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021, “Most Trusted Diagnostic Centre of the
year — India” at the Indo-Arab Leaders Summit & Awards in 2019, “Best Diagnostic Centre of the Year” by Times Healthcare
Achievers, The Times of India in 2019, “10 Most Trusted Brands of the Year” by the Business Sight Magazine in 2019 and
“Telangana Healthcare Leadership Award” by the Telangana Government in 2018.

Our Company was founded and promoted by Dr. S. Surendranath Reddy, our executive Chairman, who is a first generation entrepreneur and
has more than four decades of experience in integrated diagnostics business and is a radiologist. Our CEO, Sura Suprita Reddy, and executive
director, Sunil Chandra Kondapally, have been involved in our business and operations since 2003 and 2002, respectively. Our shareholders
include our Promoter, Dr. S. Surendranath Reddy, and marquee investors, Karakoram Limited and Kedaara Capital Alternative Investment
Fund — Kedaara Capital AIF 1; and we believe we have benefited significantly from their vision and leadership, and they along with our
senior management, have been instrumental in formulating and executing the core strategy of our Company.

During three months ended June 30, 2021, we conducted approximately 1.96 million pathology tests and 0.22 million radiology tests for
approximately 0.94 million customers. During fiscal year 2020, our tests per customer visit was 2.83, our operating revenue per customer
was & 1,213.72 and our operating revenue per test was % 428.14, all of which are higher as compared to our listed regional peers as per the
CRISIL Report.

Our leadership position and scale of operation have translated to our strong financial performance. For the three months ended June 30, 2021
and the fiscal years 2021, 2020 and 2019, our total income was % 1,259.70 million, = 3,885.93 million, 23,541.82 million and % 3,029.44
million, respectively and our profit/(loss) for the period/year was % 333.25 million, = 849.11 million, = 625.07 million and % 462.72 million,
respectively. For the three months ended June 30, 2021 and the fiscal years 2021, 2020 and 2019, our cash generated from operations was &
509.45 million, = 1,296.43 million, = 1,061.12 million and % 905.27 million, respectively. For the three months ended June 30, 2021 and the
same years, we achieved adjusted EBITDA of 2 568.55 million, = 1,659.77 million, = 1,326.21 million and % 1,081.20 million, and a return
on capital employed (pre cash) of 15.25% (Not annualised), 42.00%, 33.28% and 30.06%, respectively.

OUR COMPETITIVE STRENGTHS

Our key competitive strengths include:

. largest and fastest growing diagnostic chain with dominant position in south India (Source: CRISIL Report), well
positioned to leverage the high growth in Indian diagnostics industry;

. integrated diagnostics provider that offers one-stop solution at affordable price with focus on superior quality standards;

. high brand recall driving high individual consumer business share and customer stickiness;

. strong technical capabilities, quality infrastructure and state of the art medical technology with strong IT infrastructure;
and

. dedicated management team with significant industry experience.

Largest and Fastest Growing Diagnostic Chain with Dominant Position in South India, Well Positioned to Leverage the
High Growth in Indian Diagnostics Industry

We are the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing
diagnostic chain by revenue for fiscal year 2020 (Source: CRISIL Report). Our history can be traced back to 1981, when our
Promoter and Chairman, Dr. S. Surendranath Reddy established the first Vijaya Diagnostic Centre in Hyderabad. We have built
an extensive operational network consisting of 81 diagnostic centres including a flagship centre located at Hyderabad, and 11
co-located reference laboratories, including a national reference laboratory at our flagship diagnostic centre, across 13 cities
and towns in the states of Telangana and Andhra Pradesh and in National Capital Region and Kolkata, as of June 30, 2021. For
the three months ended June 30, 2021, we derived 87.18% and 8.73% of our revenue from operations from Telangana and
Andhra Pradesh, respectively. For the fiscal year 2021, we derived 86.21% and 9.99% of our revenue from operations from
Telangana and Andhra Pradesh, respectively.

The diagnostics industry in India is highly competitive and fragmented (Source: CRISIL Report). Standalone centres dominate
the Indian diagnostic market with approximately 45% to 50% market share, while hospital-based centres have approximately
35% to 40% market share for the fiscal year 2020 (Source: CRISIL Report). Diagnostic chains have approximately 12% to 17%
market share for the fiscal year 2020 and are further split into regional and multi-regional chains (Source: CRISIL Report). The
industry has witnessed a shift from standalone centres to diagnostics chains due to increasing trend of patients’ reliance on
organized diagnostic providers for quality services and unavailability of complex tests with standalone centres, not only on an

overall country level but also at the regional markets level (Source: CRISIL Report).
112
According to the CRISIL Report, the Indian diagnostics market was valued at approximately = 710 billion to 2 730 billion in
the fiscal year 2021, and is projected to grow at CAGR of around 12% to 13% to reach approximately 2 920 billion to = 980
billion by fiscal year 2023 driven by rise in health awareness and disposable incomes, increase in demand for better healthcare
facilities and quality of care of individuals, and increase in spending on preventive and wellness. Further, according to the
CRISIL Report, the diagnostics market in Telangana and Andhra Pradesh, the states in which we have a significant presence,
is projected to grow to approximately = 120 billion to = 130 billion by fiscal year 2023. We believe that the combination of our
strong brand position driven by our long operating history in our core geographies, our extensive operational network and our
reputation for providing quality diagnostic services positions us well to continue to grow the scale of our business in Telangana
and Andhra Pradesh market and take advantage of growing Indian diagnostic market. In addition, we expect that we will be
able to grow from potential acquisitions of standalone diagnostic centres and laboratories.

Integrated Diagnostics Provider that Offers One-Stop Solution at Affordable Price

We offer a comprehensive range of approximately 1,610 pathology tests, which are organised into approximately 740 routine
tests and 870 specialized tests, as well as approximately 220 basic and 320 advanced radiology tests that cover a range of
specialties and disciplines, as of June 30, 2021. Our test menu includes (i) pathology tests ranging from basic biochemistry and
clinical pathology to cytogenetics and high-end molecular diagnostic tests, including protein chemistry, cellular immunology,
flowcytometry, genetics, cytogenetics, immunohistochemistry and advanced microbiology tests, and (ii) radiology tests ranging
from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests such as MRI, HRCT, SPECT and PET CT.
We currently also offer RT-PCR testing and/or CT scan for COVID-19 diagnosis across 33 diagnostic centres in 11 cities and
towns and COVID-19 vaccination services at our Kolkata and Gurugram diagnostic centres. We are one of the earliest private
diagnostic service providers to be approved for COVID RT-PCR testing by India Council of Medical Research in Andhra
Pradesh and Telangana (Source: List of Private Laboratories to test COVID-19 published on March 24, 2020). Given our focus
on the provision of integrated diagnostic services, we have provided 2.8 tests per customer on average fiscal year in fiscal year
2020, that is higher than other listed regional/multi-regional diagnostic chains, according to the CRISIL Report. We believe,
our ability to provide one-stop diagnostic solution is an important factor in customers choosing us as their diagnostic service
provider, helps us in retaining our customers, and sets us apart from our competitors.

We focus on providing customers quality, hygienic and reliable diagnostic services at affordable prices in India. Our ‘hub and
spoke’ model allows specimens to be collected across multiple locations within a catchment area or a region for delivery to our
reference laboratories for diagnostic testing, that provides greater economies of scale and enhances consistency of our testing
procedures. All of our diagnostic centres offer a mix of pathology specimens collection and radiology testing services with
smaller spokes offering basic radiology and hub centres (ARCs) offering advanced radiology testing services such as MRI,
HRCT, SPECT and PET CT. As of June 30, 2021, our operational network consists of diagnostic centre network of (i) a flagship
centre located in Hyderabad, which is our main ‘hub’ and equipped to conduct all of pathology specimens collection, basic and
advanced radiology tests; (ii) 20 hub centres, which are equipped to conduct all of pathology specimens collection and basic
radiology tests and certain advanced radiology tests; and, (iii) 60 diagnostic centres, which are equipped to conduct a majority
of pathology specimens collection and certain basic radiology tests; and laboratory network of (i) a national reference laboratory
co-located with our flagship diagnostic centre; and (ii) 10 reference laboratory co-located with certain hub centres and
diagnostic centres. Our diagnostic services are provided by a medical professional team consisting of 74 laboratory doctors, 19
physicians, 105 radiologists and 1,027 well-trained technical staff in our operational network, as of June 30, 2021. As of June
30, 2021, all of our laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and
three of our diagnostic centres hold Patient Safety & Quality of Care (“NABH”) accreditations.

High Brand Recall and Commitment to Superior Quality driving High Individual Consumer Business Share and Customer
Stickiness

We have built a trusted, high quality and reliable brand of choice over the last four decades. Over the years, we have received
awards that recognize the strength of our brand and our focus on offering superior diagnostic services. For example, we were
recognized as “One of the Best Healthcare Brands-2021” by The Economic Times in 2021, “For excellence in Quality and
Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics
Leadership Summit in 2021, “Most Trusted Diagnostic Centre of the year — India” at the Indo-Arab Leaders Summit & Awards
in 2019, “Best Diagnostic Centre of the Year” by Times Healthcare Achievers, The Times of India in 2019, “10 Most Trusted
Brands of the Year” by the Business Sight Magazine in 2019 and “ Telangana Healthcare Leadership Award” by the Telangana
Government in 2018. For further details, see “History and Certain Corporate Matters — Awards, accreditations and
recognitions received by our Company ™ on page 132. Customers choose us because of our well-established brand name and
superior diagnostic service experience. A substantial majority of our customers are individual customers, with over 92.09% of
our revenue from operations for the fiscal year 2021, being directly attributed to our individual consumer business, as a result

113
of our trusted and quality diagnostic services built over decades of experience. See “~ Description of our Business — Our
Customers — Individual Consumer Business” on page 120.

We focus on a customer centric approach to delivering our best services that leads to high customer satisfaction and increasing
customer stickiness. Our diagnostic centres are designed in accordance with high quality specifications, which include
requirements in relation to design of work area, physical infrastructure and placement of technical equipment, with an aim to
provide our customers with uniformity of experience for visit across our diagnostic centres. For convenience of our customers,
we provide value-added services such as home collection of specimens, house calls and various delivery and access modes
(e., at diagnostic centres, SMS, email, web portal) to test reports. Our home collection service allows specimens to be collected
from our customers’ locations, such as their homes or offices, in nine cities in India, as of June 30, 2021. We believe our focus
on the consumer and, together with what we believe is our brand’s recognition for quality diagnostic services, results in higher
brand recall in our core geographies and enable us to have a high share of walk-in customers leading to sticky individual
consumer revenues.

Robust Technical Capability and State of the Art Technology with Strong IT Infrastructure

Our strong technical capability and ability to adopt to the latest technologies in the diagnostic industry allow us to provide high
quality and reliable diagnostic services to our customers. As of June 30, 2021, our radiology testing operations are supported
by radiology equipment including 15 CT machines, 18 MRI machines and five PET CT/Gamma machines, which we believe
represent the leading technology used in the field, and a team of 105 radiologists across our diagnostic centres. Diagnostic
centres have to constantly upgrade their technology to stay ahead of the competition which involve significant capital
investment and maintenance cost (Source: CRISIL Report). We believe that owing to our continuous investment and the long
standing relationships we enjoy with certain medical technology vendors, we have been at the forefront of introducing new tests
by adopting the latest medical technologies across our operational network. For instance, we believe that we were among the
first diagnostic services providers in south India to offer PET-CT scan in 2008.

Our diagnostic centre operations are supported by front-end centralized information technology platform. We use Laboratory
Information Management System (“LIMS”) to automate laboratory workflows, manage samples, test results and associated
data for pathology tests, a fully integrated Radiology Information Systems (“RIS”) - Picture Archive and Communication
Systems (“PACS”) to manage radiology workflows, archive and access images from multiple modalities and locations for
radiology tests. Our front-end information technology system enables us to (i) achieve standardization across our operations;
(ii) reduce incidence of errors due to human intervention; (iii) monitor technical operations; (iv) closely track our key
performance metrics and maintain the turn-around time (“TAT”); (v) provide convenience to our consumers and customers, by
allowing them to book appointments, complete registration and access test reports online; and (vi) allows consumers to make
payments online (via a secured gateway). We have also adopted back-end centralized LIMS and ERP system which allow us
to more efficiently manage every aspect of our operation, including optimal utilisation of our equipment, billing and receivables
management, inventory management, central purchasing and financial controls.

Long Track Record of Delivering Consistent Profitable Growth, with Strong Cash Generation and Return Metrics

Our business has demonstrated strong financial performance over the three months ended June 30, 2021 and the last three fiscal
years ended March 31, 2021. For the three months ended June 30, 2021, we recorded a total income of % 1,259.70 million.
During the same period, our operating revenue per test was 562.31 and OPBDIT per test was % 260.59; our operating revenue
per customer was 2 1,298.96 and OPBDIT per customer was 2 601.39. For the fiscal year 2021, we recorded a total income of
% 3,885.93 million, representing a CAGR of 13.26% for fiscal years 2019 to fiscal year 2020; our operating revenue per test
was % 428 and OPBDIT per test was 2 168 for fiscal year 2020; while our operating revenue per customer was 2 1,214 and
OPBDIT per customer was 2 475 for fiscal year 2020. Our OPBDIT margin ranked second among other major diagnostics
players as per the CRISIL Report. In addition to our high OPBDIT margins, our attractive financial profile is also evidenced
by negative working capital and high cash flow generation leading to our strong net cash position. We have also enjoyed return
on net worth of 23.64% and the return on capital employed (pre cash) of 42.00% during the fiscal year 2021.

Our financial performance is due to a combination of (i) a “hub and spoke” model that both yields economies of scale and
provides network and operation cost optimization benefits which has driven high margin as well as high return metrics, (ii) high
number of tests, revenue and Adjusted EBITDA per footfall driven by our integrated model and high individual consumer
business mix, which has translated into high cash flow conversation, and (iii) a network whose size enhances our purchasing
power with suppliers. For the fiscal year 2020, our average test per customer was 2.8, operating revenue per customer was =
1,214 and OPBDIT per customer was % 475, all of which are higher as compared to our listed peers as per the CRISIL Report.

Dedicated Management Team with Significant Industry Experience

114
We are led by a strong and dedicated team of experienced professionals with skill sets that are complementary and, we believe,
requisite for the fast-growing Indian diagnostic market. Members of our management team have experience in the healthcare
industry, and, under their leadership over the last several years, we have grown rapidly and increased both the productivity and
efficiency of our network.

Several key members of our management team including our Chairman, Chief Executive Officer, Executive Director, Chief
Financial Officer and Company Secretary have extensive functional/industry experience. In particular, our Promoter and
Chairman, Dr. S. Surendranath Reddy, has more than four decades of experience in integrated diagnostics business and is a
radiologist. Our Chief Executive Officer, Ms. S. Suprita Reddy, also has significant industry experience and has been leading
our business since 2003. For details, see “Our Management — Key Managerial Personnel” on page 152.

Our Board of Directors, includes a combination of management executives and experts from healthcare industry. The
combination of our experienced Board of Directors and our dynamic management team positions us well to capitalize on future
growth opportunities.

OUR STRATEGY

The key elements of our business strategy are as follows:
Deepen Footprint in our Core Markets

We intend to strengthen our presence in regions in which we operate, with emphasis on the states of Telangana and Andhra Pradesh. According
to the CRISIL Report, out of hospital diagnostics market was valued at approximately & 390 billion to & 395 billion in the fiscal year 2020,
and is projected to grow at CAGR of around 12% to 13% to reach approximately 2 555 billion to 2 565 billion by fiscal year 2023. We have
significant presence and operational experience in Telangana and Andhra Pradesh, and derived 87.18% and 8.73% of our revenue from
operations from these states for the three months ended June 30, 2021, respectively and 86.21% and 9.99% of our revenue from operations
from these states for the fiscal year 2021, respectively. We intend to deepen our penetration and increase customer base to consolidate leading
position in our core markets by (i) expanding service network by opening additional diagnostic centres; (ii) enhancing our laboratory capacity
and test menu by adding latest technologies; (iii) increasing our business from individual customers by offering a portfolio of additional
services; (iv) physician engagement through medical awareness initiatives and meetings with medical practitioners; and (v) increased focus
on preventive and wellness offerings. We also plan to selectively explore franchisee opportunities with strong local entrepreneurs to augment
own centres.

  

Leveraging our Existing Presence by Focusing on Setting up Spoke Centres and Increasing Home Collection in Existing
Catchment Areas

The diagnostic market in India is under-penetrated relative to its potential demand. We will continue to focus on expanding our
network through setting up spokes and select hub centres in existing catchment areas. In addition, we would also be adding
reference laboratories in our existing core geographies. In recent years, we have successfully used “hub and spoke” model to
grow our business and the total number of our spokes have grown from 45 as of April 1, 2019 to 60 as of June 30, 2021. In
light of our success, we plan to set up additional diagnostic centres in Telangana and Andhra Pradesh. In addition, increasing
competition has prompted industry players to adopt various techniques to differentiate themselves in terms of bandwidth, such
as providing home pick-up and point-of-contact testing, according to the CRISIL Report. We plan to increase our home
collection services in core geographies to reach out to more customers.

Continue to Focus on Providing Customer Centric Services and Offerings

We plan to increase the breadth of our diagnostic services by offering additional preventive and wellness services and through,
among other things, the adoption of new, cutting-edge diagnostic testing technology, as we believe this will expand our scope
of diagnostic services and further enhance the reputation of our brand. For example, we intend to offer more preventive and
wellness packages, preventive healthcare screening and chronic and lifestyle disease management services to individual and
corporate customers, given the increasing health awareness of, and concomitant increase in, chronic and lifestyle diseases in
India. This would include additional development in the areas of genetics, molecular and oncology testing, as well as an
expansion of our current chronic disease management and wellness programs.

We also intend to enhance our pathology and radiology test offerings by creating customized packages to our customers, based
on customers’ age, sex and medical history, to cater to specific their needs. We expect that these packages will increase revenue
per customer visit. Leveraging the current needs of our customer base, we offer RT-PCR testing for COVID-19 diagnosis across
25 diagnostic centres in nine cities and towns and COVID-19 vaccination services at our diagnostic centres located at Kolkata,
West Bengal and Gurugram, Haryana, and intend to grow these test offerings to few other diagnostic centres/hubs. Our

115
dedicated sales and marketing team will continue to promote our specialty tests and disease specific profiles and grow our
corporate customer base by marketing our healthcare proposition to human resource departments and other corporate decision
makers.

Expand in Adjacent Geographies and East India

We intend to establish our presence in adjacent geographies of Telangana and Andhra Pradesh and expand in concentric circles. We have
identified key cities and towns that we believe are underserved, and where our brand is well-regarded. We expect that a wider geographic
reach will expand our customer base as well as improve our profitability by allowing us to better leverage our infrastructure.

We also plan to expand our presence in east India, in particular Kolkata. We believe that the growing demand presents us with an opportunity
to establish a network of our diagnostic centres in east India. We intend to replicate our “hub and spokes” model while expanding into east
India. In 2014, we acquired a majority stake in Medinova, a diagnostic service provider which currently has an established hub in Kolkata,
and successfully integrated it into our operational network. Medinova has contributed 3.70% and 3.38% of our revenue from operations for
the three months ended June 30, 2021 and the fiscal year 2021. We plan to set up additional diagnostic centres in this region. Given the
expected increase in demand for diagnostic services in East India, we expect Kolkata to be one of the focus areas of our medium to long term
growth.

Supplement Organic Growth with Selective Acquisitions

We intend to supplement our organic growth with selective acquisitions of/strategic partnerships with brands with strong vintage
and market position in adjacent markets. According to the CRISIL Report, while the diagnostics industry is highly fragmented,
demand for quality of service and complex tests from customers, as well as high capital expenditure requirements for radiology
provides opportunity for faster consolidation in the diagnostics industry in India. In light of this opportunity, we will actively
explore select expansion opportunities through strategic acquisitions of/partner with regional diagnostic service providers who
possess brand recognition among an existing customer base to, among others:

. increase our customer base to consolidate our position in core markets in which we currently operate;
. achieve operating leverage in core markets by unlocking potential efficiency and synergy benefits;

. strengthen or expand our technological capabilities; and

. grow in new markets.

When evaluating acquisition targets, we primarily take into account a number of factors such as brand, customer base, customer
centric focus and culture, technical capability and resources. We are the largest integrated diagnostic chain in southern India,
by operating revenue (Source: CRISIL Report). Given our leading market position, in-depth industry experience and expertise,
we are well positioned to take advantage of the expected consolidation opportunities and shift towards organized providers in
the Indian diagnostics market.

DESCRIPTION OF OUR BUSINESS
Our Geographical Spread

We offer integrated diagnostic services to our customers through a network of diagnostic centres and reference laboratories
across 13 cities and towns in the states of Telangana and Andhra Pradesh and in National Capital Region and Kolkata. Over the
years, we have grown rapidly through our singular focus on expanding our core market of Hyderabad and rest of Telangana
and Andhra Pradesh.

The map below depicts the geographical spread of our network of diagnostic centres and reference laboratories in Telangana
and Andhra Pradesh, as of June 30, 2021:

     

Dara Naga Gopalapstan,
Taga Cat)

116
The chart below sets forth number of our centres by cities and/or regions for the three months ended June 30, 2021 and the
fiscal years 2021, 2020 and 2019:
(No. of Centres)

 

 

 

 

 

 

 

; 5 As of June 30, ‘As of March 31,
City Region 2021 2021 2020 2019
Hyderabad 64 63 58 46
Rest of Telangana and Andhra Pradesh 15 15 B 2
Others 2 2 2 3
Total ar 80 B 61

 

 

 

 

 

 

The chart below sets forth our revenue from operations by cities and/or regions for the three months ended June 30, 2021 and
the fiscal years 2021, 2020 and 2019:

(Zin million)

 

 

 

 

 

 

 

 

 

 

 

 

5 7 As of June 30, ‘As of March 31,
Ciyi Region 2021 2021 2020 2019
Hyderabad 1,003.07, 3,041.86 2,896.85 2,490.93
Rest of Telangana and Andhra Pradesh 173.62 582.31 370.98 279.30
Others 50.17 143.30 120.38 155.65
Total 1,226.86 3,767.46 3,388.21 2,925.87

 

Our Operational Network

 

e2

Home Collection
2B Hospitals 8 Labs

  

 

Sample Flow
—— Patient Flow
Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)
Hub = Lab Samples Collection+ Basic Radiology+ Advanced Radiology (MRV/CT Scan/SPECT)
Diagnostic Centre/ Spokes = Lab Samples Collection+ Basic Radiology
Baste Radiology = ECG2<ray/USciiammography/OMID/TMT/2D EcharEEGENMGIEdoscopy, ote

We offer comprehensive and high quality diagnostic services in India through our own operational network, comprising of a
flagship centre, hub centres and diagnostic centres as well as reference laboratories (including a national reference laboratory).
We have implemented a ‘hub and spoke’ model, whereby specimens are collected from across multiple locations within a
catchment area or region for shipment to our reference laboratories for diagnostic testing. Typically, customers come to our
diagnostic centres when they need to undergo certain pathology and/or radiology tests for preventive and/or curative purposes
either on their own or for servicing prescribed tests requests from a physician, other qualified healthcare professional or a
hospital, clinic or nursing home. Based on the particular request, our staff at diagnostic centres collect the specimens required
for pathology tests and/or conduct radiology tests. Specimens collected at our diagnostic centres are delivered through our
logistics network to a reference laboratory predesignated to process the type of test requested from the specific diagnostic centre
that collected the sample. If the test requested is of a certain nature or complexity, the sample is directed to our national reference
laboratory for processing. To the extent that tests required by our customers can be processed in the nearest laboratory, our
specialized laboratory staff will process the tests and submit the results in the LIMS, allowing for a shorter overall turnaround
time. In case the customer visiting a diagnostic centre requires an advanced radiology test, the customer is transferred to
/recommended to visit the hub centres or the flagship centre.

Our centralized testing and procurement has yielded economies of scale and has allowed us to reduce procurement cost and
implement information technology systems, thereby improving the overall efficiency of our diagnostic services. We aim to
continue to achieve economies of scale in both procurement and service provision as we expand our network to serve our
customers’ needs.

117
The chart below sets forth details of our operational network as of specified dates:

Diagnostic Centres

 

 

 

 

[Flagship Centre 1 1 i A 1
[Hub Centres 20 19 16 15
[Diagnostic Centres/Spokes 60 60 56 45
{otal 81 80 73 61

 

Laboratory (co-located with our diagnostic centres)

 

 

 

 

 

 

 

 

|National Reference Laboratory 1 1 1 1
[Reference Laboratories 10 10 10 10
(otal il 11 11 il

 

Diagnostic Centre Network

Our diagnostic centres are for the purpose of walk-in customers as well as our institutional customers to provide their specimens
for pathology tests and/or to receive radiology tests, depending on the nature of the test sought. As of June 30, 2021, we had a
total of 81 centres of which, we had one flagship centre, 20 hub centres, and 60 diagnostic centres. Our diagnostic centres are
designed in accordance with certain specifications, which include requirements in relation to design of work area, physical
infrastructure and placement of technical equipment, with an aim to provide our customers with uniformity of experience for
every visit.

Flagship Centre

Our flagship centre was established in 2005, and is currently located in an approximately 95,000 square feet built-up facility in
Himayatnagar, Hyderabad. It acts as the main ‘hub’ for the rest of our hub centres and diagnostic centres, and is equipped to
conduct all of pathology specimens collection/tests and basic and advanced radiology tests offered by us. It houses the most
advanced radiology equipment within our network for X-rays, ultrasounds and color doppler, digital mammography, bone
density scans, PET-CT scans, MRI, multi slice CT scans.

Customers either visit our flagship centre directly or are sent by our hub centres or diagnostic centres. It also serves as a
collection point for specimens coming in from our institutional customers.

Hub Centres

Our hub centres are located in Hyderabad, Vishakhapatnam, Nellore, Kurnool, Hanamkonda, Karimnagar and Kolkata. They
are equipped to conduct all pathology specimens collection and basic radiology tests and certain advanced radiology tests such
as MRI scan, multi slice CT scan and SPECT offered by us, depending on the requirements of each catchment area.

Customers either visit the hub centre directly or are sent by our diagnostic centres. Our hub centres also serve a collection point
for specimens coming from our institutional clients.

Diagnostic Centres/Spokes

Our diagnostic centres are located in Hyderabad, Vishakhapatnam, Nandyal, Kurnool, Hanamkonda, Warangal, Karimnagar,
Nizamabad, Sangareddy and Gurgaon. They are equipped to conduct a majority of pathology specimens collection and certain
basic radiology tests offered by us. Customers who visit our diagnostic centres, but requiring advanced radiology tests such as
MRI scan, multi slice CT scan, SPECT or PET-CT are transferred to our flagship centre or hub centres, for their specific needs.

Home Collection Service

Home collection service is a key part of our customer-centric approach, as we strive to provide convenient and quality services
to our consumers. Our home collection service allows specimens to be collected from our consumers’ locations, such as their

118
homes or offices. The collected specimens are then transported in a specially designed transportation box to the designated
diagnostic centre. Specimens are then delivered to our reference laboratories, depending on the nature and complexity of the
tests required.

Laboratory Network

As of June 30, 2021, our laboratory network consists of one national reference laboratory and 10 reference laboratories, which
are co-located with our flagship centre or our hub centres or our diagnostic centres for ease of operation. All of our laboratories
are accredited by NABL. Sample transits between diagnostic centres and laboratories within the same city/town are serviced
by a mix of our in-house and out-sourced third-party logistics team while intercity sample transits are serviced by third-party
logistics couriers. The mixed use of in-house and third-party logistics and couriers helps us to achieve high degree of efficiency
and operational flexibility.

National Reference Laboratory

Our national reference laboratory is co-located with our flagship centre in Himayatnagar, Hyderabad. It receives routine and
specialized testing requests and related specimens for testing from our hub centres, diagnostic centres and reference
laboratories. Our national reference laboratory is ISO certified and holds accreditation from NABL.

Our national reference laboratory has several analytical departments including (i) clinical biochemistry; (ii) haematology and
clinical pathology; (iii) histopathology, cytopathology and immune histochemistry (iv) microbiology and serology; (v)
molecular pathology; and (vi) cytogenetics.

Reference Laboratory

Our reference laboratories are co-located with our hub centres and our diagnostic centres in Hyderabad, Kurnool, Nellore,
Nandyal, Visakhapatnam, Hanamkonda, Karimnagar, Gurgaon and Kolkata. They receive routine and specialized testing
requests and related specimens for testing from our hub centres and diagnostic centres.

Our reference laboratories carry out routine and certain specialised tests in the areas of clinical biochemistry, basic serology,
cytopathology, clinical pathology and haematology. Some of reference laboratories also provide anatomic pathology and basic
microbiology testing services. All of our reference laboratories are NABL accredited.

Process of establishing new diagnostic centres

We have an experienced projects team which identifies new locations for setting up our diagnostic centres. We typically open
new diagnostic centres on premises which are taken on long term lease. For most of our new diagnostic centres, we typically
lease the ground floor or the first floor of a multistoried building for the convenience of our customers. Once the team identifies
a location, we evaluate the requirement of building approvals such as occupancy certificate and fire no objection certificates.
Our team obtains such approvals from the owner to the extent available and follow up for obtaining the balance approvals which
cover the entire building even though we occupy only a portion of the building. Our projects team carries out the building
improvements required for our diagnostic centres, depending on the services that we propose to provide from the location. The
projects team ensures that the layout of the diagnostic centre is done in such a manner so as to ensure adherence to the relevant
building codes, local laws and regulations and applicable fire safety laws. The projects team also ensures installation of various
firefighting equipment such as fire extinguishers, hose reel system, automatic sprinkler systems and fire alarms depending on
the area in which our diagnostic centre is proposed to be set up and the structure of the premises in which our diagnostic centre
is located. We have carried out a fire safety audit by a fire audit consultant for our diagnostic centres.

Our Diagnostic Services

We provide one-stop solution of pathology radiology testing services through our operational network. As of June 30, 2021,
we offer a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic
and 320 advanced radiology tests that cover a range of specialties and disciplines.

Routine Testing

Routine tests generally are performed on whole blood, serum, plasma and other body fluids and specimens such as microbiology
samples. Our routine tests include basic biochemistry, basic haematology, clinical pathology and surgical/anatomic pathology,

microbiology and cytology tests. All tests are done on high throughput automated equipment and/or instruments with integrated

119
software systems. These tests measure various important health parameters such as the functions of the kidney, heart, liver,
thyroid gland and other organs and cancer diagnosis. They also provide information to physicians in advising
treatments/management for the underlying disease conditions and clinicians in advising life style changes as and where required,
for their patients.

Specialized Testing

Specialized tests include (i) advanced biochemistry tests such as protein chemistry involving liquid chromatography mass
spectrometry, immunoassays, capillary electrophoresis, nephelometry, thin layer chromatography and freezing point depression
for osmolality test; (ii) haematology tests such as immunological parameters with immunofluorescence, immunoblot methods
and fluro-enzymatic immunoassays, flowcytometry and HPLC; (iii) advanced microbiology tests such as automated blood
culture systems (Bactec) for blood cultures and mycobacterium tuberculosis (MGIT), Vitek2 identification for sensitivity and
species identification by MALDI-TOF-MS; (iv) histopathology tests such as immunohistochemistry tests and fine needle
aspiration cytology both direct and image guided; and (v) molecular pathology tests such as cytogenetics including molecular
cytogenetics with fluorescent in-situ hybridisation (FISH) and other molecular diagnostics techniques such as dd-PCR and RT-
PCR. Given their complexity, these tests require highly skilled, well trained personnel and high precision equipment and/or
instruments of sophisticated technology, specialized collection and transport methods, which are properly incorporated into our
operations.

 

Basic Radiology Tests

Basic radiology tests include ECG, X-rays, ultrasounds, mammography and bone mineral density scan. X-rays are used to detect bone disease,
degeneration, fractures, dislocations, infections and tumours by examining parts of body such as bones, chest and abdomen. We offer 105
types of basic X-rays, including abdominal, barium, bone, chest, extremity and neck, among others. Ultrasounds are used from confirming
and dating a pregnancy to diagnosing a wide variety of conditions affecting the organs and soft tissues of the body, including the heart and
blood vessels, liver, gallbladder, spleen, pancreas, kidneys, bladder, uterus, ovaries, eyes, thyroid, and testicles. We offer a variety special
types of ultrasounds such as Echo that creates images of blood flow through vessels or blood pressure to determine the speed of the blood
flow and any obstructions. We also offer (i) conventional and 3D mammography, breast USG, breast MRI and biopsies to detect breast cancer
and other abnormalities in the breast; and (ii) bone density scan also called DEXA, to measure the bone density of spine, pelvis, lower arm
and thigh and detect osteoporosis.

Advanced Radiology Tests

Advanced radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such as SPECT (gamma scans) and
PET-CT scans, which require advanced machinery to conduct such tests. We offer (i) CT scans to provide more detailed image of the organs,
bones, soft tissue and blood vessels and detect medical conditions such as communicable diseases, trauma, musculoskeletal disorders,
appendicitis, heart disease, and cancer; (ii) MRI scans to examine various parts of body which include brain, spinal cord, bones and joints,
breasts, heart and blood vessels and other internal organs such as prostate gland, uterus and liver and diagnose various medical conditions;
(iii) our highly specialized SPECT equipment are used for therapy of various diseases and gamma scans provide crucial functional information
of diseases relating to different organs such as thyroid, kidney, bones and heart; and (iv) PET-CT scans are used to evaluate neurological
disorders, cardiac viability, diagnose cancer, detect the spread of cancer to other parts of the body or measure the effectiveness of cancer
treatment.

Preventive and Wellness Services

Given our ability to provide integrated diagnostics services across our centres, we are able to provide a comprehensive
preventive and wellness services offering for our customers. Our experience in pathological testing and radiological testing has
allowed us to selectively combine diagnostic tests into various service packages to assist customers seeking to monitor their
health and to prevent and/or treat diseases and other health conditions. These packages are a combination of a variety of early
detection and diagnostic tests to screen selected diseases and disorders with primary focus on life style diseases. Based on age,
sex, Clinical history, parental history and affordability, we offer options of several packages. With a view to provide emphasis
on women’s health, we have also put together special wellness packages for women. Being geared to create awareness among
the general population, we also conduct trainings/seminars focused on common health ailments for corporate entities or large
residential communities.

Our Customers
Our diagnostic centres cater to individual customers and institutional customers.
Individual Consumer Business

Our individual consumer business constitutes 93.06% and 92.09% of our revenue for operations for the three months ended
120
June 30, 2021 and the financial year 2021. Our individual consumer business consumers typically walk-in to our different
diagnostics centres or use our home collection services.

We actively market to our individual consumers and believe that such consumers choose us based on our strengths, particularly,
our strong brand, integrated services model, quality of our diagnostic services, centre infrastructure and customer experience,
convenience of our operational network and home collection in our core geographies.

Our individual consumer business customers comprise of: (i) customers who visit our diagnostic centres and avail our services
as per our price list; (ii) customers whose samples are collected at their residence and processed by us; (iii) customers who avail
our services basis discretionary discounts provided by us as part of our various marketing and other initiatives; and (iv)
customers who are employees of Government companies or are covered under Government initiatives or are beneficiaries of
life / health insurance policies and choose to undergo tests at our diagnostic centres.

Institutional Business

We provide diagnostics services to our institutional customers, including their employees. These institutional customers include
other smaller laboratories and hospitals, whose customers requires diagnostic services (pathology and/or radiology services),
and the samples collected by them are sent to our laboratories for analysis. In addition, we also provide diagnostics services to
several companies, for their employees, including for pre-employment checks. This category of customers typically pays on a
negotiated fee-for-service basis.

Logistics and Procedures
Logistics and Specimen Tracking

We have implemented a “hub and spoke” model, whereby specimens are collected across multiple centres/locations within a
catchment area or region for a predesigned reference laboratory for centralized diagnostic testing. Specimens are collected at
our diagnostic centres, other laboratories, hospitals, corporate sites and home collection. Once collected, a specimen is
transported to a reference laboratory capable of processing the specific type of test sought, which could be a nearby reference
laboratory or in the event a test sought is of certain specialized nature, to our national reference laboratory.

We believe that an efficient logistics network is critical to maintain quality of specimens collected by us. Our reference
laboratories within each catchment area are connected through a logistics network comprising of our in-house logistics team
and third-party logistics team, and supported by independent air-freight couriers for longer distance transport. The specimens
collected are transported, under the requisite temperature controlled conditions, to our reference laboratories via airline and
road networks. Our dedicated logistics team is responsible for monitoring, in real time, daily shipments from all locations,
recording the status of the shipment from the time of collection of the specimen or sample, until it arrives and is accepted at our
laboratories.

Sample Receipt, Registration and Barcoding

LIMS assigns a unique identification number and barcode to each specimen, which helps control and manage the entire process from
registration to specimen collection until the release of the test report. The barcode generated is tagged on to the appropriate customer tube at
the time of specimen collection.

Specimens are received in the accession department of our reference laboratories. Specimens delivered to our reference laboratories are
required to be accompanied by a sample data sheet or a test request form, which includes information such as test to be performed and the
necessary demographic, medical and billing information. Each specimen and its test request form is rechecked for completeness.

Our staff follows specimen acceptance and rejection criteria laid down by our quality assurance department to ensure that poor quality or
insufficient specimens are rejected. If the specimens meet our defined acceptance criteria, they are distributed to the relevant departments.

Testing Procedures

Most of our pathology tests are conducted through fully automated systems. The specimens are placed in the testing equipment and/or
instrument, which are interfaced bi-directionally with LIMS. The testing equipment and/or instrument can take instructions from LIMS after
it reads the sample barcode and automatically connects to LIMS for customer and test details. The process is fully automated, and once the
equipment and/or instrument concludes the testing, the results are automatically uploaded into LIMS under the relevant barcode. Authorized
signatories of the department closely monitor the results and, wherever needed, orders re-check. Validated results, if relevant, are then
transferred into LIMS for a medical review by lab doctors including pathologists, microbiologists, biochemists, histopathologists and
geneticists review and authenticate the results in reports.

121
As part of our standard operating procedure, we select certain test results for re-testing as part of our quality assurance practices. To facilitate
additional tests and re-checks, we store specimen for a specified length of time in accordance with our internal policy. Pursuant to our bio-
medical waste management agreements with authorized third parties, specimens are disposed of through a waste management system that
complies with applicable environment and health and safety laws.

Reports

We prepare detailed reports which include the precise values of the parameters requested with the biological reference ranges
and the methodology followed. Once the results are ready, the customer gets a trigger through a SMS to download the report
through email, our web portal/website or collect the reports from the centre. Our lab doctors are available to physicians to
discuss and clinically correlate the test reports.

Sales and Marketing

We have invested and expect to continually invest in sales and marketing activities. We have a dedicated team to coordinate
our sales and marketing activities and promote our brand.

Sales

The sales team focuses on developing relationships with physicians, and is also responsible for educating healthcare
professionals on the value of our service offerings and new technologies and tests provided at our diagnostic centres. We also
have a dedicated sales team, which engages with key opinion leaders and diagnostic experts, whose primary focus is to identify
the needs and upcoming trends in the fields of advance radiology, oncology, nephrology, nuclear medicine and
gastroenterology. The sales team also engage with professional medical bodies, to organise continuing medical education
(“CME”) programs and other medical education initiatives.

Marketing

We seek to utilize cost-efficient marketing to enhance our brand awareness and increase our customer base. Our main marketing activities
are in the areas of retail marketing, digital marketing and direct marketing. Our retail marketing efforts aim to increase our walk-in and home
collection customers mainly by creating awareness of our health check-ups and wellness initiatives as well as highlighting the convenience
of our home collection services. Our digital marketing is help to increase brand awareness and new customer acquisition though online
platforms. We also continue to target institutional customers and develop our business through our educational social media and online
initiatives. Direct marketing is touching people at their home and offices by doing health and wellness camps to create awareness preventive
care and stay healthy. At camps and at other marketing initiatives, we offer discount vouchers and coupons to potential individual consumers
for tests at our diagnostic centres.

Quality Assurance

Our quality assurance team consists of members with experience in implementation of various accreditation and certification standards such
as NABH, NABL and ISO accreditation and certification standards. We participate in the elective and compulsory external inspections and
proficiency testing programs required by the Government of India and other applicable regulatory agencies. We have systems in place to
emphasize and monitor quality systems and maintain reporting standards within our operational network.

Laboratory Quality Assurance

Our quality assurance system enables a process-oriented approach to ensure quality testing through use of standard operating
procedures, management of documents and records, implementation of quality control, external quality assessment (including
proficiency testing) and robust internal audits. Our quality assurance system covers the entire value chain of our laboratory
operations. Besides core laboratory operations and front-end services, our quality assurance system extends to physical
infrastructure, procedures for purchase and inventory management, equipment and instrument maintenance, customer services,
human resource management and process improvement.

Our set-up of diagnostic centres and reference laboratories are based on the guidelines of the NABL. We have adopted standard
operating procedures for our diagnostic centres designed to improve processes for customers preparation and collection,
handling, storage and transportation of specimens, as well as to ensure accurate and timely delivery of test results. We also
have systems and procedures in place to monitor quality through inter-laboratory comparisons, to maintain reporting standards
within our network. We also focus on training and competency of professional and technical staff, and continue to implement
initiatives to enhance our quality and standardization. We use customer complaints and feedbacks to review our processes, as
and when indicated, to further improve services to our customers. We also conduct regular quality assessments to ensure quality
standard of diagnostic centres. Further, we also provide support to our customers, physicians and institutional customers,

122
through our call centres, which are operated by professionally trained advisors.

We have an intensive program of quality assurance in place so as to be able to meet the international standards in clinical
laboratory testing. The laboratory participates in extensive proficiency testing programs such as Bio-Rad (USA), RIQAS (UK),
EUROIMMUN (UK), CMC Vellore, Shankar Netralaya, Anand Labs (Neuberg), CDC Atlanta, RML, TMH, PGIMER, NARI,
AIIMS and ISHTM Hematology.

All of our reference laboratories are accredited by NABL. Our flagship centre/national reference laboratories holds accreditation
from NABL and certification from ISO 9001:2015 (for quality management system in medical laboratories).

Radiology Quality Assurance

Our radiology quality assurance system is designated to provide confidence in radiation safety, maintain the optimal diagnostic
image quality and ensure the consistent provision of prompt and accurate diagnosis. Our radiology quality assurance system
essentially consists of an organized set of activities and processes that ensure equipment are functioning properly and providing
satisfactory diagnostic information in a timely manner with minimum radiation exposure to customers and staff, and
administrative procedures to ensure uniform application of recommended techniques throughout the network centres.

We have established an in-house radiation quality assurance committee which includes a team of experts responsible for
overseeing our radiology quality assurance program, formulating the standards for image quality and conducting regular review
the effectiveness of the program We have a set of defined standard operating procedures which are department and role specific
including guidelines for equipment appraisal and replacement, guidelines for the standardization of patient exposure and
guidelines for quality acceptance of diagnostic radiograms. Our adherence to defined processes is monitored by quality
assurance team through robust internal audits as well staff and facility preparedness to handle an emergency which may arise
during day to day operations is evaluated through regular mock drills.

Although only few of our diagnostic centres are accredited under NABH MIS program, we endeavour to adhere to the
recommended standards set by NABH for our diagnostic centres that provide radiology testing services. As a part of quality
assurance effort, our quality assurance team conducts quality assessment through peer review regularly.

Quality assurance also encompasses other facets of our services including turnaround time and customer satisfaction. Using
quality assessment techniques, our diagnostic services employ a variety of programs to monitor critical aspects of service to
our customers.

Information Technology

Our information technology systems are the backbone of our operations. Our core infrastructure consisting of physical and
virtual servers are configured for high availability and are scalable to support our growing needs. All our branches are
provisioned with dual internet connections to ensure very high uptime and are securely connected to data centre through VPN.
Our network and servers are proactively monitored to ensure efficient and uninterrupted service delivery. We have a mix of
servers hosted on premise and tier IV data centre.

The main components of our technology architecture include the following:
Laboratory Information Management System

LIMS application manages the complete customer lifecycle from registration to report delivery. Application supports end-to-
end barcoding of samples to ensure accurate reporting. Laboratory analysers are integrated with bi-directional interface for
seamless and accurate transfer of results to the reporting system. Application is enabled with two-level authentications to ensure
high level of accuracy and reliability. Delta checks and auto verification are an integral part of the application. Application also
supports omni channel (at diagnostic centres, SMS, email and portal) delivery of reports.

Radiology Information System
RIS/PACS application manages the workflow of radiology testing services. The RIS/PACS application is tightly integrated
with registration and despatch systems. The centralized PACS is enabled with latest DICOM viewer with high end

functionalities such as MIP, MPR and 3D. Modality work list interface ensures bi-directional integration between RIS and
imaging modalities.

123
Backend Applications

SAP is deployed to support our back-end functions including finance, banking, procurement and inventory management. SAP
is integrated with LIMS for seamless flow of revenue data.

Privacy and Security of User Data

Data security and privacy of customer data is an integral and important part of our information management. Customer
demographic and clinical details captured as part of the registration and testing process are stored in highly secure servers within
our on-premise data centre. Access to customer data and reports is enabled only via secure web portals, which are protected
with OTP and password. Only authorised staff are allowed to access to such data and reports.

Tailored Customer Program and Interface

Customer centricity is one of the key drivers to our technology platform which offers customer an easy and convenient way of accessing their
reports. Customers can access their reports through SMS, email and secured web portal. Institutional customers can track the sample status
through a client portal.

Data Collection and Analytics

As part of the registration and testing process, considerable amount of demographic data and test results are captured and stored in our secured
servers. Periodic analysis of this data gives us insights into the prescription patterns and seasonal trends which helps us to improve our
operational efficiency. Analytics also helps us to finetune our wellness and preventive health check offerings.

Data Recovery

Data protection, data loss prevention and business continuity are ensured through streamlined backup, high availability and DR strategies.
Servers are configured for high availability at the hardware, application and database levels. Backups are taken at regular intervals and stored
at multiple locations enabling point in time data recovery.

Suppliers

Our key suppliers include a diverse range of leading multi-national equipment, instrument, reagent and film manufacturers,
including some vendors who sell more than one range of products. We purchased basic and advanced radiology equipment and
instruments from Siemens Healthcare Private Limited, Philips India Limited, Wipro GE Healthcare Private Limited and Hologic
Incorporated; reagents from Siemens Healthcare Private Limited, Beckman Coulter India Private Limited and Biomerieux India
Private Limited; laboratory equipment from Beckman Coulter India Private Limited, films from Fujifilm India Private Limited,
and specialized infectious, serology and immunology equipment from Biomerieux India Private Limited. We own the radiology
equipment and instruments and some of the pathology equipment and instruments. We typically rent most of the laboratory
equipment and instruments from various vendors under reagent rental arrangements. Further, our reagent rental agreements
typically require us to meet minimum purchase levels on an annual basis.

Equipment and Instruments Maintenance

The timely and effective maintenance of our equipment and instrument is essential for our operations. Most of the laboratory
analysers are under reagent / rental basis. These analysers are maintained by the vendors in accordance with the terms of our
agreed service level agreements. All the purchased equipment and instruments has a 12 to 60 months supplier warranty which
takes care of defects, malfunctions and required repairs if any. We calibrate equipment and instruments regularly in accordance
with the manufacturers’ recommendations and schedule.

We maintain equipment and instruments either under annual maintenance contracts (“AMC”) or comprehensive maintenance
contracts (“CMC”) for major equipment’s with the respective manufacturers or their authorized dealers after completion of the
standard warranty. Pursuant to the terms of annual maintenance contracts, the manufacturer or dealer is responsible for the
maintenance and repair of the equipment and instruments. CMC for an equipment in addition, obliges the manufacturer or
dealer to replace spare parts at its own cost.

Development and Growth

Our management team seeks to expand on our existing test menu and improve our diagnostic procedures, in order to improve
sensitivity, specificity, time or costs as compared to available conventional tools. We also intend to continue to invest in
advanced testing capabilities, in order to provide the latest technologies in diagnostic testing. Throughout the four decades of

124
development of our company, our test menu has expanded to 2,150 tests. We expect to continue to add, new testing technologies
and capabilities through a combination of internal development initiatives and technology licensing. Our management meets
periodically to evaluate the potential adoption of new technologies or the indigenization of existing ones, with the aim of
maintaining our high-quality standards at low cost.

Competition

Our business is highly competitive and we face competition from organized as well as unorganized providers. In addition, we
compete with many smaller, independent clinical and anatomical laboratories as well as laboratories owned by hospitals and
physicians. For further information regarding the highly competitive nature of our industry, see “Industry Overview” on page
80.

We believe the strength of our brand, integrated services model, quality of our diagnostic services, centre infrastructure and
customer experience, convenience of our operational network and home collection in our core geographies are important
differentiating factors in customers choosing us as their preferred diagnostic service provider, which helps us in retaining our
customers, and sets us apart from our competitors.

Intellectual Property
WIUAYA

We have filed an application for the registration of our corporate logo r *, under class 44 of the Trade Mark Act,
1999 and received partial approval to the extent of words “Vijaya Diagnostic Centre”. Additionally, we are the proprietor of
certain word marks including Vijaya Diagnostic Centre and certain logo marks under classes 41, 42 and 44 with the Registrar
of Trademarks in India under the Trade Mark Act, 1999. For further details, see “Government and Other Approvals —
Intellectual Property” on page 252.

  
 

Environmental, Health and Safety matters

We are subject to Indian laws and regulations relating to the protection of the environment, human health and safety, and laws
and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and
radioactive materials/wastes. All our laboratories are subject to applicable laws and regulations relating to biohazard disposal
of all laboratory specimens. For further details, see “Key Regulations and Policies” on page 127.

We also strive to provide employees with a safe working environment. Our employees are trained and encouraged to use
protective equipment and instruments while handling biological specimen and adhere to national and local safety guidelines,
including that of biomedical waste disposal. We monitor radiation levels of all the personnel working in radiation generating
area. We imbibe knowledge of radiation safety practices to all our staff working in radiation zone through our regular academic
programs taught by qualified radiation safety officer.

Safety devices are provided and the functions of which are regularly checked. These devices include biosafety and laminar
flow cabinets, emergency showers, fire extinguishers, eye wash facilities, fire alarms, smoke detectors and fire hose reels. Fire
evacuation plans and emergency exits are displayed at provisional areas.

Corporate Social Responsibility

We have reconstituted a corporate social responsibility (“CSR”) committee in 2021 and adopted a CSR policy in line with the requirements
of the Companies Act, 2013 and the Companies (Corporate Social Responsibility) Rules, 2014 notified by Central Government and as
modified from time to time. The objective of our CSR policy is to undertake activities that have a positive impact on education and healthcare.

For the three months ended June 30, 2021 and the fiscal years 2021, 2020 and 2019, our corporate social responsibility expenditure was
4,39 million, 2 19.77 million, 14.47 million and % 9.00 million, respectively, which were primarily contributed towards skill development,
literacy, quality education and the Prime Minister Relief Fund.

Employees

As of June 30, 2021, we have 2,325 full-time employees and regular consultants on retainer basis, including 74 laboratory
doctors, 19 physicians, 105 radiologists and 1,027 technical staff and phlebotomists. Our laboratories are managed by qualified
scientific staff and supervised by a team of pathologists with specializations in relevant fields of laboratory medicine. Our
radiologists include professional who are leaders in their specialities, with numerous scientific and textbook publications, serve
on committees of various Radiology societies and regularly present at national and international conferences.

125
The following table sets forth the number of our employees and consultants as of June 30, 2021:

 

 

 

 

 

 

 

 

Particulars Number
Key Management Personnel 3
Radiologists, laboratory doctors and physicians 198
Technical Staff 1,027
Sales and marketin; qt
Support Staff 986
Total 2,325

 

 

 

We offer training to our staff on an ongoing basis and such training goes beyond the development of the required skills. This
encompasses training on knowledge, skills and attitude. This approach ensures the deployment of competent staff to deliver
quality service to our customers that earns the trust of not just our customers but the entire ecosystem of healthcare providers
at large.

The training of employees is based on a three phase training program. At the initial level, we provide training on knowledge
and skills for new joiners, while the experienced staff are trained on the protocols followed within our operational sites to ensure
standards of our Company are maintained. The second level was designed for continuous education that is done departmental
wise to ensure there is a retention and recall of the learning while refreshing the employees with the latest updated practices.
We also involve manufacturers of the radiology and laboratory equipment and instruments during the training to ensure the
comprehensiveness of the training. The third level involves the cross departmental training and upskilling of the existing staff
to prepare them for greater responsibilities.

Managerial and leadership trainings are also conducted to boost the development of the managerial competencies while building
a leadership pipeline for our Company.

Insurance

Our diagnostic centres, laboratories and office locations including our corporate office are insured against fire and certain
special perils, including earthquake and terrorism damage. We also have several other insurance policies covering equipment
and instruments, money-transit, fidelity guarantee and statutory employee liability insurance, business interruption at our
facilities resulting from various perils, all risks relating to information systems equipment, burglary causing loss of inventory.
We have also obtained management liability insurance. Additionally, our Company is also insured against professional
indemnity liability including liability arising out of breach of confidentiality, third party public liability and loss of goodwill.

We believe that our insurance coverage is of the type and in the amounts commensurate with the nature and scope of our
operations.

Property

Our Company’s registered office and corporate office are located in 3-6-16 & 17, Street No 19, Himayatnagar, Hyderabad,
Telangana - 500029 and 6-3-883/F, Ground Floor of Family Planning Association of India Panjagutta, Hyderabad-500 082,
India, respectively. Our flagship centre is located at leased premises at 3-6-16 & 17, Street No 19, Himayatnagar, Hyderabad,
Telangana - 500029. As of June 30, 2021, two of our diagnostic centres, laboratories and business premises are owned by our
Company and the remaining 79 diagnostic centres are on lease. On August 11, 2021, we purchased a parcel of land measuring
1,654 square yards in Himayatnagar, Hyderabad for a consideration of % 350.00 million with the intention of developing a
diagnostic centre at this location.

126
KEY REGULATIONS AND POLICIES

The following description is a summary of certain sector specific laws currently in force in India, which are applicable to our
Company. The information detailed in this section has been obtained from publications available in the public domain. The
regulations set out below are not exhaustive and are only intended to provide general information to the investors and are
neither designed nor intended to be a substitute for professional legal advice. The statements below are based on the current
provisions of Indian law, and the judicial and administrative interpretation thereof, which are subject to change or
modifications by subsequent legislative, regulatory, administrative or judicial decisions.

For details of regulatory approvals obtained by us in compliance with the applicable regulations, see “Government and Other
Approvals” on page 251.

The Clinical Establishments (Registration and Regulation) Act, 2010 (“CERRA”)

The CERRA is a central legislation that governs clinical establishments and provides for registration under it. It prescribes the
minimum standards for facilities and services provided by clinical establishments. In terms of the CERRA, ‘clinical
establishment’ specifically covers a hospital, maternity home, nursing home, dispensary, clinic, sanatorium or an institution by
whatever name called that offers services, facilities requiring diagnosis, treatment or care for illness, injury, deformity,
abnormality or pregnancy in any recognised system of medicine established and administered or maintained by any person or
body of persons, whether incorporated or not, including a place established in connection with the diagnosis or treatment of
diseases where pathological, bacteriological, genetic, radiological, chemical, biological investigations or other diagnostic or
investigative services with the aid of laboratory or other medical equipment, are usually carried on.

The penalty provision under CERRA also covers anyone who contravenes any provision of CERRA for which no penalty is
provided specifically, to be punished for the first offence with fine which may extend to ten thousand rupees, for any second
offence with fine which may extend to fifty thousand rupees and for any subsequent offence with fine which may extend to five
lakh rupees.

In addition, most of the states in India where we operate have legislated clinical establishment laws. These legislations inter
alia include (i) Andhra Pradesh Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002; (ii)
Telangana Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002;; (iii) Haryana Clinical
Establishments (Registration and Regulation) Act, 2014 and (vi) West Bengal Clinical Establishments (Registrations,
Regulation and Transparency) Act, 2017.

The Clinical Establishments (Central Government) Rules, 2012 (“CECG Rules”)

The CECG Rules inter alia provide conditions for registration and continuation of clinical establishments. In terms of the CECG
Rules, clinical establishments are required to charge rates for each type of procedures and services within the range of rates
determined by the Central Government and display the same in a local language as well as in English. Clinical establishments
are required to maintain electronic records of patients and statistics, in accordance with the CECG Rules.

Certain States in India have framed rules under the CERC Act or under respective state legislation for clinical establishment,
prescribing inter alia the powers of registration authority, procedure for registration of clinical establishments and applicable
fee.

Pre-Conception and Pre-Natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994 (“PCNDT Act”) and the Pre-
Natal Diagnostic Techniques (Regulation and Prevention of Misuse) Act, 1994(“PNDT Act”)

The PCNDT Act and PNDT Act prohibit sex selection, before or after conception, regulate the use of pre-natal diagnostic
techniques by restricting their usage for the purposes of detecting genetic or metabolic disorders or chromosomal abnormalities
or certain congenital malformations or sex-linked disorders and seek to prevent the misuse of such techniques for the purposes
of pre-natal sex determination leading to female foeticide. The PCNDT Act and PNDT Act also make it mandatory for all
genetic counselling centres, genetic clinics, genetic laboratories carrying out pre-natal diagnostic techniques, to register with
the appropriate authority, failing which penal actions maybe taken against them. Hospitals providing pre-natal diagnostic
facilities fall within the purview of the PNDT Act and PNDT Act. Further, the PCNDT Act and PNDT Act prohibit
advertisements relating to pre-conception and pre-natal determination of sex and the same is made punishable with a fine and
imprisonment.

Atomic Energy Act, 1962 as amended (“AE Act”)

The AE Act aims to ensure safe disposal of radioactive waste and secure public safety, including that of persons handling

radioactive substances. The AE Act empowers the Gol to, prohibit the manufacture, possession, use, and transfer, export and

import, transport and disposal, of any radioactive substances without its written consent and requires any person to make

periodical returns or other such statements as regards any prescribed substance in a person’s possession or control that can be
127
a source of atomic energy. Violation of various provisions of the AE Act is punishable fine or imprisonment, or both. Further,
the Gol, in order to prevent radiation hazards, secure public safety and safety of persons handling radioactive substances or
radiation generating plants, is empowered to ensure safe disposal of radioactive wastes at such premises. Our Company is
required to obtain licenses from the AERB for the use of radioactive substances and disposal of radioactive waste.

Atomic Energy (Radiation Protection) Rules, 2004 (“Radiation Rules”)

The Radiation Rules require that no person shall, without a license issued by the Atomic Energy Regulatory Board (“AERB”),
establish a radiation installation for siting, design, construction, commissioning or operation. Such license is valid for a period
of five years. The Radiation Rules also require a license for a person to handle radioactive material or operate a radiation
generating equipment. A registration will be required under the Radiation Rules, for sources and practices associated with
medical diagnostic x-ray equipment including therapy, simulator and analytical x-ray equipment used for research. The
Radiation Rules lay down various compliance measures regarding inter alia maintenance of radiation protection equipment and
health surveillance of workers. The Radiation Rules also prescribe certain general safety guidelines, directives for emergency
preparedness and accidents.

Atomic Energy (Safe Disposal of Radioactive Wastes) Rules, 1987 (“Radioactive Waste Rules”)

Under the Radioactive Waste Rules, an authorisation is necessary for any person to dispose of radioactive waste, and the waste
may only be disposed of in the terms of such authorisation. A Radiological Safety Officer is required to be appointed to assist
in the safe handling and disposal of radioactive waste. Further, records are required to be maintained of all disposals and
handling of radioactive waste and the persons carrying it out.

Radiation Surveillance Procedures for Medical Application of Radiation, 1989 (“Surveillance Procedures”)

The Surveillance Procedures provide for safety requirements and procedures to be complied with in connection with operating
a radiation generating equipment. The Surveillance Procedures require that a radiology safety officer, whose appointment is
approved by the AERB, be appointed with respect to the operation of radiation generating equipment.

Safety Code for Medical Diagnostic X-Ray Equipment and Installations, 2001 (the “X-Ray Safety Code”)

The AERB issued the X-Ray Safety Code intended to govern radiation safety in design, installation and operation of X-ray
generating equipment for medical diagnostic purposes. The X-Ray Safety Code stipulates that all medical X-ray machines are
required to be operated in accordance with the requirements stipulated therein and that it is the responsibility of the owner or
user of medical X-ray installation equipment to ensure compliance with the statutory provisions. The X-Ray Safety Code
mandates that only the medical X-ray machines approved by the AERB can be installed for use in compliance with the specific
requirements of the X-Ray Safety Code, including in relation to location and layout. Additionally, under the X-Ray Safety
Code, the owners of medical X-ray installations in India are required to be registered with AERB and conduct quality assurance
performance test of the X-ray unit.

Atomic Energy Regulatory Board- Safety Code on Safe Transport of Radioactive Material AERB/NRF- TS/SC- 1, 2015
(“Transport Code”)

The Transport Code which is based on the International Atomic Energy Agency regulations, regulates the transport of
radioactive material in public domain. The basic requirement for the transport of radioactive material is that the package
containing the material shall be designed and prepared in such a way that during the whole process of transport, the radioactive
material remains contained to prevent contamination and remains shielded to avoid radiation exposure to cargo handlers and
the public. The prime responsibility for ensuring compliance with the regulations lies with the consignor. Once the package is
prepared as per the prescribed procedures, it can be transported by any mode.

Atomic Energy Regulatory Board - Safety code on Nuclear Medicine Facilities dated November 4, 2010 (“Nuclear Medicine
Code”)

The Nuclear Medicine Code stipulates radiation safety requirements in handling radioactive materials for nuclear medicine
applications in order to protect workers and members of the public from radiation exposure in excess of limits specified by the
competent authority, reduce such radiation exposures to levels as low as reasonably achievable, ensure safe handling and
physical security of radioactive materials, protect and manage radioactive waste and detect hazardous situations and initiate
prompt remedial measures to mitigate such situations. The Nuclear Medicine Code mandates that nuclear medicine facilities
should not be located in residential buildings and should inter alia have active rooms, wards and areas of source storage and
handling marked with radiation symbol and a legend denoting active area and presence of a radiation hazard. The Nuclear
Medicine Code also stipulates the qualification and responsibilities of employers, nuclear medicine physicians and nuclear
medicine technologists.

Radiation Surveillance Procedure for Medical Applications of Radiation, 1989 (“RSPM Notification”)

128
The RSPM Notification was promulgated to ensure that procedures and installations involving radiation installations, radiation
equipment and radioactive material are performed in conjunction with a pre-planned surveillance programme approved by the
competent authority to ensure adequate protection. The RSPM Notification lays down that a license or an authorisation from
the competent authority must be procured by anyone handling radioactive material or radiation equipment. The RSPM
Notification stipulates the working conditions that are to be ensured at every medical radiation installation and provides safety
guidelines regarding inter alia design safety of equipment, planning of radiation instalments, commissioning of radiation
equipment and isolation and disposal of radioactive effluents or damaged radioactive material.

The Environment Protection Act, 1986 (the “Environment Protection Act”) and The Environment (Protection) Rules, 1986
(the “Environment Protection Rules”)

The Environment Protection Act was enacted to act as an “umbrella” legislation designed to provide a framework for
coordination of the activities of various central and state authorities established under previous laws. The Environment
Protection Act authorises the Central Government to protect and improve environment quality, control, and reduce pollution.

The Environment Protection Rules framed under the Environment Protection Act lay down specific provisions regarding
standards for emission or discharge of environmental pollutants, prohibition of carrying out industrial activities in certain
geographical locations, procedures for function of environmental laboratories and submission of samples. The draft
Environment (Protection) Amendment Rules, 2020 provide for regulations on use of membrane based water purification system
which, if passed, shall be applicable to all filtration based purification or wastewater treatment system, where polymer based
membrane is used and discarded at the end of its life.

Bio-Medical Waste Management Rules, 2016 (“BMW Rules”)

The BMW Rules apply to all persons who generate, collect, receive, store, transport, treat, dispose or handle bio-medical waste
in any form including hospitals, nursing homes and clinics. Our Company is required to obtain an authorisation under the BMW
Rules for the generation of bio-medical waste to ensure that such waste is handled without any adverse effect to human health
and the environment and to set up bio-medical waste treatment facilities as prescribed under the BMW Rules, including pre-
treating laboratory and microbiological waste, and proving training to health care workers and others involved in handling bio-
medical waste. We are also required to submit an annual report to the prescribed authority and also to maintain records related
to the generation, collection, storage, transportation, treatment, disposal, and/ or any form of handling of biomedical waste in
accordance with the BMW Rules and the guidelines issued thereunder. The prescribed authority may cancel, suspend or refuse
to renew an authorisation, if for reasons to be recorded in writing, the occupier/operator has failed to comply with any of the
provisions of Environment Protection Act or BMW Rules.

National Accreditation Board for Testing and Calibration Laboratories (“NABL”)

The NABL is an autonomous body established under the aegis of Department of Science and Technology, Government of India.
NABL provides government, regulators and the diagnostic industry with a scheme of laboratory accreditation through third-
party assessment for formally recognizing the quality and technical competence of the testing and calibration of laboratories in
accordance with International Organisation for Standardization Standards. NABL certification is a mandatory eligibility
condition for diagnostic centres empanelment under the Central Government Health Scheme. Diagnostic laboratories which are
not accredited by NABL may also participate in application and get empanelled under the Central Government Health Scheme
but their empanelment shall be provisional till they are inspected by Quality Council of India or NABL, and are recommended
for continuation of empanelment under the Central Government Health Scheme; however there is no legal obligation to obtain
certification from the NABL.

Guidelines for Exchange of Human Biological Material for Biomedical Research Purposes, 1997 (“HBM Guidelines”)

The HBM Guidelines, issued by the Gol, authorise the Indian Council of Medical Research (“ICMR”) to set up a committee
for consideration of proposals relating to import of biological materials, such as blood samples, for commercial purposes.
Pursuant to these guidelines, ICMR has issued the “Guidance on Transfer of Human Biological Material for Commercial
Purposes” (“ICMR Guidance”). In accordance with the ICMR Guidance, applications for import of blood samples are required
to be made to the ICMR for onward consideration by a committee. Applicant companies are required to comply with, amongst
others, the Guidance on Regulations for the Transport of Infectious Substances (2013-2014) and Laboratory Biosafety Manual
~2004, issued by the World Health Organization, United Nations, class (6.2) specifications for packing instructions, and the
Environment Protection Act, 1986, along with the rules framed thereunder.

Consumer Protection Act, 2019 (“COPRA, 2019”)

129
COPRA, 2019 has replaced the earlier Consumer Protection Act, 1986, seeking to provide better protection to the interests of
consumers, especially in the digital age and to establish competent authorities for timely and effective administration and
settlement of consumer disputes. COPRA, 2019 provides for establishment of a Central Consumer Protection Authority to
regulate, amongst other things, matters relating to violation of rights of consumers, unfair trade practices and false or misleading
advertisements which are prejudicial to the interests of public and consumers. The key features of the COPRA, 2019 include
wider definition of “consumer”, enhancement of pecuniary jurisdiction, flexibility in e-filing complaints, imposition of product
liability, wider definition of unfair trade practices, and provision for alternative dispute resolution. COPRA, 2019 provides for
penalties for, amongst others, manufacturing for sale or storing, selling or distributing or importing products containing
adulterants and for publishing false or misleading advertisements. The Consumer Protection (E-Commerce) Rules, 2020, issued
under the COPRA, 2019 apply to, amongst other things, goods and services bought or sold over digital or electronic networks,
all models of e-commerce and all forms of unfair trade practice across e-commerce models. They specify the duties of sellers,
e-commerce entities and inventory e-commerce entities and the liabilities of marketplace e-commerce entities.

Labour Laws

In addition to the aforementioned material legislations which are applicable to our Company, some of the labour legislations
that may be applicable to the operations of our Company include:

Contract Labour (Regulation and Abolition) Act, 1970;

Employees’ State Insurance Act, 1948;

Employees’ Provident Funds and Miscellaneous Provisions Act, 1952;

Payment of Gratuity Act, 1972;

Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act and Rules, 2013;
Payment of Wages Act, 1936;

Minimum Wages Act 1948;

Payment Of Bonus Act, 1965;

Maternity Benefit Act, 1961, as amended; and

Shops & Establishment Act, 1947, along with other state-wise shops and establishment regulations, and the rules made
thereunder

vrpea me ange

The Code on Wages, 2019 (enacted by the Parliament of India and assented to by the President of India) will come into force
on such date as may be notified in the official gazette by the Central Government and different date may be appointed for
different provisions of the Code on Wages, 2019. Once effective, it will subsume the Equal Remuneration Act, 1976, the
Minimum Wages Act, 1948, the Payment of Bonus Act, 1965 and the Payment of Wages Act, 1936.

The Code on Social Security, 2020 (enacted by the Parliament of India and assented to by the President of India) will come into
force on such date as may be notified in the official gazette by the Central Government and different date may be appointed for
different provisions of the Code on Social Security, 2020. Once effective, it will subsume, inter alia, the Employees
“Compensation Act, 1923, the Employees ‘State Insurance Act, 1948, the Employees Provident Funds and Miscellaneous
Provisions Act, 1952, the Maternity Benefit Act, 1961 and the Payment of Gratuity Act, 1972.

Taxation Laws

In addition to the aforementioned material legislations which are applicable to our Company, some of the tax legislations that
may be applicable to the operations of our Company include:

a. Income Tax Act 1961, the Income Tax Rules, 1962, as amended by the Finance Act in respective years;

b. Central Goods and Service Tax Act, 2017, the Central Goods and Service Tax Rules, 2017 and various state-wise
legislations made thereunder; and

c. The Integrated Goods and Service Tax Act, 2017.

Other laws

In addition to the above, our Company is also required to comply with the provisions of the Companies Act and rules framed
thereunder, Greater Hyderabad Municipal Corporation Act, 1955 and other applicable statutes imposed by the Centre or the
State Government including by local municipal corporations and gram panchayats of the areas where our Company has
operations and authorities for our day-to-day business and operations. Our Company is also amenable to various central and
state tax laws.

130
HISTORY AND CERTAIN CORPORATE MATTERS

Brief history of our Company

Our Company was incorporated as Vijaya Diagnostic Centre Private Limited on June 5, 2002 with a certificate of incorporation
issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, our Company was converted from a private
limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on
March 22, 2021 and the name of our Company was changed to Vijaya Diagnostic Centre Limited and accordingly, on March
26, 2021, a fresh certificate of incorporation consequent on change of name was granted by the RoC.

Our Company had historically, in various public documents such as annual reports and secretarial filings, named Dr. S.
Surendranath Reddy, S. Geeta Reddy, Sunil Chandra Kondapally, Sura Suprita Reddy and B. Vishnu Priya as our promoters.
Pursuant to a resolution of the Board in its meeting held on May 27, 2021, it was resolved that Dr. S. Surendranath Reddy will
be the Promoter of our Company. For details of our Promoter, see “Our Promoter and Promoter Group” on page 155.

Changes in the Registered Office

Except as disclosed below, there has been no change in registered office of our Company since the date of incorporation.

 

 

Date of change of Details of change in the Registered Office Reasons for change in the
Registered Office Registered Office
February 2, 2007 3-6-20, Tirumala Apartments, Himayatnagar, Hyderabad 500 029, | Administrative convenience

Andhra Pradesh, India to 3-6-16 & 17, Street No.19 Himayatnagar,
Hyderabad 500 029, Andhra Pradesh, India

 

November 1, 2005 9-1-7/83 and 84 Deepthi Apartments, besides St. Ann’s School, S.P. | Administrative convenience

Road, Secunderabad 500 016 Andhra Pradesh, India to 3-6-20, Tirumala
Apartments, Himayatnagar, Hyderabad 500 029, Andhra Pradesh, India

 

 

December 1, 2004 3-6-20, Thiruwala Apartments, Himayatnagar, Hyderabad 500 029, | Administrative convenience

Andhra Pradesh, India to Deepthi Apartments, Flat No. 9-1-7/83, 84 S.P.
Road, Secunderabad 500 003 Andhra Pradesh, India

 

 

 

 

Main objects of our Company

The main objects contained in our MoA are as follows:

1.

To design, construct, own or otherwise acquire and to carry on the business of setting up, managing, administering and
running of diagnostic centres, hospitals and or mobile medical units, medical service centres, clinics, nursing homes,
intensive care units on ownership basis as well as on franchise arrangements.

To carry on business, manufacture, buy, sell, import, export and generally deal in all types of surgical, medical,
pharmaceutical, scientific equipment and instruments, appliances, accessories and diagnostic reagent kits, diagnostic
equipment, aids and accessories, health care aids, health care products and instruments, chemicals, pharmaceuticals,
drugs and intermediates and bio-chemicals and software products for diagnostic and health care centers and to publish
journals, books for diagnostic and health centers.

To setup facilities for carrying medical research and to educate and train radiologists, radiographers, CT technicians,
lab technicians, lab assistants, medical students, nurses, mid-wives and other technical services as well as administrative

staff.

To conduct all kinds of research and development work required for promotion and running of diagnostic centers,
hospitals, dispensaries, maternity homes, health centers, clinics and to carry on the business of consultancy relating to
them.

To carry on business of acting as advisers and consultants on all matters and problems relating to hospitals, health
sanitarium, clinics, health resorts and to promote health care.

The main objects as contained in our MoA enable our Company to carry on the business presently being carried out and
proposed to be carried out by it.

Amendments to the MoA.

Set out below are the amendments to our MoA in the last 10 years:

131
 

Date of Particulars
Shareholders’
resolution/
Effective date
March 8, 2016# Clause V of the MoA was amended to reflect the increase in authorised share capital from 225,000,000, divided into
2,500,000 Equity Shares of 210 each to 245,000,000, divided into 4,500,000 Equity Shares of 210 each to
%80,500,000, divided into 8,050,000 Equity Shares of 210 each.
November 19, | Clause V of the MoA was amended to reflect the reclassification of the authorised share capital from %80,500,000

 

 

 

2016 divided into 8,050,000 Equity Shares of 710 each to 280,500,000 comprised of 6,600,000 Equity Shares of 210 each
and 1,450,000 0.001% (Class A CCPS) of 210 each.
March 2, 2017 Clause V of the MoA was amended to reflect the increase and reclassification of the authorised share capital from

%80,500,000 comprising of 6,600,000 Equity Shares of 210 each and 1,450,000 0.001% CCPS of 210 each to
%120,500,000 comprising of 6,631,868 Equity Shares of 210 each, 1,425,000 0.001% CCPS (Series A CCPS) of 210.
each, and 12,000 0.001% CCPS (Series B CCPS) of 33,327.61 each.

April 10, 2019 Clause V of the Memorandum of Association was amended to reflect the consolidation of authorised share capital
of 120,500,000, comprised of 6,631,868 Equity Shares of 210 each, 14,25,000 0.001% (Class A CCPS) of 210 each
and 12,000 0.001% (Class B CCPS) of 23,327.61 each to % 120,500,000 divided into 12,050,000 Equity Shares of
210 each.

March 22, 2021 Clause V of the MoA was amended to reflect the following:

 

 

1. Sub-division of face value of equity shares from 210 each to %1 each.

2. Clause V of the MoA was amended to reflect the revised authorized share capital of our Company to
2120,500,000 divided into 120,500,000 equity shares of @1 each.

3. Clause I of the MoA was amended to reflect the change in name of our Company from Vijaya Diagnostics
Centre Private Limited to Vijaya Diagnostics Centre Limited due to the conversion of our Company from a
private limited company to a public limited company.

#In terms of the scheme of amalgamation between Vijaya Diagnostic Private Limited, Bhadrakali Medical Center Private Limited, Vijaya Diagnostic Centre

(Mancherial) Private Limited and our Company (the "Scheme"), the authorised share capital of Vijaya Diagnostic Private Limited, Bhadrakali Medical Center

Private Limited, Vijaya Diagnostic Centre (Mancherial) Private Limited prior to the Scheme was merged with the authorised share capital of our Company

on the effective date (March 8, 2016) of the Scheme.

 

 

 

 

Major events and milestones of our Company

 

 

 

 

 

 

Calendar Year Event
2021 First independent diagnostic centre in the State of Telangana to get Revolution ACT 50 slice CT from Wipro GE
Healthcare Private Limited.
2016 Investment by Karakoram Limited and Kedaara Capital Alternative Investment Fund - Kedaara Capital AIF 1.
2014 Acquisition of majority shareholding in "Medinova Diagnostic Services Limited”.
2008 First independent diagnostic centre in South India to get PET CT from Wipro GE Healthcare Private Limited.
2005 Business was transferred from proprietorship to the company.

 

Awards, accreditations and recognitions received by our Company

 

Calendar Year Awards
2021 © Our Company has received the ‘Award of Excellence” as the leading Imaging Centre (Multiple City) at the Radiology
and Imaging Excellence Awards, 2021

 

© Our Company was awarded the Award of Excellence for leading from the front during the pandemic under the Leading
Diagnostic Chain of the Year by Elets Technomedia Private Limited;

© Our centre at Kurnool received scope of accreditation from National Accreditation Board for Hospitals and Healthcare
Providers (“NABH”); and

© Our centre at Karimnagar received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by National Accreditation Board for Testing and Calibration
Laboratories (“NABL”)

© Our Company received the certificate of recognition from the Economic Times as one of the Best Healthcare Brands -
2021

2020 © Our Company was awarded the Most Trusted and Best Quality Diagnostic Services in India — 2020 at the COVID

Warriors Awards, 2020 by Topgallant Media;

 

© Our centre at Himayatnagar received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by NABL;

 

 

 

 

132
 

Calendar Year Awards
© Our centre at Sarojini Devi Road received scope of accreditation from NABH;

 

Our centre at Dilshuknagar received the ISO 15189:2012 by NABL;
Our centre at Habsiguda received the ISO 15189:2012 by NABL;

© Our centre at Nandyal received Certificate for fulfilment to the requirement of NABL 128 (Quality Assurance Scheme
for Basic Composite Medical Laboratories — Entry Level); and

© Our centre at Nellore received Certificate for fulfilment to the requirement of NABL 128 (Quality Assurance Scheme
for Basic Composite Medical Laboratories — Entry Level).

2019 © Our Company was awarded the Best Diagnostic Centre of the Year, India — 2019 by the Times Healthcare Achievers,

The Times of India;

 

© Our Company was awarded the Best Diagnostic Service Provider of the Year — 2019 at the Six Sigma Healthcare
Excellence Awards, 2019;

* Our Promoter, Dr. S. Surendranath Reddy was awarded the Healthcare Entrepreneur of the year by the Six Sigma
Healthcare Excellence Awards, 2019;

© Our Company was awarded Most Trusted Diagnostic Centre of the year, India ~ 2019 at the Indo Arab Leaders Summit
Awards, 2019, Dubai;

© Our Company was recognised and honoured to be under 10 Most Trusted Brands of the Year 2019 by the Business
Sight Magazine;

© Our centre at Kukatpally received scope of accreditation from NABH;

« Our centre at Hanamkonda received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by NABL;

* Our centre at Kurnool received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by NABL; and

© Our centre at Visakhapatnam received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by NABL.
2018 © Our Company was awarded the Healthcare Leadership Award at the Telangana Healthcare Leadership Award 2018;

 

© Our Company received the certificate of excellence and “brand of the year” award in the diagnostic services category
by the CEO Magazine;

© Our Company was awarded the Fastest Growing Brand (Pride of the Nation) 2018-2019 by United Research Services;

© Our centre at Himayatnagar received the ISO 9001:2015 certification to provide medical laboratory and diagnostic
services in clinical pathology, haematology, biochemistry, radiology and imaging, nuclear medicine, microbiology,
serology and immunodiagnostics, histo and cytopathology, molecular diagnostics, cytogenetics, cardiology, neurology,
pulmonology and immunohistochemistry by Bureau Veritas Certification Holding SAS -UK Branch;

© Our centre at Gurgaon received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and
competence” for its facilities in the field of medical testing by NABL; and

© Ourcentre at Kolkata received the ISO 15189:2012 “Medical Laboratories — Requirements for quality and competence”
for its facilities in the field of medical testing by NABL.

2012 Our Company was recognised as one of the Best Imaging Centres in Hyderabad the Week- Hansa Research national

survey 2012.

 

 

 

 

 

Time and cost over-runs
There have been no significant time and cost over-runs in the development, implementation of any of our plants or facilities.
Defaults or re-scheduling of borrowings

One of our Subsidiaries, MDSL has, in the past, defaulted on certain equipment loans availed from its lenders. Due to these
133
defaults, MDSL paid 20.07 million in delay charges and interest payment on delay charges to the lender. Further, Medinova
Millennium MRI Services LLP, one of our Subsidiaries, has delayed the payment of instalments of its equipment loans in fiscals
2017, 2018 and 2019 and as a result paid delay charges and interest payment on delay charges of 20.51 million to the lender.
For further details see “Risk Factors - We depend on third-parties to provide us our testing equipment and reagents, and any
failure to continue to do so or recall of existing testing equipment and reagents could adversely affect our business, results of
operations and financial condition” on page 25, there have been no defaults or re-scheduling/ re-structuring in relation to
borrowings availed by our Company from any financial institutions or banks.

Significant financial and strategic partners
As of the date of this Prospectus, our Company does not have any significant financial or strategic partners.
Launch of key products or services, entry into new geographies or exit from existing markets

For details of key products or services launched by our Company, entry into new geographies or exit from existing markets,
see “Our Business” on page 111. For details of our acquisitions and divestments see “- Details regarding material acquisitions
or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Slump
Sale Agreement dated November 6, 2019 amongst our Company, VDC Diagnostics (Karnataka) LLP and L7H Life Resources
Pvt Ltd” on page 134.

Strikes and Lock-outs

We have not experienced any material strikes or lock-outs in respect of our operations.
Common Pursuits

There are common pursuits between our Company and our Subsidiaries. For details, see “Our Business” and “Risk Factors” on
pages 111 and 21. We shall adopt necessary procedures and practices as permitted by law to address any conflict situations, as
and when they may arise. For further details of related business transactions and their significance on the financial performance
of our Company, see “Financial Information” on page 162.

Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any
revaluation of assets, in the last 10 years

Except as disclosed below, our Company has not divested / acquired any business/ undertakings, and has not undertaken any
mergers, amalgamations or any revaluation of assets, in the last 10 years.

Amalgamation of Vijaya Diagnostic Private Limited, Bhadrakali Medical Center Private Limited, Vijaya Diagnostic Centre
(Mancherial) Private Limited (collectively the “Transferor Companies”) with our Company pursuant to the order of the
High Court for the State of Telangana and Andhra Pradesh (“High Court”) dated January 6, 2016

Our Company and its erstwhile subsidiaries namely, Vijaya Diagnostic Private Limited, Bhadrakali Medical Center Private
Limited, Vijaya Diagnostic Centre (Mancherial) Private Limited had filed a petition to amalgamate themselves with our
Company, under sections 391 and 394 of the Companies Act, 1956 (“Amalgamation Scheme”). The Transferor Companies
was amalgamated with our Company pursuant to the order of the High Court dated January 6, 2016. The Scheme of
Arrangement became effective from the appointed date i.e. on April 1, 2015 but became operative from the effective date i.e.
March 8, 2016. Upon effectiveness of the Scheme of Amalgamation, the Transferor Companies were dissolved without
winding-up with effect from the appointed date. Further, all suits, actions, claims and legal proceedings by or against the
Company pending and/or arising on or before the effective date were continued and/or enforced by the Transferor Companies.
The Amalgamation Scheme did not involve a reorganization of the share capital of the Transferor Companies and the share
capital of Transferor Companies was merged with our Company. The shareholders of each of the Transferor Companies
surrendered their share certificate for cancellation and new equity shares of our Company were issued and allotted to the eligible
shareholders of the Transferor Companies. As required under the terms of the Amalgamation Scheme, the entire undertaking
of the Transferor Companies including, inter alia, all property, rights and powers, debt, licences, approvals, liabilities and
duties, permanent staff, workmen and employees, was transferred from the Transferor Companies to our Company in manner
prescribed under the Amalgamation Scheme. The amalgamation of our Company with Transferor Companies was to ensure
synergy of operations for both the companies and to ensure integration of business facilities and infrastructure under one single
unit.

Slump Sale Agreement dated November 6, 2019 amongst our Company, VDC Diagnostics (Karnataka) LLP (“Seller”) and
L7H Life Resources Pvt Ltd (“Purchaser”) (“Slump Sale Agreement”)

134
Pursuant to the Slump Sale Agreement, Purchaser acquired the Seller which was engaged in the business of healthcare and
diagnostic services, as a whole and as a going concern on a slump sale basis together with all (i) working assets, employees,
rights, title, licenses, other business related assets and interest of the Seller in, and to the healthcare and diagnostic services
business in the manner prescribed in the Slump Sale Agreement.; and (ii) benefits, rights and obligations attached to such
business, on November 30, 2019. In consideration for the healthcare and diagnostic services business being transferred by the
Seller to the Purchaser, the Purchaser transferred a lump sum consideration of 762.03 million to the Seller. The Purchaser shall
not be liable for any losses, claims, third party claims, penalties, damages and liabilities caused by the Seller. Further, the terms
of the agreement for a non-compete and non-solicitation clause for a period of three year from the completion date, the Seller
shall participate in any business or render any services to a competitor.

Share purchase agreement dated March 27, 2014 amongst M/s. Standard Medical and Pharmaceuticals Limited (“Seller”),
our Company, and Medinova Diagnostic Services Limited ((MDSL”) (“MDSL SPA”)

Pursuant to the MDSL SPA, our Company has agreed to acquire 2,750,220 equity shares of face value of 210 of MDSL held
by Seller being 29.01% of the total paid up and issued capital of MDSL. Our Company paid an amount of 25 per equity shares
aggregating to 713.75 million. The subsequent acquisition of 3,452,000 equity shares in MDSL was through an open offer
process as prescribed under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011 and subsequent amendments thereto. As on the date of this Prospectus, our Company has acquired and holds
6,202,220 equity shares of MDSL, constituting to 62.14% of the paid-up share capital of MDSL.

Holding Company

As of the date of this Prospectus, our Company does not have a holding company.

Our Subsidiaries

As of the date of this Prospectus, our Company has five Subsidiaries.

1. Doctorslab Medical Services Private Limited
Corporate Information
Doctorslab Medical Services Private Limited was incorporated on January 24, 2006 as a private limited company under
Companies Act, 1956. Its corporate identification number is U85120TG2006PTC081715. A fresh certificate of
incorporation was granted on July 6, 2012 pursuant to change in state of registered office from Tamil Nadu to Andhra

Pradesh. It has its registered office situated at # 7-1-58, Amrutha Business Complex, Ameerpet, Hyderabad 500 016,
Telangana, India.

Doctorslab Medical Services Private Limited is primarily engaged in the business of, inter alia. establishing, promoting
and maintenance of one or more diagnostics centres, dispensaries, pharmacies, clinics, laboratories, health clubs, health
centres, hospitals to provide a comprehensive health care for the society in all the branches of medical sciences by all
available means.

Capital Structure

The authorised share capital of Doctorslab Medical Services Private Limited is 1,000,000 divided into 100,000 equity
shares of 210 each and the paid-up share capital of Doctorslab Medical Services Private Limited is 100,000 divided into
10,000 shares of 710 each.

Shareholding

The shareholding pattern of Doctorslab Medical Services Private Limited is as follows:

 

 

 

 

Name of the Shareholder Number of shares held Percentage of the total shareholding (%)
Vijaya Diagnostic Centre Limited 9,998 99.99
(Parent company)

Dr. S. Surendranath Reddy 2. 0.01
(Nominee shareholder)
Total 10,000 100

 

 

 

 

 

2. Medinova Diagnostic Services Limited

135
Corporate Information

Medinova Diagnostic Services Limited was incorporated on March 11, 1993, as a public limited company under the
Companies Act, 1956. Further, it received the certificate for commencement of business on March 26, 1993 from the
Registrar of Companies, Hyderabad. It is listed on BSE. Its corporate identification number is L85110TG1993PLC015481.
It has its registered office situated at # 7-1-58/A/FF8, Flat No.8 Amrutha Business Complex, Ameerpet Hyderabad 500
016, Telangana India.

Medinova Diagnostic Services Limited is primarily engaged in the business of setting up, managing, administering and
running of diagnostic centres, on ownership basis as well as under franchise arrangement.

Capital Structure

The authorised share capital of Medinova Diagnostic Services Limited is 110,000,000 divided into 11,000,000 shares of
210 each and the paid-up share capital of Medinova Diagnostic Services Limited is 99,568,000 divided into 9,956,800
shares of 210 each.

Shareholding

The shareholding pattern of Medinova Diagnostic Services Limited as of June 30, 2021 is as follows:

 

 

 

 

Category (1) Category of the Shareholder Number of Number of Percentage of the total
shareholders | shares held shareholding (%)
(A) Promoter and Promoter Group* 1 6,202,220 62.14
(B) Public 9,581 3,779,420 37.86
Total 9,582 9,981,640 100.00

 

 

 

 

 

 

 

*Vijaya Diagnostic Centre Limited forms part of the Promoter and Promoter Group

Share price information

The equity shares of Medinova Diagnostic Services Limited are listed on BSE. The following table provides details of the
highest and lowest price on BSE during the preceding six months.

 

 

 

 

 

 

 

 

 

 

 

 

 

Month BSE @),

High Low

July 2021 48.35, 46.00

June 2021 49.45, 32.50

May 2021 37.65 28.30

April 2021 36.90 21,55

March 2021 25.40 20.25

February 2021 25.55 17.65
Source: BSE

Medinova Millennium MRI Services, LLP
Corporate Information

Medinova Millennium MRI Services, LLP was incorporated on November 21, 2014, as a limited liability partnership under
the Limited Liability Partnership Act, 2008. Its LLPIN number is AAC-9556. It has its registered office at 1, Sarat
Chatterjee Avenue, Ravindrasarobar Stadium Kolkata 700 029 West Bengal, India.

Medinova Millennium MRI Services, LLP is primarily engaged in the business of providing MRI services.

The upper limit of contribution is 250,000,000. The capital contribution of the Medinova Millennium MRI Services, LLP
is 223,027,000. The following is the partner profit sharing ratio indicated below:

 

 

 

 

 

 

 

 

Sr.No Name of Partners Capital Contribution @® Profit sharing (%)

1. Medinova Diagnostic Services Limited 12,682,000 55.07

2. Pronab Dasgupta 7,636,000 33.14

3: Arab Dasgupta 2,709,000 11.79
Total 23,027,000 100.00

 

 

 

Namrata Diagnostic Centre Private Limited

136
Corporate Information

Namrata Diagnostic Centre Private Limited was incorporated on October 31, 2007 as a private limited company under the
Companies Act, 1956. Its corporate identification number is U85100TG2007PTC081716. A fresh certificate of
incorporation was granted on July 6, 2012 pursuant to change in state of registered office from Tamil Nadu to Andhra
Pradesh. It has its registered office at # 7-1-58, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016, Telangana,
India.

Namrata Diagnostic Centre Private Limited is primarily engaged in the business of, inter alia, establishing, promoting and
maintenance of one or more diagnostics centres, dispensaries, pharmacies, clinics, laboratories, health clubs, health centres,
hospitals to provide a comprehensive health care for the society in all the branches of medical sciences by all available
means.

Capital Structure

The authorised share capital of Namrata Diagnostic Centre Private Limited is 500,000 divided into 50,000 shares of 210
each and the paid-up share capital of Namrata Diagnostic Centre Private Limited is 100,000 divided into 10,000 shares of
210 each.

Shareholding

The shareholding pattern of Namrata Diagnostic Centre Private Limited is as follows:

 

 

 

 

 

 

Name of the Shareholder Number of shares held Percentage of the total shareholding (%)
Vijaya Diagnostic Centre Limited 9,999 99.99
(Parent company)

Dr. S. Surendranath Reddy (Nominee 1 0.01
shareholder)
Total 10,000 100

 

 

 

VDC Diagnostics (Karnataka) LLP

Corporate Information

VDC Diagnostics (Karnataka) LLP was incorporated on October 3, 2013, as a limited liability partnership under the
Limited Liability Partnership Act, 2008. Its LLPIN number is AAB-7930. It has its registered office at 2nd floor. CPWD
Building, Kendriya Sadan, Sultan Bazaar, Koti, Hyderabad 500 195, Andhra Pradesh.

VDC Diagnostics (Karnataka) LLP is engaged in the business of providing comprehensive range of diagnostic services
spanning pathological investigations, radiology and imaging, nuclear medicine, conventional, specialized lab services and
diagnostic cardiology. VDC Diagnostics (Karnataka) LLP has no business operations as on date of filing of this Prospectus.

The upper limit of contribution is %200,000,000. The capital contribution of the VDC Diagnostics (Karnataka) LLP is
%195,000,000. The following is the partner profit sharing ratio indicated below:

 

 

 

 

 

 

 

Sr.No Name of Partners Capital Contribution @ Profit sharing (%)
As Vijaya Diagnostic Centre Private Limited 194,980,500 99.55
2. Sunil Chandra Kondapally 19,500 0.01

Total 195,000,000 100.00

 

 

 

Accumulated profits or losses of Subsidiaries

As on the date of this Prospectus, there are no accumulated profits or losses of any of our Subsidiaries that have not been

accounted for by our Company.

Joint Venture

As of the date of this Prospectus, our Company has no joint ventures.

Associate

As of the date of this Prospectus, our Company has no associate company.

1st
Shareholders’ agreements and other agreements
Key terms of subsisting shareholders’ agreements

Investment Agreement dated November 23, 2016 amongst our Company, Dr. S. Surendranath Reddy, Sunil Chandra
Kondapally, Sura Suprita Reddy, S. Geeta Reddy, B Vishnu Priya, (“Major Shareholders”) Karakoram Limited and Kedaara
Capital Alternative Investment Fund — Kedaara Capital AIF 1 (“Kedaara Capital”) (Collectively the “Investors”)
(“Investment Agreement”) as amended by the waiver cum amendment agreement dated May 27, 2021 (the "WCA")

Pursuant to the Investment Agreement, Karakoram Limited and Kedaara Capital acquired 1,267,097 equity shares and 47,375
equity shares, respectively, of our Company for an aggregate consideration of 22,400 million in the first tranche and 3,62,083
equity shares of our Company for an aggregate consideration of 21,429.99 million was acquired by the Investors in the second
tranche from the Major Shareholders. Our Company agreed to issue Series B CCPS for the Series B CCPS consideration to the
Investors as defined in the Investment Agreement. Accordingly, our Company issued 3,005 Series B CCPS for an aggregate
consideration of %9.99 million to the Investors on March 17, 2017. The conversion ratio for 3,005 Series B CCPS was in the
ratio of one equity shares for every one existing CCPS. Subsequently, 3,005 Series B CCPS was converted into 2,897 equity
shares which were allotted to Karakoram Limited and 108 equity shares which were allotted to Kedaara Capital Alternative
Investment Fund — Kedaara Capital AIF 1 on April 10, 2019. As on the date of this Prospectus, the Investors collectively hold
40% of the paid-up share capital of our Company constituting 40,786,357 Equity Shares.

Pursuant to the terms of the Investment Agreement, the Investors are entitled to certain rights including (i) nomination of
directors on the Board and committees; (ii) voting rights on certain reserved matters (iii) right to delivery of periodic information
of our Company, and (iv) anti-dilution rights and certain pre-emptive rights including ROFR and tag-along rights.

Our Company, Major Shareholders and Investors have entered into the WCA. Pursuant to the WCA, the Investors have, inter
alia, waived their right to nominate an observer on the Board and committees of the Company, and their pre-emptive and anti-
dilution rights. The WCA will remain in effect until the (i) expiry of 12 months from the date of receipt of final observations
of SEBI or (ii) the date on which our Company and Selling Shareholders jointly decide not to undertake a qualified listing
which is as per the Investment Agreement means any initial public offering of the Equity Shares of our Company, or any listing
of our securities in any other manner as approved by the Investors in a manner contemplated by the Investment Agreement (the
“Termination Events”). In addition, post listing and trading of the Equity Shares of the Company, the Investors shall be entitled
to jointly nominate 1 (one) Director on our Board, for so long as the Investors continue to collectively hold at least 5% (five
percent) of the share capital of our Company on a fully diluted basis subject to the approval by shareholders by special resolution
post listing and trading of the Equity Shares of our Company. In the event that the Offer is not completed on or prior to the
Termination Events, the WCA shall stand immediately and automatically terminated without any further action by any party.
Further, the WCA provides that the Investment Agreement shall automatically terminate on the listing and trading of the Equity
Shares pursuant to the completion of the Offer.

Key terms of other subsisting material agreements

Our Company has not entered into any other material agreements, including with strategic partners or financial partners, other
than in the ordinary course of business.

Agreements with Key Managerial Personnel, Directors, Promoter or any other employee

As on the date of this Prospectus, there are no agreements entered into by a Key Managerial Personnel or Director or any other
employee of our Company, either by themselves or on behalf of any other person, with any shareholder or any other third party
with regard to compensation or profit sharing in connection with dealings in the securities of our Company.

Details of guarantees given to third parties by the Promoter Selling Shareholder

As of the date of this Prospectus, the Promoter Selling Shareholder has not provided any guarantees to third parties.

138
OUR MANAGEMENT

Board of Directors

In terms of the Companies Act and our Articles of Association, our Company is required to have not more than eight Directors.
As on the date of this Prospectus, our Board comprises of eight Directors including two executive Directors, six non-executive
Directors of which one is a nominee Director and four are independent Directors. Our Board comprises of one woman Director.

The following table sets forth details regarding our Board as of the date of this Prospectus:

 

 

 

 

 

S. | Name, designation, address, occupation, date of Age Directorships in other companies
No. birth, nationality, period and term and DIN (years)
1. | Dr. S. Surendranath Reddy 72 *  Doctorslab Medical Services Private Limited;
Designation: Executive Chairman © Kshetra Agritech Private Limited;
Address: H. No. 8-10-178/3/B, Nagarjuna Hills, © — Medinova Diagnostics Services Limited;
Punjagutta, Hyderabad 500 082, Telangana, India
* Namrata Diagnostic Centre Private Limited;
Occupation: Service
* Summit Nutraceuticals Private Limited;
Date of birth: October 29, 1948*
oo. - *  Trikona Pharmaceuticals Private Limited; and
Nationality: Indian
Vijaya Hospitals Private Limited
Period & Term: Re-appointed for a period of five NESTE SCSI SS ave eas
years with effect from October 1, 2019.
DIN: 00108599
2. | Sunil Chandra Kondapally 46 *  Medinova Diagnostics Services Limited;
Designation: Executive Director © Kshetra Agritech Private Limited;
Address: H. No. 8-12-293/82/A/603, road no. 32 and © Summit Nutraceuticals Private Limited; and
33, Jubilee Hills, Hyderabad 500 033, Telangana, India
*  Trikona Pharmaceuticals Private Limited
Occupation: Service
Date of birth: July 20, 1975
Nationality: Indian
Period & Term: Re-appointed for a period of five
years with effect from October 1, 2019.
DIN: 01409332
3. | S Geeta Reddy 62 *  Doctorslab Medical Services Private Limited;
Designation: Non-Executive Director * IFFCO Kisan SEZ Limited;
Address: 8-2-178/10/3/B Nagarjuna Hills, Panjagutta, © Namrata Diagnostic Centre Private Limited; and
Hyderabad, 500 082, Telangana, India
* Vijaya Hospitals Private Limited
Occupation: Business
Date of birth: January 24, 1959
Nationality: Indian
Period & Term: Appointed with effect from
November 21, 2019. Liable to retire by rotation.
DIN: 01073233
4. | Nishant Sharma 43 *  Aavas Financiers Limited;

 

 

 

 

 

 

139
 

 

 

 

 

 

 

Designation: Non-executive, Independent Director
Address: Flat No. 208, Aparna Chandradeep
Apartments Road No. 7, Near E Seva Center, Banjara
Hills, Hyderabad 500 034, Telangana, India

Occupation: Doctor

Date of birth: November 8, 1968

 

 

S. | Name, designation, address, occupation, date of Age Directorships in other companies
No. birth, nationality, period and term and DIN (years)
Designation: Non-executive, Nominee Director* * — Aavas Finserv Limited;
Address: Tower 2, APT 102, Planet Godrej Simplex * Ami Lifesciences Private Limited;
Mills, Mahalaxmi, Mumbai 400 011, India
* Veritas Finance Private Limited;
Occupation: Professional
* Vishal E-Commerce Private Limited; and
Date of birth: June 19, 1978
* Vishal Mega Mart Private Limited.
Nationality: Indian
Period & Term: Liable to retire by rotation
DIN: 03117012
5. | Dr. D Nageshwar Reddy 65 * Asian Institute of Gastroenterology Private
Limited;
Designation: Non-executive, Independent Director
* Asian Institute of Nephrology and Urology Private
Address: A-27 Journalist Colony, Jubilee Hills, Limited;
Shaikpet Jubilee Hill, Hyderabad, Andhra Pradesh 500
033 * Foundation of CFHE; and
Occupation: Doctor © Prolifics Corporation Private Limited
Date of birth: March 18, 1956
Nationality: Indian
Period & Term: Appointed with effect from May 26,
2021 for a period of five years. Not liable to retire by
rotation.
DIN: 00324725
6. | Shekhar Prasad Singh 63 Nil
Designation: Non-executive, Independent Director
Address: 8-2-293/82/PN/176, Road No. 72 Prashasan
Nagar, Jubilee Hills, Hyderabad, Andhra Pradesh 500
033
Occupation: Chief Secretary to Government of
Telangana, retired.
Date of birth: January 7, 1958
Nationality: Indian
Period & Term: Appointed with effect from May 26,
2021 for a period of five years. Not liable to retire by
rotation.
DIN: 00969209
7. | Manjula Anagani 52 Nil

 

140

 
 

S. | Name, designation, address, occupation, date of Age Directorships in other companies
No. birth, nationality, period and term and DIN (years)

 

Nationality: Indian
Period & Term: Appointed for a period of five years
with effect from August 22, 2021 to August 21, 2026.
Not liable to retire by rotation.

DIN: 03501757

 

8. | Satyanaryana Murthy Chavali 54 * Balaji Amines Limited;
Designation: Non-executive, Independent Director  — Gland Chemicals Private Limited;
Address: 2-293/82/A/408, Plot No.408, Road No-22A, © — Gland Pharma Limited; and
Jubilee Hills, Shaikpet, Hyderabad 500 033,
Telangana, India * — Satyarx Pharma Innovations Private Limited

Occupation: Business

Date of birth: March 12, 1967

Nationality: Indian

Period & Term: Appointed with effect from May 26,

2021 for a period of five years. Not liable to retire by
rotation.

 

 

 

 

 

DIN: 00142138
“Nishant Sharma is a nominee of Karakoram Limited, pursuant to the Investment Agreement

#The date of birth on the passport and the driving license is given as July 15, 1948. However, the Ministry of Corporate Affairs records his date of birth as
October 29, 1948.

 

Arrangement or understanding with major shareholders, customers, suppliers or others

Nishant Sharma has been appointed on the Board of our Company pursuant to the Investment Agreement. The Major
Shareholders can nominate three directors pursuant to the Investment Agreement. There is no other arrangement or
understanding with major Shareholders, customers, suppliers or others, pursuant to which any of our Directors were appointed
on our Board. Further, none of our Key Managerial Personnel have been appointed pursuant to any arrangement or
understanding with major shareholders, customers, suppliers or others.

Relationship between our Directors

Dr. S. Surendranath Reddy is the husband of S Geeta Reddy. Dr. S. Surendranath Reddy and S Geeta Reddy are the biological
parents of Sunil Chandra Kondapally. Sunil Chandra Kondapally was adopted by Kondapally Brahmananda Reddy pursuant to
an adoption deed dated January 20, 1980. For further details see “Our Promoter and Promoter Group” on page 155.

Except as disclosed above, none of our Directors are related to each other.
Brief Biographies of Directors

Dr. S. Surendranath Reddy is the executive Chairman of our Company. He holds a bachelor’s degree in medicine from Shri
Venkatesvara University and a provisional degree of Doctor of Medicine in Radiology from Osmania Medical College,
Hyderabad. He has over 19 years of experience with our Company. He is a life member of the Indian Radiological and Imaging
Association. He has also received an award from Abbott for leadership in in-vitro diagnostics and an award for the ‘Healthcare
Entrepreneur of the year” in 2019 from Six Sigma Star Healthcare, New Delhi.

Sunil Chandra Kondapally is the Executive Director of our Company. He has been associated with our Company since
incorporation. He holds a bachelor’s degree in science in electrical engineering from Florida State University. He has over 17
years of experience in the field of pharmaceutical industry. He founded a pharmaceutical services company Trikona
Pharmaceuticals Private Limited in 2016 and QPS Bioserve India Private Limited in 2004 and, which focuses on the
development of innovative pharmachemical products. He has worked in operations, quality accreditation, finance, marketing
and network expansion departments of our Company since its incorporation.

141
S Geeta Reddy is a Non-Executive Director of our Company. She holds a bachelor’s degree in law from Osmania
University.She is enrolled as an Advocate with the Andhra Pradesh High Court in 1986. She is on the board of directors of
various companies such as, Sura Agritech Private Limited, Iffco Kisan SEZ Limited, Namrata Diagnostic Centre Private
Limited, Vijaya Hospitals Private Limited and Doctorslab Medical Services Private Limited.

Nishant Sharma is the Non-Executive Director - Nominee Director of our Company. He holds a master’s degree in bio-
chemical engineering and bio-technology from the Indian Institute of Technology Delhi and a master’s degree in business
administration from the Harvard University. He has over 18 years of experience in across various fields. He has worked at Bill
& Melinda Gates Foundation, General Atlantic and McKinsey & Company before joining Kedaara Capital Advisors LLP where
he is currently the chief investment officer and managing partner.

Shekhar Prasad Singh is the Non-Executive Director — Independent Director of our Company. He is a retired IAS officer of
1983 batch. Previously, he acted as Chief Secretary to Government of Telangana.

Dr. D Nageshwar Reddy is the Non-Executive Director — Independent Director of our Company. He holds a degree from
University of Madras in general medicine and a D.M in gastroenterology from Postgraduate Institute of Medical Education and
Research, Chandigarh. He is currently the Chairman of Asian Institute of Gastroenterology, Hyderabad. He received Padma
Shri and Padma Bhushan Awards from Government of India.

Manjula Anagani is the Non-Executive — Independent Director of our Company. She holds a Doctor of Medicine in Obstetrics
and Gynaecology from N.T.R. University of Health Sciences. She is currently working as a clinical director and head of
department at the Centre of Women and Child Care at CARE Hospital, Banjara and Hi-Tech City Unit. She has received the
fourth highest honour for a civilian in India, the Padma Shri.

Satyanarayana Murthy Chavali is an Non-Executive— Independent Director of our Company. He holds a bachelor’s degree
in technology from Indian Institute of Technology, Madras and a post graduate diploma in management from Indian Institute
of Management, Bangalore. He previously worked as a chief executive officer of Aurigene Discovery Technologies Limited
and has previously worked at Dr. Reddy’s Laboratories Limited.

Details regarding directorships of our Directors in listed companies

None of our Directors is or was, during the last five years preceding the date of this Prospectus, a director of any listed company
whose shares have been or were suspended from being traded on BSE or NSE during their tenure as a director in such company.

None of our Directors is or was a director of any listed company which has been or was delisted from any stock exchange,
during their tenure as a director in such company.

Confirmations

No consideration in cash or shares or otherwise has been paid or agreed to be paid to any of our Directors or to the firms or
companies in which they are interested by any person either to induce them to become or to help them qualify as a Director, or
otherwise for services rendered by them or by the firm or company in which they are interested, in connection with the
promotion or formation of our Company.

Terms of appointment of Directors
1, Remuneration to executive Directors:

Dr. S. Surendranath Reddy is the Executive Chairman of our Company. Our Board and Shareholders in their
meetings held on July 25, 2019 and September 30, 2019, respectively approved the re-appointment of Dr. S.
Surendranath Reddy as the Executive Chairman with effect from October 1, 2019 for a period of five years. The
shareholders approved the appointment of Dr. S. Surendranath Reddy for his continuation as the Executive Chairman
after attaining the age of 70 years, pursuant to their meeting dated September 30, 2019. Further, our Board and our
Shareholders in their meetings held on May 27, 2021 approved the following remuneration for Dr. S. Surendranath
Reddy with effect from June 1, 2021, for the remaining period of his present term of appointment. The details of his
employment pursuant to the resolutions passed and the employment agreement dated December 5, 2016 are as stated
below:

 

Particulars Remuneration
Salary 220 million

 

 

 

 

 

During Financial Year 2021, Dr. S. Surendranath Reddy was paid a remuneration of 716.50 million by the Company.
142
Further, he has not been paid any remuneration in Financial Year 2021 by our Subsidiaries, including contingent or
deferred compensation for Financial Year 2021.

Sunil Chandra Kondapally. is an Executive Director of our Company. Our Board and Shareholders in their meetings
held on July 25, 2019 and September 30, 2019, respectively approved the re-appointment of Sunil Chandra Kondapally
as an Executive Director with effect from October 1, 2019 for a period of five years. Further, our Board and our
Shareholders in their meetings held on May 27, 2021 approved the following remuneration for Sunil Chandra
Kondapally with effect from June 1, 2021, The details of his employment pursuant to the resolutions passed and the
employment agreement dated December 5, 2016 are as stated below:

 

Particulars Remuneration
Salary 210 million

 

 

 

 

 

During Financial Year 2021, Sunil Chandra Kondapally was paid remuneration of 25.50 million by the Company.
Further, he has not been paid any remuneration in Financial Year 2021 by our Subsidiaries, including contingent or
deferred compensation for Financial Year 2021.

2. Remuneration to non-executive Directors:

Pursuant to the Board resolution dated May 26, 2021, each Non-Executive Independent Director (except for Manjula
Anagani) is entitled to receive an annual consolidated remuneration in the form of commission at 0.5% of the
consolidated net profit of the Company subject to a maximum of 21.20 million for each Financial Year. No sitting fees
were paid to our Non-Executive Directors in the Financial Year 2021. Pursuant to the circular resolution of the Board
dated August 22, 2021, Manjula Anagani is entitled to receive an annual consolidated remuneration in the form of
commission at 0.5% of the consolidated net profit of the Company subject to a maximum of 21.20 million per annum.
However, Manjula Anagani received 0.27 million in consultancy fees in fiscal 2021.

Our Non-Executive, Nominee Director is not entitled to be paid any sitting fees.
Shareholding of Directors in our Company

Except as disclosed below, as on the date of this Prospectus, none of our Directors hold any Equity Shares:

 

 

 

 

 

Name of Director Number of Equity Shares held

Dr. S. Surendranath Reddy 38,521,195.
Sunil Chandra Kondapally 9,106,933
S. Geeta Reddy 4,058,638

 

 

 

Our Articles of Association do not require our Directors to hold any qualification shares.
Shareholding of Directors in our Subsidiaries

Except as disclosed below, as on the date of this Prospectus, none of our Directors hold any equity shares in our Subsidiaries:

 

 

 

Name of the Director Name of Subsidiary ‘Number of equity shares | Percentage Shareholding (%)

Dr. S. Surendranath Reddy | Doctorslab Medical Services Private 2 0.02
Limited

Dr. S. Surendranath Reddy | Namrata Diagnostic Centre Private 1 0.01
Limited

 

 

 

 

 

 

Interest of Directors

All non-executive, Independent Directors may be deemed to be interested to the extent of remuneration payable to them for
attending meetings of our Board and committees thereof, and reimbursement of expenses available to them. All Executive
Directors may be deemed to be interested to the extent of remuneration and reimbursement of expenses payable to them as
stated in “Our Management — Terms of appointment of our Directors - Remuneration to executive directors” on page 142.
Except Dr. S. Surendranath Reddy, who is the Promoter of our Company and Sunil Chandra Kondapally and S Geeta Reddy,
who are a part of our Promoter Group of our Company, none of our Directors have any interest in the promotion of our
Company, except in the ordinary course of business. The Directors may also be regarded as interested in the Equity Shares held
by them or by their relatives, if any or to the extent that our Directors are associated with our Shareholders, or that may be
subscribed by or allotted to them or the companies, firms and trusts, in which they are interested as directors, members, partners,

143
trustees and promoter, pursuant to this Offer. All of the Directors may also be deemed to be interested to the extent of any
dividend payable to them and other distributions in respect of such Equity Shares.

Except as stated below, none of our directors have any interest in any property acquired or proposed to be acquired of our
Company.

Dr. S. Surendranath Reddy, Sunil Chandra Kondapally and S Geeta Reddy are lessors of the properties which have been taken
on lease by our Company to operate our diagnostic centres. These properties are located in Haryana, Andhra Pradesh and
Telangana. For further details see “Our Promoter and Promoter Group” and “Financial Statements” on page 155 and 162.

No loans have been availed by our Directors from our Company or Subsidiaries.

None of the beneficiaries of loans, advances and sundry debtors are related to the Directors of our Company.

None of our Directors are party to any bonus or profit sharing plan of our Company.

Changes in the Board in the last three years

 

Name

Date of Appointment/ Change/
Cessation

Reason

 

Manjula Anagani

August 23, 2021

Change in designation to Non-Executive — Independent Director

 

Manjula Anagani

‘August 22, 2021 (circular
resolution)

Appointment as an Additional Director

 

PS Narasimha

‘August 21, 2021

Resignation as Independent Director due to recommendation by
the Supreme Court Collegium to elevate P S Narasimha as a
judge of the Supreme Court of India

 

 

 

 

 

PS Narasimha May 26, 2021 Change in designation to Non-Executive — Independent Director
Satyanarayan Murthy Chavali May 26, 2021 Change in designation to Non-Executive — Independent Director
Dr. D Nageshwar Reddy May 26, 2021 Change in designation to Non-Executive — Independent Director
Shekhar Prasad Singh May 26, 2021 Change in designation to Non-Executive — Independent Director

 

 

 

 

 

PS Narasimha May 26, 2021 Appointed as an Additional Director
Satyanarayan Murthy Chavali May 26, 2021 Appointed as an Additional Director
Dr. D Nageshwar Reddy May 26, 2021 Appointed as an Additional Director
Shekhar Prasad Singh May 26, 2021 Appointed as an Additional Director
Aditya Vij May 26, 2021 Resigned as Non-Executive — Nominee Director

 

S Geeta Redd:

September 28, 2020

Change in designation to Director

 

S Geeta Reddy

November 21, 2019

Appointed as an Additional Director

 

 

Sura Suprita Reddy

 

October 31, 2019

 

Resigned as Managing Director

 

 

Borrowing Powers of Board

Pursuant to our Articles of Association, and pursuant to a resolution passed by the Shareholders of our Company on October
10, 2014 and in accordance with the provisions of the Companies Act and the rules made thereunder, our Board is authorised
to borrow such monies which together with the money already borrowed will or may exceed the aggregate of the paid up capital
of our Company and its free reserves, that is to say reserves not set apart for any specific purpose but, however the total amount
upto which monies may be borrowed by our Board and outstanding at any time shall not exceed the limit of 2,000 million.

Corporate Governance

The corporate governance provisions of the Listing Regulations will be applicable to us immediately upon the listing of the
Equity Shares on the stock exchanges, BSE and NSE. We are in compliance with the requirements of the applicable regulations,
including the Listing Regulations, the Companies Act and the SEBI ICDR Regulations, in respect of corporate governance
including constitution of the Board and committees thereof, as applicable. The corporate governance framework is based on an

effective independent Board, separation of the Board’s supervisory role from the executive management team and constitution
of the Board committees, as required under law.

Committees of the Board
Audit Committee

The members of the Audit Committee are:

144
3.

4.

Satyanarayana Murthy Chavali; Chairman
Shekhar Prasad Singh;
Dr. D Nageshwar Reddy;

Nishant Sharma.

The Audit Committee was constituted on May 26, 2021. The scope and function of the Audit Committee is in accordance with
Section 177 of the Companies Act, 2013 and the Listing Regulations and its terms of reference include the following:

1.

yt

Pesan gr

10.
11.
12.
13.
14.
15.

16.
17.

18.

19.
20.

21.
. Approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of

23.
24,

25.

Oversight of our Company’s financial reporting process and the disclosure of its financial information to ensure that the
financial statement is correct, sufficient and credible;

Recommendation for appointment, replacement, reappointment, remuneration and terms of appointment of auditors of our
Company;

Approval of payment to statutory auditors for any other services rendered by the statutory auditors;

Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the
board for approval, with particular reference to:

  

a) Matters required to be included in the director’s responsi
of the Companies Act, 2013;

b) Changes, if any, in accounting policies and practices and reasons for the same;

c) Major accounting entries involving estimates based on the exercise of judgment by management;

d) Significant adjustments made in the financial statements arising out of audit findings;

e) Compliance with listing and other legal requirements relating to financial statements;

f) Disclosure of any related party transactions; and

g) Qualifications and modified opinion(s) in the draft audit report.

lity statement to be included in the Board’s report, in terms

Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
Examination of the financial statement and auditor’s report thereon;

Monitoring the end use of funds raised through public offers and related matters;

Reviewing, with the management, the statement of uses/application of funds raised through an issue (public issue, rights
issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the issue
document/prospectus/notice and making appropriate recommendations to the Board to take up steps in this matter;
Reviewing and monitoring the auditor’s independence and performance, and effectiveness of audit process;

Approval or any subsequent modification of transactions of the Company with related parties;

Scrutiny of inter-corporate loans and investments;

Valuation of undertakings or assets of the Company, wherever it is necessary;

Evaluation of internal financial controls and risk management systems;

Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing
and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
Discussion with internal auditors of any significant findings and follow up there on;

Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud
or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
Discussion with statutory auditors, internal auditors, secretarial auditors and cost auditors before the audit commences,
about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;

To formulate, review and make recommendations to the Board to amend the Audit Committee charter from time to time
To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case
of non-payment of declared dividends) and creditors;

To review the functioning of the whistle blower mechanism;

the candidate;

Carrying out any other function as may be required / mandated as per the provisions of the Companies Act, 2013, Listing
Agreements and/or any other applicable laws;

Reviewing the utilization of loan and/or advances from investment by the holding company in the subsidiary exceeding
%100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments.
Considering and commenting on rationale, cost-benefits and impact of schemes involving merger, demerger,

145
amalgamation etc., on the Company and its shareholders.

The audit committee shall mandatorily review the following information:

(1) management discussion and analysis of financial condition and results of operations;
(2) statement of significant related party transactions (as defined by the Audit Committee), submitted by management;
(3) management letters / letters of internal control weaknesses issued by the statutory auditors;
(4) internal audit reports relating to internal control weaknesses; and
(5) the appointment, removal and terms of remuneration of the internal auditor shall be subject to review by the audit
committee.
statement of deviations as and when becomes applicable:
(a) quarterly statement of deviation(s) submitted to stock exchange(s) in terms of Regulation 32(1) of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015.
(b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in
terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

6

Nomination and Remuneration Committee
The members of the Nomination and Remuneration Committee are:

1. Satyanarayana Murthy Chavali; Chairman

2. Shekhar Prasad Singh;

3. Nishant Sharma.
The Nomination and Remuneration Committee was last reconstituted on May 26, 2021. The scope and function of the

Nomination and Remuneration Committee is in accordance with Section 178 of the Companies Act and the Listing Regulations.
The terms of reference of the Nomination and Remuneration Committee include:

1. Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend
to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other
employees;

The Nomination and Remuneration Committee, while formulating the above policy, should ensure that —

@ the level and composition of remuneration be reasonable and sufficient to attract, retain and motivate directors of
the quality required to run our Company successfully;
(ii) relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and

(iii) remuneration to directors, key managerial personnel and senior management involves a balance between fixed
and incentive pay reflecting short and long term performance objectives appropriate to the working of the
Company and its goals;

2. Formulating criteria for evaluation of performance of independent directors and the Board of Directors;

Devising a policy on diversity of board of directors;

4. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance
with the criteria laid down, and recommend to the Board of directors their appointment and removal;

5. Extending or continuing the term of appointment of the independent director, on the basis of the report of performance
evaluation of independent directors;

6. Recommending to the board, all remuneration, in whatever form, payable to senior management.

7. Administering, monitoring and formulating detailed terms and conditions of the ESOP Plan 2018 and ESOP Schemes 2018
including any amendments made thereto, and any other employee stock option plan that the Company adopts in the future

8. Carrying out any other function as is mandated by the Board from time to time and / or enforced/mandated by any statutory
notification, amendment or modification, as may be applicable; and

9. Performing such other functions as may be necessary or appropriate for the performance of its duties.

10. Framing suitable policies, procedures and systems to ensure that there is no violation of securities laws, as amended from
time to time, including:

oe

a. the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended; and

146,
b. the Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices Relating to the
Securities Market) Regulations, 2003, as amended, by the Company and its employees, as applicable.

Stakeholders’ Relationship Committee

The members of the Stakeholders’ Relationship Committee are:

1.

2.

3.

Dr. D Nageshwar Reddy; Chairman
Satyanarayana Murthy Chavali;

Sunil Chandra Kondapally.

The Stakeholders’ Relationship Committee was constituted by our Board at their meeting held on May 26, 2021. The scope and
function of the Stakeholders’ Relationship Committee is in accordance with Section 178 of the Companies Act and the Listing
Regulations. The terms of reference of the Stakeholders’ Relationship Committee are as follows:

ds

To resolve the grievances of the security holders of the Company including complaints related to transfer/transmission of
shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings
etc. and assisting with quarterly reporting of such complaints;

To review of measures taken for effective exercise of voting rights by shareholders;

To review of adherence to the service standards adopted by the Company in respect of various services being rendered by
the Registrar & Share Transfer Agent;

Giving effect to all transfer/transmission of shares and debentures, dematerialisation of shares and re-materialisation of
shares, split and issue of duplicate/consolidated share certificates, compliance with all the requirements related to shares,
debentures and other securities from time to time;

To review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends
and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company: and
Carrying out such other functions as may be specified by the Board from time to time or specified/provided under the
Companies Act or the Listing Regulations or by any other regulatory authority.

Corporate Social Responsibility Committee

The members of the Corporate Social Responsibility Committee are:

1.

2:

3,

4.

Shekhar Prasad Singh; Chairman
Dr. D Nageshwar Reddy;
Sunil Chandra Kondapally;

S Geeta Reddy.

The Corporate Social Responsibility Committee was constituted by our Board at their meeting held on May 26, 2021. The terms
of reference of the Corporate Social Responsibility Committee of our Company include the following:

Is

Formulation of a corporate social responsibility policy to the Board, indicating the activities to be undertaken by the
Company in areas or subject specified in the Companies Act, 2013. The activities should be within the list of permitted
activities specified in the Companies Act, 2013 and the rules thereunder;

Recommending the amount of expenditure to be incurred, amount to be at least 2% of the average net profit of the
Company in the three immediately preceding financial years or where the Company has not completed the period of three
financial years since its incorporation, during such immediately preceding financial years;

Instituting a transparent monitoring mechanism for implementation of the corporate social responsibility projects or
programs or activities undertaken by the Company;

Monitoring the corporate social responsibility policy from time to time and issuing necessary directions as required for
proper implementation and timely completion of corporate social responsibility programmes;

Identifying corporate social responsibility policy partners and corporate social responsibility policy programmes;
Identifying and appointing the corporate social responsibility team of the Company including corporate social
responsibility manager, wherever required; and

Performing such other duties and functions as the Board may require the corporate social responsibility committee to

147
undertake to promote the corporate social responsibility activities of the Company.

IPO Committee

The members of the IPO Committee are:

Is

2.

3,

Sunil Chandra Kondapally;
Satyanarayana Murthy Chavali; and

Nishant Sharma.

The IPO Committee was last constituted by our Board at their meeting held on May 27, 2021. The IPO Committee has been
authorized to approve and decide upon all activities in connection with the Offer, including, but not limited to, to approve the
Draft Red Herring Prospectus, this Prospectus and the Prospectus, to decide the terms and conditions of the Offer, to appoint
various intermediaries, negotiating and executing Offer related agreements and to submit applications and documents to relevant
statutory and other authorities from time to time.

The IPO Committee is also authorised to approve the following in connection to the initial public offering:

ds

9.

10.
11.

12.

To make applications, seek clarifications, obtain approvals and seek exemptions from, where necessary, the RBI, SEBI,
the relevant registrar of companies and any other governmental or statutory authorities as may be required in connection
with the Offer and accept on behalf of the Board such conditions and modifications as may be prescribed or imposed by
any of them while granting such approvals, permissions and sanctions as may be required and wherever necessary,
incorporate such modifications / amendments as may be required in the draft red herring prospectus, the red herring
prospectus and the prospectus as applicable;

To finalize, settle, approve, adopt and file in consultation with the BRLMs where applicable, the DRHP, the RHP the
Prospectus, the preliminary and final international wrap and any amendments, supplements, notices, addenda or corrigenda
thereto, and take all such actions as may be necessary for the submission and filing of these documents including
incorporating such alterations/corrections/ modifications as may be required by SEBI, the RoC or any other relevant
governmental and statutory authorities or in accordance with Applicable Laws;

To decide in consultation with the BRLMs on the actual Offer size, timing, pricing, discount, reservation and all the terms
and conditions of the Offer, including the price band (including offer price for anchor investors), bid period, Offer price,
and to do all such acts and things as may be necessary and expedient for, and incidental and ancillary to the Offer including
to make any amendments, modifications, variations or alterations in relation to the Offer;

To appoint and enter into and terminate arrangements with the BRLMs, underwriters to the Offer, syndicate members to
the Offer, brokers to the Offer, escrow collection bankers to the Offer, refund bankers to the Offer, registrars, legal advisors,
auditors, and any other agencies or persons or intermediaries to the Offer and to negotiate, finalise and amend the terms of
their appointment, including but not limited to the execution of the mandate letter with the BRLMs and negotiation,
finalization, execution and, if required, amendment of the offer agreement with the BRLMs;

To negotiate, finalise and settle and to execute and deliver or arrange the delivery of the DRHP, the RHP, the Prospectus,
offer agreement, syndicate agreement, underwriting agreement, share escrow agreement, cash escrow agreement,
agreements with the registrar to the offer and all other documents, deeds, agreements and instruments whatsoever with the
registrar to the Offer, legal advisors, auditors, stock exchange(s), BRLMs and any other agencies/intermediaries in
connection with the Offer with the power to authorise one or more officers of the Company to execute all or any of the
aforesaid documents or any amendments thereto as may be required or desirable in relation to the Offer;

To seek, if required, the consent and/or waiver of the lenders of the Company, customers, parties with whom the Company
has entered into various commercial and other agreements, all concerned government and regulatory authorities in India or
outside India, and any other consents and/or waivers that may be required in relation to the Offer or any actions connected
therewith;

To open and operate bank accounts in terms of the escrow agreement and to authorize one or more officers of the Company
to execute all documents/deeds as may be necessary in this regard;

To open and operate bank accounts of the Company in terms of Section 40(3) of the Companies Act, 2013, as amended,
and to authorize one or more officers of the Company to execute all documents/deeds as may be necessary in this regard;

To authorize and approve incurring of expenditure and payment of fees, commissions, brokerage, remuneration and
reimbursement of expenses in connection with the Offer;

To accept and appropriate the proceeds of the Offer in accordance with the Applicable Laws;

To approve code of conduct as may be considered necessary by the IPO Committee or as required under applicable laws,
regulations or guidelines for the Board, officers of the Company and other employees of the Company;

To approve the implementation of any corporate governance requirements that may be considered necessary by the Board

148
13.

14.

15:.

16.

17;

18.

19.
20.

21,

22.
23:
24.
25),
26.
. To withdraw the DRHP or the RHP or to decide to not proceed with the Issue at any stage in accordance with Applicable

28.

29.

or the IPO Committee or as may be required under the applicable laws or the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended and listing agreements to be entered into by the Company with the relevant
stock exchanges, to the extent allowed under law;

To issue receipts/allotment letters/confirmation of allotment notes either in physical or electronic mode representing the
underlying Equity Shares in the capital of the Company with such features and attributes as may be required and to provide
for the tradability and free transferability thereof as per market practices and regulations, including listing on one or more
stock exchange(s), with power to authorize one or more officers of the Company to sign all or any of the aforestated
documents;

To authorize and approve notices, advertisements in relation to the Offer in consultation with the relevant intermediaries
appointed for the Offer;

To do all such acts, deeds, matters and things and execute all such other documents, etc., as may be deemed necessary or
desirable for such purpose, including without limitation, to finalise the basis of allocation and to allot the shares to the
successful allottees as permissible in law, issue of allotment letters/confirmation of allotment notes, share certificates in
accordance with the relevant rules, in consultation with the BRLMs;

To do all such acts, deeds and things as may be required to dematerialise the Equity Shares and to sign and / or modify, as
the case maybe, agreements and/or such other documents as may be required with the National Securities Depository
Limited, the Central Depository Services (India) Limited, registrar and transfer agents and such other agencies, authorities
or bodies as may be required in this connection and to authorize one or more officers of the Company to execute all or any
of the aforestated documents;

To make applications for listing of the Equity Shares in one or more stock exchange(s) for listing of the Equity Shares and
to execute and to deliver or arrange the delivery of necessary documentation to the concerned stock exchange(s) in
connection with obtaining such listing including without limitation, entering into listing agreements and affixing the
common seal of the Company where necessary;

To settle all questions, difficulties or doubts that may arise in regard to the Offer, including such issues or allotment, terms
of the IPO, utilisation of the IPO proceeds and matters incidental thereto as it may deem fit;

Authorising of the maintenance of a register of holders of the Equity Shares;

To submit undertaking/certificates or provide clarifications to the SEBI, Registrar of Companies, and the relevant stock
exchange(s) where the Equity Shares are to be listed;

To negotiate, finalize, settle, execute and deliver any and all other documents or instruments and to do or cause to be done
any and all acts or things as the IPO Committee may deem necessary, appropriate or advisable in order to carry out the
purposes and intent of this resolution or in connection with the Offer and any documents or instruments so executed and
delivered or acts and things done or caused to be done by the IPO Committee shall be conclusive evidence of the authority
of the IPO Committee in so doing;

To delegate any of its powers set out under (1) to (17) hereinabove, as may be deemed necessary and permissible under
Applicable Laws to the officials of the Company;

To approve suitable policies on insider trading, whistle-blowing, risk management, and any other policies as may be
required under the Listing Regulations or any other Applicable Laws;

To approve the list of ‘group of companies’ of the Company, identified pursuant to the materiality policy adopted by the
Board, for the purposes of disclosure in the DRHP, RHP and Prospectus;

Deciding, negotiating and finalising the pricing and all other related matters regarding the Pre-IPO Placement, including
the execution of the relevant documents with the investors in consultation with the BRLMs and in accordance with
applicable laws;

Taking on record the approval of the Selling Shareholders for offering their Equity Shares in the Offer for Sale;

Laws and in consultation with the BRLMs; and

To appoint, in consultation with the BRLMs, the registrar and other intermediaries to the Offer, in accordance with the
provisions of the SEBI Regulations and other Applicable Laws including legal counsels, banks or agencies concerned and
entering into any agreements or other instruments for such purpose, to remunerate all such intermediaries/agencies
including the payments of commissions, brokerages, etc. and to terminate any agreements or arrangements with such
intermediaries/ agents; and

Doing any other act and/or deed, negotiating and executing any document(s), application(s), agreement(s), undertaking(s),
deed(s), affidavits, declarations and certificates and/or giving such direction, including any direction to settle all questions,
removing any difficulties or doubts that may arise from time to time in relation to the Offer or allotment of the Equity
Shares in the Offer and utilising the Offer proceeds, in such manner as the Board may deem fit, and giving such directions
and/or instructions as it may from time to time decide and accepting and giving effect to such modifications, changes,
variations, alterations, deletions, additions as regards the terms and conditions and taking such actions or giving such
directions as may be necessary or desirable and as it deems fit or as may be necessary or desirable with regard to the Offer.

Risk Management Committee (“RMC”)

149
The members of the Risk Management Committee are:
1. Sunil Chandra Kondapally; Chairman
2. Dr. D Nageshwar Reddy;
3. S Suprita Reddy.

The RMC was last constituted by our Board at their meeting held on May 26, 2021 . The terms of reference of the RMC of our
Company include the following:

1. To formulate a detailed risk management policy which shall include:

(a) A framework for identification of internal and external risks specifically faced by the listed entity, in particular
including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber
security risks or any other risk as may be determined by the Committee.

(b) Measures for risk mitigation including systems and processes for internal control of identified risks.

(c) Business continuity plan.

2. To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with
the business of the Company;

3. To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk
management systems;

4. To periodically review the risk management policy, at least once in two years, including by considering the changing
industry dynamics and evolving complexity;

5. To keep the board of directors informed about the nature and content of its discussions, recommendations and actions to
be taken;

6. The appointment, removal and terms of remuneration of the Chief Risk Officer (if any) shall be subject to review by the
Risk Management Committee.

The Risk Management Committee shall coordinate its activities with other committees, in instances where there is any overlap
with activities of such committees, as per the framework laid down by the board of directors.”

150
Management Organisation Chart

Board of Directors

   
     
  
  

Company Secretary
Chief Executive Officer and Compliance
Officer

  
    

  
 

tema rar)
Officer

 

  
    
   

Director — feng Corte
Nuclear Technology trie Malie Manager -
Medicine Officer Operations

  

Director - Director -
Laboratory Radiology

151
Key Managerial Personnel
The details of the Key Managerial Personnel of our Company are as follows:

Dr. S. Surendranath Reddy and Sunil Chandra Kondapally are the Executive Chairman and Executive Director,
respectively, of our Company. For further details see “~ Brief Biographies of Directors” and “- Terms of Appointment of
Directors - Remuneration to executive Directors” on pages 141 and 142, respectively.

Sura Suprita Reddy is the CEO of our Company. She has been associated with our Company since its incorporation. She
holds a bachelor’s degree in commerce from Osmania University. Since then, she has been heading the overall strategy, clinical
excellence, operations, and expansion of the company. She has previously been a director of the Medinova Diagnostic Services
Limited, Namrata Diagnostic Centre Private Limited, Park Health Systems Private Limited and Doctorslab Medical Services
Private Limited. She has also been a director of our Company from 2014 to 2019. She has been awarded the ‘Women Leadership
Award in Healthcare’ by ABP in 2019. During the Financial Year 2021, she was paid gross salary of 213.75 million*.

*The remuneration of Sura Suprita Reddy has been increased to %27.50 million with effect from June 1, 2021 pursuant to a
resolution of the Board and Shareholders dated May 27, 2021

Narasimha Raju K.A. is the Chief Financial Officer of our Company. He holds a bachelor’s degree of commerce from Osmania
University and is a member of the Institute of Chartered Accountants of India. He was associated with our Company from June
2017 to November 2020 and was a part of the finance, MIS and strategy department. He later re-joined our Company on March
15, 2021, and was appointed as the CFO with effect from May 1, 2021. He has previously worked with S.R. Batliboi & Co.,
NSL Renewable Power Private Limited and PBEL Property Development (India) Private Limited. He has over 14 years of
professional experience in audit, financial reporting, regulatory compliance and accounting advisory. During the Financial Year
2021, he was paid gross salary of %3.67 million.

SV Balaji is the Chief Technology Officer. He has been associated with our Company since November 2018. He holds a
bachelor’s degree in commerce from Osmania University He holds a diploma in computer applications from National Center
for Computing Techniques. He has more than 24 years of experience in the hospital information department, product
management customer support and presales among other things. Prior to joining our Company, he has worked at Quality Care
India Limited (Care Hospitals) and Napier Healthcare Solutions India Limited. During the Financial Year 2021, he was paid
gross salary of 24.02 million.

P Vijaya Bhavani is the General Manager - Operations. She has been associated with our Company since October 2020. She
holds a bachelor’s degree in science (computer science) from the University of Madras. She also holds a post graduate diploma
in public relations from Annamalai University and a master’s degree in business administration from Sikkim Manipal
University. She has over 20 years of experience in field of operations of which includes experience in the diagnostic services
industry. Prior to joining our Company, she has worked at Yasodha Hospitals, Elbit Medical Diagnostic Limited, Sreyas
Mediventures LLP, ICICI Bank Limited, Medinova Diagnostic Services Private Limited, Diana Hotels Limited, RPG Paging
Services Limited, Juno Online Services Development Private Limited. She has also previously worked with our Company for
over six years before being engaged at her present position. During the Financial Year 2021, she was paid gross salary of 21.09
million.

Ajay Nath is the Head of Human Resources department. He has been associated with our Company since May 2021. He holds
master’s degree in commerce, bachelor’s degree in law, from Osmania University and post graduate diploma in industrial
relations and personnel management from Bhavans Rajendra Prasad Institute of Communication and Management. He has
overall experience of 23 years in human resource functions across industries. He previously worked at L V Prasad Eye Institute
as Associate Director - Human Resources. Prior to this, he has worked at Kamineni Steels & Power India Private Limited,
Softpro Systems Limited, Transport Corporation of India Limited, Capstone Consulting Private Limited, Gulf Info-Tech (India)
Private Limited, CARE- India, Triumphant Institute of Management Education Private Limited and Totem Infrastructure
Limited. Since he was appointed in May 2021 he was not paid any salary during the Financial Year 2021.

Dr Lata Manjeshwar Kini is consultant, heading the Lab Technical Operations of our Company. She has been associated with
our Company since February 2021. She holds M.B.B.S & M.D. in pathology from Kasturba Medical College, Mangalore
University. She has over 22 years of work experience in laboratory medicine. She has worked at GM Health Care Private
Limited and CORE Diagnostics Private Limited. During the Financial Year 2021, she was paid a consultancy fee of 20.86
million.

Dr Kishore LT is a consultant and the director radiology. He has been associated with our Company since November 2019.

He holds a degree in M.B.B.S and MD in radio diagnosis from Osmania Medical College. He has also received a certification

as the diplomate of the national board from the National Board of Examinations, New Delhi. He has also completed his
152
fellowship in magnetic resonance imaging from the University of California, Los Angeles and in interventional radiology from
the University of Texas. He has over 28 years of experience in radiology services He has previously been associated with
Quality Care India Limited and Apollo Hospitals Limited. He also served as radiologist specialist in AL Hammadi Hospital,
Riyad. He also served as assistant professor for radiology at Nizam Institute of Medical Sciences. During the Financial Year
2021, he was consultancy fee of 35.93 million.

Dr Anuj Jain is a consultant, doctor-head nuclear medicine. He has been associated with our Company since February 2010.
He holds an M.B.B.S from University of Rajasthan and a diploma in radiation medicine from University of Delhi. He has 10
years of clinical experience. He has previously been associated with Max Devaki Devi Hear & Vascular Institute. He is also a
life member of the Society of Nuclear Medicine of India and a fellow of Asian Nuclear Medicine Board. During the Financial
Year 2021, he was paid a consultancy fee of 26.45 million.

V Sri Lakshmi is a Company Secretary & Compliance Officer of our Company and Medinova Diagnostic Services Limited.
She is member of the Institute of Company Secretaries of India (ICSI) and holds a master’s degree in commerce from Osmania
University and a bachelor’s degree in law from Osmania University. She has around 15 years of work experience in secretarial,
legal and compliance domain. She has previously worked with Brightcom Group Limited as their company secretary. She has
also been associated with Tera Software Limited and NCC Limited. During the Financial Year 2021, she was paid gross salary
of 20.85 million.

Status of Key Managerial Personnel

Except Dr. Anuj Jain, Dr. Kishore LT and Dr. Lata Manjeshwar Kini who are consultants to our Company, all our Key
Managerial Personnel are permanent employees of our Company.

Relationship between our Key Managerial Personnel and Directors

Except Dr. S. Surendranath Reddy who is the father of Sura Suprita Reddy and Sunil Chandra Kondapally, none of our Directors
are related to each other.

Shareholding of Key Managerial Personnel

Except as disclosed below, none of our Key Managerial Personnel hold any Equity Shares in our Company.

 

 

 

 

 

 

 

Sr.No. Name Number of Equity Shares
1. Dr. S. Surendranath Reddy 38,521,195

2. _| Sura Suprita Reddy 9,176,933

3.__| Sunil Chandra Kondapally 9,106,933

4, ‘Anuj Jain 10,000
Total 56,815,061

 

 

 

 

Bonus or Profit Sharing Plans of the Key Managerial Personnel

None of our Key Managerial Personnel are party to any bonus or profit sharing plan of our Company. However, some of our
Key Managerial Personnel are entitled to receive employee stock options pursuant to the ESOP Plan 2018 including ESOP
Schemes 2018

Interests of Key Managerial Personnel

Sura Suprita Reddy is a lessor of certain properties which have been taken on lease by our Company to operate our diagnostic
centres. These properties are located in Andhra Pradesh and Telangana

Except as disclosed in “Our Management - Interest of Directors” and “Our Promoter and Promoter Group” on page 143 and
155, our Key Management Personnel do not have any interest in our Company other than to the extent of the remuneration or
benefits to which they are entitled to as per their terms of appointment and reimbursement of expenses incurred by them during
the ordinary course of business.

The Key Management Personnel may be regarded as interested in the Equity Shares held by them, if any, and to the extent of

any dividend payable to them and other distributions in respect of such Equity Shares, as well as employee stock options under
the ESOP Plan 2018 including ESOP Schemes 2018.

153
Changes in the Key Managerial Personnel

The changes in the Key Managerial Personnel in the last three years are as follows:

 

 

 

 

 

 

 

 

 

Name Designation Date of change Reason for change
Narasimha Raju K.A. Chief Financial Officer May 1, 2021 Appointed as Chief Financial Officer
Sandhya Rani Sama Chief Financial Officer April 18, 2021 Resigned as Chief Financial Officer
Sura Suprita Reddy Chief Executive Officer | November 1, 2019 | Appointed as Chief Executive Officer
Sri Lakshmi Company Secretary July 18, 2019 Appointed as Company Secretary
Vijay Gupta Company Secretary June 3, 2019 Resigned as Company Secretary
Sandhya Rani Sama Chief Financial Officer_| December 26, 2018 | Appointed as the Chief Financial Officer
Vijay Gupta Company Secretary October 15, 2018 | Appointed as Company Secretary

 

 

 

 

 

Service Contracts with Directors and Key Managerial Personnel

Other than the statutory benefits that the KMPs are entitled to, upon their retirement, no officer of our Company, including our
Directors and the Key Managerial Personnel have entered into a service contract including termination/ retirement benefits with
our Company pursuant to which they are entitled to any benefits upon termination of employment.

Contingent and deferred compensation payable to our Director and Key Managerial Personnel

There is no contingent or deferred compensation accrued for Financial Year 2021 and payable to our Directors and Key
Managerial Personnel, which does not form a part of their remuneration.

Payment or benefit to Key Managerial Personnel
Dr. S. Surendranath Reddy, Sunil Chandra Kondapally and Sura Supritha Reddy are lessors of the properties which have been
taken on lease by our Company to operate our diagnostic centres. These properties are located in Haryana, Andhra Pradesh and

Telangana. For further details see “Our Promoter and Promoter Group” on page 155.

Except as stated above, no non-salary amount or benefit has been paid or given to any of our Key Managerial Personnel within
the two preceding years or is intended to be paid or given.

Employees Stock Options

For details in relation to ESOP Plan 2018 including ESOP Schemes 2018, see “Capital Structure — Employee Stock Option
Plan 2018 and ESOP Schemes 2018” on page 64.

154
OUR PROMOTER AND PROMOTER GROUP

Dr. S. Surendranath Reddy is the Promoter of our Company. Our Promoter currently hold an aggregate of 38,521,195 Equity
Shares, aggregating to 37.78% of the pre-Offer issued, subscribed and paid-up Equity Share capital of our Company. For further
details, see “Capital Structure — History of the Equity Share capital held by our Promoter” on page 58.

Our Individual Promoter
Dr. S. Surendranath Reddy

Dr. S. Surendranath Reddy (DIN:00108599), born on October 29, 1948 and aged 72 years, is
the Executive Chairman of our Company. He is an Indian national. For further details in respect
of his address, educational qualifications, professional experience, positions/ posts held in the
past and other directorships and special achievements, see “Our Management” on page 139.

Dr. S. Surendranath Reddy holds 38,521,195, Equity Shares in our Company, equivalent to
37.78% of the pre-Offer issued, subscribed and paid-up Equity Share capital of our Company.
Other than as disclosed in this section and “Our Management” on page 139. Dr. S. Surendranath
Reddy is not involved in any other venture.

 

His permanent account number is AGQPS3104F, his driving license number* is 1189521975
and his Aadhaar card number is 7739 8008 5159.

Our Company confirms that the PAN, passport number*and bank account number of Dr. S. Surendranath Reddy have been
submitted to the Stock Exchanges at the time of filing of the Draft Red Herring Prospectus with them.

*The driving license reflects his name as S. Surender Reddy and passport reflects his name as Sura Surender Reddy.
Interests of our Promoter

Our Promoter is interested in our Company to the extent he has promoted our Company and to the extent of his shareholding
in our Company and dividend payable, if any, and other distributions in respect of the Equity Shares held by him.

Except as disclosed below, our Promoter has no interest in any property acquired in the three years preceding the date of this
Prospectus or is proposed to be acquired by our Company or in any transaction by our Company for acquisition of land,
construction of building or supply of machinery.

Our Promoter is the lessor and co-owns properties located at multiple locations in Haryana, Andhra Pradesh and Telangana
which have been taken on lease by our Company to operate our diagnostic centres at Chandanagar, Himayatnagar, Kurnool,
Dilsuknagar, Habsiguda, Kukatpally, Vizag, Safilguda, Gurgaon, Santosh Nagar, Madina, Ameerpet, Bakaram, Dilsukhnagar
and our godown at Bala Nagar, including and our Registered Office. For further details, see “Risk Factors - Certain of our
Promoter, Directors and Key Managerial Personnel have interests in our Company in addition to their normal remuneration
or benefits and reimbursement of expenses incurred” on page 33. Our Promoter has been paid an aggregate rent of 785.16
million during Fiscals 2021, 2020 and the three month period ended June 30, 2021, from such leases. The rent agreements for
such properties have a periodic escalation clause between 5 — 15% on the base rent. Such escalation is due at the end of every
twelve months of the lease. For further details, see “Financial Statements” on page 162.

No sum has been paid or agreed to be paid to our Promoter or to the firms or companies in which our Promoter is interested as
a member in cash or shares or otherwise by any person, either to induce him to become or to qualify him, as directors or
promoter or otherwise for services rendered by such Promoter or by such firms or companies in connection with the promotion
or formation of our Company.

Payment or benefits to our Promoter or our Promoter Group

During Fiscals 2021, 2020 and the three month period ended June 30, 2021, we have paid an aggregate rent of 85.16 million
and 2190.48 million to our Promoter and Promoter Group, respectively, from leases of our diagnostic centres for certain
diagnostice centres owned and co-owned by them. The rent agreements for such properties have a periodic escalation clause
between 5 — 15% on the base rent. Such escalation is due at the end of every twelve months or three years of the lease. For
further details see “Risk Factors - Certain of our Promoter, Directors and Key Managerial Personnel have interests in our

155
Company in addition to their normal remuneration or benefits and reimbursement of expenses incurred.” and “Financial
Statements” on page 33 and 162.

Further, one of the members of our Promoter Group namely Park Health Systems Private Limited has availed certain services
from our Company while sold consumables to our Company. For further details see “Financial Statements — Annexure VII —
Note 45” on page 208.

Except as disclosed above, no amount or benefit has been paid or given to our Promoters or members of our Promoter Group
during the two years preceding the filing of this Prospectus nor is there any intention to pay or give any amount or benefit to
our Promoters or members of our Promoter Group.

Material guarantees given by our Promoter to third parties with respect to Equity Shares

Our Promoter has not given any material guarantees to any third party with respect to the Equity Shares of our Company.
Companies or firms with which our Promoter has disassociated in the last three years

As on the date of this Prospectus, our Promoter has not disassociated from any company or firm in the last three years.

Promoter Group

Apart from our Promoter, the following individuals and entities constitute our Promoter Group in terms of Regulation 2(1)(pp)
of the SEBI ICDR Regulations.

Natural persons who are a part of our Promoter Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ss. Name of the Promoter Group Relation with Promoter

No.
1 S. Geeta Redd Wife of the Promoter
2. P. Madhulika Reddy Promoter’s wife's sister
3, P.V. Sanjay Kumar Promoter’s wife’s brother
4. Sunil Chandra Kondapally* Promoter’s son
5. Sura Suprita Reddy Promoter’s daughter
6. M.Sujata Reddy Promoter’s sister
7. B. Vishnu Priya Promoter’s son’s wife
8. Birudavolu Jalaja Promoter’s daughter in law's mother
9. Birudavolu Dayakar Reddy Promoter’s daughter in law's father
10. | Birudavolu Gautam Promoter’s daughter in law's brother
11. _| Nanda Birudavolu Kumar Promoter’s daughter in law's brother
12. | Charita Birudavolu Reddy Promoter’s daughter in law's brother's wife
13. | Manjula Kankanthi Promoter’s brother’s daughter in law

 

* Dr. S. Surendranath Reddy and S Geeta Reddy are the biological parents of Sunil Chandra Kondapally. Sunil Chandra Kondapally was
adopted by Kondapally Brahmananda Reddy pursuant to an adoption deed dated January 20, 1980.

Entities who are a part of our Promoter Group

Kshetra Agritech Private Limited;

Park Health Systems Private Limited;

S Square Properties LLP;

Summit Nutraceuticals Private Limited;
Trikona Holdings LLP;

Trikona Pharmaceuticals Private Limited;
Vijaya Holdings India LLP; and

Vijaya Hospitals Private Limited

156
OUR GROUP COMPANIES

In terms of the SEBI ICDR Regulations and pursuant to the resolution passed by our Board at its meeting held on August 16,
2021 group companies of our Company shall include (i) the companies (other than our Subsidiaries) with which there were
related party transactions as per the Restated Financial Information of the Company for the Financial Years ended March 31,
2019, March 31, 2020 and March 31, 2021 and for the three month period ended June 30, 2021; and (ii) such other company as
deemed material by our Board. For the purposes of (ii) above, the Board has approved that for the purposes of disclosure in
connection with the Offer, there is no other company considered material by the Board which shall be considered as a group
company of the Company.

Accordingly, in terms of the policy adopted by our Board for determining group companies, our Board has identified Park
Health Systems Private Limited and Vijaya Hospitals Private Limited as our Group Companies.

Details of our Group Companies

1.

Park Health Systems Private Limited (“PHSPL”)
Corporate Information

PHSPL was incorporated as a private limited company under Companies Act, 1956 on February 8, 2007. Its corporate
identity number of is U85110TG2007PTC052677. Its registered office is situated at 6-3-903/A&B, Somajiguda, Hyderabad
500 082, Telangana, India.

Nature of Activities

PHSPL is engaged in the business of inter alia, acquiring and maintaining one or more hospitals for reception and treatment
of persons suffering from illness, or of persons requiring medical attention or rehabilitation and to provide medical relief
to the public in all branches of medical sciences.

Shareholding

The shareholding pattern of PHSPL is as follows:

 

 

 

 

 

‘Name of the Shareholder Number of shares held Percentage of the total shareholding (%)
C Damodar Reddy 5,933,655 72.73
S Suprita Reddy 2,189,500 26.84
C Prathima Redd) 35,000 0.43
Total 8,158,155 100

 

 

 

 

 

Financial Performance

The financial information derived from the audited financial results of PHSPL for the financial years ended 2020, 2019
and 2018 is set forth below:

(in million, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Financial Year ended March 31,
2020 2019 2018
Equity Capital 81.58 81.58 81.58
Reserves (Excluding Revaluation Reserve) 134.73 109.37 141.82
Sales 436.11 465.74 529.65
Profit/(Loss) after Tax 25.35 (89.27) 14.27
Earnings per Share (Basic) (Face Value of Rs.10) 3.1 481) 1.75
Earnings per Share (Diluted) (Face Value of Rs.10) 3.1 48) 175
Net Asset Value 216.31 190.95 223.40
Net Asset Value per share 26.52 23.41 27.38

 

 

 

Significant notes of auditors of PHSPL for the last three Financial Years

a) For Fiscal 2017-18, 2018-19 and 2019-20 - Trade receivables, trade payables and unsecured loans are subject to
confirmation.

157
b) PHSPL was generally irregular in depositing the undisputed statutory dues including provident fund, employees state
insurance, income tax, sales tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax,
cess and any other statutory dues with the appropriate authorities. Below are few undisputed amounts payable in
respect of the above were in arrears as at March 31 for a period of six months from the date on when they became

°

payable, except:

 

 

 

 

 

 

 

 

Nature of statute Nature of dues FY 2017-18 FY 2018-19
‘Amount in

Income Tax Act Tax Deducted at Source 8,592,634 7,971,721

Employee Provident Fund Act Provident Fund 1,490,768 1,332,141

Employee State Insurance ESI Dues 561,255, 1,950,823

Professional Tax PT Dues 72,000 480,300

Sales Tax Act Sales Tax - 148,296

 

 

 

 

According to the records of PHSPL, undisputed statutory dues including provident fund, investor education and
protection fund, employees state insurance, income tax, sales tax, service tax, goods and service tax, customs duty,
excise duty, value added tax, cess and any other statutory dues to the extent applicable have generally been regularly
deposited with the appropriate authorities. According to the information and explanations given to its auditors, there
were no outstanding statutory dues as on March 31, 2020 for a period of more than six months from the date they

became payable, except:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name of the Nature of Dues ‘Amount in Period for Due Date Date of
Statute millions (2) which the Payment
amount
relates
Professional Tax | Professional tax recovered 15,750 | April 2019 May 15, 2019 | January 9, 2020
from employees
Professional Tax | Professional tax recovered 16,950 | May, 2019 June 15,2019 | January 9, 2020
from employees
Professional Tax | Professional tax recovered 17,900 | June, 2019 July 15,2019 | January 9, 2020
from employees
Professional Tax | Professional tax recovered 19,650 | July, 2019 August 15, | January 9, 2020
from employees 2019
Professional Tax | Professional Tax of Company 7,500 | 2014-15 June 30,2014 | January 16,
of Company 2020
Professional Tax | Professional Tax of Company 7,500 | 2015-16 June 30,2015 | January 16,
of Company 2020
Professional Tax | Professional Tax of Company 7,500 | 2016-17 June 30,2016 | January 16,
of Company 2020
Professional Tax | Professional Tax of Company 7,500 | 2017-18 June 30,2017 | January 16,
of Compan 2020
Professional Tax | Professional Tax of Company 7,500 | 2018-19 June 30,2018 | January 16,
of Company 2020
Professional Tax | Professional Tax of Company 7,500 | 2019-20 June, 2019 January 16,
of Company 2020
ESI ESI of Employees 1,237,400 | Earlier periods | - Unpaid as on
March 31, 2020
Sales Tax Sales tax 148,200 | Earlier periods | - Unpaid as on
March 31, 2020
TDS TDS on contractors 649,900 | Earlier periods | - Unpaid as on
March 31, 2020
TDS TDS on interest 5,783,700 | Earlier periods | - Unpaid as on
March 31, 2020

 

Vijaya Hospitals Private Limited (*VHPL”)

Corporate Information

VHPL was incorporated as a private limited company under Companies Act, 1956 on October 29, 1987. Its corporate
identity number of is U85110TG1987PTC007902. Its registered office is situated at 3-6-20, Himayatnagar Hyderabad

Telangana India.

158

 
Nature of Activities

VHPL is engaged in the business of inter alia, designing, constructing and owning or otherwise acquiring and to carry on
the business of setting up, managing, administering and running of diagnostic centres, hospitals or mobile medical units,
medical services centres, clinics, nursing homes, intensive care units on ownership or franchise basis.

Shareholding

The shareholding patterns of PHSPL is as follows:

 

 

 

 

 

 

Name of the Shareholder Number of shares held Percentage of the total shareholding (%)
Dr. Surrendranath Reddy 1,005 99.60
S Geetha Reddy 4 0.40
Total 1,009 100

 

 

 

Financial Performance

The financial information derived from the audited financial results of VHPL for the financial years ended 2020, 2019 and

2018 is set forth below:

(in million, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Financial Year ended March 31,
2020 2019 2018

Equity Capital 0.10 0.10 0.10
Reserves (Excluding Revaluation Reserve) 28.68 24.00 17.58
Sales = ~ -
Profit/(Loss) after Tax 6.42 (1.18)
Earnings per Share (Basic) (Face Value of 2.100) 6,360.79 (4,166.12)
Earnings per Share (Diluted) (Face Value of 6,360.79 (1,166.12)
Rs.100)

Net Asset Value 28.78 24.10 17.68
Net Asset Value per share (Face value of 100) 28,523.30 23,885.03 17,522.30

 

 

 

 

Significant notes of auditors of VHPL for the last

three Financial Years

There are no significant notes by the auditors of VHPL in relation to the aforementioned financial statements for the specified

three immediately preceding Financial Years.

Nature and extent of interest of our Group Companies

a. In the promotion of our Company

Our Group Companies do not have any interest in the promotion of our Company.

b. In the properties acquired by us in the preceding three years before filing this Prospectus or proposed to be acquired

by our Company

Our Group Companies are not interested in the properties acquired by us in the three years preceding the filing of this
Prospectus or proposed to be acquired by us as on the date of this Prospectus.

c. In transactions for acquisition of land, construction of building and supply of machinery

Our Group Companies are not interested in any transactions for the acquisition of land, construction of building or

supply of machinery.

Defunct Group Companies

Our Group Companies are not defunct and no applications have been made to the relevant registrar of companies for striking
off their names during the five years preceding the date of filing of the Red Herring Prospectus and this Prospectus with SEBI.

Group Companies which are a sick industrial company or are under winding up/ insolvency proceedings

159
Our Group Companies do not fall under the definition of sick companies under the erstwhile Sick Industrial Companies (Special
Provisions) Act, 1985 and are not under any winding up or insolvency proceedings under applicable law.

Common Pursuits between our Group Companies and our Company

Our Group Companies are not in the same line of business as our Company and our Subsidiaries and there are no common
pursuits between our Group Companies and our Company and our Subsidiaries.

Related Business Transactions with the Group Companies and significance on the financial performance of our
Company

Other than the transactions disclosed in the section “Financial Statements — Annexure VII — Note 45” on page 208, there are no
other related business transactions with our Group Companies.

Business interest of our Group Companies in our Company

Park Health Systems Private Limited has entered into an agreement dated September 1, 2020 to avail our Company’s laboratory
services on exclusive basis, for a period of two years from the date of the agreement. During the term of the agreement, the
tests will be conducted at special prices and discounts depending upon the type of client, as prescribed in the agreement. Park
Health Systems Private Limited is required to meet our Company’s invoices within 15 days from the date of receipt of the
invoice by it. Additionally, Vijaya Hospitals Private Limited along with certain others has also entered into a rent agreement
dated June 1, 2015 pursuant to which the diagnostic centre in Himayathnagar has been leased to our Company for a period of
10 years and receives part of the total rent payable by our Company under the said agreement.

Except as disclosed in this section, our Group Companies have no business interest in our Company.

Details of losses incurred

Except for PHSPL which incurred a loss of 339.27 million in fiscal 2019 and VHPL which incurred a loss of 21.18 million in
fiscal 2018, our Group Companies have not incurred a loss.

Litigation

Our Group Companies are not party to any pending litigations which will have a material impact on our Company.
Other confirmations

None of our Group Companies are listed on any stock exchange.

None of our Group Companies have made any public or rights issue of securities in the preceding three years.

None of our Group Companies will receive any portion of the Offer Proceeds .

160
DIVIDEND POLICY

The declaration and payment of dividends will be recommended by the Board of Directors and approved by the Shareholders,
at their discretion, subject to the provisions of the Articles of Association and other applicable law, including the Companies
Act, provisions of the SEBI Listing Regulations and the dividend distribution policy adopted by our Board on May 26, 2021
(“Dividend Policy”). In terms of the Dividend Policy, the distribution of dividend depends on a number of factors, including
but not limited to our Company’s results of operations, earnings, capital requirements and surplus, general financial conditions,
contractual restrictions, applicable legal restrictions and other factors considered relevant by our Board. Our Board will take
into account, inter alia, the following factors while distributing dividends, if any, to our Shareholders (i) profitable growth of
our Company and specifically, profits earned during the financial year as compared with previous years, internal budgets, cash
flow position of our Company, accumulated reserves and future cash requirements for organic growth/expansion and/or for in
organic growth; and (ii) certain external factors such as business cycles and the economic environment.

Our Company has not declared any dividend on the Equity Shares for Fiscals 2019, 2020, 2021, during the three month period
ended June 30, 2021, or subsequently, prior to the filing of this Prospectus.

161
SECTION V: FINANCIAL INFORMATION
FINANCIAL STATEMENTS

[The remainder of this page has been intentionally left blank.]

162
INDEPENDENT AUDITOR’S EXAMINATION REPORT ON RESTATED CONSOLIDATED
FINANCIAL INFORMATION

The Board of Directors

Vijaya Diagnostic Centre Limited
3-6-16 & 17, Street# 19,
Himayatnagar,

Hyderabad — 500 029.

Dear Sirs,

)

2)

We have examined, the attached Restated Consolidated Financial Information of Vijaya Diagnostic
Centre Limited (formerly known as ‘Vijaya Diagnostic Centre Private Limited’) (the “Company” or
the “Holding Company” or the “Issuer”) and its subsidiaries (the Company and its subsidiaries
together referred to as the “Group") comprising the Restated Consolidated Balance Sheet as at 30 June
2021, 30 June 2020, 31 March 2021, 31 March 2020 and 31 March 2019, the Restated Consolidated
Statement of Profit and Loss (including Other Comprehensive Income), the Restated Consolidated
Statement of Changes in Equity, the Restated Consolidated Cash Flows for the years ended 31 March
2021, 31 March 2020 and 31 March 2019, for the three months period ended 30 June 2021 and 30
June 2020 and the statement of significant accounting policies, and other explanatory information
(collectively, the “Restated Consolidated Financial Information”), as approved by the Board of
Directors of the Company at their meeting held on 16 August 2021 for the purpose of inclusion in the
Red Herring Prospectus (“RHP”) and Prospectus prepared by the Company in connection with its
proposed Initial Public Offer of equity shares (“IPO”) prepared in terms of the requirements of:

a) Section 26 of Part I of Chapter III of the Companies Act, 2013 (the “Act");

b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)
Regulations, 2018, as amended ("ICDR Regulations"); and

c) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the
Institute of Chartered Accountants of India (“ICAI”), as amended from time to time (the
“Guidance Note”).

The Company’s Board of Directors is responsible for the preparation of the Restated Consolidated
Financial Information for the purpose of inclusion in the RHP and Prospectus to be filed with
Securities and Exchange Board of India (“SEBI”), the stock exchanges where the equity shares of the
Company are proposed to be listed (“Stock Exchanges”) and the Registrar of Companies, Telangana,
situated at Hyderabad (“ROC”), in connection with the proposed IPO. The Restated Consolidated
Financial Information have been prepared by the management of the Company on the basis of
preparation stated in note 2 of Annexure V to the Restated Consolidated Financial Information.

The responsibility of respective board of directors of the companies included in the Group includes
designing, implementing and maintaining adequate internal control relevant to the preparation and
presentation of the Restated Consolidated Financial Information. The respective board of directors of
the Group are also responsible for identifying and ensuring that the Group complies with the Act, the
ICDR Regulations and the Guidance Note.

163
3)

4)

5)

6)

We have examined such Restated Consolidated Financial Information taking into consideration:

a) The terms of reference and terms of our engagement agreed upon with you in accordance with
our engagement letter dated 28 July 2021, in connection with the proposed IPO of equity
shares of the Company;

b) The Guidance Note. The Guidance Note also requires that we comply with the ethical
requirements of the Code of Ethics issued by the ICAI;

c) Concepts of test checks and materiality to obtain reasonable assurance based on verification
of evidence supporting the Restated Consolidated Financial Information; and

d) The requirements of Section 26 of the Act and the ICDR Regulations. Our work was
performed solely to assist you in meeting your responsibilities in relation to your compliance
with the Act, the ICDR Regulations and the Guidance Note in connection with the proposed
IPO of equity shares of the Company.

These Restated Consolidated Financial Information have been compiled by the management from:

a) Asatand for the three months period ended 30 June 2021 and 30 June 2020 : From the audited
special purpose interim consolidated financial statements of the Group as at and for the three
months period ended 30 June 2021 and 30 June 2020 (being the comparative period of the
financials for the three months period ended 30 June 2021), prepared in accordance with
Indian Accounting Standard (Ind AS) 34 “ Interim Financial Reporting”, specified under
Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as
amended, and other accounting principles generally accepted in India (the “special purpose
interim consolidated financial statements”), which have been approved by the Board of
Directors at their Board meetings held on 16 August 2021;

b) As at and for the year ended 31 March 2021, 31 March 2020 and 31 March 2019: From the
audited consolidated financial statements of the Group as at and for the year ended 31 March
2021, 31 March 2020 and 31 March 2019, prepared in accordance with the Indian Accounting
Standards (referred to as “Ind AS”) as prescribed under Section 133 of the Act read with
Companies (Indian Accounting Standards) Rules 2015, as amended, and other accounting
principles generally accepted in India (the “consolidated financial statements”), which have
been approved by the Board of Directors at their Board meetings held on 27 May 2021, 16
July 2020 and 17 June 2019 respectively.

For the purpose of our examination, we have relied on Auditors’ reports issued by us dated 16 August
2021, 27 May 2021, 16 July 2020 and 17 June 2019 on the consolidated financial statements of the
Group as at and for the three months period ended 30 June 2021 and 30 June 2020 (being the
comparative period of the financials for the three months period ended 30 June 2021) and as at and
for the years ended 31 March 2021, 31 March 2020 and 31 March 2019 as referred in paragraph 4
above.

As indicated in our audit reports referred in paragraph 5 above, we did not audit the financial
statements of five subsidiaries (including step down subsidiaries) for the three months period ended
June 30, 2021 and June 30, 2020 and for the financial years ended 31 March 2021, 31 March 2020
and 31 March 2019 as listed in Annexure A(ii) whose share of total assets, total revenues, net cash
inflows / (outflows) included in the consolidated financial statements, for the relevant years is
tabulated below:

164
1)

8)

(Rs. in million)

 

 

 

 

 

 

 

 

 

 

Particulars As at / for the three As at / for the year ended
months period ended
30 June 30 June 31 March 31 March 31 March
2021 2020 2021 2020 2019

In respect of
subsidiaries:
Total assets 126.54 130.20 127.45 128.22 132.32
Total revenues 45.42 15.42 121.36 105.79 141.52
Net cash inflow/ (0.11) 3.18 (2.90) (1.78) 1.59
(outflow)

 

 

 

 

These financial statements have been audited by other auditors as mentioned in Annexure A(ii) and
whose reports have been furnished to us by the Company’s management and our audit opinions for
the relevant periods / years on the consolidated financial statements, in so far as it relates to the
amounts and disclosures included in respect of these components for the relevant periods / years, are
based solely on the reports of the other auditors.

Our opinion on the consolidated financial statements is not modified in respect of these matters.

The other auditors (SCV & Associates, Ratnam Dhaveji & Co and M. Anandam & Co.), of two step-
subsidiaries (Namrata Diagnostic Centre Private Limited and Medinova Millennium MRI Services
LLP), respectively and auditors (M. Bhaskara Rao & Co., Ratnam Dhaveji & Co, M. Anandam & Co.
and SCV & Associates) of three subsidiaries (VDC Diagnostics (Karnataka) LLP, Medinova
Diagnostic Services Limited and Doctors Lab Medical Services Private Ltd.) respectively, as
mentioned in Annexure A(ii), have examined the restated financial information and have confirmed
that the restated financial information:

a) have been prepared after incorporating adjustments for the changes in accounting policies and
regrouping/reclassifications retrospectively in the financial years ended 31 March 2021, 31
March 2020 and 31 March 2019 and for the period beginning 1 April 2020 to 30 June 2020
to reflect the same accounting treatment as per the accounting policies and
grouping/classifications followed as at and for the three months period ended 30 June 2021;

b) does not contain any qualifications requiring adjustments. However, those qualifications in
the Companies (Auditor’s Report) Order, 2016 issued by the Central Government of India in
terms of sub section (11) of section 143 of the Act, which do not require any corrective
adjustments in the Restated Consolidated Financial Information have been disclosed in
Annexure VI to the Restated Consolidated Financial Information; and

c) have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.

Based on our examination and according to the information and explanations given to us and also as
per the reliance placed on the examination report submitted by the other auditors for the respective
periods / years, we report that the Restated Consolidated Financial Information:

a) have been prepared after incorporating adjustments for the changes in accounting policies and
regrouping/reclassifications retrospectively in the financial years ended 31 March 2021, 31 March
2020 and 31 March 2019 and for the period beginning 1 April 2020 to 30 June 2020 to reflect the
same accounting treatment as per the accounting policies and grouping/ classifications followed
as at and for the three months period ended 30 June 2021;

165
b) does not contain any qualifications requiring adjustments. However, those qualifications in the
Companies (Auditor’s Report) Order, 2016 issued by the Central Government of India in terms
of sub section (11) of section 143 of the Act, which do not require any corrective adjustments in
the Restated Consolidated Financial Information have been disclosed in Annexure VI to the
Restated Consolidated Financial Information; and

c) have been prepared in accordance with the Act, ICDR Regulations and the Guidance Note.

9) The Restated Consolidated Financial Information do not reflect the effects of events that occurred
subsequent to the respective dates of the reports on the Special Purpose Interim Consolidated Financial
Statements and audited consolidated financial statements mentioned in paragraph 4 above.

10) This report should not in any way be construed as a reissuance or re-dating of any of the previous
audit reports issued by us, nor should this report be construed as a new opinion on any of the financial
statements referred to herein.

11) We have no responsibility to update our report for events and circumstances occurring after the date
of the report.

12) Our report is intended solely for use of the Board of Directors for inclusion in the RHP and Prospectus
to be filed with SEBI, Stock Exchanges and RoC in connection with the proposed IPO. Our report
should not be used, referred to, or distributed for any other purpose except with our prior consent in
writing. Accordingly, we do not accept or assume any liability or any duty of care for any other
purpose or to any other person to whom this report is shown or into whose hands it may come without
our prior consent in writing.

For BS R & Associates LLP
Chartered Accountants
ICAI Firm’s Registration No: 116231W/ W-100024

Sriram Mahalingam

Partner

Membership No: 049642

ICAI UDIN: 21049642AAAAEE1140

Place: Hyderabad
Date: 16 August 2021

166
Annexure A

@ List of Subsidiaries of Vijaya Diagnostic Centre Limited (formerly known as ‘Vijaya
Diagnostic Centre Private Limited’)

 

 

 

 

 

Name of Entity Nature of relation
Medinova Diagnostic Services Limited Subsidiary
Doctors Lab Medical Services Private Ltd. Subsidiary

VDC Diagnostics (Karnataka) LLP Subsidiary
Namrata Diagnostic Centre Private Limited Step subsidiary

 

Medinova Millennium MRI Services LLP

 

Step subsidiary

 

(ii) Details of entities for the years not audited by us and name of the other auditor for the respective
year for which restated financial information examined by other auditors.

 

 

Particulars Nature of | Period / Year | Name of the auditor
Relation ended
Medinova Diagnostic Services Limited Subsidiary 30 June 2021 M. Anandam & Co.
30 June 2020 M. Anandam & Co.

31 March 2021
31 March 2020
31 March 2019

Ratnam Dhaveji & Co
Ratnam Dhaveji & Co
Ratnam Dhaveji & Co

 

Medinova Millennium MRI Services
LLP

Step subsidiary

30 June 2021
30 June 2020
31 March 2021
31 March 2020
31 March 2019

M. Anandam & Co.
M. Anandam & Co.
Ratnam Dhaveji & Co
Ratnam Dhaveji & Co
Ratnam Dhaveji & Co

 

Doctors Lab Medical Services Private
Ltd.

Subsidiary

30 June 2021
30 June 2020
31 March 2021
31 March 2020
31 March 2019

SCV & Associates

 

VDC Diagnostics (Karnataka) LLP

Subsidiary

30 June 2021
30 June 2020
31 March 2021
31 March 2020
31 March 2019

M. Bhaskara Rao & Co.

 

Namrata Diagnostic Centre Private
Limited

 

 

Step subsidiary

 

30 June 2021
30 June 2020
31 March 2021
31 March 2020
31 March 2019

 

SCV & Associates

 

 

167
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure 1
Restated Consolidated Balance Sheet

 

 

 

 

   

 

 

 

 

   

 

 

 

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

 

 

 

 

 

(All amounts are in Rs in millions, except share data or otherwise stated)
Particulars Note No. Asat ‘As at ‘Asat ‘Asat ‘Asat
Annexure VII | June 30,2021 | June 30,2020 | March 31,2021 | March 31, 2020 | March 31, 2019
ASSETS
NON-CURRENT ASSETS
(a) Property, plant and equipment 4 395.22 1357.64 1497.29
(©) Capital work-in-progress 4 153.49, 81.82 27.09
(©) Goodwill 5 5337 0879
(2) Other intangible assets 5 9.26 601 7.46
(©) Right of use asset 6 1wz7a7 1,260.01 1078.81
(Intangible assets under development 5 3.65 1236 :
(g) Financial assets
(Investments 7 040 0.40 0.40 0.40 040
(i) Other financial assets 8 185.13 5230 12.2 54.85 48.18
(h) Deferred tax assets, (net) 2 69.55 5165 60.97 1581 178
(Income tax assets (net) 36 3.70 881 570 9.13 841
@ Other assets 9 779 34.98 61.09 66.62 650
3263.81 3,040.30 SO21 59 2,959.08 2689.71
CURRENT ASSETS
(2) Inventories, 0 6295 3531 26.44 77 2178
(©) Financial assets
() Investments n 27957 1275 276.
(ii) Trade receivables 2 55.52 7227 64.08 91.25
(ii) Cash and cash equivalents B 101.58 306.26 66.86 96.21
(Gv) Bank balances other than Cash and cash equivalents “4 2.47.90 137142 187555 626.23 430.2
(¥) Other financial assets 15 2367 51.89 5.42 2972
(©) Other current assets 16 3985 2672 2174 1714
278197 86158 2387.81 T8652 137459
TOTAL ASSETS 6,085.78 5901.83 5409.40 822.56 £064.30
EQUITY AND LIABILITIES
EQUITY
(a) Equity share capital 7 10197 4532 4532 4532 45.29
(©) __ Instruments entirely equity in nature 18a - - : . 2413,
(©) Other equity 18b 3,821.29 2,718.93 354474 2700.41 2,008.40
Equity attributable to owners of the Company 3,923.26 2,768.25 3,590.06 2,745.43 2,073.82
(2) Non-controlling interest 582 697) 26 (408) 672)
3929.08 2758.28 35232 274139 2070410
LIABILITIES
NON-CURRENT LIABILITIES
(2) Financial liabilities
() Borrowings 19 19741 3275 221.33 31535,
(ii) Lease liabilities, 6 1248.64 1264.72 1,196.10 1034.16
(i) Other financial liabilities 20 6.80 218 1873,
(®) Provisions 2 76.79 7.02 53.19
(©) Other liabilities B 091 053 137
T5305, 137.20 T2280
(CURRENT LIABILITIES
(a) Financial liabilities
( Borrowings 4 ns 109.15, us7 10707 10891
(i) Lease liabilities 6 108.23 9052 101.03 877 72.64
(ii) Trade payables 3B
= Due to micro and small enterprises 101 0.07 2.68 033 5
= Due to creditors other than micro and small enterprises 258.24 201.73 218.88 216.60 21754
(jv) Other financial liabilities 26 8297 18263, 6127 12969 114.96
(©) Income tax liabilities 36 7854 5.88 16.24 1447 15.99
(©) Provisions 7 8.88 1057 736 1037 10.80
(2) Other liabilities 28 2134 1245 2045 20.10 30.56
S7LAs 13.00 B88 386.40 S710
TOTAL EQUITY AND LIABILITIES 6015.78 5901.83 5409.40 582256 506430
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES v

 

 

 

 

Note: The above statement should be read with Significant Accounting Policies forming part of the Restated Consolidated Financial Information in Annexure V, Statement of]
Adjustments to Restated Consolidated Financial Information in Annexure VI and Notes to Restated! Consolidated Financial Information in Annexure VIL

As per our Report of even date attached

For BS R & Associates LLP
Chartered Accountants
ICAI Firm registration number: 116231W/ W-100024

Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad
Date: August 16, 2021

For and on behalf of the Board of Directors
Vijaya Diagnostic Centre Limited

(formerly known as ‘Vijaya Diagnostic Centre Private Limited’)
CIN: U851951G2002PLC039075

Dr. § Surendranath Reddy 'S Suprita Reddy
Executive Chairman Chief Executive Officer
DIN Number: 00108599

K. Sunil Chandra Narasimha Raju K.A V. Sri Lakshmi
Executive Director Chief Financial Officer Company Secretary
DIN Number: 01409832 Membership Number: F9950

Place: Hyderabad
Date: August 16, 2021

 

 

168
 

[Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure II

[Restated Consolidated Statement of Profit and Loss

(AIL amounts are in Rs iu millions, except share data or otherwise stated)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NoteNo. | For3months | For3months | For the year For the year For the year
Particulars Annexure | period ended | period ended ended ended ended
vu June 30, 2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
INCOME
Revenue from operations 29 1,226.86 517.10 3,767.46 3,388.21 2,925.87
Other income 30 32.84 22.82 118.47. 153.61 103.57,
[Total Income 1,259.70 539.92, 3885.93 3541.82 3,029.44
EXPENSES:
Cost of materials consumed 31 210.84 7554 570.95 439.06 404.78
Employee benefits expense 32 161.47 128.52 574.35 624.01 538.80
Finance costs 33 40.03 38.40 152.47 153.85 135.33,
Depreciation and amortisation expense 34 119.21 116.35 504.53 491.70 396.26
Other expenses 35 286.00 174.63, 962.39 998.93, 901.09,
|Total expenses 317.55 533.45 2,764.69 2,707.55 2,376.26
Profiy/(loss) before tax 442.15 648. 4121.24 834.27 653.18
lax expenses: 36
Current tax 74 23.60 317.41 230.64 196.66
Deferred tax (8.51)| (35.22) (45.28) 21.44) (6.20)
Total tax expense 708.90 “11.62 ‘27213 209.20 190.46
Profit for the period/year 338.25 18.10 B01 65.07 W272
Other comprehensive income /(loss) (OCD)
1. Items that will not be reclassified to profit or loss.
i. Re-measurement gains/ (losses) of post-employment defined benefit plans (0.28)| (261) (0.02) (1.75) 2.19)
ii, Income tax related to above 0.06 0.62. 0.12) od 057
JOther comprehensive income /(loss) (OCI) for the period/year, net of tax 02] 99) (0.4) ast) 1.62)
|Total comprehensive income for the period/year 333.03 T6it 897 C376 461.10
Profit for the period/year attributable to:
|Owners of the Company 329.69 19.43 842.63, 625.38 458.74
Non controlling interests, 3.56 (1.03) 648 (031) 3.98
Other comprehensive income / (loss) attributable to:
|Owners of the Company 022 (1.09) 0.04 (1.30) (156)
Non controlling interests 0.00 (0.90) (0.18) (0.01) (0.06)
|Total comprehensive income / (loss) attributable to:
|Owners of the Company 329.47 18.04 842.67 624.08 457.18
Non controlling interests 3.36 (1.93) 630 (032) 392
[Earnings per equity share (Face value of Rs 1 each)-(Non annualized for the
period ended June 30, 2021 and June 30,2020) 37
1. Basic (Rs) 323 019 8.26 613 450
2. Diluted (Rs) 323 019 8.26 6.13 450
|Summary of significant accounting policies

 

 

 

Note: The above statement should be read with Significant Accounting Policies forming part of the Restated Consolidated Financial Information in Annexure V, Statement of Adjustments to|
[Restated Consolidated Financial Information in Annexure VI and Notes to Restated Consolidated Financial Information in Annexure VIL

[As per our Report of even date attached

For BS R & Associates LLP For and on behalf of the Board of Directors
Chartered Accountants Vijaya Diagnostic Centre Limited
ICAI Firm registration number: 116231W/ W-100024 (formerly known as 'Vijaya Diagnostic Centre Private Limited’)

CIN: U85195TG2002PLC039075

[Sriram Mahalingam Dr. $ Surendranath Reddy S Suprita Reddy
Partner Executive Chairman Chief Executive Officer
Membership Number: 049642 DIN Number: 00108599
K, Sunil Chandra Narasimha Raju K.A.
Executive Director Chief Financial Officer

DIN Number: 01409332

V. Sri Lakshmi
Company Secretary
Membership Number: F9950

Place: Hyderabad Place: Hyderabad
Date: August 16, 2021 Date: August 16, 2021

 

 

169
‘Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure III
Restated Consolidated Statement of Cash Flows
(All amounts are in Rs in millions, except share data or otherwise stated)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For3months | ForSmonths | Fortheyear | Fortheyear | Forthe year
Particulars period ended | period ended ended ended ended
June 30,2021 | June 30,2020. | March 31,2021 | March 31,2020 | March 31,2019
(A) CASH FLOW FROM OPERATING ACTIVITIES,
Profit before tax: 4215 648 12.24 834.27 653.18
Adjustments for:
Depreciation and Amortisation Expense 921 11635 504.53 491.70 396.26
Net gain on sale/ retirement of property, plant and equipment os) oan) (156) (491) 6.08)
Profit on slump sale of diagnostic centre (Refer note 48) - : (1822) .
Interest income san) e077) (25.96) (4263) (28.65)
Profit on sale of investment in mutual fund (185) as) 49.02) (9.06)
Provision made / (reversed) for bad and doubtful receivables, 137 339 461 1207
Fair value movement on on financial instruments 630) 629) (16.81) (8.8)
Liabilities written back 15.44) 735) (1736)
Employee stock option expense 3.73 078 1.96 410 220
Finance cost 188 849 20.96 40.02 3781
Bad and doubtful debts written-off 332 os7 039
Advances Written Off - 259 0.86 :
Interest expense on lease liabilities 3361 2801 114.13 99.25 8469
|Operating profit before working capital adjustments 568.30 138.75 1,654.30 132644 7,084.22
Adjustments for working capital :
(Increase) /Decrease in Inventories 6651) 738) 129 695) 243
(Increase) /Decrease in trade and other receivables 855 632 919 7.03 (2654)
(Increase) /Decrease in other financial assets andl loans 28:55 (046) 19.69) 2.09) (0.48)
(Increase) in other assets 73352) caso) (640) (40.22) (2242)
Increase/ (decrease) in trade payables 37.64 495) 467 (0.82) 4180
Increase/ (decrease) in other financial liabilities 3980 629) e014) 11.90 2822
(Decrease) in provision and other liabilities 025) 684) 238) 255) 6.04)
362.56 98.88 7,608.64 7298.99 7,092.19
Income tax paid 3.10) 187) 61221) 3287) (186.92)
INET CASH FLOW FROM OPERATING ACTIVITIES 509.85, 71 7,296.43 1,061.12 905.27
(8) CASH FLOW FROM INVESTING ACTIVITIES
Payment for purchase and construction of property, plant and equipment including (6256) 4870) 62136) 47547) 61039)
movement in capital work-in-progress, capital advances and capital creditors
Proceeds from disposal of Property, plant and equipment 181 om 9.03 100.60, 19.13
Investment/ redemption of debt oriented liquid mutual funds, (net) 535.73 27531 207.46 95.83,
Deposits placed (matured) having original maturity of more than 3 months, net 631.95) 745.1) (1308.05) (196.15) (409.42)
Dividend Received : : 121
Interest received 4357 Sat 47.50 5734 5.18
INET CASH FLOW USED IN INVESTING ACTIVITIES (66913) (52.53) (129757) (606.22) (698.46)
(C) CASH FLOW FROM FINANCING ACTIVITIES
Repayment of long term borrowings 6275) 257) (282.60) (69.38) (0467)
Proceeds from long term borrowings : 2 168.77
(Repayment) / proceeds from short term borrowing (Net) (0.05) 07a (1.08) (649) 19.13
Repayment of lease liabilities (including interest) 67.62) 6570) (189.65) (16750) (136.02)
Interest paid 5.18) (6.36) (1436) (62.04) 28.98)
INET CASH FLOW FROM/(USED) IN FINANCING ACTIVITIES, (105.60) (3.90) (457.69) (095.42) (777)
INet increase/(decrease) in cash and cash equivalents (A*B+C) wa (23933) (45833) 5948 (96)
[Cash and cash equivalents at the beginning of the period /year 6686 355.69 355.69 96.21 16.7
[Cash and cash equivalents at the end of the period/ year T0158 306.26 6686 355.69 96.21

 

170

 
‘Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure III
Restated Consolidated Statement of Cash Flows

(All amounts are in Rs in millions, except share data or otherwise stated)

 

 

 

 

 

For3months | ForSmonths | Fortheyear | Fortheyear | Forthe year
Particulars period ended | period ended ended ended ended
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
Reconciliation of Cash and Cash equivalents with the Balance Sheet
[cash and Bank Balances as per Balance Sheet
Balance with banks
= Onccurrent accounts 5019 23052 3867 5352.96 87.96
- in deposit accounts having maturity less than 3 months 3625 68.5, « 3
Jcash on hand 614 759 819 273 8.25
|Cash and cash equivalents at the end of the period/ year Tors 30626 6686 5. 3621
[Movement in financial liabilities:
lopening balance
INon-current borrowings 3275 221.38 201.33 31535 330.62
|Current borrowings ng? 107.07 10707 10891 oat
Lease liabilities (Refer Annexure VI - Part B) 1365.75 1,283.87 128387 110111 :
Interest accrued but not due on borrowings 1457 13.25 13.25 11.23 842
Movement
[cash flows (205.60) (3) (487.69) 7
Interest expense 3422 35.12 12980 168
lother non-cash movements
~ Additions / Disposals to lease liabilities (net) 22985 62.98 157.41 251.02 1158.13
[Closing balance
Non-current borrowings 197.41 3275 233 315.35,
Current borrowings ng2 109.5 ug7 10707 10891
Lease liabilities (Refer Annexure VI - Part B) 157159 1339.16 136575, 1,283.87 1,106.80
Interest accrued but not due on borrowings 13.99 1457 13.25 11.28

 

 

 

 

 

 

 

Notes

i) The above Restated Consolidated Statement of Cash flows has been prepared under the ‘Indirect Method’ as set out in the Indian Accounting Standard (Ind AS) 7 - "Statement of

Cash Flows

As per our Report of even date attached

For BS R & Associates LLP
Chartered Accountants
ICAI Firm registration number: 116231W/ W-100024

Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad
Date: August 16, 2021

For and on behalf of the Board of Directors
Vijaya Diagnostic Centre Limited

(formerly known as 'Vijaya Diagnostic Centre Private Limited’)
CIN: U851957G2002PL.C039075

Dr. § Surendranath Reddy
Executive Chairman
DIN Number: 00108599

K. Sunil Chandra
Executive Director
DIN Number: 01409332

Narasimha Raju K.A,
Chief Financial Officer

Place: Hyderabad
Date: August 16, 2021

71

S Suprita Reddy
Chief Executive Officer

V. Sri Lakshmi
Company Secretary
Membership Number: F9950

 
 

[Vijaya Diagnostic Centre Limited (Formerly Vijaya Diagnostic Centre Private Limited)

Annexure IV

Restated Consolidated Statement of Changes in Equity

(AI amounts are in Rs in millions, except share data or otherwise stated)

Equity Share Capital:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 30,2021 June 30,2020 ‘March 31, 2021 ‘March 31, 2020 March 31, 2019

Number of Amount Numberof Amount Number of Amount Numberof Amount Number of Amount

shares shares shares shares
Balance at the beginning of the reporting peviod/year 355,18,150 RT ASSL BT Baz BRT 452881 BI 452855 BS
Increase in shares on account of subdivision (refer note 17(v)) : = e : 5 y = =
[Shares issued during the year on account of bonus 36.65 is g é - : :
[Conversion of Series A Cumulative Compulsorily Convertible 2 ss 2 $ 3 1 0.00 3 5
Preference Shares (CCPS) (Refer note 18a)*
|Conversion of Series B Cumulative Compulsorily Convertible - 2 = s 3,008 003 . :
Preference Shares (CCPS) (Refer note 18a)
[Shares outstanding at the end of the period/year 10,19,65,926 101.97 __45,31,819 455245318190 45324531819 45324528813 4529
* The amounts are below million hence the same are not appearing
Other equity
Particulars cps” | CcPs Reserves and surplus Total Total Total
(Series A) | (Series B) | Securities] Employee | General] Retained | attributable to | attributable to
premium | stock options | reserve | earnings | owners of the |Non- controlling}
outstanding Company interest

Balance at April 1, 2018 413] 10.00/ 49157 - 49.32 | 1,004.11 1,545.00 (7.64) 1,537.36
Profit/ (loss) for the year - - - - - 458.74 458.74 3.98 462.72
Remeasurement of defined benefit obligation, net of tax - - - - - (1.56) (1.56) (0.06) (1.62)
[Total comprehensive income - = = = = 7.18 7.18 392 61.10
[Share based payment (Refer Note 44) - - : 2.22 - : 2.22 - 2.22
[Balance at March 31,2019 413 [10.00 [491.57 2.22 [49.32 [ 146129 2,004.40 672) 2,000.68
lind AS 116 transition adjustment (Refer Annexure VI) = = - 5 - BB BB = BB
[Restated balance at April 1, 2019 mis [_1000[ 49157 222 [4932 [ 1504.72 2,087.83 672) 2,044.11
Profit/ (loss) for the year - - - - 62538 C538 (031) 625.07
Remeasurement of defined benefit obligation, net of tax - - - : - (1.30) (1.30) (0.01) (131)
[Total comprehensive income 5 = : 7 7 624.08 624.08 (032) 623.76
[Conversion of CCPS into equity share capital aa (0.00 _-24.10 - - - 24.10 ~ 2410
[Share based payment (Refer Note 44) : - - 4.10 - - 4.10 - 4.10
[Balance at March 31, 2020 s : 515.67 632 [ 49.32 | 2,128.80 2,700.11 (04) 2,696.07
Profit/ (loss) for the period ~ = - - - 19.13 19.13 (103) 18.10
/Remeasurement of defined benefit obligation, net of tax - - - - - (1.09) (1.09) (0.90) (1.99)
[Total comprehensive income ¥ = = = = 18.04 18.04 (193) 16.11
[Share based payment (Refer Note 44) = = - O78 : = O78 = O78
Balance at June 30, 2020 2 = 515.67 740 [49.32 | 214684 2,718.93 6.97) 2,712.96
Balance at April 01, 2020 . : 515.67 632[ 49.32 [ 2,128.80 2,700.11 (4.04) 2,696.07
Profit/ (loss) for the year - ~ - - - 84268 8263 68 849.11
Remeasurement of defined benefit obligation, net of tax - - - - - 0.04 0.04 (0.18) (0.14)
[Total comprehensive income = = = = = 842.67 8267 630 848.97
[Share based payment (Refer Note 44) = = 5 196 - : 196 = 196
Balance at March 31, 2021 = = 315.67 8.28 [4932 [ 297147 3544.74 2.26 3,547.00
Profit/ (loss) for the period - - - - 329.69 329.69 356 333.26
Remeasurement of defined benefit obligation, net of tax - - - - - (0.22) (0.22) (0.00) (0.22)
[Total comprehensive income = = : = 5 329.47 32947 356 333.04
[Bonus issue of shares = = 66.65) - - (66.65) - (66.65)
[Share based payment (Refer Note 44) : : : 3.73 - - 3.73 - 3.73
Balance at June 30, 2021 = : 459.02 w01[ 49.32 | 3300.94 3821.29 3.82 3,827.12

 

 

 

 

 

 

 

 

 

 

 

|As per our report of even date attached

For BS R & Associates LLP
Chartered Accountants
ICAI Firm registration number: 116231W/ W-100024

[Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad
Date: August 16, 2021

For and on behalf of the Board of Directors
Vijaya Diagnostic Centre Limited
(formerly known as ‘Vijaya Diagnostic Centre Private Limited!)
CIN: U851957G2002PLC039075

Dr. $ Surendranath Reddy
Executive Chairman
DIN Number: 00108599

K. Sunil Chandra
Executive Director
DIN Number: 01409332

Place: Hyderabad

Date: August 16,

 

S Suprita Reddy

Chief Executive Officer

Narasimha Raju K.A.
Chief Financial Officer

V. Sri Lakshmi
Company Secretary
Membership Number: F950

 

172

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

1

(i)

Gi)

(ii)

(iv)

Corporate Information
Vijaya Diagnostic Centre Limited (formerly known as Vijaya Diagnostic Centre Private Limited) ("the Company" or "the Parent Company") together with its subsidiaries (collectively, "the
Group’) is engaged in the business of providing comprehensive range of diagnostic services spanning pathological investigations, basic and high end radiology, nuclear medicine and
related healthcare services.

‘The Company and its subsidiaries have been incorporated in India under the provisions of the Companies Act and Limited Liability Partnership Act. The Company is domiciled in India,
having its registered office located at # 3-6-16 & 17, Street No 19, Himayat Nagar, Hyderabad - 500 029, India and the Corporate office is located at # 6-3-883/F, Ground Floor of Family
Planning Association of India, Panjagutta, Hyderabad - 500 082, India.

‘The Company was converted into a public limited company under the Companies Act, 2013 on March 22, 2021 and consequently, the name was changed to “Vijaya Diagnostic Centre
Limited”,

Basis of preparation and measurement

Statement of compliance & Basis of preparation
The Restated Consolidated financial information of the group comprise of the Restated Consolidated Balance Sheet as at 30 June 2021, 30 June 2020, 31 March 2021, 31 March 2020, 31
March 2019 the related Restated Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Restated Consolidated Statement of Changes in Equity, and the
Restated Consolidated Statement of Cash Flows for the periods / years ended 30 June 2021, 30 June 2020, 31 March 2021, 31 March 2020, and 31 March 2019 , and the Significant
accounting policies and Restated Consolidated Other Financial Information (together referred to as ‘Restated Consolidated Financial Information’).

The Restated Consolidated Financial Information have been prepared on a going concern basis. The accounting policies are applied consistently to all the periods presented in the
Restated consolidated Financial Information except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires change in
accounting policy hitherto in use.

The Restated Consolidated Financial Information has been prepared for inclusion in the Offer Document to be filed by the Company with the Securities and Exchange Board of India
(‘SEBI) in connection with proposed Initial Public Offering of its equity shares, in accordance with the requirements of:

- Section 26 of part I of Chapter III of the Act;

evant provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, issued by the Securities and Exchange Board of India
(SEBI') as amended in pursuance of the Securities and Exchange Board of India Act, 1992; and

- Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (“ICAI”)

 

 

‘The Restated Consolidated Financial Information has been compiled by the Group from:
+ Audited Special Purpose Interim Consolidated financial statements of the Group as at and for the three months period ended 30 June 2021 and 30 June 2020 (being comparative period,
for the financials for the three months period ended 30 June 2021) prepared in accordance with the Indian Accounting Standard 34 “Interim Financial Reporting” (referred to as “Ind AS”)
as prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended and other accounting principles generally accepted in India,

+ Audited Consolidated financial statements of the Group as at and for year ended 31 March 2021, 31 March 2020 and 31 March 2019 prepared in accordance with Ind AS as prescribed,
under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules 2015, as amended and other accounting principles generally accepted in India and

- there were no changes in accounting policies during the year / period of these financial statements, except for the new and amended Ind AS-116- 'Leases'- Refer Annexure VI and Note
3

- there were no material amounts which have been adjusted for in arriving at profit of the respective periods; and

- there were no material adjustments for reclassification of the corresponding items of income, expenses, assets and liabilities, in order to bring them in line with the groupings as per the
audited special purpose interim consolidated financial statements of the Group as at and for the period ended 30 June 2021 and the requirements of the SEBI Regulations.

‘The group has given adjustments for lease accounting in accordance with Ind AS 116 which came into effect on April 01, 2019 using modified retrospective approach and all the related
figures have been reclassified/ regrouped to give effect to the requirements of Ind AS 116, refer Annexure VI - "Statement of Restated Adjustment to Consolidated Financial Statements"

‘The Restated Consolidated Financial Information were approved by the Board of Directors and authorised for issue on August 16, 2021

Functional and presentation currency
These Restated Consolidated Financial Information are presented in Indian Rupees (INR), which is also the Group's functional currency. All financial information presented in Indian
rupees have been rounded-off to two decimal places to the nearest million except share data or as otherwise stated.

Basis of measurement
‘The Restated Consolidated Financial Information have been prepared on the historical cost basis except for the following items:

 

 

~ Certain financial assets and liabilities [Measured at fair value
- Net defined benefit (asset)/ liability Fair value of plan assets less present value of defined benefit obligations
- Borrowings | Amortised cost using effective interest rate method

- Equity Share based payment at grantdate: [Measured at fair value

 

 

 

Use of estimates and judgements
In preparing these Restated Consolidated Financial Information, Management has made judgements, estimates and assumptions that affect the application of accounting policies and the
reported amounts of assets, liabilities, income and expenses. Actual results may differ from those estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.
Judgements
Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the Restated Consolidated Financial Information,

is included in the following notes:

- Note 3(L) and 41 - lease classification.
- Note 3(L) and 41 - Whether an arrangement contains a lease and lease classification;

173
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

w)

(vi)

Assumptions and estimation uncertainties
Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year are included in the following
notes:

- Note 3(G) - Impairment testing for goodwill generated on consolidation;

- Note 4 and Note 5 - determining an asset’s expected useful life and the expected residual value at the end of its life

-Note 12 - Impairment of financial assets;

- Note 43 ~ measurement of defined benefit obligations: key actuarial assumptions;

- Notes 38 ~ recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources;

Measurement of fair values
Group accounting polices and disclosures require measurement of fair value for both financial and non-financial assets

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value
measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

In the principal market for the asset or liability or

~In the absence of a principal market, in the most advantageous market for the asset or liability

‘The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would
use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Geoup ues valuation eons shat are appropiate in the circumstances and for which sufficient data is available to measure fair value, maximizing the use of relevant observable
inputs and minimizing the use of unobservable inputs.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.
Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (ie. as prices) or indirectly (ie. derived from prices).
Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall
into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.

‘The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in the measuring fair values is included in the following notes:
- Note 47 - Financial instruments

Principles of consolidation

Subsit
Subsidiaries are entities controlled by the Group. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the
ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

(i) Power over the investee (1e. existing rights that give it the current ability to direct the relevant activities of the investee);

(Gi) Exposure, or rights, to variable returns from its involvement with the investee; and

(iii) The ability to use its power over the investee to affect its returns.

 

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights
of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including

(i) The contractual arrangement with the other vote holders of the investee;

(Gi) Rights arising from other contractual arrangements;

(iii) The Group's voting rights and potential voting rights;

(iv) The size of the group's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders.

‘The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a
subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary
acquired or disposed of during the year are included in the Restated Consolidated Financial Information from the date the Group gains control until the date the Group ceases to control
the subsidiary.

Restated Consolidated Financial Information are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the Group,
uses accounting policies other than those adopted in the Restated Consolidated Financial Information for like transactions and events in similar circumstances, appropriate adjustments
are made to that Group member's financial statements in preparing the Restated Consolidated Financial Information to ensure conformity with the Group's accounting policies.

‘The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the Parent Company, i. year ended on March 31.

Consolidation procedures:
a. Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are
based on the amounts of the assets and liabilities recognized in the Restated Consolidated Financial Information at the acquisition date.

b. Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary. Business combinations policy explains how to
account for any related goodwill

¢. Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the Group (profits or losses resulting from
intragroup transactions that are recognized in assets, such as inventory and property, plant and equipment and intangible assets, are eliminated in full). Intragroup losses may indicate an
impairment that requires recognition in the Restated Consolidated Financial Information. Ind AS 12 Income Taxes applies to temporary differences that arise from the elimination of
profit and losses resulting from intragroup transactions.

174
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies

(All amounts are in Rs int millions, except share data or otherwise stated)

©. Non-controlling interests (NCI)
Clare measured at their proportionate share of the acquiree’s net identifiable assets at the date of acquisition.

Changes in the Group’s equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

d. Loss of control
‘A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.
If the Group loses control over a subsidiary, it:
(i) Derecognises the assets (including goodwill) and liabilities of the subsidiary.
(Gi) Derecognises the carrying amount of any non-controlling interests.
(iii) Derecognises the cumulative translation differences recorded in equity.
(iv) Recognises the fair value of the consideration received.
(v) Recognises the fair value of any investment retained.
(vi) Recognises any surplus or deficit in profit or loss.
(vii) Reclassifies the parent's share of components previously recognized in OCI to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly
disposed of the related assets or liabilities

   

 

 

 

 

 

 

 

€. Subsidiaries considered in the Restated Consolidated Financial Information:
‘Ownership interest in %
S.No. Name of the entity Relationship | Countryof | June 30,2021 | June30,2020 | March3i,2021 | March3i,2020 | March3i, 2019
incorporation

T__ |Medinova Diagnostic Services Limited [Subsidiary [India ae ae ae C2 2%

VDC Diagnostic (Karnataka) LLP ISubsidiary [India TO0% 100% 100% TOO% 100%

Doctors Lab Diagnostic Centre Private [Subsidiary [India TOO% 100% 100% TOO% 100%

Limited

F_ [Medinova Millennium MRIServices LLP* [Step down India 507% 307% 35.07% BB07% SB07%
|subsidiary

5 |Namrata Diagnostic Centre Private IStep down India TOO% 100% 100% TOO% TOO%
Limited** subsidiary

 

 

 

 

 

 

 

 

 

 

"Subsidiary of Medinova Diagnostic Services Limited
“Subsidiary of Doctors Lab Diagnostic Centre Private Limited

(vii) Current and non-current classification:
‘The Schedule Ill to the Act requires assets and liabilities to be classified as either current or non-current. The Group presents assets and liabilities in the balance sheet based on current/
non-current classification.

Assets
An asset is classified as a current when:

- it is expected to be realized in, or is intended for sale or consumption in, the Group's normal operating cycle;

- it is expected to be realized within twelve months from the reporting date;

- it is held primarily for the purposes of being traded; or

- is cash or cash equivalent unless itis restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.
All other assets are classified as non current

Liabilities
A liability is classified as a current when:

- itis expected to be realized in, or is intended for sale or consumption in, the Group's normal operating cycle;

- itis due to be settled within twelve months from the reporting date;

- itis held primarily for the purposes of being traded;

- Deferred tax assets/ liabilities are classified as non-current.

- the Group does not have an unconditional right to defer settlement of liability for at least twelve months from the reporting date.
All other liabilities are classified as non-current.

Operating Cycle
Operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Group has ascertained its operating cycle as 12 months for the
purpose of current or non-current classification of assets and liabilities.

3 Summary of significant accounting policies
A. Revenue recognition

i) Income from diagnostic services
Revenue from diagnostics services is recognized on amount billed net of discounts/ concessions if any. No element of financing is deemed present as the sales are made primarily on cash
and carry basis, however for institutional/ organisational customers a credit period of 30 days is given, which is consistent with market practice

‘The Group recognises revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and when the underlying tests are
conducted, samples are processed for requisitioned diagnostic tests. Each diagnostic service is generally a separate performance obligation and therefore revenue is recognised at a point
in time when the tests are conducted, samples are processed. For multiple tests, the Group measures the revenue in respect of each performance obligation at its relative stand alone
selling price and the transaction price is allocated accordingly. The price that is regularly charged for a test separately registered is considered to be the best evidence of its stand alone
selling price. Revenue contracts are on principal to principal basis and the Group is primarily responsible for fulfilling the performance obligation.

A contract liability is the obligation to transfer services to a customer for which the Group has received consideration from the customer. If a customer pays consideration before the
Group transfers services to the customer, a contract liability is recognised when the payment is made. Contract liabilities are recognised as revenue when the Group performs its
obligation under the contract.

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

i)

i)

Income from sale of Privilege cards
The Group operates a discount scheme where certain ‘Privilege cards’ are sold to the customers against which specified discounts are given on the future diagnostic services availed by the
customer for a specified period. The Group recognises revenue from the sale of such cards over the period for which the card is valid. The difference in sale consideration received and
revenue recognised is recognised as deferred revenue,

Recognition of dividend income, interest income

Dividend income is recognised in profit or loss on the date on which the Group’s right to receive payment is established,
Interest income is recognised using the effective interest rate method.

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest
income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash
receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Borrowing cost
Borrowing costs are interest and other costs incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which,

necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the
period in which they are incurred,

Financial instruments

A financial instrument is any contract that gives rise to a Financial Asset of one entity and Financial liability or equity instrument of another entity.

Initial measurement and recognition
Financial assets and financial liabilities are initially recognised when the Group becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is,
initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue

Classification and subsequent measurement

Financial assets

All financial assets except Trade receivables are initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly
attributable to its acquisition or issue.

Subsequent measurement
For the purpose of subsequent measurement, financial assets are categorised as under:
- Amortised cost;

- Fair Value through Other Comprehensive Income (FVOCI) - equity investment; or

- Fair Value Through Profit or Loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Group changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:
~ the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
= the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding,

On initial recognition of an equity investment that is not held for trading, the Group may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated
as FVOCI - equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition,
the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI or at FVTPL if doing so eliminates or
significantly reduces an accounting mismatch that would otherwise arise.

Financial assets at FVTPL: These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost : ‘These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses.
Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Equity investments at FVOCI: ‘These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery
of part of the cost of the investment, Other net gains and losses are recognised in OCI and are not reclassified to profit or loss.

Financial Liabilities:
Financial liabilities are measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if itis classified as held-for-trading, or it is a derivative or it is designated as
such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in statement of profit or loss.
Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in
statement of profit or loss.

 

Derecognition - Financial assets
‘A Financial asset is primarily derecognised when the right to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the
financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Group enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets,
the transferred assets are not derecognised.

176
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies

(All amounts are in Rs int millions, except share data or otherwise stated)

Derecognition - Financial liabilities
The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expired.

‘The Group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability
based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified
terms is recognised in profit or loss.

 

Financial Instruments Offsetting
Financial assets and financial liabilities are offset and the net amount reported in the balance sheet if there is a currently and legally enforceable right to set off the amounts and it intends
either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

 

 

 

 

 

 

E. Property, plant and equipment
i) Recognition and measurement
Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less accumulated depreciation and accumulated impairment loss, if
any. Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and
rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on
which it is located. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of
property, plant and equipment.
Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the
item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All
other repairs and maintenance are charged to statement of profit or loss during the reporting period in which they are incurred. If an item of property, plant and equipment is purchased
with deferred credit period from supplier, such asset is recorded at its cash price equivalent value.
ii) Depreciation
Depreciation is provided using the Written down value Method (‘WDV’) over the useful lives of the assets as estimated by the Management Depreciation on additions and deletions are
restricted to the period of use. Depreciation is charged to statement of profit and loss.
The Group entities, based on technical assessment and management estimate, depreciates certain items of property, plant and equipment over estimated useful lives which are different
from the useful life prescribed in Schedule Il to the Act. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the
assets are likely to be used. The Group has estimated the following useful lives to provide depreciation on its property, plant and equipment
[Asset category Useful life | Useful life as per
estimated by the | Schedule IT
Management
Buildings 60 years 60 years
Plant and equipment:
- Medical and diagnostic equipment 5 years - 13 years 13 years
- Other equipment T years - 15 years 15 years
Electrical equipment 10 years 10 years
Furniture and fixtures 5 years - 10 years 10 years
Office equipment 3 years -5 years 5 years|
Computers
~ Servers and networks 6 years| 6 years|
- End user devises such as laptops, etc. 3 years -5 years 3 years|
Vehicles 8 years| 8 years|
In case of Building on leasehold land, the depreciation is charged based on useful life of the building or the lease period which ever is lower. In the case of leaschold building,
improvements, the depreciation is charged based on useful life of the improvements which is 10 years or lease period which ever is lower.
Residual value is considered to be 5% on all the assets, as technically estimated by the management.
An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains or losses arising
from disposal of property, plant and equipment which are carried at cost are recognised in the statement of profit and loss.
F._ Intangible assets
i) Recognition and measurement
Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is,
capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.
ii) Amortisation

Amortisation is calculated to write off the cost of intangible assets over their estimated useful lives
amortisation in statement of profit and loss.

 

ing the "written down value" (WDV) method, and is included in depreciation and
The estimated useful lives are as follows
- Software -5 years

Amortisation method and useful lives are reviewed at the end of each financial year and adjusted if appropriate.

177

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

G.

Goodwill on consolidation

Goodwill acquired in business combination is allocated, at acquisition, to the cash generating units (CGUs) that are expected to benefit from that business combination. The carrying
amount of goodwill had been allocated as follows:

 

‘Asat] ‘Asat] ‘Asat] Asal] ‘Asal
June 30,2021] June 30,2020] March 31,2021] March 31, 2020] _ March 31, 2019]

 

 

[Goodwill on consolidation
I Medinova Diagnostic Services Limited 53.37 53.37 53.37 53.37] 53.37]
VDC Diagnostic (Karnataka) LLP : : : : 15.42

 

 

 

 

 

 

‘The Group's goodwill on consolidation are tested for impairment annually or more frequently if there are indications that goodwill might be impaired.

An impairment loss recognised for goodwill is not reversed in subsequent periods.
Further information about the assumptions made in testing impairment is included in the following notes:
- Note 5 - Goodwill

Capital work in progress

Capital work-in-progress is recognized at cost. It comprises of property, plant and equipment that are not yet ready for their intended use at the reporting date.

Inventories

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables, these are valued at lower of cost and net realizable value. Cost of inventories comprises of all
costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for recoverable taxes, if any. Cost is determined on First-in-First-out basis.
Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The comparison of cost and net realisable

value is made on an item-by-item basis.

 

Impairment of assets

Impairment of financial instruments
‘The Group recognises loss allowances for expected credit losses on financial assets measured at amortised cost and trade receivables. At each reporting date, the Group assesses whether
these financial assets are credit-impaired. A financial asset is ‘credit-impaired’ when one or more events that have a detrimental impact on the estimated future cash flows of the financial
asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data

- significant financial difficulty of the borrower or issuer;

~a breach of contract;

- it is probable that the borrower will enter bankruptcy or other financial reorganization; or

- the disappearance of an active market for a security because of financial difficulties.

‘The Group measures loss allowances at an amount equal to lifetime expected credit losses.
Loss allowances for trade receivables are always measured at an amount equal to lifetime expected credit losses.
Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

12-month expected credit losses are the portion of expected credit losses that result from default events that are possible within 12 months after the reporting date (or a shorter period if
the expected life of the instrument is less than 12 months).

Inall cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Group is exposed to credit risk.

 

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, the Group considers
reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the
Group's historical experience and informed credit assessment and including forward-looking information.

Measurement of expected credit losses
Expected credit losses are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (ie. the difference between the cash flows
due to the Group in accordance with the contract and the cash flows that the Group expects to receive).

Presentation of allowance for expected credit losses in the balance sheet
Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off
The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group
determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that
are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

178

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

i)

@

7)

(ii)

(iv)

@

Impairment of non-financial assets
‘The Group's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any
such indication exists, then the asset's recoverable amount is estimated,

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets
that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell, Value in use is based on the estimated future cash flows,
discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

The Group's corporate assets (e.g,, central office building for providing support to various CGUs) do not generate independent cash inflows. To determine impairment of a corporate
asset, recoverable amount is determined for the CGUs to which the corporate asset belongs.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and
loss.

In respect of assets for which impairment loss has been recognised in prior periods, the Group reviews at each reporting date whether there is any indication that the loss has decreased or
no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the
asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss has been recognised.

Employee benefits

Short-term employee benefits
Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the
related service are recognised in respect of employees’ services up to the end of the reporting period and are measured on an undiscounted basis at the amounts expected to be paid when
the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet

Defined contribution plans:
A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to
pay further amounts. The Group makes specified monthly contributions towards Government administered provident fund scheme and other funds. Obligations for contributions to
defined contribution plans are recognised as an employee benefit expense in profit or loss in the periods during which the related services are rendered by employees.

Defined benefit plans:
A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The liability or asset recognised in the balance sheet in respect of defined benefit plans is
the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by a qualified
actuary using the projected unit credit method.

‘The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on
government bonds that have terms approximating to the terms of the related obligation,

‘The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee
benefit expense in the statement of profit ang loss.

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other
‘comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet.

Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost.

Other long-term employee benefits
The liabilities for earned leave and sick leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are
therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period by a qualified actuary
using the projected unit credit method, The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related
obligation. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in profit or loss.

Share based payments
Employees of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments. The cost of equity-settled,
transactions is determined by the fair value at the date when the grant is made using Black Scholes valuation model. The grant date fair value of options granted to employees is
recognised as employee expense with a corresponding increase in employee stock options reserve, over the period in which the eligibility conditions are fulfilled and the employees
unconditionally become entitled to the awards. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which
the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The statement of profit and loss expense or credit for a period
represents the movement in cumulative expense recognised as at the beginning and end of that period and is recognised in employee benefits expense. The dilutive effect of outstanding
options is reflected as additional share dilution in the computation of diluted earnings per share.

Leases
Lease contracts entered by the Group majorly pertains for buildings taken on lease to conduct its business in the ordinary course.

Group as a Lessor:

Leases for which the Group is a lessor are classified as a finance or operating lease. Whenever the terms of a lease transfer substantially all the risks and rewards of ownership to the

lessee, the contract is classified as a finance lease. All other leases are classified as operating leases, Rental income from operating leases is recognised on straight line basis over the term of
relevant lease.

179
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

@

(ii)

Group as a Less
‘The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make
lease payments and right-of-use assets representing the right to use the underlying assets.

 

Under Ind AS 116, the Group assesses whether a contract is or contains a lease based on the definition of lease. On transition of IND AS 116, the Group elected to apply practical expedient
to grandfather the assessment of which transactions are leases. It applied Ind AS 116 only to contracts that were previously identified as leases. Contracts that were not identified as leases
under Ind AS 17 were not reassessed for whether there is a lease. Therefore the definition of lease under Ind AS 116 was applied only to contracts entered into or changed on or after April
01, 2018.

‘The Group determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Group is reasonably certain to
exercise that option; and periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option. In assessing whether the Group is reasonably
certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the
Group to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Group revises the lease term if there is a change in the non-cancellable period of a
lease.

‘The Group used the following practical expedients when applying Ind AS 116 to leases previously classified as operating leases under Ind AS 17.
- Applied a single discount rate to a portfolio of leases with similar characteristics.

- Applied the exemption not to recognise right-of-use assets and liabilities for leases with less than 12 months of lease term and leases of low value.
- Excluded initial direct costs from measuring the right-of-use asset at the date of initial application

- Used hindsight when determining the lease term if the contract contains options to extend or terminate the lease.

Right of use asset:
‘The Group recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at
inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives
received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or
site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any
remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-
of-use asset. The estimated useful lives of right-of use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment
whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

Lease Liability:
The Group measures the lease liability at present value of the future lease payments at the commencement date of the lease. The lease payments are discounted using the interest rate
implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Group uses incremental borrowing rate as at the commencement of lease. The
lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and
remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Group recognises the amount of the re-
measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the
carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the re-
‘measurement in statement of profit and loss.

Income-tax

Income-tax comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to an item recognised directly in equity or in other comprehensive

Current tax
Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years.
‘The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using,
tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the
liability on a net basis or simultaneously.

Deferred tax
Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used,
for taxation purposes. Deferred tax is not recognised for:

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or
loss at the time of the transaction; and

- temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that
they will not reverse in the foreseeable future;

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong
evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Group recognises a deferred tax asset only to the extent that it has sufficient
taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realized. Deferred tax assets
= Unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax
benefit will be realized.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or
substantively enacted by the reporting date.

‘The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.

180
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure V

Summary of Significant Accounting Policies
(All amounts are in Rs int millions, except share data or otherwise stated)

N.

Provision, contingent liabilities and contingent assets

A provision is recognised if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of
economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows (representing the best estimate of the expenditure
required to settle the present obligation at the balance sheet date) at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
‘The unwinding of the discount is recognised under finance costs. Expected future operating losses are not provided for. Provision in respect of loss contingencies relating to claims,
litigations, assessments, fines and penalties are recognised when it is probable that a liability has been incurred and the amount can be estimated reliably.

 

Contingent liabilities and continent assets:
A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present
obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote.

Contingent assets has to be recognised in the financial statements in the period in which if it is virtually certain that an inflow of economic benefits will arise. Contingent assets are
assessed continually and no such benefits were found for the current financial year.
Earnings per share

Basic Earnings Per Share (‘EPS’) is computed by dividing the net profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the
year. Diluted earnings per share is computed by dividing the net profit by the weighted average number of equity shares considered for deriving basic earnings per share and also the
weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of
the beginning of the year, unless issued at a later date. In computing diluted earnings per share, only potential equity shares that are dilutive and that either reduces earnings per share or
increases loss per share are included. The number of shares and potentially dilutive equity shares are adjusted retrospectively for all periods presented for the share splits.

Cash flow statement
Cash flows are reported using the indirect method, whereby net profit/ (loss) before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past
or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from regular revenue generating (operating
activities), investing and financing activities of the Group are segregated.

Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly
liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value,

Investments
Investments representing equity interest carried at cost less any provision for impairment. Investments are reviewed for impairment if events or changes in circumstances indicate that the
carrying amount may not be recoverable.

Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the
financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

Recent accounting pronouncements:

Ministry of Corporate Affairs (“MCA”) notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as amended from time to
time. There are no such recently issued standards or amendments to the existing standards for which the impact on the Restated Consolidated Financial Information is required to be
disclosed.

181
   

Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VI- Statement of Adjustments to Restated Consolidated Financial Information
(All emounts are in Rs in nllions, except share data or otherwise stated)

Part A: Statement of restatement adjustments

‘Summarised below are the restatement adjustments made to the profit after tax of the Audited Consolidated Financial Statements of the Group for the periods ended June 30,2021 and June 30,2020
& for the years ended March 31, 2021, March 31, 2020 and March 31, 2019 and their consequential impact on the profi (loss) of the Group:

 

 

maaan NoteNo. | Periodended | Period ended | Year ended March | Year ended March ] Year ended March

 

 

   

   

 

June 30,2021 | June 30,2020 31, 2021 31,2020 31,2019

INet profitaftertaxas per audited consolidated Financial Satements 33325 Tsi0 wie as 68
Adjustments
Material restatement Adjustments:

Audit qual n - - - :
[Total “ * ‘ . :

Adjustments due to prior period items /other adjustments
Adjustments on account of adaption of Ind AS 116 1
Depreciation - - 2 7 (113.64)|
Finance cost - - £ 7 (64.69)
Lease expenses - - £ 7 139,06
[Taxes for earlier years - 2.16) (2.68) 929
|Trotal 2 2 2.16) (2.68) 61.98)
(ii) Deferred tax impact on adjustments in (i) and (i), as applicable
Deferred tax impact on restatement adjustments 3 - - - : 1788
[Net profit after x as per Restated Consolidated Financial Information 3a Teo wear CET Ta

 

‘Summarised below are the restatement adjustments made to the equity of the Audited Consolidated Financial Statements of the Group for the periods ended June 30, 2020 and June 30,2021 & for
the years ended March 31, 2021, March 31, 2020 and March 31, 2019 and their consequential impact on the equity of the Group:

 

Period ended | Peri

 

‘ended | Year ended March | Year ended March | Year ended March

 

   

   

 

 

 

 

 

 

 

 

 

Particulars NoteNo [June 30,2021 | June 30,2020 31,2001 31,2020 31,2019

[Total Equity as per audited consolidated financial statements 390008 275828 35022 DBD 20809
Material restatement Adjustments

‘Audit qual z # £ : 2
rota 2 S 8 2

Adjustments due to prior period items /other adjustments
Adjustments on account of adoption of Ind AS 116 1 - * Z (1.27)
[Taxes for earlier years 2 - " > 216 484
otal - + - 216 (66.43)
(ii) Deferred tax impact on adjustments in i) and (i), a applicable
Deferred tax impact on restatement adjustments 3 . < : 2 1788
[Fotal equity as per Restated Consolidated Financial Information SBS aed 3SHE Brae TOI

 

Note :1 Adjustments on account of adoption of Ind AS 116
Ind AS 116- "Leases", which is mandatory wef. April 01, 2019, has replaced existing Ind AS 17 - Leases’. The Group has applied the modified retrospective approach on transition wee, April (1, 2019.
However for the restatement purpose, modified retrospective approach has been applied w-e.f April 1, 2018. The effect of implementing the standard is as under

“= Right of use (ROU) asset recognised on April 1, 2018

Lease liability recognised on April 01, 2018,

~ Other expenses are lower in March 31, 2019 by Rs. 139,06 million

Depreciation and amortisation expenses are higher in March 31, 2019 by Rs. 115,64 million

“Finance costs are higher in March 31, 2019 by Rs, 84.69 million,

 

As required by the Guidance Note, an adjustment of Rs. 43.43 million has been recorded in retained earnings on April D1, 2019 with a corresponding impact in Right-of-use assets to reflect and carry
forward the opening balance in these ine items as per the Audited Consolidated financial statements for year-ended March 31, 2020

Note 2: Taxes for earlier years
‘Taxes pertaining to earlier years has been adjusted in the Restated Consolidated Financial Information.

Note :3 Deferred tax assets (net):
Deferred tax has been computed on adjustments made as detailed above and has been adjusted in the Restated Consolidated Financial Information.

Note :4 Material regrouping : None
Appropriate regroupings have been made in the Restated Consolidated Balance Sheet, Restated Consolidated Statement of Profit & Loss and Restated Consolidated Statement of CashFlows, wherever
required, by reclassification of the corresponding items of income, expenses, assets, liabilities and cashflows, in order to bring them in line with the accounting policies and classification as per Ind AS
financial information of the Company for the period ended June 30, 2021 prepared in accordance with Schedule II] of Companies Act, 2013, requirements of Ind AS 1 and other applicable Ind AS
principles and the requirements ofthe Securities and Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations 2018, as amended,

182
 

ted)
Annexure VI- Statement of Adjustments to Restated Consolidated Financial Information
Alla

Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Li

 

outs are in Rs in millions, except share data or otherwise stated)

Part B: Reconciliation of total equity as per audited consolidated financial statements with total equity as per Restated Consolidated Financial Information as at March 31, 201%

‘The Group has followed the same accounting policy choices (transition options as per Ind AS 16) as adopted on April OL, 2019 for transition to Ind AS 116, while preparing the Restated Consolidated
Financial Information for each of the year ended 31 March 2021, 31 March 2020 and 31 March 2019. As specified in the Guidance Note, the equity balance computed under Restated Consolidated
Financial Information for the year ended 31 March 2019 and equity balance as per audited consolidated financial statements on 01 April 2019, differs due to restatement adjustments made for the year
ended 31 March 2019, Accordingly following balances as at 31 March 2019 of the Restated Consolidated Financial Information has not been carried forward to opening balance sheet as at April O1, 2019.

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Rightto use | Deferred'ax | Othercurrent ] Lease liability | Retained earnings

asset and Non-current|

assets

ialance as per Restated Consolidated Financial information as at TORR Ths ae Ti0e8 Tate
March 31, 2019
Addl: Adjustment on account of transition to Ind ASTI6 including, B30 way was 3w Ba
[corresponding deferred tax)
Balance carried forward as at Apr OI, 201) Tina 05) BES Tina Tso
cess: Taxes for earlier years e : a aaa
Balance as at March 31, 2019 as per audited consolidated financial Tana 05) Baa Tina TABS
statements for the year ended March 31, 2019

 

 

Part C: Non-adjusting items:
Audit Qualifications in Annexure to Auditors’ Report, which do not require any corrective adjustments in the Restated Consolidated Financial Information

In addition to the audit opinion on the consolidated financial statements, the auditors are required to comment upon the matters included in the Companies (Auditor's Report) Order, 2016 ("the CARO
2016 Order’) issued by the Central Government of India under sub-section (11) of Section 143 of Companies Act, 2013 on the standalone financial statements as at and for the financial years ended 31
March 2019, 31 March 2020 and 31 March 2021 respectively. Certain statements/comments included in the CARO in the standalone financial statements, which do not require any adjustments in the
Restated Consolidated Financial Information are reproduced below in respect of the financial statements presented.

 

Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

For the year ended March 31, 2019

Clause (vi) (b) of CARO 2016 Order
According to the information and explanations given to us and on the basis of our examination of the records of the company, there are no dues of Income-tax, Goods and Service tax, which have not
been deposited with appropriate authorities on account of any dispute. According to the information and explanations given to us, the following dues of duty of customs have not been deposited by the
‘company on account of disputes:

 

 

 

Nature of dues Name of he | Amount in Period to which Forum where the
statute the amount relates |dispute is pending
[Castoms duty, interest and penalty [Gastome Act 177 [FY 2006-2007 __ | CESTAT, West
i962 !Zonal bench,
Mumbai

 

 

 

 

 

 

For the year ended March 31, 2020

Clause (vi) (b) of CARO 2016 Order
According to the information and explanations given to us and on the basis of our examination of the records of the company, there are no dues of Income-tax, Goods and Service tax, which have not
been deposited with appropriate authorities on account of any dispute. According to the information and explanations given to us, the following dues of duty of customs have not been deposited by the
‘company on account of disputes:

 

 

 

Nature of dues Name of the | Amount in Period to which Forum where the
statute Ithe amount relates |dispute is pending
[Customs duty, interest and penalty [Customs Act 17 [FY 20062007 | CESTAT, West
1962 Zonal bench,
Mumbai

 

 

 

 

 

 

For the year ended March 31, 2021

Clause (vi) (b) of CARO 2016 Order
According to the information and explanations given to us and on the basis of our examination of the records of the company, there are no dues of Income-tax, Goods and Service tax, which have not
been deposited with appropriate authorities on account of any dispute. According to the information and explanations given to us, the following dues of duty of customs have not been deposited by the
‘company on account of disputes:

 

 

 

Nature of dues Name of the | Amount in Period to which Forum where the
statute the amount relates |dispute is pending
[Customs duty, interest and penalty [Customs Act 177 [FY 2006-2007 __ | CESTAT, West
1962 Zonal bench,
Mumbai

 

 

 

 

 

 

183

 

 

 
 

Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VI- Statement of Adjustments to Restated Consolidated Financial Information

 

(All emounts are in Rs in nllions, except share data or otherwise stated)

Medinova Diagnostic Services Limited

 

For the year ended March 31, 2019

Clause (vi) (b) of CARO 2016 Order

According to the information and explanations given tous, in respect of statutory dues there were no undisputed amounts payable in respect of Provident Fund, Employee's State Insurance, Income Tax,

Goods and Service Tax, Custom's Duty, Cess and other material statutory dues in arrears as at 31 March, 2019 for a period of more than six months from the date they became payable except in the

following cases:

 

 

 

 

 

 

[Name of the statute [Nature of dues ‘Amount in million
(Castoms Act 1562 [Dues including interest and penalty 003
income Tax Act 1961 Interest on delayed payment of interest (0.02

 

For the year ended March 31, 2020

Clause (vi) (b) of CARO 2016 Order

According to the information and explanations given tous, in respect of statutory dues there were no undisputed amounts payable in respect of Provident Fund, Employee's State Insurance, Income Tax,

Goods and Service Tax, Custom's Duty, Cess and other material statutory dues in arrears as at 31 March, 2020 for a period of more than six months from the date they

following cases:

 

became payable except in the

 

Name of the statute

Nature of dues

‘Amount in million

 

Castoms Act, 1562

Dus including interest and penalty

003

 

income Tax Act 1961

 

 

Interest on delayed payment of interest

02

 

 

As per our report of even date attached.

For BS R & Associates LLP
Chartered Accountants,
ICAI Firm registration number: 116231W/ W-100024

Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad.
Date: August 16, 2021

For and on behalf of the Board of Directors
Vijaya Diagnostic Centre Limited

(formerly known as "
CIN: U85195TG2002PLC039075

 

Dr. § Surendranath Reddy
Executive Chairman
DIN Number: 00108599

Narasimha Raju KA
Chief Financial Officer

Place: Hyderabad
Date: August 16, 2021

184

 

Chief Executive Officer

‘jaya Diagnostic Centre Private Limited’)

Reddy K. Sunil Chandra
Executive Director
DIN Number: 01409332

V. Sri Lakshmi
Company Secretary
Membership Number: F9950

 

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information

(All amounts are in Rs in millions, except share data or otherwise stated)

4, Property, plant and equipment and Capital work-in-progress

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Description Tand= Building Building on Teasehold Plantand ] Plantand | Electrical | Furniture | Office | Computers ] Vehicles Total
Freehold leasehold land | improvements | equipment- | equipment- | equipment | and fixtures | equipment
Medical Others

[Costas at April 1, 2018 2336 71.99 Tas T1L67 919.60 W277 0.73 Cary 73.20 218 20.38 621.70
Additions - 99.85 388.07 32.45 17.40 40.33, an 1418 19.35 o14.34
Disposals a s 23.05) (039) (045) : oan) (007) (659) (60.66)
[Cost as at March 31, 2019 (A) 2336 7199 THL.68 2H52 728462 204.83 77.68 10447 15.80 36.29 334 2,205.38
[Additions - 3699 217.87 2091 1931 3667 537 1206 550 354.68
Disposals (Refer note 48) est) 021) 0323) (6988) 659) G04) on) 055) sy) 630) (113.43)
[Costas at March 31, 2020 (©) 2055 78 141.68 235.28 T8261 220.15 93.95 137.13 20.62 758 3534 2446.63
[Additions = - - 18H 60.30 225 228 350 035 157 - 72.09
Disposals - Z = s : - (024) : : : : (0.14)
[Cost as at June 30, 2020 (E) 20.55 o78 TH1.68 Braz TA9291 22.40 36.09 140.63 2097 oat 3534 2518.58
[Cost as at April 01, 2021 20.55 O78 141.68 235.28 T3261 220.15 93.95 137.413 20.62 758 3534 246.68
[Additions 2 Tee 2984 1649 13.08 14.03 259 929 060 302.34
Disposals 3 : 20.07) (22) (037) : : (oan) (21.03)
[Costas at March 31, 2021 (G) 205 ars 141.68 1692.38 23652 [ 10662 15116 23.21 3685 3547 2727.98
[Additions 39.30 17 403 435 076 224 077 57.90
Disposals : e7) 08) : : : (419)
[Costas at June 30,2021 (I) 20.55 o78 T4168 167797 237.21 110.65 15551 B97 5907 36.28 2781.65
Accumulated depreciation as at April 1, 2018 a 419 2839 2131 267.20 107.15 2237 24.62 748 1344 506.22
Depreciation for the year 3.36 1076 40.36 15961 18.98 1212 1458 345 812 277.08
Disposals/adjustments : : (118) 29) (0.24) 2 oan) (005) fern) (5.21)
[Accumulated depreciation as at March 31, 2019 (B) = 395 C67 415.63 125.94 3425 39.20 1049 221 13.00 768.08
Depreciation for the year 965 47.08 208.00 1701 1376 284 342 Tm 673 341.49
Disposals/adjustments 687) (4109) 6.04) 216) 258) (051) (077) 269) (61.42)
[Accumulated depreciation as at March 31, 2020 (D) = 8.68 8.80 01.88 382.59 991 5.85 5846 13.40 3155 17.08 1048.16
[Depreciation for the period 065 215 er 4626 389 3a? 520 089 209 18 7534
Disposals/adjustments : : : (oa) : : : (0.13)
[Accumulated depreciation as at fune 30, 2020 (F) = 9333 5095 Tas 28.85 143.80 48.88 3.66 1429 33.68 1847 1123.36
[Accumulated depreciation as at April 01, 2020 z 368 880 101.88 382.59 13951 585 5846 340 3155 17.04 7048.16
Depreciation for the year 259 861 4038 209.74 167 1340 aT 4B 10.89 5.86 335.68
Disposals/adjustments : - 0278) (0.06) 02a) : : (03) (1354)
[Accumulated depreciation as at March 31, 2021 (H) = 127 7a 142.26 779.55 156.62 59.98 8087 17.68 ET) 2247 137030
[Depreciation for the period Or 192 5.06 4635 3.80 36 18 O74 196 100 72.26
Disposals/adjustments i = on) (027) : : : : 2.88)
[Accumulated depreciation as at June 30,2021) z T1868 59.38 15032 23.27 160.15 oad 85.55 1837 420 Ba? 1439.68
Net carrying amount as at March 31, 2019 (Ay-(B) 23.36 oat 102.53 1493 868.99 7859 Bas G27 531 15.08 208 1437.29
Net carrying amount as at March 31, 2020 (C)- (D) 2055 53.0 92.88, 733.40 350.02 8024 8:10 7867 72 5.99 18.30 139847
[Net carrying amount as at June 30,2020 (E)-(F) 2055 5205 90:73 135.63 364.06 78.60 a7 7697 6.68 15.47 1687, 1395.22
[Net carrying amount as at March 31, 2021 (G)- (H) 20355 5051 az 109.48 862.83 73.90 16.64 70.29 558 1459 13.00 1357.64
[Net carrying amount as at June 30,2021 ()- 0) 20.55 39.90 235, 106.70 854.70 7.06 4751 0.96 14.87 277 134197

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

T Refer to note 38 for disclosure of contractual commitments for the acquisition of properly, plant and equipment

2. Refer to note 19 for details of property plant and equipment subject to charges on secured borrowings.

185

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information

(All amounts are in Rs in millions, except share data or otherwise stated)

4, Property, plant and equipment and Capital work-in-progress
Title deeds of Immovable Properties not held in name of the Company:
[Description June 30,2021 | June 30, 2020 | March 31,2021 | March 1, 2020 | March 31, 2019
Title deeds held in the name of Vijaya Diagnostic Centre Limited

 

 

Whether title deed holder is a promoter, director or relative of

 

 

 

 

 

 

promoter/ director or employee of promoter/ director NA
Reason for not being held in the name of the Company NA
Capital work.
[Description ‘Asat ‘As at sat ‘sat ‘Asat

June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
Balance at the beginning of the period/ year waa 261 261 27.09 2694
Additions during the period/year 7 133.14 291.55 420.20 e14ag
Less: Capitalisations 67.) (7226) 02.33) (354.68) (143)
[Balance at the end of the perlod/year O71 15349 a2 261 27.09

 

 

Note: The company does not have any CWIP which is overdue of has exceeded its cost compared to its original plan and hence CWIP completion schedule is not applicable
CWIP Ageing Schedule:

As at June 30, 2021

 

“Amount in CWIP fora period of

 

 

 

 

 

 

 

 

 

 

cwrr Less than T Total
Year iaveate 23Years | More Than 3 Years
Projects in progress worl > - ori
Projects temporarily suspended z * é
As at June 30, 2020
‘Amount in CWIP fora period of
cwIr Less than 1 Total
‘Year Tatar 23Years | More Than 3 Years
Projects in progress 153.49 - : 153.49
Projects temporarily suspended “ - -
As at March 31, 2021
‘Amount in CWIP fora period of
‘cwIP Tess than T Total
Year a2-Yeare 2-3Years | More Than 3 Years
Projects in progress waa s : wa2

Projects temporarily suspended 2 z z

 

As at March 31, 2020

 

‘Amount in CWIP for a period of
‘cwrP Less than T Total
Year Tae 2-3Years | More Than 3 Years
Projects in progress Crs : 261
Projects temporarily suspended = « : : -

 

 

 

As at March 31, 2019

 

‘Amount in CWIP fora period of
cwrr Less than T Total
Year a Nears. 23Years | More Than 3 Years
Projects in progress 2681 1s - B08
Projects temporarily suspended : z Z

 

 

 

 

 

 

 

 

 

 

186
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

5. Other intangible assets , Goodwill and Intangible assets under development

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Description Other intangible Goodwill
assets - Software
[Costas at April, 2018 10.86 68:79
Additions 6.68 2
[Cost as at March 31, 2019 (A) 1754 8:79
Additions 7 =
Disposals (Refer note 48) 032) 15.42)
[Cost as at March 31, 2020 (C) 26.39 53.37
Additions 007
Disposals 2 =
[Costas at June 30, 2020 (E) 2646 5337
[Costas at April 01, 2020 26.39 5337
Additions 029
Disposals z :
[Cost as at March 31, 2021 (G) 26.68 5337
Additions TO62 zi
Disposals - -
[Cost as at June 30, 2021 (I) 37.30 53.37
/Accumulated amortisation / impairment as at April 1, 2018 z
Amortisation / impairment for the year z
[Accumulated amortisation / impairment as at March 31, 2019 (B) :
“Amortisation / Impairment for the year 626 z
Disposals 031) :
[Accumulated amortisation /impairment as at March 31, 2020 (D) 16.03 z
[Amortisation / impairment for the period Liz :
Disposals : :
[Accumulated amortisation / impairment as at June 30, 2020 (F) 1720 z
[Accumulated amortisation /impairment as at April 01, 2020 16.03 =
“Amortisation / impairment for the year tot
Disposals 2 =
[Accumulated amortisation / impairment as at March 31, 2021 (H) 20.67
‘Amortisation / impairment for the period 165 =
Disposals 3 z
[Accumulated amortisation / impairment as at June 30,2021 () 2232 :
[Net carrying amount as at March 31, 2019 (A)- (B) 76 68.79
[Net carrying amount as at March 31, 2020 (C)-(D) 10.36 53.37
[Net carrying amount as at June 30, 2020 (E)- (F) 9.26 53.37
[Net carrying amount as at March 31, 2021 (G)- () or 53.37
[Net carrying amount as at June 30,2021 (0-0) 14.98 5337

 

Goodwill acquired in business combination is allocated, at acquisition, fo the cash generating units (CGUs) that are expected to benefit from that business combination.

‘The carrying amount of goodwill had been allocated as follows:

 

 

 

 

 

 

 

 

As al] ‘As at] ‘As atl ‘As at! As at]
June 30,2021} June 30,2020] March 31,2021] | March 31, 2020] March 31, 2019

[Goodwill on consolidation
Medinova Diagnostic Services Limited 53.37] 53.37 53.37 53.37] 53.37]
VDC Diagnostic (Karnataka) LLP - - - - 15.42]

 

‘The Group performed its annual impairment test for years ended March 31, 2021, March 31, 2020 and March 31, 2019.

 

Impairment testing for cash generating unit containing goodwi

The recoverable amount of the CGU, has been determined based on a value in use calculation using cash flow projections from financial budgets approved by the
Management covering a five year period. The pre-tax discount rate applied to cash flow projections for impairment testing during the years is stated in the below table
and cash flows beyond the five year period are extrapolated using a long term growth rate as stated in the below table that is the same as the long-term average growth

rate for the Diagnostic service industry

187

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

The following table sets out the key assumption for the Cash Generating Unit ("CGU’) for performing the annual impairment test

 

Medinova Diagnostic Services Limited

VDC Diagnostic
(Karnataka) LLP

 

 

 

 

 

 

March 31,2021 | March 31,2020 | March 31, 2019 March 31, 2019
Discount rate 1% 10% Tom 10%]
{Terminal growth rate 5% 5% 5% 5%

 

 

 

‘The discount rate is based on the Weighted Average Cost of Capital (WACC) which represents the weighted average return attributable to all the assets of the CGU

‘There is no impairment noted in the above CGUs based on the assessment performed by the Management. Management has performed sensitivit

analysis around the

base assumption and have concluded that no reasonable possible change in key assumptions would cause the recoverable amount of the CGU lower than the carrying

amount of CGU.

No impairment on goodwill was recognized during the current period or earlier years.

Intangible assets under development

 

 

‘Asat ‘As at ‘Asat ‘As at “Asat
Description June 30, 2021, June 30,2020 | March 31,2021 | March 31, 2020 March 31, 2019

Balance at the beginning of the period/year 1236 365 365 = 3
Additions during the period/year < a7i 3.65 -
Less: Capitalisations (8.85) 7 : %
Balance at the end of the period/year 351 3.65 12.36 3.65 =

 

 

 

 

 

 

 

Note: The Company does not have any Intangibe asset under development which is overdue or has exceeded its cost compared to its original plan and hence Intangible
assets completion schedule is not applicable.

Intangible assets under development ageing

As at June 30, 2021

 

Intangible assets under

‘Amount in Intangible assets under development for a period of

 

 

 

development Less than 1 Year] 1-2 Years 2.3 Years More Than 8 Total
Years
Projects in progress z 31 E 351
Projects temporarily suspended = i" - - :
Total = 351 3 :

 

 

As at June 30, 2020

 

Intangible assets under

‘Amount in Intangible

assets under development for a period of

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

development Lessthan1 Year| 1-2 Years 2.3 Years More thers Total
Years
Projects in progress = 365 = : 3.65
Projects temporarily suspended : - : : -
[Total = 365 5 z 365
As at March 31, 2021
; ‘Amount in Intangible assets under development for a period of
Intangible assets under es
development Less than 1 Year] 1-2 Years 2.3 Years Total
Years
Projects in progress 402 334 = - 12.36
Projects temporarily suspended . : :
[Total 402 3m ; : 1236
As at March 31, 2020
3 ‘Amount in Intangible assets under development for a period of
Intangible assets under WEST
development Less than 1 Year] 1-2 Years 2:3 Years Total
Years
Projects in progress 3.65 7 : : 365
Projects temporarily suspended - - : : -
[Total 365 : : : 365
As at March 31, 2019
ritasigb asses wna ‘Amount in Intangible assets under development for a period of
development Less than Year| 1-2 Years 2.3 Years Meee 8 Total

 

Projects in progress
Projects temporarily suspended

 

[Total

 

 

 

 

 

 

 

 

188

 
‘Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

6. Right of use asset (ROU)
A new lease standard ie, Ind AS 116 has been notified to be effective w.ef. April 1, 2019 which provide guidelines for the accounting of the lease contracts entered
in the capai

 

ty of a lessee and a lessor. For the purpose of preparation of Restated Consolidated Financial Information, the management has evaluated the impact of
change in accounting policies on adoption of Ind AS 116 for the year ended March 31, 2019. Hence in these Restated Consolidated Financial Information, Ind AS 116
has been adopted with effect from April 1, 2018 following modified retrospective method (ie. on April 1, 2018 the Group has measured the lease liability at the
present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate and a right-of-use asset at an amount equal to the lease
liability). The weighted average rate applied is 8.5%. The nature and effect of the changes as a result of adoption of Ind AS 116 is described below.

Ind AS 116 supersedes Ind AS 17 Leases including its appendices (Appendix C of Ind AS 17 Determining whether an Arrangement contains a Lease, Appendix A of
Ind AS 17 Operating Leases- Incentives and Appendix B of Ind AS 17 Evaluating the Substance of Transactions Involving the Legal Form of a Lease). The standard
sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet.

‘The Group has elected not to apply the requirements of Ind AS 116 "Leases" to short-term leases of all assets that have a lease term of 12 months or less and leases,
for which the underlying asset is of low value. The lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease
term except inflation adjustment.

‘The Group has lease contracts mainly for buildings used in its operations. Leases of building generally have lease terms between 2 and 25 years. The Group's
obligations under its leases are secured by the lessor’s title to the leased assets,

‘The Group also has certain leases of buildings with lease terms of 12 months or less with no purchase option and leases of office equipment with low value. The
Group applies the ‘short-term lease’ and ‘lease of low-value assets’ recognition exemptions for these leases.

‘The adoption of this newly issued accounting standard Ind AS 116 "Lease" resulted in recognition of "Right of Use" asset of Rs, 938.43 million and a lease liability of
Rs, 938.43 million as at April 1, 2018. Consequently, the profit before tax for the year ended March 31, 2019 is lower by Rs. 61.27 million.

Ind AS 116 has resulted in an increase in cash inflows from operating activities and an increase in cash outflows from financing activities on account of lease
payments.
Impact of IndAs 116 on the operating results of the Company:

 

 

 

 

 

 

 

June 30,2021 June 30,2020 March 31, 2021 March 31, 2020 March 31, 2019
Particulars Ind AS116 | IndASI7 | IndASI16 | Ind ASI7 | IndASII6 | IndAS17 | IndASII6 | Ind ASI7 | Ind ASII6 | Ind ASI7
[Depreciation expenses 3530 = 3o8e Tea2T = 143.95 : Tis6t =
interest expenses 33.61 = 28.01 T1413 = 99.25 : 34.69. =
[Lease payments : 37.62 = 35.70 : 189.65 : Te751 = 136.02
[Prepaid rent expense z 131 113 469 433 3.04
[Total 7891 393 67.85 3683 27834 194.34 243.20 T7184 200.33 139.06

 

 

 

 

 

 

 

 

 

 

 

 

 

189
‘Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

(i) Movement in Right of use assets and Lease liabilities is given below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Description Building
[Cost as at April 1, 2018 =
Transitional impact of Ind AS 116 938.43
Additions 219.70
Adjustment (prepaid rent on present value of security deposit) 36.32
Disposals :
[Cost as at March 31, 2019 (A) T1985
lind AS 116 transition adjustment (Refer Annexure VI- Part B) (3.34)
[Cost as at April 1, 2019 (Refer Annexure VI- Part B) T1011
Additions 301.80
Disposals 6.19)
[Cost as at March 31, 2020(C) 1397.72
Additions 6.37
Disposals (020)
[Cost as at June 30, 2020(E) 1460.89
[Cost as at April 01, 2020 139772
Additions 170.58
Disposals 7.49)
[Cost as at March 31, 2021 (G) 1,360.81
Additions 237.87
Disposals :
[Cost as at June 30, 2021 (I) 1,798.68
Accumulated Depreciation as at April 1, 2018 *
Depreciation for the year 115.64
Disposals :
‘Accumulated Depreciation as at March 31, 2019 (B) 115.68
Ind AS 116 transition adjustment (Refer Annexure VI- Part B) (15.64)
‘Accumulated Depreciation as at April 1, 2019 3
[Depreciation for the year 143.95
Disposals :
‘Accumulated Depreciation as at March 31, 2020 (D) 143.95
[Depreciation for the period 39.84
Disposals (0.07)
‘Accumulated Depreciation as at June 30, 2020 (F) 183.72
‘Accumulated Depreciation as at April 01, 2020 103.95
[Depreciation for the year Te421
Disposals (7.36)
‘Accumulated Depreciation as at March 31, 2021 (H) 300.80
[Depreciation for the period 5.30
Disposals :
‘Accumulated Depreciation as at June 30, 2021 (J) 346.10
[Net carrying amount as at March 31, 2019 (A)- (B) 1078.81
[Net carrying amount as at March 31, 2020 (C)- (D) 1258.7
[Net carrying amount as at June 30, 2020 (E)- (F) T277d7
[Net carrying amount as at March 31, 2021 (G)- (H) 7,260.01
[Net carrying amount as at June 30,2021 (1)- ) TAS258

 

‘The aggregate depreciation expense on ROU assets is shown under depreciation and amortisation expense in the Restated Consolidated Statement of Profits and

Losses.

190

 
‘Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

Set out below are the carrying amounts of lease liabilities and the movements during the period/year:

(i) Lease liabilities included in the Restated Consolidated Balance Sheet:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

‘Asat
June 30, 2021_[ June 30, 2020 [ March 31, 2021 | March 31, 2020 | March 31, 2019
[Opening Balance (Refer Annexure VI- Part B) 1,365.75 1,283.87 1,283.87 7,106.80 ~
Jind AS 116 transition adjustment as at April 1, 2019 = » : 669) -
Restated balance as at April 1, 2019 - - - 401.11 :
Recognised on adoption of Ind AS 116 - - : - 938.43
Additions during the period /year 229.85 63.12 157.55 256.21 219.70
Disposal during the period / year 6 a4) 014) 619) -
[Accretion of interest 33.61 28.01 114.13 99.25 84.69
Payment of lease liabilities 67.02) 6570) 189.65) 67.51) (136.02)
[Closing Balance TS7159 1,339.16 1365.75 1,283.87 7,106.80
Classification of lease liabilities
Current 108.23 90.52 101.03 87.77 72.64
Non-current 1,463.36 1,248.64 1,264.72, 1,196.10 1,034.16
(i) Payments recognised as expense
Period ended Year ended
June 30, 2021] June 30,2020] March 31, 2021 | March 31, 2020 [ March 31, 2019
[Short term Teases and low value assets 308 Tor 62 1478 T628
oUF oer 6.62 14.78 16.28
(ii) Contractual maturities of lease liabilities on undiscounted basis
‘Asat
June 30, 2021 _[ June 30, 2020 [ March 31, 2021 | March 31, 2020 | March 31, 2019
[Less than one year D874 20188 2432 194.46 15895
JOne to five years 954.66 852.25 880.83 813.75 e721
More than five years 1,287.99) 1,026.09 1,009.19 9795 882.05
ABT ST ZBOZ OTST T8776 T7121]

 

 

 

 

 

 

 

 

191
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

 

Particulars

‘Asat
June 30, 2021

As at
June 30, 2020

‘Asat
March 31, 2021

‘Asat
March 31, 2020

‘Asat
March 31, 2019

 

 

I7. Non current investments

Equity investment (at FVTOCI) - unquoted
ICR Broadcasting Hyderabad Limited

40,000 (June 30, 2020, March 31, 2021, March 31, 2020 and March 31, 2019: 40,000) equity
Ishares of Rs. 10 each fully paid up

| Aggregate value of unquoted investments
| Aggregate value of impairment in value of investments

1s. Other non-current financial assets

lUnsecured, considered good
Balances with bank held as margin money

[Deposit accounts with remaining maturity of more than 12 Months
ISecurity deposits *

Interest accrued on bank deposits and others

Total

+ Includes amount receivable from related parties (refer note 45)

9. Other non-current assets

lUnsecured, considered good
ICapital advances
| Advances other than capital advances
Prepaid expenses,

Total

110. Inventories

(Valued at cost or Net Realisable Value whichever is lower)
lreagents, chemicals, digital Imaging films and consumables

Total
l11. Investments

Icurrent
lInvestments at fair value through profit or loss - quoted

IIDFC Cash Fund Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil, March 31, 2020:
17,241.08 and March 31, 2019: 17,241.08) units of Rs. 1,000 each

| Aditya Birla Sunlife Floating Rate Fund - 224,182.96 (June 30, 2020: Nil, March 31, 2021

1224 182.96, March 31, 2020: Nil and March 31, 2019: Nil) units of Rs. 100 each

| Aditya Birla Sunlife Low Duration Fund - 73,574.67 (June 30, 2020: Nil, March 31, 2021:
173,574.67, March 31, 2020: Nil and March 31, 2019: Nil) units of Rs. 100 each

IDFC Low Duration Fund Growth -3,305,908.39 (June 30, 2020: Nil, March 31, 2021
13,305,908.39, March 31, 2020: Nil and March 31, 2019: 3,759,508.42) units of Rs. 10 each
IIDFC Corporate Bond Fund - Nil June 30, 2020: Nil, March 31, 2021: Nil, March 31, 2020: Nil
land March 31, 2019: 4,284,747.15) units of Rs, 10 each

IDFC Ultra Short term fund Growth - Nil (lune 30, 2020: Nil, March 31, 2021: Nil, March 31,
12020: Nil and March 31, 2019: 1,905,034.05) units of Rs. 10 each

Birla Sunlife Savings Growth - Nil une 30, 2020: Nil, March 31, 2021: Nil, March 31, 2020:
|Niil and March 31, 2019: 123,416.24) units of Rs. 100 each.

Birla Sunlife Savings Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nill, March 31, 2020:
465,980.33 and March 31, 2019: 465,980.33) units of Rs. 100 each

Reliance Prime Debt Growth - Nil (une 30, 2020: Nil, March 31, 2021: Nill, March 31, 2020:
12,215,404.46 and March 31, 2019: 2,215404.46) units of Rs. 10 each.

|HDFC Floting Rate Debt Growth - Nil (June 30, 2020: Nil, March 31, 2020: Nil, March 31,
!2020: 3,509,067.43 and March 31, 2019: 3,509,067.43) units of Rs. 10 each

Kotak Low Duration Fund - 12,724.06 June 30, 2020: Nil, March 31, 2021: 12,724.06, March
[31, 2020: Nil and March 31, 2019: Nil) units of Rs. 1,000 each

HDC Low Duration Fund - 805,643.61 (June 30, 2020: Nil, March 31, 2021: 805,643.61,
March 31, 2020: Nil and March 31, 2019: Nil) units of Rs. 10 each

Invesco India Money Market Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil, March 31,
12020: Nil and March 31, 2019: 9,295.86) units of Rs. 1,000 each.

Kotak Money Market Scheme Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil, March.
131, 2020: Nil and March 31, 2019: 3,272.57) units of Rs. 1,000 each

Invesco India Liquid Fund Growth - Nil (june 30, 2020: Nil, March 31, 2021: Nil, March 31,
12020: Nil and March 31, 2019: 7,936.60) units of Rs. 1,000 each

Invesco India Short Term Fund Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil, March
[31, 2020: 19,335.13 and March 31, 2019: Nil) units of Rs. 100 each

Invesco India Treasury Advantage Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil,
|March 31, 2020: 3,636.37 and March 31, 2019: Nil) units of Rs. 1,000 each

Invesco India Treasury Advantage Growth - Nil (June 30, 2020: Nil, March 31, 2021: Nil,
|March 31, 2020: 7,257.83 and March 31, 2019: Nil) units of Rs. 1,000 each

IDFC Cash Fund Growth - Nil (June 30, 2020: 5,249.65, March 31, 2021: Nil, March 31, 2020:
INil and March 31, 2019: Nil) units of Rs. 1,000 each

IDFC Cash Fund-Growth-Growth - Nil June 30, 2020: Nil, March 31, 2021: Nil, March 31,
12020: 5,290.91 and March 31, 2019: Nil) units of Rs. 1,000 each

lrotal

| Aggregate book value of quoted investments
|Ageregate market value of quoted investments

040

040

040

040

040

 

040

040

040

a0

a0

 

 

040

104
118.29
62.42
3.38

040

092

51.38

040

104
58.69
61.97

052

040

1.00

53.85

040

0.96

42.22

 

185.13

5230

122.22

5a85

Bas

 

 

51.48

26.43

1351
259
18.88

34.76

26.33

4141
259
292

345
259
046

 

7791

398

e109

6.62

650

 

 

62.95

3531

26.44

2773

21.78

 

6295

3531

264d

27s

278

 

 

61.50

a4

102.35

35,74

38.84

12.75

60.68

40.62

101.35

4141

186.78

96.16

124.16

5434

1041

207

Rm

39.09

100.55

55.10

2020

45.88

173.23

88.87

114.76

2017

10.10

20.42

 

BST

275

2627

Ez

e857

 

 

 

27957
27957

 

 

276.27
76.27

 

546.74
546.74

 

688.37
688.37

 

192

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

(All amounts are it Rs in millions, excep share data or otierwis stated)
Particulars ‘Asat Asat ‘sat ‘As at ‘sat
June 30,2021 | June30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
iia. Trade receivables
|- Unsecured, considered good* 5552 n27 64.08 7997 91.25
|. Unsecured Credit impaired 1532 17.91 1532 1654 18.09
7084 90.18 79.40 9651 T0934
Less: Allowance for doubtful trade receivables (expected credit loss allowance) (15.2) (1791) (15.32) (16.58) (18.09)
Hrotal 3552 7227 G08 7997 3125
F Includes amount receivable irom related partes (ofer note a5)
Itrade Receivables ageing schedule:
|As at June 30,2021,
Particulars ‘Outstanding for following periods from due date of payment
Tessthané | months-1 | I-2years 73 years More than Total
months year years
i) Undisputed Trade receivables ~ considered good a Tat Tae 038 001 3552
i) Undisputed Trade Receivables - which have significant inerease in
credit risk
ii) Undisputed Trade Receivables ~ credit impaired 023 3.07 384 213 oo 9.28
iv) Disputed Trade Receivables- considered good
(v) Disputed Trade Receivables - which have significant increase in
Jeredit risk
(vi) Disputed Trade Receivables ~ credit impaired 3.66 238 6.04
fFotal a1a6 1551 530 617 2.40 7084
|As at June 30,2020
Particulars Duistanding for following periods from due date of payment
Tessthané | months-1 | I-2years 73 years More than Total
months year years
i Undisputed Trade receivables ~ considered good 856 292 Taz 037 7227
i) Undisputed Trade Receivables - which have significant increase in
credit risk
ii) Undisputed Trade Receivables ~ credit impaired 352 541 097 1.98 1188
liv) Disputed Trade Receivables- considered good
(v) Disputed Trade Receivables - which have significant increase in
credit risk
(vi) Disputed Trade Receivables ~ credit impaired 3.66 oot 236 6.03
fFotal 856 25a 1049) 135 434 90.8
|As at March 31, 2021,
[Particulars i for following periods from due date of payment
Tess than 6 1-2 years 723 years More than 3 Total
months years
[@ Undisputed Trade receivables ~ considered good BT TS 039 ry
i) Undisputed Trade Receivables - which have significant increase in
credit risk
ii) Undisputed Trade Receivables ~ credit impaired 1.66 173 3.83 1.90 016 9.28
liv) Disputed Trade Receivables- considered good
(e) Disputed Trade Receivables - which have significant increase in
credit risk
(vi) Disputed Trade Receivables ~ credit impaired 3.66 238 604
Frotal 55 310 526 5.95 254 79.40
|As at March 31, 2020
Particulars ‘Outstanding for following periods from due date of payment
Tessthan6 | 6months-1 | I-2years 2:3 years More than Total
months year years
[i Undisputed Trade receivables ~ considered good 3178 2639 Ta 797
i) Undisputed Trade Receivables - which have significant inerease in
credit risk
ii) Undisputed Trade Receivables ~ credit impaired 021 8.06 827
liv) Disputed Trade Receivables- considered good
(v) Disputed Trade Receivables ~ which have significant increase in
credit isk
(vi) Disputed Trade Receivables ~ credit impaired 1.05 054 4.80 067 121 827
fFotal 5279 2695 664 088 927 3651
|As at March 31, 2019
Particulars ing for following periods from due date of payment
Tess than 6 T-2 years 23 years More than Total
months years
Undisputed Trade receivables ~ considered good 5995, 2918 128 037 O51 9125
i) Undisputed Trade Receivables - which have significant increase in
Jeredit risk
(ii) Undisputed Trade Receivables ~ credit impaired 016 3.89 490 674 15.69
liv) Disputed Trade Receivables- considered good
(v) Disputed Trade Receivables ~ which have significant increase in
credit risk
(vi) Disputed Trade Receivables ~ credit impaired 020 135 0.65 2.40
Total eo 3308, 638 192 7.90 109.34

 

 

 

 

 

 

 

 

 

193

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

 

Particulars ‘Asat As at ‘Asat ‘Asat ‘Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019

 

113. Cash and cash equivalents

Balances with bank

 

| On current accounts 50.19 23052 38.67 552.96 87.96
|- in Fixed deposit accounts having original maturity less than 3 months 36.25 68.15,

Icash on hand 6.4 7.59 89 273 8.25
Hrotal TOL5S 306.26 06.86 355.69 96.21

 

 

114. Bank balances other than Cash and cash equivalents

Balances with bank
Fixed deposits with original maturity more than 3 months but less than 12 months*@ 2,147.90 137142 1875.55 626.23 43012

Total 2187.90, Ta Ta 55 62623, T3012

 

 

 

|a Fixed deposits of Rs. 79.87 million (June 30, 2020: Rs. 22.10 million, March 31, 2021: Rs.
122.87 million, March 31, 2020: Rs. 22.10 million, March 31, 2019: Rs. 20 million) under lien

}* The deposits made with banks comprise of time deposits, whch are available at call

115. Other current financial assets
Unsecured, considered good

 

Interest accrued on bank deposits and others 28.99 18.40 48.08 401 22.06
ISecurity deposits * 452 524 294 037 358
IShare issue expenses receivable (Refer note-45 (¢)) 58.99

lOther receivables 0.80 0.03 087 084 4.08
Total 93.30 23.67 51.89 5az 29.72

 

 

+ Includes amount receivable from related parties (refer note 45)
116. Other current assets

Unsecured, considered good

 

|Advances to Suppliers 11.72 23.46 498 837 268
| Advance to employees 1 1.05 0.76 131 013
Prepaid expenses, 28.19 1534 20.98 12.06 14.33
lOther Receivables 033 ‘ -

Total was 3985 2672 274 174

 

 

117. Equity share capital

| Authorized
120,500,000 equity shares of Re. 1 each (June 30, 2020: 12,050,000 equity shares of Rs. 10 each 120.50 120.50 120.50 120.50 66.32
land March 31, 2021: 120,500,000 equity shares of Re. 1 each and March 31, 2020: 12,050,000
lequity shares of Rs. 10 each and March 31, 2019: 6,631,868 equity shares of Rs. 10 each)

INil June 30,2020:Nil, March 31, 2021: Nil, March 31, 2020: Nil and March 31, 2019: . 1425
1,425,000) Series A Compulsory convertible preference shares (CCPS) of Rs. 10 each
INil June 30,2020:Nil, March 31, 2021: Nil, March 31, 2020: Nil and March 31, 2019: 12,000) - 39.93
[Series B Compulsory convertible preference shares (CCPS) of Rs. 3,327.61 each

 

 

 

|Issued, subscribed and fully paid-up

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

101,965,926 equity shares of Re. 1 each ( June 30, 2020: 4,531,819 equity shares of Rs. 10 each 101.97 45.32 45.32 45.29
land March 31, 2021: 45,318,190 equity shares of Re. 1 each and March 31, 2020: 4,531,819
lequity shares of Rs. 10 each and March 31, 2019: 4,528,813 equity shares of Rs. 10 each), fully
lpaid-up

101.97 532 532 532 3529
i) Reconciliation of equity shares outstanding at the beginning and at the end of the reporting period/year

Tune 30; 20R1 Tune 30,2000 March 3, aT ‘Niaech 31 2020 Niarch
Namberof  Amouat Nomberof Amount Namberof Amount Number ef Amount Number of Amount
shares shares shares hares shares
alan at the beginning of the poring penod/ year Ea Gam SS BH 28m a7 528s =a
Increase in shares on account of subdivision (refer note 17()) i :
res issued during the year on account of bors 8665 :

Conversion of Series A Cumulative Compulaorly Convertible 1 ooo
Preference Shares (CPS) (Refer note 18a)"
Conversion of Series B Cumulative Compulsorly Convertible 3,005 oa
Preference Shares (CPS) (Refer note 183)
Shares outstanding atthe end ofthe period/year 101945925 101974531819 4532 45318190 45524531819 45524525815, 45.29

 

 

}* The amounts are below million hence the same are not appearing

 

i) The Company has only one class of equily shares having a par value of Rs, 1 per share (june 30, 2021 and March S1, 2021,) lune 0, 2000, March 31, 2020 and March 31, 2019: Rs. 10 per|
|share). Each holder of equity shares is entitled to one vote per share. The shareholders are entitled to dividends in Indian Rupees, proposed by the Board of Directors and subject to the|
lapproval of the shareholders in the Annual General Meetings. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the|
|Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

 

 

 

194
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

 

il) Shares held by shareholders holding more than 5% in the Company

 

 

‘sat ‘Asat Asat Asat Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
DiS Surendranath Reddy 38,719,183 681,605 26,816,050 681,605 681,602
Shareholding, % 37.97% 59.17% 30.17% 59.17% 59.21%
M/s. Karakoram Limited 39,316,387 1,747,395 17,473,950 1,747,395 1,744,498
Shareholding " 38.56% 38.56% 38.56% 38.56% 38.52%
K Sunil Chandra 9,176,933 30,16 304,160 30,16 30,416
Shareholding " 9.00% 067% 0.67% 067% 0.67%
S Suprita Reddy 9,176,933 2525 25,250 2525 2525
Shareholding "s 9.00% 0.06% 0.06% 0.06% 0.06%

 

 

 

 

 

 

[As per records of the Company, including lls register of sharcholder/members and other declarations received from shareholder regarding Benelicial interest, the above shareholding|

lrepresents both legal and beneficial ownership of shares.

iv) During the five years immediately preceding the reporting date, no shares have been bought back, issued for consideration other than cash except for conversion of Preference shares

into Equity shares (Refer note 18a) and bonus shares issued are as follows:

June 30, 2021 June 30, 2020 March 31, 2021 March 31,2020 March 31,2019 March 31, 2018 March 31, 2017

 

“Allotied as fully paid up equity shares by way of bonus
Shares issued for consideration other than cash :

BOG AT 736

 

|v) For details of shares reserved for issue under Employee share based payments (ESOP) of the Company [refer note 44}.

vi) Subdivision of equity shares

@) On March 22, 2021 the equity shares of the Company having the face value of Rs. 10 (Rupees ten only) each were subdivided into 10 (ten) equity shares having a face value of Re. 1
(Rupee one only) each. Accordingly, 45,31,819 equity shares of face value of Rs. 10 each were sub divided into 4,53,18,190 equity shares of face value of Re. 1 cach.
(o) The earnings per share in respect of current and previous periods has been restated considering the aforesaid sub division of shares.

vii) Shareholding of promoters

 

 

 

 

 

 

 

Ara FaRe SOT Hearne 20D ASSENT OAT ASSEN ST ITT
Drs Surendranath Reddy 38719103 3797% 21208 281603. 507% 246816030 261603 59.17% onus 2681602
5. Geetha Reddy ‘ao7eeas 4.00% 3ea% an07 are 33070 3307 007% — oak 3307,
Sunil Chanda 17693 900% RN soais 087% 306,160 30816 087 00% 30416
Tob GA 79569 e000 000% Fisg2_e00% Bi 0,520 = aeia conv aoe _aIaVAN_conIT OTT

 

 

INote

Board of Directors of the Company at its meeting held on May 27, 2021 has identified Dr. Sura Surendranath Reddy as the Promoter. Accordingly the other share holders are considered

las part of the Promoter Group

 

 

Hida, Instruments entirely equity in nature

[Preference shares

 

 

 

 

 

 

Series A Compulsory Convertible Preference Shares (CCPS) - 413,
Series B Compulsory Convertible Preference Shares (CCPS) 10.00
[Total preference shares = = = = 23

 

 

i) Reconciliation of preference shares outstanding at the beginning and at the end of the reporting period/year:

 

Beaune W020

EEE

 

 

 

[shares outstanding at the beginning ofthe period /yene uason Mas luasart Mas
[shares issued (converted) during the period year u4asa7t Pay
snares outwtanding tthe end of the period/year : 5 5 2 maason ua
[snare outstanding atthe beginning ofthe period /year 3.008 10.00 3105 1.00
[shares esac (comerted) during the period year 3.005 10.00
snares outwtanding atthe end of the period/year i Z t : 00s, 1000

 

li) Terms and rights attached to Compulsorily convertible preference shares:

\Series A Cumulative Compulsorily Convertible Preference Shares (CCPS)

ISeries A Preference Shares are cumulative, mandatorily and fully convertible preference shares of Rs. 10 each with 0.001% coupon. Series A preference shares shall be participating|
preference shares and shall be entitled to participate in any dividend distribution to holders of equity shares on a fully diluted basis. These shares are convertible into equity shares on or|
Ibefore a specified date agreed between the shareholders. Till the time the aforesaid CCPS are not converted, all of Series A preference shares shall collectively be entitled for one vote.
|These Series A preference shares are converted into one equity share during the year ended March 31, 2020.

Series B Cumulative Compulsorily Convertible Preference Shares (CCPS)

Series B Preference Shares are cumulative, mandatorily and fully convertible preference shares of Rs. 3,327.61 each with 0.001% coupon. Series B preference shares shall be participating|
preference shares and shall be entitled to participate in any dividend distribution to holders of equity shares on a fully diluted basis. These shares are convertible into equity shares on the|
loccurrence of the earlier of (i) prior to filing a red herring prospectus in connection with initial public offering (ii) at the option of the preference share holder (ii) expiry of 10 years from|
the date of issuance. Till the time the aforesaid CCPS are not converted, all of Series B preference shares shall be entitled to voting rights on a pro-rata basis with the equity shares of the|
|Company on a fully diluted basis. These Series B preference shares are converted in the ratio of 1:1 into equity shares during the year ended March 31, 2020,

|The issue proceeds of Series A CCPS and Series B CCPS have been entirely classified under equity as they are settled with fixed number of entity's own equity instruments and meets the|
|definition of "Equity Instruments” as defined in “Ind AS 32, Financial Instruments: Presentation’,

 

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

iii) Details of shareholders holding more than 5% preference shares in the Company

 

 

 

 

 

 

 

 

 

 

 

 

 

‘sat ‘Asat Asat Asat Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
COPS Series A
Dr. S. Surendranath Reddy : : : 1,393,588
Shareholding " 0% 0% 0% 0% 98.62%
CCPS Series B
M/s. Karakoram Limited : 2,897
Sharcholding 0% 0% 0% 0% 96.41%
iv) Aggregate number of bonus shares issued, shares issued for consideration other than cash during the period of five years immediately preceding the reporting date:
June 30,2021 June 30,2020 March 31,2021 March 31,2020 March31,2019 March 31,2018 March 31, 2017
[Allowed as fully paid up Series A COPS by way of bonus Nil Nil Nil Nil Nil Nid 1413071
[allotted as fully paid up Series B CPS by way of bonus Nill Nil Nil Nil Nill Nil Nil
‘sat Asat Asat Asat Asat

June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019

 

|18b. Other equity

 

 

i) Securities premium
Balance at the commencement of the period / year 515.67 515.67 515.67 491.57 491.57
Less: Issue of bonus equity shares (66.65) S

|Add: Conversion of CCPS into equity shares 24.10

Balance as at the end of the period/year 5902 BIS? BI567 315.67 PLs7

 

ii) Employee stock options outstanding account

 

Balance at the commencement of the period /year 8.28 632 632 222
|Add: Share options expense for the period /year 373 078 1.96 4.10 2
Balance as at the end of the period/year 201 7.10 328 a2 2

 

 

iii) General reserve
Balance at the commencement of the period /year 49.32 49.32 49.32 49.32 49.32
Balance as at the end of the period/year 32 32 a2 wan a2

 

 

iv) Retained earnings

 

 

 

 

 

 

 

Balance at the commencement of the period /year 2971.47 2,128.80 2,128.80 1,461.29 1,004.11
Ind AS 116 Transition Adjustment (net of taxes) (Refer Annexure V1) 43.43

|Add: Surplus as per statement of profit and loss 329.69 19.13 842.63 625.38 458.74
Items of other comprehensive income recognised directly in retained earnings

[Remeasurement of defined benefit obligation, net of tax (022) (1.09) 0.04 (130) (1.56)
Balance as at the end of the period/year 330094 2684 21a 2128.80) T6129
[Total Other equity (i+ii+iiitiv) Sao 271893 3 aaaTE 270011 20040

 

 

 

|Nature and purpose of reserve
|A. Securities premium.
\Securities premium is used to record the premium on issue of shares. Iti utilized in accordance with the provisions of the Companies Act, 2013,

B. Employee stock options outstanding,
|The Company has established equity settled share based payment plan for employees of the Company. [refer note 44 for details]

IC. General Reserve
IThe general reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. As the general reserve is created by a transfer from one component off
lequity to another and is not an item of other comprehensive income, items included in the general reserve will not be reclassified subsequently to profit or loss.

1D. OCI Remeasurement of Defined Benefit Plan
JOCT represents Re-measurement on defined employee benefit obligations: Difference between the interest income on plan assets and the return actually achieved, any changes in the|
liabilities over the year due to changes in actuarial assumptions or experience adjustments within the plans, are recognised in other comprehensive income and subsequently not|
reclassified to statement of profit and loss.

E. Retained earning
Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends or other distribution to shareholders.

 

 

 

196
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

 

Particulars ‘sat ‘Asat ‘Asat “Asat ‘Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019

 

119. Borrowings

i) Secured term loans [at Amortised cost]
|. from Banks 204.60 219.58 281.32
|. from Others 55.44 63.02 90.66

li) Unsecured Loans [at Amortised cost]

 

 

 

 

 

 

 

 

 

 

Loan from directors 32.75 32.75. 32.75
292.79 315.35 40473
Less: Current maturities of long-term borrowings (05.38) (04.02) 9.38)
3 19741 3275 221.33 315.35

INote

. Terms of secured loans from banks:
|Term loans from banks are repayable in 36 - 84 equated monthly installments and carry an interest rate of 8.50% - 10.50% per annum. These loans are secured by exclusive charge on plant|
|&e machinery medical equipments purchased out of the respective loans. Further, the loans from banks to the extent of Rs. Nil june 30, 2020: Rs. 260.03 million, March 31, 2021: Nil, March]
131, 2020: Rs. 57.43 million and March 31, 2019: Rs. 78.07 million) is secured by personal guarantee of directors and loans taken by subsidiaries amounting to Rs. Nil (June 30, 2020: Nil
[March 31, 2021: Nil, March 31, 2020: Rs. 3.60 million and March 31, 2019: Rs. 9.25 million) is further secured by corporate guarantee given by the Parent Company. These loans have been|
lrepaid during the year ended March 31, 2021

 

ii. Terms of secured loans from others:
Term loans from others are repayable in 36 - 72 equated monthly instalments and carries an interest rate of 7.4% - 9.4% per annum. These loans are secured by exclusive charge on plant|
land machinery-medical purchased out of the respective loans. These loans have been repaid during the year ended March 31, 2021

iii. Terms of unsecured loan from directors
[Loan from Directors is repayable in 3 to 5 years and carries an interest rate of 8% per annum. The loan is unsecured. These loans have been repaid during the period ended June 30, 2021

 

 

120, Other non-current financial liabilities

 

 

 

 

 

 

 

 

 

[Deferred payment liabilities - on purchase of medical equipments 073 6.80 218 875 18.73
Total 073 6.80 28 875 18.73
121. Provisions (non-current)

Provision for gratuity (Refer note 43) 2.09 23.65, 19.60 1901 1038
Provision for Compensated Absences 10.99 1291 10.89 10.73 816
Provision for Decommissioning Liability” 47.58 40.23 46.53 37.67 34.65
Total 80.66 7679 77.02 7a 539
I*Movement in provision for decommissioning liability:

lOpening balance 46.53 37.67 37.67 34.65 28.60
|Add: Unwinding of interest expense 1.05 039 377 344 292
|Add: Provision created during the period/ year Z 167 5.09 1.63 313
Less: Provision reversed during the period/year (2.05

[Closing balance 758 4023, 1653, 37.67, 365

 

 

[Decommissioning lability pertains to the cost of dismantling the assels Irom the leased premises. The lability is determined by the management based on the present value of the|
lestimated future cash outflows for dismantling the assets.

 

122, Deferred tax assets (net)

 

 

 

 

 

Deferred tax liability 749 391 863 30.48 36.40
|. On account of property, plant and equipment 5.83 391 780 718 1428
|. On account of fair value gains of mutual funds 1.66 2 083 23.30 2212
Deferred tax asset 7.04 55.56 69.60 46.29 48.18
|. On account of employee benefits 9.28 9.85 829 aa 5.64
|. On account of credit impaired debts 381 446 381 416 527
|. On account of property, plant and equipment 2.68 207 192 1.60
|. Decommissioning liability on property, plant and equipment a7 1030 179 9.46 930
|. Others, 487 5.07 440 464 849
|. On account of leases 44.23 25.88 39.24 17.96 17.84
|. MAT credit entitlement 0.04 0.08
Deferred tax assets (net) 955 5165 60.97 i581 78

 

 

 

 

 

197
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

Movement in deferred tax assets/ (liabilities)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

‘On account of Property, plant Provision for Teases Tair value of Others Total
and equipment employee Mutual Funds
including benefits
decommissioning
liability
‘As at April O1, 2018 3.86 430 = ean 626 501
(Charged)/ credited
= to profit and loss 077 1784 271) 754 6.20
-to OC 057 057
‘As at March 31, 2019 (638) 5.68 1788 (2.12) 73.80 11.78
Ind AS 116 restatement adjustment = = 07.84) = = 07.84)
‘As at April O1, 2019 638) 5a = 23) 13.80 (606)
(Charged) credited
to profit and loss 758 2.05 1796 (sy (496) 21.45
-to0Cl oa oa
‘As at March 31, 2020 520 sar 17.96 3.30) at 1581
(Charged)/ credited:
= to profit and loss 219 112 792 2330 0.69 35.22
-to OCI - 0.62 - : : 0.62
‘As at June 30,2020 639 985, 25.88 = 955 S165
‘As at March 31, 2020 420 au 17.96 (2330) 884 1581
(Charged) credited:
to profit and loss 1.86 030 21.28 2247 (063) 45.28
=to0C1 (012) (012)
‘As at March 31, 2021 6.06 829 30.25 (083) oar 60.97
(Charged)/ credited:
to profit and loss 2.96 093 499 (083) 0.46 851
-to OCI 0.06 0.06
‘As at June 30, 2021 902 9.28 23 (166) 867 69.55
Particulars Asat Asat ‘sat ‘sat ‘sat

June 30, 2021

June 30, 2020

March 31, 2021

March 31, 2020

March 31, 2019

 

 

123. Other non-current abilities

Deferred revenue

 

 

 

l24. Borrowings
ISecured

lOverdraft from bank

|Current Maturities of Longterm borrowings

 

 

 

 

 

 

082 ost 053 118 137
Taz wr Ey Tas 137
1192 1377 197 13.05 19.53

95.38 94.02 89,38
1192 10945 1197 10707 108.91

 

 

Notes:

 

Borrowing represents overdraft facility taken by the subsidiary. The said overdraft facility is secured with underlying Fixed Deposit given by Group and partner in the subsidiary. The|

loan carries an interest of 10% to 11% per annum.

 

198

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(All amounts are in Rs in millions, except share data or otherwise stated)
Particulars ‘Asat Asat ‘Asat ‘Asat ‘Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019
125. Trade payables
Due to micro and small enterprises (Refer note 39) (MSME) 101 0.07 2.68 033
Due to creditors other than micro and small enterprises* 258.24 201.73 218.88 216.60 217.54
Total 25925, 201.80 256 21693 274
|-ncludes amounts payable to related parties (refer note 45)
|Trade payables ageing schedule
|As at June 30, 2021
Particulars ‘Outstanding for following periods from due date of payment
Tess than I Year] 1-2 Years 2-3 Years More Than 3, Total
Years
i) MSME Tor Tr
ii) Others 165.86 158 2.66 7359 177.69
iii) Disputed Dues-MSME :
iv) Disputed Dues-Others -
lv) Unbilled dues 8055 80.55
Total 2a7 a2 138 266 759 259.25
|As at June 30, 2020
Particulars ‘Outstanding for following periods from due date of payment
Tess than 1 Year] 1-2 Years 2-3 Years ‘More Than Total
Years
i) MSME, 007 007
i) Others. 99.01 3.20 oaz 14.76 117.09
iii) Disputed Dues-MSME -
iv) Disputed Dues-Others *
lv) Unbilled dues shed 8464
Total 183.72 320 az 1476 201.80
|As at March 31, 2021
[Particulars ‘Outstanding for following periods from due date of payment
Tess than I Year] 1-2 Years 2-3 Years More Than3 Total
Years
i) MSME 28 268
ii) Others 136,09 2.09 286 773 148.77
iii) Disputed Dues-MSME 2
iv) Disputed Dues-Others -
lv) Unbilled dues 70.11 70.41
Total 20888 209 26 778 2256
[As on March 31, 2020
Particulars Outstanding for following periods from due date of payment
Tess than 1 Year] 1-2 Years 2-3 Years ‘More Than Total
Years
i) MSE, 033 033
ii) Others 160.29 285 1232 175.46
iil) Disputed Dues-MSME =
iv) Disputed Dues-Others 2
iv) Unbilled Dues a144 a4
Total 201.76 285 = 1232 216.93
|As on March 31, 2019
Particulars ‘Outstanding for following periods from due date of payment
Tess than I Year] 1-2 Years 2-3 Years More Than 3 Total
Years
ip SME =
ii) Others 182.08 (033) 54 193.86
iii) Disputed Dues-MSME a
iv) Disputed Dues-Others 2
iv) Unbilled Dues 23.68 23.68
[Fotal 720576 O57 oxy Tse 274

 

 

 

 

 

 

 

199

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(All amounts are in Rs in millions, except share data or otherwise stated)

Particulars ‘Asat Asat ‘Asat ‘Asat ‘Asat
June 30,2021 | June 30,2020 | March 31,2021 | March 31,2020 | March 31, 2019

126. Other current financial liabilities

Interest accrued but not due on borrowings 13.99 1457 13.25 1123

ICapital creditors 558 8298 681 24.89 1881

Deferred payment liabilities - on purchase of medical equipments 601 13.79 831 1440 1232

[Employee payables 71.38 7039 31.58 7715 70.76

lOther payable 148 184

Total 297 18263 ez 129.69 T1496

27. Pro

Provision for gratuity (Refer note 43) 5.89 461 522 4a 514

Provision for compensated absences 299 271 214 2m 241

Provision for disputed Customs duty matters* z 3.25 3.25 3.25

lrotal a8 1057 736 1037 70.80

I*sMovement in provision for disputed customs duty:

lOpening balance 3.25 3.25 3.25 3.25

|Add: Unwinding of interest expense ‘

|Add: Provision created during the period/year :

Less: Provision reversed during the period/ year 6.25 :

IClosing balance = 325 5 325 325

|:Provision of Rs 3.25 millions has been made in earlier years towards disputed customs duty

Imatters. The Company during the year ended March 31, 2021 has written back the provision|

lmade, as the Company is not intending to redeem the goods held with Customs authority.

128. Other current liabilities

IDeferred revenue 118 157 1387 157 1.68

|Advance received 10.00

[Statutory liabilities 2016 10.88 18.88 18.53 18.88

Total 2134 1245 2045 2010 30.56

 

 

 

 

 

 

 

200

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(All amounts are in Rs in millions, except share data or otherwise stated)
Particulars For3months | For3months |For the year ended] For the year ended] For the year ended]
period ended | periodended | March 31,2021 | March 31,2020 | March 31, 2019
June 30,2021 | June 30, 2020
[29, Revenue from operations
Sale of Services 1,225.89 517.02 3,764.54 3,386.79 2,924.65
lOther operating revenue
= Sale of scrap 088 “ 258 1.09 0.68
= Miscellaneous income 0.09 0.08 034 033 054
|Total revenue from operations 122686 3170 376746 338821 2o2587
130. Other income
Interest income on bank deposits and electricity deposits 27.33 19.83 92.09 39.28 2641
Interest income on other financial assets carried at amortised cost Lit 0.94 387 3.35
Profit on sale of mutual fund investments 185 1357 49.02 9.06
Fair value gain on financial assets (mutual funds) measured at FVTPL - 329 1681 B65
Net gain on sale/ retirement of property, plant and equipment 031 oa 156 1491 3.68
Liabilities no longer required written back “ Bad 735 1736
Profit on slump sale (net of acquisition goodwill of Rs. Nil (March 31,2021: Nil, 3 é 18.22 2
Jjune 30, 2020: Nil, March 31, 2020: Rs. 15.42 million, March 31, 2019: Rs. Nil) -
Refer Note 48
Insurance claim received 3 ost 284 :
JOther non operating income 056 0.09 oad 1.83, 7
By 2282 Taa7 15361 10857
|31. Cost of materials consumed
Jnventory at the beginning of the period/year 2644 2773 2773 2178 2421
|Add: Purchases 247.35 83.12 69.66 445.34 402.35
27379 T1085 397.39 467.12 226.56
Less: Inventory at the end of the period/ year (62.95) @530)| (26.44) (2178)
Less: Transfer on account of slump sale 3 : :
20s 7558 wae
a2. Employee benefits expense
Salaries, bonus and wages 143.95 13.41 513.74 S731 497.22
|Contribution to provident fund and other retirement benefits (Refer note 43) 7.88 642 29.93 wad
|Gratuity expenses 289 256 1034 893 728
|Compensated absences 266 294 249 579 275
|Share based payments - equity settled (refer note 44) 373 078 1.96 4.0
Staff welfare expensi 036 241 1589 674
161a7 12852 ead 538.80
133. Finance costs
Intrest on Borrowings measured at amortised cost oot 7 1567 3407 31.79
Interest on Deferred credit purchases and decommissioning liability 127 138 529 5.95, 6.02
Bank charges and other borrowing costs 454 1.90 17.38 14358 1283
Interest expense on lease liabilities (refer note 6) 33.61 2801 1413 99.25 84.69
70.03 3840 15247 153.85 135.33
|34. Depreciation and amortisation expense
Depreciation on Property, Plant & Equipment 72.26 7534 34149 277.08
| Amortisation of intangible assets 1.65 17 6.26 354
Depreciation of Right of use assets 4530 39.84 143.95 115.64
T1921 T1635 170 39626

 

 

 

 

 

 

 

 

 

201
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Paricalars For3 months | For3 months For the year ended] For the year ended] For the year ended]
period ended | period ended | March31,2021 | March 31,2020 | March 31,2019
June 30,2021 | June 30,2020

35. other expenses

Power and fuel 30.09 2547 10.92 10719 2289

Rent 3.08 ast 662 1478 1628

Testing charges 22 1386 46.18 890 732
lSamples collection charges 1399 438 3208 1986 1895
Repairs and maintenance : .

~ Buildings 67 3.09 1503 2029 11066
+ Plant and equipments 25.99 237 7124 7076 772
+ Others 3.50 227 16.13 1813 1632
House keeping expenses 1259 Bos 4719 51.02 4329
Security charges 9.95 908 3758 3427 2813
insurance 170 1.04 3:19 288 2a
Rates and taxes 132 094 707 529 405
Advertisement, publicity and marketing 345 317 13st 3247 36.38
Business promotion 441 275 1764 2079 16.32

Travelling and conveyance 313 148 1889 197 1683
Legal and professional fees 145.09 6470 462.01 307.03 45443
Payment to auditors [refer note (i) below] : 418 3.09 253
independent Directors Sitting Fees/ Commission 120 : a : :
Postage and communication 432 342 1430 1379 13.09
Printing and stationery 137 099 716 810 870
Provision for bad and doubtful receivables 137 339 ao 1207
Bad and doubtful debts written off s 037 039
Advances written-off : 086 :
Expenditure on Corporate Social Responsibility [refer note (i) below] 439 2683 a7 9.00
Donations “ 015 010
Miscellaneous expenses 428 233 1386 1559

600 Tass PaaS 3010
) Payment to auditors (inclusive of taxes)
statutory auditors:
Statutory audit fees* - 4 378 295 236
Reimbursement of expenses “ 40 ou 017
hrotat = = zs 309 255
| the special purpose audit fees will be recoverable from Dr. $ Surendranath|
Reddy, Kalakoram Limited and Kedara capital alternative investment fund-
Kedara capital AIF 1 upon successful completion of IPO in proportion to the
shares that are expected tobe offered tothe public in offering (Refer note 15)

) Details of Corporate social responsibility expenditure
i) Gross amount required to be spent by the Group during the period/ year 439 346 1384 120 10.5
i) Amount approved by the Board to be spent during the period/year 439 346 138 120 1015
i) Amount spent dusing the period year (in cash)

construction/ acquisition of any asset 2 “

‘on purpose other than above 439 263 197 147 9.00
iv) Ghortall) / Excess a the end of the period/year - 083) 598 207 13)
() Tota of previous years shortfall “ - 63) 620)
(i) Details of related party transactions NA NA NA NA NA
(vi) Where a provision is made with respect toa lability incurred by entering NA NA NA NA NA
nto a contractual obligation, the movements in the provision during the
period year should be shown separately
(viii) Reason for shortfall:

For the period ending June 30, 2021, une 30, 2020 & year ending March 31,
2001: No shortfall
For the year ending March 30, 2020 and March 30, 2019: The Company was in
the process of identifying prospective project as per schedule VI of the
[Companies Act, 2013
ix) Nature of CSR activities
2) Payment to Prime minister national relief fund
b) Skil development
«) Education
«Rural development
36, Tax expenses:
(2) Amount recognised in statement of profit and loss
current tax nat x00 a7 anet 19666
Deferred tax attributable to temporary differences 631) (0522) 6528) eas) 620)
{tax expense 708.50 3) 27aa3 20920 13046
(b) Amount recognised in other comprehensive income
Deferred tax related to items recognised in OCI
Deferred tax expense/ income) on zemeasurements of defined benefit (0.06) 002) on oss) 03
obligations
Income-tax expense/income) recognised in OCI os wa oy way om

 

 

 

 

 

 

 

202
 

Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information

(All amounts are in Rs in millions, except share data or otherwise stated)

Particulars For3months | For3months |For the year ended] For the year ended] For the year ended]

 

 

 

 

period ended | periodended | March 31,2021 | March 31,2020 | March 31, 2019
June 30,2021 | June 30, 2020
[(@) Reconciliation of effective tax rate:
Profit before tax 44215 68 934.27 653.18
Enacted tax rate in India" 25.7% 25.17% 25.17% 29.12%
HTax expense at enacted rates Tas Tes 209.97 7190.21
Hrax effect of:
Non-deductible expenses as) 0.66 246 us. 102
[Unrecognised deferred taxes on 022 053 rr 687
Tax exempt income & : - (a3)
lothers i) 413) (23.05) (st) 729)
[Income-tax recognised in the statement of profit and loss 7108.90 7) 2721s 20920 19046

 

 

}* The Taxation Laws (Amendment) Ordinance, 2019 (‘Ordinance’) was promulgated on September 20, 2019. The Or
tax at a reduced tax of 22 percent pl
surcharge and cess,

Act, 2019 to inter-alia provide an option to domestic companies to pay income

be met. The Group has opted for this amendment and tax rate is calculated at 22% plus applicable

lus applicable surch:

‘dinance has amended the Income Tax Act, 1961 and Finance
iarge and cess with certain conditions to

 

|The following table provides the details of income tax assets and income tax|
abilities:

Income-tax assets, (net)
|Current tax liabilities, (net)

Net income-tax liability at the beginning of the period/year
Less: Current income tax expense

|Add: Tax paid during the period/ year

INet income tax liability as at the end of the period/year

37. Earnings per equity share
Profit attributable to equity shareholders

lOriginal number of equity shares (post share split)"
|Add: Impact of bonus issue effected during period ended June 30, 2021 (Refer|
Note 51)

Weighted average number of equity shares for basic EPS (Nos.)

|Add: Unlisted, unsecured debentures/ Preference Shares compulsorily
|convertible into equity shares (Nos.)

|Add: Dilutive impact of Outstanding employee share based options

|Add: Impact of bonus issue effected during period ended June 30, 2021 (Refer|
Note 51)

Weighted average number of equity shares for dilutive EPS (Nos.) (Non|
[Annualized for the period ended June 30, 2021 and June 30, 2020)

Bas
Diluted earning per share (in Rs.)

‘earnings per share (in Rs.)

 

 

 

 

 

 

 

  

 

 

 

 

Face value per equity Share (in Rs)

 

 

370 5.70 913 sat

(6.24) (4a7) (15.99)

was) a) ey a)
639) 634) (758) 247

(23.60) e741) 230.64) (196.66)

53.1 BL87 31221 23287, 186.92
Tas) 233 aosay oH a)
329.69 1943 842.63 625.38 458.74
101,965,926] 45,318,190] 45,318,100 45,318,190] 45,288,130]
, 36,647,736 56,647,736] 56,647,736] 56,610,162)
101,965,926] 101,965,926 101,965,926 101,965,926 101,898,292
a 9368 17,39 19,463 9361

- 1,710 2144 24,329 49,276
101,965,926] 101,987,004 102,004,489 102,009,718 101,986,989
23 029 826 613 450

323 029 826 613 450

 

 

 

 

The Company on March 22, 2

T, has split the Rs, 10 equity share into 10 shares of Re. I each, Accordingly, the earnings per share has been adjusted for subdivision of shares|

for the current and previous yeats presented in accordance with the requirements of Indian Accounting Standaed (Ind. AS) 33 - Earnings per share,

 

 

 

203
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

 

38. Contingent liabilities and commitments (to the extent not provided for)
Contingent liabilities

Claims against the Company not acknowledged as debts:
Demand for Provident Fund for the year 1998-2001 [refer note (i) below]

Notes:
i, Provident fund matter relates to the years 1998-2001 towards interest and provident fund

 

‘Asat
June 30, 2021

“As at
June 30, 2020

‘Asat
March 31, 2021

As at
‘March 31, 2020

‘Asat
March 31, 2019

 

0.56

056

0.56

0.56

056

‘The Group based on its legal assessment do not believe that any of the pending claims require a provision as at the balance sheet date, as the likelihood of the probability of an outflow of

resources at this point of time is low.

Capital and other commitments

 

 

 

 

‘Asat ‘As at ‘Asat ‘Asat ‘sat
June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019
Estimated amount of contracts remaining to be executed on capital account not provided 79.09 THRSD 7323 T3487 7a8
for (net of advances)
39 Dues to micro and small enterprises
Details of dues to micro and small enterprises as defined under the MSMED Act, 2006
Particulars June 30,2021 June 30,2020 _ March 31,2021 March 31,2020 _ March 31, 2019
@ the principal amount and the interest due thereon remaining unpaid to any Supplier at
the end of each accounting period year;
- Principal 101 0.07 2.68 033 2
= Interest ° : : < -

(®) the amount of interest paid by the buyer in terms of Section 16 of the MSMED Act, along : - % <
with the amount of the payment made to the supplier beyond the appointed day during

each accounting period year;

(©) the amount of interest due and payable for the period of delay in making payment 2 2 : 2 2
(which have been paid but beyond the appointed day during the year) but without adding

the interest specified under this MSMED Act;

(d) the amount of interest accrued and remaining unpaid at the end of the each accounting - : : -
period year; and

(6) the amount of further interest remaining due and payable even in the succeeding years, = 3 “ z -
until such date when the interest dues as above are actually paid to the small enterprise, for

the purpose of disallowance of a deductible expenditure under Section 23 of the MSMED

Act.

 

Note: The list of undertakings covered under MSMED Act was determined by the Group on the basis of information available with the Group and has been relied upon by the auditors.

40. Segment reporting

A. Basis for segmentation
‘An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to
transactions with any of the Group's other components, and for which discrete financial information is available. All operating segments results are reviewed regularly by the Group's
Chairman and CEO to make decisions about resources to be allocated to the segments and assess their performance.

‘The Chief Operating Decision Maker ("CODM') evaluates the Group's performance and allocates resources based on an analysis of various performance indicators at operational unit level
and since there is single operating segment, no segment disclosures of the Group is presented. The Group's operations fall within a single business segment “Diagnostic services”.

B. Major customers
Revenue from any single customer of the Group's operating segment does not exceed 10% of the total revenue reported and hence the Management believes that there are no major
customers to be disclosed.

41. Purchase commitments towards reagent kits
The Company has entered into agreements with certain suppliers for purchase of reagents which include the right to use equipment during the life of the agreement in addition to
purchase of minimum committed quantities of reagents every year. These agreements are in substance, cost of reagents and services arrangements provided by the supplier on an annual
basis and the minimum purchase commitments therein do not result in more than insignificant penalty on termination of the agreement. The cost of reagents which includes the cost of
rental of the equipment is recorded as cost of material consumed.

42. In February 2019, the Honorable Supreme Court of India vide its judgement, clarified the definition and scope of 'Basic Wages' under the Employees' Provident Funds & Miscellaneous
Provision Act, 1952. The judgement is silent on the retrospective application and in the absence of any guidelines by the regulatory authorities and considering the practical difficulties, no
effect is given for the earlier periods as the same is currently not determinable.

 

204
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

43. Employee benefit plans

(@) Defined contribution plans
Contributions were made to provident fund and Employee State Insurance in India for the employees of the Group as per the regulations. These contributions are made to registered funds
administered by the Government of India and other funds. The obligation of the Group is limited to the amount contributed and it has no further contractual nor any other constructive
obligation. The expense recognised during the period in the restated consolidated statement of profit and loss towards defined contribution plan is Rs. 7.88 million (June 30, 2020: 6.42
million. March 31, 2021: Rs. 29.93 million, March 31, 2020: Rs. 27-14 million and March 31, 2019: Rs. 25.79 million)

(b) Defined benefit plan
‘The Group provides for Gratuity for employees in India as per the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for Gratuity.
The amount of Gratuity payable on retirement/ termination is the employee's last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of
years of service or part thereof in excess of six months, restricted to a sum of Rs. 20.00 lakhs.

The Gratuity plan of the Parent Company is administered through a Gratuity Scheme with Life Insurance Corporation of India (‘LIC). The Parent Company does not fully fund the
liability and maintains a target level of funding to be maintained over a period of time based on estimations of expected gratuity payments. The Gratuity plans of subsidiaries are
unfunded,

This defined benefit plans expose the Group to actuarial risks, such as longevity risk, interest rate risk and market (investment) risk,

Reconciliation of the net defined benefit (asset)/ liability

The amounts recognised in the balance sheet and the movements in the defined benefit obligation and fair value of plan assets over the year are as follows:
As at March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Present value of  Fairvalue of Netamount

obligation plan assets
‘Opening balance 2521 13.34 1187
Current service cost 643 : 643
Interest expense/ (income) 1.90 (2.05) 0.85
Recognised in statement of profit or loss 533, (05) 728
Remeasurements
Return on plan assets, excluding amounts included in interest expense : 1.62 1.62
Actuarial (gains)/ losses arising from:
= Changes in demographic assumptions 3 : Z
= Changes in financial assumptions oe : 0.61
- Experience variance (i.e. actual experience vs assumptions) (0.04) : (0.03)
Re-measurements recognised in other comprehensive income 057 162 219
Contribution paid fo the plan 350 50)
Benefits paid ay (1.79) (0.32)
‘Closing balance 32.00 1648 15.52
As at March 31, 2020

Present value of Fair value of Netamount

obligation plan assets,
‘Opening balance 32.00 164s 1552
Current service cost 7.86 7 7.86
Interest expense/ (income) 2.27 2.20) 1.07
Recognised in statement of profit or loss 013 1.20) 59s
Remeasurements
Return on plan assets, excluding amounts included in interest expense Bs 043 0.43
‘Actuarial (gains)/ losses arising from:
= Changes in demographic assumptions “ “ -
= Changes in financial assumptions 231 231
- Experience variance (i.e. actual experience vs assumptions) (0.99) : (0.99)
Re-measurements recognised in other comprehensive income 132 oa 175
Contribution paid to the plan : 035 (033)
Benefits paid (6.29) (2.84) (2.45)
Closing balance 38.16 1474 23.42
As at March 31, 2021

Present value of Fair value of Netamount

obligation plan assets
‘Opening balance 3816 178 2342
Current service cost 8.90 : 8.90
Interest expense/ (income) 237 (0.93) per
Recognised in statement of profit or loss Ta (0.93) T03t
Remeasurements
Return on plan assets, excluding amounts included in interest expense : 0.24 024
Actuarial (gains)/ losses arising from:
= Changes in demographic assumptions 3 # Z
= Changes in financial assumptions oat - oat
- Experience variance (i.e. actual experience vs assumptions) (0.63) : (0.63)
Re-measurements recognised in other comprehensive income (022) 024 002
Contribution paid fo the plan Bis 18)
Benefits paid (3.89) ey (0.78)
Closing balance 32 20.50 2582

 

205
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information

(All amounts are in Rs in millions, unless otherwise stated)

As at June 30, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Present value of Fair value of Netamount
obligation plan assets
‘Opening balance 3816 178 2342
Current service cost 221 . 221
Interest expense/ (income) 0358 (0.23) 0.35
Recognised in statement of profit or loss 279 (0.23) 256
Remeasurements
Return on plan assets, excluding amounts included in interest expense ona O14
Actuarial (gains)/ losses arising from:
~ Changes in demographic assumptions - - -
= Changes in financial assumptions 234 : 234
- Experience variance (i.e. actual experience vs assumptions) 012 : 0.12
Re-measurements recognised in other comprehensive income 246 oad 2.60
‘Contribution paid to the plan F - 2
Benefits paid (0.32) Z (0.32)
Closing balance 43.09 14.83 28.26
As at June 30, 2021
Present value of Fair value of Netamount
obligation plan assets

‘Opening balance 32 2050 282
Current service cost 252 8 2.52
Interest expense/ (income) 0.67 (0.31) 0.37
Recognised in statement of profit o loss 319 (031) 289
Remeasurements
Return on plan assets, excluding amounts included in interest expense - - -
Actuarial (gains)/ losses arising from:
= Changes in demographic assumptions 3 & 2
= Changes in financial assumptions 030 : 0.30
- Experience variance (i.e. actual experience vs assumptions) (0.99) 0.97, (0.02)
Re-measurements recognised in other comprehensive income (0.69) 097 0.28
Contribution paid to the plan q ; 2
Benefits paid - : -
Closing balance a782 19.84 27.98
Plan assets
Plan assets comprises of the following:

June 30,2021 June 30,2020 March 31,2021 March 31, 2020 _ March 31, 2019
Funds managed by Life Insurance Corporation of India 100% 100% 100% 100% 100%
‘Actuarial assumptions
Principal actuarial assumptions for defined benefit obligation are as follows:

June 30,2021 June 30,2020 March 31,2021 March 31,2020 _ March 31, 2019
Discount rate 6.05% 5.45% 6.15% 630% 72%
Salary escalation rate 6.00% to 8.00% 6.00% 10 8.00% 6.00% t0 8.00% 6.00% to 8.00% 6.00% to 8.00%
Attrition rate 10.00% to 15.00% 10.00% to 10.00% to 10.00% to 10.00% to

15.00% 15.00% 15.00% 15.00%

Discount rate: The discount rate is based on the prevailing market yields of Indian government securities as at the balance sheet date for the estimated term of the obligations.

Salary escalation rate: The estimates of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors.

Attrition rate: Represents the Group's best estimate of employee turnover in future (other than on account of retirement, death or disablement) determined considering various factors

such as nature of business, retention policy, industry factors, past experience, etc.

Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation

and current service cost by the amounts shown below:

 

[Change in assumption

Tmpact on defined benefit obligation

 

 

 

 

June 30, 2021] June 50,2021] June 50,2020] June 50,2020] March 31,2021] March 31,2021] March 31,2020] March 31, 2020] March 31, 2019| March 31, 2079]

Increase by| Decrease by| Increase by| Decrease by| Increase by| Decrease by| Increase by| Decrease by| Increase by| Decrease by|

[Discount rate-1% 295 330 278 3d 278 a2, 266 237 AS TSI
Salary escalation rate-1% 324 295 3.05 249 3.03 276 236 259 195 1.99
|Attrition rate-1% 292 473 3.26 556 273 439 3.79 239 243 14s

 

 

 

 

 

 

 

 

 

 

 

 

The sensitivity analysis presented above may not be representative of the actual change in the projected benefit obligation as it is unlikely that the change in assumptions would occur in
isolation of one another as some of the assumptions may be correlated. Furthermore, in presenting the above sensitivity analysis, the present value of the projected benefit obligation has

been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the projected benefit obligation as recognised

in the consolidated balance sheet.

‘The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the prior period

206
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

v. Expected contributions to the plan for the next annual reporting period
Expected contribution to post-employment benefit plans for the next year ending, June 30, 2022 is Rs. 34.30 millions (March 31, 2022: Rs. 5.22 millions, June 30, 2021: Rs. 34.56 millions,
March 31, 2021 - Rs. 4.50 millions, March 31, 2020 - Rs. 5.00 millions)

vi. Maturity profile of the defined benefit
liability
‘The weighted average duration of the defined benefit obligation is 7 years (June 30, 2020: 7 Years) & (March 31, 2021: 7 years) & (March 31, 2020: 4 years) & (March 31, 2019: 6 years). The
expected maturity analysis of defined benefit obligation on an undiscounted basis is as follows:

 

Tess thanayear  Between25  Between6-10 More than 10,

 

 

years years Years
June 30, 2027 59 2d 2095 662
June 30, 2020 461 19.76 18.28 2371
March 31, 2021 5.22 21.79 2034

March 31, 2020 4at 18.58 1691 2.18
March 31, 2019 54 16.20 14.52 18.28

 

44. Share based payments
VDCPL Employee Stock Option Plan 2018 “The Plan" or "ESOP 2018”
‘The shareholders of the Company approved "VDCPL Employee Stock Option Plan 2018 (ESOP 2018)" at the Extraordinary General Meeting held on May 03, 2018 to grant a maximum of
1,625,000 options to specified categories of employees of the Company. Each option granted and vested under ESOP 2018 shall entitle the holder to acquire one equity share of face value
of Rs. 1 each of the Company. The aforementioned shares are post subdivision of equity shares (refer note 17(vi)).
‘The Plan consists of six schemes with various vesting periods from the grant date subject to satisfaction of vesting conditions. The method of settlement under the Plan is by issue of
equity shares of the Company and there are no cash settlement alternatives for the employees.
The time and performance based options under Scheme 1 become eligible on an annual basis at 30%, 30%, 20% and 20% over a period of four years and vesting starts from second year
The time and performance based options under Scheme 2 become eligible on an annual bias at 25%, 25%, 25% and 25% over a period of four years and vesting starts from third year. The
time based options under Scheme 3 become eligible on an annual basis at 25%, 25%, 25% and 25% over a period of four years and vesting starts from third year. The time based options
under Scheme 4 become eligible on annual basis at 100% and vest on second year from the grant date. The time based options under Scheme 5 become eligible and vest on an annual basis
at 25%, 25%, and 50% over a period of three years. The time and performance based options under Scheme 6 become eligible and vest on an annual basis at 18%, 25%, 33% and 24% over a
period of four years. Vested options can be exercised over a period of ten years from the grant date. The Exercise Price is the fair value of the equity share as on the date of the grant.

‘The Company accordingly granted 933,808 options under four grants of 463,750 options, 9,000 options, 75,780 options and 385,278 options to eligible employees on May 10, 2018, October
31, 2018, April 01, 2019 and March 25, 2021 respectively, under ESOP 2018 - Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5 and Scheme 6. The aforementioned shares are post
subdivision of equity shares (refer note 17(vi)).

The fair value of equity share options is estimated at the date of grant using Black- Scholes model, taking into account the terms and conditions upon which the share options were
granted. Based on the historical trends, 50% of stock options are expected to be vested and exercised, accordingly the total compensation cost recognised in the statement of profit and loss
is Rs, 3.73 million (June 30, 2020: 0.78 million, March 31, 2021: 1.96 million, March 31, 2020: Rs. 4.10 million and March 31, 2019 - Rs 2.22 million).

Also, refer note 51 for issue of bonus shares made during the period ended June 30, 2021. Employee stock options, exercise price, fair value mentioned below are pre bonus issuance.

 

(A) Details of options granted under ESOP 2018* are as below:

 

 

 

Grant Grant date _ Number of Number of Exercise Price Fair value at
options granted —_options (in INR) grant date (in
outstanding, INR)
‘st Grant 463,750 z 220.00 D210
2nd Grant 31-Oct-18 9,000 : 233.90 233.90
3nd Grant LApr-l9 75,780 - 236.90 236.90
4th Grant 25-Mar-21 385,278 385,278 250.00 250.00

 

* The aforementioned shares are post subdivision of equity shares (refer note 17(v).

(B) The movement of stock options during the period/year (in No's)* :

 

June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

 

Balance at the beginning of the period/ year 44,508 214.230 214,230 138,450 =
Granted during the period/year E 3 385,278 75,780 472,750
Vested /exercisable during the period /year 2 Z : ss :
Forfeited during the period year 159,230 25,000 55,000 ¢ 334,300
Exercised during the period /year ‘ : _ < -
Balance at the end of the period/year 385,278 189,230 544,508 214,230 138,450

 

* The aforementioned shares are post subdivision of equity shares (refer note 17(vi).

(©) Disclosures as per IND AS 102 for outstanding options * :

 

June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

 

Weighted average exercise price for outstanding options at period/ year end (in INR) 249.70 225.19 241.89 226.56 220.90
Weighted average remaining contractual life for outstanding options at period/year end 9.74 years 8.13 years, 9.19 years 8.45 years 9.15 years
Range of exercise prices for outstanding options at period year end (in INR) 250,00 _220.00- 236,90 _ 220,00 250.00 _ 220.00 - 236.90 220.00 - 233.90

 

* The aforementioned shares are post subdivision of equity shares (refer note 17(vi).

(D) The key assumption used to estimate the fair value of stock option as on grant date:

 

 

Grant date Dividend yield Risk-free Expectedlife of Expected
interest rate options granted —_volatility
in years
T0May-is oe 7aa% 3S Yearsto7 ean 21.32%
31-Oct-18 o% 784% 55 Yearsto7 Year. 24.95%
L-Apr-l9 o% 715% «55 Yearsto7 Year, 29.52%
25-Mar-21 ow 612% 55 Yearsto7 Year 43.78%

 

207
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

45

@

(e)

Related parties

Details of related parties

 

Description of relationship ‘Name of the related parties
Persons exercing control Dr. S Surendranath Reddy (Executive Chairman) (also a KMP)
Key Management Personnel (KMP) Dr. § Surendranath Reddy (Executive Chairman)

5 Suprita Reddy (Chief Executive Officer), Retired as Managing Director w.e.f October 31, 2019 and appointed as CEO w.e.f November 01,

2019.
K Sunil Chandra (Executive Director)

5 Geetha Reddy (Additional Director w.e.f November 21, 2019)
Nishanth Sharma (Nominee Director)

Y K Priyadarshini (Company Secretary upto July 07, 2018 )

Vijay Gupta (Company Secretary w.e-f October 15, 2018 upto June 03, 2019 )

\VSri Lakshmi (Company Secretary wef July 18 2019)
Sandhya Rani.S (Chief Financial Officer upto April 18, 2021)
‘Narasimha Raju.K.A (Chief Financial Officer w.e.f May 01, 2021)

 

Subsidiaries ‘Medinova Diagnostic Services Limited
Doctors Lab Medical Services Private Limited
VDC Diagnostics (Karnataka) LLP

Step down subsidiaries Namrata Diagnostic Centre Private Limited
‘Medinova Millennium MRI Services LLP

Enterprise where KMP has Significance Vijaya Hospitals Private Limited,
Influence
‘Summit Nutracueticals Private Limited
Kshetra Agritech Private Limited
Trikona Pharmaceuticals Private Limited
Trikona Holdings LLP
Vijaya Holdings India LLP
Vaishnavi Diagnostic Private Limited
§ Square Properties LLP
Park Health Systems Private Limited
IFFCO Kisan Sez Limited

Relative of KMP. B Vishnu Priya (Wife of K Sunil Chandra)
C Damodar Reddy (Husband of S Suprita Reddy)
C Rhea Reddy (Daughter of S Suprita Reddy)
C Arjun Reddy (Son of S Suprita Reddy)
 Suhas Reddy (Gon of K Sunil Chandra)
§ Sushmita Reddy (Daughter of K Sunil Chandra)

Independent Directors Dr.D.Nageshwar Reddy
Mr. SP Singh
Mr. Satyanarayana Murthy Chavali
Mr. PS Narasimha

Controlled Trust Vijaya Diagnostic Charitable Trust

Details of transactions during the period/year:

 

 

Forthe period Forthe period Fortheyear _ Forthe year Forthe year
ended ended ended ended ended
June 30,2021 June 30,2020 March 31,2021. March 31, 2020 March 31, 2019
Rent paid
Dr. S Surendranath Reddy 1053 5.85 36.27 38.36 34.66,
K Sunil Chandra 261 1.16 722 761 718
SSuprita Reddy 175 0.65 4.08 433 421
S Geetha Reddy 921 3.69 22.78 24.16 20.44
B Vishnu Priya 0.04 0.02 015 0.16 4
Vijaya Hospitals Private Limited 2.50 1.46 8.95 9.78 9.26
Rental deposits given, net *
Dr. § Surendranath Reddy 2 : 151 5.02
SSuprita Reddy 1.26 2 0.82 0.35 017
K Sunil Chandra . : 0.82 : 0.28
S Geetha Reddy 1.26 : 424 3.85

208
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

 

Forthe period Forthe period Fortheyear _ Forthe year Forthe year
ended ended ended ended ended
June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

 

Purchase of consumables
Park Health Systems Private Limited - : 010 - -

Sale of services
Park Health Systems Private Limited 179 1.09 654 554 16.53

Loans Repaid
Dr. S Surendranath Reddy 28.50 a - 3
K Sunil Chandra 4.25 3 : . 2

Interest expense
Dr. S Surendranath Reddy 035 057 2.28 228 2.28
K Sunil Chandra 0.05 0.09, 034 034 034

Remuneration to KMP and their relatives

Dr. § Surendranath Reddy 4.67 3.00 16.50 18.00 18.00
K Sunil Chandra 1.83 1.00 5.50 6.00 6.00
SSuprita Reddy 479 250 13.75 15.00 12.00

Salaries to KMP

 

 

 

 

YK Priyadarshini : : : : 024
Vijay Gupta : : : 013 0.35
VSri Lakshmi 0.18 085 062 .
Sandhya Rani.S 149 8.65 9.08 814
Narasimha Raju KA : - - -
Independent directors sitting fee/com
Dr.D.Nageshwar Reddy 0.30 : Z 3 2
Mr. SP Singh 0.30 : - - -
Mr. Satyanarayana Murthy Chavali 0.30 : i 2 :
Mr. P'S Narasimha 0.30 : ‘ 2 -
Amounts due (to)/ from related parties
‘Asat ‘As at “As at ‘As at ‘As at

June 30,2021 June 30,2020 March 31,2021 March 31,2020 March 31, 2019
Rent payable
Dr. $ Surendranath Reddy 321 3.13 : 225 274
SSuprita Reddy 053 0.35 - 0.25 033
KSunil Chandra 0.80 057 - 0.40 051
Vijaya Hospitals Private Limited 0.76 078 - 057 0.76
S Geetha Reddy 281 197 - 142 183
B Vishnu Priya 0.01 0.02 : 0.01 5

Rental deposits *

Vijaya Hospitals Private Limited. 349 3.50 349) 349 3.49
Dr. § Surendranath Reddy 141 41 141 41 9.90
SSuprita Reddy 3.82 174 256 173 139
K Sunil Chandra 3.30 2.48 3.30 248 248
S Geetha Reddy 13.02 7.53 11.76 718 719
B Vishnu Priya 0.07 0.07 0.07 0.07 0.07

Trade receivables
Park Health Systems Private Limited 0.60 117 0.66 1.02 ost

Loans outstanding
Dr. § Surendranath Reddy - 28.50 28.50 28.50 28.50
K Sunil Chandra - 4.25 4.25 4.25 4.25

Interest payable

Dr. § Surendranath Reddy s 11.64 13.18 11.07 9.02
K Sunil Chandra s 1.16 1.39 1.07 077

Remuneration payable to KMP

Dr. § Surendranath Reddy 1.09 049 - 0.98 1.20
K Sunil Chandra 057 017 : 0.35 049.
SSuprita Reddy 141 045 : ost 0.88
Salaries payable to KMP

Sri Laxmi V 0.09 0.38 - 0.07 -
Vijay Gupta : 4 . 0.06
Narasimha Raju K.A 038 2 . : 2
Sandhya Rani S 0.35 0.05 - 148 1.10

Independent directors sitting fee/commission payable

Dr.D.Nageshwar Reddy 029 Z 3 3 :
Mr. SP Singh 029 ‘ . . :
Mr. Satyanarayana Murthy Chavali 029 z . 3 3
Mr. P'S Narasimha 029 Z 5 3 :

 

209
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

(@) Transactions within the Group: (these transactions got eliminated in Restated Consolidated Financial Information)"
Forthe period Forthe period Forthe year Forthe year Forthe year

ended ended ended ended ended

June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

 

 

“Transactions by the Company with other Group entities:
Sale of consumables

VDC Diagnostics (Karnataka) LLP s = 2 on 0.37
‘Medinova Diagnostics Services Limited z 038 039 : 3
Purchase of consumables

VDC Diagnostics (Karnataka) LLP = ° ° : oa
Sale of services

Medinova Diagnostic Services Limited 11.86 1.88 32.75, 194 258
VDC Diagnostics (Karnataka) LLP : 2 2 1.20 1.67
Medinova Millennium MRI Services LLP “ 2 - 04 036
Loans given

‘Medinova Diagnostic Services Limited 55.50 2 ° 454 2.00
VDC Diagnostics (Karnataka) LLP 2 : 2 6.99 14.50
Doctors Lab Medical Services Private Limited. 2 2 073 1.00 0.3
Loans recovered

‘Medinova Diagnostic Services Limited 15.00 2 7.62 0.40 3
VDC Diagnostics (Karnataka) LLP : 2 739 0.10 a4
Doctors Lab Medical Services Private Limited. - Z : 750 :

Conversion of Loan into Investment
VDC Diagnostics (Karnataka) LLP 2 : - 155.00 -
Interest income

Medinova Diagnostic Services Limited 0.38 017 031 055 033
Reimbursement of Expenses

VDC Diagnostics (Karnataka) LLP oot : 0.03 : -
Transactions by Doctors Lab Medical Services Private Limited

‘Namratha Diagnostic Centre Private Limited

Reimbursement of Expenses 010 Z oot 0.00 0.05
Vijaya Diagnostic Centre Limited

Loan received “ : 073 1.00 033
Repayment of Loan “ : - 750 -

Transactions by Medinova Diagnostic Services Limited
Vijaya Diagnostic Centre Limited

Diagnostic Services(Expense) 11.86 1.88 32.75 194 258
Purchase of consumables 3 - 039 7 :
Interest on Loan 038 017 031 0.55 033
Loan received 55.50 : s 454 2.00
Loan repaid 15.00 : 7.62 40 2
Medinova Millennium MRI Services LLP

Purchase of services o.o1 Z 0.02 ost 1st
Income from professional service : 0.37 0.86 1.23 :
Collection from customers - - - os. -
Rent received os ous. 072 072 072
Investment / (Withdrawal) 3 2 : “ (0.02)
Transactions by Namratha Diagnostic Centre Private Limited

Doctors Lab Medical Services Private Limited

Reimbursement of Expenses 010 Z oot 0.00 0.05
Transactions by VDC Diagnostics (Karnataka) LLP

Vijaya Diagnostic Centre Limited

Unsecured loan taken (net) 2 0.02 2 699 14.50
Unsecured loan converted into capital contribution 2 3 - 155.00 2
Unsecured loan repaid “ 2 739 0.10 040
Purchase of services “ 2 - 1.20 1.67
Purchase of Consumables - Z 2 on 037
Sale of Consumables Z Z 2 : oad
Reimbursement of Expenses oot : 0.03 - -
Transactions by Millennium MRI Services LLP

Medinova Diagnostic Services Limited

Sale of services 001 2 0.02 ost 151
Professional service 0.04 037 0.86 123 7
Payments to vendor s E 2 os. 3
Rent expenditure os os 072 072 072
Investment / (Withdrawal) from equity share capital - - - - (0.02)
Vijaya Diagnostic Centre Limited

Purchase of services “ 0.00 04 036

210
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

(©) Amounts due (to/from related parties: (these transactions got eliminated in Restated Consolidated Financial Information)*

 

 

 

 

As at ‘As at ‘As at ‘As at ‘As at
June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

Tn the Books of the Company:

Trade receivables

Medinova Diagnostic Services Limited (net of write off) 752 12.08 791 9.96 8a7

VDC Diagnostics (Karnataka) LLP 3 2 - z 9.22

Medinova Millennium MRI Services LLP 0.03 0.35 0.03 0.35 056

Loans outstanding

‘Medinova Diagnostic Services Limited 40.84 779 - 7.07 280

Doctors Lab Medical Services Private Limited. 10.50 977 10.50 977 16.26

VDC Diagnostics (Karnataka) LLP = 7.88 . 7.86 155.97

Investments

Medinova Diagnostic Services Limited aut aun su aun su

Doctors Lab Medical Services Private Limited o1 oa 0.10 0.10 0.10

VDC Diagnostics (Karnataka) LLP 183.13 183.13 183.13, 183.13 28.13

Namrata Diagnostic Centre Private Limited 0.10 0.10 0.10 0.10 0.10

Investments in Medinova Millennium MRI Services LLP 12.68, 12.68 12.68 12.68 12.68

Share of loss in LLP

VDC Diagnostics (Karnataka) LLP * (176.00) (176.00) (176.00) (176.00) (176.00)

* Pursuant to revised guidance note on Division Il - Ind AS Schedule III to the Companies Act, 2013 revised in July 2019, as per para 9.42, the Company has not recognised share of
profit/(loss) from its investment in Limited Liability Partnership (LLP) in the standalone financial statements from Financial year 2019-20.

Interest receivable
Medinova Diagnostic Services Limited

Corporate guarantees outstanding,
Medinova Diagnostic Services Limited

In the books of Doctors Lab Medical Services Private Limited
Loans outstanding - receivables
Namratha Diagnostic Centre Private Limited.

Loans outstanding - payable
Vijaya Diagnostic Centre Limited

In the books of Medinova Diagnostic Services Limited
Vijaya Diagnostic Centre Limited

Unsecured Loan

Interest payable

Creditors for services

Corporate guarantee received

Medinova Millennium MRI Services LLP
Creditors for services

Other receivables

Investments

In the books of Namratha Diagnostic Centre Private Limited
Doctors Lab Medical Services Private Limited
Payable

In the books of VDC Diagnostics (Karnataka) LLP
Vijaya Diagnostic Centre Limited

Unsecured loan payable

Partner Current Account (Share of losses transferred)
Trade payable

In the books of Medinova Millennium MRI Services LLP
Medinova Diagnostic Services Limited

Trade receivables

Other payables

Vijaya Diagnostic Centre Limited
Trade payables,

1255

10.50

4084

26.41

0.04
o.o1
12.68

12.55
(155.02)

0.04
ool

0.03

315

12.44
977
779

30.65
315

0.68
0.60
12.68

12.44

7.88
(156.67)

0.68.
0.60

0.35

1245,

10.50

26.80

019
oot
12.68

(055.46)

019
oo1

0.03

0.55

3.60

12.44

977

7.07
0.55
2881
3.60

0.86
034
12.68

12.44

7.86
(157.56)

0.86
034

0.35

033

9.25

12.44

16.26

280
013
817
9.25

ost
oo1
12.68

12.44

155.97
(176.00)
9.22

ost
0.01

0.56

 

* As per Schedule VI (Para T1()(A)((@)) of ICDR Regulations

Note:

1) Share issue expenses (refer note 15 - Share issues expenses receivable) of Rs. 58.99 million incurred by the Company is towards Initial Public Offering (‘IPO’) of the equity shares held by
the selling shareholders. As per the agreement with the selling shareholders, these expenses are recoverable from Dr. S. Surendranath Reddy, Karakoram Limited and Kedaara Capital
Alternative Investment Fund - Kedaara Capital AIF 1, upon successful completion of IPO in proportion to the shares that are expected to be offered to the public in the offering,

2) All transactions with these related parties are at arm's length basis and resulting outstanding receivables and payables including financial assets and financial liabilities balances are
settled in cash. None of the balances are secured. (All the amounts of transactions and balances disclosed in this note are gross and undiscounted.)

21
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

46 Capital management
‘The Group's policy is to maintain a stable and strong capital structure with a focus on equity so as to provide returns to shareholders, benefits to other stakeholders, creditors and to
sustain future development and growth of the business. In order to maintain the capital structure, the Group monitors the return on capital as well as debt to total equity ratio. The Group
aims to manage its capital efficiently so as to safeguard its ability to continue as a going concern and to optimise returns to all its shareholders. For the purpose of debt to total equity, debt
includes its long-term and short-term borrowings. Total equity comprises of issued share capital and all other equity reserves.

 

 

 

Gearing rati

June 30,2021 June 30,2020 _ March 31,2021 March 31, 2020 _ March 31, 2019
Total debt 1192 306.56 72 32840 424.26
Total equity 3,929.08 2,738.28 3,592.32 2,741.39 2,070.10
Debt equity ratio 0.00 ete 0.01 012 0.20

 

‘AS at 30 June 2021, the Group's bank balances are at Rs, 2,367.77 million which are significantly higher than the debt outstanding of Rs. 11,92 million.

establish credit history for any future requirements.

47, Financial instruments

A. Accounting classifications and fair values

Nominal debt is being maintained to

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy

Asat June 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Note Fair value level Amortised Cost Fair value
Financial assets,

Investments

in mutual funds - FVTPL u Level 1 . 27957
in equity instruments - FVOCI 7 Level 3 “ 040
Trade receivables 12 55.52 :
Cash and cash equivalents 13 101.58

Other bank balances 4 2,147.90

Other financial assets Sand 15 278.43 z
Total financial assets 2,583.43 279.97
Financial liabilities

Borrowings 19 and 24 11.92

Lease liabilities 6 1571.59

Trade payables 2 259.25

Other financial liabilities 20 and 26 83.70

Total financial liabilities 1,926.46 =
As at June 30, 2020

Particulars Note Fair value level Amortised Cost Fair value
Financial assets

Investments

in mutual funds - FVTPL u Level 1 : 12.75
- in equity instruments - FVOCI 7 Level 3 : 0.40
Trade receivables 12 7227 :
Cash and cash equivalents 13 306.26 :
Other bank balances 4 1371.42

Other financial assets Sand 15 7597. 2
Total financial assets 1825.91 1315
Financial liabilities

Borrowings 19 and 24 306.56 -
Lease liabilities 6 1,339.16 :
Trade payables, 3 201.80 :
Other financial liabilities 20 and 26 189.43

Total financial liabilities 2,036.95 =
As at March 31, 2021

Particulars Note Fair value level Amortised Cost Fair value
Financial assets,

Investments

in mutual funds - FVTPL 1 Level 1 : 276.27
in equity instruments - FVOCI z Level 3 3 0.40
Trade receivables 12 64.08
Cash and cash equivalents 13 66.86

Other bank balances 1 1,875.55

Other financial assets Sand 15 174.11 -
Total financial assets 2,180.60 276.67
Financial liabilities

Borrowings 19and 24 44.72 3
Lease liabilities 6 1,365.75 -
Trade payables 3 221.56

Other financial liabilities, 20 and 26 63.45

Total financial liabilities 1,695.48 =

 

212
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

‘As at March 31, 2020

 

 

 

 

 

 

 

 

 

Particulars Note Fair value level _ Amortised Cost Fair value
Financial assets,

Investments

in mutual funds - FVTPL u Level 1 z 546.74
- in equity instruments - FVOCI 7 Level 3 z 0.40
Trade receivables 12 79.97 -
Cash and cash equivalents 13 555.69 -
Other bank balances 4 626.23, :
Other financial assets Sand 15 60.27, :
Total financial assets 1322.16 3a71d
Financial liabilities

Borrowings 19 and 24 328.40 s
Lease liabilities 6 1,283.87 -
Trade payables 23 216.93 -
Other financial liabilities, 20 and 26 138.44 _
Total financial liabilities 1,967.68 =
As at March 31, 2019

Particulars Note Fair value level Amortised Cost Fair value
Financial assets

Investments

in mutual funds - FVTPL 1 Level 1 : 688.37
in equity instruments - FVOCI 7 Level 3 2 40
Trade receivables 12 1.25 :
Cash and cash equivalents 13 96.21 2
Other bank balances u 430.12 -
Other financial assets Sand 15 72.90 5
Total financial assets 690.48 688.7

 

Financial liabilities

 

Borrowings 19 and 24 424.26
Lease liabilities, 6 1,106.80 z
Trade payables 3 217.54 2
Other financial liabilities, 20 and 26 133,69, 2
Total financial liabilities 882.29 =

 

The fair value of trade receivables, loans, other financial assets, cash and cash equivalents, other bank balances, borrowings, trade payables and other financial abilities approximate their
carrying amount largely due to short-term nature of these instruments. Investments in mutual funds, which are classified as FVTPL are measured using net assets value at the reporting
date multiplied by the quantity held.

B. Measurement of fair values

i. Valuation techniques and significant unobservable inputs
Investment in equity instruments: The fair value of investment in equity instruments approximate to its carrying value. Hence, no fair value gain/ (loss) in accounted in OCL

 

 

‘Name of financial asset Valuation technique Significant unobservable inputs
Tnvestment in unquoted equity shares Discounted cash flow method was used to capture the present value of the expected future economic Long term growth rate
benefits that will flow to the Group arising from the investments in financial assets Discount rate

Revenue multiple

 

ii. Transfer between Level 1 and 2
There have been no transfers from Level 2 to Level 1 or vice-versa in the current financial year and no transfers in either direction in the last financial year.

 

Level 3 fair values

 

FVOCI Equity securities
June 30, 2021 June 30,2020 March 31, 2021 March 31,2020 March 31, 2019

Balance as at the beginning of the period/ year 0.40 0.40) 0.40 040 040
Investment made 2 a z & 2

 

 

‘Net change in fair value (Unrealised) Fi % 5 z s
Balance as at the end of the period/year 0.40 040 0.40 040 0.40

 

Aone percentage change in the unobservable inputs used in the fair valuation of level 3 assets does not have a significant impact in the fair value of the financial instrument.

C. Financial Risk Management

‘The Group activities expose it to market risk, liquidity risk and credit risk. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

 

 

Risk Exposure arising from Measurement "Management
Credit Risk Trade receivables, security _ Ageing analysis. Monitoring the credit limits of
deposits, bank deposits and Credit score of customers/ entities. customers and obtaining security
loans, deposits.
Liquidity Risk Borrowings Cash flow forecasts managed by finance team under the overview of Working capital management by
Senior Management, Senior Management.

‘The excess liquidity is channelised
through bank deposits and
investment in mutual funds.

 

‘The Group's risk management is carried out by the Senior Management under policies approved by the Board of Directors, The Board of Directors provides guiding principles for overall
risk management, as well as policies covering specific areas such as credit risk and liquidity risk

213
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

Credit risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's
receivables from customers and loans. The Group has no significant concentration of credit risk with any counterparty.

Trade receivables and loans
Customer credit risk is managed by the respective department subject to Group's established policy, procedures and control relating to customer credit risk management. Credit quality of
{dual credit limits as defined by the Group. Outstanding customer receivables are regularly monitored.

 

a customer is assessed based on indi

Expected credit loss (ECL) assessment for individual customers:
‘As per simplified approach, the Group makes provision of expected credit losses on trade receivable using a provision matrix to mitigate the risk of default payment and make
appropriate provision at each reporting date.

‘The ageing analysis of the receivables has been considered from the date the invoice falls due.

 

 

Tess than 180 _ More than 180 Provision Total
days days
June 30, 2021 HAG 2.38 5.33) 3552
June 30, 2020 48.56 41.62 (7.91) 72.27
March 31, 2021 6255 16.85 (15.32) 64.08
March 31, 2020 52.79 43.72 (16.54) 79.97
March 31, 2019 60.11 49.23 (18.09) 1.25

 

ive analysis of

 

Management believes that the unimpaired amounts that are past due by more than 180 days are still collectible in full, based on historical payment behaviour and exter
customer credit risk.

 

‘The movement in the allowance for impairment in respect of trade receivables is as follow

 

June 30,2021 June 30,2020 March 31,2021 March 31, 2020 _ March 31, 2019

 

 

Balance at the beginning of the period/year B32 T1658 1654 15.09 7a
Add: Allowance measured at lifetime expected credit loss - 137 339 461 12.07
Less: Amounts written off é “ (4.61) (6.16) (1.09)
Balance at the end of the period/year 1532 1791 15.32 1654 18.09

 

Credit risk on cash and cash equivalents, deposits with banks is generally low as the said deposits have been made with the banks who have been assigned high credit rating by credit
rating agencies. Investments of surplus funds are made only with approved financial institutions. Investments primarily include investments in mutual funds. The funds are invested as
per "Investment Policy" approved by the Board of Directors and are made only in debt funds with rating of AAA+ and with no exposure of more than 20% to a single fund house.

The security deposit pertains to rent deposit given to lessors. The Company does not expect any losses from non-performance by these counter-parties.

 

Liquidity risk
Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial
asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and
stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The finance team monitors rolling forecasts of the Group's liquidity position and cash and cash equivalents on the basis of expected cash outflows on trade payables and other financial
liabilities and any excess/ short liquidity is managed in the form of current borrowings, bank deposits and investment in mutual funds as per the approved frame work.

Exposure to liability risk
The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and
exclude the impact of netting agreements.

 

 

 

 

 

 

 

 

June 30, 2021, Carrying Total Contractual cash flows

amount Tess than l year ‘1-2years 25 years More than 5

years
Borrowings (including current maturities of long-term borrowings) 1192 1192 1192 = : 3
Lease liabilities 1571.59 2,481.39 238.74 244.10 710.56 1,287.99
Trade payables 259,25 259.25 s : 3
Deferred payment liabilities - on purchase of medical equipments 674 634 ost : -
Capital creditors 5.58. 558. - 2 3
Other financial liabilities, 71.38 7138 2 : 3
T2646 303.21 24.91 710356 1,287.99

June 30, 2020 Carrying Total ‘Contractual cash flows

amount Tess than year ‘1-2years 5 years More than 5

years
Borrowings (including current maturities of long-term borrowings) 306.56 30655 W86 wat Tas E
Lease liabilities 1,339.16 2,080.22 201.88 208.09 644.16 1,026.09
‘Trade payables 201.80 201.80 201.80 2 : :
Deferred payment liabilities - on purchase of medical equipments 20.59 22.25 14.33 7a ost z
Capital creditors 82.98, 82.98 82.98 2 : 3
Other financial liabilities, 85.86 85.86 85.86 2 : :
2036.95 2,779.66 63651 300.65 Bear 7026.09

 

214
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

 

March 31, 2021, Carrying Total ‘Contractual cash flows
amount Tess than 1 year ‘T-2yeai 25 years More than 5
years
Borrowings (including current maturities of long-term borrowings) 72 72 1197 3275 z E
Lease liabilities 1,365.75 2,104.34 214.32 221.73 659.10 1,009.19
Trade payables 201.56 221.56 21.56 ° : :
Deferred payment liabilities - on purchase of medical equipments 1049 11.13 870 243 2 3
Capital creditors 681 681 681 - - -
Other financial liabilities, 46.15 46.15 46.15 : : :
1695.48 271 30951 256.91 659.10 1009.19
March 31, 2020 Carrying Total ‘Contractual cash flows
amount TR yea 25 years More than 5
years
Borrowings (including current maturities of long-term borrowings) 328.40 328.40 107.07 2.26 129.07
Lease liabilities 1,283.87 1,987.76 194.46 197.41 616.34 979.55
Trade payables 216.93 216.93 216.93 5 3 3
Deferred payment liabilities - on purchase of medical equipments 23.15 25.30 15.17 770 243 -
Capital creditors 24.89 24.89 24.89 2 3
Other financial liabilities, 90.40 90.40 90.40 2 - 3
1967.68 2,673.68 648.92 29737 77.84 979.55
March 31, 2019 Carrying Total ‘Contractual cash flows
amount ss than 1 year 2 years 255 years ‘More than’
years
Borrowings (including current maturities of long-term borrowings) WA26 W226 T0891 94.02 233 E
Lease liabilities 1,106.80 1718.21 158.95 164.06 513.15 1882.05
Trade payables 217.54 217.54 21754 . :
Deferred payment liabilities - on purchase of medical equipments 31.05 35.72 12.94 1264 1014 z
Capital creditors 18.81 1881 18.81 3
Other financial liabilities, 83.83, 83.83 83.83 2 : -
1882.29 2,498.37 600.98 270.72 748.62 32.05

 

Except for these financial liabilities, it is not expected that cash flows included in the maturity analysis could occur significantly earlier, or at significantly different amounts.

ii, Market risk

Market risk is the risk that results from changes in market prices - such as foreign exchange rates, interest rates and others - will affect the Group's income. The objective of market risk
management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in Market interests rate. The Group's main interest rate risk
arises from short-term borrowings with variable rates, which exposes the Group to cash flow interest rate risk. The exposure of the Group's borrowing to interest rate changes at the end of

the reporting period are as follows:

 

 

 

 

 

 

Particulars ‘As atJune 30,2021  Asatfune 30, AsatMarch 31, AsatMarch 31, AsatMarch 31,
2020 2021 2020 2019
(Overdraft from banks 1192, B77, 197, 13.05 19.53
Sensitivity
Particulars Tmpact on profit and Toss
June 30,2021 June 30,2020 March 31, 2021 _March 31, 2020 _ March 31, 2019
Te Increase in interest Fate 2) iy (O12) O13) 0.20)
1% decrease in interest rate 012 oa 0.12 033 0.20

 

“The interest rate sensitivity Is Based on the closing balance of loans from Danks.

48 During the year ended March 31, 2020, VDC Diagnostics (Karnataka) LLP, subsidiary sold its business of Bangalore diagnostic centre under slump sale arrangement with effect from
November 30, 2019 for a consideration of Rs. 62.03 millions received in the form of cash & cash equivalents . All the assets and liabilities pertaining to this Bangalore diagnostic centre

‘were transferred to buyer pursuant to slump sale arrangement. The profit on slump sale (net of acquisition of good

49. Disclosure as per Ind AS 115 - Revenue from contracts with customers

A. Contract balances:

jwill of Rs. 15.42 millions) was Rs. 18.22 millions

 

‘As at
June 30, 2021

‘As at
June 30, 2020

‘As at ‘As at
March 31, 2021 March 31, 2020

As at
March 31, 2019

 

Contract assets
Contract liabilities
= Contract liability- deferred revenue

2.00

2.10

3.05

 

215
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, unless otherwise stated)

 

 

As at ‘As at ‘As at ‘As at ‘As at
June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019

 

Deferred revenue

Balance at the beginning of the period/year 210 275 2.75 3.05 307
Less: Revenue recognised from above (0.34) (0.40) 57) (1.68) 231)
Add: Addition during the period/year 0.24 oad 0.92 1.38, 1.60
Balance at the end of the period/year 2.00 249 2.10 275 3.05

 

 

C. Reconciliation of Revenue from contracts with customers

 

 

 

‘As at ‘As at ‘As at ‘As at As at
June 30,2021 June 30,2020 March 31,2021 March 31, 2020 March 31, 2019
[Revenue from contract with customer as per the contract price 125055 5348t 386191 349957 2,996.08
Adjustments made to contract price on account of
Discount / Rebates (24.66) (17.82) (97.37) (112.78) (71.38)
Revenue from contract with customer 1,225.89 517.02 3,764.54 3,386.79 2,924.65
Other operating revenue 097 0.08: 2.92 142 1.22
Revenue from operations 226.86 517.10 37676 3,388.21 2,925.87

 

530 Global Health Pandemic

During the year ended 31 March 2021 and 31 March 2020 & period ended June 30,2020 and June 30,2021 the outbreak of COVID-19 in many countries has brought about disruptions to
businesses around the world and uncertainty to the global economy. The Group is closely monitoring the impact of the pandemic on all aspects of it’s business, including how it will
impact its employees, vendors and business partners. The Group based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-
19 pandemic in assessing its impact on the financial statements. Based on the current estimates, the Group expects to fully recover the carrying amount of assets, and does not foresee any
‘material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.

51 Bonus issue of equity shares
Pursuant to the approval of shareholders granted in the extra-ordinary general meeting held on 26 May 2021, the Company issued and allotted fully paid-up “bonus shares” on 27 May
2021 at par in proportion of five new equity shares of Re. 1 each for every four existing fully paid up equity shares of Re. 1 each held as on the record date of 26 May 2021 by utilizing
securities premium account. The employee stock options granted under ESOP 2018 plan and the corresponding exercise prices will be adjusted to give effect of the allotment of bonus
shares. The basic/diluted earnings per share in respect of current period and previous years has been adjusted for issue of these bonus shares in accordance with Ind AS 33.

52 Other matter
Subsequent to the period ended June 30, 2021, the Company has received a letter dated July 5, 2021 under section 37 of the Foreign Exchange Management Act, 1999 read with section
133(6) of the Income Tax Act, 1961 from the Directorate of Enforcement, Government of India (“ED”) requesting certain information for the purpose of their investigation. The Company
has responded to the ED letter by letter dated August 5, 2021 providing the information requested for. The letter has only sought certain information, which has been complied with, and it
is not a show cause notice or demand letter at this stage, and there is no impact to the financial statements.

 

216
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

53. Ratios as per the Schedule III requirements

a) Current Ratio = Current Assets divided by Current Liabilities

 

 

 

 

 

 

 

 

 

 

Particulars June 30,2021] June 30, 2020| March 31, 2021] March 31,2020] _ March 31, 2019
(Current Assets 278197 TB6153 2387.81 T6352 Tato
Current Liabilities 571.13 613.00 439.88 586.40 571.40
Ratio 4.87 3.04 5.43 3.18 241
% Change from previous period / year =10%| 4% 71% 32%|

 

Reason for change more than 25%:

This ratio has increased from 2.41 in March 2019 to 3.18 in March 2020 mainly due to net increase in cash & bank balances and Investments in mutual funds due to

higher cashflows generated from higher revenue and profit.

This ratio has increased from 3.18 in March 2020 to 5.43 in March 2021 mainly due to net increase in cash & bank balances and Investments in mutual funds due to

higher cashflows generated from higher revenue and profit:

  

 

 

 

b) Debt Equity ratio = Total debt divided by Total equity where total debt refers to sum of current & non current borrowings
Particulars June 30,2021] June 30,2020] March 31, 2021] March 31,2020] _ March 31, 2019
[Total debt 11.92 306.56 qa72 328.40, 424.26
[Total equity 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10
Ratio 0.00 O11 0.01 0.12 0.20
% Change from previous period / year -76%| 7% -90%| 42%

 

 

 

 

 

 

 

 

Reason for change more than 25%:

This ratio has decreased from 0.20 in March 2019 to 0.12 in March 2020 mainly due to repayment of borrowings due to

operations,

 

her cashflows generated from business

This ratio has decreased from 0.12 in March 2020 to 0.01 in March 2021 mainly due to repayment (including certain prepayments) of borrowings due to higher

cashflows generated from from business operations.

This ratio has decreased from 0.01 in March 2021 to 0,00 in June 2021 mainly due to repayment of borrowings due to higher cashflows generated from from business

operations.

¢) Debt Service Coverage Ratio = Earnings available for debt services divided by Total interest and principal repayments

 

 

 

 

 

 

 

 

 

 

Particulars June 30,2021] June 30,2020] March 31, 2021[ March 31, 2020| _ March 31, 2019
Profit after tax” 333.25 18.10 849.11 625.07 462.72
|Add: Non cash operating expenses and finance cost 159.24 154.75 657.00 645.55 531.59
-Depreciation and amortizations 119.21 116.35 504.53 491.70 396.26
nance cost 40.03 38.40 152.47 153.85 135.33
Earnings available for debt services 492.49 172.85 1,506.11 1,270.62 994.31
interest cost on borrowings 0.61 711 15.67 34.07 31.79
Principal repayments (including certain prepayments during year ended March
31, 2021) 32.75 22.57 282.60 89.38 94.67
[Total Intrest and principal repayments 33.36 29.68 298.27 123.45 126.46
Ratio 14.76 5.82 5.05 10.29 7.86
"@ Change from previous period / year 153%| 51%] 31%|

 

*Profit after tax for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.

Reasons for change more than 25%:

This ratio has increased from 7.86 in March 2019 to 10.29 in March 2020 mainly due to increase in earnings available for debt services.
This ratio has decreased from 10.29 in March 2020 to 5.05 in March 2021 mainly due to prepayment of entire borrow
profit after tax from Rs. 18.10 million to Rs. 333.25 million in June 2021 as compared to June 2020 due to

 

The ratio has improved from 5.82 to 14.76 due to increas
increase in the business volumes in terms of number of tests and patient count,

d) Return on Equity Ratio / Return on Investment Ratio = Net profit after tax divided by Equity

  

gs

holding company.

 

 

 

 

 

 

 

 

 

 

Particulars June 30,2021] June 30,2020] March 31, 2021[ March 31, 2020| _ March 31, 2019
[Net profit after tax* 333.25 18.10 B49. 625.07, 272
[Total equity 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10
Ratio 8.48% 0.66%| 23.64%| 22.80%| 22.35%|
[Change in basis points (bps) from previous period / year 783, 84 a
% Change from previous period / year 1193%| 4% 2%)

 

*Profit after tax for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.

Reason for change more than 25%:

‘The return on equity has increased by 783 bps in June 2021 as compared to June 2020 mainly due to

 

business volumes in terms of number of tests and patient count.

217

 

\crease in profit after tax which was due to increase in the

 

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

53. Ratios as per the Schedule III requirements
e) Inventory Turnover Ratio = Cost of materials consumed divided by closing inventory

 

 

 

 

Particulars June 30,2021] June 30, 2020| March 31, 2021[ March 31,2020] _ March 31, 2019
[Cost of materials consumed™ 10.84 Toad 370.95 739.06 T0578
Closing Inventory 62.95 35.31 26.44 27.73 21.78
Inventory Turnover Ratio 3.35 214 21.59 15.83 18.58
% Change from previous period / year 57% 36%) =15%|

 

 

 

 

 

 

 

*Cost of materials consumed for the three months period ended June 30, 2021 and June 30, 2020 were not annualized

Reason for change more than 25%:
This ratio has increased from 15.83 in March 2020 to 21.59 in March 2021 mainly due to better working capital management.
This ratio has increased from 2.14 in June 2020 to 3.35 in June 2021 mainly due to better working capital management,

£) Trade Receivables turnover ratio = Credit Sales divided by Closing trade receivables

 

 

 

Particulars June 30,2021] June 30,2020] March 31, 2021[ March 31, 2020| _ March 31, 2019
(Credit Sales* 53.94 4161 200.56 178.18 197.68
Closing Trade Receivables 55.52 72.27 64.08 79.97 91.25
Ratio 0.97 0.58 3.13 2.23 217
% Change from previous period / year 69% 40%) 3%)

 

* Credit sales for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.
Reason for change more than 25%:
This ratio has increased from 2.23 in March 2020 to 3.13 in March 2021 mainly due to better collection efficiency and better working capital management.
This ratio has increased from 0.58 in June 2020 to 0.97 in June 2021 mainly due to better collection efficiency and better working capital management.

g) Trade payables turnover ratio = Credit purchases divided by closing trade payables

 

 

 

 

 

 

 

 

 

 

Particulars June 30,2021] June 30, 2020| March 31, 2021[ March 31,2020] _ March 31, 2019
(Credit Purchases" 333.55 257.75 T 53205 Taaa27 1305.44
Closing Trade Payables 259.25 201.80 221.56 216.93 217.54
Ratio 2.06 1.28 6.91 6.66 5.99
% Change from previous period / year 61%| 4% 11%]

 

* Credit purchase for the three months period ended June 30, 2021 and June 30, 2020 were not annualized
Reason for change more than 25%:

This ratio has increased from 1.28 in June 2020 to 2.06 in June 2021 mainly due to leveraging on our cashflows for payment to vendors to secure supplies at lower cost.

h) Net capital Turnover Ratio = Sales divided by Net Working capital whereas net working capital= current assets - current liabilities

 

 

 

 

 

 

 

 

 

 

Particulars June 30,2021] June 30, 2020| March 31, 2021] March 31,2020] _ March 31, 2019
1,226.86 31710 376746 3388.21 292587
ng Capital 2,210.85 1,248.53, 1,947.93, 1,277.12 803.19
0.55 O41 1.93 2.65 3.64
% Change from previous period / year 34%] -27%| 27%

 

 

* Sales for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.
Reason for change more than 25%:

This ratio has moved from 3.64 in March 2019 to 2.65 in March 2020 mainly due to increase in net working capital which is due to increase in balance of cash and bank
balances resulting from increase in revenue and profit.

This ratio has moved from 2.65 in March 2020 to 1.93 in March 2021 mainly due to increase in net worl
balances resulting from increase in revenue and profit.

This ratio has moved from 0.41 in June 2020 to 0.55 in June 2021 mainly due to i
of tests and patient count.

 

1g capital which is due to increase in balance of cash and bank

ease in sales which was due to increase in the business volumes in terms of number

 

i) Net profit ratio = Net profit after tax divided by Sales

 

 

 

 

Particulars June 30,2021] June 30, 2020| March 31, 2021] March 31,2020] _ March 31, 2019
[Net profit after tax* 333.25 18.10 B49. 625.07, W272
ISales 1,226.86 517.10 3,767.46 3,388.21 2,925.87
Ratio 27.16% 3.50% 22.54% 18.45% 15.81%
[Change in basis points (bps) from previous period / year 2,366 409) 263
% Change from previous period / year 676% 22% 17%|

 

 

 

 

 

 

 

* Net profit after tax for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.
Reason for change more than 25%:

This ratio has increased from 3.50% in June 2020 to 27.16% in June 2021 mainly due to increase in Net profit after tax resulting from increase in sales which was due to
increase in the business volumes in terms of number of tests and patient count and improved profitability margins.

218

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts are in Rs in millions, except share data or otherwise stated)

53. Ratios as per the Schedule III requirements

j) Return on Capital employed (pre cash)=Earnings before interest and taxes(EBIT) divided by Capital Employed(pre cash)

 

 

 

 

 

Particulars June 30,2021] June 30,2020] March 31, 2021] March 31,2020] _ March 31, 2019
Porfit before tax” (A) DS 648 TiaoF B37 655.18
Finance Costs* (B) 40.03 38.40 152.47 153.85 135.33
Other Income* (C) 32.84 22.82 118.47 153.61 103.57
EBIT (D) = (A)+(B)-(C) 449.34 22.06 1,155.24 834.51 684.94
Capital Employed (Pre Cash) (J)=(E)-(F)-(G)-(H)-(I) 2,945.60 2,598.40 2,750.84 2,507.50 2,278.20
[Total Assets (E) 6,045.78, 4,901.83, 5,409.40 4,822.56 4,064.30
Current Liabilities (F) 571.13 613.00 439.88 586.40 571.40
Current Investments (G) 27957 12.75 276.27 546.74 688.37
Cash and Cash equivalents (H) 101.58 306.26 66.86 555.69 96.21
Bank balances other than cash and cash equivalents (1) 2,147.90 1371.42 1875.55, 626.23 430.12
Ratio (D/O) 15.25% 0.85% 42.00% 33.28% 30.06%
[Change in basis points (bps) from previous period / year 14a 872 322,

% Change from previous period / year 1697%) 26% 11%]

 

 

 

 

 

 

* Amount for the three months period ended June 30, 2021 and June 30, 2020 were not annualized.

Reason for change more than 25%:

‘The return on capital employed has increased by 872 bps in March 2021 as compared to March 2020 mainly due to increase in Earnings before interest and taxes (EBIT) which is due to

higher business volumes and improved profitability margins.

‘The return on capital employed has increased by 1,441 bps in June 2021 as compared to June 2020 mainly due to increase in Earnings before interest and taxes (EBIT) which is due to

higher business volumes and improved profitability margins.

219

 
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)

Annexure VII Notes to Restated Consolidated Financial Information
(All amounts ave in Rs in millions, unless otherwise stated)

54 Additional information as required under para 2 of General Instruction of Division II of Schedule III to the Companies Act, 2013.

 

Name of Company

June 30, 2027

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net assets, Le, total assets minus Share in profil/ (loss) Share in other comprehensive income __ Share in tolal comprehensive income/,
‘Amount ‘AS % of ‘Amount “As % of profiyy ‘Amount ‘As % of other ‘Amount ‘As % of total
consolidated (loss) comprehensive comprehensive
net assets, income /(loss) income/ (loss)
Parent
Vijaya Diagnostics Centre Limited 3,931.80 10.07% 322.77 96.86% (0.26) 18.18% 322.52 96.84%
Subsidiaries (including step down subsidiaries)
Medinova Diagnostic Services Limited (44.91) 14% 10.69 3.21% (0.02) 9.09% 1067 3.20%
VDC Diagnostic (Karnataka) LLP 39.98 1.02% 0.44 0.13% : 0.00% 044
Doctors Lab Diagnostic Centre Private Limited. 11.62 0.30% 0.10 0.03% 0.00% 10
Medinova Millennium MRI Services LLP (752) 0.19% (0.73) 0.22% 0.00% 073)
Namrata Diagnostic Centre Private Limited (12.38) 0.32% (0.01) 0.00% = 0.00% (0.01)
Non-controlling interest in all subsidiaries 5.82 0.5% 3.56 1.07% (0.01) 4.55% 3.56
Total 392A 99.88% 336.82 01.07% (029) 31.82% 33655
Consolidation adjustments Tor O12e G52) 07% O07 BIE, G5)
‘Net amount 3,929.08 100.0% 333.25 00.00% (0.22) 100.009 333.03
‘Name of Company June 30, 2020
Net assets, Le, total assets minus Share in profi (oss) Share in other comprehensive income Share in tolal comprehensive income)
‘Amount ‘AS % of ‘Amount ‘As % of profiyy ‘Amount ‘As % of other ‘Amount ‘As % of total
consolidated (loss) comprehensive comprehensive
net assets income /(loss) income/ (loss)
Parent
Vijaya Diagnostics Centre Limited 2,792.07 101.3% 1814 10.22% (1.83) 91.96% 1631 101.24%
Subsidiaries (including step down subsidiaries)
Medinova Diagnostic Services Limited (76.46) 277 0.46 254% (0.16) 8.04% 030 1.86%
VDC Diagnostic (Karnataka) LLP 38.33 1.39% 0.88. 486% - 0.00% oss: 5.46%
Doctors Lab Diagnostic Centre Private Limited. 7.08 0.26% on 061% 0.00% on 0.68%
Medinova Millennium MRI Services LLP (6.01) 0.22% (1.83) “10.11% 0.00% (1.83) 11.36%
Namrata Diagnostic Centre Private Limited (0.72) 0.35% (0.02) 0.11% - 0.00% (0.02) 0.12%
Non-controlling interest in all subsidiaries 697) 0.22% (1.03) 5.69% (0.90) 45.23% (2.09) 6.77%
Total 2,739.28 99.31% 1671 92.32 (2.39) 145.239 14.66 1.00%
‘Consolidation adjustments 19.00 0.69% 139 7.68% 090. 45.23%, 15 9.00%
‘Net amount 2,758.28 100.0% 18.10 100.0% 7.99) 100.0% 16.11 10.00%
‘Name of Company March 31, 2021
Net assets, Le, total assets minus ‘Share in profi (loss) Share in other comprehensive income Share in tolal comprehensive income/
total liabilities ‘Mloss) (loss)
‘Amount ‘As % of ‘Amount ‘As % of profiyy ‘Amount ‘As % of other ‘Amount ‘As % of total
consolidated (loss) comprehensive comprehensive
net assets, income /(loss) income/ (loss)
Parent
Vijaya Diagnostics Centre Limited 3,605.49 100.37% 826.05 97.28% 038 250.0% 826.40 97.34%
Subsidiaries (including step down subsidiaries)
Medinova Diagnostic Services Limited (95.58) “1.55% 21.66 2.558% (0.49) 350.00% 2117
VDC Diagnostic (Karnataka) LLP 39.54 1.10% 2.10 0.25% s 0.00% 2.10
Doctors Lab Diagnostic Centre Private Limited. 151 032% 458 054% 0.00% 458
Medinova Millennium MRI Services LLP (678) 0.19% 61) 031% - 0.00% 61)
‘Namrata Diagnostic Centre Private Limited. (12.37) 0.34% 2.67) 031% Z 0.00% 67)
Non-controlling interest in all subsidiaries 2.26 0.06% 648. 0.76% (0.18) 128.57% 630
Total 3,588.08 9.77% 355.59 10.76% (032) 22857% 353.48
‘Consolidation adjustments B25 yy Cas) D76% oa “a8 a7 (630)
‘Net amount 3,502.32 100.0% M91 100.0% 19) 100.0% 38.97

 

 

220
Vijaya Diagnostic Centre Limited (formerly Vijaya Diagnostic Centre Private Limited)
Annexure VII Notes to Restated Consolidated Financial Information
(All amounts ave in Rs in millions, unless otherwise stated)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

‘Name of Company March 31, 2020

Net assets, Le, total assets minus ‘Share in profi (loss) Share in other comprehensive income Share in total comprehensive income

total liabilities /(loss)
‘Amount As % of ‘Amount ‘As % of profiyy ‘Amount ‘As % of other ‘Amount ‘As % of total
consolidated (loss) comprehensive comprehensive
net assets, income /(loss) income

Parent
Vijaya Diagnostics Centre Limited 2777.13 101.30% 609.47 97.50% (1.29) 98.47% 608.18 97.50%
Subsidiaries (including step down subsidiaries)
Medinova Diagnostic Services Limited (76.76) 2.80% 2.20) 035% (0.02) 1.53% (2.22) 0.36%
VDC Diagnostic (Karnataka) LLP 37.44 137% 1844 2.95% : 0.00% 18.44 2.96%
Doctors Lab Diagnostic Centre Private Limited 6.93 0.25% 15.02 2.40% : 0.00% 15.02 241%
Medinova Millennium MRI Services LLP (a7) 0.15% 0.23 0.04% 0.00% 0.23 0.04%
‘Namrata Diagnostic Centre Private Limited (9.70) 0.35% (0.14) 0.02% _ 0.00% (0.1) 0.02%
Non-controlling interest in all subsidiaries (4.08) 0.15% (0.31) 0.05% (0.01) 076% (0.32) 0.05%
Total 272683 9.5% C051 T0247% 32) 00.76% 39.19 TRA
‘Consolidation adjustments 1456 osa% (a) 2AT% at “0.76%, 15.43) ATK
‘Net amount 2741.39 00.00% 625.07 00.00% G31) 100.0% 623.76 10.00%
‘Name of Company March 31, 2019

Net assets, Le, total assets minus Share in profit/ (oss) ‘Share in other comprehensive income Share in total comprehensive income

total liabilities ‘Aloss)
‘Amount ‘As % of ‘Amount “As % of profiyy ‘Amount ‘As % of other ‘Amount ‘As % of total
consolidated (loss) comprehensive comprehensive
net assets, income /(loss) income

Parent
Vijaya Diagnostics Centre Limited 2,120.20 102.42% 451.79 97.64% (40) 86.42% 450.39 97.68%
Subsidiaries (including step down subsidiaries)
Medinova Diagnostic Services Limited (72.02) 3.48% 7.2 1.56% (0.16) 9.88% 7.06 1.53%
VDC Diagnostic (Karnataka) LLP (136.02) 657% (23.13) 5.00% (0.06) 3.70% (23.19) 5.03%
Doctors Lab Diagnostic Centre Private Limited (6.08) 0.39% (0.56) 012% : 0.00% (0.56) 0.12%
Medinova Millennium MRI Services LLP (1.66) 0.08% 0.35 0.08% - 0.00% 0.35 0.08%
‘Namrata Diagnostic Centre Private Limited. (9.56) 0.46% (0.22) 0.05% : 0.00% (0.22) 0.05%
Non-controlling interest in all subsidiaries 72) 0.18% 3.98. 0.86% (0.06) 3.70% 3.92 085%
Total 1889.14 T1.15% 13943 34.97% (68) 103.70% B75 94.95%
‘Consolidation adjustments 180.96 874% 23.29 5.03% 0.06 3.70% 23.35 5.06%
Net amount 2,070.10 10.00% W272 100.0% @.62) 100.0% H61.10 10.00%
Note:

 

‘The disclosure as above represents separate information for each of the consolidated entities after adjustment for restatement and before elimination of inter-company transactions. The net impacts on elimination of
inter company transactions  profits/consolidation adjustments have been disclosed separately. Based on the group structure, the Management is of the view that the above disclosure is appropriate under requirements

of the Act.

As per our Report of even date attached
For BSR & Associates LLP

Chartered Accountants

ICAI Firm registration number: 116231W/ W-100024

Sriram Mahalingam
Partner
Membership Number: 049642

Place: Hyderabad
Date: August 16, 2021

For and on behalf of the Board of Directors
Vijaya Diagnostic Centre Limited

(formerly known as ‘Vijaya Diagnostic Centre Private Limited’)
CIN: U851957G2002P1.C039075

Dr. $ Surendranath Reddy

Executive Chairman

S Suprita Reddy
Chief executive officer

DIN Number: 00108599

K, Sunil Chandra
Executive Director

Narasimha Raju K.A
Chief Financial Officer

DIN Number: 01409332

Place: Hyderabad
Date: August 16, 2021

221

V. Sri Lakshmi
Company Secretary

Membership Number: F9950
OTHER FINANCIAL INFORMATION

The accounting ratios required under Clause 11 of Part A of Schedule VI of the SEBI ICDR Regulations are given below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars For the year/period ended
June 30, 2021 | June 30, 2020 March 31, | March 31,
2020 2019
Basic earnings per share** (in 2) 3.23 0.19 6.13 4.50
Diluted earnings per share*” (in 2) 3.23 0.19 6.13 450
Return on net worth” (%) 8.48 0.66 22.80 22.35
Net asset value per share (in 2) 38.53 27.05 26.89 20.32
EBITDA ( in million) 601.39 ; 1,778.84 1,479.82 1,184.77
Adjusted EBITDA (2 in million) 568.55, 138.41 1,659.77 1,326.21 1,081.20

 

*Not annualised for the three month period ended June 30, 2021 and June 30, 2020
Notes: The ratios have been computed as under:

1. Basic and diluted EPS: Restated profit for the year attributable to equity shareholders of the Company divided by total weighted average number of
equity shares outstanding during the period. Basic and diluted EPS are computed in accordance with Ind AS 33 - Earnings per share
‘Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity
shares of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated
May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares.
Basic and diluted EPS are considered post sub-division and bonus issue.

N

Net worth = net worth means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities premium account
and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and
miscellaneous expenditure not written off, derived from the Restated Financial Information, but does not include reserves created out of revaluation of
assets, write-back of depreciation and amalgamation

(2 in million,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars As at

June 30, | June | March31, | March31, | March 31,

2021 _| 30, 2020 2021 2020 2019

Equity share capital (A) 101.97 | 45.32 45.32 45.32 45.29
Instruments entirely equity in nature (B) : - - - 24.13
Other equity (C) 3,821.29 | 2,718.93 3,544.74 2,700.11 2,004.40
Equity attributable to owners of the Company (D) = (A)+(B)+(C) 3,923.26 | 2,764.25 3,590.06 | 2,745.43 2,073.82
‘Non-controlling interest (E) 5.82 | (5.97) 2.26 (4.04) @.72)
‘Net Worth (F) = (D)+(E) 3,929.08 | 2,758.28 | 3,592.32 | 2,741.39 2,070.10

 

 

3. Return on net worth %: Profit(loss) for the year divided by net worth at the end of the year at the end of the year*100

(2 in million)

 

 

 

 

 

 

Particulars As at
June 30,2021 | June 30,2020 | March 31, 2021 March 31, 2020_| March 31, 2019
‘Net Worth (A) 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10
Profit/ (loss) for the year (B) 333.25 18.10 849.11 625.07, 462.72
Return on net worth’ (C) = (B)/(A)*100 8.48 0.66 23.64 22.80 22.35

 

 

 

 

‘Not annualised for the three month period ended June 30, 2021 and June 30, 2020

4. Net assets value per share (in 8): Net asset value per share is calculated by dividing net worth by number of equity shares outstanding at the end of the

 

 

 

 

 

 

 

 

 

year
(@ in million, except per share data
Particulars As at
June 30,2021 | June 30,2020 | March31,2021 | March 31,2020 | March 31, 2019
‘Net Worth (A) 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10
Nos of equity shares outstanding* (B) 101,965,926 101,965,926 101,965,926 101,965,926 101,898,292
Net asset value per share (C) 38.53 27.05 35.23 26.89 20.32

 

 

 

 

*Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity
shares of face value of 210 each to Equity Shares of face value of 21 each. Further subsequent to March 31, 2021, pursuant to a Board resolution dated
May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares. Net
asset value per share is considered post sub-division and bonus issue

w

EBITDA = Earnings before interest, taxes, depreciation and amortisation expense, which has been arrived at by obtaining the profit / (loss) for the year
and adding back finance costs, total tax expense, depreciation and amortisation expense

6. Adjusted EBITDA = EBITDA minus other income

 

 

 

 

 

 

 

 

 

 

 

 

 

(2 in million)
Particulars For the year/ period ended
June 30, June 30, | March 31,2021 | March3i,2020 | March 31,2019
2021 2020
Profit/(loss) for the year (A) 333,25 18.10 849.11 625.07 462.72
Finance costs (B) 40.03 38.40 152.47 153.85 135.33,
Total tax expense (C) 108.90 (11.62) 272.13 209.20 190.46
Depreciation and amortisation expense (D) 119.21 116.35, 504.53 491.70 396.26
EBITDA (E) = (A)+(B)+(C)+(D) 601.39 161.23 1,778.24 1,479.82 1,184.77
Other income (F) 32.84 22.82 118.47 153.61 103.57
‘Adjusted EBITDA (G) = (E)-(F) 568.55 138.41 1,659.77 1,326.21 7,081.20

 

 

 

 

222
7. Accounting and other ratios are derived from the Restated Financial Information.

In accordance with the SEBI ICDR Regulations, the audited financial information of our Company for Financial Years 2019,
2020 and 2021 (“Audited Financial Statements”) are available on our website at
https://vijayadiagnostic.com/miscellaneous/annual-report. Our Company is providing a link to this website solely to comply
with the requirements specified in the SEBI ICDR Regulations. The Audited Financial Statements do not constitute, (i) a part
of this Prospectus; or (ii) a prospectus, a statement in lieu of a prospectus, an offering circular, an offering memorandum, an
advertisement, an offer or a solicitation of any offer or an offer document or recommendation or solicitation to purchase or sell
any securities under the Companies Act, the SEBI ICDR Regulations, or any other applicable law in India or elsewhere. The
Audited Financial Statements should not be considered as part of information that any investor should consider subscribing for
or purchase any securities of our Company and should not be relied upon or used as a basis for any investment decision. None
of our Company or any of its advisors, nor BRLMs or the Selling Shareholders, nor any of their respective employees, directors,
affiliates, agents or representatives accept any liability whatsoever for any loss, direct or indirect, arising from any information
presented or contained in the Audited Financial Statements, or the opinions expressed therein.

223
CAPITALISATION STATEMENT

The following table sets forth our capitalisation as at June 30, 2021, derived from our Restated Financial Information, and as
adjusted for the Offer. This table should be read in conjunction with “Management's Discussion and Analysis of Financial
Condition and Results of Operations”, “Financial Statements” and “Risk Factors” on pages 226, 162, and 21, respectively.

( in million)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars Pre-Offer (as at June 30, 2021) Post Offer
Debt
Current borrowings (A) 11.92 11.92
Non-current borrowings (including current maturity) (B) - -
Total borrowings (C=A+B) 11.92 11.92
Equity
Equity share capital (D) 101.97 101.97
Other equity (E) 3,827.11 3,827.11
Total Equity (F= D+E) 3,929.08 3,929.08
Total Capitalisation (G= C+F) 3,941.00 3,941.00
Total non-current borrowings (including current maturities) - -
/Total equity (B/F)
Total borrowings/Total equity (C/F) 0.00 0.00

 

 

 

Notes:

i

224

The above statement does not include lease liability as per Ind AS 116 disclosed under other financial liability in the Restated Financial Information
FINANCIAL INDEBTEDNESS

Set forth below is a brief summary of aggregate borrowings of our Companies and our Subsidiaries as of June 30, 2021

 

 

 

 

 

(in million
Category of borrowings Sanctioned amount Outstanding amount*
Fund based facilities Principal Interest
Overdraft 75.50 11.92 -
Total 75.50 11.92 :

 

 

 

 

 

* As certified by M. Anandam & Co, Chartered Accountants, in their certificate dated August 24, 2021

Principal terms of the facilities sanctioned to our Company and Subsidiaries:

A.

Interest: In respect of certain facilities sanctioned to our Company and Subsidiaries, the interest rate is based on the
bank’s fixed deposit rate extending from 5.25- 9.35% spread.

Tenor: The facilities are repayable on demand from the lender.

Security: The fixed deposit overdraft loan facilities sanctioned are typically secured by way of first charge on our
Company’s and our Subsidiaries deposits with the lender bank.

Pre-payment: Our Company and our Subsidiaries may repay all amounts of the credit facilities as mentioned in
documentation executed in relation to the facilities.

Penal interest: The penal interest charged by the lenders for the loans availed by our Company and our Subsidiaries
is typically 3% per month.

Re-payment: Our Company and Subsidiaries may repay all amounts of the credit facilities as mentioned in
documentation executed in relation to the facilities.

Events of Default: Borrowing arrangements entered into by our Company and our Subsidiaries contain standard events
of default, including in relation to a failure or inability to pay loan amounts on due dates. This is indicative and there
may be additional terms that may amount to an event of default under the borrowing arrangements entered into by our
Company and our Subsidiaries.

Consequences of occurrence of events of default: In terms of our borrowing arrangements, the lender bank may
terminate and cancel either whole or part of the facility following the occurrence of an event of default

Restrictive Covenants: The facilities sanctioned to our Company contain certain restrictive covenants, including,
intimating the lender bank with regards to any changes in the shareholding pattern of our Company. This is indicative
list there may be such other additional terms under the borrowing arrangements entered into by our Company.

For the purpose of the Offer, our Company does not require to obtain any consents from our lenders for undertaking activities
relating to the Offer.

225
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS

You should read the following discussion in conjunction with our restated consolidated financial statements as of the three
months ended June 30, 2021 and 2020 and the financial years ended March 31, 2021, 2020, and 2019 including the related
notes, schedules and annexures. These restated consolidated financial statements have been prepared under Indian Accounting
Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rules, 2015 read with Section 133 of the
Companies Act, 2013 to the extent applicable. For further information, see our Restated Financial Statements under “Financial
Statements” on page 162.

 

Our financial year ends on March 31 of each year. Accordingly, all references to a particular financial year are to the 12-
month period ended March 31 of that year.

Unless otherwise indicated or the context otherwise requires, the financial information for the three months ended June 30,
2021 and 2020 and the Financial Years 2021, 2020 and 2019 included herein is derived from the Restated Financial Statements,
included in this Prospectus, which have been derived from our audited financial statements and restated in accordance with
the SEBI ICDR Regulations and the Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the ICAI,
as amended from time to time. For further information, see “Financial Statements” on page 162.

The industry-related information contained in this section is derived from the CRISIL Report. We commissioned and paid for
the CRISIL Report for the purposes of confirming our understanding of the industry specifically for the purpose of the Offer.

This discussion contains forward-looking statements that involve risks and uncertainties and reflects our current view with
respect to future events and financial performance. Actual results may differ from those anticipated in these forward-looking
statements as a result of factors such as those set forth under “Forward-Looking Statements” and “Risk Factors” on pages 20
and 21, respectively.

Overview

We are the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing
diagnostic chain by revenue for fiscal year 2020 (Source: CRISIL Report). We offer an one-stop solution for pathology and
radiology testing services to our customers through our extensive operational network, which consists of 81 diagnostic centres
and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National
Capital Region and Kolkata as on 30 June, 2021. During the fiscal year 2021, we derived 96.2% of our revenue from operations
from our core geographies, Hyderabad and rest of Telangana and Andhra Pradesh.

Our history can be traced back to 1981, when our Promoter and Chairman, Dr. S. Surendranath Reddy established the first
Vijaya Diagnostic Centre in Hyderabad, with a vision of providing comprehensive, innovative and high quality diagnostic
services under one roof, in a reliable, affordable and customer-centric manner. The business was carried out under sole
proprietorship, which was later taken over by our Company in 2005. According to the CRISIL Report, the Indian diagnostics
market was valued at approximately = 710 billion to 2 730 billion in the fiscal year 2021, and is projected to grow at CAGR of
around 12% to 13% to reach approximately 2 920 billion to 2 980 billion by fiscal year 2023, driven by rise in health awareness
and disposable incomes, increase in demand for better healthcare facilities and quality of care of individuals, and increase in
spending on preventive and wellness. Furthermore, according to the CRISIL Report, the diagnostics market in Telangana and
Andhra Pradesh, the states in which we have a significant presence, is projected to grow to approximately 2 120 billion to =
130 billion by fiscal year 2023. We believe that the combination of our strong brand position driven by our long operating
history in our core geographies, extensive network and reputation for providing quality diagnostic services positions us well to
continue to grow our business in Telangana and Andhra Pradesh markets and take advantage of the growth of the Indian
diagnostic industry.

We offer a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic
and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Our test menu includes
pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests,
and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including CT
scans, MRI scans, SPECT and advanced PET CT. We also offer a broad spectrum of health and wellness packages to our
customers as per their requirements. We focus on a customer centric approach to enhance the overall quality of our services for
optimal customer satisfaction. For convenience of our customers, we provide value-added services such as home collection of
specimens, house calls and various delivery or access modes (i.e., at diagnostic centres, SMS, email and web portal) for test
reports. Several factors, including the strength of our brand, integrated services model, quality of our diagnostic services, center
infrastructure and customer experience, convenience of our operational network and home collection in our core geographies
are important differentiating factors in customers choosing us as their preferred diagnostic service provider, which helps us in
retaining our customers, and sets us apart from our competitors.

We have implemented a ‘hub and spoke’ model, whereby specimens are collected across multiple locations within a catchment

226
area or a region for delivery to our reference laboratories for diagnostic testing. This model provides greater economies of scale
and enhances consistency of our testing procedures and results. All of our centres offer integrated diagnostics services
(pathology and radiology tests under one roof) with smaller spokes offering pathology tests and basic radiology tests and hub
centres (ARCs) offering pathology tests, basic radiology tests and advanced radiology tests such as MRI, HRCT, SPECT and
PET CT. As of June 30, 2021, our operational network consists of diagnostic centre network of (i) a flagship centre located in
Hyderabad, which is our main ‘hub’ and equipped to conduct all of pathology specimens collection, basic and advanced
radiology tests; (ii) 20 hub centres, which are equipped to conduct all of pathology specimens collection, basic radiology tests
and certain advanced radiology tests; and (iii) 60 diagnostic centres, which are equipped to conduct a majority of pathology
specimen collection and certain basic radiology tests; and a laboratory network of (i) a national reference laboratory co-located
with our flagship centre; and (ii) 10 reference laboratories co-located with certain hub centres and diagnostic centres. Our
diagnostic services are provided by a medical professional team consisting of 74 laboratory doctors, 19 physicians, 105
radiologists and 1,027 well-trained technical staff in our operational network, as of June 30, 2021. As of June 30, 2021, all of
our laboratories hold NABL and three of our diagnostic centres hold NABH accreditations.

Our individual consumer business contributed to 92.09% of our revenue from operations for the fiscal year 2021, owing to the
trust built while rendering, over decades, quality diagnostic services and experience gained. Over the years, we have received
several awards that recognize the strength of our brand and our focus on offering superior diagnostic services. For examples,
we were recognized as “One of the Best Healthcare Brands-2021” by The Economic Times in 2021, “For excellence in Quality
and Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics
Leadership Summit in 2021, “Most Trusted Diagnostic Centre of the year — India” at the Indo-Arab Leaders Summit & Awards
in 2019, “Best Diagnostic Centre of the Year” by Times Healthcare Achievers, The Times of India in 2019, “10 Most Trusted
Brands of the Year” by the Business Sight Magazine in 2019 and “Telangana Healthcare Leadership Award” by the Telangana
Government in 2018.

Our Company was founded and promoted by Dr. S. Surendranath Reddy, our executive Chairman, who is a first generation
entrepreneur and has more than four decades of experience in integrated diagnostics business and is a radiologist. Our CEO,
Sura Suprita Reddy, and executive director, Sunil Chandra Kondapally, have been involved in our business and operations since
2003 and 2002, respectively. Our shareholders include our Promoter, Dr. S. Surendranath Reddy, and marquee investors,
Karakoram Limited and Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1; and we believe we have
benefited significantly from their vision and leadership, and they along with our senior management, have been instrumental in
formulating and executing the core strategy of our Company.

During three months ended June 30, 2021, we conducted approximately 1.96 million pathology tests and 0.22 million radiology
tests for approximately 0.94 million customers. During fiscal 2020, our tests per customer visit was 2.8, our operating revenue
per customer was 2 1,214 and our operating revenue per test was 2 428, all of which are higher as compared to our listed
regional peers as per the CRISIL Report.

The table below shows our key financial and operational metrics:

 

 

Particulars As of and for the Asofandforthe | Asofandforthe | Asofandthefor | As of and for the
three months ended | three months ended year ended the year ended year ended
June 30, 2021 June 30, 2020 March 31,2021 | March 31,2020 | March 31, 2019
Number of 81 74 80 73 61

diagnostic centres

 

Clinical qt dL i 4 i
laboratories

 

 

 

 

 

Number of 0.94 0.40 2.63 2.79 2.38
customer visits (in

million)

Number of tests 2.18 1.05 7.09 7.91 6.99
performed (in

million)

Number of tests per 2,31 2.61 2.69 2.83 2.93
customer visit!

Revenue per test” 562 491 531 428 419
(in 2)

Revenue per 1,299 1,280 1,431 1,214 1,228

 

 

 

 

 

 

 

customer visit? (in

 

227
 

Particulars As of and for the Asofand forthe | Asofandforthe | Asofandthe for | As of and for the
three months ended | three months ended year ended the year ended year ended
June 30, 2021 June 30, 2020 March 31,2021 | March 31,2020 | March 31, 2019

 

»

 

 

 

 

 

 

 

 

Notes:

 

This figure is derived by dividing the number of tests performed by the number of customer visits.
This figure is derived by dividing revenue from operations, as per Restated Financial Statements, by the number of tests performed.
This figure is derived by dividing revenue from operations as per Restated Financial Statements, by the number of customer visits.

Significant Factors Affecting Our Results of Operations
Number of Customers Served and Tests Conducted

The key drivers affecting the growth of our revenue from operations are the number of pathology and radiology tests that we
conduct as well as the number of customers served by us. During the three months ended June 30, 2021 and 2020, we conducted
approximately 2.18 million tests from approximately 0.94 million customer visits and approximately 1.05 million tests from
approximately 0.40 million customer visits, respectively. During the financial years 2021, 2020 and 2019, we conducted
approximately 7.09 million, 7.91 million and 6.99 million tests from 2.63 million, 2.79 million and 2.38 million customer visits,
respectively. We offer a comprehensive range of approximately 740 routine and 870 specialised pathology tests and 220 basic
and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. Our operations are
supported by a laboratory network consisting of 11 laboratories, including our national reference laboratory and 10 reference
laboratories, co-located with our diagnostic centres, and a service network consisting of one flagship diagnostic centre, 20 hub
centres and 60 diagnostic centres, as of June 30, 2021.

The number of customer visit is also dependent on our ability to maintain and improve our brand image, which in turn depends
on several factors such as the quality and efficiency of our pathology tests, radiology tests, turnaround time and customer
satisfaction, the performance of our service network, the introduction of new tests and services and our ability to maintain
strong relationships with customers and vendors. While we expect to continue to serve a higher number of customer visit in the
future, the diagnostics industry in India is highly competitive, and it is challenging to improve market share and profitability.
Consequently, our ability to grow our revenues depends on our ability to compete successfully and attract new customers.

Revenue Mix between Individual Customers and Institutional Customers

Our results of operations are affected by the customer mix serviced by us. In general, a higher percentage of individual
customers will have a positive impact on our revenues as services rendered to such customers tend to have higher profit margins
than services rendered to institutional customers. A substantial majority of our customers are individual customers, with over
92.09% of our revenues from operations for the financial year 2021, being directly attributed to our individual consumer
business, as a result of the strength of our brand, our integrated services model, quality of our diagnostics, our centre
infrastructure and customer experience, the convenience of our centre network and home collection in our core geographies.
We intend to continue to focus on increasing the number of our individual customers through various initiatives such as
expanding our service network to create visibility, increase our presence in the market, boost our home collection services and
preventive and wellness services. In addition, we have employed focused sales and support team for our institutional customer
and aim to strive for growth in volume and revenue generated from institutional customers concurrently.

Cost of Materials Consumed

During our course of business, we regularly consume reagents, chemicals, radiology supplies and other related consumables.
For the three months ended June 30, 2021 and 2020, our cost of materials consumed was 2% 210.84 million and % 75.54 million,
or 25.79% and 14.16% of our total expenses. For the financial years 2021, 2020 and 2019, our cost of materials consumed was
% 570.95 million, = 439.06 million and = 404.78 million, or 20.65%, 16.22% and 17.03%, respectively of our total expenses.
Our cost of materials as percentage of total revenue from operations is affected by various factors including repricing of vendor
contracts for reagents, initiatives for improving operational efficiencies and increased economies of scale of our operations.

As we continue to expand our operations and test portfolio, we would need to procure additional volumes of raw materials. We
depend on third-party vendors and suppliers to procure our testing reagents, chemicals, radiology supplies. The procurement
cost of foreign produced reagents and other materials may change due to several factors including depreciation of Indian Rupee,
and our suppliers may therefore demand to re-negotiate the supply contracts with us. In the event of an increase in the price of
such items, we may not be able to correspondingly increase the price of our services.

Periods of Disease Outbreaks
Our revenues and results of operations have fluctuated in the past and may continue to fluctuate significantly due to periods of

disease outbreaks, such as COVID-19, malaria and dengue. Diagnostic healthcare testing volumes typically increase during the
228
monsoon season, when there is a greater prevalence of malaria and dengue, as well as gastrointestinal and respiratory diseases.
The increased prevalence of a particular virus or other pathogen in the general population often causes an increased demand for
specific diagnostic healthcare testing for that virus. However, certain of our expenses are less impacted by fluctuations in
demand, as a significant portion of our costs and expenses such as employee benefits expense, annual maintenance contracts
for radiology equipment, housekeeping, security expenses are fixed, unlike the costs of medical consumables. As a result of
such seasonal and other factors, we experience year-on-year fluctuations and we expect such seasonal patterns in our results of
operations to continue in the foreseeable future.

There is significant uncertainty regarding the duration and long-term impact of the COVID-19 pandemic, as well as possible
future responses by the Government, which makes it impossible for us to predict with certainty the impact that COVID-19 will
have on our business, operations or potential expansion plans in the future. The recent surge in COVID-19 infections has led to
states in India having imposed and other states considering the imposition of additional regional or local lockdowns or curfews.
For example, the state of Telangana on May 12, 2021 had imposed a complete lock down, and the state of Andhra Pradesh had
on May 5, 2021 imposed a partial lock down, each to prevent the further spread of COVID-19. The COVID-19 pandemic has
affected and may continue to affect our business, results of operations and financial condition in a number of ways such as
reduction of working hours at a few of our centres, reduction of demand of certain tests, preference of COVID-19 test over the
others and delays in expansion plans. We currently provide RT-PCR tests for detection of COVID-19 at 25 diagnostic centres
across nine cities and towns. The continuing impact of COVID-19 pandemic on our financial condition remains uncertain and
is dependent on the spread of COVID-19 and steps taken by the Government to mitigate the economic impact and may differ
from our estimates. We are closely monitoring the impact of COVID-19 on our financial condition, liquidity, operations,
suppliers and work force. Any intensification of the COVID-19 pandemic or any future outbreak of another highly infectious
or contagious disease may adversely affect our business, results of operations and financial condition. Further, we have
experienced and may further experience, Government instructions to reduce or cap the price of COVID-19 tests, for example,
the Government of Telangana had in November 2020 reduced the maximum price of the RT-PCR tests from % 2,200 to = 850
and subsequently in December 2020 to % 500 (for samples collected at laboratories), and the Government of Andhra Pradesh
had fixed the price of the RT-PCR tests for samples sent by individuals to approved laboratories from to = 2,900 to 2 1,000 in
November 2020 and subsequently to 2 499 in December 2020, which may adversely affect our business, results of operations
and financial condition. See “Risk Factors — Our business, financial condition and results of operations may be adversely
affected by global health epidemics, including the recent COVID-19 outbreak, and the continuing effect of the same cannot be
predicted.” on page 22.

Changes in Government Regulations and Policies

We are subject to government regulations, which can affect our results of operations. These regulations could change at any
time, with little or no warning or time for us to prepare. For example, the prices that we charge for our services could become
subject to recommended or maximum fees set by the Government or other authorities. In addition, we are required to obtain
and maintain a number of statutory and regulatory registrations, permits and approvals under central, state and local government
tules in India, generally for carrying out our business and for each of our facilities. The implementation and/or changes in
Government regulations and policies affecting the prices we charge and licensing requirements may, in effect, limit our ability
to charge customers higher prices for our services and affect our operation capability. For further details, see “Risk Factors —
Non-compliance with and changes in any of the applicable laws, rules or regulations, including pricing, safety, health and
environmental laws, may adversely affect our business, results of operations and financial condition and cash flows”, “Risk
Factors —We require certain approvals, licenses, registrations and permits for conducting our business and our inability to
obtain, retain or renew them in a timely manner, or at all, may adversely affect our business, results of operations and financial
condition.” and “Risk Factors —Implementation of pricing policies by the Government or other authorities could adversely
affect our business, results of operations and financial condition” on pages 26, 27 and 29, respectively.

  

Currently, the provision of diagnostic services in India is exempt from GST. Any change in Government regulation in this
regard may significantly affect our operations due to an increase in operating costs.

Statement of Significant Accounting Policies

Use of estimates and judgements

In preparing our consolidated financial statements, our management has made judgements, estimates and assumptions that
affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised
prospectively in the consolidated statement of profit and loss in the period in which the estimates are revised and in any future
periods affected.

The areas involving critical estimates or judgements are:

229
. Classification of lease;

. Impairment test for goodwill generated on consolidation;

. Determination of useful lives of property, plant and equipment and intangibles;
. Impairment of financial assets;

. Measurement of defined benefit obligations; and

. Recognition and measurement of provisions and contingencies.

Principles of consolidation

Subsidiaries

The consolidated financial statements are prepared by adopting uniform accounting policies for like transactions and other
events in similar circumstances and are presented to the extent possible, in the same manner as the parent company’s separate
financial statements unless stated otherwise.

Non-controlling interests

Non-controlling interests (“NCI”) are measured at their proportionate share of the acquiree’s net identifiable assets at the date
of acquisition. Profit or loss and each component of other comprehensive income are attributed to the equity holders of our
Company and to the non-controlling interest, even if this results in the non-controlling interests have a deficit balances. Changes
in our equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. When we
lose control over a subsidiary, we derecognise the assets and liabilities of the subsidiary, and any related NCI and other
components of equity. Any interest retained in the former subsidiary is measured at fair value at the date the control is lost. Any
resulting gain or loss is recognized in profit or loss.

Business combinations

In accordance with Ind AS 103, we account for these business combinations using the acquisition method when the control is
transferred to us. The consideration transferred for the business combinations is generally measured at fair value as at the date
the control is acquired (acquisition date), as are the net identifiable assets acquired. Any goodwill that arises is tested annually
for impairment. Transaction costs are expensed as incurred, except to the extent related to the issue of debt or equity securities.

Property plant and equipment
Recognition and measurement

Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at historical cost less
accumulated depreciation and accumulated impairment loss, if any. Cost of an item of property, plant and equipment comprises
its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any
directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling
and removing the item and restoring the site on which it is located.

Subsequent costs

Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is
probable that the future economic benefits associated with the item will flow to us and the cost of the item can be measured
reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other
repair and maintenance are charged to statement of profit or loss during the reporting period in which they are incurred.

Depreciation
Depreciation on property, plant and equipment, other than leasehold improvements, is provided under the written down value
method in the manner prescribed under Schedule II of the Companies Act, 2013, except in the following case where the life is

different than as indicated in Schedule II of the Companies Act, 2013, which is based on the technical assessment and
management estimates of useful life carried out by the management:

230
 

 

 

 

 

 

Particulars Management's estimate of useful life Useful life as per Schedule II
Medical and diagnostic equipment 5 years — 13 years 13 years
Other equipment 7 years — 15 years 15 years
Furniture and Fixtures 5 years — 10 years 10 years
Office equipment 3 years — 5 years 5 years
End user devices such as laptops, etc. 3 years — 5 years 3 years

 

 

 

 

 

For building on leasehold land, the depreciation is charged based on useful life of the building or the lease period whichever is
lower. In the case of leased hold building improvements, the depreciation is charged based on useful life of the improvements
which is 10 years or lease period whichever is lower.

Intangible assets

Intangible assets that are acquired, are recognised at cost initially and carried at cost less accumulated amortisation and
accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits
embodied in the specific asset to which it relates.

Goodwill

Goodwill acquired in business combination is allocated, at acquisition, to the cash generating units (CGUs) that are expected
to benefit from that business combination. Our goodwill on consolidation is tested for impairment annually or more frequently
if there are indications that goodwill might be impaired.

Amortisation

Amortisation is calculated to write off the cost of intangible assets over their estimated useful lives using the written down value
method, and is recognised in depreciation and amortisation in statement of profit and loss. The estimated useful lives for current
and comparative periods are as follows:

. Software — 5 years

Amortisation method and useful lives are reviewed at the end of each financial year and adjusted if appropriate.
Impairment of assets

Impairment of financial assets

We recognise loss allowances for expected credit losses on financial assets measured at amortised cost and trade receivables.
At each reporting date, we assesses whether these financial assets are credit-impaired. A financial asset is ‘credit-impaired’
when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

We measure loss allowances at an amount equal to lifetime expected credit losses. When determining whether the credit risk
of a financial asset has increased significantly since initial recognition and when estimating expected credit losses, we consider
reasonable and supportable information that is relevant and available without undue cost or effort. This includes both
quantitative and qualitative information and analysis, based on our historical experience and informed credit assessment and
including forward-looking information.

Impairment of non-financial assets

Our non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether
there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount.
Impairment losses are recognised in the statement of profit and loss.

In respect of assets for which impairment loss has been recognised in prior periods, we review at each reporting date whether

there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change

in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset’s carrying
231
amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no
impairment loss has been recognised.

Inventories

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables. Inventories are valued at lower of cost
and net realisable value. Cost of inventories comprises of all costs of purchase and other costs incurred in bringing the
inventories to their present location after adjusting for recoverable taxes. The comparison of cost and net realisable value is
made on an item-by-item basis.

Cash and Cash Equivalents

Cash and cash equivalents in the statement of cash flows includes cash on hand, deposits held at call with financial institutions,
other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known
amounts of cash and which are subject to an insignificant risk of changes in value.

Revenue Recognition

Revenue comprise of income from diagnostic services and income from sale of privilege cards. Revenue from diagnostic
services is recognised on amount billed minus any discounts or concessions and when the testing samples are processed for
requisitioned test, to the extent that it is probable that the economic benefits will flow to us and revenue can be reliably
measured. For multiple tests, we measure the revenue in respect of each performance obligation at its relative standalone selling
price, being the price that is regularly charged for a test separately registered, and the transaction price is allocated accordingly.
Revenue from sale of privilege cards is recognised from the sale of such cards over the period of which the card is valid. Such
privilege cards are sold to customers against which specified discounts are given on the future diagnostic services availed by
the customer for a specific period.

Interest income

Interest income is recorded using the effective interest rate method (“EIR”). EIR is the rate which exactly discounts estimated
future cash receipts through the expected life of the financial asset to that asset’s net carrying amount on initial recognition.
When calculating the EIR we estimate the expected cash flows by considering all the contractual terms of the financial
instrument (for example, prepayments, extensions, call and similar options); expected credit losses are considered if the credit
risk on that financial instrument has increased significantly since initial recognition.

Dividend income

Dividends are recognised in the statement of profit and loss on the date on which our right to receive payment is established.
Employee Benefits

Short-term Employee benefits

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within twelve months
after the end of the period in which the employees render the related service are recognised in respect of employees’ services
up to the end of the reporting period and are measured on an undiscounted basis at the amounts expected to be paid when the
liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Share based payments

Our employees receive remuneration in the form of share-based payments, whereby employees render services as consideration
for equity instruments. The cost of equity-settled transactions is determined by the fair value at the date when the grant is made
using Black Scholes valuation model. The grant date fair value of options granted to employees is recognised as employee
expense with a corresponding increase in employee stock options reserve, over the period in which the eligibility conditions
are fulfilled and the employees unconditionally become entitled to the awards. The cumulative expense recognised for equity-
settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and
our best estimate of the number of equity instruments that will ultimately vest. The statement of profit and loss expense or credit
for a period represents the movement in cumulative expense recognised as at the beginning and end of that period and is
recognised in employee benefits expense. The dilutive effect of outstanding options is reflected as additional share dilution in
the computation of diluted earnings per share.

Other long-term employee benefits

232
The liabilities for earned leave and sick leave are not expected to be settled wholly within twelve months after the end of the
period in which the employees render the related service. They are therefore measured as the present value of expected future
payments to be made in respect of services provided by employees up to the end of the reporting period by a qualified actuary
using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period
that have terms approximating to the terms of the related obligation. Remeasurements as a result of experience adjustments and
changes in actuarial assumptions are recognised in profit or loss.

Post-Employment Benefits

Defined Contribution Plan:

 

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate
entity and will have no legal or constructive obligation to pay further amounts. We make specified monthly contributions
towards Government administered provident fund scheme. Obligations for contributions to defined contribution plans are
recognised as an employee benefit expense in profit or loss in the periods during which the related services are rendered by
employees.

Defined Benefit Plans:

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The liability or asset recognised
in the balance sheet in respect of defined benefit plans is the present value of the defined benefit obligation at the end of the
reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by a qualified actuary
using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the
estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have
terms approximating to the terms of the related obligation.

Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognised in
the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement
of changes in equity and in the balance sheet.

Leases
Lease contracts entered by us majorly pertains for buildings taken on lease to conduct our business in the ordinary course.
We as a Lessor:

Leases for which we are a lessor are classified as a finance or operating lease. Whenever the terms of a lease transfer
substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases
are Classified as operating leases. Rental income from operating leases is recognised on straight line basis over the term of
relevant lease.

We as a Lessee:

We apply a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value
assets. We recognise lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying
assets.

Previously, we assessed leases at contract inception whether an arrangement is or contains a lease under Ind AS 17. Under Ind
AS 116, we assess whether a contract is or contains a lease based on the definition of lease. On transition of IND AS 116, we
elected to apply practical expedient to grandfather the assessment of which transactions are leases. It applied Ind AS 116 only
to contracts that were previously identified as leases. Contracts that were not identified as leases under Ind AS 17 were not
reassessed for whether there is a lease. Therefore the definition of lease under Ind AS 116 was applied only to contracts entered
into or changed on or after April 01, 2018.

We determine the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend
the lease if we are reasonably certain to exercise that option; and periods covered by an option to terminate the lease if we are
reasonably certain not to exercise that option. In assessing whether we are reasonably certain to exercise an option to extend a
lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic
incentive for us to exercise the option to extend the lease, or not to exercise the option to terminate the lease. We revise the
lease term if there is a change in the noncancelable period of a lease.

At transition, lease liabilities were measured at the present value of the remaining lease payments, discounted at our incremental
borrowing rate as at April 01, 2018. Right-of-use assets are measured at their carrying amountas if Ind AS 116 had been applied

233
since the commencement date, discounted using the lessee’s incremental borrowing rate at the date of initial application.

We used the following practical expedients when applying Ind AS 116 to leases previously classified as operating leases under
Ind AS 17.

- Applied a single discount rate to a portfolio of leases with similar characteristics.

- Applied the exemption not to recognise right-of-use assets and liabilities for leases with less than 12 months of lease term
and leases of low value.

- Excluded initial direct costs from measuring the right-of-use asset at the date of initial application.

- Used hindsight when determining the lease term if the contract contains options to extend or terminate the lease.

Right of use asset:

We recognise right-of-use asset representing our right to use the underlying asset for the lease term at the lease commencement
date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the
lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received,
plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the
underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured
at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the
lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the
shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of use assets are determined on the
same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any
indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit
and loss.

Lease Liability:

We measure the lease liability at present value of the future lease payments at the commencement date of the lease. The lease
payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be
readily determined, we use incremental borrowing rate as at the commencement of lease. The lease liability is subsequently
remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect
the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect
revised in-substance fixed lease payments. We recognise the amount of the re-measurement of lease liability due to modification
as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where
the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease
liability, we recognise any remaining amount of the re-measurement in statement of profit and loss.

Income-tax

Income-tax comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to an item
recognised directly in equity or in other comprehensive income.

Current Tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to
the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount
expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates
(and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts,
and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred Tax

Deferred Income tax is recognised in respect of temporary differences between the carrying amount of assets and liabilities for
financial reporting purposes and the corresponding amounts used for taxation purpose.

Deferred tax liabilities are not recognised for temporary differences arising on the initial recognition of assets or liabilities in a
transaction that is not a business combination and that affects neither accounting nor taxable profit or loss at the time of the
transaction and temporary differences related to investments in subsidiaries to the extent that we are able to control the timing
of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they
can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in
234
case of a history of recent losses, we recognise a deferred tax asset only to the extent that it has sufficient taxable temporary
differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax
asset can be realised. Deferred tax assets are reviewed at each reporting date and are recognised/ reduced to the extent that it is
probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is
settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which we expect, at the
reporting date, to recover or settle the carrying amount of its assets and liabilities.

Segmental Information

Basis for segmentation

Our operations fall within a single business segment, diagnostic services.
Geographic information

We operate within India and there is no assets or liabilities outside India.
Components of our Income and Expenses

Our income and expenditure is reported in the following manner:
Income

Total income consists of revenue from operations and other income.

Revenue from operations. Revenue from operations comprises of revenue from providing diagnostic services such as health
check-up and laboratory services to individual and institutional customers, income from franchise and sale of scrap.

Other Income. Other income primarily comprises of interest on bank deposits, electricity deposits and other financial assets
carried at amortised cost, profit on sale of mutual fund investments, fair value gain on mutual funds measured at fair value
through profit or loss, net gain on sale or retirement of property, plant and equipment, liabilities no longer required written
back, profit on slump sale and insurance claim received.

Expenses

Total expenses comprise of cost of materials consumed, employee benefits expenses, finance costs, depreciation and
amortisation expenses and other expenses.

Cost of Materials Consumed. Cost of materials consumed comprises costs incurred towards the purchase of all the raw materials
that we require for conducting clinical laboratory tests and profiles.

Employee Benefits Expenses. Employee benefits expenses comprise of salaries, wages and bonus, contribution to provident and
other funds, gratuity expenses, share based payments expenses and staff welfare expenses.

Finance Costs. Finance costs comprise of interest on term loans, interest on deferred purchase consideration measured at
amortised cost and interest expense on lease liabilities.

Depreciation and Amortisation Expenses. Depreciation and amortisation expenses comprise of depreciation on property plant
and equipment, amortisation of intangible assets and depreciation on right of use assets.

Other Expenses. Other expenses primarily comprise of legal and professional expenses, repairs and maintenance, power and
fuel, house-keeping expenses, testing charges, security expenses, samples collection charges, postage and communication
expenses, advertisement, publicity and marketing expenses, expenditure on corporate social responsibility and rates and taxes.

Our Results of Operations

The following table sets forth select financial data from our restated consolidated statement of profit and loss for the period of
three months ended June 30, 2021 and June 30, 2020 and the financial years 2021, 2020 and 2019, the components of which
are also expressed as a percentage of total income for such periods:

235
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended June 30, 2021 Financial Year
2021 2020 2021 2020 2019
@in (% of @in (% of (in (% of @in (% of (Zin (% of
million) Total million) Total million) Total million) Total million) Total

Income) Income) Income) Income) Income)
Income:
Revenue from 1,226.86 97.39 | 517.10 95.77 3,767.46 96.95 | 3,388.21 95.66 | 2,925.87 96.58
operations
Other income 32.84 2.61 22.82 4.23 118.47 3.05 153.61 4.34 103.57 3.42
Total Income 1,259.70 100 | 539.92 100 3,885.93 100 | 3,541.82 100 | 3,029.44 100
Expenses:
Cost of materials 210.84 16.74 75.54 13.99 570.95 14.69 439.06 12.40 404.78 13.36
consumed
Employee 161.47 12.82 | 128.52 23.80 574.35, 14.78 624.01 17.62 538.80 17.79
benefits expenses
Finance costs 40.03 3.18 38.40 7AL 152.47 3.92 153.85 4.34 135.33 4.47
Depreciation and 119.21 9.46 | 116.35 21.55 504.53, 12.98 491.70 13.88 396.26 13.08
amortisation
expense
Other expenses 286.00 22.70 | 174.63 32.34 962.39 24.77 998.93 28.20 901.09 29.74
Total Expenses 817.55 64.90 | 533.44 98.80 2,764.69 71.15 | 2,707.55 76.45 | 2,376.26 78.44
Profit before tax 442.15 35.10 6.48 1.20 1,121.24 28.85 834.27 23.55 653.18 21.56
Income Tax
expenses:
Current Tax 117.41 9.32 23.60 4.37 317.41 8.17 230.64 6.51 196.66 6.49
Deferred Tax (8.51) (0.68) | (35.22) | (6.52) (45.28) (1.17) | (21.44) (0.61) (6.20) (0.20)
expense/(income)
Total tax 108.90 8.64 | (11.62) (2.15) 272.13 7.00 209.20 5.91 190.46 6.29
expense
Profit for the 333.25 26.45 18.10 3.35 849.11 21.85 625.07 17.65 462.72 15.27
period/ year
Other (0.22) (0.02) | (1.99) (0.37) (0.14) . (1.31) (0.04) (1.62) (0.05)
Comprehensive
Income /
(Expense) for the
period/ year (Net
of tax)
Total 333.03 26.44 16.11 2.98 848.97 21.85 623.76 17.61 461.10 15.22
Comprehensive
Income for the
period/ year

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended June 30, 2021 compared to three months ended June 30, 2020

Our total income increased by 133.31% to = 1,259.70 million for the three months ended June 30, 2021 from % 539.92 million

236

 
for the three months ended June 30, 2020, due to an increase in both the revenue from operations and other income.

Revenue from Operations. Our revenue from operations increased to 2 1,226.86 million for the three months ended June 30,
2021 from % 517.10 million for the three months ended June 30, 2020, primarily due to the increase in the volumes both in
terms of number of tests and the footfall count.

Other income. Our other income increased by 43.91% to % 32.84 million for the three months ended June 30, 2021 from % 22.82
million for the for the three months ended June 30, 2020, primarily due to the increase in interest income from fixed deposits
with banks and the increase in gain of fair value of mutual funds.

Expenses

Cost of material consumed. Cost of materials consumed increased by 179.11% to %210.84 million for the three months ended
June 30, 2021 from 2 75.54 million for the three months ended June 30, 2020, primarily due to the purchase of higher volumes
of reagent kits, chemicals, films and other materials required for performing the diagnostic tests. As a percentage of revenue
from operations, our cost of materials consumed was 17.19% and 14.61% for the three months ended June 30, 2021 and 2020,
respectively.

Employee benefits expense. Employee benefits expense increased by 25.64% to = 161.47 million for the three months ended
June 30, 2021 from 2 128.52 million for the three months ended June 30, 2020, primarily due to an increase in salaries, wages
and bonus to 2 143.95 million for the three months ended June 30, 2021 from 2 113.41 million for the three months ended June
30, 2020. The increase in salaries and other benefits was due to an increase in number of employees due to the commencement
of business of the new centres post June 30, 2020 and the annual salary increments given to our employees. The number of
employees increased to 2,325 as at June 30, 2021 from 1,993 as at June 30, 2020.

Finance costs. Our finance costs increased by 4.24% to = 40.03 million for the three months ended June 30, 2021 from % 38.40
million for the three months ended June 30, 2020, primarily due to the increase in notional interest cost on lease liabilities
computed as per accounting standard IND AS 116 by 20.00% to 33.61 million for the three months ended June 30, 2021 from
% 28.01 million for the three months ended June 30, 2020 on account of new leases entered into by our company subsequent to
June 30, 2020.

Depreciation and amortisation expense. Our depreciation and amortisation expense increased by 2.46% to = 119.21 million for
the three months ended June 30, 2021 from % 116.35 million for the three months ended June 30, 2020, primarily due to an
increase in amortisation of right to use assets computed as per accounting standard IND AS 116 by 13.70% to 2 45.30 million
for the three months ended June 30, 2021 from = 39.84 million for the three months ended June 30, 2020.

Other expenses. Our other expenses increased by 63.77% to = 286.00 million for the three months ended June 30, 2021 from 2
174.63 million for the three months ended June 30, 2020, primarily due to an increase in legal and professional expenses to 2
145.09 million for the three months ended June 30, 2021 from 2 64.70 million for the three months ended June 30, 2020, which
was due to an increase in services availed from various consultants in line with increase in volume of the business, an increase
in power and fuel expenses to = 30.09 million for the three months ended June 30, 2021 from 2 25.47 million for the three
months ended June 30, 2020, which was primarily due to an increase in the volume of business and an increase in repairs and
maintenance fees to % 37.26 million for the three months ended June 30, 2021 from 2 27.73 million for the three months ended
June 30, 2020, which was primarily due to an increase in maintenance activities over the period.

Tax expenses. Our total tax expense increased to = 108.90 million for the three months ended June 30, 2021 from total tax
income of 2 11.62 million for the three months ended June 30, 2020. Our tax expenses for the three months ended June 30,
2021 comprised a current tax expense of = 117.41 million and a deferred tax income of 2 8.51 million, while our tax expenses
for the three months ended June 30, 2020 comprised a current tax expense of % 23.60 million and a deferred tax income of =
35.22 million. Our effective tax rate was 24.63% for the three months ended June 30, 2021 and the net tax expense was negative
for the three months ended June 30, 2020 due to deferred tax income arising out of sale of mutual funds..

Profit for the year. Our profit for the year increased to = 333.25 million for the three months ended June 30, 2021 from 2 18.10
million for the three months ended June 30, 2020.

Financial Year 2021 compared to Financial Year 2020
Income

Our total income increased by 9.72% to = 3,885.93 million for the financial year 2021 from 2 3,541.82 million for the financial
year 2020, due to an increase in revenue from operations, which was partially offset by a decrease in other income.

Revenue from Operations. Despite the adverse impact brought by the ongoing COVID-19 pandemic, in particular in the first
quarter of financial year 2021, our revenue from operations increased by 11.19% to = 3,767.46 million for the financial year
237
2021 from % 3,388.21 million for the financial year 2020, primarily due to the increase in revenue from COVID RT-PCR tests
and the commencement of operation of seven new diagnostic centres, partially offset by the decrease in revenue from other
pathology and radiology tests caused by the pandemic.

Other income. Our other income decreased by 22.88% to 2 118.47 million for the financial year 2021 from = 153.61 million
for the financial year 2020, primarily due to the decreases in sale (including profit) of mutual fund investments, fair value gain
on mutual funds and sale (including net gain) on retirement of property, plant and equipment, while partially offset by the
increases in interest income on bank deposits and electricity deposits and liabilities no longer required to be written back.

Expenses

Cost of material consumed. Cost of materials consumed increased by 30.04% to 570.95 million for the financial year 2021
from % 439.06 million for the financial year 2020, primarily due to the purchase of higher volumes of reagent kits, chemicals,
films and other materials required for performing the diagnostic tests. The difference in percentage increase in cost of materials
consumed and the revenue from operations was brought by the change in mix of tests conducted. As a percentage of revenue
from operations, our cost of materials consumed was 15.15% and 12.96% for the financial year 2021 and 2020, respectively.

Employee benefits expense. Employee benefits expense decreased by 7.96% to = 574.35 million for the financial year 2021
from 2 624.01 million for the financial year 2020, primarily due to a decrease in salaries, wages and bonus to = 513.74 million
for the financial year 2021 from % 571.31 million for the financial year 2020, which was partially offset by the increase in staff
welfare expenses. The decrease in salaries and other benefits was due to certain cost control measures undertaken by us as a
result of and during the COVID-19 pandemic, such as salary adjustments. The number of employees increased to 2,218 as at
March 31, 2021 from 2,116 as at March 31, 2020.

Finance costs. Our finance costs decreased to = 152.47 million for the financial year 2021 from 2 153.85 million for the financial
year 2020, primarily due to an decrease in interest on borrowings measured at amortised cost to 15.67 million for the financial
year 2021 from % 34.07 million for the financial year 2020, which was partially offset by an increase in interest paid on lease
liabilities to 2 114.13 million for the financial year 2021 from % 99.25 million for the financial year 2020, as a result of the
application of Ind AS 116.

 

Depreciation and amortisation expense. Our depreciation and amortisation expense increased by 2.61% to = 504.53 million for
the financial year 2021 from % 491.70 million for the financial year 2020, primarily due to an increase in depreciation of rights-
of-use assets to 2 164.21 million for the financial year 2021 from = 143.95 million for the financial year 2020, which was
partially offset by the decrease in depreciation of tangible assets to ¥ 335.68 million for the financial year 2021 from 2 341.49
million for the financial year 2020 and decrease in amortisation of intangible assets to = 4.64 million for the financial year 2021
from % 6.26 million for the financial year 2020.

Other expenses. Our other expenses decreased by 3.66% to 2 962.39 million for the financial year 2021 from 998.93 million
for the financial year 2020, primarily due to a decrease in legal and professional expenses to 462.01 million for the financial
year 2021 from % 507.03 million for the financial year 2020, which was due to certain cost control measures undertaken by us
during the COVID-19 pandemic and a decrease in advertisement, publicity and marketing expenses to = 13.81 million for the
financial year 2021 from 2 32.47 million for the financial year 2020, which was primarily due to reduction in advertisement
activities during the COVID-19 pandemic, which was partially offset by the increase in testing charges to = 46.18 million for
the financial year 2021 from 8.90 million for the financial year 2020, due to the change in mix of tests conducted.

Tax expenses. Our total tax expense increased by 30.08% to = 272.13 million for the financial year 2021 from % 209.20 million
for the financial year 2020. Our tax expenses for the financial year 2021 comprised a current tax expense of = 317.41 million
and a deferred tax income of ? 45.28 million, while our tax expenses for the financial year 2020 comprised a current tax expense
of = 230.64 million and a deferred tax income of % 21.44 million. Our effective tax rate was 24.27% and 25.08% for the financial
year 2021 and 2020, respectively.

Profit for the year. Our profit for the year increased by 35.84% to = 849.11 million for the financial year 2021 from % 625.07
million for the financial year 2020.

Financial Year 2020 compared to Financial Year 2019
Income

Our total income increased by 16.91% to % 3,541.82 million for the financial year 2020 from % 3,029.44 million for the financial
year 2019, due to an increase in revenue from operations and other income.

Revenue from Operations. Our revenue from operations increased by 15.80% to = 3,388.21 million for the financial year 2020

from % 2,925.87 million for the financial year 2019, primarily due to an overall growth in our business as we conducted 7.91

million tests and profiles for the financial year 2020 as compared to 6.99 million tests and profiles for the financial year 2019,
238
and the increase in number of diagnostic centres to 73 diagnostic centres as at March 31, 2020 from 61 diagnostic centres as at
March 31, 2019.

Other income. Our other income increased by 48.32% to = 153.61 million for the financial year 2020 from % 103.57 million for
the financial year 2019, primarily due to an increase in profit on sale of mutual fund investments to = 49.02 million for the
financial year 2020 from 2 9.06 million for the financial year 2019, a one-off profit on slump sale of % 18.22 million during the
financial year 2020 and an increase in interest income on bank deposits and electricity deposits to = 39.28 million for the
financial year 2020 from 2 26.41 million for the financial year 2019, which was partially offset by a decrease in gain on fair
valuation of mutual fund investments to = 16.81 million for the financial year 2020 from 2 43.65 million for the financial year
2019.

Expenses

Cost of material consumed. Cost of materials consumed increased by 8.47% to = 439.06 million for the financial year 2020
from % 404.78 million for the financial year 2019, primarily due to the purchase of higher volumes of reagent kits, chemicals,
films and other materials required for performing the diagnostic tests. As a percentage of revenue from operations, our cost of
materials consumed was 12.96% and 13.83% for the financial year 2020 and 2019, respectively, the slight decrease in
percentage of cost of materials over revenue from operations was due to the change in mix of tests conducted during the financial
year 2020 as compared to financial year 2019.

Employee benefits expense. Employee benefits expenses increased by 15.81% to % 624.01 million for the financial year 2020
from 2 538.80 million for the financial year 2019, primarily due to an increase in salaries, wages and bonus to = 571.31 million
for the financial year 2020 from 2 497.22 million for the financial year 2019. The increase in salaries and other benefits was
due to an increase in number of employees employed by us due to the opening of 13 diagnostic centres during financial year
2020, an increase in employee benefit expenses due to full year operations for diagnostic centres which were opened during
financial year 2019 and annual increments for existing employees. The number of employees increased to 2,116 as at March
31, 2020 from 1,927 as at March 31, 2019.

Finance costs. Our finance costs increased by 13.69% to = 153.85 million for the financial year 2020 from 2 135.33 million for
the financial year 2019, primarily due to increase in interest paid on lease liabilities adjusted on account of transition to Ind AS
116 to 2 99.25 million for the financial year 2020 from % 84.69 million for the financial year 2019 and an increase in interest
paid on borrowings measured at amortised cost to = 34.07 million for the financial year 2020 from % 31.79 million for the
financial year 2019.

Depreciation and amortisation expense. Our depreciation and amortisation expense increased by 24.09% to = 491.70 million
for the financial year 2020 from 2 396.26 million for the financial year 2019, primarily due to an increase in depreciation on
assets to 2 341.49 million for the financial year 2020 from 2 277.08 million for the financial year 2019 and an increase in
depreciation of right of use of assets due to the implementation of Ind AS 116 to = 143.95 million for the financial year 2020
from % 115.64 million for the financial year 2019, as a result of the increase in our number of diagnostic centres.

Other expenses. Our other expenses increased by 10.86% to = 998.93 million for the financial year 2020 from % 901.09 million
for the financial year 2019, primarily due to an increase in legal and professional fees caused by an increase in volume of
services availed from various consultants to = 507.03 million for the financial year 2020 from % 454.43 million for the financial
year 2019, an increase in power and fuel to = 107.19 million for the financial year 2020 from % 92.89 million for the financial
year 2019, which was due to an increase in the number of diagnostic centres operated by us and an increase in repairs and
maintenance expenses to = 115.18 million for the financial year 2020 from 2 102.10 million for the financial year 2019, which
was due to increase in maintenance activities led by expansion of diagnostic centres, such as repairs and upgrading of buildings
and maintenance of machines and equipment.

Tax expenses. Our total tax expense increased by 9.84% to = 209.20 million for the financial year 2020 from = 190.46 million
for the financial year 2019. Our tax expenses for the financial year 2020 comprised a current tax expense of = 230.64 million
and a deferred tax income of 2 21.44 million, while our tax expenses for the financial year 2019 comprised a current tax expense
of = 196.66 million and a deferred tax income of 2 6.20 million. Our effective tax rate was 25.08% and 29.16% for the financial
year 2020 and 2019, respectively.

Profit for the year. Our profit for the year increased by 35.09% to % 625.07 million for the financial year 2020 from % 462.72
million for the financial year 2019.

Cash Flows

The following table sets forth our cash flows for the periods indicated:

239
(2 in million)

 

 

 

 

 

 

‘Three months ended June Financial Year
30,
2021 2020 2021 2020 2019
Net cash generated from Operating Activities 509.45 67.01 1,296.43 1,061.12 905.27
Net cash (used) in Investing Activities (369.13) (252.53) (1,297.57) (306.22) (898.46)
Net cash (used) in Financing Activities (105.60) (63.91) (487.69) (295.42) (71.77)
Net increase/ (decrease) in Cash and Cash Equivalents 34.72 (249.43) (488.83) 459.48 (64.96)

 

 

 

 

 

 

 

 

Operating Activities

Net cash generated from operating activities was = 509.45 million for the three months ended June 30, 2021. While our net
profit before tax was = 442.15 million, we had an operating profit before working capital changes of % 568.30 million, primarily
due to depreciation and amortisation of = 119.21 million and interest expense on lease liabilities of = 33.61 million, partially
offset by interest income of % 28.47 million. Our changes in working capital for the three months ended June 30, 2021 primarily
consisted of increase in other assets of = 73.52 million, an increase in other financial liabilities of 39.80 million, an increase
in trade payables of = 37.64 million, an increase of inventories of = 36.51 million and a decrease in other financial assets and
loans of = 28.55 million. Our income taxes paid was 2 53.11 million for the three months ended June 30, 2021.

 

Net cash generated from operating activities was = 67.01 million for the three months ended June 30, 2020. While our net profit
before tax was 26.48 million, we had an operating profit before working capital changes of 2 138.75 million, primarily due to
depreciation and amortisation of = 116.35 million and interest expense on lease liabilities of ¥ 28.01 million, partially offset by
interest income of % 20.77 million. Our changes in working capital for the three months ended June 30, 2020 primarily consisted
of a decrease in trade payables of = 14.95 million, an increase in other assets of = 14.07 million, an increase of inventories of =
7.58 million and a decrease in trade and other receivables of 6.32 million. Our income taxes paid was 2 31.87 million for the
three months ended June 30, 2020.

Net cash generated from operating activities was 2 1,296.43 million for the financial year 2021. While our net profit before tax
was % 1,121.24 million, we had an operating profit before working capital changes of 2 1,654.30 million, primarily due to
depreciation and amortisation of % 504.53 million and interest expense on lease liabilities of = 114.13 million, partially offset
by interest income 2 95.96 million and liabilities written back of = 15.44 million. Our changes in working capital for the financial
year 2021 primarily consisted of a decrease in other financial liabilities of % 30.14 million, a decrease in trade and other
receivables of = 9.19 million and an increase in other financial assets and loans of = 19.69 million. Our income taxes paid was
% 312.21 million for the financial year 2021.

Net cash generated from operating activities was 2 1,061.12 million for the financial year 2020. While our net profit before tax
was 2 834.27 million, we had an operating profit before working capital changes of 2 1,326.44 million, primarily due to
depreciation and amortisation of 491.70 million and interest expense on lease liabilities of 7 99.25 million, partially offset by
gain on sale of and dividend income from mutual funds of % 49.02 million and interest income of 2 42.63 million. Our changes
in working capital for the financial year 2020 primarily consisted of an increase in other assets of % 40.22 million, partially
offset by an increase in other financial liabilities of 11.90 million. Our income taxes paid was % 232.87 million for the financial
year 2020.

Net cash generated from operating activities was = 905.27 million for the financial year 2019. While our net profit before tax
was 2 653.18 million, we had an operating profit before working capital changes of 2 1,084.22 million, primarily due to
depreciation and amortisation of = 396.26 million and interest expense on lease liabilities of = 84.69 million, partially offset by
fair value movement on financial instrument of 2 43.65 million. Our changes in working capital for the financial year 2019
primarily consisted of an increase in trade payables of = 41.80 million, partially offset by an increase in trade and other
receivables of = 26.54 million and an increase in other assets of % 22.42 million. Our incomes taxes paid was 2 186.92 million
for the financial year 2019.

Investing Activities
Net cash used in investing activities was = 369.13 million for the three months ended June 30, 2021, primarily comprising
deposits placed of = 331.95 million and payment for purchase and construction of property, plant and equipment including

movement in capital work-in-progress, capital advances and capital creditors of = 82.56 million, partially offset by interest
received of 2 43.57 million.

240
Net cash used in investing activities was = 252.53 million for the three months ended June 30, 2020, primarily comprising
deposits placed of = 745.11 million, partially offset by investment and redemption of debt oriented liquid mutual funds of =
535.73 million and interest received of % 5.44 million.

Net cash used in investing activities was 2 1,297.57 million for the financial year 2021, primarily comprising deposits placed
of 2 1,308.05 million and payment for purchase and construction of property, plant and equipment for both existing and new
diagnostic centres and laboratories of = 321.36 million, partially offset by investment and redemption of debt oriented liquid
mutual funds of = 275.31 million and interest received of = 47.50 million.

Net cash used in investing activities was = 306.22 million for the financial year 2020, primarily comprising payment for
purchase and construction of property, plant and equipment for both existing and new diagnostic centres and laboratories of =
475.47 million and deposits placed of = 196.15 million, partially offset by investment and redemption of debt oriented liquid
mutual funds of 2 207.46 million and proceeds from disposal of Property, Plant and equipment of = 100.60 million generated.

Net cash used investing activities was = 898.46 million for the financial year 2019, primarily comprising payment for purchase
and construction of property, plant and equipment for both existing and new diagnostic centres and laboratories of = 610.39
million and deposits placed of = 409.42 million, partially offset by investment and redemption of debt oriented liquid mutual
funds of 2 95.83 million and proceeds from disposal of used machines and equipment of 2 19.13 million.

Financing Activities

Net cash used in financing activities was = 105.60 million for the three months ended June 30, 2021, primarily comprising
repayment of lease liabilities of 2 57.62 million, repayment of long term borrowings of = 32.75 million and interest paid of &
15.18 million.

Net cash used in financing activities was = 63.91 million for the three months ended June 30, 2020, primarily comprising
repayment of lease liabilities of 2 35.70 million, repayment of long term borrowings of % 22.57 million and interest paid of =

6.36 million.

Net cash used in financing activities was = 487.69 million for the financial year 2021, primarily comprising repayment of long
term borrowings of = 282.60 million, repayment of lease liabilities of = 189.65 million and interest paid of = 14.36 million.

Net cash used in financing activities was 2 295.42 million for the financial year 2020, primarily comprising repayment of lease
liability of 167.51 million, repayment of long term borrowings of 89.38 million and interest paid of = 32.04 million.

Net cash used in financing activities was = 71.77 million for the financial year 2019, primarily comprising of repayment of
lease liabilities of 2 136.02 million, repayment of long term borrowings of = 94.67 million and interest paid of = 28.98 million,
partially offset by proceeds from long term borrowings of = 168.77 million.

Indebtedness

As of June 30, 2021, we had outstanding consolidated total borrowings of = 11.92 million comprising of non-current borrowings
of % nil and current borrowings of = 11.92 million. We had no borrowings denominated in foreign currencies as of such date.

In the event our lenders declare an event of default, such current and any future defaults could lead to acceleration of our
obligations, termination of one or more of our financing agreements or force us to sell our assets, which may adversely affect
our business, results of operations and financial condition.

Capital and Other Commitments

As of June 30, 2021, our estimated amount of contracts remaining to be executed on capital account and not provided for was
% 79.09 million.

The following table sets forth a summary of the maturity profile of our contractual obligations as of June 30, 2021:

(Zin millions)

 

 

Other : More than 5
contractual ale Total ey aa on 2 years
obligations y veers

Borrowings 11.92 11.92 11.92 - - -

(including

current maturities

 

 

 

 

 

 

 

 

 

241
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other . More than 5
contractual ad Total ie 1 1 2 wan years
obligations ar ye y

of long-term

borrowings)

Lease Liabilities 1,571.59 2,481.39 238.74 244.10 710.56 1,287.99

Trade payables 259.25 259.25, 259.25 - - -

Deferred 6.74 715 6.34 0.81 - -

payment

liabilities on

purchase of

medical

equipment

Capital creditors 5.58 5.58 5.58 - - -

Other financial 71.38 71.38 71.38 - - -

liabilities

Total 1,926.46 2,836.67 593.21 244.91 710.56 1,287.99
Capital Expenditure

For the three months ended June 30, 2021, we added fixed assets of property, plant and equipment of % 57.90 million, primarily
for medical plant and equipment. For the financial year 2021, we added fixed assets of property, plant and equipment of =
302.34 million, primarily for medical plant and equipment. For the financial year 2020, we added fixed assets of property, plant
and equipment of % 354.68 million, primarily for medical plant and equipment, leasehold improvements and furniture and
fixtures. For the financial year 2019, we added fixed assets of property, plant and equipment of = 614.34 million, primarily for
medical plant and equipment, leasehold improvements and furniture and fixtures.

We plan to continue to expand in our key cities and towns by opening new diagnostic centres in the next 12 months, which will
in turn incur further capital expenditure.

Contingent Liabilities

As at June 30, 2021, we have contingent liability of % 0.56 million for claims against our Company for the demand for Provident
Fund for the years 1998 to 2001. For details, see “Financial Statements —Annexure VII — Note 38” on page 204.

Off-Balance Sheet Commitments and Arrangements

We do not have any off-balance sheet arrangements, derivative instruments, swap transactions or relationships with affiliates
or other unconsolidated entities or financial partnerships that would have been established for the purpose of facilitating off-
balance sheet arrangements.

Related Party Transactions

We have engaged in the past, and may engage in the future, in transactions with related parties. For details of our related party
transactions, see “Financial Information — Annexure VII — Note 45” on page 208.

Bank Balances Other Than Cash and Cash Equivalent

Our bank balances other than cash and cash equivalent increased by 56.62% to% 2,147.90 million as at June 30, 2021, as
compared to and @ 1,371.42 million as at June 30, 2020, primarily due to increase in net profit. Our bank balances other than
cash and cash equivalent increased by 199.5% to 2 1,875.55 million as at March 31, 2021, as compared to 2 626.23 million as
at March 31, 2020, primarily due to increase in net profit. Our bank balances other than cash and cash equivalent increased by
45.6% to % 626.23 million as at March 31, 2020, as compared to 2 430.12 million as at March 31, 2019, primarily due to increase
in net profit

242
Quantitative and Qualitative Analysis of Market Risks

Our Board has overall responsibility for the establishment and oversight of our risk management framework. We are exposed
to the following risks arising from financial instruments:

Credit risk

Credit risk is the risk of financial loss to us if a customer or counterparty to a financial instrument fails to meet its contractual
obligations, and arises principally from our receivables from customers and loans. The maximum exposure to credit risk in case
of all the financial instruments is restricted to their respective carrying amount.

Trade Receivables and Loans

Our exposure to credit risk is influenced mainly by the individual characteristics of each customer. Customer credit risk is
managed by designated department subject to our established policy, procedures and control relating to customer credit risk
management. Credit quality of individual customer is assessed based on individual credit limits as defined by us, we also

monitor outstanding customer receivables regularly. We have no significant concentration of credit risk.

For further information on our credit risk, see “Financial Statements — Notes to Restated Consolidated Financial Information
— Note 49” on page 215.

Liquidity risk

 

Liquidity risk is the risk that we will encounter difficulty in meeting the obligations associated with our financial liabilities that
are settled by delivering cash or another financial asset. Prudent liquidity risk management implies maintaining sufficient cash
and marketable securities, the availability of funding through an adequate amount of committed credit facilities. Our approach
to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are
due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to our reputation.

Market risk

Market risk is the risk that results from changes in market prices such as foreign exchange rates, interest rates and others which
will affect our income. We are exposed to market risk primarily related to interest rate risk. The objective of market risk
management is to manage and control market risk exposures within acceptable parameters while optimizing return.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in
market interests rate. Our main interest rate risk arises from short-term borrowings with variable interest rate.

Unusual or Infrequent Events or Transactions

Except as described in this Prospectus, to our knowledge, there have been no unusual or infrequent events or transactions that
have in the past or may in the future affect our business operations or future financial performance.

Known Trends or Uncertainties

Our business has been subject, and we expect it to continue to be subject, to significant economic changes arising from the
trends identified above in “-Significant Factors Affecting our Results of Operations” above and the uncertainties described in
“Risk Factors” page 21. To our knowledge, except as disclosed in this Prospectus, there are no known factors which we expect
to have a material adverse effect on our income.

Future Relationship between Cost and Revenue

Other than as described in “Risk Factors” and “Our Business” on pages 21 and 111, respectively, to our knowledge there are
no known factors that may adversely affect our business prospects, results of operations and financial condition.

New Products or Business Segments

Other than as disclosed in this section and in “Our Business” on page 111, there are no new products or business segments that
have or are expected to have a material impact on our business prospects, results of operations or financial condition.

Dependence on a Few Customers or Suppliers

243
Given the nature of our business operations, we do not believe our business is dependent on any single or a few customers or
suppliers.

Seasonality of Business
Our business experiences marginal seasonality during the monsoon season, as a result of the onslaught of dengue and malaria.
Competitive Conditions

We operate in a competitive environment. Please refer to “Our Business”, “Industry Overview” and “Risk Factors” on pages
111, 80 and 21, respectively for further information on our industry and competition.

Significant Developments subsequent to June 30, 2021

On August 11, 2021, we purchased a parcel of land measuring 1,654 square yards in Himayatnagar, Hyderabad for a
consideration of 350.00 million with the intention of developing a diagnostic centre at this location.

Except as set out above, to our knowledge, no circumstances have arisen since the date of the last financial statements as

disclosed in this Prospectus which materially or adversely affect or are likely to affect, our operations or profitability, or the
value of our assets or our ability to pay our material liabilities within the next 12 months.

244
SECTION VI: LEGAL AND OTHER INFORMATION
OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Except as disclosed in this section, there is no outstanding (i) criminal proceeding; (ii) action taken by regulatory or statutory
authorities; (iii) claim related to direct and indirect taxes (in a consolidated manner); and (iv) other pending litigation or
arbitration as determined to be material as per the materiality policy adopted pursuant to the Board resolution dated May 27,
2021, in each case involving our Company, its Subsidiaries, Promoter and Directors (‘Relevant Parties"). Further, except as
disclosed in this section, there are no (i) outstanding proceedings involving the Relevant Parties, the outcome of which may
have a bearing on the business, operations, prospects, or reputation of the Company; or (ii) disciplinary actions including
penalties imposed by SEBI or the Stock Exchanges against our Promoter in the last five financial years including any
outstanding action.

For the purpose of identification of material litigation in (iv) above, our Board has considered and adopted the following policy
on materiality with regard to outstanding litigation to be disclosed by our Company in this Prospectus pursuant to the Board
resolution dated May 27, 2021:

All outstanding litigation, including any litigation involving the Relevant Parties, other than criminal proceedings, actions by
regulatory authorities and statutory authorities, disciplinary action including penalty imposed by SEBI or stock exchanges
against the Promoter in the last five financial years and any outstanding action and tax matters (direct or indirect), would be
considered ‘material’ if: (i) the monetary amount of claim by or against the entity or person in any such pending proceeding is
in excess of 1% of the consolidated profit for the year of our Company for the last completed Financial Year as per the Restated
Financial Information i.e. 1% of the restated consolidated profit for the year of our Company for the Fiscal 2021 (i.e. %8.49
million); or (ii) where monetary liability is not quantifiable, the outcome of any such pending proceedings may have a material
bearing on the business, operations, performance, prospects or reputation of our Company.

It is clarified that for the above purposes, pre-litigation notices received by Relevant Parties or our Group Companies from
third parties (excluding statutory/ regulatory/ tax authorities or notices threatening criminal action), have not and shall not be
considered as litigation until such time that the Relevant Parties or our Group Companies are impleaded as a defendant in the
litigation proceedings before any judicial forum.

Except as stated in this section, there are no outstanding material dues to creditors of our Company. For this purpose, our
Board has pursuant to the Board resolution dated August 16, 2021, considered and adopted a policy of materiality for
identification of material creditors to whom the amount is due. In terms of this materiality policy, a creditor has been considered
‘material’ if the amount due to such creditor exceeds 5% of the consolidated amount due to creditors (other than micro and
small enterprises and excluding any amounts not attributable to any creditor) of our Company based on the Restated Financial
Information of our Company as at June 30, 2021, disclosed in this Prospectus. Accordingly, as on June 30, 2021, a creditor
has been considered ‘material’ if the amount due to such creditor exceeds %6.90 million for the purposes of disclosure in this
section.

For outstanding dues to any party which is a micro, small or medium enterprise, the disclosure will be based on information
available with the Company regarding the status of the creditor as defined under Micro, Small and Medium Enterprises
Development Act, 2006, as amended read with the rules and notifications thereunder, as has been relied upon by its Statutory
Auditors.

Except as disclosed below in this section, our Group Companies are not party to any pending litigations which will have a
material impact on our Company.

Unless stated to the contrary, the information provided below is as of the date of this Prospectus. All terms defined in a
particular litigation disclosure below are for that particular litigation only.

Litigation involving our Company
Litigation against our Company
Criminal Litigation

1. Our Company received a notice dated September 25, 2017 under section of 41(A) of the Criminal Procedure Code seeking
explanation from our Company with respect to a criminal complaint registered against Naga Bhairavudu, an employee of
our Company under section 336 of Indian Penal Code (“IPC”) by Shafi Khan at police station, Humayunnagar on grounds
of negligence. Our Company through its letter submitted an explanation before the police station at Humayun Nagar,
Hyderabad. The matter is currently pending.

2. Sri Nagireddipally Ram Mohan Reddy (“Complainant”) filed a complaint before the Police Commissioner, Rachakonda
Police Commissionerate, the report of which was forwarded by the Commissioner to the Saroornagar police station. The
Saroornagar police station filed a permission before the VI Additional Metropolitan Magistrate cum J.F.C.M Special

245
(Mobile) — VI Additional Junior Civil Judge, Cyberabad at LB Nagar, Ranga Reddy (“Magistrate”) to register the
complaint. The Magistrate granted the permission for investigation through an order dated January 7, 2021. The
Complainant registered a first information report with the Saroornagar, Rachakonda police station against our centre at
Karmanghat under section 197 of IPC alleging that the Complainant and his wife suffered a monetary loss of 70.15 million
as they missed their flight to the United States of America, where a mandatory negative Covid 19 report is required, due
to the false Covid-19 reports by our centre at Karmanghat. Our Company has filed a petition to quash the permission of
investigation passed by the Magistrate on various grounds, inter alia, including, lack of documentary evidence, the alleged
grievance is does not fall under the purview of the IPC. The matter is currently pending.

Civil Litigation

1.

G. Ram Manohar (“Complainant”) filed a complaint under Section 17(a)(i) of the Consumer Protection Act, 1986 against
our Company, Dr. Pritam Patil, a consultant radiologist at Vijaya Diagnostic Centre, Himayathnagar and others
(“Respondents”) before the Telangana State Consumer Disputes Redressal Commission at Hyderabad (“CDRC,
Hyderabad”) on grounds of alleged gross negligence and recklessness in the accuracy of diagnosis and subsequent
treatment of his wife. The Complainant has jointly claimed 29.90 million in damages against the Respondents. The CDRC,
Hyderabad through its order dated February 20, 2018 directed the Respondents to file their written statements and appear
before it along with the document to support their response. Our Company in its written statement dated June 4, 2018 has
denied all the allegations. The matter is currently pending.

Other matters

A.

Our Company has received an order from the Directorate of Enforcement, Government of India (“ED”) throught a letter
dated July 5, 2021 (“ED Letter”) directing us to produce certain documents/information, such as details of our Directors,
details of foreign inward/outward remittances along with supporting documents, and financials and income tax returns of
our Company for the last five years, for the purpose of investigation under the Foreign Exchange Management Act, 1999.
Our Company has responded to the aforesaid ED Letter by way of a letter dated August 5, 2021 and have submitted the
requisite documents and information sought in the ED Letter. We are yet to hear back from the ED.

Litigation by our Company

Criminal Litigation

1.

Our Company filed a complaint against Apex Diagnostics and Medical Imaging Centre, Naveen Kumar Kutumbaka,
Swapna Samineni, and Gadiparthy Dileep Bhoopal (“Accused”) under Section 138 of the Negotiable Instruments Act,
1881 before the III" Additional Chief Metropolitan Magistrate, City Civil Court, Nampally. The Accused availed services
from our Company from time to time on an understanding that payments would be made by the Accused on issuance of
bills by our Company for the services rendered. Our Company was providing services to the Accused right from the year
2013 at very competitive rates. However, from June 2016 the Accused has not cleared several payments for the services
rendered to them. Our Company has by way of letter dated April 3, 2017 to the Accused the stated that an amount of 30.78
million was due for the services rendered by our Company. The cheque issued to our Company by the Accused returned
unpaid on account of insufficient funds on July 20, 2017. Our Company orally intimated about the dishonour of cheque
to the Accused and it was agreed that within two months the Accused shall arrange for sufficient funds to honour the
cheque. Our Company presented the cheque again on September 29, 2017 but the cheque was returned unpaid with
endorsement that the account is blocked. Our Company issued a legal notice against the Accused on October 24, 2017 that
the Accused has not paid a sum of 20.50 million for the services rendered by our Company. The Accused responded to
the notice on November 9, 2017 denying all the liability. The matter is currently pending

Litigation involving our Subsidiary

Litigation against our Subsidiary

Criminal Litigation

1.

MDSL and Dr. K Bhaskara Reddy, an employee of MDSL (“Appellants”) filed eleven criminal appeals bearing number
188/2005, 189/2005, 190/2005, 192/2005, 193/2005, 194/2005, 195/2005, 196/2005, 198/2005, 199/2005 and 200/2005
against the Provident Fund Inspector and the State of Andhra Pradesh before the Court of the Metropolitan Sessions Judge,
Hyderabad against the order passed by the XII Additional Chief Metropolitan Magistrate cum Metropolitan Magistrate
wherein MDSL and Dr K Bhasakara Reddy were imposed with a fine of 22,000 each and Dr K. Bhaskara Reddy was
sentenced to undergo a simple imprisonment of three months and to pay a fine of ?1,000 for the offences punishable under
14(1A) and 14(2) of the Employees Provident Fund and Miscellaneous Provisions Act, 1952 read with Para 76(b) of the
Employees Provident Fund Scheme, 1952 for non-payment of contributions within the prescribed time period. The
Appellants approached the High Court of Andhra Pradesh for quashing the proceedings on the ground that the Company
is sick and due to financial difficulties, the contributions could not be paid, and returns could not be submitted. The High
Court of Andhra Pradesh permitted the Appellants to pay the arrears of the contributions to the provident fund in
instalments. It was further submitted that the Appellants have paid the contributions due for the period in instalments as
246
per the directions of the High Court of Andhra Pradesh and since, the Appellants have paid the contributions due they are
not liable for prosecution under14(1A) and 14(2) of the Employees Provident Fund and Miscellaneous Provisions Act,
1952. Through its orders, each dated June 7, 2006 Metropolitan Sessions Judge, Hyderabad (i) set aside the order passed
by the XII Additional Chief Metropolitan Magistrate cum Metropolitan Magistrate and allowed the appeals bearing
number 188/2005, 189/2005, 190/2005, 193/2005, 195/2005 and 200/2005; (ii) confirmed the conviction and sentence
passed by the XII Additional Chief Metropolitan Magistrate cum Metropolitan Magistrate with modification of the
sentence of imprisonment for a period of three months passed against Dr K Bhasakara Reddy being converted into a fine
of 21,000, and dismissed the appeals bearing number 192/2005, 194/2005, 196/2005, 198/2005 and 199/2005. The matters
are currently pending.

Civil Litigation

1.

A civil suit bearing O.S. No. 218 of 2015 was filed by M. Prameela Reddy and others (“Plaintiffs”) against Medinova
Diagnostic Services Limited (“MDSL”), its ex-chairman, Adala Raghava Reddy and Executive Director of our Company,
Sunil Chandra Kondapally (in his capacity as the managing director of MDSL) (“Defendants”) for eviction, recovery of
arrears of rent, mesne profits and damages on April 6, 2015 before XI Additional Chief Judge, City Civil Court, Hyderabad
(“City Civil Court, Hyderabad”). The subject matter of the suit is a portion of premises bearing municipal no. 6-3-652/2,
situated at Somajiguda, Hyderabad admeasuring 15,031 square feet (“Suit Property”) owned by the Plaintiffs. The
original lease expired on December 31, 2007. Subsequently, the lease was renewed for a period of 36 months from January
1, 2008 till December 31, 2010 and the lease was freshly executed on May 24, 2008 with new terms and condition
including the enhanced and fixed rent of 20.32 million per month. The lease expired on December 31, 2010 but was
continued as per the understanding between the parties without any formal lease deed on the terms and conditions of the
lease dated May 24, 2008. The Plaintiff issued a notice against the Defendants on November 3, 2010 to clear off the arrears
of rent from April 2010. The Plaintiff issued another notice on December 1, 2014 demanding vacant possession of the
Suit Property and to pay the arrears of rent. Additionally, the Plaintiffs alleged that the Defendants were not paying rent
regularly and committed defaults in payment of rent for the period between April 2014 till March 2015 making the total
arrear of rent to 3.93 million, the cheques issued were mostly dishonoured and as a result of which the Plaintiffs had to
pay the cheque bounce charges to the bank. Additionally, the Plaintiffs also demanded that the Defendants to pay the rent
of %55 per square feet as paid by other tenant in the same building but the Defendants did not pay the prevailing rent and
also defaulted in paying their monthly rent. The Defendants responded to the notice on December 14, 2014 that the
Plaintiffs did not provide adequate water supply, lift facilities, and parking area as agreed as per the term of the lease deed.
The Defendant installed the lift, incurred expenditure of 20.03 million per month for procuring water from private water
tankers and there was no parking area as agreed under the lease deed. Further, there was leakage and seepage in the walls
due to the weakening of the inbuilt pipe lines and lack of maintenance because of which there was difficulties in the
maintenance of the medical equipment installed which was not rectified by the Plaintiffs which adversely affected their
business and incurred a loss of 210.00 million. The Plaintiffs prayed for, inter alia, (i) a decree for eviction of the
Defendants from Suit Property, (ii) recovery of total arrear of rent of 33.94 million together with interest of 18% per
annum, (iii) grant of past mesne profits of 17.78 million with interest of 18% per annum from the date of the suit till the
recovery of the suit till the realisation of amount, and (iv) a sum of 25.00 million as damages for repair of the leased
properties.

Pursuant to this, MDSL, its ex-chairman, Adala Raghava Reddy and Executive Director of our Company, Sunil Chandra
Kondapally (“Petitioners”) filed before the City Civil Court, Hyderabad (i) a counter to an interlocutory application
forming part of the aforementioned suit and (ii) written statement along with rejection of plaint, against M. Prameela
Reddy and others. The City Civil Court returned the rejection of plaint and passed an ex-parte order on account of
incomplete cause title. The Petitioners through its petition dated October 5, 2015, prayed to set aside the ex-parte order
dated October 28, 2015 and pass such order as it deem fit and proper and in the interest of justice.

A title suit was filed by Sailesh Memorial Educational Trust, Kishore Trust, Krishna Banerjee for self and as a trustee of
Sailesh Memorial Educational Trust, Subrata Chatterjee as trustee of Kishore Trust, Sri Lakshmi Pada Mookherjee and
Arijit Mookherjee (“Plaintiffs”) against MDSL on December 23, 2017 before the Civil Judge, Senior Division, Alipore
(“CJ, Alipore”). The subject matter of the suit is a land parcel situated at Sarat Chatterjee Avenue, Kolkata (“Suit
Property”), one of our existing centres, owned by the Plaintiffs. The Suit Property was leased to MDSL through lease
deeds dated May 25, 1987 and September 22, 2009. The Plaintiffs issued letters dated April 4, 2017 and July 31, 2017, to
MDSL to make payment of the rent, remove its belongings and vacate the Suit Property on expiry of the lease i.e. on
August 31, 2017 since MDSL has defaulted in the payment of rent on and from the month of December 2016 and breached
the terms of the lease. MDSL responded to the letter dated April 4, 2017 on May 17, 2017 that they want to resolve the
issue by way of discussion and have issued cheques to cover up rent to April 2017. Further, MDSL through its letter dated
August 26, 2017 stated, inter alia, that they incurred an expenditure of 215.00 million in the repairs of the suit property
and have made investment of 292.50 million on medical equipment installed therein on the belief that the terms of the
lease will be extended and further offered to increase the lease consideration by 50%. Pursuant to the letter dated August
26, 2017 by MDSL, the Plaintiffs responded to the August 26, 2017 letter denying the allegations. MDSL responded by
way of a letter dated October 18, 2017 claimed that (i) there was a change in the management in the year of 2014 because
of which the business operation was affected, (ii) incurred 215.00 million for maintenance of the Suit property, (iii) spent
292.50 million on acquiring medical equipment and (iv) intended to renew the lease. The Plaintiffs issued letter to MDSL
247
on November 6, 2017 to deliver vacant possession of the suit property and denied renewal of the lease agreement. The
Plaintiffs alleged that the lease term has expired on August 31, 2017 and MDSL has no locus standi in the said suit property
and its act is illegal, unlawful and is of a trespasser. The Plaintiffs claimed that they are entitled to a decree for eviction
and recovery of peaceful vacant possession of the suit property upon eviction of MDSL.

Thereafter, MDSL filed a suit for specific performance against Krishna Banerjee for self and as a trustee of Sailesh
Memorial Educational Trust, Subrata Chatterjee as trustee of Kishore Trust, Sri Lakshmi Pada Mookherjee and Arijit
Mookherjee (“Defendants”) on May 8, 2018 before CJ, Alipore. MDSL stated that MDSL and the Defendants orally
agreed to, inter alia, execute a fresh deed of lease for a period of nine years and accordingly, MDSL has prayed for, inter
alia, (i) a decree of declaration that the oral agreement is valid, (ii) decree of specific performance of the oral agreement,
(iii) damages amounting to 20.50 million; and (iv) a decree of perpetual injunction restraining the Defendants from
interfering the peaceful possession of the suit property.

Actions Taken by Regulatory and Statutory Authorities against our Subsidiaries

1. The Ministry of Corporate Affairs, Office of the Registrar of Companies, Hyderabad, Telangana, (“RoC Hyderabad”)
has issued notices of inquiry dated October 21, 2020 and February 15, 2021 under section 206(4) of Companies Act, 2013,
against our Subsidiary, MDSL, in the matter of technical scrutiny of its balance sheet as at March 31, 2019 enlisting
alleged non-compliances with various provisions of the Companies Act, 2013 and accordingly sought certain information
on the balance sheet for the financial year 2019 and explanations as to why such non-compliances should not be treated
as violations under applicable provisions of the Companies Act, 2013. MDSL, submitted the required information along
with relevant documents through its responses dated November 3, 2020 and February 26, 2021 to such notices of inquiry.
MDSL has not received any further communications from the RoC Hyderabad in this matter.

Litigation by our Subsidiary

Civil Litigation

1. MDSL filed a suit for specific performance against Krishna Banerjee for self and as a trustee of Sailesh Memorial
Educational Trust, Subrata Chatterjee as trustee of Kishore Trust, Sri Lakshmi Pada Mookherjee and Arijit Mookherjee
(“Defendants”) on May 8, 2018 before the Civil Judge, Senior Division, Alipore. For details in relation to suit see “—
Litigation against our Subsidiary — Civil Litigation” on page 247.

Litigation involving our Promoter

As on the date of this Prospectus, there is no outstanding criminal litigation, civil litigation or actions taken by statutory or

regulatory authorities involving our Promoter. Further, no actions have been taken, nor any penalty has been imposed against

our Promoter by SEBI or stock exchanges.

Litigation involving our Directors

Civil Litigation involving our Director, Sunil Chandra Kondapally

1. For details in relation to O.S. 218 of 2015, see — “Litigation against our Subsidiaries — Civil Litigation” on page 247.

Tax Claims

Except as disclosed below, there are no claims related to direct and indirect taxes involving our Company, Directors,
Subsidiaries and Promoter:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nature of case Number of cases ‘Amount involved (@ in million)
Litigation involving our Company

Direct Tax 3 2.26
Indirect Tax 1 1.77
Litigation involving our Subsidiary

Direct Tax Nil Nil
Indirect Tax Nil Nil
Litigation involving the Directors

Direct Tax Nil Nil
Indirect Tax Nil Nil
Litigations involving the Promoter

Direct Tax Nil Nil
Indirect Tax Nil Nil

 

 

 

 

248
Except as disclosed below, there are no outstanding proceedings involving the Relevant Parties, the outcome of which may
have a bearing on the business, operations, prospects, or reputation of the Company:

Criminal Litigation involving our CEO, Sura Suprita Reddy

The State represented by sub-inspector of police, P.S. Panjagutta (“Complainant”), filed a complaint and subsequently a charge
sheet which was taken on file by the XXIII Special Magistrate, Hyderabad for the offences under Sections 304-A, 336 and 338
of the Indian Penal Code, 1860 (“IPC”) on February 2, 2010 alleging that there was a fire accident at Park Hospital, Hyderabad
(“Park Hospital”) in which several persons were injured and three persons subsequently lost their life while undergoing
treatment for injuries sustained due to the fire. The Park Hospital was operated by, Park Health Systems Private Limited (“Park
Health”), and therefore the directors of Park Health namely, Chinchod Damodhar Reddy and Sura Suprita Reddy, our CEO
(collectively together the “Defendants”) were impleaded in the matter. The Defendants were tried before the XXIII Special
Magistrate, Hyderabad alleging that the fire accident was on account of their negligence based on the allegations that (i) Park
Hospital operated without any fire NOC and fire-fighting equipment; (ii) Chinchod Damodhar Reddy (being the owner of the
building in which Park Hospital was located) had illegally constructed a fifth floor; (iii) the building did not have a contingency
evacuation plan in place nor an alternative fire or emergency exit; and (iv) the fire had started due to an electrical short circuit.

The Defendants pleaded not guilty to the charges contending, inter alia, that (i) there was no negligence on the part of the
Defendants; (ii) there was no violation of the building plan as the Greater Hyderabad Municipal Corporation (“GHMC”) had
granted its sanction and that there were no conditions in the sanction which mandated obtaining a fire NOC; and (iii) the fire
was caused due to a blast of the transformer. On conclusion of the trial, the XXIII Special Magistrate, Hyderabad by way of
its judgement dated November 24, 2017 (“Judgement”) convicted the Defendants for the above mentioned offences and
sentenced the Defendants to (I) (a) undergo six months imprisonment each; and (b) a fine of 310,000 each and in default two
months simple imprisonment for offence under Section 304-A of the IPC; (II) (a) undergo simple imprisonment for a period of
six months each; and (b) a fine of 31,000 each and in default one month simple imprisonment each for offence under Section
338 of the IPC; and (III) a fine of 3250 each and in default one week simple imprisonment for the offence under Section 336
of the IPC. All the aforesaid sentences pronounced pursuant to the Judgement are to run concurrently and the remand period of
the Defendants if any was set-off under Section 428 of CrPC. The Defendants paid monetary penalty imposed under the
Judgement.

Aggrieved by the Judgement, the Defendants preferred a criminal appeal before the Metropolitan Sessions Judge, Hyderabad
(“Sessions Judge”) on the grounds, inter alia, that (a) the Judgement is illegal and contrary to the weight of evidence and against
probabilities of the case; (b) the XXIII Special Magistrate had erred in its finding that there was no fire extinguishment
equipment and fire safety measures in the Park Hospital; and (c) The XXIII Special Magistrate, Hyderabad had failed to
appreciate, inter alia, that (i) there was no evidence against the Defendants to prove the offences under Sections 304A, 336 and
338 of the IPC and that the ingredients of such offences were absent; (ii) Sura Suprita Reddy was involved in the operations of
our Company in her capacity as a wholetime director while holding the position of a non-executive director on the board of
Park Health and therefore she was not responsible for the day to day management of Park Health; (iii) the death and injuries
were not on account of any direct result of rash or negligent acts of the Defendants; and (iv) the no objection certificate from
the fire department is not required for buildings which are less than 15 metres; which applies to the building in question as it is
less than 15 metres in height;

The Defendants by way of the criminal appeal prayed for setting aside the Judgement on the above grounds and have also
prayed for suspension of sentence of imprisonment pending disposal of the criminal appeal. The Sessions Judge by way of its
order dated December 20, 2017 suspended the sentence of imprisonment on the same conditions as imposed by the XXIII
Special Magistrate, Hyderabad pending disposal of criminal appeal which is currently pending.

Outstanding dues to Creditors

As of June 30, 2021, our Company has 776 creditors, and the aggregate outstanding dues to these creditors by our Company
are 7138.92 million.

As per the materiality policy, creditors of our Company to whom an amount having a monetary value which exceeds 5% of the
consolidated amount due to creditors (other than micro and small enterprises and excluding any amounts not attributable to any
creditor) of our Company based on the Restated Financial Information of our Company as at June 30, 2021, as disclosed in this
Prospectus, shall be considered as ‘material’ i.e., creditors of our Company to whom our Company owes an amount exceeding
%6.90 million have been considered material (“Material Creditors”).

Details of outstanding dues owed to Material Creditors, micro, small and medium enterprises as defined under the Micro, Small
and Medium Enterprises Development Act, 2006 (“MSME”) and other creditors as of June 30, 2021 are set out below:

 

‘Types of Creditors Number of Creditors Amount payable (in million)
MSME 6 1.01
Material Creditors 3 30.62

 

 

 

 

 

 

 

249
 

‘Types of Creditors Number of Creditors Amount payable (@ in million)
Other Creditors 767 107.29
Total Outstanding Dues* 776 138.92
* Represents total creditors as per the Restated Financial Information after reduction of provision for expenses of 2106.64 million and stale cheques of 713.69
million

 

 

 

 

 

 

 

The details pertaining to net outstanding dues towards our material creditors are available on the website of our Company at
https://www.vijayadiagnostic.com/miscellaneous/material-creditors.

It is clarified that such details available on our website do not form a part of this Prospectus. and should not be deemed to be
incorporated by reference. Anyone placing reliance on any other source of information, including our Company’s website,
would be doing so at their own risk.

Material Developments

Other than as stated in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” on page
226, there have not arisen, since June 30, 2021, any circumstances which materially and adversely affect, or are likely to affect,
our operations or earnings taken as a whole, our trading, our profitability or the value of our assets or our ability to pay our
liabilities within the next 12 months.

250
GOVERNMENT AND OTHER APPROVALS

We have set out below an indicative list of approvals obtained by us which are considered material and necessary for the
purpose of undertaking its business activities. In view of these key approvals, we can undertake this Offer and our business
activities. In addition, certain of our key approvals may have expired or may expire in the ordinary course of business and we
have either already made an application to the appropriate authorities for renewal of such key approvals or are in the process
of making such renewal applications. In relation to our centres which are material for undertaking our business, we have
disclosed below (i) approvals applied for but not received; and (ii) approvals that have expired and renewal to be applied for.

I,

i.

Incorporation details

Certificate of incorporation dated June 5, 2002 issued to our Company, under the name Vijaya Diagnostic Centre
Private Limited by the Registrar of Companies, Andhra Pradesh at Hyderabad.

Fresh certificate of incorporation consequent on change of name issued by the Registrar of Companies, Telangana at
Hyderabad on March 26, 2021 pursuant to change of name from Vijaya Diagnostic Centre Private Limited to Vijaya
Diagnostic Centre Limited

The CIN of our Company is U85195TG2002PLC039075.
Approvals in relation to the Offer

For details regarding the approvals and authorisations obtained by our Company in relation to the Offer, see “Other
Regulatory and Statutory Disclosures - Authority for the Offer” on page 253.

Key approvals in relation to our Company
Approvals in relations to our business operations

* Our Company holds an Importer-Exporter Code 0904015149 issued by the Ministry of Commerce of the
Government of India is valid in perpetuity.

e¢ Our Company is an empanelled health care organisation under the Central Government Health Scheme. Such
empanelment is valid till September 30, 2021.

Weare required to obtain various approvals and licenses under applicable laws, rules and regulations in order to operate
our diagnostic centres at multiple locations situated in the states of Telangana, Andhra Pradesh, Haryana and West
Bengal details of which are set out below.

1. Registration under the Clinical Establishments (Registration and Regulations) Act, 2010 or under respective State
clinical establishment legislation, specifically Telangana Allopathic Private Medical Care Establishments
(Registration and Regulation) Act, 2002 and Andhra Pradesh Allopathic Private Medical Care Establishments
(Registration and Regulation) Act, 2002 and rules thereunder, as applicable, issued by the appropriate State
authority, wherever applicable.

2. Trade license under applicable local municipality laws, issued by appropriate local municipality, as applicable.

3. Authorisation under the Bio-Medical Waste (Management and Handling) Rules, 2016, issued by the respective
State Pollution Control Board, wherever applicable.

4. Registration for operation and procurement, as applicable, of medical diagnostic x-ray equipment issued by the
Atomic Energy Regulatory Board, for diagnostic centres wherever applicable.

5. Registration under the Pre-Natal Diagnostic Techniques (Regulation and Prevention of Misuse) Act, 1994 and
the rules thereunder, issued by appropriate State authority, wherever applicable.

6. Fire safety approvals, specifically, no objection certificates in relation to certain of our properties which exceed
the height limit from the relevant state authorities.

Tax related registrations
1. The permanent account number of our Company is AABCV5096R.
2. The tax deduction account number of our Company is HYDV01464B.

3. The GST registration number of our Company, for the states where our business operations are spread, are as
follows:

251
 

 

 

 

 

 

State Registration Number
Andhra Pradesh 37AABCV5096R1ZE
Telangana 36AABCV5096R1ZG
Haryana O6AABCV5096R1ZJ
West Bengal 19AABCV5096R1ZC

 

 

 

The tax related registrations given above are all one time registrations obtained by the Company.
Labour related approvals

e We have obtained relevant registrations under the Employees’ State Insurance Act, 1948, Telangana Tax on
Profession Trade, Calling and Employment Act, 1987 and a shops and establishments registration, under the
relevant states.

* Our Company has been registered with the Employees’ Provident Fund Organisation with code no.
APHYD0047750000, under the Employees’ Provident Funds and Miscellaneous Provisions Act, 1952.

The labour related approvals mentioned above are one time approvals except the shops and establishments
registrations held by the Company whose validity varies from each state the registration has been procured in.

Approval applied for but not received

As on the date of this Prospectus, following are the approvals that have been applied for by our Company but not
received.

e Telangana Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002 and Andhra
Pradesh Allopathic Private Medical Care Establishments (Registration and Regulation) Act, 2002 for some of our
centres in Telangana and Andhra Pradesh;

e Authorisation under the Bio-Medical Waste (Management and Handling) Rules, 2016 for some of our centres in
Telangana and Andhra Pradesh;

«Trade license under applicable local municipality laws, issued by appropriate local municipality, for some of our
centres in Telangana and Andhra Pradesh; and

e  Pre-Natal Diagnostic Techniques (Regulation and Prevention of Misuse) Act, 1994 for some of our centres in
Telangana and Andhra Pradesh.

Approvals expired and renewal to be applied for
As on the date of this Prospectus, there are no approvals that have expired but have not been renewed by our Company.
Intellectual property

As on the date of this Prospectus, we have six trademark registrations under class 41, 42 and 44. We filed an application

 

for registering our corporate logo ”, with the Registrar of Trademarks in India under class 44 of the
Trade Mark Act, 1999 and received partial approval to the extent of words “Vijaya Diagnostic Centre”. Furthermore,
seven of our trademarks have been objected by the Registrar of Trademarks.

252
OTHER REGULATORY AND STATUTORY DISCLOSURES
Authority for the Offer

The Offer has been approved by our Board of Directors pursuant to the resolution passed at its meeting dated June 4, 2021, the
Draft Red Herring Prospectus has been approved by our Board pursuant to a resolution passed on June 4, 2021 and the Red
Herring Prospectus has been approved by our Board pursuant to a resolution passed on August 24, 2021 for filing with RoC,
SEBI and the Stock Exchanges. This Prospectus was approved by our Board/ IPO Committee pursuant to a resolution passed
on September 6, 2021.

Our Board took on record the approval for the Offer for Sale for the Offered Shares by the Selling Shareholders pursuant to a
resolution dated June 4, 2021. Each Selling Shareholder has, severally and not jointly, confirmed and approved its participation
in the Offer for Sale in relation to its portion of the Offered Shares. For details, see “The Offer” on page 41.

Our Company has received in-principle approval from BSE and NSE for the listing of the Equity Shares pursuant to letters
dated July 5, 2021 and June 30, 2021, respectively.

Prohibition by SEBI, RBI or other Governmental Authorities

Our Company, Promoter, Promoter Group, Directors, the persons in control of our Company and the persons in control of our
Promoter are not prohibited from accessing the capital market or debarred from buying, selling or dealing in securities under
any order or direction passed by the Board or any securities market regulator in any other jurisdiction or any other
authority/court.

None of the companies with which our Promoter, Directors or persons in control of our Company are or were associated as
promoter, directors or persons in control have been debarred from accessing capital markets under any order or direction passed
by SEBI or any other authorities.

None of our Directors are associated with securities market related business, in any manner and there has been no outstanding
actions initiated by SEBI against our Directors in the five years preceding the date of this Prospectus.

Our Company, Promoter or Directors have not been declared as wilful defaulters by any bank or financial institution or
consortium thereof in accordance with the guidelines on wilful defaulters issued by the RBI.

Our Promoter or Directors have not been declared as fugitive economic offenders.
Confirmation under Companies (Significant Beneficial Ownership) Rules, 2018

Our Company, Selling Shareholders, our Promoter and members of Promoter Group are in compliance with the Companies
(Significant Beneficial Owners) Rules, 2018, to the extent applicable, as on the date of this Prospectus.

Directors associated with the Securities Market

Except Nishant Sharma, who is associated with the securities market in his capacity an authorised representative of Kedaara
Capital Advisors LLPand associated with Kedaara Capital Alternative Investment Fund ~ Kedaara Capital AIF 1 and Kedaara
Capital Alternative Investment Fund II, none of our Directors are, in any manner, associated with the securities market and
there is no outstanding action initiated by SEBI against any of our Directors in the five years preceding the date of this
Prospectus.

Eligibility for the Offer

Our Company is eligible for the Offer in accordance with the Regulation 6(1) of the SEBI ICDR Regulations, and is in
compliance with the conditions specified therein in the following manner: Our Company has had net tangible assets of at least
30 million, calculated on a restated and consolidated basis, in each of the preceding three full years (of 12 months each). As
the Offer is being made entirely through an offer for sale, the limit of not more than 50% of the net tangible assets being
monetary assets, is not applicable;

e¢ Our Company has an average operating profit of at least 7150 million, calculated on a restated and consolidated basis,
during the preceding three years (of 12 months each), with operating profit in each of these preceding three years;

© Our Company has a net worth of at least 710 million in each of the preceding three full years (of 12 months each), calculated
on a restated and consolidated basis; and

¢ Our Company has not changed its name in the last one year other than conversion from a private limited company to a
public limited company.

253
Our Company’s average operating profit, net worth and net tangible assets derived from the Restated Financial Information
included in this Prospectus as at, and for the last three Financial Years are set forth below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Particulars As of and for the Financial Period / Year ended
June 30, 2021 June 30,2020 | March 31,2021 | March 3i, March 31,
2020 2019
Net tangible assets), as restated and 3,857.22 2,692.00 3,520.58 2,674.01 1,993.85
consolidated
Net worth®, as restated and 3,929.08 2,758.28 3,592.32 2,741.39 2,070.10
consolidated
‘Average operating profit, as restated 449.34 22.06 1,155.24 834.51 684.94
and consolidated
Notes:
() “Net tangible assets” means the sum of all net assets of our Company excluding intangible assets including goodwill and intangible assets under
development, each on restated basis and as defined in Indian Accounting Standard 38.
(in million)
Particulars As of and for the Financial Period / Year ended
June 30, June 30, March 31, March 31, March 31, 2019
2021 2020 2021 2020
Total Assets (A) 6,045.78 4,901.83 5,409.40 4,822.56 4,064.30
Other intangible assets (B) 14.98 9.26 6.01 10.36 7.46
Goodwill (C) 53.37 53.37 53.37 53.37 68.79
Intangible assets under development (D) 3.51 3.65 12.36 3.65, :
Total (E) = (A)-(B)-(C)-(D) 5,973.92 4,835.55 5,337.66 4,755.18 3,988.05
‘Non-current liabilities (F) 1,545.57 1,530.55 1,377.20 1,494.77 1,422.80
Current liabilities (G) 571.13 613.00 439.88 586.40 571.40
Net tangible assets (H) = (E)-(F)-(G) 3,857.22 2,692.00 3,520.58 2,674.01 1,993.85
Q “Net worth” means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities premium account and
debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and
miscellaneous expenditure not written off, derived from the Restated Financial Information, but does not include reserves created out of revaluation
of assets, write-back of depreciation and amalgamation.
(2 in million)
Particulars As of and for the Financial Period / Year ended
June 30, | June 30, | March 31, ‘March 31, | March 31,
2021 2020 2021 2020 2019
Equity share capital (A) 101.97 45.32 45.32 45.32 45.29
> - - 24.13
Instruments entirely equity in nature (B) -
Other equity (C) 3,821.29 | 2,718.93 3,544.74 2,700.11 | 2,004.40
Equity attributable to owners of the Company (D) = (A)+(B)+(G) | 3,923.26 | 2,764.25 3,590.06 2,745.43 | 2,073.82
‘Non-controlling interest (E) 5.82 6.97) 2.26 (4.04) 3.72)
‘Net Worth (F) = (D)+(E) 3,929.08 | 2,758.28 3,592.32 2,741.39 | __ 2,070.10
(3) "Average operating profit" means restated profit before tax excluding other income and finance expense
(in million)
Particulars As of and for the Financial Period / Year ended
June 30, | June 30,2020 | March 31, ‘March 31, ‘March 31,
2021 2021 2020 2019
Profit/(loss) before tax (A) 442.15 6.48 | 1,121.24 834.27 653.18
Other income (B) 32.84 22.82 118.47 153.61 103.57
Finance costs (C) 40.03 38.40 152.47 153.85, 135.33
Average operating profit (D) = (A)-(B)+() 449.34 22.06 | __1,155.24 834.51 684.94

 

 

 

 

 

 

 

 

The status of compliance of our Company with the conditions as specified under Regulations 5 and 7(1) of the SEBI ICDR
Regulations are as follows:

@

Gi)

(iii)

(iv)

(v)

Our Company, the Promoter, the Promoter Group, the Selling Shareholders and our Directors are not debarred from
accessing the capital markets by SEBI;

The companies with which our Promoter or our Directors are associated as promoter or director are not debarred from
accessing the capital markets by SEBI;

Neither our Company, nor our Promoter, or Directors have been identified as a wilful defaulter (as defined in the SEBI
ICDR Regulations);

None of our Directors or individual Promoter has been declared as a fugitive economic offender under Section 12 of
the Fugitive Economic Offenders Act, 2018;

Except employee stock options granted pursuant to ESOP Schemes 2018, there are no outstanding convertible
securities of our Company or any other right which would entitle any person with any option to receive Equity Shares
of our Company as on the date of filing of this Prospectus;

254
(vi) Our Company along with the Registrar to our Company, has entered into tripartite agreements dated November 16,
2016 and November 2, 2016 with NSDL and CDSL, respectively, for dematerialization of the Equity Shares;

(vii) The Equity Shares of our Company held by the Promoter are in the dematerialised form;

(viii) | The Equity Shares are fully paid-up and there are no partly paid-up Equity Shares as on the date of filing of this
Prospectus; and

(ix) Since the Offer is through an Offer for Sale, Regulation 7(1)(e) (which requires firm arrangements of finance through
verifiable means for 75% of the stated means of finance for a specific project proposed to be funded from the Offer
proceeds, excluding the amount to be raised through the Offer and existing identifiable internal accruals) shall not
apply.

DISCLAIMER CLAUSE OF SEBI

IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF THE DRAFT RED HERRING PROSPECTUS
TO SEBI SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED
OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL
SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE OFFER IS PROPOSED TO BE MADE
OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE DRAFT RED
HERRING PROSPECTUS. THE BRLMS BEING, ICICI SECURITIES LIMITED, EDELWEISS FINANCIAL
SERVICES LIMITED AND KOTAK MAHINDRA CAPITAL COMPANY LIMITED HAVE CERTIFIED THAT
THE DISCLOSURES MADE IN THE DRAFT RED HERRING PROSPECTUS ARE GENERALLY ADEQUATE
AND ARE IN CONFORMITY WITH THE SEBI ICDR REGULATIONS. THIS REQUIREMENT IS TO
FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING AN INVESTMENT IN THE
PROPOSED OFFER.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE COMPANY IS PRIMARILY
RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT
INFORMATION IN THE DRAFT RED HERRING PROSPECTUS, THE BRLMs ARE EXPECTED TO EXERCISE
DUE DILIGENCE TO ENSURE THAT THE COMPANY DISCHARGES ITS RESPONSIBILITY ADEQUATELY
IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE BRLMs BEING, ICICI SECURITIES LIMITED,
EDELWEISS FINANCIAL SERVICES LIMITED AND KOTAK MAHINDRA CAPITAL COMPANY LIMITED
HAVE FURNISHED TO SEBI A DUE DILIGENCE CERTIFICATE DATED JUNE 5, 2021 IN ACCORDANCE
WITH SEBI (MERCHANT BANKERS) REGULATIONS, 1992, IN THE FORMAT PRESCRIBED UNDER
SCHEDULE V (FORM A) OF THE SEBI ICDR REGULATIONS.

THE FILING OF THE DRAFT RED HERRING PROSPECTUS DOES NOT, HOWEVER, ABSOLVE THE
COMPANY FROM ANY LIABILITIES UNDER THE COMPANIES ACT, 2013 OR FROM THE REQUIREMENT
OF OBTAINING SUCH STATUTORY OR OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE
OF THE PROPOSED OFFER. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP, AT ANY POINT OF TIME,
WITH THE BRLMs ANY IRREGULARITIES OR LAPSES IN THE DRAFT RED HERRING PROSPECTUS.

The filing of this Prospectus also does not absolve the Selling Shareholders from any liabilities to the extent of the statements
specifically made or confirmed by themselves in respect of themselves and of their respective Offered Shares, under Section
34 or Section 36 of Companies Act

All legal requirements pertaining to this Offer were complied with at the time of filing the Red Herring Prospectus with the
RoC in terms of Section 32 of the Companies Act. All legal requirements pertaining to this Offer will be complied with at the
time of filing of this Prospectus with the RoC in terms of Sections 26, 30, 32, 33(1) and 33(2) of the Companies Act.

Disclaimer from our Company, our Directors and BRLMs

Our Company, our Directors and the BRLMs accept no responsibility for statements made otherwise than in this Prospectus or
in the advertisements or any other material issued by or at our Company’s instance and anyone placing reliance on any other
source of information, including our Company’s website www.vijayadiagnostic.com, or the respective websites of our
Promoter, Promoter Group or any affiliate of our Company would be doing so at his or her own risk.

The BRLMs accept no responsibility, save to the limited extent as provided in the Offer Agreement and the Underwriting
Agreement.

All information shall be made available by our Company, and the BRLMs to the Bidders and the public at large and no selective

or additional information would be made available for a section of the investors in any manner whatsoever, including at road
show presentations, in research or sales reports, at the Bidding Centres or elsewhere.

255
Bidders will be required to confirm and will be deemed to have represented to our Company, the Underwriters and their
respective directors, officers, agents, affiliates, and representatives that they are eligible under all applicable laws, rules,
regulations, guidelines and approvals to acquire the Equity Shares and will not sell, pledge, or transfer the Equity Shares to any
person who is not eligible under any applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares.
Our Company, the Underwriters and their respective directors, officers, agents, affiliates, and representatives accept no
responsibility or liability for advising any investor on whether such investor is eligible to acquire the Equity Shares.

The BRLMs and their respective associates and affiliates in their capacity as principals or agents may engage in transactions
with, and perform services for, our Company, our Promoter, their respective directors and officers, group companies, affiliates
or associates or third parties in the ordinary course of business and have engaged, or may in the future engage, in commercial
banking and investment banking transactions with our Company, the Promoter, and their respective directors, officers, agents,
group companies, affiliates or associates or third parties, for which they have received, and may in the future receive,
compensation.

Disclaimer from our Selling Shareholders

Each of the Selling Shareholder, its respective directors, affiliates, associates, and officers accept no responsibility for any
statements made in this Prospectus other than those specifically made or confirmed by such Selling Shareholder in relation to
itself as a Selling Shareholder and its proportion of the Offered Shares and anyone placing reliance on any other source of
information, including our Company’s website www.vijayadiagnostic.com, or the respective websites of our Promoter,
Promoter Group or any affiliate of our Company would be doing so at his or her own risk.

None among the Selling Shareholders shall be liable for any failure in (i) uploading the Bids due to faults in any software/
hardware system or otherwise; or (ii) the blocking of Bid Amount in the ASBA Account on receipt of instructions from the
Sponsor Bank on account of any errors, omissions or non-compliance by various parties involved in, or any other fault,
malfunctioning or breakdown in, or otherwise, in the UPI Mechanism.

Bidders will be required to confirm and will be deemed to have represented to the Selling Shareholders and their respective
directors, officers, agents, affiliates, and representatives that they are eligible under all applicable laws, rules, regulations,
guidelines and approvals to acquire the Equity Shares and will not sell, pledge, or transfer the Equity Shares to any person who
is not eligible under any applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares. The Selling
Shareholders and their respective directors, officers, agents, affiliates, and representatives accept no responsibility or liability
for advising any investor on whether such investor is eligible to acquire the Equity Shares.

The BRLMs and their respective associates and affiliates may engage in transactions with, and perform services for, the Selling
Shareholders and their respective group companies, affiliates or associates or third parties in the ordinary course of business
and have engaged, or may in the future engage, in commercial banking and investment banking transactions with the Selling
Shareholders and their respective group companies, affiliates or associates or third parties, for which they have received, and
may in the future receive, compensation

Disclaimer in respect of Jurisdiction

This Offer is being made in India to persons resident in India (who are competent to contract under the Indian Contract Act,
1872, including Indian nationals resident in India, HUFs, companies, other corporate bodies and societies registered under the
applicable laws in India and authorised to invest in shares, domestic Mutual Funds registered with the SEBI, VCFs,, Indian
financial institutions, commercial banks, regional rural banks, co-operative banks (subject to RBI permission), or trusts under
applicable trust law and who are authorised under their constitution to hold and invest in equity shares, state industrial
development corporations, insurance companies registered with IRDAI, provident funds (subject to applicable law) public
financial institutions, scheduled commercial banks permitted pension funds, and national investment fund, insurance funds set
up and managed by army, navy or air force of Union of India, insurance funds set up and managed by the Department of Posts,
Gol, systemically important NBFCs registered with the RBI) and permitted Non-Residents including FPIs and Eligible NRIs
and AIFs that are eligible under all applicable laws and regulations to purchase the Equity Shares. This Red Herring Prospectus
does not constitute an offer to sell or purchase or an invitation to subscribe to Equity Shares offered hereby, in any jurisdiction
to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession this
Prospectus comes is required to inform him or herself about, and to observe, any such restrictions. Any dispute arising out of
this Offer will be subject to the jurisdiction of appropriate court(s) in Hyderabad, Telangana, India only.

No action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that
purpose, except that this Prospectus will be registered with the RoC. Accordingly, the Equity Shares represented hereby may
not be offered or sold, directly or indirectly, and this Prospectus may not be distributed, in any jurisdiction, except in accordance
with the legal requirements applicable in such jurisdiction

Neither the delivery of this Prospectus nor the Offer of the Offered Shares shall, under any circumstances, create any implication
that there has been no change in the affairs of our Company or any of the Selling Shareholders since the date of this Prospectus
or that the information contained herein is correct as of any time subsequent to this date.

256
Invitations to subscribe to or purchase the Equity Shares in the Offer were made only pursuant to the Red Herring Prospectus
if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises this Prospectus and the
preliminary international wrap for the Offer, if the recipient is outside India.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any
other applicable law of the United States and, unless so registered, may not be offered or sold within the United States,
except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S.
Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within
the United States only to persons believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S.
Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore
transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of
the jurisdiction where those offers and sales are made.

Bidders are advised to ensure that any Bid from them does not exceed investment limits or the maximum number of
Equity Shares that can be held by them under applicable law. Further, each Bidder where required must agree in the
Allotment Advice that such Bidder will not sell or transfer any Equity Shares or any economic interest therein, including
any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar
security, other than in accordance with applicable laws.

Disclaimer Clause of BSE

As required, a copy of the Draft Red Herring Prospectus was submitted to the BSE. The disclaimer clause as intimated by the
BSE to us through in-principle approval dated July 5, 2021 is set forth below:

BSE Limited (“the Exchange”) has given vide its letter dated July 5, 2021 permission to this Company to use the Exchange’s
name in this offer document as one of the stock exchanges on which this company’s securities are proposed to be listed. The
Exchange has scrutinized this offer document for its limited internal purpose of deciding on the matter of granting the aforesaid
permission to this Company. The Exchange does not in any manner: -

a) warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; or
b) warrant that this Company’s securities will be listed or will continue to be listed on the Exchange; or

c) take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme
or project of this Company;

and it should not for any reason be deemed or construed that this offer document has been cleared or approved by the Exchange.
Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent
inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which
may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything
stated or omitted to be stated herein or for any other reason whatsoever.

Disclaimer Clause of the NSE

As required, a copy of this Offer Document has been submitted to National Stock Exchange of India Limited (hereinafter
referred to as NSE). NSE has given vide its letter Ref.: NSE/LIST/1043 dated June 30, 2021 permission to the Issuer to use the
Exchange’s name in this Offer Document as one of the Stock Exchanges on which this Issuer’s securities are proposed to be
listed. The Exchange has scrutinized this draft offer document for its limited internal purpose of deciding on the matter of
granting the aforesaid permission to this Issuer. It is to be distinctly understood that the aforesaid permission given by NSE
should not in any way be deemed or construed that the offer document has been cleared or approved by NSE; nor does it in any
manner warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; nor does it
warrant that this Issuer’s securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility
for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer.

Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent
inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which
may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of
anything stated or omitted to be stated herein or any other reason whatsoever.

Listing
The Equity Shares issued through the Red Herring Prospectus and this Prospectus are proposed to be listed on the Stock

Exchanges. Application will be made to the Stock Exchanges for obtaining permission for listing and trading of the Equity
Shares. NSE will be the Designated Stock Exchange with which the Basis of Allotment will be finalised.

257
Our Company has received in-principle approvals from the BSE and the NSE for the listing of the Equity Shares pursuant to
letters dated July 5, 2021 and June 30, 2021, respectively.

Consents

Consents in writing of: each of the Selling Shareholders, our Directors, our Company Secretary and Compliance Officer, lenders
to our Company legal counsels appointed for the Offer, the BRLMs, the Registrar to the Offer, in their respective capacities,
have been obtained, experts to the Offer, CRISIL Limited, the Syndicate Members, the Banker(s) to the Offer/ Escrow
Collection Bank(s)/ Refund Bank(s), Sponsor Bank and Banker(s) to the Company, to act in their respective capacities, have
been obtained and filed along with a copy of this Prospectus with the RoC as required under the Companies Act and such
consents have not been withdrawn up to the time of delivery of this Prospectus.

Expert to the Offer
Except as stated below, our Company has not obtained any expert opinions:

Our Company has received written consent dated August 16, 2021 from our Statutory Auditors to include their name as an
“expert” as defined under Section 2(38) of the Companies Act, read with Section 26(5) of the Companies Act, read with SEBI
ICDR Regulations in relation to the Restated Financial Information, the examination report dated August 16, 2021 on the
Restated Financial Information, and the statement of special tax benefits dated June 5, 2021 included in this Prospectus, and
such consent has not been withdrawn as on the date of this Prospectus. However, the term “expert” shall not be construed to
mean an “expert” as defined under the U.S. Securities Act.

The restated financial statements of our Company as of June 30, 2021, and for the period then ended, included in this Prospectus,
have been examined by B S R & Associates LLP, independent auditors, as stated in their report appearing herein

Particulars regarding capital issues by our Company and/or listed Group Companies, Subsidiaries or Associates during
the last three years

Other than as disclosed in “Capital Structure” on page 56, our Company has not made any capital issues during the three years
preceding the date of this Prospectus. Further, our Company’s listed Subsidiary, Medinova Diagnostic Services Limited has not
made any capital issues during the last three years. Additionally, our Company does not have any other listed Group Companies,
Subsidiaries or Associates.

Commission and Brokerage paid on previous issues of the Equity Shares in the last five years

Since this is the initial public issue of the Equity Shares, no sum has been paid or has been payable as commission or brokerage
for subscribing to or procuring or agreeing to procure subscription for any of the Equity Shares since our Company’s
incorporation.

Performance vis-a-vis objects — Public/ rights issue of our Company

Our Company has not undertaken any public or rights issue (as defined under the SEBI ICDR Regulations) in the five years
immediately preceding the date of this Prospectus.

Performance vis-a-vis objects — Public/ rights issue of the listed subsidiaries/listed Promoter of our Company
Except for the securities of our Subsidiary Medinova Diagnostic Services Limited which are listed on the BSE Limited the
securities of our other Subsidiaries are not listed on any stock exchange. Additionally, Medinova Diagnostic Services Limited

has not made any public/rights issue of its securities in the last five years.

Our Promoter is an individual and hence does not have any listed securities.

258
Price information of past issues handled by the BRLMs

A.

ICICI Securities Limited

Price information of past issues handled by ICICI Securities Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.No. Issue name Tssue size Offer Price Listing date | Opening price | +/- % change in closing | _+/- % change in closing | +/- % change in closing
(@ in million) ®@ on listing date | price, [+/- % change in | price, [+/- % change in | price, [+/ % change in
®@ closing benchmark]- | closing benchmark]- 90" | closing benchmark]-
30" calendar days from | calendar days from listing | 180" calendar days from
listing listing
1. |Suryoday Small Finance Bank 5,808.39 305.00(1)/26-Mar-21 292.00 -18.38%,[-1.14%] -26.87%,[+8.13%] NA*
Limited
2.__ |Nazara Technologies Limited 5,826.91 1, 101.00(2) [30-Mar-21 1,990.00 +62.57%,[+0.13%] ¥37.59%[+6.84%] NA*
3. /Macrotech Developers Limited 25,000.00! 486.00/19-Apr-21 436.00 +30.22%,[+5.21%] +75.43%,[+10.89%] NA*
4. Shyam Metalics and Energy 9,087.97) 306.00(3)]24-Jun-21 380.00 +40.95%,[+0.42%] NA* NA*
Limited
5. [Dodla Dairy Limited 5,201.77 428.00 /28-Jun-21 550.00 +44.94%,[-0.43%] NA* NA*
6. G R Infraprojects Limited 9,623.34) 837.00(4) {19-Jul-21 1,715.85 +90.82%,[+5.47%] NA* NA*
7%. \Tatva Chintan Pharma Chem 5,000.00 1,083.00)29-July-21 2,111.85 +92.54%,[+5.87%] NA* NA*
Limited
8. [Nuvoco Vistas Corporation Limited 50,000.00) 570.00|23-Aug-21 485.00 NA* NA* NA*
, (Chemplast Sanmar Limited 38,500.00] 541.00/24-Aug-21 550.00 NA* NA* NA*
10. |Aptus Value Housing Finance India 27,800.52! 353.00/24-Aug-21 333.00 NA* NA* NA*
Limited

 

*Data not available

Notes:

(1) Discount of Rs. 30 per equity share offered to eligible employees All calculations are based on Issue Price of Rs. 305.00 per equity share.
(2) Discount of Rs. 110 per equity share offered to eligible employees All calculations are based on Issue Price of Rs. 1,101.00 per equity share.
(3) Discount of Rs. 15 per equity share offered to eligible employees All calculations are based on Issue Price of Rs. 306.00 per equity share.
(4) Discount of Rs. 42 per equity share offered to eligible employees All calculations are based on Issue Price of Rs. 837.00 per equity share.

Summary statement of price information of past issues handled by ICICI Securities Limited

 

 

 

 

 

 

Financial] Total | Totalamount of | No. of IPOs trading at discount | No. of IPOs trading at premium | No. of IPOs trading at discount as_| No. of IPOs trading at premium as on
Year | no.of funds raised as on 30" calendar day from as on 30" calendar day from | on 180"calendar day from listing | 180" calendar day from listing date
IPOs in million) listing date listing date date
Over | Between | Lessthan | Over | Between | Lessthan | Over 50% | Between | Less than | Over50% | Between | Less than
50% | 25%-50% | 25% 50% | 25%-50% | 25% 25%-50% | 25% 25%-50% | 25%
2021-22* 8 1,70,213.60 - - 2 3 - - - - -
2020-21 14 1,74,546.09 - - 5. 5 2 2 - 5 4 3 2
2019-20 4 49,850.66 - - 2 - 1 1 1 2 - =

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* This data covers issues upto YTD

Notes:

259

 
wns

All data sourced from www.nseindia.com, except for Computer Age Management Services Limited for which the data is sourced from www.bseindia.com
Benchmark index considered is NIFTY
30", 90", 180" calendar day from listed day have been taken as listing day plus 29, 89 and 179 calendar days, except wherever 30", 90", 180" calendar day is a holiday, in which case we have considered the closing data of the
previous trading day

Edelweiss Financial Services Limited

Price information of past issues handled by Edelweiss Financial Services Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.No. Tssue name Tssue size Offer Price | Listing date | Opening price | +/- % change in closing | ¥/- % change in dosing | #/- % change in dosing
(in million) ® on listing date | price, [+/- % change in | price, [+/- % change in | price, [+/ % change in
@ closingbenchmark]- | closing benchmark]- 90 | closing benchmark]-
30" calendar days from | calendar days from listing | 180" calendar days from
listing listing
& pps vane Housing Finance India 27,800.52] 353,00|August 24, 2021 333,00] Not Applicable Not Applicable Not Applicable
2, [Devyani Intemational Limited 18,380.00) 90.00/August 16, 2021 140.90| __ Not Applicable Not Applicable Not Applicable
3: powers Infrastructure Investment 77,349.91 100.00|May 14, 2021 104.00] 14.00% [7.64%] 22.04% [10.93%] Not Applicable
Z____|[Macrotech Developers Limited 25,000.00 786.00|April 19, 2021 36.00 30.22% [521%] 75.43% [10.89%] Not Applicable
5. |stove Kraft Limited 4,126.25 385.00|February 5, 2021 498.00 30-68% [0.09%] 28.92% [-2.05%] 115.34% [8.08%]
: oan 0a
6 Iindigo Paints Limited’ 11,691.24] 1,490.00/)February 2, 2021 2,607.50 DETZ#1S08%| 55.40% [-0.11%] 74.84% [7.61%]
5% 7a
7. [Burger King India Limited 8,100.00 60.00 pecember 14, 112.50 146.5% [7.41%] 135,08% [10.86%] 168,25% [16.53%]
8. Equitas Small Finance Bank rT 33,00[November 2, Sib 5.45% [12.34%] 19.55% [16.84%] SiR
Limited 2020
2 eae Bock Shipbuilders 4,436.86 145,00|October 12, 2020 214.90 18.90% [5.8796] 52.90% [20.25%] 45.79% [24.34%]
TE
10. angel Broking Limited 6,000.00 306.00 October 5, 2020 275.00 -2,32% [2.70%] 10.02% [21.86%] -3,74% [29.24%]

 

Source: www.nseindia.com

‘Indigo Paints Limited - A discount of ® 148 per equity share was offered to eligible employees bidding in the employee reservation portion. All calculations are based on the offer price of 21490 per equity share
‘Notes

ie
2,

aA ew

Based on date of listing.

% of change in closing price on 30 / 90" / 180" calendar day from listing day is calculated vs issue price. % change in closing benchmark index is calculated based on closing index on listing
day vs closing index on 30"/ 90" / 180" calendar day from listing day.
Wherever 30"/ 90" / 180" calendar day from listing day is a holiday, the closing data of the previous trading day has been considered.
The Nifty 50 index is considered as the benchmark index
Not Applicable. — Period not completed

Disclosure in Table-1 restricted to 10 issues.

Summary statement of price information of past issues handled by Edelweiss Financial Services Limited

260

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial] Total | Totalamount of | No. of IPOs trading at discount | No. of IPOs trading at premium | No. of IPOs trading at discount as_| No. of IPOs trading at premium as on
Year | no.of funds raised as on 30" calendar day from as on 30" calendar day from | on 180"calendar day from listing | 180" calendar day from listing date
IPOs in million) listing date listing date date

Over | Between | Lessthan | Over | Between | Lessthan | Over50% | Between | Less than | Over50% | Between | Less than

50% | 25%-50% | 25% 50% | 25%-50% | 25% 25%-50% | 25% 25%-50% | 25%
2021-22* 4 1,48,530.43 - : - - 1 1 : : - -
2020-21 a 45,530.35, - - 1 3 1 2 - - 1 5 1 -
2019-20 2 23,208.49 : : : : 1 2 : y 1 : y

 

 

The information is as on the date of the document
1. Based on date of listing.

2. Wherever 30" and 180” calendar day from listing day is a holiday, the closing data of the previous trading day has been considered.
3. The Nifty 50 index is considered as the Benchmark Index.

“For the financial year 2021-22- 4 issues have been completed of which 2 issues have completed 90 calendar days.

Kotak Mahindra Capital Company Limited

Price information of past issues handled by Kotak Mahindra Capital Company Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.No. Issue name Tssue size Offer Price | Listing date | Opening price | +/- % change in dosing | +/- % change in closing | +/- % change in Closing
(& in million) ®@ on listing date | price, [+/- % change in | price, [+/- % change in | price, [+/ % change in
®@ closing benchmark]- | closing benchmark]- 90" | closing benchmark]-
30" calendar days from | calendar days from listing | 180" calendar days from
listing listing
& |Aptus Value Housing Finance India 27,800.52! 353)/August 24, 2021 333.00 - - -
Limited
2. Cartrade Tech Limited 29,985.13} 1,618}August 20, 2021 1,599.80 - : -
3. /Devyani International Limited 18,380.00 90|August 16, 2021 140.90 : : :
4. Glenmark Life Sciences Limited 15,136.00 720|August 021 750.00 ~6.40%,[+6.68%] a :
5, Zomato Limited 93,750.00] 76\July 23, 2021 116.00 +83.29%,[+3.75%] = 7
6. [Clean Science and Technology 15,466.22 900|July 19, 2021 1,755.00 +66.33%,[+5.47%] = z
Limited
Fe G R Infraprojects Limited 837! [July 19, 2021 1,715.85 +90.82%,[+5.47%] a :
8. [Krishna Institute of Medical 8252 (June 28, 2021 7,009.00 +48,10%,[-0.43%] = =
Sciences Limited
9. Sona BLW Precision Forgings 55,000.00) 291)\June 24, 2021 301.00 +45.45%, [+0.42%] - -
Limited
10. [Macrotech Developers Limited 25,000.00} 486/April 19, 2021 436.00 +30.22%[+5.21%] +75.43%[+10.89%] <
Source: www.nseindia.com and www.bseindia.com
Notes:
1. InGR Infraprojects Limited, the issue price to eligible employees was & 795 after a discount of & 42 per equity share
2. InKrishna Institute of Medical Sciences Limited, the issue price to eligible employees was & 785 afier a discount of @ 40 per equity share
3, In the event any day falls on a holiday, the price/index of the immediately preceding trading day has been considered.
4. The 30th, 90th, 180th calendar days from listed day have been taken as listing day plus 29, 89 and 179 calendar days.
5. Restricted to last 10 equity initial public issues.

Summary statement of price information of past issues handled by Kotak Mahindra Capital Company Limited

261

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial] Total | Totalamount of | No. of IPOs trading at discount | No. of IPOs trading at premium | No. of IPOs trading at discount as_| No. of IPOs trading at premium as on
Year | no.of funds raised as on 30" calendar day from as on 30" calendar day from | on 180"calendar day from listing | 180" calendar day from listing date
IPOs in million) listing date listing date date
Over | Between | Lessthan | Over | Between | Lessthan | Over50% | Between | Less than | Over50% | Between | Less than
50% | 25%-50% | 25% 50% | 25%-50% | 25% 25%-50% | 25% 25%-50% | 25%
2021-22 10 311,578.65 - - if 3 3 - - - - - - -
2020-21 6 140,143.77 - - 1 2 1 2 - - - 4 1 1
2019-20 4 136,362.82 - 1 : : 1 2 : : 1 - 1 2
Notes:

 

 

 

 

1. The information is as on the date of this Prospectus.
2. The information for each of the financial years is based on issues listed during such financial year.

Track record of past issues handled by the BRLMs

For details regarding the track record of the BRLMs, as specified in circular reference CIR/MIRSD/1/2012 dated January 10, 2012 issued by SEBI, see the websites of the BRLMs, as set forth
in the table below:

 

 

 

 

 

Sr.No. Name of BRLM Website
E ICICI Securities Limited www. icicisecurities.com
2. Edelweiss Financial Services Limited www.edelweissfin.com
3. Kotak Mahindra Capital Company Limited hitps://investmentbank.kotak.com

 

 

 

 

262

 
Stock Market Data of Equity Shares

This being an initial public offer of our Company, the Equity Shares are not listed on any stock exchange and accordingly, no
stock market data is available for the Equity Shares.

Mechanism for Redressal of Investor Grievances

The Registrar Agreement provides for the retention of records with the Registrar to the Offer for a period of at least eight years
from the date of listing and commencement of trading of the Equity Shares on the Stock Exchanges, subject to agreement with
our Company for storage of such records for longer period, to enable the investors to approach the Registrar to the Offer for
redressal of their grievances.

In terms of SEBI circular SEBI/HO/CFD/DIL2/CIR/P/2018/22 dated February 15, 2018, SEBI circular
SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular
SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and subject to applicable law, any ASBA Bidder whose Bid has not
been considered for Allotment, due to failure on the part of any SCSB, shall have the option to seek redressal of the same by
the concerned SCSB within three months of the date of listing of the Equity Shares. SCSBs are required to resolve these
complaints within 15 days, failing which the concerned SCSB would have to pay interest at the rate of 15% per annum for any
delay beyond this period of 15 days. Further, the investors shall be compensated by the SCSBs at the rate higher of 7100 or
15% per annum of the application amount in the events of delayed or withdrawal of applications, blocking of multiple amounts
for the same UPI application, blocking of more amount than the application amount, delayed unblocking of amounts for non-
allotted/partially-allotted applications for the stipulated period. In an event there is a delay in redressal of the investor grievance
in relation to unblocking of amounts, the Book Running Lead Managers shall compensate the investors at the rate higher of
2100 or 15% per annum of the application amount

All grievances in relation to the Bidding process may be addressed to the Registrar to the Offer with a copy to the relevant
Designated Intermediary to whom the Bid cum Application Form was submitted. The Bidder should give full details such as
name of the sole or first Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of the submission of
Bid cum Application Form, address of the Bidder, number of the Equity Shares applied for, the name and address of the
Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and ASBA Account number (for
Bidders other than RIBs bidding through the UPI Mechanism) in which the amount equivalent to the Bid Amount was blocked
or UPI ID in case of RIBs applying through the UPI Mechanism.

The Registrar to the Offer shall obtain the required information from the SCSBs and Sponsor Banks for addressing any
clarifications or grievances of ASBA Bidders. Our Company, the BRLMs and the Registrar to the Offer accept no responsibility
for errors, omissions, commission or any acts of the Designated Intermediaries including any defaults in complying with its
obligations under applicable SEBI ICDR Regulations. Investors can contact our Company Secretary and Compliance Officer
or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems such as non-receipt of letters of Allotment,
non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund intimations and non-receipt of
funds by electronic mode.

Our Company has obtained authentication on the SCORES and is in compliance with the SEBI circular
(CIR/OIAE/1/2014CIR/OIAE/1/2013) dated December 18, 2014 in relation to redressal of investor grievances through
SCORES.

Anchor Investors are required to address all grievances in relation to the Offer to the BRLMs.

Further, the Bidder shall also enclose a copy of the Acknowledgment Slip duly received from the concerned Designated
Intermediary in addition to the information mentioned hereinabove.

Disposal of Investor Grievances by our Company

Our Company has not received any investor grievances in the last three Financial Years prior to the filing of the Red Herring
Prospectus and this Prospectus.

After June 30, 2021, our Company and Subsidiaries have not received any investor grievances which were not resolved. As at
the date of the Red Herring Prospectus and this Prospectus there are no outstanding investor grievances. Our Company estimates
that the average time required by our Company or the Registrar to the Offer or the relevant Designated Intermediary, for the
redressal of routine investor grievances shall be 15 Working Days from the date of receipt of the complaint. In case of non-
routine complaints and complaints where external agencies are involved, our Company will seek to redress these complaints as
expeditiously as possible.

Our Company has appointed V. Sri Lakshmi, as the Company Secretary and Compliance Officer for the Offer and she may be
contacted in case of any pre-Offer or post-Offer related problems. For details, see “General Information — company Secretary
and Compliance Officer” on page 48. The Selling Shareholders have authorised the Company Secretary and Compliance Officer
of our Company, and the Registrar to the Offer to redress any complaints received from Bidders in respect of the Offer for Sale.

263
Our Company has also constituted a Stakeholders’ Relationship Committee comprising of Dr. D Nageshwar Reddy
(Chairperson), Satyanaryana Murthy Chavali and Sunil Chandra Kondapally as members, to review and redress shareholder
and investor grievances. For details, see “Our Management — Stakeholders’ Relationship Committee” on page 147.

Disposal of Investor Grievances by our listed Subsidiary Medinova Diagnostic Services Limited

All share related matters, namely transfer, transmission, transposition, dividend, change of name, address and signature of
mandate and power of attorney, replacement, split, consolidation, dematerialization and rematerialization of shares, issue of
duplicate certificates etc. are handled by Medinova’s registrar and transfer agent being XL Softech Systems Limited.

As on June 30, 2021, there no outstanding investor grievance pending against Medinova.

264
SECTION VII: OFFER INFORMATION
TERMS OF THE OFFER

The Equity Shares being offered and Allotted pursuant to the Offer shall be subject to the provisions of the Companies Act,
SEBI ICDR Regulations, SCRA, SCRR, the MoA, AoA, Listing Regulations, the terms of the Red Herring Prospectus, this
Prospectus, the Abridged Prospectus, Bid cum Application Form, the Revision Form, the CAN/Allotment Advice and other
terms and conditions as may be incorporated in the Allotment Advice and other documents/certificates that may be executed in
respect of the Offer. The Equity Shares shall also be subject to laws as applicable, guidelines, rules, notifications and regulations
relating to the issue of capital, Offer for Sale and listing and trading of securities issued from time to time by SEBI, the
Government of India, the Stock Exchanges, RoC and/or other authorities, as in force on the date of the Offer and to the extent
applicable or such other conditions as may be prescribed by the SEBI, the Government of India, the Stock Exchanges, the RoC
and/or any other authorities to the extent applicable or such other conditions as maybe prescribed by such governmental and/or
regulatory authority while granting its approval for the Offer.

Ranking of the Equity Shares

The Allottees upon Allotment of Equity Shares under the Offer will be entitled to dividend and other corporate benefits, if any,
declared by our Company after the date of Allotment. The Equity Shares being offered and Allotted in the Offer shall rank pari
passu with the existing Equity Shares in all respects including dividends and other corporate benefits. For further details, see
“Description of Equity Shares and Terms of Articles of Association” on page 287.

Mode of Payment of Dividend

Our Company shall pay dividends, if declared, to the Shareholders as per the provisions of the Companies Act, our MoA, AoA,
the Listing Regulations and other applicable laws including guidelines or directives that may be issued by the Gol in this respect.
All dividends, declared by our Company after the date of Allotment (pursuant to the Allotment of Equity Shares), will be
payable to the Allottees, for the entire year, in accordance with applicable law. For further details in relation to dividends, see
“Dividend Policy” and “Description of Equity Shares and Terms of the Articles of Association” on pages 161 and 287,
respectively.

Face Value, Offer Price and Price Band

The face value of each Equity Share is 21. The Floor Price is 2522 per Equity Share and Cap Price is 2531 per Equity Share.
The Anchor Investor Offer Price is 2531 per Equity Share and the Offer Price is 531 per Equity Share.

The Price Band, the minimum Bid Lot size and the amount of the Employee Discount, will be decided by our Company and
the Selling Shareholders in consultation with the BRLMs, and have been advertised, at least two Working Days prior to the
Bid/ Offer Opening Date, in all editions of Financial Express, an English national daily newspaper and all editions of Jansatta,
a Hindi national daily newspaper and Hyderabad edition of Surya Telugu Daily, a Telugu daily newspaper (Telugu being the
regional language of Telangana, where our Registered Office is located), each with wide circulation, and were made available
to the Stock Exchanges for the purpose of uploading on their respective websites. The Price Band, along with the relevant
financial ratios calculated at the Floor Price and at the Cap Price, were required to be pre-filled in the Bid cum Application
Forms available on the respective websites of the Stock Exchanges.

At any given point of time, there shall be only one denomination for the Equity Shares.

Compliance with Disclosure and Accounting Norms

Our Company shall comply with all disclosure and accounting norms as specified by the SEBI from time to time.

Rights of the Shareholders

Subject to applicable laws, rules, regulations and guidelines and the AoA, our Shareholders shall have the following rights:

e Right to receive dividends, if declared;

e Right to attend general meetings and exercise voting rights, unless prohibited by law;

¢ Right to vote on a poll either in person or by proxy or e-voting, in accordance with the provisions of the Companies Act;
e Right to receive offers for rights shares and be allotted bonus shares, if announced;

e — Right to receive surplus on liquidation, subject to any statutory and preferential claim being satisfied;

e — Right of free transferability of their Equity Shares, subject to applicable laws including any RBI rules and regulations;
and

265
e Such other rights, as may be available to a shareholder of a listed public company under the Companies Act, the Listing
Regulations and the AoA of our Company and other applicable laws.

For a detailed description of the main provisions of the AoA of our Company relating to voting rights, dividend, forfeiture and
lien, transfer, transmission and/or consolidation/splitting, see “Description of Equity Shares and Terms of Articles of
Association” on page 287.

Employee Discount

Employee Discount, if any, may be offered to Eligible Employees bidding in the Employee Reservation Portion. Eligible
Employees bidding in the Employee Reservation Portion at a price within the Price Band can make payment at Bid Amount,
that is, Bid Amount net of Employee Discount, at the time of making a Bid. Eligible Employees bidding in the Employee
Reservation Portion at the Cut-Off Price have to ensure payment at the Cap Price, less Employee Discount, at the time of
making a Bid.

Market Lot and Trading Lot

Pursuant to Section 29 of the Companies Act and the SEBI ICDR Regulations, the Equity Shares shall be Allotted only in
dematerialised form. As per the SEBI ICDR Regulations and the Listing Regulations, the trading of the Equity Shares shall
only be in dematerialised form. In this context, two agreements have been entered into amongst our Company, the respective
Depositories and Registrar to the Offer:

e Tripartite agreement dated November 16, 2016 amongst our Company, NSDL and Registrar to the Offer.
e Tripartite agreement dated November 2, 2016 amongst our Company, CDSL and Registrar to the Offer.

Since trading of the Equity Shares is in dematerialised form, the tradable lot is one Equity Share. Allotment in this Offer will
be in multiples of 28 Equity Share subject to a minimum Allotment of 28 Equity Shares. For the method of basis of allotment,
see “Offer Procedure” on page 272.

Joint Holders

Subject to the provisions of the AoA where two or more persons are registered as the holders of the Equity Shares, they will be
deemed to hold such Equity Shares as joint tenants with benefits of survivorship.

Nomination facility to investors

In accordance with Section 72 of the Companies Act, read with the Companies (Share Capital and Debentures) Rules, 2014,
the sole Bidder, or the first Bidder along with other joint Bidders, may nominate any one person in whom, in the event of the
death of sole Bidder or in case of joint Bidders, death of all the Bidders, as the case may be, the Equity Shares Allotted, if any,
shall vest to the exclusion of the other persons, unless the nomination is varied or cancelled in the prescribed manner. A person,
being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall be entitled to the same
advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the
nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled
to Equity Share(s) in the event of his or her death during the minority. A nomination shall stand rescinded upon a
sale/transfer/alienation of Equity Share(s) by the person nominating. A buyer will be entitled to make a fresh nomination/ cancel
nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at our
Registered Office or to the registrar and transfer agents of our Company.

Any person who becomes a nominee by virtue of the provisions of Section 72 of the Companies Act shall upon the production
of such evidence as may be required by the Board, elect either:

a) to register himself or herself as the holder of the Equity Shares; or

b) to make such transfer of the Equity Shares, as the deceased holder could have made.

Further, our Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to
transfer the Equity Shares, and if the notice is not complied with within a period of 90 days, the Board may thereafter withhold
payment of all dividends, bonuses or other monies payable in respect of the Equity Shares, until the requirements of the notice
have been complied with.

Since the Allotment of Equity Shares in the Offer will be made only in dematerialized mode, there is no need to make a separate
nomination with our Company. Nominations registered with respective Depository Participant of the Bidder would prevail. If

the Bidder wants to change the nomination, they are requested to inform their respective Depository Participant.

Withdrawal of the Offer

266
Our Company and the Selling Shareholders in consultation with the BRLMs, reserve the right not to proceed with the Offer,
after the Bid/ Offer Opening Date but before the Allotment. In such an event, our Company would issue a public notice in the
newspapers in which the pre-Offer advertisements were published, within two days of the Bid/ Offer Closing Date or such other
time as may be prescribed by SEBI, providing reasons for not proceeding with the Offer and inform the Stock Exchanges
simultaneously. The BRLMs, through the Registrar to the Offer, shall notify the SCSBs and the Sponsor Bank, to unblock the
bank accounts of the ASBA Bidders within one Working Day from the date of receipt of such notification and also inform the
Escrow Collection Banks to process refunds to the Anchor Investors within one Working Day from the date of receipt of such
notification,. Our Company shall also inform the same to the Stock Exchanges on which Equity Shares are proposed to be
listed.

If our Company and the Selling Shareholders in consultation with the BRLMs, withdraw the Offer after the Bid/ Offer Closing
Date and thereafter determine that they will proceed with an issue of the Equity Shares, our Company shall file a fresh draft red
herring prospectus with SEBI. Notwithstanding the foregoing, this Offer is also subject to obtaining the final listing and trading
approvals of the Stock Exchange, which our Company shall apply for after Allotment, and the final RoC approval of the
Prospectus after it is filed with the RoC.

 

 

Bid/ Offer Programme
BID/ OFFER OPENED September 1, 20210)
BID/ OFFER CLOSED ON September 3, 20212

 

 

() The Anchor Investor Bid/ Offer Period was August 31, 2021

An indicative timetable in respect of the Offer is set out below:

 

 

 

 

 

 

 

 

 

Event Indicative Date
Bid/ Offer Closing Date September 3, 2021
Finalisation of Basis of Allotment with the Designated Stock Exchange On or about September 8, 2021
Initiation of refunds (if any, for Anchor Investors)/mblocking of funds from ASBA Account” On or about September 9, 2021
Credit of Equity Shares to demat accounts of Allottees On or about September 13, 2021
Commencement of trading of the Equity Shares on the Stock Exchanges On or about September 14, 2021

 

* Tn case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding four Working Days
from the Bid/Offer Closing Date, the Bidder shall be compensated in accordance with the applicable law by the intermediary responsible for causing such
delay in unblocking. The BRLMs shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in
unblocking. The Bidder shall be compensated in the manner specified in the SEBI circular no. SEBI/HO/CFD/DIL1/CIR/P/2021/47 dated March 31, 2021 and
SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M_ dated March 16, 2021, as amended pursuant to SEBI circular no.
SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, which for the avoidance of doubt, shall be deemed to be incorporated in the deemed agreement of
the Company with the SCSBs, to the extent applicable.

The above timetable, is indicative and does not constitute any obligation or liability on our Company, our Selling
Shareholders, or the BRLMs.

Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the
commencement of trading of the Equity Shares on the Stock Exchanges are taken within six Working Days of the Bid/
Offer Closing Date, or such other period as may be prescribed by the SEBI, the timetable may be extended due to
various factors, such as extension of the Bid/ Offer Period by our Company and the Selling Shareholders in consultation
with the BRLMs, revision of the Price Band or any delay in receiving the final listing and trading approval from the
Stock Exchanges, and delay in respect of final certificates from SCSBs. The commencement of trading of the Equity
Shares will be entirely at the discretion of the Stock Exchanges and in accordance with the applicable laws. Each of the
Selling Shareholders, severally and not jointly, confirm that they shall extend such reasonable support and co-operation
required by our Company and the BRLMs for completion of the necessary formalities for listing and commencement of
trading of the Equity Shares at the Stock Exchanges within six Working Days from the Bid/Offer Closing Date or such
other period as may be prescribed by SEBI.

SEBI is in the process of streamlining and reducing the post issue timeline for IPOs. Any circulars or notifications from
SEBI after the date of the Draft Red Herring Prospectus or the Red Herring Prospectus may result in changes to the
above mentioned timelines. Further, the offer procedure is subject to change to any revised SEBI circulars to this effect.

In terms of the UPI Circulars, in relation to the Offer, the BRLMs will submit reports of compliance with T+6 listing timelines

and activities, identifying non-adherence to timelines and processes and an analysis of entities responsible for the delay and the
reasons associated with it

267
Submission of Bids (other than Bids from Anchor Investors):

 

 

 

 

 

Bid/ Offer Period (except the Bid/ Offer Closing Date)
Submission and Revision in Bids Only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time IST”)
Bid/ Offer Closing Date
Submission and Revision in Bids Only between 10.00 a.m. and 3.00 p.m. IST

 

 

 

On the Bid/ Offer Closing Date, the Bids have been uploaded until:
(i) 4.00 p.m. IST in case of Bids by QIBs and Non-Institutional Bidders, and

(ii) until 5.00 p.m. IST or such extended time as permitted by the Stock Exchanges, in case of Bids by RIBs and Eligible
Employees Bidding under the Employee Reservation Portion

On Bid/ Offer Closing Date, extension of time would have been granted by the Stock Exchanges only for uploading Bids
received by Retail Individual Bidders and Eligible Employees Bidding under the Employee Reservation Portion, after taking
into account the total number of Bids received and as reported by the BRLMs to the Stock Exchanges.

Due to limitation of time available for uploading the Bids on the Bid/ Offer Closing Date, Bidders were advised to submit their
Bids one day prior to the Bid/ Offer Closing Date, and in any case no later than 3:00 p.m. IST on the Bid/ Offer Closing Date.
Any time mentioned in this Prospectus is IST. Bidders were cautioned that, in the event a large number of Bids are received on
the Bid/ Offer Closing Date, some Bids would not have been uploaded due to lack of sufficient time. Such Bids that could not
be uploaded would not have been considered for allocation under this Offer. Bids will be accepted only during Working Days,
during the Bid/ Offer Period. Bids were accepted only during Monday to Friday (excluding any public holiday), during the
Bid/Offer period. Bids and revisions were accepted on Saturdays and public holidays. It is clarified that Bids not uploaded on
the electronic bidding system or in respect of which the full Bid Amount was not blocked by SCSBs or not blocked under the
UPI Mechanism in the relevant ASBA Account, as the case may be, were rejected.

Neither the Selling Shareholders, nor our Company, nor any member of the Syndicate are liable for any failure in (i) uploading
the Bids due to faults in any software/ hardware system or otherwise; and (ii) the blocking of Bid Amount in the ASBA Account
on receipt of instructions from the Sponsor Bank on account of any errors, omissions or non-compliance by various parties
involved in, or any other fault, malfunctioning or breakdown in, or otherwise, in the UPI Mechanism.

In case of discrepancy in data entered in the electronic book vis-vis data contained in the Bid cum Application Form for a
particular Bidder, the details as per the Bid file received from the Stock Exchanges would be taken as the final data for the
purpose of Allotment.

Minimum Subscription

The requirement of minimum subscription is not applicable to the Offer in accordance with the SEBI ICDR Regulations.
However, if our Company does not make the minimum Allotment as specified under terms of the Rule 19(2)(b) of the SCRR,
including devolvement of Underwriters, if any, within 60 days from the date of Bid/ Offer Closing Date, the Selling
Shareholders, to the extent applicable, and our Company shall forthwith refund the entire subscription amount received. If there
is a delay beyond the prescribed time, the Selling Shareholders, to the extent applicable, and our Company shall pay interest
prescribed under the applicable law.

Further, the Selling Shareholders and our Company and will ensure that the number of prospective Allottees to whom the Equity
Shares will be Allotted shall not be less than 1,000 in compliance with Regulation 49(1) of the SEBI ICDR Regulations failing
which the entire application money shall be unblocked in the respective ASBA Accounts of the Bidders. In case of delay, if
any, in unblocking the ASBA Accounts within such timeline as prescribed under applicable laws, the our Company shall be
liable to pay interest on the application money in accordance with applicable laws. If there is a delay beyond four days after our
Company becomes liable to pay the amount, our Company and every Director of our Company, who are officers in default,
shall pay interest at the rate of 15% per annum. In case of an undersubscription in the Offer, the Equity Shares proposed for
sale by each Selling Shareholder shall be in proportion to the Offered Shares by such Selling Shareholder.

Arrangements for Disposal of Odd Lots

There are no arrangements for disposal of odd lots since our Equity Shares will be traded in dematerialised form only and
market lot for our Equity Shares will be one Equity Share.

Restrictions, if any on Transfer and Transmission of Equity Shares
Except for lock-in of the pre-Offer capital of our Company, lock-in of the Promoters’ minimum contribution and the Anchor
Investor lock-in as provided in “Capital Structure — Details of Promoter Contribution and Lock-in” and “Capital Structure —

Other Lock-in requirements on page 59 and 60, respectively, and except as provided under the AoA, there are no restrictions
on transfer of the Equity Shares. Further, there are no restrictions on transmission of any shares of our Company and on their

268
consolidation or splitting, except as provided in the AoA. For details, see “Description of Equity Shares and terms of Articles
of Association” on page 287.

Impersonation

Attention of the applicants is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act,
which is reproduced below:

“Any person who:

(a) makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its
securities; or

(b) makes or abets making of multiple applications to a company in different names or in different combinations of his
name or surname for acquiring or subscribing for its securities; or

© otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any
other person in a fictitious name,

shall be liable for action under Section 447.”

The liability prescribed under Section 447 of the Companies Act, for fraud involving an amount of at least 21 million or 1% of
the turnover of the Company, whichever is lower, includes imprisonment for a term which shall not be less than six months
extending up to 10 years and fine of an amount not less than the amount involved in the fraud, extending up to three times such
amount (provided that where the fraud involves public interest, such term shall not be less than three years.) Further, where the
fraud involves an amount less than 21 million or one per cent of the turnover of the company, whichever is lower, and does not
involve public interest, any person guilty of such fraud shall be punishable with imprisonment for a term which may extend to
five years or with fine which may extend to %5 million or with both.

269
OFFER STRUCTURE

Offer of 35,688,064 Equity Shares for cash at a price of 7531 per Equity Share aggregating to 718,942.56 million, comprising
of an Offer for Sale of 35,688,064 Equity Shares, 5,098,296 Equity Shares aggregating up to 22,706.08 million by Dr. S.
Surendranath Reddy, 29,487,290 Equity Shares aggregating up to 15,651.30 million by Karakoram Limited and 1,102,478
Equity Shares aggregating up to 7585.18 million by Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1.
The Offer constituted up to 35.00% of the post-Offer paid-up Equity Share capital of our Company. The Offer includes a

reservation of 150,000 Equity Shares aggregating to 271.85 million for subscription by Eligible Employees.

The Offer and the Net Offer shall constitute at least 35.00% and 34.85%, respectively, of the post-Offer paid-up Equity Share
capital of our Company. The face value of the Equity Shares is 1 each.

The Offer is being made through the Book Building Process.

 

 

 

Size available for
Allotment/allocation

Portion constituted to 0.42% of
the Offer Size

has been made available for
allocation to QIBs. However, 5% of
the QIB Portion (excluding the
Anchor Investor Portion) has been
made available for allocation
proportionately to Mutual Funds
only. Mutual Funds participating in
the Mutual Fund Portion were also
be eligible for allocation in the
remaining balance QIB Portion
(excluding the Anchor Investor
Portion). The unsubscribed portion
in the Mutual Fund Portion has
been made available for allocation
to other QIBs

the Net Offer or the
Net Offer less
allocation to QIB
Bidders and RIBs has
been made available
for allocation

Particulars Eligible Employees* QIBs) Non-Institutional Retail Individual
Bidders Bidders

Number of Equity | Not more than 150,000* Equity | Not more than 17,769,031" Equity|Not less than/Not less __ than
Shares available for|Shares aggregating up _ to| Shares 5,330,710" Equity] 12,438,323" Equity
Allotmenvallocation | %71.85° million Shares available for|Shares available for
@ allocation or Net Offer] allocation or Net Offer
Jess allocation to QIB| less allocation to QIB
Bidders and RIBs Bidders and Non-

Institutional Bidders
Percentage of Offer)The Employee Reservation | Not more than 50% of the Net Offer] Not less than 15% of} Not less than 35% of

the Net Offer or the

Net Offer less
allocation to QIB
Bidders and Non-
Institutional Bidders
has been made

available for allocation

 

 

multiples of 28 Equity Shares
thereafter

the Bid Amount exceeds 2200,000
and in multiples of 28 Equity
Shares thereafter

Equity Shares that the
Bid Amount exceeds
%200,000 and in
multiples of 28 Equity
Shares thereafter

Basis of |Proportionate’; unless _ the | Proportionate as follows (excluding | Proportionate Proportionate, subject
Allotmenvallocation | Employee Reservation Portion | the Anchor Investor Portion): to minimum Bid Lot.
if respective category | is under-subscribed, the value of|1. At least 355,381 Equity For details, see “Offer
is oversubscribed allocation to an Eligible Shares has been made Procedure” on page
Employee were not exceeded available for allocation on a 272
200,000. In the event of under- proportionate basis to Mutual
subscription in the Employee Funds only; and
Reservation Portion, the|2. 6,752,232 Equity Shares has
unsubscribed portion has been been made available for
Allotted, on a proportionate allocation on a proportionate
basis, to Eligible Employees for basis to all other QIBs,
value exceeding 200,000, including Mutual Funds
subject to total Allotment to an receiving allocation as per (a)
Eligible | Employee not above
exceeding %500,000 (net of
Employee Discount) Not more than 10,661,418 Equity
Shares have been allocated on a
discretionary basis to Anchor
Investors
Minimum Bid 28 Equity Shares and in| Such number of Equity Shares that|Such number of |28 Equity Shares and

in multiples of 28
Equity Shares
thereafter

 

Maximum Bid

 

 

Such number of Equity Shares
in multiples of 28 Equity Shares
so that the Bid Amount does not
exceed %500,000 (net of
Employee Discount) ©

 

Such number of Equity Shares and
in multiple of 28 Equity Shares not
exceeding the size of the Net Offer,
subject to applicable limits

 

Such number of
Equity Shares and in
multiples of 28 Equity
Shares not exceeding
the size of the Net
Offer (excluding QIB

 

Such number of Equity
Shares and in
multiples of 28 Equity
Shares so that the Bid
Amount does not
exceed %200,000

 

270

 
 

Particulars Eligible Employees* QIBs) Non-Institutional Retail Individual
Bidders Bidders

 

portion), subject to
applicable limits

 

 

 

 

 

 

 

 

 

Mode of Bidding Through ASBA process only (except Anchor Investors)

Bid Lot 28 Equity Shares and in multiples of 28 Equity Shares thereafter

Mode of Allotment _|Compulsorily in dematerialised form

Allotment Lot ‘A minimum of 28 Equity Shares and in multiples of one Equity Share thereafter

Trading Lot One Equity Share

Who can apply Eligible Employees (such that|Public financial institutions _as | Resident Indian | Resident Indian
the Bid Amount does not exceed | specified in Section 2(72) of the| individuals, Eligible| individuals, Eligible
500,000) Companies Act, __scheduled| NRIs, HUFs (in the| NRIs and HUFs (in the

commercial banks, Mutual Funds,|name of the karta),| name of karta)

FPIs (other than individuals, | companies, corporate

corporate bodies and family | bodies, scientific

offices), VCFs, AIFs, FVClIs| institutions societies
registered with SEBI, multilateral | and trusts, and FPIs
and bilateral development financial | who are individuals,
institutions, state industrial | corporate bodies and
development corporation, | family offices and
insurance companies registered | registered with SEBL

with IRDAI, provident funds

(subject to applicable law) with

minimum corpus of %250 million,

pension funds with minimum
corpus of %250 million, National

Investment Fund set up by the

Government of India through

resolution F. No.2/3/2005-DD-II

dated November 23, 2005, the
insurance funds set up and
managed by army, navy or air force
of the Union of India, insurance
funds set up and managed by the

Department of Posts, India and

Systemically Important NBFCs.

Terms of Payment | In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of

their Bids)

In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder

or by the Sponsor Bank through the UPI Mechanism (other than Anchor Investors) that is specified in the ASBA Form

at the time of submission of the ASBA Form
‘Subject to finalisation of the Basis of Allotment

“A discount of 852 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion

* Eligible Employees Bidding in the Employee Reservation portion could Bid up to a Bid Amount of %500,000. However, a Bid by an Eligible Employee in the

Employee Reservation Portion has been considered for allocation, in the first instance, for a Bid Amount of up to 200,000. In the event of under-subscription

in the Employee Reservation Portion, the unsubscribed portion has been made available for allocation and Allotment, proportionately to all Eligible Employees

who have Bid in excess of %200,000, subject to the maximum value of Allotment made to such Eligible Employee not exceeding %500,000. Further, an Eligible

Employee Bidding in the Employee Reservation Portion could also Bid in the Net Offer and such Bids were not be treated as multiple Bids subject to applicable

limits. The unsubscribed portion if any, in the Employee Reservation Portion has been added back to the Net Offer. In case of under-subscription in the Net

Offer, spill-over to the extent of such under-subscription has been permitted from the Employee Reservation Portion.

Including 150,000 Equity Shares to be Allotted under the Employee Reservation Portion at a price of % 479 aggregating to % 71.85 million, subject to

finalization of Basis of Allotment

(@_ Our Company and the Selling Shareholders in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a
discretionary basis, in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual
Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being made to other Anchor Investors.

In the event of under-subscription or non-Allotment in the Anchor Investor Portion, the balance Equity Shares in the Anchor Investor Portion shall be
added to the Net QIB Portion. For details, see “Offer Procedure” on page 272.

(2) This Offer is made in accordance with the Rule 19(2)(b) of the SCRR and is being made through the Book Building Process, in compliance with Regulation
6(1) of the SEBI ICDR Regulations.

(3) Full Bid Amount was required to be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms, provided that
any difference between the price at which Equity Shares are allocated to the Anchor Investors and the Anchor Investor Offer Price, was required to be
payable by the Anchor Investor Pay-in Date as mentioned in the CAN. For details of terms of payment of applicable to Anchor Investors, see General
Information Document available on the website of the Stock Exchanges and the BRLMs.

(4) Incase of joint Bids, the Bid cum Application Form could contain only the name of the First Bidder whose name should also appear as the first holder
of the beneficiary account held in joint names. The signature of only such First Bidder is required in the Bid cum Application Form and such First Bidder
has been deemed to have signed on behalf of the joint holders. Bidders were required to confirm and were deemed to have represented to our Company,
the Selling Shareholders, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under
applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

(©) Allotment to an Eligible Employee in the Employee Reservation Portion may exceed %200,000 (net of Employee Discount) in value.

 

 

 

 

 

 

 

Subject to valid Bids having been received at or above the Offer Price, under-subscription, if any, in the Non-Institutional

Portion or the Retail Portion has been allowed to be met with spill-over from other categories or a combination of categories at

the discretion of our Company and the Selling Shareholders in consultation with the BRLMs and the Designated Stock

Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion has not been allowed to be met

with spill-over from other categories or a combination of categories. For further details, see “Terms of the Offer” on page 265.
271

 
OFFER PROCEDURE

All Bidders should read the General Information Document for Investing in Public Issues prepared and issued in accordance
with the circular no. SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020 and the UPI Circulars (the ‘General
Information Document”) which highlights the key rules, processes and procedures applicable to public issues in general in
accordance with the provisions of the Companies Act, the SCRA, the SCRR and the SEBI ICDR Regulations which is part of
the abridged prospectus accompanying the Bid cum Application Form. The General Information Document is available on the
websites of the Stock Exchanges and the BRLMs. Please refer to the relevant provisions of the General Information Document
which are applicable to the Offer, especially in relation to the process for Bids by RIBs through the UPI Mechanism. The
investors should note that the details and process provided in the General Information Document should be read along with
this section.

Additionally, all Bidders may refer to the General Information Document for information in relation to (i) category of investors
eligible to participate in the Offer; (ii) maximum and minimum Bid size; (iii) price discovery and allocation; (iv) payment
instructions for ASBA Bidders/Applicants; (v)Issuance of CAN and allotment in the Offer; (vi) General instructions (limited to
instructions for completing the Bid cum Application Form,); (vii) submission of Bid cum Application Form; (viii) other
instructions (limited to joint bids in cases of individual, multiple bids and instances when an application would be rejected on
technical grounds); (ix) applicable provisions of the Companies Act relating to punishment for fictitious applications; (x) mode
of making refunds; (xi) Designated Date, (xii) interest in case of delay in allotment or refund; and (xiii) disposal of application.

SEBI vide the UPI Circulars, has introduced an alternate payment mechanism using Unified Payments Interface (“UPI”) and
consequent reduction in timelines for listing in a phased manner. From January 1, 2019, the UPI Mechanism for RIBs applying
through Designated Intermediaries was made effective along with the existing process and existing timeline of T+6 days. (“UPI
Phase I”). The UPI Phase I was effective till June 30, 2019.

With effect from July 1, 2019, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, read with
circular bearing number SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 with respect to Bids by RIBs through
Designated Intermediaries (other than SCSBs), issued by SEBI, the existing process of physical movement of forms from such
Designated Intermediaries to SCSBs for blocking of funds has been discontinued and only the UPI Mechanism for such Bids
with existing timeline of T+6 days will continue for a period of three months or launch of five main board public issues,
whichever is later (“UPI Phase II”). Subsequently however, SEBI vide its circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133
dated November 8, 2019 extended the timeline for implementation of UPI Phase II till March 31, 2020. However, given the
prevailing uncertainty due to the COVID-19 pandemic, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated
March 30, 2020, has decided to continue with the UPI Phase II till further notice. The final reduced timeline of T+3 days for
the UPI Mechanism for applications by RIBs (“UPI Phase III”) and modalities of the implementation of UPI Phase III maybe
notified and made effective subsequently, as may be prescribed by SEBI. The Offer has been undertaken pursuant to the
processes and procedures under UPI Phase II, subject to any circulars, clarification or notification issued by the SEBI from
time to time. Further, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 as
amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, has introduced certain
additional measures for streamlining the process of initial public offers and redressing investor grievances. This
circular shall come into force for initial public offers opening on/or after May 1, 2021, except as amended pursuant to SEBI
circular SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, and the provisions of this circular, are deemed to form part
of this Prospectus

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism)
exceeding four Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of %100 per
day for the entire duration of delay exceeding four Working Days from the Bid/Offer Closing Date by the intermediary
responsible for causing such delay in unblocking. The BRLMs shall, in their sole discretion, identify and fix the liability on such
intermediary or entity responsible for such delay in unblocking. Further, SEBI vide its circular no.
SEBI/HO/CFD/DIL1/CIR/P/2021/47 dated March 31, 2021, has reduced the timelines for refund of Application money to four
days.

The BRLMs shall be the nodal entity for any issues arising out of public issuance process.

In terms of Regulation 23(5) and Regulation 52 of SEBI ICDR Regulations, the timelines and processes mentioned in SEBI
Circular. No. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 shall continue to form part of the agreements
being signed between the intermediaries involved in the public issuance process and lead managers shall continue to coordinate
with intermediaries involved in the said process.

Our Company, the Selling Shareholders and the members of the Syndicate do not accept any responsibility for the completeness
and accuracy of the information stated in this section and the General Information Document and are not liable for any
amendment, modification or change in the applicable law which may occur after the date of the Red Herring Prospectus and
this Prospectus. Bidders were advised to make their independent investigations and ensure that their Bids are submitted in
accordance with applicable laws and do not exceed the investment limits or maximum number of the Equity Shares that can be
held by them under applicable law or as specified in the Draft Red Herring Prospectus, the Red Herring Prospectus and this
Prospectus.

272
Further, our Company, the Selling Shareholders and the Syndicate are not liable for any adverse occurrences consequent to
the implementation of the UPI Mechanism for application in this Offer.

Book Building Procedure

The Offer has been made in terms of Rule 19(2)(b) of the SCRR, through the Book Building Process in accordance with
Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer was required to be allocated on a
proportionate basis to QIBs. Our Company and the Selling Shareholders in consultation with the BRLMs, allocated 60% of the
QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations, of which one-third
were required to be reserved for domestic Mutual Funds, subject to valid Bids having been received from domestic Mutual
Funds at or above the Anchor Investor Allocation Price. Further, 5% of the Net QIB Portion was required to be made available
for allocation on a proportionate basis only to Mutual Funds, and spill-over from the remainder of the Net QIB Portion was
required to be made available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual
Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Net Offer was required
to be made available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35% of the Net
Offer was required to be made available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR
Regulations, subject to valid Bids having been received at or above the Offer Price. Further, 150,000" Equity Shares,
aggregating to 271.85 million were made available for allocation on a proportionate basis only to Eligible Employees Bidding
in the Employee Reservation Portion, subject to valid Bids having been received at or above the Offer Price, if any.

“Subject to finalisation of the Basis of Allotment

‘A discount of €52 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.

The Equity Shares, on Allotment, shall be traded only in the dematerialized segment of the Stock Exchanges.

Investors should note that the Equity Shares will be Allotted to all successful Bidders only in dematerialised form. The
Bid cum Application Forms which did not have the details of the Bidders’ depository account, including DP ID, Client
ID, PAN and UPI ID, as applicable, were to be treated as incomplete and were liable to be rejected. Bidders did not have
the option of being Allotted Equity Shares in physical form. However, they may get the Equity Shares rematerialised
subsequent to Allotment of the Equity Shares in the IPO.

Phased implementation of UPI Mechanism

SEBI has issued the UPI Circulars in relation to streamlining the process of public issue of, inter alia, equity shares. Pursuant
to the UPI Circulars, the UPI Mechanism has been introduced in a phased manner as a payment mechanism (in addition to
mechanism of blocking funds in the account maintained with SCSBs under ASBA) for applications by RIBs through Designated
Intermediaries with the objective to reduce the time duration from public issue closure to listing from six Working Days to up
to three Working Days. Considering the time required for making necessary changes to the systems and to ensure complete and
smooth transition to the UPI payment mechanism, the UPI Circulars have introduced the UPI Mechanism in three phases in the
following manner:

Phase I: This phase was applicable from January 1, 2019 until March 31, 2019 or floating of five main board public issues,
whichever was later. Subsequently, the timeline for implementation of Phase I was extended till June 30, 2019. Under this
phase, an RIB had the option to submit the ASBA Form with any of the Designated Intermediary and use his/ her UPI ID for
the purpose of blocking of funds. The time duration from public issue closure to listing continued to be six Working Days.

Phase II: This phase has become applicable from July 1, 2019. Under this phase, submission of the ASBA Form without UPI
by RIBs to Designated Intermediaries (other than SCSBs) for blocking of funds will be discontinued. However, the time
duration from public issue closure to listing would continue to be six Working Days during this phase. SEBI vide its circular
no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 extended the timeline for implementation of UPI Phase II
till March 31, 2020. Further, pursuant to SEBI circular dated March 30, 2020, this phase has been extended till further notice.

Phase III: The commencement period of Phase III is yet to be notified. In this phase, the time duration from public issue closure
to listing would be reduced to three Working Days.

All SCSBs offering facility of making application in public issues shall also provide facility to make application using UPI.
Our Company will be required to appoint one of the SCSBs as a sponsor bank to act as a conduit between the Stock Exchanges
and NPCI in order to facilitate collection of requests and / or payment instructions of the Retail Individual Bidders using the
UPI.

Pursuant to the UPI Circulars, SEBI has set out specific requirements for redressal of investor grievances for applications that
have been made through the UPI Mechanism. The requirements of the UPI Circular include, appointment of a nodal officer by
the SCSB and submission of their details to SEBI, the requirement for SCSBs to send SMS alerts for the blocking and
unblocking of UPI mandates, the requirement for the Registrar to submit details of cancelled, withdrawn or deleted applications,
and the requirement for the bank accounts of unsuccessful Bidders to be unblocked no later than one Working Day from the
date on which the Basis of Allotment is finalised. Failure to unblock the accounts within the timeline would result in the SCSBs
being penalised under the relevant securities law

273
For further details, refer to the General Information Document available on the websites of the Stock Exchanges and the
BRLMs.

Bid cum Application Form

Copies of the Bid cum Application Form (other than for Anchor Investors) and the abridged prospectus were made available
with the Designated Intermediaries at the Bidding Centres, and our Registered Office. An electronic copy of the Bid cum
Application Form was also made available for download on the websites of the Stock Exchanges (www.nseindia.com and
www.bseindia.com) at least one day prior to the Bid/ Offer Opening Date.

Copies of the Anchor Investor Application Form were made available at the offices of the BRLMs.

All Bidders (other than Anchor Investors) were required to mandatorily participate in the Offer only through the ASBA process.
RIBs are mandatorily required to use the UPI Mechanism for submitting their bids to Designated Intermediaries and are allowed
to use ASBA Process by way of ASBA Forms to submit their bids directly to SCSBs. Anchor Investors were not permitted to
participate in the Offer through the ASBA process.

RIBs bidding using the UPI Mechanism were required to provide the UPI ID in the relevant space provided in the Bid cum
Application Form and the Bid cum Application Form that does not contain the UPI ID are liable to be rejected.

ASBA Bidders (including Bidders using UPI Mechanism) must provide bank account details and authorisation to block funds
in their respective ASBA Accounts in the relevant space provided in the ASBA Form and the ASBA Forms that did not contain
such details were liable to be rejected or the UPI ID, as applicable, in the relevant space provided in the ASBA Form.
Applications made using third party bank account or using third party linked bank account UPI ID were liable for rejection.
RIBs using the UPI Mechanism may also apply through the mobile applications using the UPI handles as provided on the
website of the SEBI.

ASBA Bidders were required to ensure that the Bids were made on ASBA Forms bearing the stamp of the Designated
Intermediary, submitted at the Bidding Centres only (except in case of electronic ASBA Forms) and the ASBA Forms not
bearing such specified stamp were liable to be rejected. RIBs using UPI Mechanism, were required to submit their ASBA
Forms, including details of their UPI IDs, with the Syndicate, Sub-Syndicate members, Registered Brokers, RTAs or CDPs.
RIBs authorising an SCSB to block the Bid Amount in the ASBA Account were required to submit their ASBA Forms with the
SCSBs. ASBA Bidders were required to ensure that the ASBA Account had sufficient credit balance such that an amount
equivalent to the full Bid Amount could be blocked by the SCSB or the Sponsor Bank, as applicable, at the time of submitting
the Bid.

The prescribed colour of the Bid cum Application Form for the various categories is as follows:

 

 

 

 

 

 

 

 

 

Category Colour of Bid cum
Application Form*
Resident Indians, including resident QIBs, Non-Institutional Investors, Retail Individual Bidders and Eligible White
NRIs applying on a non-repatriation basis
Eligible NRIs, FVCls, FPIs and registered bilateral and multilateral development financial institutions applying Blue
on a repatriation basis
Anchor Investors White
Eligible Employees bidding in the Employee Reservation Portion Pink
* ~~ Excluding electronic Bid cum Application Forms
Notes:

(1) Electronic Bid cum Application forms and the abridged prospectus were also made available for download on the websites of the Stock Exchanges
(www.nseindia.com and www.bseindia.com).

(2) Bid cum Application Forms for Anchor Investors were made available at the offices of the BRLMs.

(3) Bid cum Application Forms for Eligible Employees were made available at the Registered and Corporate Office of the Company.

In case of ASBA Forms, the relevant Designated Intermediaries were required to upload the relevant bid details (including UPI
ID in case of ASBA Forms under the UPI Mechanism) in the electronic bidding system of the Stock Exchanges. For RIBs using
UPI Mechanism, the Stock Exchanges shall share the Bid details (including UPI ID) with the Sponsor Bank on a continuous
basis to enable the Sponsor Bank to initiate UPI Mandate Request to RIBs for blocking of funds. For ASBA Forms (other than
RIBs) Designated Intermediaries (other than SCSBs) were required to submit/ deliver the ASBA Forms to the respective SCSB
where the Bidder had an ASBA bank account and were restricted from submitting it to any non-SCSB bank or any Escrow
Collection Bank. Stock Exchanges shall validate the electronic bids with the records of the CDP for DP ID / Client ID and
PAN, on a real time basis and bring inconsistencies to the notice of the relevant Designated Intermediaries, for rectification and
re-submission within the time specified by Stock Exchanges. Stock Exchanges were allowed modification of either DP ID /
Client ID or PAN ID, bank code and location code in the Bid details already uploaded.

For RIBs using UPI Mechanism, the Stock Exchanges were required to share the Bid details (including UPI ID) with the
Sponsor Bank on a continuous basis through API integration to enable the Sponsor Bank to initiate UPI Mandate Request to
RIBs for blocking of funds.The Sponsor Bank was required to initiate request for blocking of funds through NPCI to RIBs,
who was required to accept the UPI mandate request for blocking of funds on their respective mobile applications associated

274
with UPI ID linked bank account. For all pending UPI mandate requests, the Sponsor Bank was required to initiate requests for
blocking of funds in the ASBA Accounts of relevant Bidders with a confirmation cut-off time of 12:00 pm on the first Working
Day after the Bid/Offer Closing Date (“Cut-Off Time”). Accordingly, RIBs Bidding using through the UPI Mechanism should
accept UPI mandate requests for blocking of funds prior to the Cut-Off Time and all pending UPI mandate requests at the Cut-
Off Time shall lapse. For ensuring timely information to investors, SCSBs were required to send SMS alerts as specified in
SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular
no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021.

Participation by Promoter and Promoter Group of the Company, the BRLMs and the Syndicate Members

The BRLMs and the Syndicate Members are not allowed to purchase Equity Shares in this Offer in any manner, except towards
fulfilling their underwriting obligations. However, the associates and affiliates of the BRLMs and the Syndicate Members could
Bid for Equity Shares in the Offer, either in the QIB Portion or in the Non-Institutional Portion as was applicable to such
Bidders, where the allocation is on a proportionate basis and such subscription could be on their own account or on behalf of
their clients. All categories of investors, including associates or affiliates of the BRLMs and Syndicate Members, were required
to be treated equally for the purpose of allocation to be made on a proportionate basis.

Neither (i) the BRLMs or any associates of the BRLMs (except Mutual Funds sponsored by entities which are associates of the
BRLMs or insurance companies promoted by entities which are associate of BRLMs or AIFs sponsored by the entities which
are associate of the BRLMs or FPIs other than individuals, corporate bodies and family offices sponsored by the entities which
are associates of the BRLMs) nor; (ii) any “person related to the Promoter/ Promoter Group” shall apply in the Offer under the
Anchor Investor Portion.

For the purposes of this section, a QIB who has any of the following rights was deemed to be a “person related to the Promoter
or Promoter Group”: (a) rights under a shareholders’ agreement or voting agreement entered into with the Promoter or Promoter
Group; (b) veto rights; or (c) right to appoint any nominee director on our Board.

Further, an Anchor Investor was deemed to be an associate of the BRLMs, if: (a) either of them controls, directly or indirectly
through its subsidiary or holding company, not less than 15% of the voting rights in the other; or (b) either of them, directly or
indirectly, by itself or in combination with other persons, exercises control over the other; or (c) there is a common director,
excluding a nominee director, amongst the Anchor Investor and the BRLMs.

Except to the extent of participation in the Offer for Sale by the Promoter, the Promoter Group will not participate in the Offer.
Bids by Mutual Funds

With respect to Bids by Mutual Funds, a certified copy of their SEBI registration certificate was required to be lodged along
with the Bid cum Application Form. Failing this, our Company and the Selling Shareholders, reserve the right to reject any Bid
without assigning any reason thereof.

Bids made by asset management companies or custodians of Mutual Funds were required to specifically state names of the
concerned schemes for which such Bids are made.

In case of a Mutual Fund, a separate Bid could be made in respect of each scheme of the Mutual Fund registered with SEBI
and such Bids in respect of more than one scheme of the Mutual Fund were not treated as multiple Bids provided that the Bids
clearly indicated the scheme concerned for which the Bid was made.

No Mutual Fund scheme shall invest more than 10% of its net asset value in equity shares or equity related instruments of any
single company provided that the limit of 10% shall not be applicable for investments in case of index funds or sector or industry
specific schemes. No Mutual Fund under all its schemes should own more than 10% of any company’s paid-up share capital
carrying voting rights.

Bids by Eligible NRIs

Eligible NRIs could obtain copies of Bid cum Application Form from the Designated Intermediaries. Only Bids accompanied
by payment in Indian Rupees or freely convertible foreign exchange will be considered for Allotment. Eligible NRI Bidders
bidding on a repatriation basis by using the Non-Resident Forms could authorize their respective SCSB or confirm or accept
the UPI Mandate Request (in case of Retail Individual Investors Bidding through the UPI Mechanism) to block their Non-
Resident External (“NRE”) accounts (including UPI ID, if activated), or Foreign Currency Non-Resident (“FCNR”) Accounts,
and eligible NRI Bidders bidding on a non-repatriation basis by using Resident Forms could authorize their respective SCSB
confirm or accept the UPI mandate request (in case of RIBs using the UPI Mechanism) to block their Non-Resident Ordinary
(“NRO”) accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. NRIs applying in
the Offer through the UPI Mechanism are advised to enquire with the relevant bank, whether their account is UPI linked, prior
to submitting a Bid cum Application Form.

275
Eligible NRIs Bidding on non-repatriation basis were advised to use the Bid cum Application Form for residents (white in
colour). Eligible NRIs Bidding on a repatriation basis were advised to use the Bid cum Application Form meant for Non-
Residents (blue in colour).

Participation by Eligible NRIs in the Offer shall be subject to the FEMA Non-Debt Instruments Rules. Only Bids accompanied
by payment in Indian rupees or fully converted foreign exchange will be considered for Allotment.

In accordance with the FEMA Non-Debt Instruments Rules, the total holding by any individual NRI, on a repatriation basis,
shall not exceed 5% of the total paid-up equity capital on a fully diluted basis or shall not exceed 5% of the paid-up value of
each series of debentures or preference shares or share warrants issued by an Indian company and the total holdings of all NRIs
and OCIs put together shall not exceed 10% of the total paid-up equity capital on a fully diluted basis or shall not exceed 10%
of the paid-up value of each series of debentures or preference shares or share warrant. Provided that the aggregate ceiling of
10% may be raised to 24% if a special resolution to that effect is passed by the general body of the Indian company.

For further details, see “Restrictions on Foreign Ownership of Indian Securities” on page 286.
Bids by HUFs

Bids by HUFs Hindu Undivided Families or HUFs, were required to be made in the individual name of the karta. The
Bidder/Applicant was required to specify that the Bid is being made in the name of the HUF in the Bid cum Application
Form/Application Form as follows: “Name of sole or first Bidder/Applicant: XYZ Hindu Undivided Family applying through
XYZ, where XYZ is the name of the karta”. Bids/Applications by HUFs were considered at par with Bids/Applications from
individuals.

Bids by FPIs

In terms of the SEBI FPI Regulations, the investment in Equity Shares by a single FPI or an investor group (which means
multiple entities registered as FPIs and directly or indirectly having common ownership of more than 50% or common control)
must be below 10% of our post-Offer Equity Share capital. Further, in terms of the FEMA Non-Debt Instruments Rules, the
total holding by each FPI or an investor group shall be below 10% of the total paid-up Equity Share capital of our Company
and the total holdings of all FPIs put together with effect from April 1, 2020, can be up to the sectoral cap applicable to the
sector in which our Company operates (i.e., up to 100%). In terms of the FEMA Non-Debt Instruments Rules, for calculating
the aggregate holding of FPIs in a company, holding of all registered FPIs shall be included.

In case of Bids made by FPIs, a certified copy of the certificate of registration issued under the SEBI FP! Regulations is required
to be attached to the Bid cum Application Form, failing which our Company reserves the right to reject any Bid without
assigning any reason.

To ensure compliance with the above requirement, SEBI, pursuant to its circular dated July 13, 2018, has directed that at the
time of finalisation of the Basis of Allotment, the Registrar shall (i) use the PAN issued by the Income Tax Department of India
for checking compliance for a single FPI; and (ii) obtain validation from Depositories for the FPIs who have invested in the
Offer to ensure there is no breach of the investment limit, within the timelines for issue procedure, as prescribed by SEBI from
time to time.

A FPI may purchase or sell equity shares of an Indian company which is listed or to be listed on a recognized stock exchange
in India, and/ or may purchase or sell securities other than equity instruments

FPIs were permitted to participate in the Offer subject to compliance with conditions and restrictions which may be specified
by the Government from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 21 of
the SEBI FPI Regulations, an FPI, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under
the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held
by it in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only
by persons registered as Category I FPIs; (ii) such offshore derivative instruments are issued only to persons eligible for
registration as Category I FPIs; (iii) such offshore derivative instruments are issued after compliance with “know your client’
norms; and (iv) such other conditions as may be specified by SEBI from time to time.

In case the total holding of an FPI increases beyond 10% of the total paid-up Equity Share capital, on a fully diluted basis or
10% or more of the paid-up value of any series of debentures or preference shares or share warrants issued that may be issued
by our Company, the total investment made by the FPI will be re-classified as FDI subject to the conditions as specified by
SEBI and the RBI in this regard and our Company and the investor will be required to comply with applicable reporting
requirements.

An FPI issuing offshore derivate instruments is also required to ensure that any transfer of offshore derivative instrument is
made by, or on behalf of it subject to, inter alia, the following conditions:

276
(a) each offshore derivative instruments are transferred to persons subject to fulfilment of SEBI FPI Regulations; and

(b) prior consent of the FPI is obtained for such transfer, except when the persons to whom the offshore derivative instruments
are to be transferred to are pre-approved by the FPI.

The FPIs who wish to participate in the Offer are advised to use the Bid cum Application Form for non-residents.

Further, Bids received from FPIs bearing the same PAN were treated as multiple Bids and are liable to be rejected, except for
Bids from FPIs that utilize the multiple investment manager structure in accordance with the Operational Guidelines for Foreign
Portfolio Investors and Designated Depository Participants which were issued in November 2019 to facilitate implementation
of SEBI (Foreign Portfolio Investors) Regulations, 2019 (such structure “MIM Structure”) provided such Bids have been
made with different beneficiary account numbers, Client IDs and DP IDs. Accordingly, it should be noted that multiple Bids
received from FPIs, who do not utilize the MIM Structure, and bear the same PAN, are liable to be rejected. In order to ensure
valid Bids, FPIs making multiple Bids using the same PAN, and with different beneficiary account numbers, Client IDs and
DP IDs, were required to provide a confirmation along with each of their Bid cum Application Forms that the relevant FPIs
making multiple Bids utilize the MIM Structure and indicate the names of their respective investment managers in such
confirmation. In the absence of such confirmation from the relevant FPIs, such multiple Bids will be rejected.

Bids by SEBI registered VCFs, AIFs and FVCIs

The SEBI AIF Regulations prescribe, amongst others, the investment restrictions on AIFs. Post the repeal of the SEBI VCF
Regulations venture capital funds which have not re-registered as AIFs under the SEBI AIF Regulations shall continue to be
regulated by the SEBI VCF Regulations until the existing fund or scheme managed by the fund is wound up and such fund shall
not launch any new scheme after the notification of the SEBI AIF Regulations. The SEBI FVCI Regulations prescribe the
investment restrictions on FVCIs.

Accordingly, the holding in any company by any individual VCF or FVCIs registered with SEBI should not exceed 25% of the
corpus of the VCF or FVCI. Further, VCFs and FVCIs can invest only up to 33.33% of the investible funds in various prescribed
instruments, including in public offering.

Category I and II AIFs cannot invest more than 25% of the investible funds in one investee company. A Category III AIF cannot
invest more than 10% of the investible funds in one investee company. A VCF registered as a Category I AIF, as defined in the
SEBI AIF Regulations, cannot invest more than one-third of its investible funds by way of subscription to an initial public
offering of a venture capital undertaking whose shares are proposed to be listed. Additionally, the VCFs which have not re-
registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the SEBI VCF Regulations until the
existing fund or scheme managed by the fund is wound up and such funds shall not launch any new scheme after the notification
of the SEBI AIF Regulations.

Participation of AIFs, VCFs and FVCIs shall be subject to the FEMA Rules

All non-resident investors should note that refunds (in case of Anchor Investors), dividends and other distributions, if
any, will be payable in Indian Rupees only and net of bank charges and commission.

Our Company, the Selling Shareholders or the BRLMs will not be responsible for loss, if any, incurred by the Bidder on account
of conversion of foreign currency.

Bids by Eligible Employees
Bids under Employee Reservation Portion by Eligible Employees were:
(a) Made only in the prescribed Bid cum Application Form or Revision Form (i.e. Pink colour form).

(b) The Bid were for a minimum of 28 Equity Shares and in multiples of 28 Equity Shares thereafter so as to ensure that
the Bid Amount payable by the Eligible Employee did not exceed 500,000 (net of Employee Discount). However, a
Bid by an Eligible Employee in the Employee Reservation Portion was required to be considered for allocation, in the
first instance, for a Bid amounting up to 200,000 (net of Employee Discount). In the event of any under-subscription
in the Employee Reservation Portion, the unsubscribed portion was required to be available for allocation and
Allotment, proportionately to all Eligible Employees, who have bid in excess of 200,000 (net of Employee Discount),
provided however that the maximum Bid in this category by an Eligible Employee could not exceed %500,000 (net of
Employee Discount).

(©) The Bidder were required to been Eligible Employee as defined above in this Prospectus. In case of joint bids, the first
Bidder was required to be an Eligible Employee.

(d) Only Eligible Employees were eligible to apply in this Offer under the Employee Reservation Portion.

(e) Only those Bids, which were received at or above the Offer Price, were considered for allocation under this category.

277
(6) Eligible Employees could apply at Cut-off Price.

(g) Bids by Eligible Employees could be made also in the “Net Offer to the Public” and such Bids were required to not be
treated as multiple Bids.

If the aggregate demand in this category is less than or equal to 150,000" Equity Shares at or above the Offer Price, full

allocation shall be made to the Eligible Employees to the extent of their demand.
“Subject to finalisation of the Basis of Allotment
‘A discount of 852 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.

(h) Under-subscription, if any, in the Employee Reservation Portion is required to be added back to the Net Offer.
@ Eligible Employees were not required to Bid through the UPI Mechanism in the Employee Reservation Portion.

In case of under-subscription in the Net Offer, spill over to the extent of under-subscription was required to be permitted from
the Employee Reservation Portion subject to the Net Offer constituting 34.85% of the post-Offer share capital of our Company.
If the aggregate demand in this category was greater than 150,000” Equity Shares at or above the Offer Price, the allocation
was required to be made on a proportionate basis.

“Subject to finalisation of the Basis of Allotment
“A discount of %52 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.

Bids by limited liability partnerships

In case of Bids that were made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a
certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, was required to be attached
to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders in consultation with the BRLMs
reserved the right to reject any Bid without assigning any reason thereof.

Bids by banking companies

In case of Bids made by banking companies registered with RBI, certified copies of: (i) the certificate of registration issued by
RBI, and (ii) the approval of such banking company’s investment committee were required to be attached to the Bid cum
Application Form, failing which our Company and the Selling Shareholders in consultation with the BRLMs reserved the right
to reject any Bid without assigning any reason. The investment limit for banking companies in non-financial services companies
shall be in accordance with the Banking Regulation Act, 1949 and the Master Direction — Reserve Bank of India (Financial
Services provided by Banks) Directions, 2016.

Bids by SCSBs

SCSBs participating in the Offer were required to comply with the terms of the SEBI circulars (Nos. CIR/CFD/DIL/12/2012
and CIR/CFD/DIL/1/2013) dated September 13, 2012 and January 2, 2013. Such SCSBs are required to ensure that for making
applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI
registered SCSBs. Further, such account was required to be used solely for the purpose of making application in public issues
and clear demarcated funds were required to be available in such account for such applications.

Bids by insurance companies

In case of Bids made by insurance companies registered with the IRDAI, a certified copy of certificate of registration issued by
IRDAI was required to be attached to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders
in consultation with the BRLMs reserved the right to reject any Bid without assigning any reason thereof.

The exposure norms for insurers, prescribed under the Insurance Regulatory and Development Authority (Investment)
Regulations, 2016 as amended are broadly set forth below:

(a) equity shares of a company: the lower of 10%” of the outstanding equity shares (face value) or 10% of the respective
fund in case of life insurer or 10% of investment assets in case of general insurer or reinsurer;

(b) the entire group of the investee company: not more than 15% of the respective fund in case of a life insurer or 15% of
investment assets in case of a general insurer or reinsurer or 15% of the investment assets in all companies belonging
to the group, whichever is lower; and

(©) the industry sector in which the investee company operates: not more than 15% of the fund of a life insurer or a general
insurer or a reinsurer or 15% of the investment asset, whichever is lower.

The maximum exposure limit, in the case of an investment in equity shares, cannot exceed the lower of an amount of 10% of

the investment assets of a life insurer or general insurer and the amount calculated under (a), (b) and (c) above, as the case may
be.

278
The above limit of 10% shall stand substituted as 15% of outstanding equity shares (face value) for insurance companies with investment
assets of 22,500,000 million or more and 12% of outstanding equity shares (face value) for insurers with investment assets of 2500,000
million or more but less than 2,500,000 million.

 

Insurance companies participating in this Offer were required to comply with all applicable regulations, guidelines and circulars
issued by IRDAI from time to time.

Bids by provident funds/pension funds

In case of Bids made by provident funds/pension funds, subject to applicable laws, with minimum corpus of 2250 million, a
certified copy of a certificate from a chartered accountant certifying the corpus of the provident fund/pension fund was required
to be attached to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders in consultation with
the BRLMs reserved the right to reject any Bid, without assigning any reason thereof.

Bids under power of attorney

In case of Bids made pursuant to a power of attorney or by limited companies, corporate bodies, registered societies, Eligible
FPIs, Mutual Funds, insurance companies, NBFC-SI insurance funds set up by the army, navy or air force of India, insurance
funds set up by the Department of Posts, India or the National Investment Fund and provident funds with a minimum corpus of
2250 million and pension funds with a minimum corpus of 2250 million, in each case, subject to applicable law and in
accordance with their respective constitutional documents, a certified copy of the power of attorney or the relevant resolution
or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or
bye laws was required to be lodged along with the Bid cum Application Form. Failing this, our Company and the Selling
Shareholders in consultation with the BRLMs reserved the right to accept or reject any Bid in whole or in part, in either case,
without assigning any reason thereof.

Our Company and the Selling Shareholders in consultation with the BRLMs in their absolute discretion, reserve the right to
relax the above condition of simultaneous lodging of the power of attorney along with the Bid cum Application Form subject
to such terms and conditions that our Company and the Selling Shareholders in consultation with the BRLMs may deem fit.

Bids by Systemically Important Non-Banking Financial Companies

In case of Bids made by Systemically Important NBFCs registered with RBI, certified copies of: (i) the certificate of registration
issued by RBI, (ii) certified copy of its last audited financial statements on a standalone basis and a net worth certificate from
its statutory auditor, and (iii) such other approval as may be required by the Systemically Important NBFCs, were required to
be attached to the Bid cum Application Form. Failing this, our Company and the Selling Shareholders in consultation with the
BRLMs, reserved the right to reject any Bid without assigning any reason thereof. Systemically Important NBFCs participating
in the Offer shall comply with all applicable regulations, guidelines and circulars issued by RBI from time to time.

The investment limit for Systemically Important NBFCs shall be as prescribed by RBI from time to time.

The above information is given for the benefit of the Bidders. Our Company, the Selling Shareholders and the members
of the Syndicate are not liable for any amendments or modification or changes in applicable laws or regulations, which
may occur after the date of the Red Herring Prospectus or may occur after the date of the Prospectus. Bidders were
advised to make their independent investigations and ensure that any single Bid from them did not exceed the applicable
investment limits or maximum number of the Equity Shares that can be held by them under applicable law or regulation
or as specified in the Red Herring Prospectus and this Prospectus.

In accordance with existing regulations issued by the RBI, OCBs could not participate in this Offer.

General Instructions

Do’s:

1. Check if you are eligible to apply as per the terms of the Red Herring Prospectus and under applicable law, rules,
regulations, guidelines and approvals. All Bidders (other than Anchor Investors) should submit their Bids through the
ASBA process only;

2. Ensure that you have Bid within the Price Band;

3. Read all the instructions carefully and complete the Bid cum Application Form, as the case may be, in the prescribed
form;

4. Ensure that you (other than Anchor Investors) have mentioned the correct ASBA Account number and such ASBA

account belongs to you and no one else if you are not an RIB bidding using the UPI Mechanism in the Bid cum
Application Form (with maximum length of 45 characters) and if you are an RIB using the UPI Mechanism ensure that
you have mentioned the correct UPI ID in the Bid cum Application Form;

279
10.

11.

12.

13.

14.

15,

16.

17.

18.

19.

20.

Ensure that your Bid cum Application Form bearing the stamp of a Designated Intermediary is submitted to the
Designated Intermediary at the Bidding Centre within the prescribed time. Retail Individual Bidders using UPI
Mechanism, may submit their ASBA Forms with Syndicate Members, Registered Brokers, RTAs or CDPs and should
ensure that the ASBA Form contains the stamp of such Designated Intermediary;

Ensure that you have funds equal to the Bid Amount in the ASBA Account maintained with the SCSB, before
submitting the ASBA Form to any of the Designated Intermediaries;

In case of joint Bids, ensure that first Bidder is the ASBA Account holder (or the UPI-linked bank account holder, as
the case may be) and the signature of the first Bidder is included in the Bid cum Application Form;

Ensure that you request for and receive a stamped acknowledgement counterfoil by specifying the application number
for all your Bid options as proof of registration of the Bid cum Application Form for all your Bid options from the
concerned Designated Intermediary;

If the first Bidder is not the ASBA Account holder (or the UPI-linked bank account holder, as the case may be), ensure
that the Bid cum Application Form is signed by the ASBA Account holder (or the UPI-linked bank account holder, as
the case may be;

Ensure that the name(s) given in the Bid cum Application Form is/are exactly the same as the name(s) in which the
beneficiary account is held with the Depository Participant. In case of joint Bids, the Bid cum Application Form should
contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account
held in joint names. Ensure that the signature of the First Bidder is included in the Bid cum Application Forms. PAN
of the First Bidder is required to be specified in case of joint Bids;

RIBs bidding in the Offer to ensure that they shall use only their own ASBA Account or only their own bank account
linked UPI ID which is UPI 2.0 certified by NPCI (only for RIBs using the UPI Mechanism) to make an application
in the Offer and not ASBA Account or bank account linked UPI ID of any third party;

Ensure that you submit the revised Bids to the same Designated Intermediary, through whom the original Bid was
placed and obtain a revised acknowledgment;

Retail Individual Bidders not using the UPI Mechanism, should submit their Bid cum Application Form directly with
SCSBs and not with any other Designated Intermediary;

Ensure that you have correctly signed the authorisation/undertaking box in the Bid cum Application Form, or have
otherwise provided an authorisation to the SCSB or Sponsor Bank, as applicable, via the electronic mode, for blocking
funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form, as the case
may be, at the time of submission of the Bid. In case of RIBs submitting their Bids and participating in the Offer
through the UPI Mechanism, ensure that you authorise the UPI Mandate Request raised by the Sponsor Bank for
blocking of funds equivalent to Bid Amount and subsequent debit of funds in case of Allotment;

Except for Bids (i) on behalf of the Central or State Governments and the officials appointed by the courts, who, in
terms of the SEBI circular dated June 30, 2008, may be exempt from specifying their PAN for transacting in the
securities market, (ii) submitted by Bidders who are exempt from the requirement of obtaining/specifying their PAN
for transacting in the securities market, and (iii) Bids by persons resident in the state of Sikkim, who, in terms of a
SEBI circular dated July 20, 2006, may be exempted from specifying their PAN for transacting in the securities market,
all Bidders should mention their PAN allotted under the IT Act. The exemption for the Central or the State Government
and officials appointed by the courts and for investors residing in the State of Sikkim is subject to (a) the Demographic
Details received from the respective depositories confirming the exemption granted to the beneficiary owner by a
suitable description in the PAN field and the beneficiary account remaining in “active status”; and (b) in the case of
residents of Sikkim, the address as per the Demographic Details evidencing the same. All other applications in which
PAN is not mentioned were liable to be rejected;

Ensure that the Demographic Details are updated, true and correct in all respects;

Ensure that thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the
Constitution of India are attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official
seal;

Ensure that the category and the investor status is indicated in the Bid cum Application Form;

Ensure that in case of Bids under power of attorney or by limited companies, corporates, trust, etc., relevant documents
are submitted;

Ensure that Bids submitted by any person resident outside India is in compliance with applicable foreign and Indian
laws;

280
21. Ensure that the Bidder’s depository account is active, the correct DP ID, Client ID, the PAN, UPI ID, if applicable,
are mentioned in their Bid cum Application Form and that the name of the Bidder, the DP ID, Client ID, the PAN and
UPI ID, if applicable, entered into the online IPO system of the Stock Exchanges by the relevant Designated
Intermediary, as applicable, matches with the name, DP ID, Client ID, PAN and UPI ID, if applicable, available in the
Depository database;

22, Ensure that when applying in the Offer using UPI, the name of your SCSB appears in the list of SCSBs displayed on
the SEBI website which are live on UPI. Further, also ensure that the name of the mobile application and the UPI
handle being used for making the application in the Offer is also appearing in the “list of mobile applications for using
UPI in public issues” displayed on the SEBI website;

23. RIBs who wish to revise their Bids using the UPI Mechanism, should submit the revised Bid with the Designated
Intermediaries, pursuant to which RIBs should ensure acceptance of the UPI Mandate Request received from the
Sponsor Bank to authorise blocking of funds equivalent to the revised Bid Amount in the RIB’s ASBA Account;

24, Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 12:00 p.m. of the
Working Day immediately after the Bid/ Offer Closing Date;

25. RIBs shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate
Request and then proceed to authorize the UPI Mandate Request using his/her UPI PIN. Upon the authorization of the
mandate using his/her UPI PIN, an RIB may be deemed to have verified the attachment containing the application
details of the RIB in the UPI Mandate Request and have agreed to block the entire Bid Amount and authorized the
Sponsor Bank to block the Bid Amount mentioned in the Bid Cum Application Form;

26. Ensure that Anchor Investors submit their Bid cum Application Forms only to the BRLMs;

27. FPIs making MIM Bids using the same PAN, and different beneficiary account numbers, Client IDs and DP IDs, are
required to submit a confirmation that their Bids are under the MIM structure and indicate the name of their investment
managers in such confirmation which shall be submitted along with each of their Bid cum Application Forms. In the
absence of such confirmation from the relevant FPIs, such MIM Bids shall be rejected; and

28. Ensure that while Bidding through a Designated Intermediary, the Bid cum Application Form (other than for Anchor
Investors and RIBs bidding using the UPI Mechanism) is submitted to a Designated Intermediary in a Bidding Centre
and that the SCSB where the ASBA Account, as specified in the ASBA Form, is maintained has named at least one
branch at that location for the Designated Intermediary to deposit ASBA Forms (a list of such branches is available on
the website of SEBI at www.sebi.gov.in).

The Bid cum Application Form was liable to be rejected if the above instructions, as applicable, were not complied with.
Application made using incorrect UPI handle or using a bank account of an SCSB or SCSBs which is not mentioned in the
Annexure ‘A’ to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 were liable to be rejected.

Don'ts:

1 Do not Bid for lower than the minimum Bid size;

2. Do not Bid for a Bid Amount exceeding 2200,000 (for Bids by Retail Individual Bidders) and 500,000 (for Bids by
Eligible Employees);

3. Do not pay the Bid Amount in cheques, demand drafts or by cash, money order, postal order or by stock invest;

4. Do not send Bid cum Application Forms by post; instead submit the same to the Designated Intermediary only;

5. Do not Bid at Cut-off Price (for Bids by QIBs and Non-Institutional Bidders);

6. Do not instruct your respective banks to release the funds blocked in the ASBA Account under the ASBA process;

Z. Do not submit the Bid for an amount more than funds available in your ASBA account.

8. Do not submit Bids on plain paper or on incomplete or illegible Bid cum Application Forms or on Bid cum Application

Forms in a colour prescribed for another category of a Bidder;
9. In case of ASBA Bidders, do not submit more than one ASBA Forms per ASBA Account;
10. If you are a RIB and are using UPI mechanism, do not submit more than one ASBA Form for each UPI ID;

1. Anchor Investors should not Bid through the ASBA process;

281
12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24,

25.

26.

27.

28.

29.

30.

31.

32.

Do not submit the ASBA Forms to any Designated Intermediary that is not authorised to collect the relevant ASBA
Forms or to our Company;

Do not Bid on a Bid cum Application Form that does not have the stamp of the relevant Designated Intermediary;
Do not submit the General Index Register (GIR) number instead of the PAN;

Do not submit incorrect details of the DP ID, Client ID, PAN and UPI ID, if applicable, or provide details for a
beneficiary account which is suspended or for which details cannot be verified by the Registrar to the Offer;

Do not submit a Bid in case you are not eligible to acquire Equity Shares under applicable law or your relevant
constitutional documents or otherwise;

Do not Bid if you are not competent to contract under the Indian Contract Act, 1872 (other than minors having valid
depository accounts as per Demographic Details provided by the depository);

Do not submit a Bid/revise a Bid Amount, with a price less than the Floor Price or higher than the Cap Price;

Do not submit your Bid after 3.00 pm on the Bid/Offer Closing Date;

If you are a QIB, do not submit your Bid after 3:00 pm on the QIB Bid/Offer Closing Date;

Do not Bid on another ASBA Form after you have submitted a Bid to any of the Designated Intermediaries;

Do not Bid for Equity Shares in excess of what is specified for each category;

Do not fill up the Bid cum Application Form such that the Equity Shares Bid for, exceeds the Offer size and/or
investment limit or maximum number of the Equity Shares that can be held under applicable laws or regulations or
maximum amount permissible under applicable laws or regulations, or under the terms of the Red Herring Prospectus;
Do not submit the Bid without ensuring that funds equivalent to the entire Bid Amount are available for blocking in
the relevant ASBA Account or in the case of Retail Individual Bidders Bidding using the UPI Mechanism, in the UPI-
linked bank account where funds for making the Bid are available;

Do not withdraw your Bid or lower the size of your Bid (in terms of quantity of the Equity Shares or the Bid Amount)
at any stage, if you are a QIB or a Non-Institutional Bidder. Retail Individual Bidders and Eligible Employees Bidding
in the Employee Reservation Portion can revise or withdraw their Bids on or before the Bid/ Offer Closing Date;

Do not submit Bids to a Designated Intermediary at a location other than the Bidding Centres;

If you are an RIB which is submitting the ASBA Form with any of the Designated Intermediaries and using your UPI
ID for the purpose of blocking of funds, do not use any third party bank account or third party linked bank account
UPI ID;

Do not Bid if you are an OCB;

Do not link the UPI ID with a bank account maintained with a bank that is not UPI 2.0 certified by the NPCI in case
of Bids submitted by RIBs using the UPI Mechanism;

Do not submit more than one Bid cum Application Form for each UPI ID in case of RIBs Bidding using the UPI
Mechanism;

Do not submit a Bid cum Application Form with a third party UPI ID or using a third party bank account (in case of
Bids submitted by Retail Individual Bidders using the UPI Mechanism); and

RIBs Bidding through the UPI Mechanism using the incorrect UPI handle or using a bank account of an SCSB or a
bank which is not mentioned in the list provided in the SEBI website is liable to be rejected; and

The Bid cum Application Form was liable to be rejected if the above instructions, as applicable, were not complied with.

Further, in case of any pre-Offer or post Offer related issues regarding share certificates/demat credit/refund orders/unblocking
etc., investors shall reach out to our Company Secretary and Compliance Officer. For details of Company Secretary and
Compliance Officer, see “General Information —- Company Secretary and Compliance Officer” on page 48.

For details of grounds for technical rejections of a Bid cum Application Form, please see the General Information Document.

Further, helpline details of the BRLMs pursuant to the SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 are
set forth in the table below:

282
 

 

 

 

 

 

 

 

S.No. Name of BRLM Enmail

1. ICICI Securities Limited vijaya.ipo@icicisecurities.com

2. Edelweiss Financial Services Limited vijayadiagnostic.ipo@edelweissfin.com
3. Kotak Mahindra Capital Company Limited vijayadiagnostic.ipo@kotak.com

 

Names of entities responsible for finalising the basis of allotment in a fair and proper manner

The authorised employees of the Stock Exchanges, along with the BRLMs and the Registrar, shall ensure that the basis of
allotment is finalised in a fair and proper manner in accordance with the procedure specified in SEBI ICDR Regulations.

Method of allotment as may be prescribed by SEBI from time to time

Our Company will not make any allotment in excess of the Equity Shares through the Offer Document except in case of
oversubscription for the purpose of rounding off to make allotment, in consultation with the Designated Stock Exchange.
Further, upon oversubscription, an allotment of not more than 1% of the Offer may be made for the purpose of making allotment
in minimum lots.

The allotment of Equity Shares to applicants other than to the Retail Individual Bidders and Anchor Investors shall be on a
proportionate basis within the respective investor categories and the number of securities allotted shall be rounded off to the
nearest integer, subject to minimum allotment being equal to the minimum application size as determined and disclosed.

The allotment of Equity Shares to each Retail Individual Bidders shall not be less than the minimum bid lot, subject to the
availability of shares in Retail Individual Bidders Portion, and the remaining available shares, if any, shall be allotted on a
proportionate basis.

Payment into Escrow Account(s) for Anchor Investors

Our Company and the Selling Shareholders in consultation with the BRLMs, in their absolute discretion, has decided the list of
Anchor Investors to whom the CAN will be sent, pursuant to which the details of the Equity Shares allocated to them in their
respective names were notified to such Anchor Investors. Anchor Investors are not permitted to Bid in the Offer through the
ASBA process. Instead, Anchor Investors should transfer the Bid Amount (through direct credit, RTGS, NACH or NEFT) to
the Escrow Accounts. For Anchor Investors, the payment instruments for payment into the Escrow Account(s) were required
to be drawn in favour of:

(a) In case of resident Anchor Investors: “Vijaya Diagnostics Centre Ltd. - Anchor Resident Account”
(b) In case of Non-Resident Anchor Investors: “Vijaya Diagnostics Centre Ltd — Non Resident Anchor Account”

Anchor Investors should note that the escrow mechanism is not prescribed by SEBI and has been established as an arrangement
between our Company, the Selling Shareholders, the Syndicate, the Escrow Collection Bank and the Registrar to the Offer to
facilitate collections of Bid amounts from Anchor Investors.

Pre-Offer Advertisement

Our Company shall, after filing the Red Herring Prospectus with the RoC, published a pre-Offer advertisement, in the form
prescribed by the SEBI ICDR Regulations, in: (i) all editions of Financial Express, a widely circulated English national daily
newspaper; (ii) all editions of Jansatta, a Hindi national daily newspaper; and (iii) Hyderabad editions of Surya Telugu Daily,
a widely circulated Telugu national daily newspaper, Telugu also being the regional language of Telangana, where our
Registered Office is located), each with wide circulation.

In the pre-Offer advertisement, we stated the Bid/ Offer Opening Date and the Bid/ Offer Closing Date and the QIB Bid/Offer
Closing Date. This advertisement, subject to the provisions of Section 30 of the Companies Act, was in the format prescribed
in Part A of Schedule X of the SEBI ICDR Regulations.

The above information is given for the benefit of the Bidders/applicants. Our Company, the Selling Shareholders and
the members of the Syndicate are not liable for any amendments or modification or changes in applicable laws or
regulations, which may occur after the date of the Red Herring Prospectus and which may occur after the date of this
Prospectus. Bidders/applicants were advised to make their independent investigations and ensure that the number of
Equity Shares Bid for did not exceed the prescribed limits under applicable laws or regulations and as specified in this
Prospectus.

Signing of the Underwriting Agreement and the RoC Filing

(a) Our Company, the Selling Shareholders and the Syndicate have entered into an Underwriting Agreement.

283
(b)

After signing the Underwriting Agreement, an updated Red Herring Prospectus is being filed with the RoC in
accordance with applicable law, which is termed as the ‘Prospectus’. The Prospectus contain details of the Offer Price,
the Anchor Investor Offer Price, Offer size, and underwriting arrangements and is complete in all material respects.

Depository Arrangements

The Allotment of the Equity Shares in the Offer shall be only in a dematerialised form, (i.e., not in the form of physical
certificates but be fungible and be represented by the statement issued through the electronic mode). For more information, see
“Terms of the Offer” on page 265.

Undertakings by our Company

Our Company undertakes the following:

adequate arrangements were made to collect all Bid cum Application Forms submitted by Bidders.
the complaints received in respect of the Offer shall be attended to by our Company expeditiously and satisfactorily;

all steps for completion of the necessary formalities for listing and commencement of trading at the Stock Exchanges
where the Equity Shares are proposed to be listed shall be taken within six Working Days of the Bid/ Offer Closing
Date or such other period as may be prescribed;

if Allotment is not made within the prescribed time period under applicable law, the entire subscription amount
received will be refunded/unblocked within the time prescribed under applicable law. If there is delay beyond the
prescribed time, our Company shall pay interest prescribed under the Companies Act, the SEBI ICDR Regulations
and applicable law for the delayed period;

the funds required for making refunds (to the extent applicable) as per the mode(s) disclosed shall be made available
to the Registrar to the Offer by our Company;

where refunds (to the extent applicable) are made through electronic transfer of funds, a suitable communication shall
be sent to the unsuccessful Bidder within six Working Days from the Bid/ Offer Closing Date or such other prescribed
under applicable law, giving details of the bank where refunds shall be credited along with amount and expected date
of electronic credit of refund;

Promoters’ contribution, if any, shall be brought in advance before the Bid/ Offer Opening Date and the balance, if
any, shall be brought in on a pro rata basis before calls are made on the Allottees;

Except for Equity Shares that may be allotted pursuant to the conversion of employee stock options granted under
ESOP 2001, no further issue of Equity Shares shall be made till the Equity Shares offered through the Red Herring
Prospectus and this Prospectus are listed or until the Bid monies are unblocked in ASBA Account/refunded on account
of non-listing, under-subscription, etc.

Undertakings by the Selling Shareholders

Each Selling Shareholder severally and not jointly undertakes that:

the Equity Shares being sold by it pursuant to the Offer have been held by them for a period of at least one year prior
to the date of filing this Prospectus with SEBI, are fully paid-up and are in dematerialised form;

they shall provide all reasonable co-operation as requested by our Company in relation to the completion of allotment
and dispatch of the Allotment Advice and CAN, if required, and refund orders to the extent of their respective portion
of Offered Shares pursuant to the Offer;

they are the legal and beneficial owner of the Equity Shares which are offered by them pursuant to the Offer for Sale
and are free and clear of any pre-emptive rights, liens, charges, pledges, or transfer restrictions;

that they shall provide such reasonable support and extend such reasonable cooperation as may be required by our
Company and the BRLMs in redressal of such investor grievances that pertain to the extent of their respective portion
of Offered Shares pursuant to the Offer;

they shall deposit their respective portions of Offered Shares in an escrow demat in accordance with the share escrow
agreement to be executed between the parties to such share escrow agreement;

they are not debarred from accessing the capital markets or debarred from buying, selling or dealing in securities
under any order or direction passed by the SEBI;

284
. it shall not have recourse to the proceeds of the Offer, which shall be held in escrow in its favour, until final approval
for trading of the Equity Shares from the Stock Exchanges where listing is sought has been received.

. The filing of this Prospectus does not absolve the Selling Shareholders from any liabilities to the extent of the
statements specifically made or confirmed by themselves in respect of themselves and of their respective Offered
Shares, under Section 34 or Section 36 of Companies Act, 2013.

Utilisation of Offer Proceeds

Our Company and the Selling Shareholders, severally and not jointly, specifically confirm that all monies received out of the

Offer shall be credited/transferred to a separate bank account other than the bank account referred to in sub-section (3) of
Section 40 of the Companies Act.

285
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991 of the Government of India and FEMA.
While the Industrial Policy, 1991 prescribes the limits and the conditions subject to which foreign investment can be made in
different sectors of the Indian economy, FEMA regulates the precise manner in which such investment may be made. Under
the Industrial Policy, unless specifically restricted, foreign investment is freely permitted in all sectors of the Indian economy
up to any extent and without any prior approvals, but the foreign investor is required to follow certain prescribed procedures
for making such investment. The RBI and the concerned ministries/departments are responsible for granting approval for
foreign investment under the FDI Policy and FEMA.

The Government has from time to time made policy pronouncements on foreign direct investment (“FDI”) through press notes
and press releases. The Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry,
Government of India (earlier known as Department of Industrial Policy and Promotion) (“DPIIT”), issued the FDI Policy,
which is effective from October 15, 2020 (the “FDI Policy”), which subsumes and supersedes all previous press notes, press
releases and clarifications on FDI issued by the DPIIT that were in force and effect prior to October 15, 2020. The FDI Policy
will be valid until the DPIIT issues an updated circular. FDI in companies engaged in sectors/ activities which are not listed in
the FDI Policy is permitted up to 100% of the paid-up share capital of such company under the automatic route, subject to
compliance with certain prescribed conditions. For details, see “Key Regulations and Policies” on page 127.

The transfer of shares between an Indian resident and a non-resident does not require the prior approval of the RBI, provided
that (i) the activities of the investee company are under the automatic route under the FDI policy and transfer does not attract
the provisions of the Takeover Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI policy;
and (iii) the pricing is in accordance with the guidelines prescribed by the SEBI/RBI.

As per the existing policy of the Government of India, OCBs were not permitted to participate in this Offer. For details, see
“Offer Procedure” on page 272.

Further, in accordance with Press Note No. 3 (2020 Series), dated April 17, 2020 issued by the DPIIT and the FEMA Non-Debt
Instruments Rules, any investment, subscription, purchase or sale of equity instruments by entities of a country which shares
land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country,
will require prior approval of the Government of India, as prescribed in the FDI Policy and the FEMA Non-Debt Instruments
Rules. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India,
directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent
change in the beneficial ownership will also require approval of the Government of India. Each Bidder should seek independent
legal advice about its ability to participate in the Offer. In the event such prior approval of the Government of India is required,
and such approval has been obtained, the Bidder shall intimate our Company and the Registrar in writing about such approval
along with a copy thereof within the Offer Period.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933,
as amended (the “U.S. Securities Act”), or any other applicable law of the United States and, unless so registered, may
not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject
to, the registration requirements of the U.S. Securities Act and the applicable state securities laws. Accordingly, the
Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified
institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities
Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under
the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be
no public offering of Equity Shares in the United States.

The above information is given for the benefit of the Bidders. Our Company, the Selling Shareholders and the BRLMs are not
liable for any amendments or modification or changes in applicable laws or regulations, which have occurred after the date of
the Red Herring Prospectus and this Prospectus. Bidders were advised to make their independent investigations and ensure that
the number of Equity Shares Bid for did not exceed the applicable limits under laws or regulations.

286
SECTION VIII: DESCRIPTION OF EQUITY SHARES AND TERMS OF ARTICLES OF ASSOCIATION

Capitalized terms used in this section have the meanings that have been given to such terms in the Articles of Association of
our Company. Pursuant to Schedule I of the Companies Act and the SEBI ICDR Regulations, the main provisions of the Articles
of Association of our Company are detailed below:

The Articles of Association of the Company comprise of two parts, Part A and Part B, which parts shall, unless the context
otherwise requires, co-exist with each other. In case of any conflict, inconsistency or contradiction between Part A and Part
B, the provisions of Part B shall prevail and override. However, Part B shall automatically terminate and cease to have any
force and effect (save and except as expressly set out therein) from the date of Listing of Equity Shares of the Company on a
Recognized Stock Exchange (as defined in Part B) without any further action, including any corporate action, by the Company
or by the Shareholders.

Authorised Share Capital

The authorized share capital of the Company shall be such amount, divided into such class(es), denomination(s) and number of
shares in the Company as stated in Clause V of the MoA or as altered from time to time, with power to increase or reduce such
capital from time to time and power to divide the shares in the capital for the time being into other classes and to attach thereto
such preferential, convertible, deferred, qualified, or other special rights, privileges, conditions or restrictions and to vary,
modify or abrogate the same in such manner as may be determined by or in accordance with the Articles of the Company
Alteration of Capital

Power to sub-divide, consolidate and cancel share certificate.

The Company may, by Ordinary Resolution, from time to time, alter the conditions of MoA as follows:

a. Increase the share capital by such amount to be divided into shares of such amount as it thinks expedient;

b. Consolidate and divide all or any its share capital into shares of larger amount than its existing shares; provided that

any consolidation and division which results in changes in the voting percentage of Members shall require applicable
approvals under the Act;

c. Sub-divide its existing shares or any of them into shares of smaller amount than is fixed by MoA;

d. Cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any
person; and

e. Convert all or any one its fully paid-up shares into stock and reconvert that stock into fully paid-up shares of any
denomination.

Allotment of Shares

Subject to the provisions of the Act and these Articles, the shares in the capital of the Company for the time being shall be
under the control of the Board who may issue, allot or otherwise dispose of the same or any of them to such persons, in such
proportion and on such terms and conditions and either at a premium or at par or at a discount and at such time as they may
from time to time think fit and with the sanction of the Company in the General Meeting to give to any person the option or
right to call for any shares either at par or premium during such time and for such consideration as the Board think fit.

Forfeiture and Lien

The Company shall subject to applicable law have a first and paramount lien on every share / debenture (not being a fully paid
share / debenture) registered in the name of each Member (whether solely or jointly with others) and upon the proceeds of sale
thereof for all moneys (whether presently payable or not) called, or payable at a fixed time, in respect of that share / debenture
and no equitable interest in any share shall be created upon the footing and condition that this article will have full effect. The
Company may sell, in such manner as the Board thinks fit, any shares on which the Company has a lien: provide that no sale
shall be made until the expiration of 14 days’ after a notice in writing stating and demanding payment of such part of the amount
in respect of which the lien exists as is presently payable, has been given to the registered holder of the share or the person
entitled thereto by reason of his death or insolvency.

Certificate

Every Member of the Company shall be entitled, without payment to one or more certificates in marketable lots, for all the
shares of each class or denomination registered in his name, or if the Directors approve, to several certificates, each for one or
more of such shares and the Company shall complete and have ready for delivery such certificates, unless prohibited by any
provision of law or any order of court, tribunal or other authority having jurisdiction, within two (2) months from the date of
allotment, or within one (1) month of the receipt of application of registration of transfer, transmission, sub division,

287
consolidation or renewal of any of its shares as the case maybe. The provisions of the Act shall be complied with in the issue,
reissue, renewal of share certificates and the format, sealing and signing of the certificates and records of the certificates issued
shall be maintained in accordance with the said Act.

Every certificate of shares shall be under the Seal of the Company and shall specify the shares to which it relates and the amount
paid-up thereon.

If any certificate be defaced, mutilated, torn or old, decrepit, worn- out or if there be no further space on the back thereof for
endorsement of transfer, then upon production and surrender thereof to the Company, a new certificate may be issued in lieu
thereof, and if any certificate is lost or destroyed then upon proof thereof to the satisfaction of the Company and on execution
of such indemnity as the Company deem adequate, being given, a new certificate in lieu thereof shall be given to the party
entitled to such lost or destroyed certificate.

No fee shall be charged for sub-division and consolidation of share / debenture certificates and for sub-division of letters of
allotment, split and consolidation.

Transfer of Shares

The instrument of transfer of any share shall be in writing and all the provisions of the Act shall be duly complied with in
respect of all transfer of shares and registration thereof. The Company shall use the form of transfer, as prescribed under the
Act, in all cases. In case of transfer of shares, where the Company has not issued any certificates and where the shares are held
in dematerialized form, the provisions of the Depositories Act, 1996 shall apply. The Board may decline to recognize any
instrument of transfer unless the instrument of transfer is in the form prescribed under the Act, is in respect of only one class
of shares and is accompanied by the certificate of shares to which it relates, and such other evidence as the Board may reasonably
require to show the right of the transferor to make the transfer.

Transmission of shares

The executors or administrators or the holders of a succession certificate issued in respect of the shares of a deceased Member
and not being one of several joint holders shall be the only person whom the Company shall recognize as having any title to the
shares registered in the name of such Members and in case of the death of one or more of the joint holders of any registered
share, the survivor or survivors shall be entitled to the title or interest in such shares but nothing herein contained shall be taken
to release the estate of a deceased joint holder from any liability on shares held by him jointly with any other person. Before
recognizing any legal representative or heir or a person otherwise claiming title to the shares the Company may require him to
obtain a grant of probate or letters of administration or succession certificate or other legal representation as the case may be
from a competent court, provided nevertheless that in any case where the Board in its absolute discretion think fit, it shall be
lawful for the Board to dispense with production of the probate or letter of administration or a secession certificate or such other
legal representation upon such terms as to indemnity or otherwise as the Board may consider desirable.

Any person becoming entitled to shares in consequence of the death, lunacy, bankruptcy or insolvency of any Members, or by
any lawful means other than by a transfer in accordance with these Articles, may with the consent of the Board (which it shall
not be under any obligation to give), upon producing such evidence as the Board thinks sufficient, that he sustains the character
in respect of which he proposes to act under this Article, or of his title, elect to either be registered himself as holder of the
shares or elect to have some person nominated by him and approved by the Board, registered as such holder or to make such
transfer of the share as the deceased or insolvent member could have made. If the person so becoming entitled shall elect to be
registered as holder of the share himself, he shall deliver or send to the Company a notice in writing signed by him stating that
he so elects. Provided, nevertheless, if such person shall elect to have his nominee registered, he shall testify that election by
executing in favour of his nominee an instrument of transfer in accordance with the provision herein contained and until he
does so he shall not be freed from any liability in respect of the shares.

Borrowing Powers

The Board may, from time to time and at its discretion, raise or borrow or secure the payment of any sums or sum of money for
the purposes of the Company in such manner and upon such terms and conditions in all respects as it thinks fit.

General Meetings

All General Meetings of the Company other than the Annual General Meeting shall be called an Extra-ordinary General
Meeting. The notice of a General Meeting shall be given to the Members of the Company, legal representative of any deceased
Shareholder or the assignee of an insolvent member of the Company the Directors of the Company and the auditors for the time
being of the Company.

Meetings of Directors

The Board of Directors shall meet at least once in every three months with a maximum gap of 120 days between two meetings

of the Board for the dispatch of business, adjourn and otherwise regulate its meetings and proceedings as it thinks fit in

accordance with the Act, provided that at least four such meetings shall be held in every year. Notice of at least seven days, in
288
writing of every meeting of the Board shall be given to every Director and every alternate Director at his usual address whether
in India or abroad.

The quorum for a meeting of the Board shall be one third of its total strength (any fraction contained in that one-third being
rounded off as one) or two Directors whichever is higher and the participation of the Directors by video conferencing or by
other audio visual means shall also be counted for the purposes of quorum. If within half an hour from the time appointed for a
meeting of the Board, a quorum is not present, the meeting, shall stand adjourned to the same day in the next week at the same
time and place or to such other day and at such other time and place as the Directors may determine.

Managing Directors

Subject to the provisions of Section 196, 197 and 203 of the Companies Act and of the Articles of Association, the Board shall
have the power to appoint from time to time any full time employee of the Company as managing director/ whole time director
or executive director or manager of the Company.

Appointment of Directors

Subject to the applicable provisions of the Act, the number of Directors of the Company shall not be less than 3 (three) and not
more than 15 (fifteen). The Company shall also comply with the provisions of the Companies (Appointment and Qualification
of Directors) Rules, 2014 and the provisions of the Listing Regulations. The Board shall have an optimum combination of
executive and Independent Directors with at least 1 (one) woman Director, as may be prescribed by law from time to time.

Votes of Members

On a show of hands every Member present in person and being a holder of Equity Shares shall have one vote and every person
present either as a Proxy on behalf of a holder of Equity Shares or as a duly authorized representative of a body corporate being
a holder of Equity Shares, if he is not entitled to vote in his own right, shall have one vote.

On a poll, the voting rights of holder of Equity Shares shall be in proportion to his share in the paid-up Equity Share capital of
the Company. A Member may exercise his vote at a meeting by electronic means in accordance with the Act and shall vote
only once.

A person becoming entitled to a share shall not before being registered as Member in respect of the share be entitled to exercise
in respect thereof any right conferred by membership in relation to meeting of the Company.

No Member shall be entitled to exercise any voting rights either personally or by Proxy at any meeting of the Company in
respect of any shares registered in his name on which any calls or other sums presently payable by him have not been paid or
in regard to which the Company has exercised any right or lien.

Dividend

The Company in General Meeting may declare the dividends, but no dividend shall exceed the amount recommended by the
Board. The Board may from time to time pay to the Members such interim dividends of such amount on such class of shares
and at such times as it may think fit.

All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any
portion or portions of the period in respect of which the dividend is paid; but if any share is issued on terms providing that it
shall rank for dividend as from a particular date such share shall rank for dividend accordingly.

No dividend shall bear interest against the Company.
Unpaid or Unclaimed Dividend

Any dividend remaining unpaid or unclaimed after having been declared shall be dealt in accordance with the provisions of the
applicable law.

Where the Company has declared a dividend but which has not been paid or claimed within 30 days from the date of declaration
to any shareholder entitled to the payment of the dividend, the Company shall within seven days from the date of expiry of the
said period of 30 days, open a special account in that behalf in any scheduled bank and transfer to such account, the total amount
of the dividend which remains unpaid or in relation to which no divided warrant has been posted.

Any money transferred to the said special account of the Company which remains unpaid or unclaimed for a period of seven
years from the date of such transfer, shall be transferred by the Company to the fund known as “Investors Education and
Protection Fund” established under the Act.

No unclaimed or unpaid dividend shall be forfeited by the Board before the claim becomes barred by law and the Company
shall comply with the provisions of the applicable laws in respect of such dividend.

289
Winding Up

Subject to the provisions of applicable law, the assets of the Company shall, on its winding up, be applied in satisfaction of its
liabilities pari passu and, subject to such application, such assets shall be distributed among the Members according to their
rights and interests in the Company.

Indemnity

Subject to the provisions the Act, the Company shall indemnify every Director and Officer of the Company against any liability
incurred by them in defending any proceedings, whether civil or criminal, in which judgment is given in their favour or in which
they are acquitted or in which relief is granted to them by the court or the tribunal. However, such indemnification shall not
apply in respect of any cost or loss or expenses to the extent it is finally judicially determined to have resulted from the
negligence, willful misconduct or bad faith acts or omissions of such Director.]

PARTB

The Articles of Association of our Company comprise of two parts, Part A and Part B, which parts shall, unless the context
otherwise requires, co-exist with each other until the commencement of the listing of equity shares of the Company pursuant to
the Offer. In case of inconsistency or contradiction, conflict or overlap between Part A and Part B, the provisions of Part B
shall, subject to applicable law, prevail and be applicable. Part B of the Articles of Association of the Company provides for
the rights and obligations of the parties to the Investment Agreement dated November 23, 2016 amongst our Company, Dr. S.
Surendranath Reddy, K. Sunil Chandra, S. Suprita Reddy, S. Geetha Reddy, B Vishnu Priya, Karakoram Limited and Kedaara
Capital Alternative Investment Fund — Kedaara Capital AIF 1 as amended by waiver cum amendment agreement. All articles
of Part B shall automatically terminate, without any further corporate or other action by the Company or by its shareholders,
and cease to have any force and effect from the date of listing of Equity Shares of the Company on a recognized stock exchange
in India pursuant to the Offer and the provisions of Part A shall continue to be in effect and be in force, without any further
corporate or other action, by our Company or by our Shareholders.

290
SECTION IX: OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The copies of the following documents and contracts which have been entered into by our Company (not being contracts entered
into in the ordinary course of business carried on by our Company or contracts entered into more than two years before the date
of the Red Herring Prospectus) which are deemed material were attached to the copy of the Red Herring Prospectus which was
delivered to the RoC for filing, and will also be attached to the copy of this Prospectus and the Prospectus, as applicable, which
will be delivered to the RoC for filing. Copies of the abovementioned documents and contracts and also the documents for
inspection referred to hereunder, were provided for inspection at the Registered Office between 10 a.m. and 5 p.m. on all
Working Days from date of the Red Herring Prospectus until the Bid/ Offer Closing Date.

A. Material Contracts for the Offer

1. Offer Agreement dated June 5, 2021 between our Company, the Selling Shareholders and the BRLMs.

2. Registrar Agreement dated June 4, 2021 between our Company, the Selling Shareholders and the Registrar
to the Offer.

3. Cash Escrow and Sponsor Bank Agreement dated August 19, 2021 between our Company, the Selling
Shareholders, the Registrar to the Offer, the BRLMs, the Syndicate Members, the Escrow Collection Bank,
Sponsor Bank, Public Offer Bank and the Refund Bank.

4. Share Escrow Agreement dated August 19, 2021 between our Company, the Selling Shareholders and the
Share Escrow Agent.

5. Syndicate Agreement dated August 23, 2021 between our Company, the Selling Shareholders, the BRLMs,
the Registrar to the Offer and Syndicate Members.

6. Underwriting Agreement dated September 6, 2021 between our Company, the Registrar to the Offer, Selling
Shareholders and the Underwriters.

B. Material Documents

1. Certified copies of the updated MoA and AoA of our Company as amended from time to time.

2. Certificate of incorporation dated June 5, 2002 issued to our Company, under the name Vijaya Diagnostic
Centre Private Limited by the Registrar of Companies, Andhra Pradesh at Hyderabad.

3. Fresh certificate of incorporation consequent on change of name issued by the Registrar of Companies,
Telangana at Hyderabad on March 26, 2021 pursuant to change of name from Vijaya Diagnostic Centre
Private Limited to Vijaya Diagnostic Centre Limited.

4. ESOP Plan 2018 and ESOP Schemes 2018.

5. Investment agreement dated November 23, 2016 amongst our Company, Dr. S. Surendranath Reddy, K. Sunil
Chandra, S. Suprita Reddy, S. Geeta Reddy, B Vishnu Priya, Karakoram Limited and Kedaara Capital
Alternative Investment Fund — Kedaara Capital AIF 1

6. Waiver cum amendment agreement dated May 27, 2021 amongst our Company, Dr. S. Surendranath Reddy,
K. Sunil Chandra, S. Suprita Reddy, S. Geeta Reddy, B Vishnu Priya, Karakoram Limited and Kedaara
Capital Alternative Investment Fund — Kedaara Capital AIF 1

7; Slump sale agreement dated November 6, 2019 amongst our Company, VDC Diagnostics (Karnataka) LLP
and L7H Life Resources Pvt Ltd

8. Resolution of the Board dated June 4, 2021, authorising the Offer and resolution of the Board dated June 4,
2021 approving the Draft Red Herring Prospectus.

9. Scheme of amalgamation between Vijaya Diagnostic Private Limited, Bhadrakali Medical Center Private
Limited, Vijaya Diagnostic Centre (Mancherial) Private Limited with our Company, under Section 233 and
certain other provisions of the Companies Act, 2013 filed pursuant to the order of the High Court for the State
of Telangana and Andhra Pradesh dated January 6, 2016

10. Resolution of our Board dated August 24, 2021 approving the Red Herring Prospectus for filing with the
Registrar of Companies and subsequently with SEBI and the Stock Exchanges

11. Resolution of our Board dated September 6, 2021 approving this Prospectus.

291
12.

13.

14.

15.

16.

17.

18.

19.

20.

21;

22.

23.

24,

25.

26.

Copies of the annual reports of our Company for the Financial Years 2021, 2020 and 2019.

The examination report dated August 16, 2021 of the Statutory Auditor, on our Restated Financial
Information, included in this Prospectus along with the Restated Financial Information.

The statement of special tax benefits dated June 5, 2021 from the Statutory Auditors.

Shareholders’ resolution dated May 27, 2021 approving remuneration for Dr. S. Surendranath.
Shareholders’ resolution dated May 27, 2021 approving remuneration for Sunil Chandra Kondapally.
Written consent of the Selling Shareholders, Directors, the BRLMs, the Syndicate Members, Domestic Legal
Counsel to our Company, Legal Counsel to the BRLMs as to Indian Law, International Legal Counsels to the
BRLMs, Legal Counsel to Selling Shareholders, Registrar to the Offer, Escrow Collection Bank, Public Offer
Bank, Refund Bank, Sponsor Bank, Bankers to our Company, Company Secretary and Compliance Officer
as referred to in their specific capacities.

Written consent of the Statutory Auditors dated August 16, 2021 and independent chartered accountant dated
August 24, 2021 to include their name as required under Section 26(5) of the Companies Act in this

Prospectus and as an “expert” as defined under Section 2(38) of the Companies Act.

Report titled “Assessment of the diagnostic industry in India” dated May, 2021 read with the addendum to the
report dated August 2021, prepared and issued by CRISIL Limited.

Written consent dated August 12, 2021 issued by CRISIL Limited with respect to the report titled “Assessment
of the diagnostic industry in India” dated May, 2021 read with the addendum to the report dated August 2021,
and engagement pursuant to email dated March 20, 2021 between the Company and CRISIL Limited
Consent letters from the Selling Shareholders, authorising their participation in the Offer.

Due diligence certificate dated June 5, 2021, addressed to SEBI from the BRLMs.

In principle listing approval dated July 5, 2021 and June 30, 2021 issued by BSE and NSE, respectively.
Tripartite agreement dated November 16, 2016 between our Company, NSDL and the Registrar to the Offer.

Tripartite agreement dated November 2, 2016 between our Company, CDSL and the Registrar to the Offer.

SEBI observation letter bearing reference number SEBI/HO/CFD/DIL-1/P/OW/2021/0000016198/1 and
dated July 23, 2021.

Any of the contracts or documents mentioned in this Prospectus may be amended or modified at any time if so required in the
interest of our Company or if required by the other parties, without notice to the shareholders subject to compliance of the
provisions contained in the Companies Act and other relevant statutes.

292
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Dr. Sura Surendranath Reddy

(Executive Chairman)
Place: Hyderabad

Date: September 6, 2021

293
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

S Geeta Reddy

(Non-Executive Director)
Place: Hyderabad

Date: September 6, 2021

294
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Sunil Chandra Kondapally

(Executive Director)
Place: Hyderabad

Date: September 6, 2021

295
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Nishant Sharma

(Non-Executive, Nominee Director)
Place: Mumbai

Date: September 6, 2021

296
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Dr. D Nageshwar Reddy

(Non-Executive, Independent Director)
Place: Hyderabad

Date: September 6, 2021

297
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Shekhar Prasad Singh

(Non-Executive, Independent Director)
Place: Hyderabad

Date: September 6, 2021

298
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Satyanaryana Murthy Chavali

(Non-Executive, Independent Director)
Place: Hyderabad

Date: September 6, 2021

299
DECLARATION
We hereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by
the Government of India or the rules/guidelines/regulations issued by SEBI, as the case may be, have been complied with and
no statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act
or rules made or guidelines or regulations issued there under, as the case may be. We further certify that all statements in this
Prospectus are true and correct.
SIGNED BY THE DIRECTORS OF OUR COMPANY

Manjula Anagani

(Non-Executive, Independent Director)
Place: Hyderabad

Date: September 6, 2021

300
DECLARATION
Thereby certify and declare that all relevant provisions of the Companies Act and the rules, guidelines/regulations issued by the
Government of India or the guidelines/regulations issued by SEBI, as the case may be, have been complied with and no
statement made in this Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act or
rules made or guidelines or regulations issued there under, as the case may be. I further certify that all statements in this
Prospectus are true and correct.

SIGNED BY CHIEF FINANCIAL OFFICER

Narasimha Raju K.A
Place: Hyderabad

Date: September 6, 2021
DECLARATION
Dr. Sura Surendranath Reddy hereby confirms that all statements, disclosures and undertakings made or confirmed by him in
this Prospectus about or in relation to himself, as a Promoter Selling Shareholder and his portion of the Offered Shares, are true
and correct. Dr. Sura Surendranath Reddy, as a selling shareholder assumes no responsibility for any other statements,

disclosures and undertakings, including any statements made or confirmed by, or relating to, the Company or any other Selling
Shareholder or any other person(s) in this Prospectus.

Signed by Dr. Sura Surendranath Reddy
Date: September 6, 2021

Place: Hyderabad
DECLARATION

Karakoram Limited hereby confirms that all statements, disclosures and undertakings made or confirmed by it in this Prospectus
about or in relation to itself, as an Investor Selling Shareholder and its portion of the Offered Shares, are true and correct.
Karakoram Limited assumes no responsibility for any other statements, disclosures and undertakings, including any statements,
disclosures or undertakings made or confirmed by, or relating to, the Company or any other Selling Shareholder or any other
person(s) in this Prospectus.

Signed on and on behalf of Karakoram Limited
Name: Santosh K. Gujadhur

Designation: Director

Date: September 6, 2021

Place: Mauritius

303
DECLARATION

Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1 hereby confirms that all statements, disclosures and
undertakings made or confirmed by it in this Prospectus about or in relation to itself, as an Investor Selling Shareholder and its
portion of the Offered Shares, are true and correct. Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1
assumes no responsibility for any other statements, disclosures and undertakings, including any statements, disclosures or
undertakings made or confirmed by, or relating to, the Company or any other Selling Shareholder or any other person(s) in this
Prospectus.

‘Signed on and on behalf of Kedaara Capital Alternative Investment Fund — Kedaara Capital AIF 1
Name: Nishant Sharma

Designation: Authorised, Investment Manager, Kedaara Capital Advisors LLP

Date: September 6, 2021

Place: Mumbai

304
